<SEC-DOCUMENT>0001159036-23-000039.txt : 20230509
<SEC-HEADER>0001159036-23-000039.hdr.sgml : 20230509
<ACCEPTANCE-DATETIME>20230509161705
ACCESSION NUMBER:		0001159036-23-000039
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230509
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HALOZYME THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001159036
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				880488686
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32335
		FILM NUMBER:		23902279

	BUSINESS ADDRESS:	
		STREET 1:		12390 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 794-8889

	MAIL ADDRESS:	
		STREET 1:		12390 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HALOZYME THERAPEUTICS INC
		DATE OF NAME CHANGE:	20040312

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GLOBAL YACHT SERVICES INC
		DATE OF NAME CHANGE:	20010912
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>halo-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:5667a7fc-e0e0-4ae8-9db7-13762e0ab1e4,g:df8c4c1a-0af9-473f-aa3c-bddd63ebeeb8,d:2807c465c47449f58323217d8928fdb2--><html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:halo="http://www.halozyme.com/20230331" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>halo-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80L2ZyYWc6M2M0ZWMyZDcyNjZlNGU0M2E3MTM2YjhjMTY3NzcxMzMvdGFibGU6YTAxMzMyYWExZWVmNDcyYWJkNmI2MTNlNjYxYjc1MmYvdGFibGVyYW5nZTphMDEzMzJhYTFlZWY0NzJhYmQ2YjYxM2U2NjFiNzUyZl8xLTEtMS0xLTk3ODM5_f0d519b2-fec7-41c1-9d1b-80942cc5203c">0001159036</ix:nonNumeric><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80L2ZyYWc6M2M0ZWMyZDcyNjZlNGU0M2E3MTM2YjhjMTY3NzcxMzMvdGFibGU6YTAxMzMyYWExZWVmNDcyYWJkNmI2MTNlNjYxYjc1MmYvdGFibGVyYW5nZTphMDEzMzJhYTFlZWY0NzJhYmQ2YjYxM2U2NjFiNzUyZl8yLTEtMS0xLTk3ODM5_42fbd222-cf60-4337-9da8-e8f94526ba1f">false</ix:nonNumeric><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80L2ZyYWc6M2M0ZWMyZDcyNjZlNGU0M2E3MTM2YjhjMTY3NzcxMzMvdGFibGU6YTAxMzMyYWExZWVmNDcyYWJkNmI2MTNlNjYxYjc1MmYvdGFibGVyYW5nZTphMDEzMzJhYTFlZWY0NzJhYmQ2YjYxM2U2NjFiNzUyZl8zLTEtMS0xLTk3ODM5_97c37082-4627-4f4d-b7de-91d5c9994530">2023</ix:nonNumeric><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80L2ZyYWc6M2M0ZWMyZDcyNjZlNGU0M2E3MTM2YjhjMTY3NzcxMzMvdGFibGU6YTAxMzMyYWExZWVmNDcyYWJkNmI2MTNlNjYxYjc1MmYvdGFibGVyYW5nZTphMDEzMzJhYTFlZWY0NzJhYmQ2YjYxM2U2NjFiNzUyZl80LTEtMS0xLTk3ODM5_0de42ceb-3d55-441d-aeb0-0b0da5212324">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80L2ZyYWc6M2M0ZWMyZDcyNjZlNGU0M2E3MTM2YjhjMTY3NzcxMzMvdGFibGU6YTAxMzMyYWExZWVmNDcyYWJkNmI2MTNlNjYxYjc1MmYvdGFibGVyYW5nZTphMDEzMzJhYTFlZWY0NzJhYmQ2YjYxM2U2NjFiNzUyZl81LTEtMS0xLTk3ODM5_9e762000-a1d8-48dd-98d8-f66a96f92f6c">12/31</ix:nonNumeric><ix:nonNumeric contextRef="icd9786c1eb264d80a62f434a14aac146_I20230331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82MS9mcmFnOjcxYzdlNDczNTdhMDRiMTI4YTM3MzA4NzUzNDUxNWE1L3RhYmxlOjVkNGQ1YmI3MjRiMzRmNjE5MTdlYjA2MzE5OWQ3YTBmL3RhYmxlcmFuZ2U6NWQ0ZDViYjcyNGIzNGY2MTkxN2ViMDYzMTk5ZDdhMGZfMS0xLTEtMS05NzgzOQ_0df02f8f-ea62-4d5b-a88c-bede3498527f">12</ix:nonNumeric><ix:nonNumeric contextRef="i859ed6ba27774ade9888f1c580577c1a_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RleHRyZWdpb246MTYzZDU4ODI5MmUwNGM4ZGEwZGI0YzJjNWY0NjIwZWJfNTU2_7b1e4645-8507-4bdd-a7da-977a1bcbb72c">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="i335649d465744f89957988f0508a596e_D20211201-20211231" name="us-gaap:StockRepurchaseProgramPeriodInForce1" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMTU2Nw_a30831a4-f6f2-4774-9f18-5ca5ed367463">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="halo-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic69506cb60d54b0a81669b48b2a0720f_I20230428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i135c9d6e5363476397deb7376556416f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i18f57f446331441d9650bc51a98fef4b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iff52cfa922bd4a86a7aed2b93a6ae7b7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02fe07952df9422992b4f26248091821_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aebf4236d314680b3e3c0a72977aef1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff57a29a29d64188b30a100687f1c479_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4ce36d68328465ea06f53e7683604f0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33911352c8cf4d3a8a5655b090781af3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0705f79cf1bd46bcaee4afc74fd6c446_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b2c4a20e00545ee9fa2fa2f54922dfc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fa2dc7b7b064cb99cda5c7d5980ae6b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b299dba797b49119fe3c2869cbaf39c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9905a464af014a85bc6f52a18e89e039_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0766222d7af490eb043ec6ffb786970_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f658ce1d6a2456c8372b0a418d493e9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a6aa3f2f5da44ffbb88bbeeb79b6e56_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84c942c19de040e2bca58d2705871d43_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72b6265ecd0a45ccb0aab3916e41a95c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5998c0ad8cb74ba3b06cbd6c2a277c24_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0432ad1ce41f4fc3bbc7778eedfc105d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i021aeb69fccf46cb9a81f74872450bc2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32b531446d00413c935a571e48773de0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38e034be49cf4c1387b7a092a63f997c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9f57fa1e6ff47c8a4b0c2f4270f8890_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f33835107a94cc08d1aa2cd3aad8d31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8890ea7491a742b486450ebcf13b21de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if89afe2a91d940bfadc08e4c9ffc41c6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6708ca65ef9487b8ff8abff52cfb4b9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5a21714774e40ffb9b1684869c5a218_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02a2a1340b5245dea5832883a6cd93ae_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ac0a4f26d31423b9dc549a8198fd81b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61fd7db612a2481293d23ce396675ed6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14262341c01e414e9cd5feb0ef8cd2dd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i986a9c4e8321407fabcf25854ef0b832_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="collaborator"><xbrli:measure>halo:collaborator</xbrli:measure></xbrli:unit><xbrli:context id="i0e6992830095415c90ee103cb5429d20_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:BaxaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>halo:product</xbrli:measure></xbrli:unit><xbrli:context id="i7137d05d5f4045da8aacbc2092346351_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia457f78bd8504520987402033058bd04_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:JanssenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26d023fcab96411da642d788b3f4972f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c07e926241e4fcea8142ef7b8204548_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>halo:segment</xbrli:measure></xbrli:unit><xbrli:context id="i278958ca21434e13ac5e9b20db531704_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icab3fab76ada402db8fe4009786133b9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74ddf974e26d4522a765f4b90853db19_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9508cd66d39746d1ab48f1c43c197c90_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i094f2eeb06f242e3ac6bed7262ca9174_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i785729d9e19d43c9874a0e5eb4644380_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfbf3f7b961745d186224a612c84b694_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00ffb999a0c746d5bbbfb9ce0f56de51_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if283cea3fe1d4a6a91ac40d41123cd0b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a820e39ab6e40f887d12c0d67623ad2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9cf1d8f181a422daa99c4f7cb0bae61_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5537e8e933a456da81116ac3891b12a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>halo:security</xbrli:measure></xbrli:unit><xbrli:context id="if8ff50c7e57541459bb9e2d11625d308_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ac12a8fcf7d4256b1c58e9d42cb1c4e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4c6ea833f4e4d4d8e62e3e2a8a60dd7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica79dc0bdab840cba3dd0e9299d602b2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6ee6e33f59c4afbba6c572de982c78a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ac74b74a58e4c778cbccec9b7a58c03_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5f15c4e1aaa429cbc707bcf75d4d317_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33428793de6741fe9231fd34e586de77_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0971204a009d4734a0ecb98a017e3a11_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d798995adad4c12bb8d4fa1faf537eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibceadab060e443d8beb30c8b6c154f6b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6952ec39a8ea49e9acc3bd6d2f0d8165_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i739a42f476d6422e927a07b0a6b5e866_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic958d8a4445145abae1f919a5908815c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60e05f4ffbae45dfb1945eb2ab5d061a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40dd3bd58ac142339fe5aa795ac93db9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24130c3f089b46b6857ad5fc1d6bf622_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i455b329b075a48c29ca83f974487d0d2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia88d5d7bf4c148048b1766fdfc7b91e8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ec8a06ba4b34aafb950e3a31d87cc34_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b9d9e738fde4ed2857f748c87e3787d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f8f8b13262e4f419f206a41f9565cc3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b874a74f5924476b565a9f6bcfca413_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ace94c58553416888e3d388acdf4e1f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i562e413729c347808d2b496afa73e048_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b8ac74092c34340beea79e2b5c3eaef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d3aaf097a2b46f7a4fde671aaa22952_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0a569c32a674df0839180908bd55f41_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51cd82ac5a0347999d0942cb559d69f1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e036a3c236442fcbc74bb9450bb41b6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2ded6c148b24f77bf4d9c161e49d9de_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f6244ff2fcd468a96760b50de6410df_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie15ed974b99c4d81aa1e6764b03ef509_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f2e433d91b04a038142f3674a77dbab_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b20fa8736c942e5a6d16eb5dd856c4d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8349bd4411084a29b491605b9e981c86_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5040df1f6b0340d2b9bdc087ac6bc75a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e44c7bdff0d4afab55d0f20c2a08e26_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f57590019f4701b5d3b0b88015539e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4051c56e33f74f188cc8eccd23a7f58f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:UpfrontfeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d4b107661c44956a8eb7be6f8c14f9d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:UpfrontfeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if58b9fca0ec74a9995562d09ff0ab3ac_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DeviceLicensingAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39a11b871a3346cd9599297d2004c0c3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DeviceLicensingAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic22dc841bc6041cba127ce0958181fb1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:LicenseFeesAndEventBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafdfb78b51284e9cb1aba46fd7125d17_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:OthercollaboratorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff33634f84774f3e98705b7f0fa793f5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd9786c1eb264d80a62f434a14aac146_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f4f1582f5974e0fa962b63fed33147c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68980f1c77a7473ab18bec2713ab9e05_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib377635631014ff39344d0ec6e220cf8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifed31096856d45c5a8a866ba7b9fccce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1795cd05c98547769da8f152dffa740b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47f684ec05774a41841a55c9d11bc8ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i429394b48f8f49c9bd5c34d8ea70ef6f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i463667de7a9840d9887b692b9090956f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04990caa9f1d4feeb66916e444f5b67f_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i859ed6ba27774ade9888f1c580577c1a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81c6c189dc1c414db846950051a68f58_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48becb7672924502ac96083bb5cd5d79_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeb34905ee5a413ba8c2930d948203a1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia90c2ed74ead443583b931534d578bb2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa015d0540a840c79bc449df56401a5f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25336e1752ef44b4b8ba6f295a047c8d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:TLANDOProductRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e130d5a6e9b4d66b803cb5e487a55ef_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:TLANDOProductRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3d4edc7f65c461d9431d7d9efcc56e9_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd6f3969e6c8426fa1c64cce894e6e50_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5418d7fce8df4268a313fe8e25d35226_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="trading_day"><xbrli:measure>halo:trading_day</xbrli:measure></xbrli:unit><xbrli:context id="ia9437143ea354b0fb66fc8e352a8fad9_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="businessday"><xbrli:measure>halo:businessDay</xbrli:measure></xbrli:unit><xbrli:context id="i4b687461f70242228d9fa67322314ce3_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic03a55962ac146dfb9a17293e7c10f01_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i875da9e8bc6f447e83c35dccc1bce549_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i297284b6b3114aa4a934c8c77af6a7ef_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49ac4e10c151449aa37064756bff906c_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib53c28890ced4a5e81b120e58423d483_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62e04ec34e84456a9a1c1c9fce36d738_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a51169caaa348e8906636fb88af0a07_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98820adb7b114fab89f1dcfab8fb0f09_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bd17b29b4a74fd99bf9cb4435a081cf_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i295b45eca4f04978ad6b88c2a0a40c9b_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf91861e2376494b8f674c6a659fb5c1_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc695c8e9d5e48179ccc383f1676101c_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09030ba483314a21b46d9dd361c0aa83_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cf5bff84e7842eab1e94ae576059f7e_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b9f1075f25446e3857aa8ab0613536f_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbcb0ae49876436997c9d2b2422116d1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eda99a3ab274f3189aed8a7cd000ecc_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7511bded3501417cb4e2415a6bcbd39b_D20230301-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e312be945a2402db2f373983b98f7d7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82c04eddabc54f759c9fb4de56fb03f4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aafe649a1244a06b7cb31af4030dfbd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6816f5120aee4e1790a693cbeb24b81b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i256de7cb03ee49139431754c4ae916aa_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i166af7e00a904a83b5854157af961f65_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03816f914d7a447986a953007197bb96_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fb3535e833444bdbbab874679ac6563_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9afd86f45c5e469cbf3764deb77b2e92_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5ffcb548d7140e1ac76a8652c62766b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a88cde3434f468b8176c193c6db698f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i818a916aac4f44ffa2bd008ffe38a30a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96d86a86d4dc47ecb2dfffda2f52ab0f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i388d4ea90c0548c39bda4283394ecd6c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62ec2ac8d55a4479a3ff4cc2ff76befb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46a442da67054fd9b76638faf6b88d76_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd4da77d8421473cb59e66faa8374380_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic86e248bcecd4584b1f877e96f7336cd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66a48adbd00143d6b8660e90fb91cae0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e21cdfacc224f85abe16a6d40aec853_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d608edf583c4031bb38b269eb42b8ea_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d5d7ddddf33471496c67ca9c24baf70_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib68465c427954f66928ec69ce2d8bcfe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96dbb0d9515a4b9983f224b01c185b89_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0426add4fd0d41e9ac294788c419aadb_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i064840ce987b44589b1984f31ec23ee9_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52bc8208b75542fe834c04c4a32935e2_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80af1fed659d4797a60c80b15182657c_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92b9cedcf3f2470db29567877e9ab56b_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c4153c5687046e5b97fe69b5b5dd0a7_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i849dc496423d470899ceba933ef3cddb_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic433e02b2e524802bd9b3db31defcb80_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic21b915c10f948c5be0345f6cca32742_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i921873efde3f4390ba5cf90029a46dfe_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaccbd76f32744459bd6ce7634d990a3e_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbbefd52056444bfada4f4742cd5491a_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b315f13ef0b4d7da409254361bf6681_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c4765296dd7441193e31a2d3b55cc50_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab25dbdafb934ddaa1edddfd20909764_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77ffcd92787e44a4b19b0c3b9575a7ab_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5ac304dab2f4cac876a9781e63af963_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4bb445d76ad4d60806edb24823f807a_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice8cda3f37824ceaadbd1c40fb40a92e_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04c8df8cf25c44f5aab2fcfc36944999_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb2e8da7a634478895e75cec60c5c338_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26ffd244af4f411f8cd2468455cda38a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e27c05190e1407887ac69c8d7d33adf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84f9ba0217ca4943af62f30063a6142b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id845f28873224a6287ebf2f2b47ef3d0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a6aae30a5394516b3ad5c031cec59c6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia721a5e3252544d3821885e9d7a30919_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i457c8fcb2ad444429cbae63ee2c523ba_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16324593b4c9487687f61647a729634f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c3a0c9ac8ff414aa0504ce40bfa1e50_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92a039cdfbbf4fa8af99885fb9696846_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic595728a50dc437dbd456b98049dd40d_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ed2833f90c64a0b9b7117a1df7588fe_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98636a07909a4eb082fd10e5a0c20ab2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6ab22e429fd4490ace65357489d0522_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0e2d808937f41cb849c6d6eec760399_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c07ee50572b4618820f8dd73892a316_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c8cad373a064499b7994b46613c260c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aabdf6a6ae54c86b1cc74c5d60a1f07_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b6b375c49834699b6901ea74bf476d4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf2b9ab6a89d4df59dd4955dcef17ae1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1343ec306ed4444b65da6a899a7f2c3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida5a69f1405a496f802d78313d35c0c3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i335649d465744f89957988f0508a596e_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f605f48fb46486b8c32365ccf871ecf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f8d6a392c1d4fe8b9e5be6142532df5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RestrictStockUnitsPerformanceSharesAndESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i752be5578b5b423d8fc0ff6e421f4f83_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RestrictStockUnitsPerformanceSharesAndESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b70d8e746f94570afba56b0ac99fe35_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71746ecec304430aa330b98c5496d867_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2807c465c47449f58323217d8928fdb2_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xODAx_d96bd9be-cd6d-4fe1-953b-61fc3cd9f0b8">10-Q</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6ZTM4MWRiMjEwODQ5NGUwZWI1YjUwNzliNTI1NzRmNTkvdGFibGVyYW5nZTplMzgxZGIyMTA4NDk0ZTBlYjViNTA3OWI1MjU3NGY1OV8wLTAtMS0xLTk3ODM5_66645477-e82e-42fb-ba4b-6394133d9cc8">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xMzQ_e2d2fbdb-9e7c-45d3-a2f1-ce14770415ab">March&#160;31, 2023</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6YWZmN2Q1OWU3MTU2NGM4ZWI4MjBmMzc0NTczZmE0ZjIvdGFibGVyYW5nZTphZmY3ZDU5ZTcxNTY0YzhlYjgyMGYzNzQ1NzNmYTRmMl8wLTAtMS0xLTk3ODM5_c05487bb-ca46-42f0-932c-dea53064bfe8">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xODAy_a94785c1-1e00-47ca-a8b6-33be488ad6b8">001-32335</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><img src="halo-20230331_g1.jpg" alt="Halo Logo updated.jpg" style="height:75px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">___________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xODAz_7ae1884a-b12b-4afa-adec-d9d9d5be549c">HALOZYME THERAPEUTICS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Exact name of registrant as specified in its charter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">___________________________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6YWRjOGQxN2VjNzc0NDZlMTk1NTgyMjRlMWQ5MDE2NWEvdGFibGVyYW5nZTphZGM4ZDE3ZWM3NzQ0NmUxOTU1ODIyNGUxZDkwMTY1YV8wLTAtMS0xLTk3ODM5_a8e5d858-0863-4858-8244-beb7915ed547">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6YWRjOGQxN2VjNzc0NDZlMTk1NTgyMjRlMWQ5MDE2NWEvdGFibGVyYW5nZTphZGM4ZDE3ZWM3NzQ0NmUxOTU1ODIyNGUxZDkwMTY1YV8wLTItMS0xLTk3ODM5_917caed3-6d8f-4054-8e80-6d281b5ad9dd">88-0488686</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6YWRjOGQxN2VjNzc0NDZlMTk1NTgyMjRlMWQ5MDE2NWEvdGFibGVyYW5nZTphZGM4ZDE3ZWM3NzQ0NmUxOTU1ODIyNGUxZDkwMTY1YV8zLTAtMS0xLTk3ODM5_8b5f80d2-b1d8-4c86-80c2-c1363d6c86c3">12390 El Camino Real</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6YWRjOGQxN2VjNzc0NDZlMTk1NTgyMjRlMWQ5MDE2NWEvdGFibGVyYW5nZTphZGM4ZDE3ZWM3NzQ0NmUxOTU1ODIyNGUxZDkwMTY1YV8zLTItMS0xLTk3ODM5_fc905586-af08-40f6-a617-d3f51a2c5816">92130</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6YWRjOGQxN2VjNzc0NDZlMTk1NTgyMjRlMWQ5MDE2NWEvdGFibGVyYW5nZTphZGM4ZDE3ZWM3NzQ0NmUxOTU1ODIyNGUxZDkwMTY1YV80LTAtMS0xLTk3ODM5_c894ed68-f5fe-4cca-999f-d4995427581c">San Diego</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Zip Code)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6YWRjOGQxN2VjNzc0NDZlMTk1NTgyMjRlMWQ5MDE2NWEvdGFibGVyYW5nZTphZGM4ZDE3ZWM3NzQ0NmUxOTU1ODIyNGUxZDkwMTY1YV81LTAtMS0xLTk3ODM5_7d95e45b-a1b0-4fe8-ab30-76e7e64c3719">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xODA0_1c9be45b-4965-4574-9872-766c370dae6c">858</ix:nonNumeric>) <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xODA1_a534bbd0-1714-4a70-b332-83b41fd3dae9">794-8889</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.277%"><tr><td style="width:1.0%"></td><td style="width:33.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.104%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6NDRlZGMzYjUzNzk0NDQ3YmFkMzcxMTE1NGU3ZTcwZTQvdGFibGVyYW5nZTo0NGVkYzNiNTM3OTQ0NDdiYWQzNzExMTU0ZTdlNzBlNF8xLTAtMS0xLTk3ODM5_c6c8e19f-224e-4e5e-8ebb-e438699e45f6">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6NDRlZGMzYjUzNzk0NDQ3YmFkMzcxMTE1NGU3ZTcwZTQvdGFibGVyYW5nZTo0NGVkYzNiNTM3OTQ0NDdiYWQzNzExMTU0ZTdlNzBlNF8xLTEtMS0xLTk3ODM5_88b293d1-4b77-4761-abe5-ceb6ced8e42d">HALO</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6NDRlZGMzYjUzNzk0NDQ3YmFkMzcxMTE1NGU3ZTcwZTQvdGFibGVyYW5nZTo0NGVkYzNiNTM3OTQ0NDdiYWQzNzExMTU0ZTdlNzBlNF8xLTItMS0xLTk3ODM5_8968fe28-cd66-4831-bcbf-5ae8d2759ce4">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xNzk4_95f43754-8fd1-488f-bfdb-86612507acc8">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xNzk5_9379dae8-6117-46aa-a2a4-86e7979f3c0d">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.277%"><tr><td style="width:1.0%"></td><td style="width:31.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6OGRiYmQ1NzBjMzNhNGIzNWJmODk0ZjU0OWI4N2ExYTUvdGFibGVyYW5nZTo4ZGJiZDU3MGMzM2E0YjM1YmY4OTRmNTQ5Yjg3YTFhNV8wLTAtMS0xLTk3ODM5_8357dfec-5ace-4c84-8e36-2ad366292f18">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6OGRiYmQ1NzBjMzNhNGIzNWJmODk0ZjU0OWI4N2ExYTUvdGFibGVyYW5nZTo4ZGJiZDU3MGMzM2E0YjM1YmY4OTRmNTQ5Yjg3YTFhNV8xLTMtMS0xLTk3ODM5_b947aea3-505a-4cd1-a51b-e3d79b5eb00a">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6OGRiYmQ1NzBjMzNhNGIzNWJmODk0ZjU0OWI4N2ExYTUvdGFibGVyYW5nZTo4ZGJiZDU3MGMzM2E0YjM1YmY4OTRmNTQ5Yjg3YTFhNV8yLTMtMS0xLTk3ODM5_49520257-6c99-41fd-b3f1-325ab83d8c9d">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.472%"><tr><td style="width:1.0%"></td><td style="width:17.517%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#168;</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xODAw_3881ad8e-8e2e-4be0-9132-7c87b0985bf7">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s common stock, par value $0.001 per share, was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic69506cb60d54b0a81669b48b2a0720f_I20230428" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xNzgz_736438b5-6382-40d8-abf4-8c8730b927be">131,680,440</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> as of April&#160;28, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160; </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:9.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.161%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_10">Summary of Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_10">3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_13">PART&#160;I &#8212; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_19">Condensed Consolidated Balance Sheets (Unaudited) - March 31, 2023 and December 31, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_19">6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_25">Condensed Consolidated Statements of Income (Unaudited) - Three Months Ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_25">7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_28">Condensed Consolidated Statements of Comprehensive Income (Unaudited) - Three Months Ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_28">8</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_31">Condensed Consolidated Statements of Cash Flows (Unaudited) - Three Months Ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_31">9</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_34">Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited) - Three Months Ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_34">10</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_37">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_40">11</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_88">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_88">39</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_106">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_106">75</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_109">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_109">75</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_112">PART&#160;II &#8212; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_115">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_115">76</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_118">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_118">76</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_121">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_121">76</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_124">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_124">76</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_127">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_127">76</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_130">Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_130">76</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_133">Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_133">77</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_136">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2807c465c47449f58323217d8928fdb2_136">78</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks and uncertainties, including those described in the section labeled &#8220;Risk Factors&#8221; in &#8220;Part I, Item 2, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of this Quarterly Report. These risks include the following:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related To Our Business</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our partnered or proprietary product candidates do not receive and maintain regulatory approvals, or if approvals are not obtained in a timely manner, such failure or delay would substantially impair our ability to generate revenues.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Use of our partnered or proprietary products and product candidates could be associated with adverse events or product recalls.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our contract manufacturers or vendors are unable or unwilling for any reason to manufacture and supply to us bulk rHuPH20 or other raw materials, reagents, components or devices in the quantity and quality required by us or our partners for use in the production of Hylenex or other proprietary or partnered products and product candidates, our and our partners&#8217; product development or commercialization efforts could be delayed or suspended and our business results of operations and our collaborations could be harmed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to perform necessary services for our products including services related to the distribution, invoicing, rebates and contract administration, co-pay program administration, sample distribution and administration, storage and transportation of our products. If anything should impede their ability to meet their commitments this could impact our business performance.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we or any party to a key collaboration agreement fail to perform material obligations under such agreement, or if a key collaboration agreement, is terminated for any reason, our business could suffer.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Hylenex and our partners&#8217; ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products and product candidates rely on the rHuPH20 enzyme, and any adverse development regarding rHuPH20 could substantially impact multiple areas of our business, including current and potential ENHANZE collaborations, as well as any proprietary programs.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business strategy is focused on growth of our ENHANZE technology, auto-injector technology, commercial products and potential growth through acquisition. Currently, ENHANZE is the largest revenue driver and as a result there is a risk for potential negative impact from adverse developments. Future expansion of our strategic focus to additional applications of our ENHANZE technology or by acquiring new technologies may require the use of additional resources, result in increased expense and ultimately may not be successful.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our partnered or proprietary product candidates may not receive regulatory approvals or their development may be delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory requirements or safety concerns. If we or our partners fail to obtain, or have delays in obtaining, regulatory approvals for any product candidates, our business, financial condition and results of operations may be materially adversely affected or delayed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our third-party partners are responsible for providing certain proprietary materials that are essential components of our partnered products and product candidates, and any failure to supply these materials could delay the development and commercialization efforts for these partnered products and product candidates and/or harm our collaborations. Our partners are also responsible for distributing and commercializing their products, and any failure to successfully commercialize their products could materially adversely affect our revenues.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we or our partners fail to comply with regulatory requirements applicable to promotion, sale and manufacturing of approved products, regulatory agencies may take action against us or them, which could harm our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to successfully integrate the Antares business, or failure of the Antares business to perform could adversely impact our future business and operations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Business interruptions resulting from pandemics or similar public health crises could cause a disruption of the development of our and our partnered product candidates and commercialization of our approved and our partnered products, impede our ability to supply bulk rHuPH20 to our ENHANZE partners or procure and sell our proprietary products and otherwise adversely impact our business and results of operations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need to raise additional capital in the future and there can be no assurance that we will be able to obtain such funds.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently have significant debt and expect to incur additional debt. Failure by us to fulfill our obligations under the applicable debt agreements may cause repayment obligations to accelerate.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The conditional conversion feature of the Convertible Notes, if triggered, may adversely affect our financial condition and operating results.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conversion of our Convertible Notes may dilute the ownership interest of existing stockholders or may otherwise depress the price of our common stock.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If proprietary or partnered product candidates are approved for commercialization but do not gain market acceptance resulting in commercial performance below that which was expected or projected, our business may suffer.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to license our ENHANZE and device technologies to our partners depends on the validity of our patents and other proprietary rights.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developing, manufacturing and marketing pharmaceutical products for human use involves significant product liability risks for which we may have insufficient insurance coverage.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our partners do not achieve projected development, clinical, or regulatory goals in the timeframes publicly announced or otherwise expected, the commercialization of our partners products may be delayed and, as a result, our business, financial condition, and results of operations may be adversely affected or delayed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Future acquisitions could disrupt our business and impact our financial condition.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related To Ownership of Our Common Stock</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price is subject to significant volatility.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Future transactions where we raise capital may negatively affect our stock price.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anti-takeover provisions in our charter documents, the Indentures and Delaware law may make an acquisition of us more difficult.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Industry</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our or our partnered products must receive regulatory approval before they can be sold, and compliance with the extensive government regulations is expensive and time consuming and may result in the delay or cancellation of our or our partnered product sales, introductions or modifications.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because some of our and our partnered products and product candidates are considered to be drug/device combination products, the approval and post-approval requirements that we and they are required to comply with can be more complex.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject, directly or indirectly, to various broad federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be required to initiate or defend against legal proceedings related to intellectual property rights, which may result in substantial expense, delay and/or cessation of certain development and commercialization of our products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may incur significant liability if it is determined that we are promoting or have in the past promoted the &#8220;off-label&#8221; use of drugs or medical devices, or otherwise promoted or marketed approved products in a manner inconsistent with the FDA&#8217;s requirements.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For certain of our products, we and our independent contractors, distributors, prescribers, and dispensers are required to comply with regulatory requirements related to controlled substances, which will require the expenditure of additional time and will incur additional expenses to maintain compliance and may subject us to additional penalties for noncompliance, which could inhibit successful commercialization.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patent protection for biotechnology inventions and for inventions generally is subject to significant scrutiny. If patent laws or the interpretation of patent laws change, our business may be adversely impacted because we may lose the ability to enforce our intellectual property rights against competitors who develop and commercialize products based on our discoveries.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If third-party reimbursement and customer contracts are not available, our proprietary and partnered products may not be accepted in the market resulting in commercial performance below that which was expected or projected.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rising cost of healthcare and related pharmaceutical product pricing has led to cost containment pressures from third-party payers as well as changes in federal coverage and reimbursement policies and practices that could cause us and our partners to sell our products at lower prices, and impact access to our and our partnered products, resulting in less revenue to us.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face competition and rapid technological change that could result in the development of products by others that are competitive with our proprietary and partnered products, including those under development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risks</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to attract, hire and retain key personnel our business could be negatively affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cyberattacks, security breaches or system breakdowns may disrupt our operations and harm our operating results and reputation.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8212; FINANCIAL INFORMATION</span></div><div id="i2807c465c47449f58323217d8928fdb2_16"></div><div style="padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;Financial Statements</span></div><div id="i2807c465c47449f58323217d8928fdb2_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMy0yLTEtMS05NzgzOQ_0875a742-a983-4f5a-a37d-8015c5ad74c8">96,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMy00LTEtMS05NzgzOQ_8f7f5ac5-2908-4eff-985e-039c393458d5">234,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, available-for-sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfNC0yLTEtMS05NzgzOQ_fc881290-e620-4284-b3e2-d33a30d9cf87">179,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfNC00LTEtMS05NzgzOQ_6ab6437a-81bb-42ea-ad14-810935def97a">128,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net and contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfNS0yLTEtMS05NzgzOQ_1b4d77d6-64c9-4f3c-bbb5-f2d55283b4e0">194,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfNS00LTEtMS05NzgzOQ_f493e8c8-0c07-4377-ad05-a0eed50580e0">231,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfNi0yLTEtMS05NzgzOQ_a0c423f6-ea1e-450d-b738-233961f8cc7a">107,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfNi00LTEtMS05NzgzOQ_84c82732-b6dd-4049-8956-b6d623c935a2">100,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfNy0yLTEtMS05NzgzOQ_548c8159-ae59-4ccc-a361-9f920aade76b">37,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfNy00LTEtMS05NzgzOQ_a545694e-297c-42a2-84df-403fd41f1534">45,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfOC0yLTEtMS05NzgzOQ_602a2729-3b32-4534-8ea1-e70378968a00">615,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfOC00LTEtMS05NzgzOQ_63810561-cc02-4ad5-9284-2cd7c6581c5d">739,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfOS0yLTEtMS05NzgzOQ_78c2a10d-915f-4b4c-93b7-977d8f20e47c">77,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfOS00LTEtMS05NzgzOQ_761e4fe7-dee6-42e0-a593-b3660036ed6f">75,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTAtMi0xLTEtOTc4Mzk_efc2f052-06e9-4d85-93fe-b6337d662bdd">25,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTAtNC0xLTEtOTc4Mzk_857b3e3f-58f9-41a0-8522-c15a4aa2d792">26,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTEtMi0xLTEtOTc4Mzk_914c34f5-3071-4609-ba64-7b7a8332b50f">416,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTEtNC0xLTEtOTc4Mzk_00abfe9f-961f-4a19-8f44-1b00379d11f8">409,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTItMi0xLTEtOTc4Mzk_49c7c425-5da4-4647-a614-6d6e2423b822">528,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTItNC0xLTEtOTc4Mzk_a379c9ac-14f8-4736-bd7a-a9a13fa14454">546,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTMtMi0xLTEtOTc4Mzk_c8f23cdc-dce0-477d-9b21-fa2681db8537">35,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTMtNC0xLTEtOTc4Mzk_799695de-a1e7-4168-975f-02af04cc9f7c">44,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTQtMi0xLTEtOTc4Mzk_53d0495d-fdfe-4976-9049-0ff1b075b824"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTQtMi0xLTEtOTc4Mzk_f75cf02e-0bcc-40de-a4e9-b69b6ce4f1d9">500</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTQtNC0xLTEtOTc4Mzk_a4c0eb52-64be-457d-8034-62a0de985814">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTUtMi0xLTEtOTc4Mzk_3f95ee2f-8571-48ff-b0f1-4c68bf221bb4">1,699,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTUtNC0xLTEtOTc4Mzk_d5be142e-80fb-4947-9dc9-33ccecfbc6fc">1,841,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTktMi0xLTEtOTc4Mzk_6facecaa-1e0c-4576-a1a3-450d33074cd9">8,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTktNC0xLTEtOTc4Mzk_85b874bb-73a4-4e6d-9a40-c2467253a596">17,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjAtMi0xLTEtOTc4Mzk_4aba9fea-283d-4024-8b2d-fff1bee3a58b">79,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjAtNC0xLTEtOTc4Mzk_daea1b25-dda8-4fb2-8e1b-e57a8c2ce208">96,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjEtMi0xLTEtOTc4Mzk_2120e3ca-15a5-47a8-afa8-924f3af4ff64">3,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjEtNC0xLTEtOTc4Mzk_006c64a8-9e4b-4037-828b-791137cd7e5d">3,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjItMi0xLTEtOTc4Mzk_69825864-2a9b-42d1-9407-03c23c03f810">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjItNC0xLTEtOTc4Mzk_c85420fc-5eb0-46dd-90cf-5a84b4a8b95c">13,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjMtMi0xLTEtOTc4Mzk_2930cf5a-600e-46b4-bc46-55efb770eaad">91,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjMtNC0xLTEtOTc4Mzk_e3ef670a-7b30-4139-a400-6326d576f9ad">130,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjQtMi0xLTEtOTc4Mzk_17f7b04b-e6b7-4fda-97b6-8ef669d96021">2,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjQtNC0xLTEtOTc4Mzk_f14bb70b-5e0b-4d39-9061-92654e5d0b13">2,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjUtMi0xLTEtOTc4Mzk_21646df0-abe0-4871-b042-2bac6b950061">1,494,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjUtNC0xLTEtOTc4Mzk_c96e87e5-4aad-4937-843e-791600b317f6">1,492,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjYtMi0xLTEtOTc4Mzk_4385028e-8a0f-4273-81b3-73753729ebc9">29,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjYtNC0xLTEtOTc4Mzk_3fbb4482-f2bc-4371-8ad4-5c99cc81498f">30,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjgtMi0xLTEtOTc4Mzk_d55b40ea-eee7-4257-b4ae-ba3e83c1abfc">15,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjgtNC0xLTEtOTc4Mzk_fc4da0d1-f0c5-430f-8a89-a4750022c55e">15,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjktMi0xLTEtMTEyOTQ2_144b413f-22d0-44db-a578-6551bdf8b49e">1,633,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjktNC0xLTEtMTEzMzY1_d466a083-d837-4490-9e6d-7495ad15b697">1,671,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 12)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjktMi0xLTEtOTc4Mzk_875b0dc7-8d88-4c7c-9664-645427026476"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjktNC0xLTEtOTc4Mzk_7bd08627-dccf-41c1-99d3-b9f0e1759944"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjowN2EwYTI5MDRhNzQ0YmNhYjY3MzgyNDllYWNlYmQ4OV8yMg_b0145f05-311a-4a9e-a3e6-1ee979caaf3f"><ix:nonFraction unitRef="usdPerShare" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjowN2EwYTI5MDRhNzQ0YmNhYjY3MzgyNDllYWNlYmQ4OV8yMg_dee80915-7e8a-49cd-8583-441ada17dcc4">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjowN2EwYTI5MDRhNzQ0YmNhYjY3MzgyNDllYWNlYmQ4OV8zNg_454a56fd-0d8a-4f37-8a25-63f3f3564151"><ix:nonFraction unitRef="shares" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjowN2EwYTI5MDRhNzQ0YmNhYjY3MzgyNDllYWNlYmQ4OV8zNg_d71271b7-2ec3-44bf-9e0d-630e431fca89">20,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjowN2EwYTI5MDRhNzQ0YmNhYjY3MzgyNDllYWNlYmQ4OV81OA_11dee7d2-4023-4221-95a6-1ed00c312010"><ix:nonFraction unitRef="shares" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjowN2EwYTI5MDRhNzQ0YmNhYjY3MzgyNDllYWNlYmQ4OV81OA_6ed8ec3d-eff4-4ab0-8cfe-25989b6eb112"><ix:nonFraction unitRef="shares" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjowN2EwYTI5MDRhNzQ0YmNhYjY3MzgyNDllYWNlYmQ4OV81OA_b3f4587e-84c1-4418-9398-ab33dc71c17c"><ix:nonFraction unitRef="shares" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjowN2EwYTI5MDRhNzQ0YmNhYjY3MzgyNDllYWNlYmQ4OV81OA_fa19de7c-efa4-4bf9-9c14-f77fdbf666e3">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;issued and outstanding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtMi0xLTEtOTc4Mzk_2131d2dc-0cf9-416f-94cd-d0f2111d027d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtNC0xLTEtOTc4Mzk_0a71dff4-f9da-46ee-a49a-6295f604d068">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzItMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjo5MDA2MTQxZDg0NjM0MGZjODgyNDE1ODFiNGU0Y2NjNV8xOQ_3927048e-057d-48be-aaf3-70d8bae641fc"><ix:nonFraction unitRef="usdPerShare" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzItMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjo5MDA2MTQxZDg0NjM0MGZjODgyNDE1ODFiNGU0Y2NjNV8xOQ_aa1d73c7-f085-4b1a-9379-97b6ef9ff783">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzItMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjo5MDA2MTQxZDg0NjM0MGZjODgyNDE1ODFiNGU0Y2NjNV8zMw_96907a6c-a19b-4493-be21-26bdad455a77"><ix:nonFraction unitRef="shares" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzItMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjo5MDA2MTQxZDg0NjM0MGZjODgyNDE1ODFiNGU0Y2NjNV8zMw_d78e7f6e-a88b-416c-97aa-c008b1203d1f">300,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzItMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjo5MDA2MTQxZDg0NjM0MGZjODgyNDE1ODFiNGU0Y2NjNV81NQ_9d23cd6d-4da7-4884-9af7-9409edbaf244"><ix:nonFraction unitRef="shares" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzItMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjo5MDA2MTQxZDg0NjM0MGZjODgyNDE1ODFiNGU0Y2NjNV81NQ_c31fcaf3-9ea9-49ec-9f51-735bb0dd55cb">131,662</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iff52cfa922bd4a86a7aed2b93a6ae7b7_I20221231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzItMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjo5MDA2MTQxZDg0NjM0MGZjODgyNDE1ODFiNGU0Y2NjNV82Mg_28033cec-e60d-47b4-9bab-d559ecbf62c6">135,154</ix:nonFraction> shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzItMi0xLTEtOTc4Mzk_435b39c0-1e21-4445-854c-584bc53b9e88">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzItNC0xLTEtOTc4Mzk_b04ee4cb-8690-4027-96ee-9a5d799adaae">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzMtMi0xLTEtOTc4Mzk_056149a7-87f7-4d4e-b3ff-f833beb59979">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzMtNC0xLTEtOTc4Mzk_5903b02c-c76e-419c-8041-4dc254b5dedf">27,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzQtMi0xLTEtOTc4Mzk_77250e63-2ad6-4d29-9e19-8035f61bdf34">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzQtNC0xLTEtOTc4Mzk_7561ebc8-882e-4d2d-9762-31be4ce559ce">922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzUtMi0xLTEtOTc4Mzk_17a2f79d-01c0-48ce-9c50-509e2e895b97">65,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzUtNC0xLTEtOTc4Mzk_58baa6a3-a4fd-4a42-951d-f513e9c3761f">143,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzYtMi0xLTEtOTc4Mzk_63c0b4ff-e40f-4efe-8529-2a9f3185346e">65,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzYtNC0xLTEtOTc4Mzk_27ddceba-d845-4a1c-9a3d-d2cfce69c146">169,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzctMi0xLTEtOTc4Mzk_40102e95-1b75-4f23-b98f-79d958248348">1,699,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzctNC0xLTEtOTc4Mzk_49516b24-b5b2-42cb-8219-0327f75b00ab">1,841,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.734%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02fe07952df9422992b4f26248091821_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMy0yLTEtMS05NzgzOQ_5c1f8fc9-dbbb-4eae-8239-00687adb17ac">99,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aebf4236d314680b3e3c0a72977aef1_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMy00LTEtMS05NzgzOQ_73ed1339-a647-4fcc-a2b5-ff6939b64cdd">69,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff57a29a29d64188b30a100687f1c479_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfNC0yLTEtMS05NzgzOQ_91abc59b-21e6-4586-9184-5c364e3552ee">60,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4ce36d68328465ea06f53e7683604f0_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfNC00LTEtMS05NzgzOQ_a676622e-dac7-48cd-851f-7685f903a430">22,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33911352c8cf4d3a8a5655b090781af3_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfNS0yLTEtMS05NzgzOQ_6a450291-f693-4010-b5cb-dfc938d46c2f">1,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0705f79cf1bd46bcaee4afc74fd6c446_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfNS00LTEtMS05NzgzOQ_3ce52400-7450-4a58-b0ba-9d08869648a0">25,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfNi0yLTEtMS05NzgzOQ_aa48af5d-9116-48c9-ba93-b880329acf3c">162,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfNi00LTEtMS05NzgzOQ_72e9a009-e518-4787-bf5f-1a9a5713ccd9">117,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfOC0yLTEtMS05NzgzOQ_f8a0a52e-f317-4737-afa2-2c99ea9a28d4">35,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfOC00LTEtMS05NzgzOQ_c587b972-55a4-487c-938b-c44b5d83bfc7">15,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfOS0yLTEtMS05NzgzOQ_a87b6df8-93f3-418b-8d0d-37d5173e31d9">17,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfOS00LTEtMS05NzgzOQ_79bcd59a-c745-4177-b597-717c9f9c30d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTAtMi0xLTEtOTc4Mzk_1b1b9b40-4e3b-46d7-9b3e-a1ad0d2f22e8">17,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTAtNC0xLTEtOTc4Mzk_ea98ae8e-baa4-4622-aea5-5f14f9a6cd73">11,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTEtMi0xLTEtOTc4Mzk_e804189b-0542-408a-aa4e-4710f12e6d00">37,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTEtNC0xLTEtOTc4Mzk_75678afa-7390-48bd-a625-4ac7d3784146">13,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTItMi0xLTEtOTc4Mzk_38c018e1-23cf-47f1-b8aa-713f0e3dcc5f">108,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTItNC0xLTEtOTc4Mzk_04b1858f-1c33-4e32-a64b-53665f0f6d4c">41,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTMtMi0xLTEtOTc4Mzk_a6e0fd2c-7ff5-446e-8b91-0af44c2ff497">53,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTMtNC0xLTEtOTc4Mzk_39c60277-024b-481e-837c-b56f92d3ac1b">75,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment and other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTUtMi0xLTEtOTc4Mzk_a943b249-71e8-464c-8ad5-aff471e42d68">2,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTUtNC0xLTEtOTc4Mzk_670c43d7-9d84-4303-ad70-a9066ca57d5e">498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTctMi0xLTEtOTc4Mzk_33dec92f-21f7-4160-87c2-2e2ad85412ab">4,543</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTctNC0xLTEtOTc4Mzk_10bfb479-4285-4c97-9813-19b231d3f124">1,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTgtMi0xLTEtOTc4Mzk_fd65778b-7847-434a-85a4-bcab0db827f4">52,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTgtNC0xLTEtOTc4Mzk_e2601ccb-dda4-4100-ad0a-c811dc212ce1">74,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTktMi0xLTEtOTc4Mzk_e25a52ac-6d0f-4432-993d-ff82c1385986">12,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTktNC0xLTEtOTc4Mzk_d561eee6-8870-47eb-af50-3e27e2d6b67a">14,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjAtMi0xLTEtOTc4Mzk_a05dc2af-f6f2-4211-8a21-4e617c2266e5">39,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjAtNC0xLTEtOTc4Mzk_bf9b4e8e-c062-41f4-afaf-c7a1bffe2e71">60,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjMtMi0xLTEtOTc4Mzk_4e97d3e5-ed1b-4d18-93a5-21f3e27e9685">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjMtNC0xLTEtOTc4Mzk_cf0076d6-441a-42e6-b71e-4b31214efe85">0.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjQtMi0xLTEtOTc4Mzk_c9d1d16d-0b01-4663-bf3a-6ee44ae1db14">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjQtNC0xLTEtOTc4Mzk_d3e970b5-b3de-41e1-995f-c961b08ab46d">0.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjctMi0xLTEtOTc4Mzk_17513582-fc31-4a13-b423-149043fe44d8">135,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjctNC0xLTEtOTc4Mzk_8ceb9378-f96a-49e2-9016-6616c9cc1011">137,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjgtMi0xLTEtOTc4Mzk_19ac4b41-4f8e-4052-8dfe-f1b30fb63010">137,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjgtNC0xLTEtOTc4Mzk_b2901024-1e68-4f96-9800-eba073ed0029">141,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"></td><td style="width:70.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yOC9mcmFnOjNmNWE0ZGZmYTQwMzRjMWRiN2RlOTdhNTliMDQ2ODE4L3RhYmxlOmU2ZTBkYTYwOGRhYTRlMzdhMzlkYWNiMWUzZDFiMmFjL3RhYmxlcmFuZ2U6ZTZlMGRhNjA4ZGFhNGUzN2EzOWRhY2IxZTNkMWIyYWNfMi0yLTEtMS05NzgzOQ_e3aef642-ff83-4de9-9fe7-ff6f76710f3a">39,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yOC9mcmFnOjNmNWE0ZGZmYTQwMzRjMWRiN2RlOTdhNTliMDQ2ODE4L3RhYmxlOmU2ZTBkYTYwOGRhYTRlMzdhMzlkYWNiMWUzZDFiMmFjL3RhYmxlcmFuZ2U6ZTZlMGRhNjA4ZGFhNGUzN2EzOWRhY2IxZTNkMWIyYWNfMi00LTEtMS05NzgzOQ_5661f12f-3bca-47b6-bf65-8c8f864f219b">60,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yOC9mcmFnOjNmNWE0ZGZmYTQwMzRjMWRiN2RlOTdhNTliMDQ2ODE4L3RhYmxlOmU2ZTBkYTYwOGRhYTRlMzdhMzlkYWNiMWUzZDFiMmFjL3RhYmxlcmFuZ2U6ZTZlMGRhNjA4ZGFhNGUzN2EzOWRhY2IxZTNkMWIyYWNfNC0yLTEtMS05NzgzOQ_434dff0e-c28e-49ec-9c75-0b0cec97c371">924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yOC9mcmFnOjNmNWE0ZGZmYTQwMzRjMWRiN2RlOTdhNTliMDQ2ODE4L3RhYmxlOmU2ZTBkYTYwOGRhYTRlMzdhMzlkYWNiMWUzZDFiMmFjL3RhYmxlcmFuZ2U6ZTZlMGRhNjA4ZGFhNGUzN2EzOWRhY2IxZTNkMWIyYWNfNC00LTEtMS05NzgzOQ_e178ecaa-45d4-406f-9180-c0500cbf37ce">2,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yOC9mcmFnOjNmNWE0ZGZmYTQwMzRjMWRiN2RlOTdhNTliMDQ2ODE4L3RhYmxlOmU2ZTBkYTYwOGRhYTRlMzdhMzlkYWNiMWUzZDFiMmFjL3RhYmxlcmFuZ2U6ZTZlMGRhNjA4ZGFhNGUzN2EzOWRhY2IxZTNkMWIyYWNfNS0yLTEtMS05NzgzOQ_a852e564-132c-4cb9-b149-2a6c8c2243f6">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yOC9mcmFnOjNmNWE0ZGZmYTQwMzRjMWRiN2RlOTdhNTliMDQ2ODE4L3RhYmxlOmU2ZTBkYTYwOGRhYTRlMzdhMzlkYWNiMWUzZDFiMmFjL3RhYmxlcmFuZ2U6ZTZlMGRhNjA4ZGFhNGUzN2EzOWRhY2IxZTNkMWIyYWNfNS00LTEtMS05NzgzOQ_266fb7db-38e6-44bd-916c-48f976f48246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yOC9mcmFnOjNmNWE0ZGZmYTQwMzRjMWRiN2RlOTdhNTliMDQ2ODE4L3RhYmxlOmU2ZTBkYTYwOGRhYTRlMzdhMzlkYWNiMWUzZDFiMmFjL3RhYmxlcmFuZ2U6ZTZlMGRhNjA4ZGFhNGUzN2EzOWRhY2IxZTNkMWIyYWNfNy0yLTEtMS05NzgzOQ_23ababfd-a8d6-4249-ab29-ae7942af5e40">40,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yOC9mcmFnOjNmNWE0ZGZmYTQwMzRjMWRiN2RlOTdhNTliMDQ2ODE4L3RhYmxlOmU2ZTBkYTYwOGRhYTRlMzdhMzlkYWNiMWUzZDFiMmFjL3RhYmxlcmFuZ2U6ZTZlMGRhNjA4ZGFhNGUzN2EzOWRhY2IxZTNkMWIyYWNfNy00LTEtMS05NzgzOQ_db088e26-87db-41f7-88f1-1fbb75b8962f">57,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:77.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.328%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNC0yLTEtMS05NzgzOQ_c8721cb6-1ba9-4832-8a51-077773ca09fb">39,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNC00LTEtMS05NzgzOQ_6a2a34c4-3988-435e-845f-bd655584d211">60,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNi0yLTEtMS05NzgzOQ_a0d7a229-178f-4357-a787-b8ea1eb03800">7,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNi00LTEtMS05NzgzOQ_47fa9571-6d3d-40d3-bc3c-2f87d7cc0eb3">4,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNy0yLTEtMS05NzgzOQ_379e6773-df6c-4df6-8f8c-5fb4bd141b07">2,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNy00LTEtMS05NzgzOQ_d6705206-4c48-48ec-aafe-b9964b199277">778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfOC0yLTEtMS05NzgzOQ_09489f4e-f2dd-4ab4-89c3-0e2397f759fc">17,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfOC00LTEtMS05NzgzOQ_b76da42e-f9b5-49ec-a138-e794350ada50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfOS0yLTEtMS05NzgzOQ_ef22c717-d3f4-474c-b78c-97a4d4d09067">1,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfOS00LTEtMS05NzgzOQ_b3e96c50-06e8-4582-b193-d2e56913c380">971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of (premium) discounts on marketable securities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMTEtMi0xLTEtOTc4Mzk_e2612630-efc3-4f53-82b4-0b485fabae28">917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMTEtNC0xLTEtOTc4Mzk_466765f5-f5f4-43cf-a7d2-01fdb897f4b3">541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMTMtMi0xLTEtOTc4Mzk_fbb8d738-1d60-4134-9063-c25057281688">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMTMtNC0xLTEtOTc4Mzk_4bd95f78-58f3-4fc4-bfac-c3de734965d3">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of deferred revenue </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMTUtMi0xLTEtOTc4Mzk_02408076-8396-40c4-89cf-100c0b0163e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMTUtNC0xLTEtOTc4Mzk_fc4f5ba4-21ed-4bb4-9967-f811c0c50d17">499</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease payments recognized (deferred)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" sign="-" name="halo:DeferredRentPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMTYtMi0xLTEtOTc4Mzk_6ac22dd6-30c0-4efa-abd3-dd80f88658f4">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="halo:DeferredRentPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMTYtNC0xLTEtOTc4Mzk_3eac5228-89a0-406e-a4c2-568d671a6b29">183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjAtMi0xLTEtOTc4Mzk_9d25a356-46d5-4ff8-b152-9d1510514487">3,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjAtNC0xLTEtOTc4Mzk_fb5e3cd6-a016-4bde-bcf7-cad8d47e8e92">12,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net and other contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjMtMi0xLTEtOTc4Mzk_b669099d-a95e-4cac-86ac-8c186b5930f8">36,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjMtNC0xLTEtOTc4Mzk_ac02a855-447c-41cd-92d6-ce5430581d38">22,787</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjQtMi0xLTEtOTc4Mzk_a4de22dd-fba9-4807-8d82-6e813a701337">7,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjQtNC0xLTEtOTc4Mzk_10d5d3d5-4630-454f-b196-c41bca3f9001">6,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjUtMi0xLTEtOTc4Mzk_f10fb532-0a41-4165-9c59-60bbb32fb33e">8,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjUtNC0xLTEtOTc4Mzk_f173f171-2516-438a-b93a-264df7aeb3a8">9,168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjYtMi0xLTEtOTc4Mzk_7a734486-1bdf-4f57-9eab-e6078c2608ef">24,006</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjYtNC0xLTEtOTc4Mzk_f23e9817-0a0b-4891-a83b-7354208afced">6,010</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjctMi0xLTEtOTc4Mzk_b638fcf3-a24f-4eaa-8d5a-382d172a940c">86,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjctNC0xLTEtOTc4Mzk_4fc447dc-8c53-4dfb-b526-751a25603c43">47,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjktMi0xLTEtOTc4Mzk_671f37df-238b-466e-8b94-61e3d279cf54">109,919</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjktNC0xLTEtOTc4Mzk_3528d7ae-f3ef-47a2-a0b2-9e1d1f800a4c">184,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMzAtMi0xLTEtOTc4Mzk_7fcb8226-a550-4279-92f8-94af5fb1c928">61,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMzAtNC0xLTEtOTc4Mzk_fcd8ea81-3bc1-4f16-9fbf-50d37cc4463d">136,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMzItMi0xLTEtOTc4Mzk_2491f04a-3dd2-4292-bc83-f93fb4f92e94">11,377</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMzItNC0xLTEtOTc4Mzk_d61ef9c6-f7ca-4760-b873-b690ed6aeb79">490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMzQtMi0xLTEtOTc4Mzk_fa45a0a5-0c72-4e06-9a5a-3a1ccb8ed082">60,162</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMzQtNC0xLTEtOTc4Mzk_79b524ee-7b87-4fcd-8810-c2fd2e3894d0">49,305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of 2024 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDItMi0xLTEtOTc4Mzk_646d9097-ad5a-4514-8f3d-929600068872">13,483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDItNC0xLTEtOTc4Mzk_3aa5d605-da9f-4d46-9739-1e1df75a30a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDYtMi0xLTEtOTc4Mzk_4b3361a9-d3a1-4322-bd5a-c86ff2ed833d">150,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDYtNC0xLTEtOTc4Mzk_e52731d4-8c8b-4ffa-af1f-a774c9bbaa46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" sign="-" name="halo:ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDctMi0xLTEtOTc4Mzk_3b531ee8-4660-4cac-b3de-0179b945ffaf">1,048</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="halo:ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDctNC0xLTEtOTc4Mzk_3abd0211-788c-4f7d-a157-93556dbbadb7">624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDgtMi0xLTEtOTc4Mzk_541a2118-811f-451c-bce3-43d7456e981f">164,614</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDgtNC0xLTEtOTc4Mzk_22be2780-9c53-4e24-aa93-f79bd337db02">624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDktMi0xLTEtOTc4Mzk_e036c677-dd5a-47cb-a8d4-ff032a9706b0">137,812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDktNC0xLTEtOTc4Mzk_429d6185-1b29-4ad2-95a9-0dfb7707df71">884</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTAtMi0xLTEtOTc4Mzk_51e1b28a-4ca0-433b-8156-e2ffa42f1c3f">234,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b2c4a20e00545ee9fa2fa2f54922dfc_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTAtNC0xLTEtOTc4Mzk_84b38600-24d3-4331-a753-227877954e92">119,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTEtMi0xLTEtOTc4Mzk_6fac3701-358c-487a-b8a3-a856046c4ff4">96,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fa2dc7b7b064cb99cda5c7d5980ae6b_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTEtNC0xLTEtOTc4Mzk_441b6964-cd33-4824-ad58-986f60bf2f3d">118,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts accrued for purchases of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTQtMi0xLTEtOTc4Mzk_edf87ca4-02d1-4f67-a5b4-bf72394d1405">390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTQtNC0xLTEtOTc4Mzk_b630f69b-11c0-45ca-a269-14908701d997">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTUtMi0xLTEtOTc4Mzk_9d1643fe-05e5-4e1d-b526-613965bc1887">406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTUtNC0xLTEtOTc4Mzk_d53f293d-c4e8-4313-a3e7-37210824aa09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued for conversion of 2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTgtMi0xLTEtOTc4Mzk_5c5aa0e5-9df6-4cf3-8530-1063ad2c0eb1">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTgtNC0xLTEtOTc4Mzk_41feedd4-9089-4df2-95c4-0dbf5642e17a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_34"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income/(Loss)</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained Earnings </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">BALANCE AS OF DECEMBER 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff52cfa922bd4a86a7aed2b93a6ae7b7_I20221231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMy0yLTEtMS05NzgzOQ_c41ce06e-e034-4bf3-9bd9-ad5fc8e16ed2">135,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff52cfa922bd4a86a7aed2b93a6ae7b7_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMy00LTEtMS05NzgzOQ_276af887-b45e-4bdd-88e2-b0c90326e570">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b299dba797b49119fe3c2869cbaf39c_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMy02LTEtMS05NzgzOQ_343e8416-9a37-4ee1-9f4e-31c85a7af780">27,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9905a464af014a85bc6f52a18e89e039_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMy04LTEtMS05NzgzOQ_8f1ff4e7-45ad-4412-b977-46a9c78428da">922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0766222d7af490eb043ec6ffb786970_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMy0xMC0xLTEtOTc4Mzk_e04e9c51-fdf5-4a9e-a7f3-61b74ec44de7">143,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMy0xMi0xLTEtOTc4Mzk_df0d1275-b538-4bbe-8008-d303ee4ea6be">169,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f658ce1d6a2456c8372b0a418d493e9_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNS02LTEtMS05NzgzOQ_b04247d7-7176-49ce-b83f-ce25764b493a">7,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNS0xMi0xLTEtOTc4Mzk_808c0e4d-acda-446a-b3ce-f86aa4b5261a">7,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock for the conversion of 2024 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a6aa3f2f5da44ffbb88bbeeb79b6e56_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNi0yLTEtMS05NzgzOQ_2f09ee45-6c97-45d6-849d-9d73d8995b43">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a6aa3f2f5da44ffbb88bbeeb79b6e56_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNi00LTEtMS05NzgzOQ_082c2663-8b66-41a9-b878-0aeee1545d5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f658ce1d6a2456c8372b0a418d493e9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNi02LTEtMS05NzgzOQ_bb56360f-f3e2-4d7e-b82c-178d4e8066df">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNi0xMi0xLTEtOTc4Mzk_153d07df-b7bb-4f70-87be-ee0bd97416f4">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock and performance stock units, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a6aa3f2f5da44ffbb88bbeeb79b6e56_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNy0yLTEtMS05NzgzOQ_0fca664d-5da4-44db-a893-ef80922367dd">384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a6aa3f2f5da44ffbb88bbeeb79b6e56_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNy00LTEtMS05NzgzOQ_cd1bc484-bac8-434c-ad37-23bc3de53b0c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f658ce1d6a2456c8372b0a418d493e9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNy02LTEtMS05NzgzOQ_f609d7af-c3ef-455e-a478-d46d9beff896">1,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNy0xMi0xLTEtOTc4Mzk_a00f820a-7b3e-4a4a-9b3f-de330608c514">1,048</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Repurchase of  common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2a6aa3f2f5da44ffbb88bbeeb79b6e56_D20230101-20230331" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTAtMi0xLTEtOTc4Mzk_71c25089-346b-4016-9c32-0f690231415a">4,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a6aa3f2f5da44ffbb88bbeeb79b6e56_D20230101-20230331" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTAtNC0xLTEtOTc4Mzk_d7f32c65-5031-4f51-b491-1780178fa7bf">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f658ce1d6a2456c8372b0a418d493e9_D20230101-20230331" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTAtNi0xLTEtOTc4Mzk_520d9753-ba05-413f-bcc8-b4d730a22847">34,159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84c942c19de040e2bca58d2705871d43_D20230101-20230331" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTAtMTAtMS0xLTExMDcxNw_75c58b92-a3bb-44bb-9fac-010dae983f42">117,138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTAtMTItMS0xLTk3ODM5_1dc00844-35b6-417c-bd35-aa49d83c5ccf">151,301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b6265ecd0a45ccb0aab3916e41a95c_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTEtOC0xLTEtOTc4Mzk_b35cedbd-1bed-4639-9218-f25be1354021">946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTEtMTItMS0xLTk3ODM5_5ab80d27-bdd1-4a10-abe2-9c0ee74bca72">946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c942c19de040e2bca58d2705871d43_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTItMTAtMS0xLTk3ODM5_11ca4ab1-0ccd-4abb-80d0-c21e99904df2">39,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTItMTItMS0xLTk3ODM5_93a732b3-a49e-4049-9527-6775eafa3288">39,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">BALANCE AS OF MARCH 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5998c0ad8cb74ba3b06cbd6c2a277c24_I20230331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTMtMi0xLTEtOTc4Mzk_277fb509-deda-43f4-a18e-a0b8c24a44a9">131,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5998c0ad8cb74ba3b06cbd6c2a277c24_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTMtNC0xLTEtOTc4Mzk_c320e5cc-a3b9-435d-808e-a9ac5288c3ef">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0432ad1ce41f4fc3bbc7778eedfc105d_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTMtNi0xLTEtOTc4Mzk_0a781828-b620-4229-bd6b-69ce030ff9e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i021aeb69fccf46cb9a81f74872450bc2_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTMtOC0xLTEtOTc4Mzk_2054b948-1e94-4f4a-b31f-5b8cec02b858">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32b531446d00413c935a571e48773de0_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTMtMTAtMS0xLTk3ODM5_b175bdc8-98fa-4ad7-aa1f-b68a5b7ac649">65,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTMtMTItMS0xLTk3ODM5_2bd0c0c4-8530-45c1-868b-6f8503c22ff6">65,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">BALANCE AS OF DECEMBER 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38e034be49cf4c1387b7a092a63f997c_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzQtMi0xLTEtOTc4Mzk_42776422-e6e9-48be-aad2-9a5afdb9d960">137,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e034be49cf4c1387b7a092a63f997c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzQtNC0xLTEtOTc4Mzk_09fc1c82-43bf-492c-aefa-36748d956da8">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f57fa1e6ff47c8a4b0c2f4270f8890_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzQtNi0xLTEtOTc4Mzk_208e2fd2-7302-4feb-b743-09faba495b7b">256,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f33835107a94cc08d1aa2cd3aad8d31_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzQtOC0xLTEtOTc4Mzk_9b3bd26f-72fb-4ec8-a8d4-05fafd69040c">620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8890ea7491a742b486450ebcf13b21de_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzQtMTAtMS0xLTk3ODM5_88cad2a0-9dcb-4389-81b4-14509f5d7a6a">58,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b2c4a20e00545ee9fa2fa2f54922dfc_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzQtMTItMS0xLTk3ODM5_82606457-bba3-4472-91cf-aede5639cea7">196,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89afe2a91d940bfadc08e4c9ffc41c6_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzYtNi0xLTEtOTc4Mzk_d5efefc6-f078-45f8-bdb3-d845cc239acc">4,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzYtMTItMS0xLTk3ODM5_b52336d4-b5f5-4f81-9e3b-49cc335d6e2d">4,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6708ca65ef9487b8ff8abff52cfb4b9_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzgtMi0xLTEtOTc4Mzk_e1ddcb4e-6c91-4170-a685-c524e5c4945b">390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6708ca65ef9487b8ff8abff52cfb4b9_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzgtNC0xLTEtOTc4Mzk_8d5da50e-6814-4c84-b454-871cefcaaa20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89afe2a91d940bfadc08e4c9ffc41c6_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzgtNi0xLTEtOTc4Mzk_3f809e1b-738a-4298-a322-66065adc27e3">624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzgtMTItMS0xLTk3ODM5_9fdfeca3-9e2c-4704-8f76-410bcc117de4">624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5a21714774e40ffb9b1684869c5a218_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDItOC0xLTEtOTc4Mzk_48907bff-2287-4eec-acbe-66a68eef167b">2,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDItMTItMS0xLTk3ODM5_8fc65890-fb88-4ce6-a8af-8352f8b8f230">2,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a2a1340b5245dea5832883a6cd93ae_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDMtMTAtMS0xLTk3ODM5_4418e13e-a35a-49ed-9fa3-95d8a642be0a">60,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDMtMTItMS0xLTk3ODM5_0c173f22-971f-4ee2-81b0-28df0201fcd7">60,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">BALANCE AS OF MARCH 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ac0a4f26d31423b9dc549a8198fd81b_I20220331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDQtMi0xLTEtOTc4Mzk_4211be5a-3c1f-486e-8bcd-33b17a0ab6ed">137,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac0a4f26d31423b9dc549a8198fd81b_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDQtNC0xLTEtOTc4Mzk_6a204307-cbab-453f-a016-decf07d39239">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61fd7db612a2481293d23ce396675ed6_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDQtNi0xLTEtOTc4Mzk_1e90fb34-5df5-4310-9b12-d7f2d3d56e3a">261,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14262341c01e414e9cd5feb0ef8cd2dd_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDQtOC0xLTEtOTc4Mzk_09357979-54f1-4bf0-adde-cb3e0d341646">2,791</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i986a9c4e8321407fabcf25854ef0b832_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDQtMTAtMS0xLTk3ODM5_4fc13640-58c7-46a7-8d88-3f4553b0d6ea">1,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fa2dc7b7b064cb99cda5c7d5980ae6b_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDQtMTItMS0xLTk3ODM5_b790b32c-c165-4878-bd06-44b9b2e42038">260,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i2807c465c47449f58323217d8928fdb2_40"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80MC9mcmFnOjU2ZDNkMGZkMjJlYTRhMWNhMDI0N2I1NTRjMmVhYjcyL3RleHRyZWdpb246NTZkM2QwZmQyMmVhNGExY2EwMjQ3YjU1NGMyZWFiNzJfNTAyOQ_4bc0d48b-57ee-454f-9595-62def5cc38e4" continuedAt="id8d95623a09345109b3ad433712ec3bf" escape="true">Organization and Business </ix:nonNumeric></span></div><ix:continuation id="id8d95623a09345109b3ad433712ec3bf" continuedAt="i0a12656b9733408ba980fd9fac4e7a61"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving the patient experience and potentially outcomes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary enzyme, rHuPH20, is used to facilitate the subcutaneous (&#8220;SC&#8221;) delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology (&#8220;ENHANZE&#8221;) with the partners&#8217; proprietary compounds. We also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first commercially approved product Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recombinant (&#8220;Hylenex&#8221;), and our ENHANZE partners&#8217; approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in Hylenex that works by breaking down hyaluronan (&#8220;HA&#8221;), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the SC space. This temporarily reduces the barrier to bulk fluid flow allowing for improved and more rapid SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as ENHANZE. We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (&#8220;IV&#8221;) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing typically required for IV administration, extend the dosing interval for drugs that are already administered subcutaneously and potentially allow for lower rates of infusion related reactions.&#160;ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient or caregiver. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of the proprietary IV drug.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&#8220;Roche&#8221;), Takeda Pharmaceuticals International AG and Baxalta US Inc. (&#8220;Takeda&#8221;), Pfizer Inc. (&#8220;Pfizer&#8221;), Janssen Biotech, Inc. (&#8220;Janssen&#8221;), AbbVie, Inc. (&#8220;AbbVie&#8221;), Eli Lilly and Company (&#8220;Lilly&#8221;), Bristol-Myers Squibb Company (&#8220;BMS&#8221;), Alexion Pharma International Operations Unlimited Company (an indirect wholly owned subsidiary of AstraZeneca PLC) (&#8220;Alexion&#8221;), argenx BVBA (&#8220;argenx&#8221;), Horizon Therapeutics plc. (&#8220;Horizon&#8221;), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (&#8220;ViiV&#8221;) and Chugai Pharmaceutical Co., Ltd (&#8220;Chugai&#8221;). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE. We currently receive royalties from <ix:nonFraction unitRef="collaborator" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="INF" name="halo:RoyaltiesReceivedNumberOfCollaborators" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80MC9mcmFnOjU2ZDNkMGZkMjJlYTRhMWNhMDI0N2I1NTRjMmVhYjcyL3RleHRyZWdpb246NTZkM2QwZmQyMmVhNGExY2EwMjQ3YjU1NGMyZWFiNzJfMzM2OQ_060827fa-a2b9-4b79-8a74-b2fe52b14930">three</ix:nonFraction> of these collaborations, including royalties from sales of <ix:nonFraction unitRef="product" contextRef="i0e6992830095415c90ee103cb5429d20_D20230101-20230331" decimals="INF" name="halo:RoyaltiesReceivedNumberOfProductsSold" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80MC9mcmFnOjU2ZDNkMGZkMjJlYTRhMWNhMDI0N2I1NTRjMmVhYjcyL3RleHRyZWdpb246NTZkM2QwZmQyMmVhNGExY2EwMjQ3YjU1NGMyZWFiNzJfMzQzMQ_257b9a8a-6c72-4d16-80c6-11fd98cd7864">one</ix:nonFraction> product from the Takeda collaboration, <ix:nonFraction unitRef="product" contextRef="i7137d05d5f4045da8aacbc2092346351_D20230101-20230331" decimals="INF" name="halo:RoyaltiesReceivedNumberOfProductsSold" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80MC9mcmFnOjU2ZDNkMGZkMjJlYTRhMWNhMDI0N2I1NTRjMmVhYjcyL3RleHRyZWdpb246NTZkM2QwZmQyMmVhNGExY2EwMjQ3YjU1NGMyZWFiNzJfMzQ3Mw_f79227fe-2a5b-4fa8-a297-fadc5c03e48a">three</ix:nonFraction> products from the Roche collaboration and <ix:nonFraction unitRef="product" contextRef="ia457f78bd8504520987402033058bd04_D20230101-20230331" decimals="INF" name="halo:RoyaltiesReceivedNumberOfProductsSold" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80MC9mcmFnOjU2ZDNkMGZkMjJlYTRhMWNhMDI0N2I1NTRjMmVhYjcyL3RleHRyZWdpb246NTZkM2QwZmQyMmVhNGExY2EwMjQ3YjU1NGMyZWFiNzJfMzUxOA_fc5f38ef-393b-45c1-8113-2ede1b0f8064">one</ix:nonFraction> product from the Janssen collaboration. Future potential revenues from ENHANZE collaborations and from the sales and/or royalties of our approved products will depend on the ability of our partners, in some areas supported by Halozyme to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our commercial portfolio of proprietary products also includes XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NOCDURNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have commercialized auto-injector products with several pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (&#8220;Teva&#8221;), Covis Group S.a.r.l. (&#8220;Covis&#8221;) and Otter Pharmaceuticals, LLC (&#8220;Otter&#8221;). We have development programs including auto-injectors with Idorsia Pharmaceuticals Ltd. (&#8220;Idorsia&#8221;) and Pfizer.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0a12656b9733408ba980fd9fac4e7a61">Except where specifically noted or the context otherwise requires, references to &#8220;Halozyme,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; in these notes to the condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and each of its directly and indirectly wholly owned subsidiaries</ix:continuation> as disclosed in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU4MTA_d77363f4-90a5-455e-ae01-cb518c816dca" continuedAt="i8a705172f6c645a8b24c71b21b922975" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i8a705172f6c645a8b24c71b21b922975" continuedAt="i9e13de2249df448bb6dad18d2e3efe18"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU3NzA_e5333fc2-9447-4032-ae7a-ae9208b9d18d" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements have been prepared for purposes of and in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on February&#160;21, 2023. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU3NTI_325b5c42-6db3-4baa-b8da-e6199907fe12" escape="true">The accompanying interim unaudited condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., and Antares Pharma, Inc.&#8217;s wholly owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated.</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU3NDk_180153c3-cf88-45b2-abfe-29e704d04f14" continuedAt="i6e80d651c0bf4cf3be20123560eb554c" escape="true">Use of Estimates</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6e80d651c0bf4cf3be20123560eb554c">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in our interim unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that we believe to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from our estimates</ix:continuation>.</span></div><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU4NzA_ca379771-3aae-4f5c-a965-89c65bfee251" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within 90 days or less from the date of purchase. As of March&#160;31, 2023, our cash and cash equivalents consisted of money market funds, bank certificate of deposits and demand deposits at commercial banks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are investments with original maturities of more than 90 days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#8217;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders&#8217; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the interim unaudited condensed consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in the interim unaudited condensed consolidated statements of income.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the lease terms of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. As of March&#160;31, 2023 and December&#160;31, 2022, restricted cash of $<ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDIxMQ_53d0495d-fdfe-4976-9049-0ff1b075b824"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDIxMQ_f75cf02e-0bcc-40de-a4e9-b69b6ce4f1d9">0.5</ix:nonFraction></ix:nonFraction> million was pledged as collateral for the letters of credit.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU4NzU_25c47da6-c574-4c15-b9ee-0f909c0d62dd" continuedAt="i17c60d9cf5aa4ae0bb6af2b9e686e495" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </span></div></ix:nonNumeric></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9e13de2249df448bb6dad18d2e3efe18" continuedAt="i7832ea2d5848432bb9225abb93168743"><ix:continuation id="i17c60d9cf5aa4ae0bb6af2b9e686e495"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses, long-term debt and a contingent liability. Fair value estimates of these instruments are made at a specific point in time based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore, cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</span></div></ix:continuation><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU4MTU_c2a1c061-acd7-4de2-a20b-d64e073e2851" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU4MDI_62cca281-2bf7-4c7e-9f72-182966dfd08f" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from <ix:nonNumeric contextRef="i26d023fcab96411da642d788b3f4972f_I20230331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNzMwOA_9d171877-952c-4721-b408-cc5b8ca8f96a">3</ix:nonNumeric> years to <ix:nonNumeric contextRef="i2c07e926241e4fcea8142ef7b8204548_I20230331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNzMxNA_7042dd3c-b33b-4a5c-9cff-ec6d7583c712">12</ix:nonNumeric> years. We determine if an arrangement contains a lease at inception. Right of use (&#8220;ROU&#8221;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option. Short-term leases with an initial term of 12 months or less are not recorded on the condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU4MzQ_a533e6c1-c3ba-47a6-859e-9dc3b663e982" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs incurred to complete a business combination, such as legal and other professional fees, are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the condensed consolidated statements of income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="halo:GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU3NTA_a5574ab0-c15f-4ad0-9160-4a896a005f87" continuedAt="ifee82dd6edb4405ba201e98686bfa467" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Asset</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and in-process research and development (&#8220;IPR&amp;D&#8221;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D </span></div></ix:nonNumeric></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7832ea2d5848432bb9225abb93168743" continuedAt="ida84e8a1919349128f485032ae111af5"><ix:continuation id="ifee82dd6edb4405ba201e98686bfa467"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets with finite useful lives are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div></ix:continuation><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU3Mjk_75e8ade7-13ed-4e25-8818-decce92eb8a8" continuedAt="i886928aaa43947b3bed67a7fde2d4fed" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE and Device Royalties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. In general, when there are no valid claims of a specified patent developed under the collaboration covering the product in a given country, the royalty rate is reduced for those sales in that country upon the expiration of our patents covering rHuPH20. Janssen&#8217;s patents covering DARZALEX SC do not impact the timing for this royalty reduction. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="halo:RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfMTYzMzA_00ca7c3a-0eca-4abe-9c40-3bc1b5674db2">90</ix:nonNumeric> days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted will become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div></ix:nonNumeric></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ida84e8a1919349128f485032ae111af5" continuedAt="i5c73244fc06a431fb0d820b667f6a8ba"><ix:continuation id="i886928aaa43947b3bed67a7fde2d4fed" continuedAt="i394277b61b614e28a373daa3007d61c2"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also earn royalties in connection with several of our licenses granted under license and development arrangements with our device partners. These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#8217; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days after the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue under ENHANZE and Device Collaborative Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement generally require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner&#8217;s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally collect an upfront license payment from collaboration partners, and are also entitled to receive event-based payments subject to collaboration partners&#8217; achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for respective consideration. Under these collaborative agreements, our partners lead development of assets, and we do not share in significant financial risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to U.S. GAAP. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under all of our ENHANZE collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs. Each of the licenses grants the partners rights to use our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, we provide indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#8217; representations and are not obligations to provide goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our partners, which represent separate contracts. In addition to our licenses, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or (&#8220;SSP&#8221;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target </span></div></ix:continuation></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5c73244fc06a431fb0d820b667f6a8ba" continuedAt="i615ebf54fce24a5c98ae006a74b7ac72"><ix:continuation id="i394277b61b614e28a373daa3007d61c2" continuedAt="ie2a9fef8866d47fa8acdb66a1e5b1e85"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g., dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#8217;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of Investigational New Drug (&#8220;IND&#8221;) or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#8217;s commitment of resources to the program. We do not include any amounts subject to uncertainties in the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using an income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time, we have already transferred the related license to the partner. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Device License, Development and Supply Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several license, development and supply arrangements with pharmaceutical partners, under which we grant a license to our device technology and provide research and development services that often involve multiple performance obligations and highly-customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception of the contract and allocate consideration to each performance obligation based on relative SSP, which is generally determined based on the expected cost plus mark-up. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and we have a present right to payment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction </span></div></ix:continuation></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i615ebf54fce24a5c98ae006a74b7ac72" continuedAt="icfeb3424e8f649ffadfaaf6697616e54"><ix:continuation id="ie2a9fef8866d47fa8acdb66a1e5b1e85" continuedAt="ie2390c83ded6466a8dcc60e87e577a95"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in the condensed consolidated balance sheets and recognized as revenue in the condensed consolidated statements of income when the associated performance obligations have been satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and milestones received in exchange for the grant of a license to our functional intellectual property, such as patented technology and know-how in connection with a partnered development arrangement, are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal of revenue will not occur when the associated uncertainty is resolved.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion on our collaborative arrangements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proprietary Product Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recombinant</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (&#8220;GPOs&#8221;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in accrued liabilities and net of accounts receivable in the condensed consolidated balance sheet. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance. </span></div></ix:continuation></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icfeb3424e8f649ffadfaaf6697616e54" continuedAt="i3e0ec34def9848ae96bdcd85c0ad0dae"><ix:continuation id="ie2390c83ded6466a8dcc60e87e577a95" continuedAt="ifc4b48855f4a4ac2bdd63f59d823fc8d"><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Proprietary Product Sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial portfolio of proprietary products includes XYOSTED, TLANDO and NOCDURNA, which we sell primarily to wholesale and specialty distributors. Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued liabilities and net of accounts receivable in the condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnered Product Sales</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bulk rHuPH20</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Devices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the exclusive supplier of  OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to Otter. Because this product is custom manufactured with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in the condensed consolidated balance sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit-sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal of revenue based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our condensed consolidated statements of income, we report the upfront payments, event-based development and regulatory milestones and sales milestones as revenues under collaborative agreements. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from partners as a separate line in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of our proprietary and partnered products are included in product sales, net in our condensed consolidated statements of income.</span></div></ix:continuation></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3e0ec34def9848ae96bdcd85c0ad0dae" continuedAt="i2722bc7476d54e83a0d7d75f7ef72c13"><ix:continuation id="ifc4b48855f4a4ac2bdd63f59d823fc8d"><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the footnotes to our condensed consolidated financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and device licensing, and development revenues), and additionally, by type of payment stream received under collaborative agreements (upfront license and target nomination fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.</span></div></ix:continuation><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU4NjE_c505a0c1-d6c4-469c-adb4-d2bd89e39f6a" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include salaries and benefits, facilities and other overhead expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU4Nzg_69aface7-dc7c-469a-9f5a-0da4fc31f00f" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record compensation expense associated with stock options, restricted stock units (&#8220;RSUs&#8221;), performance stock units (&#8220;PSUs&#8221;) and shares issued under our employee stock purchase plan (&#8220;ESPP&#8221;) in accordance with the authoritative guidance for share-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU3NDA_f6f37319-2f9e-4d6c-9a29-64b8bf2bfa2b" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#8220;DTA&#8221;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized. We recorded a provision for income taxes of $<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNTQ5NzU1ODY4OTk1_40725f8a-565c-4b5e-948c-6c8f0154de42">12.6</ix:nonFraction>&#160;million using an effective tax rate of <ix:nonFraction unitRef="number" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDQ0MzI_6bbbf637-7319-4869-ae5a-c4231402752d">24.1</ix:nonFraction>% for the three months ended March&#160;31, 2023. The difference between our effective tax rate and the U.S. federal statutory rate of 21% is primarily due to tax benefits on Foreign Derived Intangible Income Deduction (&#8220;FDII&#8221;), tax detriments on 162(m) and other share-based compensation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU4MDQ_7cb5c240-9153-4129-a7fb-a404cec0716b" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate our business in <ix:nonFraction unitRef="segment" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDQ5NjA_786a9d62-e81d-49f1-a8d4-bae1443cbf7b">one</ix:nonFraction> operating segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties, and (ii)&#160;product sales of proprietary and partnered products. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.</span></div></ix:nonNumeric></ix:continuation><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:24.75pt"><span><br/></span></div><ix:continuation id="i2722bc7476d54e83a0d7d75f7ef72c13"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU3Nzk_8a7d562b-e078-4b97-8741-0b2bf5162625" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption and Pending Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no relevant recently issued accounting pronouncements that would materially impact our condensed consolidated financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80OS9mcmFnOmEyY2RjNTI3ZGVjZDRiNWZiNGY0NTA3MjhhNGMyY2M2L3RleHRyZWdpb246YTJjZGM1MjdkZWNkNGI1ZmI0ZjQ1MDcyOGE0YzJjYzZfODA5Mw_12bdd894-1a57-40c4-8326-b697164d9858" continuedAt="ic7d909a166c745f3b14711899d3b26a3" escape="true">Business Combination</ix:nonNumeric></span></div><ix:continuation id="ic7d909a166c745f3b14711899d3b26a3"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, we acquired all outstanding equity interests of Antares Pharma, Inc. according to the terms and conditions of the Agreement and Plan of Merger, dated as of April 12, 2022 (the &#8220;Merger Agreement&#8221;). Antares is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. We acquired Antares as a part of our strategy to expand as a drug delivery company and include specialty products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase consideration of Antares was $<ix:nonFraction unitRef="usd" contextRef="i278958ca21434e13ac5e9b20db531704_D20220524-20220524" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80OS9mcmFnOmEyY2RjNTI3ZGVjZDRiNWZiNGY0NTA3MjhhNGMyY2M2L3RleHRyZWdpb246YTJjZGM1MjdkZWNkNGI1ZmI0ZjQ1MDcyOGE0YzJjYzZfNjEz_e46cbb6e-58b5-4646-b661-0fbe142d77bb">1,045.7</ix:nonFraction>&#160;million. Each share of Antares common stock issued and outstanding was converted into the right to receive $<ix:nonFraction unitRef="usdPerShare" contextRef="i278958ca21434e13ac5e9b20db531704_D20220524-20220524" decimals="2" name="halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80OS9mcmFnOmEyY2RjNTI3ZGVjZDRiNWZiNGY0NTA3MjhhNGMyY2M2L3RleHRyZWdpb246YTJjZGM1MjdkZWNkNGI1ZmI0ZjQ1MDcyOGE0YzJjYzZfNzE1_8ca8206f-a13b-4ef7-853a-e2117088f68d">5.60</ix:nonFraction> in cash without interest, less any applicable withholding taxes (&#8220;Merger Consideration&#8221;). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Antares has been accounted for using the acquisition method of accounting in accordance with ASC 805, Business Combinations, with Halozyme treated as the accounting acquirer, which requires, among other things, that the assets acquired and liabilities assumed be recognized at their fair value on the acquisition date. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our results of operations. We are still finalizing the liabilities assumed related to accrued expenses which are subject to change as additional information is received to complete our analysis. <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80OS9mcmFnOmEyY2RjNTI3ZGVjZDRiNWZiNGY0NTA3MjhhNGMyY2M2L3RleHRyZWdpb246YTJjZGM1MjdkZWNkNGI1ZmI0ZjQ1MDcyOGE0YzJjYzZfODA5MA_2a2060ed-a93f-4559-87c8-baf15e135fc3" escape="true">As a result, the preliminary estimates may be revised during the measurement period. These differences could have a material impact on our results of operations and financial position.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2023, we recorded measurement period adjustments which increased goodwill by $<ix:nonFraction unitRef="usd" contextRef="icab3fab76ada402db8fe4009786133b9_D20230101-20230331" decimals="-3" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80OS9mcmFnOmEyY2RjNTI3ZGVjZDRiNWZiNGY0NTA3MjhhNGMyY2M2L3RleHRyZWdpb246YTJjZGM1MjdkZWNkNGI1ZmI0ZjQ1MDcyOGE0YzJjYzZfNTQ5NzU1ODQ2NDY5_7b595070-781d-4a6d-831f-0269b2d8411f">7.1</ix:nonFraction>&#160;million to adjust accrued expenses by $<ix:nonFraction unitRef="usd" contextRef="icab3fab76ada402db8fe4009786133b9_D20230101-20230331" decimals="-3" name="halo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80OS9mcmFnOmEyY2RjNTI3ZGVjZDRiNWZiNGY0NTA3MjhhNGMyY2M2L3RleHRyZWdpb246YTJjZGM1MjdkZWNkNGI1ZmI0ZjQ1MDcyOGE0YzJjYzZfNTQ5NzU1ODQ2MzU0_34a25537-0b1f-472f-b5c4-ede4c602bc05">2.3</ix:nonFraction>&#160;million and deferred tax liabilities by $<ix:nonFraction unitRef="usd" contextRef="icab3fab76ada402db8fe4009786133b9_D20230101-20230331" decimals="-3" name="halo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80OS9mcmFnOmEyY2RjNTI3ZGVjZDRiNWZiNGY0NTA3MjhhNGMyY2M2L3RleHRyZWdpb246YTJjZGM1MjdkZWNkNGI1ZmI0ZjQ1MDcyOGE0YzJjYzZfNTQ5NzU1ODQ2MzY4_9282060c-e027-4158-ad1d-0a915df33127">4.8</ix:nonFraction>&#160;million. The measurement period adjustments have been recorded to reflect facts and circumstances that existed as of the acquisition date.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfMjEzNA_346c7db0-01cc-4a7b-813b-52f23cd32c4a" continuedAt="i206e2bb965a5480b9a878f1bc0f534e0" escape="true">Fair Value Measurement</ix:nonNumeric></span></div><ix:continuation id="i206e2bb965a5480b9a878f1bc0f534e0" continuedAt="i07b1d1e5011c4c8cb9010cff3da98aa2"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfMjE0Ng_3086169e-ff48-4ae1-afb0-2fff306c0299" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:52.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ddf974e26d4522a765f4b90853db19_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfMi0yLTEtMS05NzgzOQ_89f69f16-b35e-42d1-8440-a82cc189155f">6,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ddf974e26d4522a765f4b90853db19_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfMi00LTEtMS05NzgzOQ_26903bd7-7d85-4bc4-a680-9a40448bbf04">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ddf974e26d4522a765f4b90853db19_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfMi02LTEtMS05NzgzOQ_2d773898-9ad3-42ae-af6d-4ee8d769a6ef">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ddf974e26d4522a765f4b90853db19_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfMi04LTEtMS05NzgzOQ_07984dff-f5b1-4fc5-82d6-fb105e3ee468">6,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9508cd66d39746d1ab48f1c43c197c90_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfMy0yLTEtMS05NzgzOQ_1137dd32-97b8-4e0f-a658-a68a7a12f594">10,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9508cd66d39746d1ab48f1c43c197c90_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfMy00LTEtMS05NzgzOQ_28438864-85ed-426f-9746-0af9a4991f4b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9508cd66d39746d1ab48f1c43c197c90_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfMy02LTEtMS05NzgzOQ_b3f07a41-a4d4-4f9a-8155-557caffce162">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9508cd66d39746d1ab48f1c43c197c90_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfMy04LTEtMS05NzgzOQ_ff69365e-466b-46f3-8442-473fbb5af5fa">10,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i094f2eeb06f242e3ac6bed7262ca9174_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNC0yLTEtMS05NzgzOQ_36b8fadd-84ab-407f-b0f0-2527a9e3cf88">120,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i094f2eeb06f242e3ac6bed7262ca9174_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNC00LTEtMS05NzgzOQ_24bc664e-0fb8-4082-baea-600ccbeb4e7d">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i094f2eeb06f242e3ac6bed7262ca9174_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNC02LTEtMS05NzgzOQ_59a19720-94c1-4bae-9ea5-ab19b599d35c">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i094f2eeb06f242e3ac6bed7262ca9174_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNC04LTEtMS05NzgzOQ_92c3e5fb-bd67-4231-89e1-7d1be306ab07">120,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i785729d9e19d43c9874a0e5eb4644380_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNi0yLTEtMS0xMDAzOTc_21deb1a3-7b13-49d7-a8f1-a9b6816dc751">18,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i785729d9e19d43c9874a0e5eb4644380_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNi00LTEtMS0xMDA0MDE_a4411341-6e0c-4b01-954e-7c5e3cf3c5d7">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i785729d9e19d43c9874a0e5eb4644380_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNi02LTEtMS0xMDA0MDU_eccce0d1-42ea-4d88-b719-9bc788928159">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i785729d9e19d43c9874a0e5eb4644380_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNi04LTEtMS0xMDYyNDU_e12c7718-36a5-4d8b-ad86-0d29b7a2473a">18,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbf3f7b961745d186224a612c84b694_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNi0yLTEtMS05NzgzOQ_cba1c33e-4f51-49b0-80c3-2db406ec41b1">23,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbf3f7b961745d186224a612c84b694_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNi00LTEtMS05NzgzOQ_2507b89b-f0fb-415e-8c8b-8d8259a8329a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfbf3f7b961745d186224a612c84b694_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNi02LTEtMS05NzgzOQ_b0f849f0-7852-4c40-b9f3-bf63f0e46671">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbf3f7b961745d186224a612c84b694_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNi04LTEtMS05NzgzOQ_2ef835c6-8e8b-48b8-9f0f-8d101401abbf">23,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNy0yLTEtMS05NzgzOQ_7a392e41-704d-4fbd-9a17-a84447304cd0">179,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNy00LTEtMS05NzgzOQ_8eb4e037-c30f-4858-93f7-b5c5d9cf9a6b">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNy02LTEtMS05NzgzOQ_54a3dddd-707e-4fbf-9854-4c046e61770f">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNy04LTEtMS05NzgzOQ_960fdfb5-acc1-4711-903e-a44a16605f93">179,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:52.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ffb999a0c746d5bbbfb9ce0f56de51_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfMi0yLTEtMS05NzgzOQ_6c45ea28-302f-4e40-bb92-b92a512ad22b">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ffb999a0c746d5bbbfb9ce0f56de51_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfMi00LTEtMS05NzgzOQ_5d49b3ce-e479-4b9f-b186-b475920f8ad1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ffb999a0c746d5bbbfb9ce0f56de51_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfMi02LTEtMS05NzgzOQ_11bc47c7-3eab-4644-b5e2-61f6556d0ede">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ffb999a0c746d5bbbfb9ce0f56de51_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfMi04LTEtMS05NzgzOQ_d08a02b5-0d37-4d9c-b856-07e08b775f24">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if283cea3fe1d4a6a91ac40d41123cd0b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfMy0yLTEtMS05NzgzOQ_476e38db-e340-4eea-b248-ab65e194a0ac">7,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if283cea3fe1d4a6a91ac40d41123cd0b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfMy00LTEtMS05NzgzOQ_831b538f-e19e-432c-b361-383cf73c0919">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if283cea3fe1d4a6a91ac40d41123cd0b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfMy02LTEtMS05NzgzOQ_2f06e77b-3e70-460d-b406-f9ee2ebd09a0">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if283cea3fe1d4a6a91ac40d41123cd0b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfMy04LTEtMS05NzgzOQ_6e9c3473-0e10-4156-8096-528026f92386">7,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a820e39ab6e40f887d12c0d67623ad2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNC0yLTEtMS05NzgzOQ_c39540bd-f967-4155-ac40-686b4ba56fe1">111,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a820e39ab6e40f887d12c0d67623ad2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNC00LTEtMS05NzgzOQ_4a9969c3-fa3d-4bda-99ae-a25e8cf06e62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a820e39ab6e40f887d12c0d67623ad2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNC02LTEtMS05NzgzOQ_fc40ef6d-8eb2-4b2c-9700-67a609cac865">934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a820e39ab6e40f887d12c0d67623ad2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNC04LTEtMS05NzgzOQ_7472d948-e2b8-44af-90d1-ea0479833b48">110,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9cf1d8f181a422daa99c4f7cb0bae61_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNS0yLTEtMS0xMDA0Mjk_a6d8d404-d10f-4b29-b8ce-96b735729eeb">2,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9cf1d8f181a422daa99c4f7cb0bae61_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNS00LTEtMS0xMDA0MTY_606fe906-9828-493b-a2ba-bda288a4cf0d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9cf1d8f181a422daa99c4f7cb0bae61_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNS02LTEtMS0xMDA0NDM_651d5272-abd6-4741-98ea-f6a5bc3869fd">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9cf1d8f181a422daa99c4f7cb0bae61_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNS04LTEtMS0xMDYyNDc_9457e7ef-99ca-4f4b-b12f-f83cca6b19ae">2,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5537e8e933a456da81116ac3891b12a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNi0yLTEtMS05NzgzOQ_24f0b536-a613-4b0f-b7f3-301b9e4f5e88">7,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5537e8e933a456da81116ac3891b12a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNi00LTEtMS05NzgzOQ_4e6a0fb2-b6e9-4820-b059-9b2e2840d8f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5537e8e933a456da81116ac3891b12a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNi02LTEtMS05NzgzOQ_8033e6be-71b7-46a5-b4ae-8e6fb454756a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5537e8e933a456da81116ac3891b12a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNi04LTEtMS05NzgzOQ_f27cb643-b16d-4190-8207-953e1792ba6e">7,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNy0yLTEtMS05NzgzOQ_038dd454-a123-4ea7-9066-c0ffb3209181">129,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNy00LTEtMS05NzgzOQ_9fbe69ed-690d-4af8-976c-428029c56868">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNy02LTEtMS05NzgzOQ_0f837b75-9cfd-45ef-aa8e-1a4c310dc156">944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNy04LTEtMS05NzgzOQ_be765c6d-6d48-4f03-97cb-8e968c013ca0">128,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, <ix:nonFraction unitRef="security" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfMTI5_20ccd232-b262-4145-84c8-34793bef58e3">thirty-four</ix:nonFraction> available-for-sale marketable securities with a fair market value of $<ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfMjAx_36416b88-6308-430a-989a-64e5f07b1dcd">96.2</ix:nonFraction> million were in a gross unrealized loss position of $<ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfMjQ4_210cd5bc-645f-41d2-a932-f1435db07086">0.1</ix:nonFraction>&#160;million. Based on our review of these marketable securities, we believe <ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfMzE1_eb25609e-9d8d-4e57-b198-5f9147055a98">none</ix:nonFraction> of the unrealized loss is as a result of a credit loss as of&#160;March&#160;31, 2023, because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.</span></div><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfMjEzMQ_0fcb9931-4635-492e-a929-4b12d1a3e631" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our contractual maturities of available-for-sale debt securities were as follows (in thousands):</span></div><div style="margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:67.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjc5ZjI2OTg3NDgwZjQyZTU5YmI4MmIyYzdjYWJkYmE2L3RhYmxlcmFuZ2U6NzlmMjY5ODc0ODBmNDJlNTliYjgyYjJjN2NhYmRiYTZfMi0yLTEtMS05NzgzOQ_39e86570-9067-4cf2-b326-314f77055fc1">154,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjc5ZjI2OTg3NDgwZjQyZTU5YmI4MmIyYzdjYWJkYmE2L3RhYmxlcmFuZ2U6NzlmMjY5ODc0ODBmNDJlNTliYjgyYjJjN2NhYmRiYTZfMi00LTEtMS05NzgzOQ_000287ff-dc08-4edf-b401-b4216906639e">114,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year but within five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjc5ZjI2OTg3NDgwZjQyZTU5YmI4MmIyYzdjYWJkYmE2L3RhYmxlcmFuZ2U6NzlmMjY5ODc0ODBmNDJlNTliYjgyYjJjN2NhYmRiYTZfMy0yLTEtMS05NzgzOQ_2102fc40-76e4-42e9-82ff-b5104ac9f7b2">24,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjc5ZjI2OTg3NDgwZjQyZTU5YmI4MmIyYzdjYWJkYmE2L3RhYmxlcmFuZ2U6NzlmMjY5ODc0ODBmNDJlNTliYjgyYjJjN2NhYmRiYTZfMy00LTEtMS05NzgzOQ_64ce472f-bc7e-48d4-91e6-d9ae2f9be39b">14,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjc5ZjI2OTg3NDgwZjQyZTU5YmI4MmIyYzdjYWJkYmE2L3RhYmxlcmFuZ2U6NzlmMjY5ODc0ODBmNDJlNTliYjgyYjJjN2NhYmRiYTZfNC0yLTEtMS05NzgzOQ_90b6ea49-ebb9-43e6-a68c-c5c9f6542ffa">179,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjc5ZjI2OTg3NDgwZjQyZTU5YmI4MmIyYzdjYWJkYmE2L3RhYmxlcmFuZ2U6NzlmMjY5ODc0ODBmNDJlNTliYjgyYjJjN2NhYmRiYTZfNC00LTEtMS05NzgzOQ_8434fc74-1966-4f6d-9ba0-8bf3d898b6d3">128,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfMjEzOQ_45ff0e0a-56a8-4035-9f65-3be530d515f4" continuedAt="i097bdef3b2e64e1dbb8f06822efc0a9e" escape="true">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:4.5pt"><ix:continuation id="i097bdef3b2e64e1dbb8f06822efc0a9e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:29.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total estimated fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8ff50c7e57541459bb9e2d11625d308_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMy0yLTEtMS05NzgzOQ_c55aa793-90df-4c76-8f43-29559e9fb08d">70,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ac12a8fcf7d4256b1c58e9d42cb1c4e_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMy00LTEtMS05NzgzOQ_b9b1dfb0-2cdd-4d46-8e0e-67f0afd3410d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4c6ea833f4e4d4d8e62e3e2a8a60dd7_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMy02LTEtMS05NzgzOQ_d17b7492-a334-4149-886c-4db035f41fd3">70,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica79dc0bdab840cba3dd0e9299d602b2_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMy04LTEtMS05NzgzOQ_a6656851-a7b8-4068-92a4-0fdf1106ba8b">191,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ee6e33f59c4afbba6c572de982c78a_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMy0xMC0xLTEtOTc4Mzk_13083cb4-6e40-47b9-83a3-fa793178ce30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac74b74a58e4c778cbccec9b7a58c03_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMy0xMi0xLTEtOTc4Mzk_b25e8251-0f36-4464-9e56-a069ddf213b2">191,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable <br/>&#160;&#160;&#160;securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5f15c4e1aaa429cbc707bcf75d4d317_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfNy0yLTEtMS05NzgzOQ_d621c880-853c-4b1a-a279-b69ff952c892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33428793de6741fe9231fd34e586de77_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfNy00LTEtMS05NzgzOQ_a93b4418-e355-4b80-933c-4608a9c1b209">6,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ddf974e26d4522a765f4b90853db19_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfNy02LTEtMS05NzgzOQ_947c4487-de24-4572-bbf0-5a4165c5ea7c">6,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0971204a009d4734a0ecb98a017e3a11_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfNy04LTEtMS05NzgzOQ_ed6c293f-4701-4910-9991-5eacd6b885e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d798995adad4c12bb8d4fa1faf537eb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfNy0xMC0xLTEtOTc4Mzk_d77fd8af-ae30-44a3-9a7f-a49de2ab75b2">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ffb999a0c746d5bbbfb9ce0f56de51_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfNy0xMi0xLTEtOTc4Mzk_b20fa466-e230-4457-ae66-0ad77997761e">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibceadab060e443d8beb30c8b6c154f6b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOC0yLTEtMS05NzgzOQ_60f0c7b9-bd90-438b-a5e3-6e2c1f8c9481">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6952ec39a8ea49e9acc3bd6d2f0d8165_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOC00LTEtMS05NzgzOQ_07fe72af-488c-4395-b469-0a2e2a522fab">10,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9508cd66d39746d1ab48f1c43c197c90_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOC02LTEtMS05NzgzOQ_c5c478d2-1ebf-4d7c-b5e9-610c9ab6d844">10,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739a42f476d6422e927a07b0a6b5e866_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOC04LTEtMS05NzgzOQ_c2cd3a24-573f-43c5-b873-6987e926b328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic958d8a4445145abae1f919a5908815c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOC0xMC0xLTEtOTc4Mzk_66cce6a0-0ab2-4700-98be-2fd1164d7ad5">7,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if283cea3fe1d4a6a91ac40d41123cd0b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOC0xMi0xLTEtOTc4Mzk_37a30529-eb1c-4252-86da-155d00182703">7,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60e05f4ffbae45dfb1945eb2ab5d061a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOS0yLTEtMS05NzgzOQ_336dc3b6-1bfd-4c99-877e-10e40117896c">120,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40dd3bd58ac142339fe5aa795ac93db9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOS00LTEtMS05NzgzOQ_4da8eace-eed1-44f5-a0ab-a0575c05a99f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i094f2eeb06f242e3ac6bed7262ca9174_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOS02LTEtMS05NzgzOQ_f818087c-7763-457e-80b5-8254d75f57ad">120,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24130c3f089b46b6857ad5fc1d6bf622_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOS04LTEtMS05NzgzOQ_f40b4df8-5528-42e3-bf02-bc8cf04340ca">110,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i455b329b075a48c29ca83f974487d0d2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOS0xMC0xLTEtOTc4Mzk_784b8e22-9a71-4f37-8394-3627f9a87989">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a820e39ab6e40f887d12c0d67623ad2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOS0xMi0xLTEtOTc4Mzk_9160c44b-b420-4a69-9adf-7b74f6a7de81">110,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia88d5d7bf4c148048b1766fdfc7b91e8_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTAtMi0xLTEtMTAwNDY2_3d8db391-0c7b-4ec5-a7e2-f8a45a853d3d">18,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ec8a06ba4b34aafb950e3a31d87cc34_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTAtNC0xLTEtMTAwNDcx_71fbf03f-00c4-4807-b755-c42d1184c476">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i785729d9e19d43c9874a0e5eb4644380_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTAtNi0xLTEtMTA2MjU3_f0d1c0c0-fdac-4070-8805-92e3087b745c">18,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b9d9e738fde4ed2857f748c87e3787d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTAtOC0xLTEtMTAwNDc4_1beb87bf-068b-4e25-84f3-6bd5582b15c2">2,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f8f8b13262e4f419f206a41f9565cc3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTAtMTAtMS0xLTEwMDQ4OA_ef55fda6-2c9a-4caf-bdf8-2eae803b6da3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9cf1d8f181a422daa99c4f7cb0bae61_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTAtMTItMS0xLTEwNjI1OQ_fed73bb3-cdcc-46da-84e4-bfa5b60041d3">2,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b874a74f5924476b565a9f6bcfca413_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTEtMi0xLTEtOTc4Mzk_d6a68dc2-9858-4b8b-876a-472d7e1ef7cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ace94c58553416888e3d388acdf4e1f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTEtNC0xLTEtOTc4Mzk_fffff83c-6007-4663-8bb5-2fc53427c1b2">23,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbf3f7b961745d186224a612c84b694_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTEtNi0xLTEtOTc4Mzk_52712408-a287-4a94-bfae-4c4ea304f69f">23,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562e413729c347808d2b496afa73e048_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTEtOC0xLTEtOTc4Mzk_fcadb062-92b2-458f-9e2c-3f4ad8794595">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b8ac74092c34340beea79e2b5c3eaef_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTEtMTAtMS0xLTk3ODM5_b45b277d-3405-474a-9c48-bb1433d58dec">7,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5537e8e933a456da81116ac3891b12a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTEtMTItMS0xLTk3ODM5_e62460b5-ddf6-4b47-a21c-88df01a2c674">7,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d3aaf097a2b46f7a4fde671aaa22952_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTItMi0xLTEtOTc4Mzk_9d6cc9e0-28b8-44cf-9081-33567c487620">209,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0a569c32a674df0839180908bd55f41_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTItNC0xLTEtOTc4Mzk_b444bc28-756e-413b-b63f-ebb12f303c7a">39,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTItNi0xLTEtOTc4Mzk_206e8987-da3f-46b8-a490-f359a0713d0b">249,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51cd82ac5a0347999d0942cb559d69f1_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTItOC0xLTEtOTc4Mzk_db1a2a13-5dfd-4713-a94c-9cdba65ca44d">305,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e036a3c236442fcbc74bb9450bb41b6_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTItMTAtMS0xLTk3ODM5_8951dce7-8ce4-4cb1-b275-74508fcd7a9f">15,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTItMTItMS0xLTk3ODM5_e4189d18-5577-4f9b-a55d-6d27b8d53cde">320,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had <ix:nonFraction unitRef="usd" contextRef="if2ded6c148b24f77bf4d9c161e49d9de_I20230331" decimals="INF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt-sec:numwordsen" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfOTQx_0ec6a141-6786-4c5b-b6f2-be51c015c874"><ix:nonFraction unitRef="usd" contextRef="i4f6244ff2fcd468a96760b50de6410df_I20221231" decimals="INF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt-sec:numwordsen" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfOTQx_2ad87e83-6a6c-40d9-98ae-27dc674140e9">no</ix:nonFraction></ix:nonFraction> available for sale securities that were classified within Level 3 as of March&#160;31, 2023 and December&#160;31, 2022.</span></div></ix:continuation><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i07b1d1e5011c4c8cb9010cff3da98aa2">A contingent liability with a value of $<ix:nonFraction unitRef="usd" contextRef="ie15ed974b99c4d81aa1e6764b03ef509_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfMTA3OA_ec4aebbe-323c-43e2-a9d7-01d729f2fea7">15.7</ix:nonFraction>&#160;million was assumed as part of the Antares acquisition related to TLANDO. The acquisition date fair value was measured using the income approach, specifically the probability weighted expected return method for the development milestone payments and the option pricing methodology using the Monte Carlo simulation for commercial milestone payments and royalty payments. The fair value of the contingent liability will be remeasured on a quarterly basis. Estimates and assumptions used in the Monte Carlo simulation include forecasted revenues, cost of debt, risk free rate, weighted average cost of capital, revenue market price risk and revenue volatility. Estimates and assumptions used in the income approach include the probability of achieving certain milestones and a discount rate. These unobservable inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. Changes in the fair value subsequent to the acquisition date will be recognized in our condensed consolidated statements of income.</ix:continuation></span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMjM3MA_72864c8f-c9e4-4b15-a72f-7bf278b6133c" continuedAt="ib6bd9e4a1e084a8ca174924afdf1b218" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="ib6bd9e4a1e084a8ca174924afdf1b218"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMjM3OA_88a28a3d-ee36-4f1e-b2da-40ca9a0855bd" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disaggregated revenues were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:78.555%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.292%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02fe07952df9422992b4f26248091821_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMi0yLTEtMS05NzgzOQ_2b8cef10-5e1c-4d8f-bdbd-b4908ab959df">99,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aebf4236d314680b3e3c0a72977aef1_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMi00LTEtMS05NzgzOQ_69a8ed10-4294-4240-858b-fb23d5edaf2a">69,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Sales of bulk rHuPH20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2e433d91b04a038142f3674a77dbab_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfNS0yLTEtMS05NzgzOQ_fb43bc53-d98b-42ca-992f-e6243cd66d23">22,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b20fa8736c942e5a6d16eb5dd856c4d_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfNS00LTEtMS05NzgzOQ_b1e84c31-b7ac-4938-8724-704bfd755278">16,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of proprietary products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8349bd4411084a29b491605b9e981c86_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfNi0yLTEtMS05NzgzOQ_9ab82552-06ba-45b8-8c29-528ee71a1092">27,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5040df1f6b0340d2b9bdc087ac6bc75a_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfNi00LTEtMS05NzgzOQ_b103f2c0-8bce-461c-8112-7af5e649bc7c">5,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of device partnered products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e44c7bdff0d4afab55d0f20c2a08e26_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfNy0yLTEtMS05NzgzOQ_2844c4bc-1679-4b5a-8fdb-3d17d176f614">10,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f57590019f4701b5d3b0b88015539e_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfNy00LTEtMS05NzgzOQ_38dcbcda-76dd-40e4-8005-0c467b404199">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff57a29a29d64188b30a100687f1c479_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfOC0yLTEtMS05NzgzOQ_c21d5757-b24f-4612-85c7-07967753e539">60,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4ce36d68328465ea06f53e7683604f0_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfOC00LTEtMS05NzgzOQ_a10ac197-3199-40a1-bd44-64e4666fcc06">22,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Upfront license and target nomination fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4051c56e33f74f188cc8eccd23a7f58f_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMTEtMi0xLTEtOTc4Mzk_ba5e1819-9e42-46e2-8fc9-a57f33ec01dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d4b107661c44956a8eb7be6f8c14f9d_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMTEtNC0xLTEtOTc4Mzk_dc638c4d-8254-40eb-8670-e7dd709e55a5">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Device Licensing and development revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if58b9fca0ec74a9995562d09ff0ab3ac_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMTQtMi0xLTEtOTc4Mzk_cdf08752-8b65-433b-b835-eaef4a6d7064">1,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a11b871a3346cd9599297d2004c0c3_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMTQtNC0xLTEtOTc4Mzk_53414200-2ff9-4a7d-814c-1885203f6e26">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33911352c8cf4d3a8a5655b090781af3_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMTUtMi0xLTEtOTc4Mzk_e4586a7b-134e-48e1-bbf7-f9914fad9c16">1,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0705f79cf1bd46bcaee4afc74fd6c446_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMTUtNC0xLTEtOTc4Mzk_f601584a-08d3-40a1-96ab-fb3ee31c9aee">25,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMTctMi0xLTEtOTc4Mzk_6bb21707-b43b-4483-ad0f-4ea26078f152">162,143</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMTctNC0xLTEtOTc4Mzk_d92565cf-b280-4410-a29d-368e070f5bd4">117,279</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we recognized revenue related to licenses granted to partners in prior periods in the amount of $<ix:nonFraction unitRef="usd" contextRef="ic22dc841bc6041cba127ce0958181fb1_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMjAz_4aa3aaa1-2a7e-4c20-b885-14fc7e9c3665">99.6</ix:nonFraction> million. This amount represents royalties earned in the current period. We also recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfNDc2_32d212bd-b232-40f5-bd99-fe1b1c2762fe">0.4</ix:nonFraction>&#160;million during the three months ended March&#160;31, 2023 that had been included in deferred revenues in the condensed consolidated balance sheets as of December&#160;31, 2022. </span></div><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMjM3Mg_b6e9310f-8bac-4344-bc98-5096fb0f5797" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands): </span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:76.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.176%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="halo:AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjcxMTZlYTc0OTQ1MTRkNDI5NjQ3MzdmZWQ2ZjJlZDg3L3RhYmxlcmFuZ2U6NzExNmVhNzQ5NDUxNGQ0Mjk2NDczN2ZlZDZmMmVkODdfMS0yLTEtMS05NzgzOQ_29604a05-8724-46cc-b0a4-e478b1e00c8d">162,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="halo:AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjcxMTZlYTc0OTQ1MTRkNDI5NjQ3MzdmZWQ2ZjJlZDg3L3RhYmxlcmFuZ2U6NzExNmVhNzQ5NDUxNGQ0Mjk2NDczN2ZlZDZmMmVkODdfMS00LTEtMS05NzgzOQ_3c98827b-410c-45ca-8bfb-71529ada15b2">186,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjcxMTZlYTc0OTQ1MTRkNDI5NjQ3MzdmZWQ2ZjJlZDg3L3RhYmxlcmFuZ2U6NzExNmVhNzQ5NDUxNGQ0Mjk2NDczN2ZlZDZmMmVkODdfMi0yLTEtMS05NzgzOQ_7cae7cb1-bf55-4f21-864c-091adc8dff41">32,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjcxMTZlYTc0OTQ1MTRkNDI5NjQ3MzdmZWQ2ZjJlZDg3L3RhYmxlcmFuZ2U6NzExNmVhNzQ5NDUxNGQ0Mjk2NDczN2ZlZDZmMmVkODdfMi00LTEtMS05NzgzOQ_fccba1ad-563f-4fed-9322-2ee3fbd7a91c">44,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:DeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjcxMTZlYTc0OTQ1MTRkNDI5NjQ3MzdmZWQ2ZjJlZDg3L3RhYmxlcmFuZ2U6NzExNmVhNzQ5NDUxNGQ0Mjk2NDczN2ZlZDZmMmVkODdfMy0yLTEtMS05NzgzOQ_7647f70f-3c6a-480a-bee2-6c66730a561b">5,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:DeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjcxMTZlYTc0OTQ1MTRkNDI5NjQ3MzdmZWQ2ZjJlZDg3L3RhYmxlcmFuZ2U6NzExNmVhNzQ5NDUxNGQ0Mjk2NDczN2ZlZDZmMmVkODdfMy00LTEtMS05NzgzOQ_19fd8799-e5d3-4f9d-abc1-4b5fdda08d64">5,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $<ix:nonFraction unitRef="usd" contextRef="iafdfb78b51284e9cb1aba46fd7125d17_I20230331" decimals="-5" name="us-gaap:DeferredRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMTU5NQ_15a79e3e-3a57-48d9-8c82-406a65409d7f">123.6</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="iff33634f84774f3e98705b7f0fa793f5_I20230331" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMTYwOA_7f7faa8d-e771-4e27-ae7b-ef49010b722f">118.1</ix:nonFraction> million relates to unfulfilled product purchase orders and $<ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMTY1OQ_f6895d07-20a4-4c1b-8bba-a05051c68eda">5.5</ix:nonFraction> million has been collected and is reported as deferred revenues in the condensed consolidated balance sheets. The unfulfilled product purchase orders are estimated to be delivered by the end of 2024. Of the total deferred revenues of $<ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMTg4NQ_f6895d07-20a4-4c1b-8bba-a05051c68eda">5.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="icd9786c1eb264d80a62f434a14aac146_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMTg4OQ_f0b8e14a-0436-47cf-b51d-10d1b6a9b456">3.2</ix:nonFraction> million is expected to be used by our customers within the next 12 months. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized contract assets of $<ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMjUyODg3Njc0NDQyNjQ_3fea4cc2-e0b5-462e-ad97-e186498f825b">32.3</ix:nonFraction>&#160;million as of March&#160;31, 2023, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods and for goods or services when control has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to the customer in accordance with the terms of the contract.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTU1NA_b3561bce-3d89-4add-9dc7-785dcaf0b04e" continuedAt="idb795c85646f49ebb45ec24a2db37776" escape="true">Certain Balance Sheet Items</ix:nonNumeric></span></div><ix:continuation id="idb795c85646f49ebb45ec24a2db37776" continuedAt="ie98d3055d9aa44e581b5dc5e81e5259f"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTU3OA_0887bbea-df4e-4315-a41a-32825b975e5a" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net and contract assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from product sales to partners</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="halo:Accountsreceivablefromproductsalestocollaborators" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfMS0yLTEtMS05NzgzOQ_eee67c55-7dba-4a77-a8bf-86e6cf43d7a5">58,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="halo:Accountsreceivablefromproductsalestocollaborators" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfMS00LTEtMS05NzgzOQ_f566b19c-74e3-4001-9546-3a6ca0f6fb2b">62,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="halo:Accountsreceivablefromcollaborators" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfMi0yLTEtMS05NzgzOQ_c035c340-2add-43c3-8462-36bcafe26147">2,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="halo:Accountsreceivablefromcollaborators" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfMi00LTEtMS05NzgzOQ_ae6a5f10-315d-4f9a-972c-60274961e9de">18,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from royalty payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="halo:Accountsreceivablefromroyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfMy0yLTEtMS05NzgzOQ_d69f3183-b442-4f7c-a919-acd3aa5d587f">100,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="halo:Accountsreceivablefromroyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfMy00LTEtMS05NzgzOQ_5aa710e1-4147-49ed-a599-16a5800fc62d">100,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from other product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="halo:Accountsreceivablefromproductsales" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfNC0yLTEtMS05NzgzOQ_702d2708-25ff-4717-937e-539bf31337f8">6,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="halo:Accountsreceivablefromproductsales" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfNC00LTEtMS05NzgzOQ_ea52d587-a656-4b8c-a897-3bcf430c6e4f">6,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfNi0yLTEtMS05NzgzOQ_7cae7cb1-bf55-4f21-864c-091adc8dff41">32,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfNi00LTEtMS05NzgzOQ_fccba1ad-563f-4fed-9322-2ee3fbd7a91c">44,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accounts receivable and contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfNy0yLTEtMS05NzgzOQ_00e91ba5-771d-400c-8b5e-1942ffe27f17">200,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfNy00LTEtMS05NzgzOQ_bd5e4f79-b274-477c-b782-bbbf83512c19">232,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for distribution fees and discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="halo:AllowanceforDistributionFeesandDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfOC0yLTEtMS05NzgzOQ_d61fde90-8e0d-49e7-a5fb-4ae117e355f2">5,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="halo:AllowanceforDistributionFeesandDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfOC00LTEtMS05NzgzOQ_3ad5f8f6-0eb5-4bae-8470-6478f7b0e7ae">1,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accounts receivable, net and contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfOS0yLTEtMS05NzgzOQ_49112911-d7b6-4a1d-a5f6-4633b8880f6d">194,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfOS00LTEtMS05NzgzOQ_18121d21-adc9-4f27-b493-027e10fcc359">231,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTU2OQ_1518d764-680f-471d-8f2a-f0f89ec39e5e" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOmVjYmEyMjM1MDc0NzQzNWU5NzM2OTUyM2M0MmNhMDY1L3RhYmxlcmFuZ2U6ZWNiYTIyMzUwNzQ3NDM1ZTk3MzY5NTIzYzQyY2EwNjVfMS0yLTEtMS05NzgzOQ_458a8cb1-6b1e-436d-bb04-84378434c5bc">22,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOmVjYmEyMjM1MDc0NzQzNWU5NzM2OTUyM2M0MmNhMDY1L3RhYmxlcmFuZ2U6ZWNiYTIyMzUwNzQ3NDM1ZTk3MzY5NTIzYzQyY2EwNjVfMS00LTEtMS05NzgzOQ_fd7c6bd8-8b2d-4b43-a438-8c674393bf4e">13,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOmVjYmEyMjM1MDc0NzQzNWU5NzM2OTUyM2M0MmNhMDY1L3RhYmxlcmFuZ2U6ZWNiYTIyMzUwNzQ3NDM1ZTk3MzY5NTIzYzQyY2EwNjVfMi0yLTEtMS05NzgzOQ_38461262-a04c-4ce8-8087-64ebb932400d">27,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOmVjYmEyMjM1MDc0NzQzNWU5NzM2OTUyM2M0MmNhMDY1L3RhYmxlcmFuZ2U6ZWNiYTIyMzUwNzQ3NDM1ZTk3MzY5NTIzYzQyY2EwNjVfMi00LTEtMS05NzgzOQ_dc83d6ae-1402-45af-81ff-eb2aceb06adb">40,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOmVjYmEyMjM1MDc0NzQzNWU5NzM2OTUyM2M0MmNhMDY1L3RhYmxlcmFuZ2U6ZWNiYTIyMzUwNzQ3NDM1ZTk3MzY5NTIzYzQyY2EwNjVfMy0yLTEtMS05NzgzOQ_406e2c2f-3816-490d-9c10-7ef9fd28efcf">57,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOmVjYmEyMjM1MDc0NzQzNWU5NzM2OTUyM2M0MmNhMDY1L3RhYmxlcmFuZ2U6ZWNiYTIyMzUwNzQ3NDM1ZTk3MzY5NTIzYzQyY2EwNjVfMy00LTEtMS05NzgzOQ_7125f20e-95c2-4a9d-ab6f-4b0db360b23a">45,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOmVjYmEyMjM1MDc0NzQzNWU5NzM2OTUyM2M0MmNhMDY1L3RhYmxlcmFuZ2U6ZWNiYTIyMzUwNzQ3NDM1ZTk3MzY5NTIzYzQyY2EwNjVfNC0yLTEtMS05NzgzOQ_26166d8c-8f8b-4cd2-8eb1-01122aaad727">107,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOmVjYmEyMjM1MDc0NzQzNWU5NzM2OTUyM2M0MmNhMDY1L3RhYmxlcmFuZ2U6ZWNiYTIyMzUwNzQ3NDM1ZTk3MzY5NTIzYzQyY2EwNjVfNC00LTEtMS05NzgzOQ_c7e653e5-3ab0-4c49-aebb-cfedba6141cc">100,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTU4NA_6b8bdd0d-c048-4895-8af1-7a6609f63a98" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfMS0yLTEtMS05NzgzOQ_b1210f5a-7a77-41d2-a594-5adadd9636f8">50,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfMS00LTEtMS05NzgzOQ_e4c7781d-1622-4908-9d31-a4dd6f4f6351">51,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfMy0yLTEtMS05NzgzOQ_6425d082-8c77-4b44-a07e-c3633a486c33">4,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfMy00LTEtMS05NzgzOQ_238fa135-d13a-4069-b767-f7f4ef894d2e">4,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfNC0yLTEtMS05NzgzOQ_8be55ce2-b26e-4a04-9b8f-62869b82bdb9">7,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfNC00LTEtMS05NzgzOQ_b6222df6-eb8b-401f-9643-a98bd3bba9a4">14,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfNS0yLTEtMS05NzgzOQ_36d3daed-e8d7-453b-966a-90a8fce24f03">62,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfNS00LTEtMS05NzgzOQ_767f5d7c-32ef-474c-9468-ceba4028530e">71,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfNi0yLTEtMS05NzgzOQ_50017a16-b06f-4906-bc43-8eb41ed163fd">25,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfNi00LTEtMS05NzgzOQ_d5c0338f-f0e7-4906-9e78-2e162904b782">26,301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfNy0yLTEtMS05NzgzOQ_851625e6-0a0e-4170-827d-722110bcb753">37,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfNy00LTEtMS05NzgzOQ_0ae89138-d163-4e46-a58c-e92aa90bba66">45,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract manufacturing organizations.&#160;Such amounts are reclassified to work-in-process inventory as materials are used or the contract manufacturing organization services are complete.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTU5MQ_75da8702-ddcb-425a-b26d-abc6e8b045b1" continuedAt="i6c989a07b14e4861a9713ae0f91092b6" escape="true">Property and equipment, net consisted of the following (in thousands):</ix:nonNumeric></span></div><div style="text-align:center;text-indent:22.5pt"><ix:continuation id="i6c989a07b14e4861a9713ae0f91092b6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f4f1582f5974e0fa962b63fed33147c_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfMS0yLTEtMS05NzgzOQ_95d2a6d6-e9eb-4455-862f-cc490ba9f744">8,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68980f1c77a7473ab18bec2713ab9e05_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfMS00LTEtMS05NzgzOQ_18187332-fcf3-4d3d-8839-c9bd4eaad687">7,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib377635631014ff39344d0ec6e220cf8_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfMi0yLTEtMS05NzgzOQ_4733e8d8-948c-4e4e-945f-9a807c5a4e0d">31,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed31096856d45c5a8a866ba7b9fccce_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfMi00LTEtMS05NzgzOQ_6a3e1fed-f557-44f9-9643-3de159b2411e">27,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1795cd05c98547769da8f152dffa740b_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfMy0yLTEtMS05NzgzOQ_60ccf84f-185f-4831-8b38-90d53763f2ea">8,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47f684ec05774a41841a55c9d11bc8ab_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfMy00LTEtMS05NzgzOQ_86dd82a5-dbfb-4361-99ae-ae138b0fc67a">7,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i429394b48f8f49c9bd5c34d8ea70ef6f_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfNC0yLTEtMS05NzgzOQ_52d21daa-9164-4a7a-8467-ab9d73966643">6,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i463667de7a9840d9887b692b9090956f_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfNC00LTEtMS05NzgzOQ_8fc52b52-c8a8-4497-87db-b8e49398a510">6,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfNS0yLTEtMS05NzgzOQ_c063bcc7-28bf-453a-9037-701a4d145096">54,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfNS00LTEtMS05NzgzOQ_9cfb9d7b-a2ee-4616-9899-1e405f629982">49,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfNi0yLTEtMS05NzgzOQ_3225f686-a984-4552-ba5f-3bef565fe7a1">16,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfNi00LTEtMS05NzgzOQ_c66f5eba-1837-4115-8d52-7ef615279a1b">14,756</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfNy0yLTEtMS05NzgzOQ_db650520-a02c-42cb-8ff7-0b3c892f496c">38,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfNy00LTEtMS05NzgzOQ_f54a662c-d98c-446b-8b60-48e09d4058d9">35,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfOC0yLTEtMS05NzgzOQ_3425b502-7f65-45ba-82c5-0b8f2c5dab92">39,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfOC00LTEtMS05NzgzOQ_46f43087-dfd3-4c86-8fab-4da92a98ee90">40,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfOS0yLTEtMS05NzgzOQ_abbc1d78-2dab-4b57-8e94-427c39fc04d9">77,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfOS00LTEtMS05NzgzOQ_60f52cb2-b06e-4136-95ee-c43eedabf686">75,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                            </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was approximately $<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfNjg2_76d0e78d-f4a5-4f37-aaeb-d9fad8170bc0">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfNjkz_f39f84a2-7995-4679-bb3e-b981e60d9eeb">0.8</ix:nonFraction> million, inclusive of ROU asset amortization of $<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfNTQ5NzU1ODE2MjE1_9d995671-6d12-4312-bbbb-9931a1dc8787">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfNzQz_77905fc3-8ccf-449e-b5cf-e2d0dcd60a98">0.4</ix:nonFraction> million for the three months ended March&#160;31, 2023 and 2022, respectively. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie98d3055d9aa44e581b5dc5e81e5259f"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTU5Mg_99a48d41-5d1a-4a65-bf50-d4c00062c5df" escape="true"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and payroll taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfMi0yLTEtMS05NzgzOQ_24505cd4-fe29-4ef8-9028-4e6fca954132">10,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfMi00LTEtMS05NzgzOQ_6f46a6f3-1cb2-4663-863c-c1d8696b6328">19,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued outsourced manufacturing expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="halo:Accruedmanufacturingexpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfMy0yLTEtMS05NzgzOQ_b6d8ee9b-2daf-49cf-a367-27d41b85fef8">12,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="halo:Accruedmanufacturingexpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfMy00LTEtMS05NzgzOQ_498880f0-76df-4df0-b019-96b5ddf28e7b">12,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfNC0yLTEtMS05NzgzOQ_ded44106-fd4c-4b22-bdab-9a97629e2fdf">2,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfNC00LTEtMS05NzgzOQ_53bf67b7-c6fe-4de6-a988-d8c92aba502a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns and sales allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfNS0yLTEtMS05NzgzOQ_91987079-a850-4272-9320-a92696d3aff7">29,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfNS00LTEtMS05NzgzOQ_a71048dd-5f69-44ff-b4f9-cbed3f48a085">30,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfNi0yLTEtMS05NzgzOQ_2a978923-7b4a-4125-85a1-54a13b7ebe6b">19,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfNi00LTEtMS05NzgzOQ_4a9ab397-9795-45e2-a4d1-929a9af5a267">29,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfNy0yLTEtMS05NzgzOQ_339f0d64-753e-4e47-b2da-ac4a6d4828af">34,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfNy00LTEtMS05NzgzOQ_b78565a8-cfa1-40cd-9f10-555bcaa2635a">34,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfOC0yLTEtMS05NzgzOQ_23ed6aa6-5867-47d7-8409-b8b452383fd4">109,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfOC00LTEtMS05NzgzOQ_3d967cc5-a7fd-42e1-a067-1ca2072853f6">126,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="halo:AccruedLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfOS0yLTEtMS05NzgzOQ_d789e655-1de2-43bc-9808-304dbcdd2cb5">29,573</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="halo:AccruedLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfOS00LTEtMS05NzgzOQ_235b1fc9-883e-4f95-8ccd-7e9bfb27847c">30,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accrued expenses, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfMTAtMi0xLTEtOTc4Mzk_f5644a30-4749-41a7-8455-9f667251d386">79,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfMTAtNC0xLTEtOTc4Mzk_519166b9-69ab-47fa-b77b-a563167d7a75">96,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense associated with the accretion of the lease liabilities was approximately $<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-5" name="halo:OperatingLeaseAccretionOfLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTEwNQ_29da5d2a-3b81-4271-ad8b-71381b5d1a9b">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-5" name="halo:OperatingLeaseAccretionOfLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTExMg_6952adb2-20f3-4b25-8eb7-54d2d47bbd34">0.1</ix:nonFraction> million for the three months ended March&#160;31, 2023 and 2022, respectively. Total lease expense for the three months ended March&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTI4NA_fb1ee0ce-eebb-4456-ace6-ecd6abb2ebed">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTI5MQ_bae0a391-21f2-49b3-9fa2-0c4c162a58c5">0.5</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts related to leases for the three months ended March&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTQ1Mg_22f1db9b-7f49-4b3c-b992-bdf23c8407d0">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTQ1OQ_3d59a287-252d-4367-9301-066077a2fc9f">0.7</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RleHRyZWdpb246MTYzZDU4ODI5MmUwNGM4ZGEwZGI0YzJjNWY0NjIwZWJfMTAyOA_c28fdaa5-e774-4147-95c5-bb21557c42ab" continuedAt="i5fb2725e451747cd99dbe661ff0df91d" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="i5fb2725e451747cd99dbe661ff0df91d"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, we acquired all outstanding equity interests of Antares. A goodwill balance of $<ix:nonFraction unitRef="usd" contextRef="i04990caa9f1d4feeb66916e444f5b67f_I20220524" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RleHRyZWdpb246MTYzZDU4ODI5MmUwNGM4ZGEwZGI0YzJjNWY0NjIwZWJfMTQ0_289bc0ed-2e84-4fa6-8050-709eaa5e2211">409.0</ix:nonFraction>&#160;million was recognized for the excess of the consideration transferred over the net assets acquired and represents the expected revenue and cost synergies of the combined company and assembled workforce.</span></div><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RleHRyZWdpb246MTYzZDU4ODI5MmUwNGM4ZGEwZGI0YzJjNWY0NjIwZWJfMTAyOQ_2467bea4-2153-4a5c-aceb-6b9d68adc7f3" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity impacting goodwill is presented below (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"></td><td style="width:84.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjk0N2VlYTAxM2FjMjQ4MDJiMmVjNTVjYzI5ZmU3MDM0L3RhYmxlcmFuZ2U6OTQ3ZWVhMDEzYWMyNDgwMmIyZWM1NWNjMjlmZTcwMzRfMC0yLTEtMS05NzgzOQ_b4b653aa-eeb4-4664-9125-93ac2a9aa05d">409,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjk0N2VlYTAxM2FjMjQ4MDJiMmVjNTVjYzI5ZmU3MDM0L3RhYmxlcmFuZ2U6OTQ3ZWVhMDEzYWMyNDgwMmIyZWM1NWNjMjlmZTcwMzRfMS0yLTEtMS05NzgzOQ_6cd17fec-b06b-431f-ac78-a59409492426">7,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjk0N2VlYTAxM2FjMjQ4MDJiMmVjNTVjYzI5ZmU3MDM0L3RhYmxlcmFuZ2U6OTQ3ZWVhMDEzYWMyNDgwMmIyZWM1NWNjMjlmZTcwMzRfMi0yLTEtMS05NzgzOQ_737bb8fa-fc05-4bdc-bd9f-fe34414ade20">416,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our acquired intangible assets are amortized using the straight-line method over their estimated useful lives of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RleHRyZWdpb246MTYzZDU4ODI5MmUwNGM4ZGEwZGI0YzJjNWY0NjIwZWJfNTU2_7b1e4645-8507-4bdd-a7da-977a1bcbb72c">seven</span> to <ix:nonNumeric contextRef="i81c6c189dc1c414db846950051a68f58_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RleHRyZWdpb246MTYzZDU4ODI5MmUwNGM4ZGEwZGI0YzJjNWY0NjIwZWJfNTYy_8a3a8d49-68b6-478d-a697-143e9afb83e4">ten years</ix:nonNumeric>. <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RleHRyZWdpb246MTYzZDU4ODI5MmUwNGM4ZGEwZGI0YzJjNWY0NjIwZWJfMTAyNg_1eedb7fa-46c8-45e7-bd6d-7dcebb5c3025" continuedAt="i4db78bab398249bbaf18cfa9d2cd1c86" escape="true">The following table shows the cost, accumulated amortization and weighted average useful life in years for our acquired intangible assets as of March&#160;31, 2023 (in thousands).</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><ix:continuation id="i4db78bab398249bbaf18cfa9d2cd1c86"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:47.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average useful life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48becb7672924502ac96083bb5cd5d79_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMS0yLTEtMS05NzgzOQ_9fef4a34-dc88-4e4a-87d6-c4edcf486551">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeb34905ee5a413ba8c2930d948203a1_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMS00LTEtMS05NzgzOQ_a83add82-8a8d-4a65-a38a-5554c8b7f9ac">402,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeb34905ee5a413ba8c2930d948203a1_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMS02LTEtMS05NzgzOQ_432c7631-36af-482d-84d7-c2d4af666fd8">49,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeb34905ee5a413ba8c2930d948203a1_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMS04LTEtMS05NzgzOQ_f9972e24-f338-4240-84d6-355e80ce81f4">352,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia90c2ed74ead443583b931534d578bb2_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMi0yLTEtMS05NzgzOQ_8833b42d-a083-4b93-8298-b38ba290e8ef">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa015d0540a840c79bc449df56401a5f_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMi00LTEtMS05NzgzOQ_a355c7c4-af34-41ac-aa87-39d9ff7680c5">136,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa015d0540a840c79bc449df56401a5f_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMi02LTEtMS05NzgzOQ_e1cb9677-dea5-436a-9fdf-48f614734974">11,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa015d0540a840c79bc449df56401a5f_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMi04LTEtMS05NzgzOQ_b43e3eb7-77ed-44d1-b34f-4e192d7d11bd">124,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLANDO product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i25336e1752ef44b4b8ba6f295a047c8d_D20230101-20230331" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMy0yLTEtMS05NzgzOQ_41968bcc-f5e2-464d-aef3-708c5d4ea1fd">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e130d5a6e9b4d66b803cb5e487a55ef_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMy00LTEtMS05NzgzOQ_ecb8fc3a-cdf0-42c9-bb78-b93c4a7c917b">2,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e130d5a6e9b4d66b803cb5e487a55ef_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMy02LTEtMS05NzgzOQ_acf6675b-0cf7-414e-944b-b783b11d3406">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e130d5a6e9b4d66b803cb5e487a55ef_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMy04LTEtMS05NzgzOQ_0fcc30cb-e17e-4ef8-8a61-620a1da805e4">2,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfNC00LTEtMS05NzgzOQ_b0d75b35-a520-44ef-a286-a3beb80b3e78">541,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfNC02LTEtMS05NzgzOQ_827f7593-9a27-4c85-93b4-d3b3206ef7d3">60,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfNC04LTEtMS05NzgzOQ_8486e8d8-156a-4459-8a13-7899dd5d248e">480,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfNS04LTEtMS05NzgzOQ_ef2fedf4-afae-44b5-8876-9c35878f7173">48,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfNi04LTEtMS05NzgzOQ_28120e1d-e943-432a-b6cb-c9a66aaa8404">528,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RleHRyZWdpb246MTYzZDU4ODI5MmUwNGM4ZGEwZGI0YzJjNWY0NjIwZWJfMTAyNw_f3b8e324-d458-4902-b09d-55b186cffb85" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future annual amortization of finite-lived intangible assets is shown in the following table (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:82.561%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjczZjIwODU3NjIyNDQyODc4NTY5YjdjM2RmZDViM2RlL3RhYmxlcmFuZ2U6NzNmMjA4NTc2MjI0NDI4Nzg1NjliN2MzZGZkNWIzZGVfMS0yLTEtMS05NzgzOQ_6e177a1f-b4c1-45da-86c8-e56b61dea278">53,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjczZjIwODU3NjIyNDQyODc4NTY5YjdjM2RmZDViM2RlL3RhYmxlcmFuZ2U6NzNmMjA4NTc2MjI0NDI4Nzg1NjliN2MzZGZkNWIzZGVfMi0yLTEtMS05NzgzOQ_b1b5aa02-43e2-4d77-887c-0f7d04cdc2d8">71,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjczZjIwODU3NjIyNDQyODc4NTY5YjdjM2RmZDViM2RlL3RhYmxlcmFuZ2U6NzNmMjA4NTc2MjI0NDI4Nzg1NjliN2MzZGZkNWIzZGVfMy0yLTEtMS05NzgzOQ_914c84d4-3350-40ba-941a-831642db48e9">71,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjczZjIwODU3NjIyNDQyODc4NTY5YjdjM2RmZDViM2RlL3RhYmxlcmFuZ2U6NzNmMjA4NTc2MjI0NDI4Nzg1NjliN2MzZGZkNWIzZGVfNC0yLTEtMS05NzgzOQ_d27c21ed-1396-4959-b59b-60342bd87dbc">71,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjczZjIwODU3NjIyNDQyODc4NTY5YjdjM2RmZDViM2RlL3RhYmxlcmFuZ2U6NzNmMjA4NTc2MjI0NDI4Nzg1NjliN2MzZGZkNWIzZGVfNS0yLTEtMS05NzgzOQ_98107109-e18a-4838-857a-78844df81dbb">71,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="halo:FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjczZjIwODU3NjIyNDQyODc4NTY5YjdjM2RmZDViM2RlL3RhYmxlcmFuZ2U6NzNmMjA4NTc2MjI0NDI4Nzg1NjliN2MzZGZkNWIzZGVfNi0yLTEtMS05NzgzOQ_ad3cdc01-f9b3-4cdc-b0da-f46cbf178411">141,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjczZjIwODU3NjIyNDQyODc4NTY5YjdjM2RmZDViM2RlL3RhYmxlcmFuZ2U6NzNmMjA4NTc2MjI0NDI4Nzg1NjliN2MzZGZkNWIzZGVfNy0yLTEtMS05NzgzOQ_7bc5ed5f-cb4f-434c-9b25-7150dcb1dd6f">480,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTc5Mjg_45c9a0fc-4405-4666-b43a-61b41a04ac64" continuedAt="icd0fd56b4e114b09851b77262b901c8c" escape="true">Long-Term Debt, Net</ix:nonNumeric></span></div><ix:continuation id="icd0fd56b4e114b09851b77262b901c8c" continuedAt="i8d0610c128f0439689cff9c3d42eea72"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="if3d4edc7f65c461d9431d7d9efcc56e9_I20220831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMjk_fcfca158-4410-4b60-959c-8ce1c7665e1f">1.00</ix:nonFraction>% Convertible Notes due 2028</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we completed the sale of $<ix:nonFraction unitRef="usd" contextRef="if3d4edc7f65c461d9431d7d9efcc56e9_I20220831" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTAw_e4e98dea-51c7-49bc-a7d0-d3c0a588431f">720.0</ix:nonFraction>&#160;million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="if3d4edc7f65c461d9431d7d9efcc56e9_I20220831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTM2_47868e88-502e-4360-b2f9-18cce3107dc6">1.00</ix:nonFraction>% Convertible Senior Notes due 2028 (the &#8220;2028 Convertible Notes&#8221; and collectively with the 2024 and the 2027 Convertible Notes the &#8220;Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2028 Convertible Notes, after deducting the initial purchasers&#8217; fee of $<ix:nonFraction unitRef="usd" contextRef="if3d4edc7f65c461d9431d7d9efcc56e9_I20220831" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNDE4_547292b0-3112-428f-9200-743b794564bc">18.0</ix:nonFraction>&#160;million, was approximately $<ix:nonFraction unitRef="usd" contextRef="ifd6f3969e6c8426fa1c64cce894e6e50_D20220801-20220831" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNDQw_5b55822e-ffc2-4b96-81bb-c704dd86d567">702.0</ix:nonFraction>&#160;million. We also incurred additional debt issuance costs totaling $<ix:nonFraction unitRef="usd" contextRef="ifd6f3969e6c8426fa1c64cce894e6e50_D20220801-20220831" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTAx_058fd478-28e3-4a0e-87f1-c6b2da28179e">1.0</ix:nonFraction>&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Convertible Notes pay interest semi-annually in arrears on February 15th and August 15th of each year at an annual rate of <ix:nonFraction unitRef="number" contextRef="if3d4edc7f65c461d9431d7d9efcc56e9_I20220831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNzI0_56f4126d-c814-4245-9526-1dbef82d25b0">1.00</ix:nonFraction>%. The 2028 Convertible Notes are general unsecured obligations and rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2028 Convertible Notes, rank equally in right of payment with all existing and future liabilities that are not so subordinated, are effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2028 Convertible Notes have a maturity date of August 15, 2028.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2028 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2022, if the last reported sale price per share of common stock exceeds <ix:nonFraction unitRef="number" contextRef="i5418d7fce8df4268a313fe8e25d35226_D20220801-20220831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTYyOQ_d5b0a876-6983-481c-b29e-96ea504ee93d">130</ix:nonFraction>% of the conversion price for each of at least <ix:nonFraction unitRef="trading_day" contextRef="i5418d7fce8df4268a313fe8e25d35226_D20220801-20220831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTY3Nw_b154625b-f4c5-4fed-8970-562c74280ef9">20</ix:nonFraction> trading days during the <ix:nonFraction unitRef="trading_day" contextRef="i5418d7fce8df4268a313fe8e25d35226_D20220801-20220831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTcwNA_b319c04f-d319-4e80-b3dd-f324ded7ae9c">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the <ix:nonFraction unitRef="businessday" contextRef="ia9437143ea354b0fb66fc8e352a8fad9_D20220801-20220831" decimals="INF" name="halo:DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTg0MQ_f9e768c3-4581-4e0f-a105-9ca97d329eb3">five</ix:nonFraction> consecutive business days immediately after any <ix:nonFraction unitRef="trading_day" contextRef="ia9437143ea354b0fb66fc8e352a8fad9_D20220801-20220831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTg5Mg_b4b0410d-ccd3-473a-a1db-b413088a305b">five</ix:nonFraction> consecutive trading day period (such <ix:nonFraction unitRef="trading_day" contextRef="ia9437143ea354b0fb66fc8e352a8fad9_D20220801-20220831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTkzMg_88bae73b-fdcc-46e2-99b8-52a1090f4204">five</ix:nonFraction> consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="ia9437143ea354b0fb66fc8e352a8fad9_D20220801-20220831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMjExOA_bdbf4cff-ac55-41fe-8d87-ced9c56a6277">98</ix:nonFraction>% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2028 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, February 15, 2028 until the close of business on the second scheduled trading day immediately before the maturity date. As of March&#160;31, 2023, the 2028 Convertible Notes are not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal, and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2028 Convertible Notes is <ix:nonFraction unitRef="number" contextRef="ifd6f3969e6c8426fa1c64cce894e6e50_D20220801-20220831" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMjk2OQ_92b4d427-453a-4162-b3bf-1784d546cd35">17.8517</ix:nonFraction> shares of common stock per $1,000 in principal amount of 2028 Convertible Notes, equivalent to a conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="if3d4edc7f65c461d9431d7d9efcc56e9_I20220831" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMzA5OQ_a68517f1-e365-4f89-974e-576ee870b0c7">56.02</ix:nonFraction> per share of our common stock. The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued or unpaid interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capped Call Transactions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the 2028 Convertible Notes, we entered into capped call transactions with certain counterparties (the &#8220;Capped Call Transactions&#8221;). The Capped Call Transactions are expected generally to reduce potential dilution to holders of our common stock upon conversion of the 2028 Convertible Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the principal amount of such converted 2028 Convertible Notes. The cap price of the Capped Call Transactions is initially $<ix:nonFraction unitRef="usdPerShare" contextRef="i4b687461f70242228d9fa67322314ce3_I20220831" decimals="4" name="halo:DebtInstrumentCapCallTransactionCapPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMzk3Mg_3c793a2d-4881-460a-ab3b-0b6a37168ebc">75.4075</ix:nonFraction> per share of common stock, representing a premium of <ix:nonFraction unitRef="number" contextRef="ic03a55962ac146dfb9a17293e7c10f01_D20220801-20220831" decimals="INF" name="halo:SaleOfStockPremiumOverLastReportedSalePricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNDAyOA_ed55bce7-e453-406c-ae54-99c2c6c6a416">75</ix:nonFraction>% above the last reported sale price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i875da9e8bc6f447e83c35dccc1bce549_I20220815" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNDA3MA_9c5273f6-5d2d-482a-8612-ddcdc4b817cd">43.09</ix:nonFraction> per share of common stock on August 15, 2022, and is subject to certain adjustments under the terms of the Capped Call Transactions. As of March&#160;31, 2023, no capped calls have been exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to their terms, the capped calls qualify for classification within stockholders&#8217; equity in the condensed consolidated balance sheets, and their fair value is not remeasured and adjusted as long as they continue to qualify for stockholders&#8217; equity classification. We paid approximately $<ix:nonFraction unitRef="usd" contextRef="ic03a55962ac146dfb9a17293e7c10f01_D20220801-20220831" decimals="-5" name="halo:PaymentForCappedCallTransactions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNDU0Nw_59213aaa-ae2a-4c51-9263-c9652dcde8af">69.1</ix:nonFraction>&#160;million for the Capped Calls, including applicable transaction costs, which was recorded as a reduction to additional paid-in capital in the condensed consolidated balance sheets. The Capped Call Transactions are separate transactions entered into by us with the capped call Counterparties, are not part of the terms of the Convertible Notes, and do not affect any holder&#8217;s rights under the Convertible Notes. Holders of the Convertible Notes do not have any rights with respect to the Capped Call Transactions.</span></div></ix:continuation><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:continuation id="i8d0610c128f0439689cff9c3d42eea72" continuedAt="ia71f8dd3666242aa853096ff80417009"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i297284b6b3114aa4a934c8c77af6a7ef_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTA1Nw_bdad9cb9-8172-4e9d-97f0-503ef5d52475">0.25</ix:nonFraction>% Convertible Notes due 2027</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed the sale of $<ix:nonFraction unitRef="usd" contextRef="i297284b6b3114aa4a934c8c77af6a7ef_I20210331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTEyNw_31f90907-ae57-4791-9d2b-d6e368666eaa">805.0</ix:nonFraction>&#160;million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i297284b6b3114aa4a934c8c77af6a7ef_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTE2Mw_5abda9d4-c34f-414f-991c-eb60301a2cc8">0.25</ix:nonFraction>% Convertible Senior Notes due 2027 (the &#8220;2027 Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2027 Convertible Notes, after deducting the initial purchasers&#8217; fee of $<ix:nonFraction unitRef="usd" contextRef="i297284b6b3114aa4a934c8c77af6a7ef_I20210331" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTM1OQ_87e519c0-59ba-4039-90f0-bf48b039720a">20.1</ix:nonFraction>&#160;million, was approximately $<ix:nonFraction unitRef="usd" contextRef="i49ac4e10c151449aa37064756bff906c_D20210301-20210331" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTM4MQ_ededc773-d749-4909-abee-a82d1d382039">784.9</ix:nonFraction>&#160;million. We also incurred additional debt issuance costs totaling $<ix:nonFraction unitRef="usd" contextRef="ib53c28890ced4a5e81b120e58423d483_D20210301-20210331" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTQ0Mg_982498c9-3fe9-4054-ae7e-29ebb00452fe">0.4</ix:nonFraction>&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Convertible Notes pay interest semi-annually in arrears on March 1st and September 1st of each year at an annual rate of <ix:nonFraction unitRef="number" contextRef="i297284b6b3114aa4a934c8c77af6a7ef_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTY2Mg_21fc5e68-b760-4d95-a852-f2a76847546e">0.25</ix:nonFraction>%. The 2027 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2027 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2027 Convertible Notes have a maturity date of March 1, 2027.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2027 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021, if the last reported sale price per share of common stock exceeds <ix:nonFraction unitRef="number" contextRef="i62e04ec34e84456a9a1c1c9fce36d738_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNjU3OA_b9809cf8-31d7-4510-a2d1-99cfe8343970">130</ix:nonFraction>% of the conversion price for each of at least <ix:nonFraction unitRef="trading_day" contextRef="i62e04ec34e84456a9a1c1c9fce36d738_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNjYyNg_20383e8e-580b-4f85-92d4-5b8c4c7867e6">20</ix:nonFraction> trading days during the <ix:nonFraction unitRef="trading_day" contextRef="i62e04ec34e84456a9a1c1c9fce36d738_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNjY1Mw_bc9cc1e0-5c6a-4662-9d40-371677bbb15b">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the <ix:nonFraction unitRef="businessday" contextRef="i0a51169caaa348e8906636fb88af0a07_D20210301-20210331" decimals="INF" name="halo:DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNjc5MA_c47ce75d-4f31-48dc-8a98-c8485d3e8714">five</ix:nonFraction> consecutive business days immediately after any <ix:nonFraction unitRef="trading_day" contextRef="i0a51169caaa348e8906636fb88af0a07_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNjg0MQ_c6272799-d1bf-4ea1-9ba7-05470ebb42d0">five</ix:nonFraction> consecutive trading day period (such <ix:nonFraction unitRef="trading_day" contextRef="i0a51169caaa348e8906636fb88af0a07_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNjg4MQ_d978ef21-76ea-460d-b030-2be6d5c1dc1d">five</ix:nonFraction> consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="i0a51169caaa348e8906636fb88af0a07_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNzA2Nw_ce819a59-6993-46d1-832a-08e88e268678">98</ix:nonFraction>% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2027 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately before the maturity date. The 2027 Convertible Notes will be convertible, regardless of the foregoing circumstances, at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately preceding the maturity date. As of March&#160;31, 2023, the 2027 Convertible Notes are not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal, and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2027 Convertible Notes will be <ix:nonFraction unitRef="number" contextRef="ib53c28890ced4a5e81b120e58423d483_D20210301-20210331" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfODE1Ng_d2e495a9-2f85-4483-8bb9-4cda721f212f">12.9576</ix:nonFraction> shares of common stock per $1,000 in principal amount of 2027 Convertible Notes, equivalent to a conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i297284b6b3114aa4a934c8c77af6a7ef_I20210331" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfODI5MA_a66b7393-3f97-4aae-ba3c-160532ae288d">77.17</ix:nonFraction> per share of our common stock. The conversion rate is subject to adjustment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i98820adb7b114fab89f1dcfab8fb0f09_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfODUwNA_c4c79ef2-31a1-4436-90ca-3afe65bf31ee">1.25</ix:nonFraction>% Convertible Notes due 2024</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we completed the sale of $<ix:nonFraction unitRef="usd" contextRef="i98820adb7b114fab89f1dcfab8fb0f09_I20191130" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfODU3Nw_640a8746-24cf-4c71-bc29-3028371e212e">460.0</ix:nonFraction> million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i98820adb7b114fab89f1dcfab8fb0f09_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfODYxMw_67288958-0884-456a-ac66-4b32079a9b36">1.25</ix:nonFraction>% Convertible Senior Notes due 2024 (&#8220;2024 Convertible Notes&#8221;). The net proceeds in connection with 2024 Convertible Notes, after deducting the initial purchases&#8217; fee of $<ix:nonFraction unitRef="usd" contextRef="i98820adb7b114fab89f1dcfab8fb0f09_I20191130" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfODc5MA_6428512b-b020-43e3-8c7c-1a1660ccbabf">12.7</ix:nonFraction>&#160;million, was approximately $<ix:nonFraction unitRef="usd" contextRef="i2bd17b29b4a74fd99bf9cb4435a081cf_D20191101-20191130" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfODgxMg_3cd90b24-ad16-406e-89ed-0ef3ed8bf525">447.3</ix:nonFraction> million. We also incurred debt issuance cost totaling $<ix:nonFraction unitRef="usd" contextRef="i295b45eca4f04978ad6b88c2a0a40c9b_D20191101-20191130" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfODg2MQ_bbff20f3-bc6b-4988-b69a-cad26c1266ea">0.3</ix:nonFraction>&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Convertible Notes pay interest semi-annually in arrears on June 1st and December 1st of each year, beginning on June 1, 2020, at an annual rate of <ix:nonFraction unitRef="number" contextRef="i98820adb7b114fab89f1dcfab8fb0f09_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfOTEwNw_b0dad8f2-a3f8-487d-ae0c-74c063d705be">1.25</ix:nonFraction>%. The 2024 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2024 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2024 Convertible Notes have a maturity date of December 1, 2024.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia71f8dd3666242aa853096ff80417009" continuedAt="i94baba7fa4e84edd988604fe5bbfeb36"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2024 Convertible Notes at their option only in the following circumstances: (1)&#160;during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2020, if the last reported sale price per share of common stock exceeds <ix:nonFraction unitRef="number" contextRef="icf91861e2376494b8f674c6a659fb5c1_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTAwMjY_bd7c5675-c4b5-4031-af19-a2470da5be29">130</ix:nonFraction>% of the conversion price for each of at least <ix:nonFraction unitRef="trading_day" contextRef="icf91861e2376494b8f674c6a659fb5c1_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTAwNzQ_40a38738-cc10-4e33-a178-4c124a688348">20</ix:nonFraction> trading days during the <ix:nonFraction unitRef="trading_day" contextRef="icf91861e2376494b8f674c6a659fb5c1_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTAxMDE_3dfeddf8-bb92-428c-8770-eda137ad2a7e">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2)&#160;during the <ix:nonFraction unitRef="trading_day" contextRef="ibc695c8e9d5e48179ccc383f1676101c_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTAyMzg_ae66e4fa-9f30-4dfa-93dd-bbde3ade61f6">five</ix:nonFraction> consecutive business days immediately after any <ix:nonFraction unitRef="trading_day" contextRef="ibc695c8e9d5e48179ccc383f1676101c_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTAyODk_8fec02ed-18eb-40af-8e32-a73ad38fe88d">five</ix:nonFraction> consecutive trading day period (such <ix:nonFraction unitRef="trading_day" contextRef="ibc695c8e9d5e48179ccc383f1676101c_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTAzMjk_d6bbecc0-3530-4c4e-8993-eec19174fb60">five</ix:nonFraction> consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="ibc695c8e9d5e48179ccc383f1676101c_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTA1MTU_68e48dcc-1c3c-4bd2-8e85-82361fff416d">98</ix:nonFraction>% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3)&#160;upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2024 Convertible Notes; (4)&#160;if we call such notes for redemption; and (5)&#160;at any time from, and including, June&#160;1, 2024 until the close of business on the scheduled trading day immediately before the maturity date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we notified the note holders of our irrevocable election to settle the principal of the 2024 Convertible Notes in cash and for the premium, if applicable, to deliver shares of common stock. The conversion rate for the 2024 Convertible Notes will be <ix:nonFraction unitRef="number" contextRef="i09030ba483314a21b46d9dd361c0aa83_D20210101-20210131" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTE0MTQ_437a3f1a-86ad-413f-b30f-ed648a6ef95f">41.9208</ix:nonFraction> shares of common stock per $1,000 in principal amount of 2024 Convertible Notes, equivalent to a conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i8cf5bff84e7842eab1e94ae576059f7e_I20210131" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTE1NDg_c13f9b7a-a696-464a-9898-671e4b2706a2">23.85</ix:nonFraction> per share of our common stock. The conversion rate was subject to adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed a privately negotiated induced conversion of $<ix:nonFraction unitRef="usd" contextRef="i0b9f1075f25446e3857aa8ab0613536f_D20210301-20210331" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTE3MDE_65462db2-ff69-4bfd-bff7-6c7c6a3b71d0">369.1</ix:nonFraction>&#160;million principal amount of the 2024 Convertible Notes (&#8220;2021 Note Repurchases&#8221; or the &#8220;2021 Induced Conversion&#8221;). In connection with the 2021 Induced Conversion, we paid approximately $<ix:nonFraction unitRef="usd" contextRef="i0b9f1075f25446e3857aa8ab0613536f_D20210301-20210331" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTE4ODE_2d2321c1-510c-4f00-b8bd-35a90657a8bc">370.2</ix:nonFraction>&#160;million in cash, which includes principal and accrued interest, and issued approximately <ix:nonFraction unitRef="shares" contextRef="i0b9f1075f25446e3857aa8ab0613536f_D20210301-20210331" decimals="-4" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTE5NjU_94c354bd-33f6-4c1e-8a78-abaf7272768f">9.08</ix:nonFraction>&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the 2021 Induced Conversion, we recorded $<ix:nonFraction unitRef="usd" contextRef="ifbcb0ae49876436997c9d2b2422116d1_D20210101-20211231" decimals="-5" name="us-gaap:InducedConversionOfConvertibleDebtExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTIxODE_57c6168e-bfaf-470c-bdc8-7a36bf409ff3">0.0 million</ix:nonFraction> in induced conversion expense which was included in other income (expense) of the condensed consolidated statements of income in 2021. The induced conversion expense represented the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we completed a privately negotiated induced conversion of $<ix:nonFraction unitRef="usd" contextRef="i3eda99a3ab274f3189aed8a7cd000ecc_D20220801-20220831" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTI1ODc_2eb1fe05-5d9a-4dc8-b11f-a77fd9ecc1a5">77.4</ix:nonFraction>&#160;million principal amount of the 2024 Convertible Notes (&#8220;2022 Note Repurchases&#8221; or the &#8220;2022 Induced Conversion&#8221;). In connection with the 2022 Induced Conversion, we paid approximately $<ix:nonFraction unitRef="usd" contextRef="i3eda99a3ab274f3189aed8a7cd000ecc_D20220801-20220831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTI3Njc_0a1a61c8-b843-454b-8ed0-b0e9f50c730b">77.6</ix:nonFraction>&#160;million in cash, which includes principal and accrued interest, and issued approximately <ix:nonFraction unitRef="shares" contextRef="i3eda99a3ab274f3189aed8a7cd000ecc_D20220801-20220831" decimals="-4" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTI4NTE_f8f8f669-f4a1-47d7-8b37-ee3a10733d83">1.51</ix:nonFraction>&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the 2022 Induced Conversion, we recorded $<ix:nonFraction unitRef="usd" contextRef="i3eda99a3ab274f3189aed8a7cd000ecc_D20220801-20220831" decimals="-5" name="us-gaap:InducedConversionOfConvertibleDebtExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTMwNjc_7f617ab1-6c3c-48c6-91e3-4fe2be79484e">2.7</ix:nonFraction>&#160;million in induced conversion expense which was included in other income (expense) of the condensed consolidated statements of income in 2022. The induced conversion expense represented the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we issued a notice for the redemption of 2024 Convertible Notes. Holders of the notes may convert their notes at any time prior the close of business day prior to the redemption date. In March 2023, holders of the notes elected to convert the 2024 Convertible Notes in full. In connection with the conversion, we paid approximately $<ix:nonFraction unitRef="usd" contextRef="i7511bded3501417cb4e2415a6bcbd39b_D20230301-20230331" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTQ5NzU1ODMyODgx_eae86732-3be1-4803-b3f6-9528c5c349b5">13.5</ix:nonFraction> million in cash which includes principal and accrued interest, and issued <ix:nonFraction unitRef="shares" contextRef="i7511bded3501417cb4e2415a6bcbd39b_D20230301-20230331" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTQ5NzU1ODMzMTcz_8ba37d8c-d701-4827-8540-7e09c8b3d6c5">288,886</ix:nonFraction> shares of our common stock representing the intrinsic value based on the contractual conversion rate.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:continuation id="i94baba7fa4e84edd988604fe5bbfeb36" continuedAt="i4657598d71c841cab1c99e4e362e1fc3"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTc5MjI_3e9d95ae-a21d-44dd-b415-ef2e1febc6df" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Carrying Amounts of our Convertible Notes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and fair value of our Convertible Notes were as follows (in thousands). </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:69.570%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.474%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e312be945a2402db2f373983b98f7d7_I20230331" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMi0yLTEtMS05NzgzOQ_d6661092-716c-4c4b-bd43-6fabeabe2b0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c04eddabc54f759c9fb4de56fb03f4_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMi00LTEtMS05NzgzOQ_c31434f4-ecba-4a59-a1bb-812b89567b8c">13,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aafe649a1244a06b7cb31af4030dfbd_I20230331" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMy0yLTEtMS05NzgzOQ_0d1199da-f48e-4af5-9c07-f27f9c1da4c1">805,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6816f5120aee4e1790a693cbeb24b81b_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMy00LTEtMS05NzgzOQ_049111be-dcc4-4c50-a9d7-f75a2abc48da">805,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i256de7cb03ee49139431754c4ae916aa_I20230331" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfNC0yLTEtMS05NzgzOQ_2202e26d-1144-4621-8f27-ac5d9157f99f">720,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i166af7e00a904a83b5854157af961f65_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfNC00LTEtMS05NzgzOQ_8f964dbc-c1b2-4c38-8625-93fcdc303ba1">720,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Principal Amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfNS0yLTEtMS05NzgzOQ_010ceb4a-4d82-4949-a067-94033f41728a">1,525,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfNS00LTEtMS05NzgzOQ_7259345b-8e8e-419a-8322-7d62c59f6a6d">1,538,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e312be945a2402db2f373983b98f7d7_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfOC0yLTEtMS05NzgzOQ_8a1c9d6b-f2ce-4d38-a8db-4f3edd083004">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82c04eddabc54f759c9fb4de56fb03f4_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfOC00LTEtMS05NzgzOQ_2a99291e-2a7e-4c01-81c8-c9c0dbbe25d0">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3aafe649a1244a06b7cb31af4030dfbd_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfOS0yLTEtMS05NzgzOQ_6e47b544-cea2-4058-8f9e-7e03815815ba">13,509</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6816f5120aee4e1790a693cbeb24b81b_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfOS00LTEtMS05NzgzOQ_d9968260-a5cf-440e-bebc-995dc85e741d">14,359</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i256de7cb03ee49139431754c4ae916aa_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTAtMi0xLTEtOTc4Mzk_19500276-bc4d-46bd-9785-0f8f0c0ee784">17,111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i166af7e00a904a83b5854157af961f65_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTAtNC0xLTEtOTc4Mzk_7b0c3964-d021-4b6d-8b0d-9f4adf5c36cc">17,875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTEtMi0xLTEtOTc4Mzk_79e4d2de-d8d4-4b2f-b72a-56a71871e51b">30,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTEtNC0xLTEtOTc4Mzk_ab864574-c4b9-40e7-a1c3-a89cfab460bb">32,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e312be945a2402db2f373983b98f7d7_I20230331" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTQtMi0xLTEtOTc4Mzk_dcc0cfa7-3ef4-4e80-8db9-c74710be44f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c04eddabc54f759c9fb4de56fb03f4_I20221231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTQtNC0xLTEtOTc4Mzk_a943227a-20d4-4d0b-9c16-67185fe74de8">13,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aafe649a1244a06b7cb31af4030dfbd_I20230331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTUtMi0xLTEtOTc4Mzk_5b79fdff-73a9-46ff-804a-b884ff4ceea7">791,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6816f5120aee4e1790a693cbeb24b81b_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTUtNC0xLTEtOTc4Mzk_fea7e419-9eca-4103-86b8-c4ff016be99b">790,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i256de7cb03ee49139431754c4ae916aa_I20230331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTYtMi0xLTEtOTc4Mzk_3eac5eaf-9170-4765-aa75-2c0df8149be4">702,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i166af7e00a904a83b5854157af961f65_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTYtNC0xLTEtOTc4Mzk_018b210d-baae-49af-82c0-a58901406bb0">702,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTctMi0xLTEtOTc4Mzk_53d4a18b-c0be-4e24-886a-59c17454940e">1,494,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTctNC0xLTEtOTc4Mzk_edb2605a-9d85-42c8-90cf-a20f24063bfc">1,506,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value based on trading levels (Level 2):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e312be945a2402db2f373983b98f7d7_I20230331" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjAtMi0xLTEtOTc4Mzk_e580f19b-1ccd-4e6e-bed2-816cee40fb65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c04eddabc54f759c9fb4de56fb03f4_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjAtNC0xLTEtOTc4Mzk_aa6d3da3-f3fe-4415-bb0a-ff38bf5c0444">32,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aafe649a1244a06b7cb31af4030dfbd_I20230331" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjEtMi0xLTEtOTc4Mzk_e73db72b-ad9a-4399-837a-9f9d1ece2634">682,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6816f5120aee4e1790a693cbeb24b81b_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjEtNC0xLTEtOTc4Mzk_738965d0-782b-42bc-a44a-981d559fbf01">784,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i256de7cb03ee49139431754c4ae916aa_I20230331" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjItMi0xLTEtOTc4Mzk_763bda3f-e07e-4726-87bb-6fa69c5ff6cd">680,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i166af7e00a904a83b5854157af961f65_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjItNC0xLTEtOTc4Mzk_e5d11e3b-ea58-45b0-abbb-8c87ec725bcc">849,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of outstanding notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135c9d6e5363476397deb7376556416f_I20230331" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjMtMi0xLTEtOTc4Mzk_cf3fc32d-2bda-4493-b953-45767b874352">1,363,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjMtNC0xLTEtOTc4Mzk_0841f982-e70e-495a-8cd6-73d20a2cc365">1,666,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization per period of debt discount (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03816f914d7a447986a953007197bb96_D20220101-20221231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjYtNC0xLTEtOTc4Mzk_31fc0e90-d005-44fd-b0e8-5f21863de70c">1.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4fb3535e833444bdbbab874679ac6563_D20230101-20230331" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjctMi0xLTEtOTc4Mzk_942f60f0-319c-4328-9b37-b1b1498849c6">3.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9afd86f45c5e469cbf3764deb77b2e92_D20220101-20221231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjctNC0xLTEtOTc4Mzk_aba8d88b-c006-4737-a21f-a9581b20e472">4.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib5ffcb548d7140e1ac76a8652c62766b_D20230101-20230331" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjgtMi0xLTEtOTc4Mzk_c720884d-f1c0-40e0-8d7f-5eec0a97d27e">5.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7a88cde3434f468b8176c193c6db698f_D20220101-20221231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjgtNC0xLTEtMTA2Mjgw_29873911-6e83-4bd2-b1f9-bfc7d03e55f5">5.6</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:continuation id="i4657598d71c841cab1c99e4e362e1fc3" continuedAt="i4100fa2df1684a24b9e57b6d91c5e633"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTc5MzE_fb0d4e70-fa0a-463d-8574-90783929796b" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes (in thousands).</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:71.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818a916aac4f44ffa2bd008ffe38a30a_D20230101-20230331" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMy0yLTEtMS05NzgzOQ_17717c9f-59ff-4b32-a5b5-8027f92a6aac">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d86a86d4dc47ecb2dfffda2f52ab0f_D20220101-20220331" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMy00LTEtMS05NzgzOQ_5f917379-5f2e-4dad-9b27-14e69daa7d4f">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i388d4ea90c0548c39bda4283394ecd6c_D20230101-20230331" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfNC0yLTEtMS05NzgzOQ_340c78f0-f333-4dc3-99b7-047e5b9f3d37">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ec2ac8d55a4479a3ff4cc2ff76befb_D20220101-20220331" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfNC00LTEtMS05NzgzOQ_645b06ba-db49-4db5-af5b-213c4c78073a">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46a442da67054fd9b76638faf6b88d76_D20230101-20230331" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfNS0yLTEtMS05NzgzOQ_1638edb8-7304-48e9-96d2-1763cef8c663">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4da77d8421473cb59e66faa8374380_D20220101-20220331" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfNS00LTEtMS05NzgzOQ_da3914b4-f13d-4a4d-9849-3992e766b99a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total coupon interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic86e248bcecd4584b1f877e96f7336cd_D20230101-20230331" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfNi0yLTEtMS05NzgzOQ_f765ede6-a4a2-4a57-b8cc-64624564564a">2,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a48adbd00143d6b8660e90fb91cae0_D20220101-20220331" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfNi00LTEtMS05NzgzOQ_442b987b-7818-44ca-adb7-60b73bc42f73">787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818a916aac4f44ffa2bd008ffe38a30a_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfOS0yLTEtMS05NzgzOQ_17f8f3d7-ecbd-43fc-a43f-f0a802c537c1">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d86a86d4dc47ecb2dfffda2f52ab0f_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfOS00LTEtMS05NzgzOQ_25937cac-f39a-4f1e-b230-a35181bcdb4b">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i388d4ea90c0548c39bda4283394ecd6c_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTAtMi0xLTEtOTc4Mzk_e509d405-0708-49c7-b93b-0720c8430d46">850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ec2ac8d55a4479a3ff4cc2ff76befb_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTAtNC0xLTEtOTc4Mzk_8a33de40-dc8c-402e-b191-3144de91540f">844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46a442da67054fd9b76638faf6b88d76_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTEtMi0xLTEtOTc4Mzk_a523074d-38a4-438b-9db1-3201c50ce46f">764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4da77d8421473cb59e66faa8374380_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTEtNC0xLTEtOTc4Mzk_13bf92db-f059-42b2-a9d0-d1111ad8b5a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic86e248bcecd4584b1f877e96f7336cd_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTItMi0xLTEtOTc4Mzk_aaa1e944-a31f-4794-a1ed-a1557c1eed72">1,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a48adbd00143d6b8660e90fb91cae0_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTItNC0xLTEtOTc4Mzk_0cb28d0d-5f00-4a6a-b332-c30e5c6fde25">971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818a916aac4f44ffa2bd008ffe38a30a_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTUtMi0xLTEtOTc4Mzk_1a518d50-ad01-4582-8ec5-d33153f71af2">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d86a86d4dc47ecb2dfffda2f52ab0f_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTUtNC0xLTEtOTc4Mzk_544097d2-33b8-4a15-ada2-6066f3837b52">411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i388d4ea90c0548c39bda4283394ecd6c_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTYtMi0xLTEtOTc4Mzk_999550e3-8c19-46e1-b0d3-7a7ec4922ecc">1,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ec2ac8d55a4479a3ff4cc2ff76befb_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTYtNC0xLTEtOTc4Mzk_1c940053-805f-447c-8835-4cb023ca751b">1,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46a442da67054fd9b76638faf6b88d76_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTctMi0xLTEtOTc4Mzk_5e344a8d-bfba-400c-9498-b6c0301ea16d">2,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4da77d8421473cb59e66faa8374380_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTctNC0xLTEtOTc4Mzk_295a6e87-0bc8-494f-9746-25dc7ef00406">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic86e248bcecd4584b1f877e96f7336cd_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTgtMi0xLTEtOTc4Mzk_6b40a6f3-d2cd-4d89-8cab-44fe12784065">3,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a48adbd00143d6b8660e90fb91cae0_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTgtNC0xLTEtOTc4Mzk_7a4ff7d2-488f-48fd-ab61-b9be0dbcf0ad">1,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e21cdfacc224f85abe16a6d40aec853_I20230331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMjEtMi0xLTEtOTc4Mzk_8ea3cb33-c4e1-41b2-811b-7330f02bbd91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d608edf583c4031bb38b269eb42b8ea_I20220331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMjEtNC0xLTEtOTc4Mzk_b4e91584-7f9d-44bf-be43-c25bfe543283">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d5d7ddddf33471496c67ca9c24baf70_I20230331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMjItMi0xLTEtOTc4Mzk_71c0b3c0-8531-46c0-b062-b4614cd941f7">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib68465c427954f66928ec69ce2d8bcfe_I20220331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMjItNC0xLTEtOTc4Mzk_6229a131-fde1-4ce9-b672-6f4caa09214d">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i96dbb0d9515a4b9983f224b01c185b89_I20230331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMjMtMi0xLTEtOTc4Mzk_233f326a-a170-4f17-8fc2-19d81bf8d552">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit and Term Loan Facilities (May 2022)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, in connection with the closing of the Antares acquisition, we entered into a credit agreement, which was subsequently amended, with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#8220;2022 Credit Agreement), evidencing a credit facility (the &#8220;2022 Facility&#8221;) that provides for (i) a $<ix:nonFraction unitRef="usd" contextRef="i0426add4fd0d41e9ac294788c419aadb_I20220524" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTQyNzE_92936ffa-d7b1-42bd-8c29-62649f84b14e">350</ix:nonFraction>&#160;million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and (ii) a $<ix:nonFraction unitRef="usd" contextRef="i064840ce987b44589b1984f31ec23ee9_I20220524" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTQzNDU_aba66ffb-b9e4-4e38-afb2-64a1ea0a6052">250</ix:nonFraction>&#160;million term loan facility (the &#8220;Term Facility&#8221;). Proceeds from a $<ix:nonFraction unitRef="usd" contextRef="i52bc8208b75542fe834c04c4a32935e2_D20220524-20220524" decimals="-6" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTQ0MDY_cccdd739-ae16-4aeb-8b3f-63f6fabbc6a1">120</ix:nonFraction>&#160;million draw on the Revolving Credit Facility and the $<ix:nonFraction unitRef="usd" contextRef="i80af1fed659d4797a60c80b15182657c_D20220524-20220524" decimals="-6" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTQ0NTU_58fb721b-6cbe-4021-a46e-4ec0cc90bacf">250</ix:nonFraction>&#160;million Term Facility were used to fund a portion of the Antares acquisition, repay Antares&#8217; existing debt and pay fees and expenses in connection with the Antares acquisition. The 2022 Credit Agreement contains an expansion feature, which allows us, subject to certain conditions, to increase the aggregate principal amount of the 2022 Facility, provided we remain in compliance with underlying financial covenants on a pro forma basis including the consolidated interest coverage ratio and the consolidated net leverage ratio covenants set forth in the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth years following the Closing in annual amounts equal to <ix:nonFraction unitRef="number" contextRef="i92b9cedcf3f2470db29567877e9ab56b_I20220524" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTUzOTE_47c21c24-23d3-4173-8e17-1d76f0f271fe">2.50</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i6c4153c5687046e5b97fe69b5b5dd0a7_I20220524" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTUzOTU_491e05b9-c099-4ea1-a511-1c025d434f16">5.00</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i849dc496423d470899ceba933ef3cddb_I20220524" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTUzOTk_abe166bf-9547-4b8b-96df-5107e8c1567a">7.50</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ic433e02b2e524802bd9b3db31defcb80_I20220524" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTU0MDY_113a815c-51a5-40bd-bb83-bb3cba04cc6d">10.00</ix:nonFraction>% of the initial principal amount of the term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales, subject to our right to reinvest the proceeds thereof.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4100fa2df1684a24b9e57b6d91c5e633"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the applicable Term Secured Overnight Financing Rate (SOFR) (which includes a SOFR adjustment of <ix:nonFraction unitRef="number" contextRef="ic21b915c10f948c5be0345f6cca32742_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTU4NDA_de4cfaa0-c9a9-4060-8a28-0a8ab23d64ec">0.10</ix:nonFraction>%), or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus <ix:nonFraction unitRef="number" contextRef="i921873efde3f4390ba5cf90029a46dfe_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTU5NDg_8f6974f1-5364-4d79-930a-5d144181a8b8">0.50</ix:nonFraction>%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus <ix:nonFraction unitRef="number" contextRef="iaccbd76f32744459bd6ce7634d990a3e_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTYwNTI_f90683eb-7ec5-4be4-8780-6148b202718e">1.10</ix:nonFraction>%, and (4) <ix:nonFraction unitRef="number" contextRef="idbbefd52056444bfada4f4742cd5491a_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTYwNjQ_8588f10b-2d37-4e2a-853f-bf974444180f">1.00</ix:nonFraction>%. The margin for the 2022 Facility ranges, based on our consolidated total net leverage ratio, from <ix:nonFraction unitRef="number" contextRef="i9b315f13ef0b4d7da409254361bf6681_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTYxNjY_6357648b-3aeb-4c1a-979e-74d720769a86">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i1c4765296dd7441193e31a2d3b55cc50_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTYxNzI_0a4fae26-5c41-42bd-923d-24e33b0e7cc5">1.25</ix:nonFraction>% in the case of base rate loans and from <ix:nonFraction unitRef="number" contextRef="iab25dbdafb934ddaa1edddfd20909764_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTYyMTU_e570db9b-8f1d-45f9-b7ab-1d1b0a3467c0">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i77ffcd92787e44a4b19b0c3b9575a7ab_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTYyMjE_0a7b6044-d022-48fb-8486-6e34d65ce2bf">2.25</ix:nonFraction>% in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the Facility, we will pay (i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency fees. The commitment fees range from <ix:nonFraction unitRef="number" contextRef="if5ac304dab2f4cac876a9781e63af963_D20220524-20220524" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTY1MTU_ef7503bd-d99e-4d42-ae6b-b21cd64b5a01">0.15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ie4bb445d76ad4d60806edb24823f807a_D20220524-20220524" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTY1MjE_de94cea7-0605-4abb-bfad-59ddbe8cb2ad">0.35</ix:nonFraction>% per annum based on our consolidated net leverage ratio. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we entered into Amendment No. 1 to the Credit Agreement (the &#8220;Amendment&#8221;) among the Company, the Guarantors (as defined in the Credit Agreement), each L/C Issuer from time to time party thereto, Bank of America, N.A., as Administrative Agent (in such capacity, the &#8220;Administrative Agent&#8221;) and swing line lender (in such capacity, the &#8220;Swing Line Lender&#8221;), and each lender party thereto, which amends the Credit Agreement dated as of May 24, 2022 (the &#8220;Credit Agreement&#8221;) among the Company, the Guarantors, the Administrative Agent, the Swing Line Lender, each Lender and the L/C Issuers. The Amendment, among other things, increased the size of the revolving credit facility from $<ix:nonFraction unitRef="usd" contextRef="i0426add4fd0d41e9ac294788c419aadb_I20220524" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTcyNzg_ee296d26-29b5-4c82-8fd6-4b15603aba49">350</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="ice8cda3f37824ceaadbd1c40fb40a92e_I20220831" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTcyODQ_b1db399f-7812-4009-a773-a3984799c1d0">575</ix:nonFraction>&#160;million. The terms of the Revolving Credit Facility are otherwise unchanged. Concurrently with the entry into the Amendment, we repaid the entire outstanding Term Loan Facility and repaid all outstanding loans under the Revolving Credit Facility under the 2022 Credit Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Revolving Credit Facility was undrawn. We incurred a total of $<ix:nonFraction unitRef="usd" contextRef="i0426add4fd0d41e9ac294788c419aadb_I20220524" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTc2MzU_6605c917-c345-440c-ad40-d9dd85b6fc1b">3.6</ix:nonFraction>&#160;million in third-party costs related to the 2022 Credit Agreement which is recorded as debt issuance cost within prepaid expenses and other assets in the condensed consolidated balance sheets. As of March&#160;31, 2023, the unamortized debt issuance cost related to the revolving credit facility was $<ix:nonFraction unitRef="usd" contextRef="i04c8df8cf25c44f5aab2fcfc36944999_I20230331" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTc5MTM_e8d78b3e-b9c4-44a6-96fd-a4770086db23">2.9</ix:nonFraction> million.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMjU0NA_865ed7d3-96cf-4793-aed0-0a62c6e5f5c5" continuedAt="i29b9ddd15b2447d4acbd9e64e644765d" escape="true">Share-based Compensation</ix:nonNumeric></span></div><ix:continuation id="i29b9ddd15b2447d4acbd9e64e644765d" continuedAt="idbadd16a94fa4324a3f85ec456e48012"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMjU2MQ_fbeda742-1add-4886-b355-5b5bd0bf1865" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total following table summarized share-based compensation expense included in our condensed consolidated statements of income related to share-based awards (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:78.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.322%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2e8da7a634478895e75cec60c5c338_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmE0MDg1MTRlNWRlNTQ3NjRhZDE4NWVjMGFjNDk5MzUxL3RhYmxlcmFuZ2U6YTQwODUxNGU1ZGU1NDc2NGFkMTg1ZWMwYWM0OTkzNTFfMi0yLTEtMS05NzgzOQ_7cbe0a1a-38ee-4345-aa59-a0b0dd1a534b">3,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26ffd244af4f411f8cd2468455cda38a_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmE0MDg1MTRlNWRlNTQ3NjRhZDE4NWVjMGFjNDk5MzUxL3RhYmxlcmFuZ2U6YTQwODUxNGU1ZGU1NDc2NGFkMTg1ZWMwYWM0OTkzNTFfMi00LTEtMS05NzgzOQ_2c80e801-b55d-4725-80b8-82a8354082a5">2,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e27c05190e1407887ac69c8d7d33adf_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmE0MDg1MTRlNWRlNTQ3NjRhZDE4NWVjMGFjNDk5MzUxL3RhYmxlcmFuZ2U6YTQwODUxNGU1ZGU1NDc2NGFkMTg1ZWMwYWM0OTkzNTFfMy0yLTEtMS05NzgzOQ_c8039d70-12a5-4b39-8154-2b7ac7df83b0">4,865</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f9ba0217ca4943af62f30063a6142b_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmE0MDg1MTRlNWRlNTQ3NjRhZDE4NWVjMGFjNDk5MzUxL3RhYmxlcmFuZ2U6YTQwODUxNGU1ZGU1NDc2NGFkMTg1ZWMwYWM0OTkzNTFfMy00LTEtMS05NzgzOQ_5def9469-e3f6-4783-b7c5-99a94fb2dd73">2,725</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmE0MDg1MTRlNWRlNTQ3NjRhZDE4NWVjMGFjNDk5MzUxL3RhYmxlcmFuZ2U6YTQwODUxNGU1ZGU1NDc2NGFkMTg1ZWMwYWM0OTkzNTFfNC0yLTEtMS05NzgzOQ_2c32eda8-806f-4592-b131-4c71edb28c5a">7,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmE0MDg1MTRlNWRlNTQ3NjRhZDE4NWVjMGFjNDk5MzUxL3RhYmxlcmFuZ2U6YTQwODUxNGU1ZGU1NDc2NGFkMTg1ZWMwYWM0OTkzNTFfNC00LTEtMS05NzgzOQ_6e756b25-0ac8-411a-b23f-5c153ea8fd05">4,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMjU2Mg_ebad31d8-6c42-47ec-ba34-fb2bf94ed710" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:78.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.322%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id845f28873224a6287ebf2f2b47ef3d0_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmViMmFjZjcyNzdhZjQ2MDk5ZmM5NjhjZjI1NDQ4MzQxL3RhYmxlcmFuZ2U6ZWIyYWNmNzI3N2FmNDYwOTlmYzk2OGNmMjU0NDgzNDFfMi0yLTEtMS05NzgzOQ_d0a6d64c-2864-4b58-a32b-e8fabb0bfed9">3,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6aae30a5394516b3ad5c031cec59c6_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmViMmFjZjcyNzdhZjQ2MDk5ZmM5NjhjZjI1NDQ4MzQxL3RhYmxlcmFuZ2U6ZWIyYWNmNzI3N2FmNDYwOTlmYzk2OGNmMjU0NDgzNDFfMi00LTEtMS05NzgzOQ_9eeea65e-0418-480f-a4dd-b431cbbe942f">2,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs, PSUs and ESPP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia721a5e3252544d3821885e9d7a30919_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmViMmFjZjcyNzdhZjQ2MDk5ZmM5NjhjZjI1NDQ4MzQxL3RhYmxlcmFuZ2U6ZWIyYWNmNzI3N2FmNDYwOTlmYzk2OGNmMjU0NDgzNDFfMy0yLTEtMS05NzgzOQ_41f02de5-4bd6-4fd9-b852-4c346018b926">4,511</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i457c8fcb2ad444429cbae63ee2c523ba_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmViMmFjZjcyNzdhZjQ2MDk5ZmM5NjhjZjI1NDQ4MzQxL3RhYmxlcmFuZ2U6ZWIyYWNmNzI3N2FmNDYwOTlmYzk2OGNmMjU0NDgzNDFfMy00LTEtMS05NzgzOQ_5735c0e0-d77d-4bbf-a5ee-f3149b2aab87">2,122</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmViMmFjZjcyNzdhZjQ2MDk5ZmM5NjhjZjI1NDQ4MzQxL3RhYmxlcmFuZ2U6ZWIyYWNmNzI3N2FmNDYwOTlmYzk2OGNmMjU0NDgzNDFfNC0yLTEtMS05NzgzOQ_e21524aa-d4ce-45f6-a5d6-51b1f6078a26">7,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmViMmFjZjcyNzdhZjQ2MDk5ZmM5NjhjZjI1NDQ4MzQxL3RhYmxlcmFuZ2U6ZWIyYWNmNzI3N2FmNDYwOTlmYzk2OGNmMjU0NDgzNDFfNC00LTEtMS05NzgzOQ_292c0418-4bdf-4a3d-950f-b8206cff2f02">4,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We granted stock options to purchase approximately <ix:nonFraction unitRef="shares" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMzQ0_e958b6cd-1d76-4349-9910-08667c83e7a1">1.2</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMzUx_3d50737a-4038-4f60-a394-efe8c55fc3be">1.3</ix:nonFraction> million shares of common stock during the three months ended March&#160;31, 2023 and 2022, respectively. The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (&#8220;Black-Scholes model&#8221;). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMjU0Nw_f918b76f-780e-4708-85ec-4e4840bfd48b" continuedAt="i44a143766b9e42a6bfc5351c43c5175f" escape="true">The assumptions used in the Black-Scholes model were as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><ix:continuation id="i44a143766b9e42a6bfc5351c43c5175f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:65.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.851%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i859ed6ba27774ade9888f1c580577c1a_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfMi0yLTEtMS05NzgzOS90ZXh0cmVnaW9uOjRmZjU3ZTEzOTAxYTQzMjlhMDkxOTkyYzA1YTU1NzYzXzQ_8204905f-c412-4e9f-b2ad-8b8dd4900ab1">39.68</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="i81c6c189dc1c414db846950051a68f58_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfMi0yLTEtMS05NzgzOS90ZXh0cmVnaW9uOjRmZjU3ZTEzOTAxYTQzMjlhMDkxOTkyYzA1YTU1NzYzXzc_895505d1-01b7-4111-827a-69ece6c5fd17">39.98</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i16324593b4c9487687f61647a729634f_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfMi00LTEtMS05NzgzOS90ZXh0cmVnaW9uOjQ5ZjllZWNkNGY1NDQwMjc4MDhiMDExZTI5ODI3ZmY2XzQ_ffc76af4-44a8-4e66-8d2d-13a9942ca82b">41.14</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="i5c3a0c9ac8ff414aa0504ce40bfa1e50_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfMi00LTEtMS05NzgzOS90ZXh0cmVnaW9uOjQ5ZjllZWNkNGY1NDQwMjc4MDhiMDExZTI5ODI3ZmY2Xzc_9b2447f4-0794-4900-9962-5f92e476e7cc">41.23</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfMy0yLTEtMS05NzgzOQ_b7165deb-f401-46fa-be2d-935ed33a2aaf">4.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfMy00LTEtMS05NzgzOQ_edb54079-38dc-480d-ac37-de39c51d1c99">4.7</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfNC0yLTEtMS05NzgzOS90ZXh0cmVnaW9uOjk5ZTliMGFhYzQ2OTQ3YTBhYTk5NGNmMDZiMTY1ZDYxXzQ_237d8a3e-924a-419f-a793-58737bc95d3e">3.48</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfNC0yLTEtMS05NzgzOS90ZXh0cmVnaW9uOjk5ZTliMGFhYzQ2OTQ3YTBhYTk5NGNmMDZiMTY1ZDYxXzc_441414eb-ab48-4142-b764-5682da76187b">4.27</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfNC00LTEtMS05NzgzOS90ZXh0cmVnaW9uOjk2YTlkMDYzMTFiYjRjYWViNDIzODc3M2ZmMjZmNDg3XzQ_4a7429f9-74a2-40fb-9227-2ece99a276b9">1.37</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfNC00LTEtMS05NzgzOS90ZXh0cmVnaW9uOjk2YTlkMDYzMTFiYjRjYWViNDIzODc3M2ZmMjZmNDg3Xzc_1a1b4327-4b2b-4ebe-9e28-be99539c49c9">1.90</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfNS0yLTEtMS05NzgzOQ_c0a9ac73-475c-4cb9-8a0d-835369110693">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfNS00LTEtMS05NzgzOQ_0050166e-43d1-4a82-b522-df19ee1bf926">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, our Board of Directors approved our 2021 ESPP and our stockholders approved the plan in May 2021. The ESPP enables eligible employees to purchase shares of our common stock at the end of each offering period at a price equal to <ix:nonFraction unitRef="number" contextRef="i92a039cdfbbf4fa8af99885fb9696846_D20210201-20210228" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMTU0MA_b377cf3e-a805-457b-be6d-ce134fe764aa">85</ix:nonFraction>% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Share purchases are funded through payroll deduction of at least <ix:nonFraction unitRef="number" contextRef="ic595728a50dc437dbd456b98049dd40d_I20210228" decimals="INF" name="halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMTc0Mg_fa5104b4-bb19-4608-ac7e-f05b55ca97f5">1</ix:nonFraction>% and up to <ix:nonFraction unitRef="number" contextRef="ic595728a50dc437dbd456b98049dd40d_I20210228" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMTc1NQ_37088511-7d0c-46f8-8378-a141cd6bdd16">15</ix:nonFraction>% of an employee&#8217;s compensation for each payroll period, and no employee may purchase shares under the ESPP that exceeds $<ix:nonFraction unitRef="usd" contextRef="i92a039cdfbbf4fa8af99885fb9696846_D20210201-20210228" decimals="-3" name="halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMTg3Nw_f61e0b0c-adae-4d08-8a11-29a2dafac6a8">25,000</ix:nonFraction> worth of our common stock for a calendar year. As of March&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="i5ed2833f90c64a0b9b7117a1df7588fe_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMTkzNw_4a63e288-da99-48cf-bf86-b406e4025d57">2,650,103</ix:nonFraction> shares were available for future purchase. The offering period is generally for a <ix:nonNumeric contextRef="i92a039cdfbbf4fa8af99885fb9696846_D20210201-20210228" name="halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMjU0Mw_da510416-07a7-4d7d-aa20-71120fe38d80">six-month</ix:nonNumeric> period and the first offering period commenced on June 16, 2021. Offering periods shall commence on or about the sixteenth day of June and December of each year and end on or about the fifteenth day of the next December and June, respectively, occurring thereafter. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idbadd16a94fa4324a3f85ec456e48012"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMjU1OQ_6154242f-d77d-4221-8b0f-7c326e807d97" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized was as follows (in thousands, unless otherwise noted):</span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"><tr><td style="width:1.0%"></td><td style="width:66.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.030%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining<br/>Weighted-Average<br/>Recognition Period<br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98636a07909a4eb082fd10e5a0c20ab2_I20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMyMDcyNTA2NjJjNzQ4ZTU4ZTJiYzVhMWY4YzJiNWQ0L3RhYmxlcmFuZ2U6YzIwNzI1MDY2MmM3NDhlNThlMmJjNWExZjhjMmI1ZDRfMi0yLTEtMS05NzgzOQ_45e9e64e-f393-492a-b959-6c20f2793aa1">45,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id845f28873224a6287ebf2f2b47ef3d0_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMyMDcyNTA2NjJjNzQ4ZTU4ZTJiYzVhMWY4YzJiNWQ0L3RhYmxlcmFuZ2U6YzIwNzI1MDY2MmM3NDhlNThlMmJjNWExZjhjMmI1ZDRfMi00LTEtMS05NzgzOQ_af5ae3b7-4bd7-4a93-a054-6475c3ed5086">3.00</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6ab22e429fd4490ace65357489d0522_I20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMyMDcyNTA2NjJjNzQ4ZTU4ZTJiYzVhMWY4YzJiNWQ0L3RhYmxlcmFuZ2U6YzIwNzI1MDY2MmM3NDhlNThlMmJjNWExZjhjMmI1ZDRfNC0yLTEtMS05NzgzOQ_8462b5fa-bd91-4d5f-aa5b-9043d4d7ee85">44,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if0e2d808937f41cb849c6d6eec760399_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMyMDcyNTA2NjJjNzQ4ZTU4ZTJiYzVhMWY4YzJiNWQ0L3RhYmxlcmFuZ2U6YzIwNzI1MDY2MmM3NDhlNThlMmJjNWExZjhjMmI1ZDRfNC00LTEtMS05NzgzOQ_0aa91662-f35a-4b9c-a3fb-9f27f01a1a7d">2.94</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c07ee50572b4618820f8dd73892a316_I20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMyMDcyNTA2NjJjNzQ4ZTU4ZTJiYzVhMWY4YzJiNWQ0L3RhYmxlcmFuZ2U6YzIwNzI1MDY2MmM3NDhlNThlMmJjNWExZjhjMmI1ZDRfNS0yLTEtMS05NzgzOQ_b6c599ac-9186-43d8-bd64-7723e1f34468">9,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9c8cad373a064499b7994b46613c260c_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMyMDcyNTA2NjJjNzQ4ZTU4ZTJiYzVhMWY4YzJiNWQ0L3RhYmxlcmFuZ2U6YzIwNzI1MDY2MmM3NDhlNThlMmJjNWExZjhjMmI1ZDRfNS00LTEtMS05NzgzOQ_a2aef425-c318-4216-9b83-2fb760237cf4">2.12</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aabdf6a6ae54c86b1cc74c5d60a1f07_I20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMyMDcyNTA2NjJjNzQ4ZTU4ZTJiYzVhMWY4YzJiNWQ0L3RhYmxlcmFuZ2U6YzIwNzI1MDY2MmM3NDhlNThlMmJjNWExZjhjMmI1ZDRfNi0yLTEtMS05NzgzOQ_783c3dae-dcbb-4b74-99de-0960bbd9dedc">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1b6b375c49834699b6901ea74bf476d4_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMyMDcyNTA2NjJjNzQ4ZTU4ZTJiYzVhMWY4YzJiNWQ0L3RhYmxlcmFuZ2U6YzIwNzI1MDY2MmM3NDhlNThlMmJjNWExZjhjMmI1ZDRfNi00LTEtMS05NzgzOQ_796cea2a-7fb9-4775-9ae2-3898e6057172">0.21</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center;text-indent:24.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMjcyMw_fcd23c89-c32b-4911-b7d5-1397617717e7" continuedAt="i4b115135a79d4eaea955806f442621a0" escape="true">Stockholders&#8217; Equity </ix:nonNumeric></span></div><ix:continuation id="i4b115135a79d4eaea955806f442621a0"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, we issued an aggregate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id845f28873224a6287ebf2f2b47ef3d0_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfOTU_02538ec0-a379-4ce9-a18f-d29303bb67bc">143,931</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and <ix:nonFraction unitRef="shares" contextRef="i4a6aae30a5394516b3ad5c031cec59c6_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMTAy_44049df0-2a60-4949-affb-40d5c6c9f7b0">172,607</ix:nonFraction> shares of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id845f28873224a6287ebf2f2b47ef3d0_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMjMz_9e574452-067f-4efc-a28b-994ed1410795">16.87</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i4a6aae30a5394516b3ad5c031cec59c6_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMjQw_7b285d3d-0fc9-4542-b2ad-df56bf2ab187">17.21</ix:nonFraction> per share, respectively, for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="id845f28873224a6287ebf2f2b47ef3d0_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMzAy_f151d1d2-ab93-4619-9d7c-874c831bae45">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4a6aae30a5394516b3ad5c031cec59c6_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMzA5_ebc4d628-5a50-4fea-b004-d59a3f6a9c6b">3.0</ix:nonFraction> million, respectively. For the three months ended March&#160;31, 2023 and 2022, we issued <ix:nonFraction unitRef="shares" contextRef="if0e2d808937f41cb849c6d6eec760399_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMzcy_a102cfc4-5307-4ea9-a841-b3bd65ffe397">239,919</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="idf2b9ab6a89d4df59dd4955dcef17ae1_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMzc5_2914aabd-09f6-49b0-916e-6fa2f07adb22">216,886</ix:nonFraction> shares of common stock, respectively, upon vesting of certain RSUs and PSUs for which <ix:nonFraction unitRef="shares" contextRef="if0e2d808937f41cb849c6d6eec760399_D20230101-20230331" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNDY4_080a8e99-8fd3-4817-84d5-9f44f0cd4182">70,733</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="idf2b9ab6a89d4df59dd4955dcef17ae1_D20220101-20220331" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNDc1_578e8169-e3f9-48c7-b949-9496207e35fc">68,425</ix:nonFraction> RSUs were withheld from the RSU holders, respectively, to pay for minimum withholding taxes totaling approximately $<ix:nonFraction unitRef="usd" contextRef="if0e2d808937f41cb849c6d6eec760399_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNTkz_022a003f-0736-4fa2-9385-f7c7620ed8a5">6.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idf2b9ab6a89d4df59dd4955dcef17ae1_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNjAw_d517bf0c-17e7-479f-8127-a82f1e88872d">4.3</ix:nonFraction> million, respectively. Stock options and unvested restricted units totaling approximately <ix:nonFraction unitRef="shares" contextRef="ia1343ec306ed4444b65da6a899a7f2c3_I20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNjg1_f95d084d-85f2-418e-981d-73b857e3db0b">7.8</ix:nonFraction> million shares and <ix:nonFraction unitRef="shares" contextRef="ida5a69f1405a496f802d78313d35c0c3_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNjk5_8e29b016-cae4-41f4-9493-de4672c8ad1b">6.6</ix:nonFraction> million shares of our common stock were outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, the Board of Directors authorized a capital return program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i6b2c4a20e00545ee9fa2fa2f54922dfc_I20211231" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMTUzNg_55149783-759f-4a3e-a520-d8a192d08c34">750.0</ix:nonFraction>&#160;million of outstanding stock over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMTU2Nw_a30831a4-f6f2-4774-9f18-5ca5ed367463">three</span>-year period. During 2021, we repurchased <ix:nonFraction unitRef="shares" contextRef="ifbcb0ae49876436997c9d2b2422116d1_D20210101-20211231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNTQ5NzU1ODE4NDE1_d8b49568-7ac1-4519-ae1d-c328b995497a">3.9</ix:nonFraction>&#160;million shares of common stock for $<ix:nonFraction unitRef="usd" contextRef="i335649d465744f89957988f0508a596e_D20211201-20211231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMTY5OQ_7efe87e5-64ca-432a-859d-884129ce7840">150.0</ix:nonFraction>&#160;million at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifbcb0ae49876436997c9d2b2422116d1_D20210101-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNTQ5NzU1ODE4NDI4_610fc134-c123-4edc-924b-d4280551cdef">38.51</ix:nonFraction>. During 2022, we repurchased <ix:nonFraction unitRef="shares" contextRef="i6f605f48fb46486b8c32365ccf871ecf_D20220101-20221231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNTQ5NzU1ODE4NDM2_3b993e1a-b6f8-4a66-8728-9a2ef8a2eaf3">4.5</ix:nonFraction>&#160;million shares of common stock for $<ix:nonFraction unitRef="usd" contextRef="i6f605f48fb46486b8c32365ccf871ecf_D20220101-20221231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNTQ5NzU1ODE4NDQ5_0318b22d-5dee-49d8-8f18-f3a1194b1964">200.0</ix:nonFraction>&#160;million at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6f605f48fb46486b8c32365ccf871ecf_D20220101-20221231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNTQ5NzU1ODE4NDY1_eb5400ce-d8be-4555-9d51-9c24d13fdee0">44.44</ix:nonFraction>. All shares repurchased under our capital return programs have been retired and have resumed their status of authorized and unissued shares.</span></div><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ScheduleOfTreasuryStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMjcyNw_c4837e7b-0024-4bbb-aaf9-50ce01a6189c" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We had the following activity under the approved share repurchase programs (dollars in thousands, except share and per share data):</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:50.368%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Price paid Per Share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RhYmxlOmYxNWY1NDI3NDAwZjRhN2Q5ZTcwNDkzMDk2Y2Y2YzNkL3RhYmxlcmFuZ2U6ZjE1ZjU0Mjc0MDBmNGE3ZDllNzA0OTMwOTZjZjZjM2RfMi0yLTEtMS05NzgzOQ_cb7a2000-de1d-47b7-81d4-33d4aa37ebc5">4,165,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RhYmxlOmYxNWY1NDI3NDAwZjRhN2Q5ZTcwNDkzMDk2Y2Y2YzNkL3RhYmxlcmFuZ2U6ZjE1ZjU0Mjc0MDBmNGE3ZDllNzA0OTMwOTZjZjZjM2RfMi00LTEtMS05NzgzOQ_706de026-92c6-4eb8-98d1-6370300a949e">36.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RhYmxlOmYxNWY1NDI3NDAwZjRhN2Q5ZTcwNDkzMDk2Y2Y2YzNkL3RhYmxlcmFuZ2U6ZjE1ZjU0Mjc0MDBmNGE3ZDllNzA0OTMwOTZjZjZjM2RfMi02LTEtMS05NzgzOQ_b80ff3ef-2c99-4f32-8301-4096db06d604">150,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RhYmxlOmYxNWY1NDI3NDAwZjRhN2Q5ZTcwNDkzMDk2Y2Y2YzNkL3RhYmxlcmFuZ2U6ZjE1ZjU0Mjc0MDBmNGE3ZDllNzA0OTMwOTZjZjZjM2RfNi0yLTEtMS05NzgzOQ_2c69a68e-28d7-4361-bea8-6e431ae136b6">4,165,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RhYmxlOmYxNWY1NDI3NDAwZjRhN2Q5ZTcwNDkzMDk2Y2Y2YzNkL3RhYmxlcmFuZ2U6ZjE1ZjU0Mjc0MDBmNGE3ZDllNzA0OTMwOTZjZjZjM2RfNi00LTEtMS05NzgzOQ_a9798caa-eec3-46fd-ac33-57546593b5ef">36.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RhYmxlOmYxNWY1NDI3NDAwZjRhN2Q5ZTcwNDkzMDk2Y2Y2YzNkL3RhYmxlcmFuZ2U6ZjE1ZjU0Mjc0MDBmNGE3ZDllNzA0OTMwOTZjZjZjM2RfNi02LTEtMS05NzgzOQ_29b0231e-c597-48ac-8201-546223cae975">150,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)   Included in the total cost of shares purchased is a commission fee of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="2" name="halo:TreasuryStockAcquiredFeeCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMjYyMg_ead554ff-ee8c-4af4-8609-51c782d8523f">0.02</ix:nonFraction> per share.</span></div></ix:nonNumeric></ix:continuation><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. Earnings <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RleHRyZWdpb246MDQzYWYyZmNkOThiNDA4OWJkNWEyZDllNzVkNTEzNWJfMTY1MA_f887dbc0-098c-436b-9f3e-8e7238810a69" continuedAt="i8d248592c56143cea81bf8949290999a" escape="true">per share</ix:nonNumeric></span></div><ix:continuation id="i8d248592c56143cea81bf8949290999a" continuedAt="i6a082c83e8d84e9b845b389c196ebabf"><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per common share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and the Convertible Notes are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares issuable upon vesting of stock options, RSUs and PSUs are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of our Convertible Notes are determined using the if-converted method. Since we have committed to settle the principal amount of the Convertible Notes in cash upon conversion only, the number of shares for the conversion spread will be included as a dilutive common stock equivalent. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RleHRyZWdpb246MDQzYWYyZmNkOThiNDA4OWJkNWEyZDllNzVkNTEzNWJfMTY1MQ_14f553ae-05dc-47b0-a753-c2bca2a4ff7e" continuedAt="ib0a538974a4748a68a74f4f2cacd3dcf" escape="true">A reconciliation of the numerators and the denominators of the basic and diluted earning per common share computations is as follows (in thousands, except per share amounts):</ix:nonNumeric></span></div><div style="margin-top:11pt;text-align:center;text-indent:24.75pt"><ix:continuation id="ib0a538974a4748a68a74f4f2cacd3dcf"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.237%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfMy0yLTEtMS05NzgzOQ_e3aef642-ff83-4de9-9fe7-ff6f76710f3a">39,615</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfMy00LTEtMS05NzgzOQ_5661f12f-3bca-47b6-bf65-8c8f864f219b">60,108</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for basic earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfNS0yLTEtMS05NzgzOQ_11edaa67-6878-4231-864f-d2f537206da7">135,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfNS00LTEtMS05NzgzOQ_ea021a79-a6d8-471a-9b7a-7b7e17afa9d8">137,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common stock outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id845f28873224a6287ebf2f2b47ef3d0_D20230101-20230331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfNy0yLTEtMS05NzgzOQ_31c0e694-8363-470c-86c6-e19179ebfcfe">2,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a6aae30a5394516b3ad5c031cec59c6_D20220101-20220331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfNy00LTEtMS05NzgzOQ_05741a63-2235-40c0-a3fc-c598a848f9ed">2,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs, PSUs and ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f8d6a392c1d4fe8b9e5be6142532df5_D20230101-20230331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfOC0yLTEtMS05NzgzOQ_b76e3990-54f1-48f6-9eac-5df1c4426ca5">468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i752be5578b5b423d8fc0ff6e421f4f83_D20220101-20220331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfOC00LTEtMS05NzgzOQ_b5f21748-288c-4e46-b0e0-579638d96972">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b70d8e746f94570afba56b0ac99fe35_D20230101-20230331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfOS0yLTEtMS05NzgzOQ_0afb597f-b63d-4945-96c3-8702241833f9">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i71746ecec304430aa330b98c5496d867_D20220101-20220331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfOS00LTEtMS05NzgzOQ_68418482-e713-41d0-bd5e-5529faa8f086">1,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfMTAtMi0xLTEtOTc4Mzk_d9d0273a-dd22-4e07-b4ec-d092b39bae07">137,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfMTAtNC0xLTEtOTc4Mzk_4a7e5f45-4abd-4fa5-a73e-9a321d23cc4e">141,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfMTItMi0xLTEtOTc4Mzk_4e97d3e5-ed1b-4d18-93a5-21f3e27e9685">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfMTItNC0xLTEtOTc4Mzk_cf0076d6-441a-42e6-b71e-4b31214efe85">0.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfMTMtMi0xLTEtOTc4Mzk_c9d1d16d-0b01-4663-bf3a-6ee44ae1db14">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfMTMtNC0xLTEtOTc4Mzk_d3e970b5-b3de-41e1-995f-c961b08ab46d">0.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RleHRyZWdpb246MDQzYWYyZmNkOThiNDA4OWJkNWEyZDllNzVkNTEzNWJfMTY1Mg_e3db26e4-1ebf-4c2a-9aea-0c3c74b9cd24" continuedAt="i23be9e092d994683a6a84c5b44a6d976" escape="true"><div style="margin-top:11pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from the calculation of diluted earnings per common share because their effect was anti-dilutive, include the following (shares in millions):</span></div><div style="margin-top:11pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:78.100%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmY3ZDM1Mjg5NGYyZTQ2M2Q5YzBjZGJlZmYzYjcwOGMwL3RhYmxlcmFuZ2U6ZjdkMzUyODk0ZjJlNDYzZDljMGNkYmVmZjNiNzA4YzBfMi0yLTEtMS05NzgzOQ_9df5382e-78b7-402a-9d79-040a7ebb1701">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmY3ZDM1Mjg5NGYyZTQ2M2Q5YzBjZGJlZmYzYjcwOGMwL3RhYmxlcmFuZ2U6ZjdkMzUyODk0ZjJlNDYzZDljMGNkYmVmZjNiNzA4YzBfMi0zLTEtMS05NzgzOQ_a9f68aea-5c7a-40ff-be21-d7e30e4a8cce">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:2pt;padding-left:49.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6a082c83e8d84e9b845b389c196ebabf"><ix:continuation id="i23be9e092d994683a6a84c5b44a6d976">(1)    The anti-dilutive securities include outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and Convertible Notes</ix:continuation></ix:continuation>.</span></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84NS9mcmFnOmI3YjJmNjM3OTk3ZDQxNTRiOTlhY2NmNzcxYzJjMTM1L3RleHRyZWdpb246YjdiMmY2Mzc5OTdkNDE1NGI5OWFjY2Y3NzFjMmMxMzVfMTAwNQ_acb8cfeb-c0cc-4cb4-975e-f161f6ea3411" continuedAt="id0993d0a393d4a008d5931a287a9a6f9" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id0993d0a393d4a008d5931a287a9a6f9">From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our condensed consolidated statements of income and balance sheets. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in our opinion, individually or in the aggregate, would have a material adverse effect on our condensed consolidated statements of income or balance sheets.</ix:continuation></span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. &#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="i2807c465c47449f58323217d8928fdb2_91"></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> used in this report, unless the context suggests otherwise, references to &#8220;Halozyme,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; and &#8220;us&#8221; refer to Halozyme Therapeutics, Inc., its wholly owned subsidiaries, Halozyme, Inc., Antares Pharma Inc., and Antares Pharma Inc.s&#8217; wholly-owned subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. References to &#8220;Notes&#8221; refer to the Notes to Condensed Consolidated Financial Statements included herein (refer to Item 1 of Part I).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following information should be read in conjunction with the interim unaudited condensed consolidated financial statements and Notes thereto included in Item&#160;1 of this Quarterly Report on Form 10-Q, as well as the audited financial statements and notes thereto and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations for the fiscal year ended December&#160;31, 2022, included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022. Past financial or operating performance is not necessarily a reliable indicator of future performance, and our historical performance should not be used to anticipate results or future period trends.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This report contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this report other than statements of historical fact are, or may be deemed to be, forward-looking statements. Words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;think,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;likely,&#8221; &#8220;opportunity,&#8221; &#8220;project&#8221; and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this report. Additionally, statements concerning future matters such as the development or regulatory approval of new partner products, enhancements of existing products or technologies, timing and success of the launch of new products by us and our partners, third party performance under key collaboration agreements, the ability to successfully integrate Antares Pharma, Inc, into our business, the ability of our bulk drug manufacturers to provide adequate supply for our partners, revenue, expense, cash burn levels and our ability to make timely repayments of debt, anticipated amounts and timing of share repurchases, anticipated profitability and expected trends, the potential impact of the COVID-19 global pandemic on our business and trends and other statements regarding matters that are not historical are forward-looking statements. Such statements reflect management&#8217;s current forecast of certain aspects of our future, are based on currently available operating, financial and competitive information and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially from those anticipated or implied in our forward-looking statements due to a number of factors including, but not limited to, those set forth below under the section entitled &#8220;Risks Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q and our most recent Annual Report on Form 10-K. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Quarterly Report.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving the patient experience and potentially outcomes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary enzyme, rHuPH20, is used to facilitate the SC delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery technology (&#8220;ENHANZE&#8221;) with the partners&#8217; proprietary compounds. We also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first commercially approved product, Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recombinant, (&#8220;Hylenex&#8221;), and our ENHANZE partners&#8217; approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in Hylenex, that works by breaking down hyaluronan (&#8220;HA&#8221;), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the SC space. This temporarily reduces the barrier to bulk fluid flow allowing for improved and more rapid SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as ENHANZE. We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (&#8220;IV&#8221;) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing typically required for IV administration, extend the dosing interval for drugs that are already administered subcutaneously and potentially allow for lower rates of infusion-related reactions. ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient or caregiver. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of the proprietary IV drug.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&#8220;Roche&#8221;), Takeda Pharmaceuticals International AG and Baxalta US Inc. (&#8220;Takeda&#8221;), Pfizer Inc. (&#8220;Pfizer&#8221;), Janssen Biotech, Inc. (&#8220;Janssen&#8221;), AbbVie, Inc. (&#8220;AbbVie&#8221;), Eli Lilly and Company (&#8220;Lilly&#8221;), Bristol Myers Squibb Company (&#8220;BMS&#8221;), Alexion Pharma International Operations Unlimited Company (an indirect wholly owned subsidiary of AstraZeneca PLC) (&#8220;Alexion&#8221;), argenx BVBA (&#8220;argenx&#8221;), Horizon Therapeutics plc. (&#8220;Horizon&#8221;), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (&#8220;ViiV&#8221;) and Chugai Pharmaceutical Co., Ltd (&#8220;Chugai&#8221;). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE. We currently receive royalties from three of these collaborations, including royalties from sales of one product from the Takeda collaboration, three products from the Roche collaboration and one product from the Janssen collaboration. Future potential revenues from ENHANZE collaborations and from the sales and/or royalties of our approved products will depend on the ability of our partners, in some areas supported by Halozyme to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our commercial portfolio of proprietary products also includes XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NOCDURNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We also have commercialized auto-injector products with several pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (&#8220;Teva&#8221;), Covis Group S.a.r.l. (&#8220;Covis&#8221;) and Otter Pharmaceuticals, LLC (&#8220;Otter&#8221;). We have development programs including auto-injectors with Idorsia Pharmaceuticals Ltd. (&#8220;Idorsia&#8221;) and Pfizer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first quarter of 2023 and recent key events are as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partners</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">In April 2023, Takeda announced that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved a supplemental Biologics License Application (&#8220;sBLA&#8221;) to expand the use of HYQVIA to treat primary immunodeficiency in children.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2023, BMS initiated a Phase 3 trial to demonstrate the drug exposure levels of nivolumab and relatlimab fixed-dose combination with ENHANZE is not inferior to IV administration in participants with previously untreated metastatic or unresectable melanoma (RELATIVITY-127).</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In January 2023, argenx announced that FDA extended the Prescription Drug User Free Act (&#8220;PDUFA&#8221;) date for SC efgartigimod for the treatment of adults with generalized myasthenia gravis (gMG) to June 20, 2023.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In January 2023, the FDA accepted the Biologics License Application (&#8220;BLA&#8221;) for the SC formulation of Tecentriq with a PDUFA goal date of September 15, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the first quarter of 2023, we repurchased 4.2 million shares of common stock in open market for $150.0 million at an average price per share of $36.01. As of March 31, 2023, we have repurchased a total of 12.6 million shares for $500.0 million at an average price per share of $39.81 under our $750 million 3-year share repurchase plan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2023, the outstanding amount of the 2024 Convertible Notes converted in full and paid $13.5 million in cash and issued 288,886 shares.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product and Product Candidates</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table summarizes our marketed proprietary products and product candidates under development and our marketed partnered products and product candidates under development with our partners:</span></div><div style="margin-top:9pt;text-align:center;text-indent:18pt"><img src="halo-20230331_g2.jpg" alt="Slide 1.jpg" style="height:850px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center;text-indent:18pt"><img src="halo-20230331_g3.jpg" alt="Slide 2.jpg" style="height:850px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-top:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proprietary Products and Product Candidates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hylenex Recombinant (hyaluronidase human injection)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market and sell Hylenex recombinant which is a formulation of rHuPH20 that facilitates SC administration for achieving hydration, increases the dispersion and absorption of other injected drugs and, in SC urography, to improve resorption of radiopaque agents. Hylenex recombinant is currently the number one prescribed branded hyaluronidase. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XYOSTED (testosterone enanthate) Injection</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market and sell our proprietary product XYOSTED for SC administration of testosterone replacement therapy (&#8220;TRT&#8221;) in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadism). XYOSTED is the only FDA-approved SC testosterone enanthate product for once-weekly, at-home self-administration and is approved and marketed in the U.S. in three dosage strengths, 50 mg, 75 mg and 100 mg. Safety and efficacy of XYOSTED in males less than 18 years old have not been established.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOCDURNA (desmopressin acetate) Sublingual Tablets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market and sell NOCDURNA, which is the first and only sublingual tablet indicated for the treatment of nocturia due to nocturnal polyuria (&#8220;NP&#8221;) in adults who awaken at least two times per night to urinate. In the NOCDURNA clinical trials, NP was defined as night-time urine production exceeding one-third of the 24-hour urine production. NOCDURNA is a sublingual tablet, marketed in two dosage strengths in the U.S., that dissolves quickly under the tongue without water and has been shown in clinical studies to reduce nighttime urination by nearly one-half (in patients who average three nighttime bathroom visits.) We license NOCDURNA from Ferring. In October 2022, we notified Ferring that we are terminating the NOCDURNA license agreement with an effective termination date in October 2023.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TLANDO (testosterone undecanoate) Oral Formulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TLANDO is a twice daily oral formulation of testosterone indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadotropic hypogonadism). TLANDO was granted FDA approval in March 2022. In June 2022, we announced the commercial launch of TLANDO in the U.S. Safety and efficacy of TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in males less than 18 years old have not been established.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATRS - 1902</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ongoing program to develop a proprietary drug device combination product for the endocrinology market, for patients who require additional supplemental hydrocortisone, identified as ATRS-1902. The development program uses a novel proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we submitted an IND application with the FDA for the initiation of a Phase 1 clinical study of ATRS-1902 for adrenal crisis rescue. The IND application includes the protocol for an initial clinical study to compare the pharmacokinetic profile of our novel formulation of hydrocortisone versus Solu-Cortef</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is an anti-inflammatory glucocorticoid and is the current standard of care for the management of acute adrenal crises.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the FDA accepted our IND for ATRS-1902 enabling us to initiate our Phase 1 clinical study. The Phase 1 clinical study, designed to evaluate the safety, tolerability and pharmacokinetics (&#8220;PK&#8221;) of a liquid stable formulation of hydrocortisone, was initiated in September 2021. The study was a cross-over design to establish the PK profile of ATRS-1902 (100 mg) compared to Solu-Cortef (100 mg), the reference-listed drug, in 32 healthy adults. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we announced the positive results from the Phase 1 clinical study and were granted Fast Track designation by the FDA. The positive results supported the advancement of our ATRS-1902 development program to a pivotal study for the treatment of acute adrenal insufficiency, using our Vai novel proprietary rescue pen platform to deliver a liquid stable formulation of hydrocortisone. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Partnered Products</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE Collaborations</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Roche Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we and Roche entered into a collaboration and license agreement under which Roche obtained a worldwide license to develop and commercialize product combinations of rHuPH20 and up to twelve Roche target compounds (the Roche Collaboration). Under this agreement, Roche elected a total of eight targets, two of which are exclusive. </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2013, Roche launched a SC formulation of Herceptin (trastuzumab) (Herceptin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SC) in Europe for the treatment of patients with HER2-positive breast cancer followed by launches in additional countries. This formulation utilizes our ENHANZE technology and is administered in two to five minutes, compared to 30 to 90 minutes with the standard IV form. In September 2018, we announced that Roche received approval from Health Canada for Herceptin SC. In February 2019, we announced that Roche received approval from the FDA for Herceptin SC under the brand name Herceptin Hylecta&#8482;. In October 2022, Roche Pharmaceuticals China announced the approval of Herceptin in China.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the FDA approved the fixed-dose combination of Perjeta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pertuzumab) and Herceptin for SC injection (Phesgo&#8482;) utilizing ENHANZE technology for the treatment of patients with HER2-positive breast cancer. In December 2020, the European Commission (&#8220;EC&#8221;) also approved Phesgo. In July 2022, Roche submitted the Initial Marketing Application (&#8220;IMA&#8221;) for the fixed-dose combination of Perjeta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(pertuzumab) and Herceptin for SC injection (Phesgo) to the Center for Drug Evaluation (&#8220;CDE&#8221;) in China. In September 2022, Chugai Pharmaceutical Co., Ltd. (a Member of the Roche Group) announced the submission of a NDA in Japan for the fixed-dose SC combination of pertuzumab and trastuzumab (same monoclonal antibodies as in Perjeta and Herceptin) with ENHANZE. This application is based on data from two clinical studies including the results from the global Phase 3 FeDeriCa study in patients with HER2-positive breast cancer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, Roche launched MabThera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SC in Europe for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL) followed by launches in additional countries. This formulation utilizes our ENHANZE technology and is administered in approximately five minutes compared to the approximately 1.5 to 4 hour IV infusion. In May 2016, Roche announced that the European Medicines Agency (&#8220;EMA&#8221;) approved Mabthera SC to treat patients with chronic lymphocytic leukemia (&#8220;CLL&#8221;). In June 2017, the FDA approved Genentech&#8217;s RITUXAN HYCELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a combination of rituximab using ENHANZE technology (approved and marketed under the MabThera SC brand in countries outside the U.S. and Canada), for CLL and two types of NHL, follicular lymphoma and diffuse large B-cell lymphoma. In March 2018, Health Canada approved a combination of rituximab and ENHANZE (approved and marketed under the brand name RITUXAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SC) for patients with CLL. In November 2022, Roche submitted the IMA for Mabthera SC to CDE in China.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017 and October 2018, we entered into agreements with Roche to develop and commercialize additional exclusive target using ENHANZE technology. The upfront license payment may be followed by event-based payments subject to Roche&#8217;s achievement of specified development, regulatory and sales-based milestones. In addition, Roche will pay royalties to us if products under the collaboration are commercialized.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, Roche initiated a Phase 1b/2 study in patients with non-small cell lung cancer (&#8220;NSCLC&#8221;) for TECENTRIQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (atezolizumab) using ENHANZE technology, followed by initiation of a Phase 3 study in December 2020. In August 2022, Roche announced that the Phase 3 study met its co-primary endpoints showing non-inferior levels of Tecentriq in the blood (pharmacokinetics), when injected subcutaneously, compared with IV infusion, in cancer immunotherapy-na&#239;ve patients with advanced or metastatic NSCLC for whom prior platinum therapy has failed. The safety profile of the SC formulation was consistent with that of IV Tecentriq. In November 2022, Roche submitted BLA to the FDA and a Marketing Authorization Application (&#8220;MAA&#8221;) to the EMA for the SC formulation of Tecentriq with ENHANZE across all approved indications of IV Tecentriq. In January 2023, the FDA accepted the BLA with the official PDUFA goal date of September 15, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Roche initiated a Phase 1 study evaluating OCREVUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ocrelizumab) with ENHANZE technology in subjects with multiple sclerosis, followed by initiation of a Phase 3 study in April 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, Roche nominated a new undisclosed exclusive target to be studied using ENHANZE technology. In November 2021, Roche initiated a Phase 1 study with the undisclosed target and ENHANZE.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2007, we and Takeda entered into a collaboration and license agreement under which Takeda obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 with GAMMAGARD LIQUID (HYQVIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) (the Takeda Collaboration). HYQVIA is indicated for the treatment of primary immunodeficiency disorders associated with defects in the immune system.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2013, the EC granted Takeda marketing authorization in all European Union (&#8220;EU&#8221;) Member States for the use of HYQVIA as replacement therapy for adult patients with primary and secondary immunodeficiencies. Takeda launched HYQVIA in the first EU country in July 2013 and has continued to launch in additional countries. In May 2016, Takeda announced that HYQVIA received a marketing authorization from the EC for a pediatric indication.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2014, HYQVIA was approved by the FDA for treatment of adult patients with primary immunodeficiency in the U.S. HYQVIA is the first SC immune globulin (IG) treatment approved for adult primary immunodeficiency patients with a dosing regimen requiring only one infusion up to once per month (every three to four weeks) and one injection site per infusion in most patients, to deliver a full therapeutic dose of IG.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Takeda announced that the EMA approved a label update for HYQVIA broadening its use and making it the first and only facilitated SC immunoglobulin replacement therapy in adults, adolescents and children with an expanded range of secondary immunodeficiencies (SID).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Takeda initiated a Phase 1 single-dose, single-center, open-label, three-arm study to assess the tolerability and safety of immune globulin SC (human), 20% solution with ENHANZE (TAK-881) at various infusion rates in healthy adult subjects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Takeda announced positive topline results from pivotal Phase 3 trial evaluating HYQVIA, for maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and Takeda confirmed its intention to submit regulatory applications in the U.S. and EU in its fiscal year 2022. In July 2022, Takeda filed sBLA for the potential expanded use of HYQVIA for pediatric indication for primary immunodeficiency. In April 2023, Takeda announced that the FDA approved the sBLA to expand the use of HYQVIA to treat primary immunodeficiency in children.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2012, we and Pfizer entered into a collaboration and license agreement, under which Pfizer has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Pfizer proprietary biologics in primary care and specialty care indications. Pfizer has elected five targets and has returned two targets. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2014, we and Janssen entered into a collaboration and license agreement, under which Janssen has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Janssen proprietary biologics directed to up to five targets. Targets may be selected on an exclusive basis. Janssen elected CD38 and initiated several Phase 3 studies, Phase 2 studies and Phase 1 studies of DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(daratumumab), directed at CD38, using ENHANZE technology in patients with amyloidosis, smoldering myeloma and multiple myeloma.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, Janssen&#8217;s development partner, Genmab, announced positive Phase 3 trial results from the COLUMBA study evaluating SC DARZALEX in comparison to IV DARZALEX in patients with relapsed or refractory multiple myeloma. DARZALEX SC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (utilizing ENHANZE technology) was found to be non-inferior to DARZALEX IV with regard the co-primary endpoints of Overall Response Rate and Maximum Trough concentration. In May 2020, we announced that Janssen received U.S. FDA approval and launched the commercial sale of DARZALEX FASPRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in four regimens across five indications in multiple myeloma patients, including newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients. As a fixed-dose formulation, DARZALEX FASPRO can be administered over three to five minutes, significantly less time than DARZALEX IV which requires multi-hour infusions. In June 2020, we announced that Janssen received European marketing authorization and launched the commercial sale of DARZALEX SC utilizing ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the EU. Subsequent to these approvals, Janssen received several additional regulatory approvals for additional indications and patient populations in the U.S., EU, Japan and China. Beginning with the U.S., in January 2021, Janssen received FDA approval for DARZALEX FASPRO in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplant. In January 2021, Janssen received accelerated approval from the FDA for DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed AL amyloidosis (not recommended for the treatment of patients with AL amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials). In July 2021, Janssen received FDA approval for DARZALEX FASPRO in combination with pomalidomide and dexamethasone (D-Pd) for patients with multiple myeloma after first or subsequent relapse. In July 2021, Janssen received FDA approval for DARZALEX FASPRO in combination with D-Pd for patients with multiple myeloma after first or subsequent relapse. In November 2021, Janssen received FDA approval for DARZALEX FASPRO in combination with Kyprolis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (carfilzomib) and dexamethasone for patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. In the EU, in June 2021, we announced that Janssen received marketing authorization from the EC for DARZALEX SC in two new indications, in combination with D-VCd in newly diagnosed adult patients with AL amyloidosis and in combination with D-Pd in adult patients with relapsed or refractory multiple myeloma. In Japan, in March 2021, Janssen announced approval from Japan&#8217;s Ministry of Health, Labour and Welfare (MHLW) for the SC formulation of DARZALEX (known as DARZQURO in Japan) for the treatment of multiple myeloma, and in May 2021 Janssen commenced commercial sale in Japan. In August 2021, Janssen received approval of DARZQURO for systemic AL amyloidosis in Japan. In China, in October 2021, Janssen&#8217;s DARZALEX FASPRO was approved by the China National Medical Products Administration (NMPA) for the treatment of primary light chain amyloidosis, in combination with D-VCd in newly diagnosed patients.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen elected EGFR and cMET as a bispecific antibody (amivantamab) target on an exclusive basis, which is being studied in solid tumors. In November 2020, Janssen initiated a Phase 1 study of amivantamab and ENHANZE. In September 2022, Janssen initiated a Phase 3 study of lazertinib and amivantamab with ENHANZE in patients with epidermal growth factor receptor (EGFR)-mutated advanced or metastatic non-small cell lung cancer (PALOMA-3). In November 2022, Janssen initiated a Phase 2 study of amivantamab with ENHANZE in multiple regimens in patients with advanced or metastatic solid tumors including epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (PALOMA-2).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, Janssen elected the target HIV reverse transcriptase limited to non-nucleoside reverse transcriptase inhibitors. In December 2021, Janssen initiated a Phase 1 clinical trial combining rilpivirine and ENHANZE. Janssen and ViiV are exploring the possibility of an ultra-long acting version of CABENUVA using ENHANZE</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, we and AbbVie entered into a collaboration and license agreement, under which AbbVie has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with AbbVie proprietary biologics directed to up to nine targets. Targets may be selected on an exclusive basis. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lilly Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, we and Lilly entered into a collaboration and license agreement, under which Lilly has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Lilly proprietary biologics. Lilly currently has the right to select up to three targets. Targets may be selected on an exclusive basis. Lilly has elected two targets on an exclusive basis and one target on a semi-exclusive basis.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BMS Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, we and BMS entered into a collaboration and license agreement, which became effective in November 2017, under which BMS had the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with BMS products directed at up to eleven targets. Targets may be selected on an exclusive basis or non-exclusive basis. BMS has designated multiple immuno-oncology targets including programmed death 1 (PD-1) and has an option to select 3 additional targets by November 2024. In October 2019, BMS initiated a Phase 1 study of relatlimab, an anti-LAG-3 antibody, in combination with nivolumab using ENHANZE technology. In May 2021, BMS initiated a Phase 3 of nivolumab using ENHANZE technology for patients with advanced or metastatic clear cell renal cell carcinoma (CheckMate-67T), leveraging data and insights from Phase 1/2 CA209-8KX study in patients with solid tumors. In June 2022, BMS nominated a new undisclosed target. In March 2023, BMS initiated a Phase 3 trial to demonstrate the drug exposure levels of nivolumab and relatlimab fixed-dose combination with ENHANZE is not inferior than IV administration in participants with previously untreated metastatic or unresectable melanoma (RELATIVITY-127).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alexion Collaboration </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we and Alexion entered into a collaboration and license agreement, under which Alexion has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Alexion&#8217;s portfolio of products directed at up to four exclusive targets and has access to utilize ENHANZE with up to three exclusive targets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">argenx Collaboration </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we and argenx entered into an agreement for the right to develop and commercialize one exclusive target, the human neonatal Fc receptor FcRn, which includes argenx's lead asset efgartigimod (ARGX-113), and an option to select two additional targets using ENHANZE technology. In May 2019, argenx nominated a second target to be studied using ENHANZE technology, a human complement factor C2 associated with the product candidate ARGX-117, which is being developed to treat severe autoimmune diseases in Multifocal Motor Neuropathy (MMN). In October 2020, we and argenx entered into an agreement to expand the collaboration relationship, adding three targets for a total of up to six targets under the collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, argenx dosed the first subject in a phase 1 clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of ARGX-113, using ENHANZE technology. In December 2020, argenx initiated a Phase 3 study of ARGX-113 using ENHANZE technology for patients with immune thrombocytopenia (ITP), an immune disorder in which the blood does not clot normally. In January 2021, argenx initiated a Phase 3 study of ARGX-113 using ENHANZE technology in pemphigus vulgaris and foliaceus (PV), a rare autoimmune disease that causes painful blisters on the skin and mucous membranes. In February 2021, argenx initiated a Phase 3 study of ARGX-113 using ENHANZE technology for patients with chronic inflammatory demyelinating polyneuropathy (CIDP) and a Phase 3 study of ARGX-113 using ENHANZE technology in myasthenia gravis (MG), an autoimmune disorder of the musculoskeletal system caused by IgG autoantibodies. In December 2021, argenx announced the FDA approval of efgartigimod (VYVGARTTM) for the treatment of generalized myasthenia gravis for the IV dosing regimen. In March 2022, argenx announced that data from argenx&#8217;s phase 3 ADAPT-SC study evaluating SC efgartigimod (1000mg efgartigimod-PH20) for the treatment of generalized myasthenia gravis (gMG) achieved </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the primary endpoint of total IgG reduction from baseline at day 29, demonstrating statistical non-inferiority to VYVGART (efgartigimod alfa-fcab) IV formulation in gMG patients. In June 2022, argenx initiated a study, BALLAD, evaluating Efgartigimod with ENHANZE in bullous pemphigoid. In September 2022, argenx announced the submission of BLA to the FDA for SC efgartigimod for the treatment of adults with gMG, and in November 2022, argenx announced the acceptance of the BLA application with a priority review and a PDUFA date of March 20, 2023. In January 2023, argenx announced the review time was extended by the FDA to June 20, 2023 to allow the FDA sufficient time to review. Argenx has also submitted a marketing authorization application to the European Medicines Agency for SC efgartigimod for the treatment of adults with gMG with an anticipated regulatory approval decision in the fourth quarter of 2023. argenx is currently conducting  a Phase 2 study of ARGX-113 (ALKIVIA) using ENHANZE technology for patients with active idiopathic inflammatory myopathy (Myositis). argenx intends to initiate a registrational trial of ARGX-113 using ENHANZE technology for patients with thyroid eye disease in 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we and Horizon entered into a global collaboration and license agreement that gives Horizon exclusive access to ENHANZE technology for SC formulation of medicines targeting IGF-1R. Horizon intends to use ENHANZE to develop a SC formulation of TEPEZZA&#174; (teprotumumab-trbw), indicated for the treatment of thyroid eye disease, a serious, progressive and vision-threatening rare autoimmune disease, potentially shortening drug administration time, reducing healthcare practitioner time and offering additional flexibility and convenience for patients. In March 2021, Horizon completed dosing in a Phase 1 study exploring the SC formulation of TEPEZZA. The trial was a small, single-dose Phase 1 pharmacokinetic trial which included evaluation of ENHANZE technology for a SC formulation. In March 2022, Horizon announced the completion of a Phase 1 trial for the TEPEZZA SC program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ViiV Healthcare Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a global collaboration and license agreement with ViiV. The license gives ViiV exclusive access to our ENHANZE technology for four specific small and large molecule targets for the treatment and prevention of HIV. These targets are integrase inhibitors, reverse transcriptase inhibitors limited to nucleoside reverse transcriptase inhibitors (NRTI) and nucleoside reverse transcriptase translocation inhibitors (NRTTIs), capsid inhibitors and broadly neutralising monoclonal antibodies (bNAbs), that bind to the gp120 CD4 binding site. In December 2021, ViiV initiated enrollment of a Phase 1 study to evaluate cabotegravir administered subcutaneously with ENHANZE. In February 2022, ViiV initiated enrollment of a Phase 1 study to evaluate the safety and pharmacokinetics of N6LS, a broadly neutralizing antibody, administered subcutaneously with ENHANZE technology. In June 2022, ViiV initiated enrollment of a Phase 1 single dose escalation study to evaluate pharmacokinetics, safety and tolerability of long-acting cabotegravir administered subcutaneously with ENHANZE technology.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chugai Collaboration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we entered into a global collaboration and license agreement with Chugai Pharmaceutical Co., Ltd. The license gives Chugai exclusive access to ENHANZE technology for an undisclosed target. Chugai intends to explore the potential use of ENHANZE for a Chugai drug candidate. In May 2022, Chugai initiated a Phase 1 study to evaluate the pharmacokinetics, pharmacodynamics, and safety of targeted antibody administered subcutaneously with ENHANZE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">NIH CRADA</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we announced a Cooperative Research and Development Agreement (&#8220;CRADA&#8221;) with the National Institute of Allergy and Infectious Diseases&#8217; Vaccine Research Center (VRC), part of National Institute of Health (NIH), enabling the VRC&#8217;s use of ENHANZE technology to develop SC formulations of VRC07-523LS and N6LS broadly neutralizing antibodies (bnAbs) against HIV for HIV treatment. In April 2021, we were notified that the first patient was dosed with N6LS and ENHANZE in VRC 609 Phase 1 dose-escalation study to evaluate safety, tolerability, and pharmacokinetics of N6LS using ENHANZE technology. In October 2022, the VRC 609 Phase 1 study was completed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Device and Other Drug Product Collaborations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teva License, Development and Supply Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2006, we entered into an exclusive license, development and supply agreement with Teva for an epinephrine auto- injector product to be marketed in the U.S. and Canada. We are the exclusive supplier of the device, which we developed, for Teva&#8217;s generic Epinephrine Injection USP products, indicated for emergency treatment of severe allergic reactions including those that are life threatening (anaphylaxis) in adults and certain pediatric patients. Teva&#8217;s Epinephrine Injection, utilizing our patented VIBEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> injection technology, was approved by the FDA as a generic drug product with an AB rating, meaning that it is therapeutically equivalent to the branded products EpiPen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and EpiPen Jr</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and therefore, subject to state law, substitutable at the pharmacy. </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2007, we entered into a license, development and supply agreement with Teva under which we developed and supply a disposable pen injector for teriparatide. Under the agreement, we received an upfront payment and development milestones, and are entitled to receive royalties on net product sales by Teva in territories where commercialized. We are the exclusive supplier of the multi-dose pen, which we developed, used in Teva&#8217;s generic teriparatide injection product. In 2020, Teva launched Teriparatide Injection, the generic version of Eli Lilly&#8217;s branded product Forsteo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> featuring our multi-dose pen platform, for commercial sale in several countries outside of the U.S. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2012, we entered into a license, supply and distribution agreement with Teva for an auto-injector product containing sumatriptan for the treatment of migraines.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Covis Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2014, we entered into a development and license agreement with Covis, to develop and supply a SC auto-injector system for use with Makena, a progestin drug (hydroxyprogesterone caproate) indicated to reduce the risk of preterm birth in women pregnant with one baby and who spontaneously delivered one preterm baby in the past. Under the agreement, we were granted an exclusive, worldwide, royalty-bearing license, with the right to sublicense, to certain intellectual property rights, including know-how, patents and trademarks. In March 2018, we entered into a manufacturing agreement with Covis for the exclusive supply of the device, a variation of our VIBEX QuickShot SC auto-injector.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, the FDA issued a final decision ordering the withdrawal of the approval for Makena. Covis is in the process of implementing the withdrawal of the product, and other than a limited supply of product currently in the channel, the product is no longer available.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, we entered into a development agreement with Pfizer to jointly develop a combination drug device rescue pen utilizing the QuickShot auto-injector and an undisclosed Pfizer drug. Pfizer has provided the intellectual property rights for further development of the product to us and has retained an option to assist in the marketing, distribution and sale if we complete development of the product and submit for regulatory approval. We are continuing to evaluate the next steps for this program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a global agreement with Idorsia to develop a novel, drug-device product containing selatogrel. A new chemical entity, selatogrel is being developed for the treatment of a suspected acute myocardial infarction (AMI) in adult patients with a history of AMI. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, Idorsia disclosed that recruitment of their Phase 3 study with selatogrel for acute myocardial infarction had reached more than 3,330 patients.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ferring Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we entered into an exclusive license and commercial supply agreement with Ferring for the marketed product NOCDURNA (desmopressin acetate) in the U.S. In October 2022, we notified Ferring that we are terminating the NOCDURNA license agreement with an effective termination date in October 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lipocine Agreement</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, we entered into an exclusive license agreement with Lipocine for the product TLANDO (testosterone undecanoate) in the U.S. In June 2022, we announced the commercial launch of TLANDO. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Otter Agreement</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into a supply agreement with Otter to manufacture the VIBEX auto-injection system device, designed and developed to incorporate a pre-filled syringe for delivery of methotrexate, assemble, package, label and supply the final OTREXUP product and related samples to Otter at cost plus mark-up. Otter is responsible for manufacturing, formulation and testing of methotrexate and the corresponding pre-filled syringe for assembly with the device manufactured by us, along with the commercialization and distribution of OTREXUP. OTREXUP is a SC methotrexate injection for once weekly self-administration with an easy-to-use, single dose, disposable auto injector, indicated for adults with severe active rheumatoid arthritis (&#8220;RA&#8221;), children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. Further, we entered into a license agreement with Otter in which we granted Otter a worldwide, exclusive, fully paid-up license to certain patents relating to OTREXUP that may also relate to our other products for Otter to commercialize and otherwise exploit OTREXUP in the field as defined in the license agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended March&#160;31, 2023 Compared to Three Months Ended March&#160;31, 2022 </span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Royalties were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:55.255%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase was mainly driven by continued sales uptake of DARZALEX FASPRO by Janssen and Phesgo by Roche in all geographies and contribution from new device royalty revenue as a result of the Antares acquisition, partially offset by slightly lower sales of Herceptin SC and MabThera SC by Roche. We expect royalty revenue to continue to grow as a result of our 2020 ENHANZE partner product launches, offsetting the ongoing impact from biosimilars related to our mature ENHANZE partner products.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Product sales, net were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:55.255%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of proprietary products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of bulk rHuPH20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of device partnered product</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,794&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,140&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,654&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in product sales was due to contribution from our proprietary and device partnered products as the result of the Antares acquisition. We expect that sales of proprietary products will grow in future years as we work to expand market share in the TRT market. We expect that product sales of bulk rHuPH20 and device partnered products will fluctuate in future periods based on the needs of our partners. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues Under Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Revenues under collaborative agreements were as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:55.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront license fees, license fees for the election of additional targets, event-based payments, license maintenance fees and amortization of deferred upfront and other license fees:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chugai</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device licensing and development revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,534&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,825)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in revenue from license fees was primarily due to the timing of milestones driven by partner activities. Revenue from upfront licenses fees, license fees for the election of additional targets, license maintenance fees and other license fees and event-based payments vary from period to period based on our ENHANZE collaboration activity. We expect these revenues to continue to fluctuate in future periods based on our partners&#8217; ability to meet various clinical and regulatory milestones set forth in such agreements and our ability to obtain new collaborative agreements.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating expenses - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:55.255%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,922&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of our proprietary products, device partnered products and bulk rHuPH20. The increase in cost of product sales was mainly due to an increase in sales in our proprietary and device partnered products as a result of the Antares acquisition and amortization of inventory step-up associated with purchase accounting for the Antares acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Amortization of intangibles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The amortization of intangibles expense was due to the acquisition of Antares in May 2022, in which we acquired intangible assets that are amortized over their useful lives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Research and development expenses consist of external costs, salaries and benefits and allocation of facilities and other overhead expenses related to research manufacturing, preclinical and regulatory activities related to our collaborations, our development platforms. The increase in research and development expense was primarily due to  an increase in compensation expense related to the ongoing combined larger workforce as a result of the Antares acquisition, which added device platform resources in regulatory, quality and manufacturing as well as planned investments in ENHANZE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Selling, General and Administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; Selling, general and administrative (SG&amp;A) expenses consist primarily of salaries and related costs for personnel in executive, selling and administrative functions as well as professional fees for legal and accounting, business development, commercial operations support for proprietary products and alliance management and marketing support for our collaborations. The increase in selling, general and administrative expense was primarily due to an increase in compensation expense related to the ongoing combined larger workforce, including the addition of commercial resources in sales and marketing for the testosterone replacement therapy products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Interest expense was as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:55.255%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase was primarily due to an increase in interest expense related to the revolving credit facility and 2028 Convertible Notes, partially offset by the decrease in interest expense related to 2024 Convertible Notes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Income taxes were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:55.255%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,678)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The decrease in income tax expense was due a lower income during the current quarter. We estimate our annual effective tax rate to be approximately 20% for the full year 2023, which differs from the U.S. federal statutory rate due to state income taxes, nondeductible executive compensation, and the reduced rate on foreign export sales. Our quarterly effective tax rate of 24.09% for the three months ended March 31, 2023 was primarily due to a change in our state effective rate resulting from a statutory change in our filing methodology in certain states relating to our acquisition of Antares, and discrete excess tax benefits recognized for share-based compensation for employees, net of limitations on executive compensation.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal sources of liquidity are our existing cash, cash equivalents and available-for-sale marketable securities. As of March&#160;31, 2023, we had cash, cash equivalents and marketable securities of $275.6 million. We believe that our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. We expect to fund our operations going forward with existing cash resources, anticipated revenues from our existing collaborative agreements and cash that we may raise through future transactions. We may raise cash through any one of the following financing vehicles: (i) new collaborative agreements; (ii) expansions or revisions to existing collaborative relationships; (iii) private financings; (iv) other equity or debt financings; (v) monetizing assets; and/or (vi) the public offering of securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, in the future, draw on our existing line of credit or offer and sell additional equity, debt securities and warrants to purchase any of such securities, either individually or in units to raise capital for additional working capital, capital expenditures, share repurchases, acquisitions or for other general corporate purposes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:55.756%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.878%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.878%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,797&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,305)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,857)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164,614)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,812)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(884)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,928)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in cash provided by operations was mainly due to a decrease in working capital spend and an increase in royalties and product revenue, partially offset by a decrease in collaboration revenue.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in cash used in investing activities was primarily due to an increase in capital spend for the purchase of manufacturing equipment and new facility improvements. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in net cash used in financing activities was mainly due to a $13.5 million cash payment related to the 2024 Convertible Notes conversion, a $150.1 million increase in repurchase of common stock and a $1.7 million decrease in net proceeds during the current quarter from the issuance of common stock under equity incentive plans.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, our Board of Directors approved a share repurchase program to repurchase up to $750.0 million of our outstanding common stock over a three-year period. Refer to Note 10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Stockholders&#8217; Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of our condensed consolidated financial statements for additional information regarding our share repurchases.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.00% Convertible Notes due 2028</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we completed the sale of $720.0&#160;million in aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the &#8220;2028 Convertible Notes&#8221; and collectively with the 2024 and the 2027 Convertible Notes the &#8220;Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2028 Convertible Notes, after deducting the initial purchasers&#8217; fee of $18.0&#160;million, was approximately $702.0&#160;million. We also incurred additional debt issuance costs totaling $1.0&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Convertible Notes pay interest semi-annually in arrears on February 15th and August 15th of each year at an annual rate of 1.00%. The 2028 Convertible Notes are general unsecured obligations and rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2028 Convertible Notes, rank equally in right of payment with all existing and future liabilities that are not so subordinated, are effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2028 Convertible Notes have a maturity date of August 15, 2028.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2028 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2022, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2028 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, February 15, 2028 until the close of business on the second scheduled trading day immediately before the maturity date. As of March&#160;31, 2023, the 2027 Convertible Notes are not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal, and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2028 Convertible Notes will be 17.8517 shares of common stock per $1,000 in principal amount of 2028 Convertible Notes, equivalent to a conversion price of approximately $56.02 per share of our common stock. The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued or unpaid interest.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">0.25% Convertible Notes due 2027</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed the sale of $805.0&#160;million in aggregate principal amount of 0.25% Convertible Senior Notes due 2027 (the &#8220;2027 Convertible Notes&#8221;). The net proceeds in connection with the 2027 Convertible Notes, after deducting the initial purchasers&#8217; fee of $20.1&#160;million, was approximately $784.9&#160;million. We also incurred additional debt issuance costs totaling $0.4&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Convertible Notes pay interest semi-annually in arrears on March 1st and September 1st of each year at an annual rate of 0.25%. The 2027 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2027 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2027 Convertible Notes have a maturity date of March 1, 2027.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2027 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2027 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately before the maturity date. The 2027 Convertible Notes will be convertible, regardless of the foregoing circumstances, at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately preceding the maturity date. As of March&#160;31, 2023, the 2027 Convertible Notes are not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal, and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2027 Convertible Notes is 12.9576 shares of common stock per $1,000 in principal amount of 2027 Convertible Notes, equivalent to a conversion price of approximately $77.17 per share of our common stock. The conversion rate is subject to adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.25% Convertible Notes due 2024</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we completed the sale of $460.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due 2024 (&#8220;2024 Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2024 Convertible Notes, after deducting the initial purchasers&#8217; fee of $12.7&#160;million, was approximately $447.3 million. We also incurred debt issuance cost totaling $0.3&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Convertible Notes pay interest semi-annually in arrears on June 1st and December 1st of each year, beginning on June 1, 2020, at an annual rate of 1.25%. The 2024 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2024 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of the our current or future subsidiaries. The 2024 Convertible Notes have a maturity date of December 1, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2024 Convertible Notes at their option only in the following circumstances: (1)&#160;during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2020, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2)&#160;during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3)&#160;upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2024 Convertible Notes; (4)&#160;if we call such notes for redemption; and (5)&#160;at any time from, and including, June&#160;1, 2024 until the close of business on the scheduled trading day immediately before the maturity date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we notified the note holders our irrevocable election to settle the principal of the 2024 Convertible Notes in cash and for the premium, if applicable, deliver shares of common stock. The conversion rate for the 2024 Convertible Notes is 41.9208 shares of common stock per $1,000 in principal amount of 2024 Convertible Notes, equivalent to a conversion price of approximately $23.85 per share of our common stock. The conversion rate was subject to adjustment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed a privately negotiated and induced conversion of $369.1 million principal amount of the 2024 Convertibles (&#8220;2021 Note Repurchases&#8221; or the &#8220;2021 Induced Conversion&#8221;). In connection with the 2021 Induced Conversion, we paid approximately $370.2&#160;million in cash, which includes principal and accrued interest, and issued approximately 9.08&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the 2021 Induced Conversion, we recorded $21.0 million in induced conversion expense which was included in other income (expense) of the condensed consolidated statements of income in 2021. The induced conversion expense represented the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we completed a privately negotiated induced conversion of $77.4&#160;million principal amount of the 2024 Convertible Notes (&#8220;2022 Note Repurchases&#8221; or the &#8220;2022 Induced Conversion&#8221;). In connection with the 2022 Induced Conversion, we paid approximately $77.6&#160;million&#160;million in cash, which includes principal and accrued interest, and issued approximately 1.51&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the 2022 Induced Conversion, we recorded $2.7&#160;million in induced conversion expense which was included in other income (expense) of the condensed consolidated statements of income in 2022. The induced conversion expense represented the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we issued a notice for the redemption of 2024 Convertible Notes. Holders of the notes may convert their notes at any time prior the close of business day prior to the redemption date. In March 2023, holders of the notes elected to convert the 2024 Convertible Notes in full. In connection with the conversion, we paid approximately $13.5 million in cash which includes principal and accrued interest, and issued 288,886 shares of our common stock representing the intrinsic value based on the contractual conversion rate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit and Term Loan Facilities (May 2022)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, in connection with the closing of Antares acquisition, we entered into a credit agreement with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#8220;2022 Credit Agreement), evidencing a credit facility (the &#8220;2022 Facility&#8221;) that provides for (i) a $350 million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and (ii) a $250 million term loan facility (the &#8220;Term Facility&#8221;). The proceeds from a $120 million draw on the Revolving Credit Facility and the $250 million Term Facility were used to fund a portion of the Antares acquisition, refinance Antares&#8217; existing debt and pay fees and expenses in connection with the Antares acquisition. The 2022 Credit Agreement contains an expansion feature, which allows us, subject to certain conditions, to increase the aggregate principal amount of the 2022 Facility, provided we remain in compliance with underlying financial covenants on a pro forma basis including the consolidated interest coverage ratio and the consolidated net leverage ratio covenants set forth in the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth years following the Closing in annual amounts equal to 2.50%, 5.00%, 7.50% and 10.00% of the initial principal amount of the term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales, subject to our right to reinvest the proceeds thereof.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the applicable Term Secured Overnight Financing Rate (SOFR) (which includes a SOFR adjustment of 0.10%), or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus 0.50%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus 1.10%, and (4) 1.00%. The margin for the 2022 Facility ranges, based on our consolidated total net leverage ratio, from 0.25% to 1.25% in the case of base rate loans and from 1.25% to 2.25% in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the Facility, we will pay (i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency fees. The commitment fees range from 0.15% to 0.35% per annum based on our consolidated net leverage ratio.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we entered into Amendment No. 1 to the Credit Agreement (the &#8220;Amendment&#8221;) among the Company, the Guarantors (as defined in the Credit Agreement), each L/C Issuer from time to time party thereto, Bank of America, N.A., as Administrative Agent (in such capacity, the &#8220;Administrative Agent&#8221;) and swing line lender (in such capacity, the &#8220;Swing Line Lender&#8221;), and each lender party thereto, which amends the Credit Agreement dated as of May 24, 2022 (the &#8220;Credit Agreement&#8221;) among the Company, the Guarantors, the Administrative Agent, the Swing Line Lender, each Lender and the L/C Issuers. The Amendment, among other things, increases the size of the revolving credit facility from $350&#160;million to $575&#160;million. The terms of the revolving credit facility are otherwise unchanged. Concurrently with the entry into the Amendment, the Company repaid the entire outstanding term loan facility and repaid all outstanding loans under the revolving credit facility under the Credit Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of March&#160;31, 2023, the revolving credit facility was undrawn. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Capital Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expected working capital and other capital requirements are described in our 2021 Annual Report on Form 10-K in &#8220;Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; As of March&#160;31, 2023, other than the additional financing obtained to complete the Antares acquisition, which was completed on May 24, 2022, and the changes disclosed in the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; and &#8220;Liquidity and Capital Resources&#8221; in this Quarterly Report, there have been no other material changes to our expected working capital and other capital requirements described in our 2021 Annual Report on Form 10-K.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Note 2 to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022. The accounting policies and estimates that are most critical to a full understanding and evaluation of our reported financial results are described in &#8220;Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022. There were no material changes to our critical accounting policies or estimates during the three months ended March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of our condensed consolidated financial statements for a discussion of recent accounting pronouncements and their effect, if any.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related To Our Business</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our partnered or proprietary product candidates do not receive and maintain regulatory approvals, or if approvals are not obtained in a timely manner, such failure or delay would substantially impair our ability to generate revenues.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval from the FDA or equivalent health authorities is necessary to design, develop, test, manufacture and market pharmaceutical products and medical devices in the U.S. and the other countries in which we anticipate doing business have similar requirements. The process for obtaining FDA and other regulatory approvals is extensive, time-consuming, risky and costly, and there is no guarantee that the FDA or other regulatory bodies will approve any applications that may be filed with respect to any of our partnered or proprietary product candidates, or that the timing of any such approval will be appropriate for the desired product launch schedule for a product candidate. We and our partners may provide guidance as to the timing for the filing and acceptance of such regulatory approvals, but such filings and approvals may not occur when we or our partners expect, or at all. The FDA or other foreign regulatory agency may refuse or delay approval of our partnered or proprietary product candidates for failure to collect sufficient clinical or animal safety data and require additional clinical or animal safety studies which may cause lengthy delays and increased costs to our or our partners&#8217; development programs. Any such issues associated with rHuPH20 could have an adverse impact on future development of our partners&#8217; products which include rHuPH20, future sales of Hylenex recombinant, or our ability to maintain our existing ENHANZE collaborations or enter into new ENHANZE collaborations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners may not be successful in obtaining approvals for any additional potential products in a timely manner, or at all. Refer to the risk factor titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our partnered or proprietary product candidates may not receive regulatory approvals or their development may be delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory requirements or safety concerns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for additional information relating to the approval of product candidates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, even with respect to products which have been approved for commercialization, in order to continue to manufacture and market pharmaceutical products, we or our partners must maintain our regulatory approvals. If we or any of our partners are unsuccessful in maintaining the required regulatory approvals, our revenues would be adversely affected.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of our partnered or proprietary and the products and product candidates could be associated with adverse events or product recalls.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with most pharmaceutical products, our partnered or proprietary products and product candidates could be associated with adverse events which can vary in severity (from minor reactions to death) and frequency (infrequent to very common) or product recalls. Adverse events associated with the use of our partnered or proprietary products or product candidates may be observed at any time, including in clinical trials or when a product is commercialized, and any such adverse events may negatively affect our or our partners&#8217; ability to obtain or maintain regulatory approval or market such products and product candidates. Adverse events such as toxicity or other safety issues associated with the use of our partnered or proprietary products and product candidates could require us or our partners to perform additional studies or halt development or commercialization of these products and product candidates or expose us to product liability lawsuits which will harm our business. For example, we experienced a clinical hold on patient enrollment and dosing in our phase 2 study of PEGPH20 in patients with PDA (a discontinued program), which was not resolved until we implemented steps to address an observed possible difference in TE event rates between the arms of the study. We or our partners may be required by regulatory agencies to conduct additional animal or human studies regarding the safety and efficacy of our pharmaceutical products or product candidates which we have not planned or anticipated. There can be no assurance that we or our partners will resolve any issues related to any product or product candidate adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a product fails to conform to its specifications or comply with the applicable laws or regulations, we or our partners may be required to or may decide to voluntarily recall the product or regulatory authorities may request or require that we recall a product even if there is no immediate potential harm to a patient. Any recall of our products or their components that we supply to our partners could materially adversely affect our business by rendering us unable to sell those products or components for some time and by adversely affecting our reputation. Recalls are costly and take time and effort to administer. Even if a recall only initially relates to a single product, product batch, or a portion of a batch, recalls may later be expanded to additional products or batches or we or our partners may incur additional costs and need to dedicate additional efforts to investigate and rule out the potential for additional impacted products or batches. Moreover, if any of our partners recall a product due to an issue with a product or component that we supplied, they may claim that we are responsible for such issue and may seek to recover the costs related to such recall or be entitled to certain contractual remedies from us. Recalls may further result in decreased demand for our partnered or proprietary products, could cause our partners or distributors to return products to us for which we may be required to provide refunds or replacement products, or could result in product shortages. Recalls may also require regulatory reporting and prompt regulators to conduct additional inspections of our or our partners&#8217; or contractors&#8217; facilities, which could result in findings of noncompliance and regulatory enforcement actions. A recall could also result in product liability claims by individuals and third-party payers. In addition, product liability claims or other safety issues </span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could result in an investigation of the safety or efficacy of our products, our manufacturing processes and facilities, or our marketing programs conducted by the FDA or the authorities of the EU member states and other jurisdictions. Such investigations could also potentially lead to a recall of our products or more serious enforcement actions, limitations on the indications for which they may be used, or suspension, variation, or withdrawal of approval. Any such regulatory action by the FDA, the EMA or the competent authorities of the EU member states could lead to product liability lawsuits as well.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our contract manufacturers or vendors are unable to or unwilling for any reason to manufacture and supply to us bulk rHuPH20 or other raw materials, reagents, components or devices in the quantity and quality required by us or our partners for use in the production of Hylenex or our other proprietary or partnered products and product candidates, our and our partners&#8217; product development and commercialization efforts could be delayed or stopped and our business results of operations and our collaborations could be harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of third parties in our supply chain for the supply and manufacture of our partnered and proprietary products and the availability of such products depends upon our ability to procure the raw materials, components, packaging materials and finished products from these third parties, several of which are currently our single source for the materials necessary for certain of our products. We have entered into supply agreements with numerous third-party suppliers. For example, we have existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. (Avid) and Catalent Indiana LLC (Catalent) to produce bulk rHuPH20.&#160;These manufacturers each produce bulk rHuPH20 under cGMP for use in Hylenex recombinant, and for use in partnered products and product candidates. We rely on their ability to successfully manufacture bulk rHuPH20 according to product specifications. In addition to supply obligations, our contract manufacturers will also provide support for the chemistry, manufacturing and controls sections for FDA and other regulatory filings. We also rely on vendors to supply us with raw materials to produce reagents and other materials for bioanalytical assays used to support our partners&#8217; clinical trials. We also have a commercial manufacturing and supply agreement with Patheon under which Patheon provides the final fill and finishing steps in the production process of Hylenex recombinant. If any of our contract manufacturers or vendors: (i) is unable to retain its status as an FDA approved manufacturing facility; (ii) is unable to otherwise successfully scale up production to meet corporate or regulatory authority quality standards; (iii) is unable to procure the labor, raw materials, reagents or components necessary to produce our proprietary products, including bulk rHuPH20 and Hylenex recombinant, our bioanalytical assays or our partnered products or (iv) fails to manufacture and supply our partnered and proprietary products, including bulk rHuPH20 in the quantity and quality required by us or our partners for use in Hylenex and partnered products and product candidates for any other reason, our business will be adversely affected. In addition, a significant change in such parties&#8217; or other third-party manufacturers&#8217; business or financial condition could adversely affect their abilities or willingness to fulfill their contractual obligations to us. We have not established, and may not be able to establish, favorable arrangements with additional bulk rHuPH20 manufacturers and suppliers of the ingredients necessary to manufacture bulk rHuPH20 should the existing manufacturers and suppliers become unavailable or in the event that our existing manufacturers and suppliers are unable or unwilling to adequately perform their responsibilities. We have attempted to mitigate the impact of a potential supply interruption through the establishment of excess bulk rHuPH20 inventory where possible, but there can be no assurances that this safety stock will be maintained or that it will be sufficient to address any delays, interruptions or other problems experienced by any of our contract manufacturers. Any delays, interruptions or other problems regarding the ability or willingness of our contract manufacturers to supply bulk rHuPH20 or the ability or willingness of other third-party manufacturers, to supply other raw materials or ingredients necessary to produce our other proprietary or partnered products on a timely basis could: (i) cause the delay of our partners&#8217; clinical trials or otherwise delay or prevent the regulatory approval of our partners&#8217; product candidates; (ii) delay or prevent the effective commercialization of proprietary or partnered products and product candidates; and/or (iii) cause us to breach contractual obligations to deliver bulk rHuPH20 to our partners. Such delays could damage our relationship with our partners, and they could have a material adverse effect on royalties and thus our business and financial condition. Additionally, we rely on third parties to manufacture, prepare, fill, finish, package, store and ship our proprietary and partnered products and product candidates on our behalf. If the third parties we identify fail to perform their obligations, the progress of partners&#8217; clinical trials could be delayed or even suspended and the commercialization of our partnered or proprietary products could be delayed or prevented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our Minnetonka, Minnesota facility supports our administrative functions, product development and quality operations and is intended to eventually provide additional manufacturing and warehousing capabilities in the future. If we begin manufacturing and producing commercial products in the future, we will be subject to relevant risks comparable to those of our third-party manufacturers. For example, we may not be able to begin product manufacturing and production due to a number of different reasons including, but not limited to, an ability to obtain necessary supplies and materials, labor and expertise. To the extent we rely on our ability to manufacture and ship any of our proprietary and partnered products, our inability to do so could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to perform necessary services for our products including services related to the distribution, invoicing, rebates and contract administration, co-pay program administration, sample distribution and administration, </span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">storage and transportation of our products. If anything should impede their ability to meet their commitments this could impact our business performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the product, we have retained third-party service providers to perform a variety of functions related to the distribution, invoicing, rebates and contract administration, co-pay program administration, sample distribution and administration, storage and transportation of our products, key aspects of which are out of our direct control. We place substantial reliance on these providers as well as other third-party providers that perform services for us, including, depending on the product, entrusting our inventories of products to their care and handling. We also may rely on third parties to administer our drug price reporting and rebate payments and contracting obligations under federal programs. Despite our reliance on third parties, we have responsibilities for compliance with the applicable legal and program requirements. By example, in certain states, we are required to hold licenses to distribute our products in these states and must comply with the associated state laws. Moreover, if these third-party service providers fail to meet expected deadlines, or otherwise do not carry out their contractual duties to us or encounter physical damage or a natural disaster at their facilities, our ability to deliver products to meet commercial demand would be significantly impaired. In addition, we may use third parties to perform various other services for us relating to regulatory monitoring, including adverse event reporting, safety database management and other product maintenance services. If our employees or any third-party service providers fail to comply with applicable laws and regulations, we and/or they may face regulatory or False Claims Act enforcement actions. Moreover, if the quality or accuracy of the data maintained by these service providers is insufficient, our ability to continue to market our products could be jeopardized or we and/or they could be subject to regulatory sanctions. We do not currently have the internal capacity to perform these important commercial functions, and we may not be able to maintain commercial arrangements for these services on reasonable terms.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or any party to a key collaboration agreement fail to perform material obligations under such agreement, or if&#160;a key collaboration agreement, is terminated for any reason, our business could suffer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple collaboration agreements under which we may receive significant future payments in the form of milestone payments, target designation fees, maintenance fees and royalties. We are heavily dependent on our partners to develop and commercialize product candidates subject to our collaborations in order for us to realize any financial benefits, including revenues from milestones, royalties and product sales from these collaborations. Our partners may not devote the attention and resources to such efforts that we would ourselves, change their clinical development plans, promotional efforts or simultaneously develop and commercialize products in competition to those products we have licensed to them. Any of these actions may not be visible to us immediately and could negatively impact our ability to forecast and our ability to achieve the benefits and revenue we receive from such collaboration. In addition, in the event that a party fails to perform under a key collaboration agreement, or if a key collaboration agreement is terminated, the reduction in anticipated revenues could negatively impact our operations. In addition, the termination of a key collaboration agreement by one or more of our partners could have a material adverse impact on our ability to enter into additional collaboration agreements with new partners on favorable terms, if at all. In certain circumstances, the termination of a key collaboration agreement would require us to revise our corporate strategy going forward and may lead us to reevaluate the applications and value of our technology.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hylenex and our partners&#8217; ENHANZE products and product candidates rely on the rHuPH20 enzyme, and any adverse development regarding rHuPH20 could substantially impact multiple areas of our business, including current and potential ENHANZE collaborations, as well as any proprietary programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rHuPH20 is a key technological component of Hylenex and our ENHANZE technology and most of our ENHANZE partnered products and product candidates, including the current and future products and product candidates under our ENHANZE collaborations. We derive a substantial portion of our revenues from our ENHANZE collaborations. Therefore, if there is an adverse development for rHuPH20 (e.g., an adverse regulatory determination relating to rHuPH20, if we are unable to obtain sufficient quantities of rHuPH20, if we are unable to obtain or maintain material proprietary rights to rHuPH20 or if we discover negative characteristics of rHuPH20), multiple areas of our business, including current and potential collaborations, as well as proprietary programs would be substantially impacted. For example, elevated anti-rHuPH20 antibody titers were detected in the registration trial for HYQVIA as well as in a former partner&#8217;s product in a Phase 2 clinical trial with rHuPH20, but have not been associated, in either case, with any adverse events. We monitor for antibodies to rHuPH20 in our collaboration and proprietary programs, and although we do not believe at this time that the incidence of non-neutralizing anti-rHuPH20 antibodies in either the HYQVIA program or the former partner&#8217;s program will have a significant impact on our proprietary product and our partners&#8217; product and product candidates, there can be no assurance that there will not be other such occurrences in the foregoing programs or that concerns regarding these antibodies will not also be raised by the FDA or other health authorities in the future, which could result in delays or discontinuations of our Hylenex commercialization activities, the development or commercialization activities of our ENHANZE partners, or deter our entry into additional ENHANZE collaborations with third parties. </span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business strategy is focused on growth of our ENHANZE technology, our auto-injector technology, our commercial products and potential growth through acquisition. Currently, ENHANZE is the largest revenue driver and as a result there is a risk for potential negative impact from adverse developments. Future expansion of our strategic focus to additional applications of our ENHANZE technology or by acquiring new technologies may require the use of additional resources, result in increased expense and ultimately may not be successful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We routinely evaluate our business strategy, and may modify this strategy in the future in light of our assessment of unmet medical needs, growth potential, resource requirements, regulatory issues, competition, risks and other factors. As a result of these strategic evaluations, we may focus our resources and efforts on one or a few programs or fields and may suspend or reduce our efforts on other programs and fields. For example, in the fourth quarter of 2019, we decided to focus our resources on our ENHANZE technology and our commercial product, Hylenex. By focusing primarily on these areas, we increase the potential impact on us if one of those partner programs does not successfully complete clinical trials, achieve commercial acceptance or meet expectations regarding sales and revenue. We may also expand our strategic focus by seeking new therapeutics applications of our technology or by acquiring new technologies which may require the use of additional resources, increased expense and would require the attention of senior management. For example, in May 2022, we acquired Antares as a means to diversify the sources of our revenues. There can be no assurance that our investment in Antares or any such future investment of resources in new technologies will ultimately result in additional approved proprietary or partnered products or commercial success of new therapeutic applications of our technology.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our partnered or proprietary product candidates may not receive regulatory approvals or their development may be delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory requirements or safety concerns. If we or our partners fail to obtain, or have delays in obtaining, regulatory approvals for any product candidates, our business, financial condition and results of operations may be materially adversely affected or delayed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing of pharmaceutical products is a long, expensive and uncertain process, and the failure or delay of a clinical trial can occur at any stage, including the patient enrollment stage. Even if initial results of preclinical and nonclinical studies or clinical trial results are promising, our partners may obtain different results in subsequent trials or studies that fail to show the desired levels of dose safety and efficacy, or we or our partners may not obtain applicable regulatory approval for our products for a variety of other reasons. Preclinical, nonclinical, and clinical trials for proprietary or partnered product candidates could be unsuccessful, which would delay or preclude regulatory approval and commercialization of the product candidates. In the U.S. and other jurisdictions, regulatory approval can be delayed, limited or not granted for many reasons, including, among others:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">during the course of clinical studies, the final data from later Phase 3 studies may differ from data observed in early phase clinical trials, and clinical results may not meet prescribed endpoints for the studies or otherwise provide sufficient data to support the efficacy of our partners&#8217; product candidates;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical and nonclinical test results may reveal inferior pharmacokinetics, adverse events or unexpected safety issues associated with the use of our partners&#8217; product candidates;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory review may not find that the data from preclinical testing and clinical trials justifies approval;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require that we or our partners change our studies or conduct additional studies which may significantly delay or make continued pursuit of approval commercially unattractive; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a regulatory agency may reject our and our partners&#8217; trial data or disagree with their interpretations of either clinical trial data or applicable regulations;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a regulatory agency may require additional safety monitoring and reporting through Risk Evaluation and Mitigation Strategies including conditions to assure safe use programs and we or a partner may decide to not pursue regulatory approval for a such a product;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a regulatory agency may not approve our manufacturing processes or facilities, or the processes or facilities of our partners, our contract manufacturers or our raw material suppliers;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our or our partners&#8217; contract research organization, or CRO, to properly perform the clinical trial in accordance with the written protocol, our contractual obligations with them or applicable regulatory requirements; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a regulatory agency may identify problems or other deficiencies in our existing manufacturing processes or facilities, or the existing processes or facilities of our partners, our contract manufacturers or our raw material suppliers; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a regulatory agency may change its formal or informal approval requirements and policies, act contrary to previous guidance, adopt new regulations or raise new issues or concerns late in the approval process; or</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a proprietary or partnered product candidate may be approved only for indications that are narrow or under conditions that place the product at a competitive disadvantage, which may limit the sales and marketing activities for such product candidate or otherwise adversely impact the commercial potential of a product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a proprietary or partnered product candidate is not approved in a timely fashion or approval is not obtained on commercially viable terms, or if development of any product candidate is terminated due to difficulties or delays encountered in the regulatory approval process, it could have a material adverse impact on our business, financial condition and results of operation and we would become more dependent on the development of other proprietary or partnered product candidates and/</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or our ability to successfully acquire other technologies. There can be no assurances that we or our any partnered product candidate will receive regulatory approval in a timely manner, or at all. There can be no assurance that partners will be able to gain clarity as to the FDA&#8217;s requirements or that the requirements may be satisfied in a commercially feasible way, in which case our ability to enter into collaborations with third parties or explore other strategic alternatives to exploit an opportunity will be limited or may not be possible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that certain proprietary or partnered products will be marketed, and perhaps manufactured, in foreign countries. The process of obtaining regulatory approvals in foreign countries is subject to delay and failure for the reasons set forth above, as well as for reasons that vary from jurisdiction to jurisdiction. The approval process varies among countries and jurisdictions and can involve additional testing. The time required to obtain approval may differ from that required to obtain FDA approval. Foreign regulatory agencies may not provide approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or jurisdictions or by the FDA.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our third-party partners are responsible for providing certain proprietary materials that are essential components of our partnered products and product candidates, and any failure to supply these materials could delay the development and commercialization efforts for these partnered products and product candidates and/or harm our collaborations. Our partners are also responsible for distributing and commercializing their products, and any failure to successfully commercialize their products could materially adversely affect our revenues.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development and commercialization partners are responsible for providing certain proprietary materials that are essential components of our partnered products and product candidates. For example, Roche is responsible for producing the Herceptin and MabThera required for its subcutaneous products and Takeda is responsible for producing the GAMMAGARD LIQUID for its product HYQVIA. If a partner, or any applicable third party service provider of a partner, encounters difficulties in the manufacture, storage, delivery, fill, finish or packaging of the partnered product or product candidate or component of such product or product candidate, such difficulties could (i) cause the delay of clinical trials or otherwise delay or prevent the regulatory approval of partnered product candidates; and/or (ii) delay or prevent the effective commercialization of partnered products. Such delays could have a material adverse effect on our business and financial condition. We also rely on our partners to commercialize and distribute their products and if they are unsuccessful in commercializing their products, the resulting royalty revenue we would receive may be lower than expected.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners fail to comply with regulatory requirements applicable to promotion, sale and manufacturing of approved products, regulatory agencies may take action against us or them, which could harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any approved products, along with the manufacturing processes, post-approval clinical data requirements, labeling, advertising and promotional activities for these products, are subject to continual requirements and review by the FDA, state and foreign regulatory bodies. Regulatory authorities subject a marketed product, its manufacturer and the manufacturing facilities to continual review and periodic inspections. We, our partners and our respective contractors, suppliers and vendors, will be subject to ongoing regulatory requirements, including complying with regulations and laws regarding advertising, promotion and sales of drug products, required submissions of safety and other post-market information and reports, registration requirements, cGMP regulations (including requirements relating to quality control and quality assurance, as well as the corresponding maintenance of records and documentation), and the requirements regarding the distribution of samples to physicians and recordkeeping requirements. Further, because some of our proprietary and partnered products and product candidates are drug/device combination products, we and our partners will have to comply with extensive regulatory requirements than would otherwise be required for products that are not combination products. Regulatory agencies may change existing requirements or adopt new requirements or policies. We, our partners and our respective contractors, suppliers and vendors, may be slow to adapt or may not be able to adapt to these changes or new requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, regulatory requirements applicable to pharmaceutical products make the substitution of suppliers and manufacturers costly and time consuming. We have minimal internal manufacturing capabilities and are, and expect to be in the future, substantially dependent on contract manufacturers and suppliers for the manufacture of our products and for their active and other ingredients. The disqualification of these manufacturers and suppliers through their failure to comply with regulatory requirements could negatively impact our business because the delays and costs in obtaining and qualifying alternate suppliers (if such alternative suppliers are available, which we cannot assure) could delay our or our partners&#8217; clinical trials or otherwise inhibit our or partners&#8217; ability to bring approved products to market, which would have a material adverse effect on our business and financial condition. Likewise, if we, our partners and our respective contractors, suppliers and vendors involved in sales and promotion of our products do not comply with applicable laws and regulations, for example off-label or false or misleading promotion, this could materially harm our business and financial condition.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with regulatory requirements may result in adverse regulatory actions including but not limited to, any of the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on our or our partners&#8217; products or manufacturing processes;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of our or our partners&#8217; products from the market;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">voluntary or mandatory recall;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of regulatory approvals;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or termination of any of our partners&#8217; ongoing clinical trials;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to permit the import or export of our or our partners&#8217; products;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions; or</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of civil or criminal penalties. </span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to successfully integrate the Antares business, or failure of the Antares business to perform could adversely impact our stock price and future business and operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we completed the acquisition of Antares. Our integration of the Antares business into our operations will be a complex and time-consuming process that may not be successful. The primary areas of focus for successfully combining the business of Antares with our operations may include, among others: retaining and integrating key employees, integrating information, communications and other systems; and managing the growth of the combined company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we successfully integrate the business of Antares into our operations, we may not realize the anticipated benefits. We acquired Antares with the expectation that the acquisition will result in various benefits for the combined company, including providing an opportunity for increased revenues through growth of device revenue and commercial products and development of a new high volume auto-injector. Increased competition, unresolvable technical issues and/or deterioration in business conditions may limit our ability to grow this business. As such, we may not be able to realize the benefits anticipated in connection with the acquisition.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business interruptions resulting from pandemics or similar public health crises could cause a disruption of the development of our and our partnered product candidates and commercialization of our approved and our partnered products, impede our ability to supply bulk rHuPH20 to our ENHANZE partners or procure and sell our proprietary products and otherwise adversely impact our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health crises such as pandemics or similar outbreaks could adversely impact our business and results of operations by, among other things, disrupting the development of our and our partnered product candidates and commercialization of our and our partnered approved products, causing disruptions in the operations of our third-party contract manufacturing organizations upon whom we rely for the production and supply of our proprietary products, including Hylenex and the bulk rHuPH20 we supply to our partners, and causing other disruptions to our operations.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the COVID-19 pandemic led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. The extent to which future pandemics impact our operations and/or those of our partners will depend on future developments, which are highly uncertain and unpredictable, including the duration or recurrence of outbreaks, potential future government actions, new information that will emerge concerning the severity and impact of that pandemic and the actions to contain the pandemic or address its impact in the short and long term, among others.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The business disruptions associated with a global pandemic could impact the business, product development priorities and operations of our partners, including potential delays in manufacturing their product candidates or approved products. For example, clinical trial conduct may be impacted in geographies affected by a pandemic. The progress or completion of these clinical trials could be adversely impacted by the pandemic. Additionally, interruption or delays in the operations of the FDA, the EMA and other similar foreign regulatory agencies, or changes in regulatory priorities to focus on the pandemic, may affect required regulatory review, inspection, clearance and approval timelines. Disruptions such as these could result in delays in the development programs of our partnered products or impede the commercial efforts for approved products, resulting in potential reductions or delays in our revenues from partner royalty or milestone payments. </span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on many third parties to source active pharmaceutical ingredient and drug products, manufacture and assemble our devices, distribute finished products and provide various logistics activities in order to manufacture and sell our partnered and proprietary products. For example, we rely on third-party manufacturers to manufacture the bulk rHuPH20 that we supply to our partners for their commercial products and product candidates, as well as our commercial product Hylenex. If any such third party manufacturer is adversely impacted by a pandemic and related consequences, including staffing shortages, production slowdowns and disruptions in delivery systems, availability of raw materials, reagents or components or if they divert resources or manufacturing capacity to accommodate the development of coronavirus treatments or vaccines, our supply chain may be disrupted, limiting our ability to sell Hylenex or supply bulk rHuPH20 to our partners. Any such disruptions to the operations of the third parties upon whom we rely to manufacture and sell our partnered and proprietary products could result in reductions or delays in our revenues.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to raise additional capital in the future and there can be no assurance that we will be able to obtain such funds.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to raise additional capital in the future to fund our operations for general corporate purposes if we do not achieve the level of revenues we expected. Our current cash reserves and expected revenues may not be sufficient for us to fund general operations and conduct our business at the level desired. In addition, if we engage in acquisitions of companies, products or technologies in order to execute our business strategy, we may need to raise additional capital. We may raise additional capital in the future through one or more financing vehicles that may be available to us including (i)&#160;new collaborative agreements; (ii)&#160;expansions or revisions to existing collaborative relationships; (iii) private financings; (iv) other equity or debt financings; (v)&#160;monetizing assets; and/or (vi) the public offering of securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required to raise additional capital in the future, it may not be available on favorable financing terms within the time required, or at all. If additional capital is not available on favorable terms when needed, we will be required to raise capital on adverse terms or significantly reduce operating expenses through the restructuring of our operations or deferral of strategic business initiatives. If we raise additional capital through a public offering of securities or equity, a substantial number of additional shares of our common stock may be issued, which will dilute the ownership interest of our current investors and may negatively affect our stock price.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have significant debt and expect to incur additional debt. Failure by us to fulfill our obligations under the applicable debt agreements may cause repayment obligations to accelerate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of our consolidated indebtedness, net of debt discount, as of&#160;March&#160;31, 2023&#160;was $1,494.4 million, which includes $805.0 million in aggregate principal amount of the 2027 Convertible Notes and $720.0 million in aggregate principal of the 2028 Convertible Notes, net of unamortized debt discount of $13.5 million and $17.1 million for 2027 Convertible Notes and 2028 Convertible Notes, respectively. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness may:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make it difficult for us to satisfy our financial obligations, including making scheduled principal and interest payments on our indebtedness;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions or other general corporate purposes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our ability to use our cash flow or obtain additional financing for future working capital, capital expenditures, acquisitions, share repurchases or other general business purposes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to use a portion of our cash flow from operations to make debt service payments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our flexibility to plan for, or react to, changes in our business and industry;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">place us at a competitive disadvantage compared to our less leveraged competitors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase our vulnerability to the impact of adverse economic and industry conditions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our 2022 Credit Agreement includes certain affirmative and negative covenants, that, among other things, may restrict our ability to: create liens on assets; incur additional indebtedness; make investments; make acquisitions and other fundamental changes; and sell and dispose of property or assets. The 2022 Credit Agreement also includes financial covenants requiring us to maintain, measured as of the end of each fiscal quarter, a maximum consolidated net leverage ratio of 4.75 to 1.00 initially, which declines to 4.00 to 1.00 over the term of the loan facility, and a minimum consolidated interest coverage ratio of 3.00 to 1.00. The 2022 Credit Agreement also contains customary representations and warranties and events of default. Complying with the covenants contained in the 2022 Credit Agreement could make it more difficult for us to execute our business strategy. Further, in the event of default by us under the 2022 Credit Agreement, the lenders would be entitled to exercise their remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the 2022 Credit Agreement which would harm our financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make payments on our existing or any future debt will depend on our future operating performance and ability to generate cash and may also depend on our ability to obtain additional debt or equity financing. It will also depend on financial, business or other factors affecting our operations, many of which are beyond our control. We will need to use cash to pay principal and interest on our debt, thereby reducing the funds available to fund operations, strategic initiatives and working </span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital requirements. If we are unable to generate sufficient cash to service our debt obligations, an event of default may occur under any of our debt instruments which could result in an acceleration of such debt upon which we may be required to repay all the amounts outstanding under some or all of our debt instruments. Such an acceleration of our debt obligations could harm our financial condition. From time to time, we may seek to retire or repurchase our outstanding debt through cash purchases and/or exchanges for equity or debt, in open-market purchases, privately negotiated transactions or otherwise. Any such repurchases or exchanges would be on such terms and at such prices as we determine, and will depend on current market conditions, our liquidity needs, any restrictions in our contracts and other factors. The amounts involved in such transactions could be material.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The conditional conversion feature of the Convertible Notes, if triggered, may adversely affect our financial condition and operating results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the conditional conversion feature of the Convertible Notes is triggered, holders of the Convertible Notes will be entitled to convert the notes at any time during specified periods at their option. If one or more holders elect to convert their notes, we would be required to settle a portion or all of our conversion obligation in cash, which could adversely affect our liquidity. Even if holders of the Convertible Notes do not elect to convert their notes, we are required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the notes as a current rather than long-term liability when the conditional conversion feature is triggered, which results in a material reduction of our net working capital. For example, as of March&#160;31, 2023, the conditional conversion feature was triggered and our 2024 Convertible Notes are classified as a current liability. </span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion of our Convertible Notes may dilute the ownership interest of existing stockholders or may otherwise depress the price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion of some or all of our Convertible Notes, to the extent we deliver shares upon conversion, will dilute the ownership interests of existing stockholders. Any sales in the public market of the Convertible Notes or our common stock issuable upon conversion of the Convertible Notes could adversely affect prevailing market prices of our common stock. In addition, the existence of the Convertible Notes may encourage short selling by market participants because the conversion of the Convertible Notes could be used to satisfy short positions, or anticipated conversion of the Convertible Notes into shares of our common stock could depress the price of our common stock.</span></div><div style="margin-top:6pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If proprietary or partnered product candidates are approved for commercialization but do not gain market acceptance resulting in commercial performance below that which was expected or projected, our business may suffer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming that existing or future proprietary or partnered product candidates obtain the necessary regulatory approvals for commercial sale, a number of factors may affect the market acceptance of these newly-approved products, including, among others:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree to which the use of these products is restricted by the approved product label;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the price of these products relative to other therapies for the same or similar treatments;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which reimbursement for these products and related treatments will be available from third-party payers including government insurance programs and private insurers;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of generic or biosimilar competitors to these products; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception by patients, physicians and other members of the health care community of the effectiveness and safety of these products for their prescribed treatments relative to other therapies for the same or similar treatments;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability and willingness of our partners to fund sales and marketing efforts; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of the sales and marketing efforts of our partners.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If these proprietary or partnered products do not gain or maintain market acceptance or experience reduced sales resulting in commercial performance below that which was expected or projected, the revenues we expect to receive from these products will be diminished which could harm our ability to fund future operations, including conduct acquisitions, execute our planned share repurchases, or affect our ability to use funds for other general corporate purposes and cause our business to suffer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our proprietary or partnered product candidates will be restricted to the labels approved by FDA and applicable regulatory bodies, and these restrictions may limit the marketing and promotion of the ultimate products. If the approved labels are restrictive, the sales and marketing efforts for these products may be negatively affected.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to license our ENHANZE and device technologies to our partners depends on the validity of our patents and other proprietary rights.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are essential to our business. Our success will depend in part on our ability to obtain and maintain patent protection for our inventions, to preserve our trade secrets and to operate without infringing the proprietary rights of third parties.&#160;We have multiple patents and patent applications throughout the world pertaining to our recombinant human hyaluronidase and methods of use and manufacture, including an issued U.S. patent which expires in 2027 and an issued </span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">European patent which expires in 2024, which we believe cover the products and product candidates under our existing collaborations, and Hylenex.&#160;Although we believe our patent filings represent a barrier to entry for potential competitors looking to utilize these hyaluronidases, upon expiration of our patents other pharmaceutical companies may (if they do not infringe our other patents) seek to compete with us by developing, manufacturing and selling biosimilars to the active drug ingredient in our ENHANZE technology used by our partners in combination with their products.&#160;Any such loss of patent protection or proprietary rights could lead to a reduction or loss of revenues, incentivize one or more of our key ENHANZE partners to terminate their relationship with us and impact our ability to enter into new collaboration and license agreements.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Developing, manufacturing and marketing pharmaceutical products for human use involves significant product liability risks for which we may have sufficient insurance coverage.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, manufacture, testing, marketing and sale of pharmaceutical products and medical devices involves the risk of product liability claims by consumers and other third parties. Product liability claims may be brought by individuals seeking relief for themselves, or by groups seeking to represent a class of injured patients. Further, third-party payers, either individually or as a putative class, may bring actions seeking to recover monies spent on one of our products. Although we maintain product liability insurance coverage, product liability claims can be high in the pharmaceutical industry, and our insurance may not sufficiently cover our actual liabilities. If product liability claims were to be made against us, it is possible that the liabilities may exceed the limits of our insurance policy, or our insurance carriers may deny, or attempt to deny, coverage in certain instances. If a lawsuit against us is successful, then the insurance coverage may not be sufficient and could materially and adversely affect our business and financial condition. Furthermore, various distributors of pharmaceutical products require minimum product liability insurance coverage before purchase or acceptance of products for distribution. Failure to satisfy these insurance requirements could impede our ability to achieve broad distribution of our proposed products, and higher insurance requirements could impose additional costs on us. In addition, since many of our partnered product candidates include the pharmaceutical products of a third-party, we run the risk that problems with the third-party pharmaceutical product will give rise to liability claims against us. Product liability claims can also result in additional regulatory consequences including, but not limited to, investigations and regulatory enforcement actions, as well as recalls, revocation or approvals, or labeling, marketing or promotional restrictions or changes. Product liability claims could also harm our reputation and the reputation of our products, adversely affecting our ability to market our products successfully. In addition, defending a product liability lawsuit is expensive and can divert the attention of our key employees from operating our business.  Such claims can also impact our ability to initiate or complete clinical trials.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our partners do not achieve projected development, clinical, or regulatory goals in the timeframes publicly announced or otherwise expected, the commercialization of our partners products may be delayed and, as a result, our business, financial condition, and results of operations may be adversely affected or delayed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, our collaborators may publicly articulate the estimated timing for the accomplishment of certain scientific, clinical, regulatory and other product development goals. The accomplishment of any goal is typically based on numerous assumptions, and the achievement of a particular goal may be delayed for any number of reasons both within and outside of our and our collaborators&#8217; control. If scientific, regulatory, strategic or other factors cause a collaboration partner to not meet a goal, regardless of whether that goal has been publicly articulated or not, our stock price may decline rapidly. Stock price declines may also trigger direct or derivative shareholder lawsuits. As with any litigation proceeding, the eventual outcome of any legal action is difficult to predict. If any such lawsuits occur, we will incur expenses in connection with the defense of these lawsuits, and we may have to pay substantial damages or settlement costs in connection with any resolution thereof. Although we have insurance coverage against which we may claim recovery against some of these expenses and costs, the amount of coverage may not be adequate to cover the full amount or certain expenses and costs may be outside the scope of the policies we maintain. In the event of an adverse outcome or outcomes, our business could be materially harmed from depletion of cash resources, negative impact on our reputation, or restrictions or changes to our governance or other processes that may result from any final disposition of the lawsuit. Moreover, responding to and defending pending litigation significantly diverts management&#8217;s attention from our operations.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the consistent failure to meet publicly announced milestones may erode the credibility of our management team with respect to future milestone estimates. </span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future acquisitions could disrupt our business and impact our financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to augment and extend our revenue, we acquired Antares in May 2022 and we may decide to acquire additional businesses, products and technologies. As we have limited experience in evaluating and completing acquisitions, our ability as an organization to make such acquisitions is unproven. Acquisitions could require significant capital infusions and could involve many risks, including, but not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to issue additional convertible debt or equity securities to complete an acquisition, which would dilute our stockholders and could adversely affect the market price of our common stock;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an acquisition may negatively impact our results of operations because it may require us to amortize or write down amounts related to goodwill and other intangible assets, or incur or assume substantial debt or liabilities, or it may cause adverse tax consequences, substantial depreciation or deferred compensation charges;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may encounter difficulties in assimilating and integrating the business, products, technologies, personnel or operations of companies that we acquire;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain acquisitions may impact our relationship with existing or potential partners who are competitive with the acquired business, products or technologies;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquisitions may require significant capital infusions and the acquired businesses, products or technologies may not generate sufficient value to justify acquisition costs;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may take on liabilities from the acquired company such as debt, legal liabilities or business risk which could be significant;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an acquisition may disrupt our ongoing business, divert resources, increase our expenses and distract our management;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquisitions may involve the entry into a geographic or business market in which we have little or no prior experience; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">key personnel of an acquired company may decide not to work for us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks occurred, it could adversely affect our business, financial condition and operating results. There is no assurance that we will be able to identify or consummate any future acquisitions on acceptable terms, or at all. If we do pursue any future acquisitions, it is possible that we may not realize the anticipated benefits from such acquisitions or that the market will not view such acquisitions positively.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability between different tax jurisdictions, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on September 30, 2021, we determined, based on our facts and circumstances, that it was more likely than not that a substantial portion of our deferred tax assets would be realized and, as a result, substantially all of our valuation allowance against our deferred tax assets was released. This resulted in substantially and disproportionately increasing our reported net income and our earnings per share compared to our operating results for 2021. Historical and future comparisons to these amounts are not, and will not be, indicative of actual profitability trends for our business. Starting in 2022, we recorded income tax expense at an estimated tax rate that approximate statutory tax rates, resulting a reduction in our net income and net income per share.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related To Ownership of Our Common Stock</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price is subject to significant volatility.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in a highly dynamic industry which often results in significant volatility in the market price of common stock irrespective of company performance. The high and low sales prices of our common stock during the twelve months ended March&#160;31, 2023 were $59.46 and $32.83, respectively. In addition to the other risks and uncertainties described elsewhere in this Quarterly Report on Form 10-Q and all other risks and uncertainties that are either not known to us at this time or which we deem to be immaterial, any of the following factors may lead to a significant drop in our stock price:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the presence of competitive products to those being developed by our partners;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure (actual or perceived) of our partners to devote attention or resources to the development or commercialization of partnered products or product candidates licensed to such partner;</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a dispute regarding our failure, or the failure of one of our partners, to comply with the terms of a collaboration agreement; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the termination, for any reason, of any of our collaboration agreements;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sale of common stock by any significant stockholder, including, but not limited to, direct or indirect sales by members of management or our Board of Directors;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the resignation, or other departure, of members of management or our Board of Directors;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general negative conditions in the healthcare industry;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pandemics or other global crises;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general negative conditions in the financial markets;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost associated with obtaining regulatory approval for any of our proprietary or partnered product candidates;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure, for any reason, to secure or defend our intellectual property position;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure or delay of applicable regulatory bodies to approve our proprietary or partnered product candidates;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identification of safety or tolerability issues associated with our proprietary or partnered products or product candidates;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our or our partners&#8217; clinical trials to meet efficacy endpoints;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspensions or delays in the conduct of our or our partners&#8217; clinical trials or securing of regulatory approvals;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse regulatory action with respect to our proprietary or partnered products and product candidates such as loss of regulatory approval to commercialize such products, clinical holds, imposition of onerous requirements for approval or product recalls;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure, or the failure of our partners, to successfully commercialize products approved by applicable regulatory bodies such as the FDA;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure, or the failure of our partners, to generate product revenues anticipated by investors;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions in our clinical or commercial supply chains, including disruptions caused by problems with a bulk rHuPH20 contract manufacturer or a fill and finish manufacturer for any product or product collaboration candidate; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sale of additional debt and/or equity securities by us;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to obtain financing on acceptable terms or at all; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a restructuring of our operations;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an inability to execute our share repurchase program in the time and manner we expect due to market, business, legal or other considerations; or </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a conversion of the Convertible Notes into shares of our common stock.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future transactions where we raise capital may negatively affect our stock price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently a &#8220;Well-Known Seasoned Issuer&#8221; and may file automatic shelf registration statements at any time with the SEC. Sales of substantial amounts of shares of our common stock or other securities under any future shelf registration statements could lower the market price of our common stock and impair our ability to raise capital through the sale of equity securities. </span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents, the Indentures and Delaware law may make an acquisition of us more difficult.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-takeover provisions in our charter documents, the Indentures and Delaware law may make an acquisition of us more difficult. First, our Board of Directors is classified into three classes of directors. Under Delaware law, directors of a corporation with a classified board may be removed only for cause unless the corporation&#8217;s certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation does not provide otherwise. In addition, our bylaws limit who may call special meetings of stockholders, permitting only stockholders holding at least 50% of our outstanding shares to call a special meeting of stockholders. Our amended and restated certificate of incorporation does not include a provision for cumulative voting for directors. Under cumulative voting, a minority stockholder holding a sufficient percentage of a class of shares may be able to ensure the election of one or more directors. Finally, our bylaws establish procedures, including advance notice procedures, with regard to the nomination of candidates for election as directors and stockholder proposals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions in our charter documents may discourage potential takeover attempts, discourage bids for our common stock at a premium over market price or adversely affect the market price of, and the voting and other rights of the holders of, our common stock. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors other than the candidates nominated by our Board of Directors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in connection with our Convertible Notes issuances, we have entered into indentures, dated as of March 1, 2021 and August 18, 2022 (the&#8220;Indentures&#8221;), with The Bank of New York Mellon Trust Company, N.A., as trustee. Certain provisions in the Indentures could make it more difficult or more expensive for a third-party to acquire us. For example, if a takeover would constitute a fundamental change, holders of the Convertible Notes will have the right to require us to repurchase their Convertible Notes in cash. In addition, if a takeover constitutes a make-whole fundamental change, we may be required to increase the conversion rate for holders who convert their Convertible Notes in connection with such takeover. In addition, a </span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">change of control constitutes an event of default under our 2022 Credit Agreement. Such event of default could result in the administrative agent or the lender parties thereto declaring the unpaid principal, all accrued and unpaid interest, and all other amounts owing or payable under the 2022 Credit Agreement to be immediately due and payable. In either case, and in other cases, our obligations under the Convertible Notes, and the Indentures could increase the cost of acquiring us or otherwise discourage a third-party from acquiring us or removing incumbent management.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which may prohibit large stockholders from consummating a merger with, or acquisition of, us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may deter an acquisition of us that might otherwise be attractive to stockholders.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Industry</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our or our partnered products must receive regulatory approval before they can be sold, and compliance with the extensive government regulations is expensive and time consuming and may result in the delay or cancellation of our or our partnered product sales, introductions or modifications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Extensive industry regulation has had, and will continue to have, a significant impact on our business. All pharmaceutical and medical device companies, including ours, are subject to extensive, complex, costly and evolving regulation by the health regulatory agencies including the FDA (and with respect to controlled drug substances, the U.S. Drug Enforcement Administration (DEA)) and equivalent foreign regulatory agencies and state and local/regional government agencies. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other domestic and foreign statutes and regulations govern or influence the testing, manufacturing, packaging, labeling, storing, recordkeeping, safety, approval, advertising, promotion, sale and distribution of our products and our partners&#8217; products and product candidates. We are dependent on receiving FDA and other governmental approvals, including regulatory approvals in jurisdictions outside the United States, prior to manufacturing, marketing and shipping our products. Consequently, there is always a risk that the FDA or other applicable governmental authorities, including those outside the United States, will not approve our or our partners&#8217; products or may impose onerous, costly and time-consuming requirements such as additional clinical or animal testing. Regulatory authorities may require that our partners&#8217; change our studies or conduct additional studies, which may significantly delay or make continued pursuit of approval commercially unattractive to our partners. For example, the approval of the HYQVIA BLA was delayed by the FDA until we and our partner provided additional preclinical data sufficient to address concerns regarding non-neutralizing antibodies to rHuPH20 that were detected in the registration trial. Although these antibodies have not been associated with any known adverse clinical effects, and the HYQVIA BLA was ultimately approved by the FDA, the FDA or other foreign regulatory agency may, at any time, halt our and our partners&#8217; development and commercialization activities due to safety concerns. In addition, even if our proprietary or partnered products are approved, regulatory agencies may also take post-approval action limiting or revoking our or our partners&#8217; ability to sell these products. Any of these regulatory actions may adversely affect the economic benefit we may derive from our proprietary or our partnered products and therefore harm our financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain of these regulations, in addition to our partners, we and our contract suppliers and manufacturers are subject to periodic inspection of our or their respective facilities, procedures and operations and/or the testing of products by the FDA, the DEA and other authorities, which conduct periodic inspections to confirm that we and our contract suppliers and manufacturers are in compliance with all applicable regulations. The FDA also conducts pre-approval and post-approval reviews and plant inspections to determine whether our systems, or our contract suppliers&#8217; and manufacturers&#8217; processes, are in compliance with cGMP and other FDA regulations. If our partners, we, or our contract suppliers and manufacturers, fail these inspections, our partners may not be able to commercialize their products in a timely manner without incurring significant additional costs, or at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA imposes a number of complex regulatory requirements on entities that advertise and promote pharmaceuticals including, but not limited to, standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the Internet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because some of our and our partners&#8217; products and product candidates are considered to be drug/device combination products, the approval and post-approval requirements that we and they are required to comply with can be more complex.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our and our partners&#8217; products and product candidates are considered to be drug/device combination products by the FDA, consisting of a drug product and a drug delivery device. If marketed individually, each component would be subject to different regulatory pathways and reviewed by different centers within the FDA. A combination product, however, is assigned to a center that will have primary jurisdiction over its pre-market review and regulation based on a determination of the product&#8217;s primary mode of action, which is the single mode of action that provides the most important therapeutic action. In the case of our and our partners&#8217; products and product candidates, the primary mode of action is typically attributable to the drug component of the products, which means that the Center of Drug Evaluation and Research has primary jurisdiction over the products&#8217; premarket development and review. These products and product candidates will be and have been subject to the FDA drug approval process and will not require a separate FDA clearance or approval for the device component. Even though </span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these products and product candidates will not require a separate FDA clearance or approval, both the drug and device centers within the FDA will review the marketing application for safety, the efficacy of both the drug and device component, including the design and reliability of the injector, and a number of other different areas, such as to ensure that the drug labeling adequately discloses all relevant information and risks, and to confirm that the instructions for use are accurate and easy to use. These reviews could increase the time needed for review completion of a successful application and may require additional studies, such as usage studies, to establish the validity of the instructions for use. Such reviews and requirements may extend the time necessary for the approval of drug-device combinations. In the case of combination product candidates for which we or our partners are seeking approval via the ANDA pathway, it is also possible that the agency may decide that the unique nature of combination products leads it to question the claims of bioequivalence and/or same labeling, resulting in the need to refile the application under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act. This may result in delays in product approval and may cause us or our partners to incur additional costs associated with testing, including clinical trials. Approval via the 505(b)(2) pathway may also result in additional selling expenses and a decrease in market acceptance due to the lack of substitutability by pharmacies or formularies. In addition, approval under the 505(b)(2) or ANDA regulatory pathway is not a guarantee of an exclusive position for the approved product in the marketplace.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, although precedent and guidance exist for the approval of such combination products, the FDA could change what it requires or how it reviews submissions. Changes in review processes or the requirement for the study of combination products could delay anticipated launch dates or be cost prohibitive. Such delay or failure to launch these products or devices could adversely affect our revenues and future profitability. If our or our partners&#8217; combination product candidates are approved, we, our partners, and any of our respective contractors will be required to comply with FDA regulatory requirements related to both drugs and devices. For instance, drug/device combination products must comply with both the drug cGMPs and device QSRs. Depending on whether the drug and device components are at the same facility, however, the FDA regulations provide a streamlined method to comply with both sets of requirements. The FDA has specifically promulgated guidance on injectors, which discuss the FDA&#8217;s requirements with respect to marketing application and post-market injector design controls and reliability analyses. Additionally, drug/device combination products will be subject to additional FDA and constituent part reporting requirements. Compliance with these requirements will require additional effort and monetary expenditure.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject, directly or indirectly, to various broad federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and activities may be directly, or indirectly, subject to various broad federal and state healthcare laws, including without limitation, anti-kickback laws, the Foreign Corrupt Practices Act (FCPA), false claims laws, civil monetary penalty laws, data privacy and security laws, tracing and tracking laws, as well as transparency (or &#8220;sunshine&#8221;) laws regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as sales, marketing and education programs. Many states have similar healthcare fraud and abuse laws, some of which may be broader in scope and may not be limited to items or services for which payment is made by a government health care program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. While we have adopted a healthcare corporate compliance program, it is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws. If our operations or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any sales of products outside the U.S. will also likely subject us to the FCPA and foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be required to initiate or defend against legal proceedings related to intellectual property rights, which may result in substantial expense, delay and/or cessation of certain development and commercialization of our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We primarily rely on patents to protect our intellectual property rights. The strength of this protection, however, is uncertain. For example, it is not certain that:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will be able to obtain patent protection for our products and technologies;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of any of our issued patents will be sufficient to provide commercially significant exclusivity for our products and technologies;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not independently develop similar or alternative technologies or duplicate our technologies and obtain patent protection before we do; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our issued patents, or patent pending applications that result in issued patents, will be held valid, enforceable and infringed in the event the patents are asserted against others.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently own or license several patents and also have pending patent applications applicable to rHuPH20 and other proprietary materials. There can be no assurance that our existing patents, or any patents issued to us as a result of our pending patent applications, will provide a basis for commercially viable products, will provide us with any competitive advantages, or will not face third-party challenges or be the subject of further proceedings limiting their scope or enforceability. Any weaknesses or limitations in our patent portfolio could have a material adverse effect on our business and financial condition. In addition, if any of our pending patent applications do not result in issued patents, or result in issued patents with narrow or limited claims, this could result in us having no or limited protection against generic or biosimilar competition against our product candidates which would have a material adverse effect on our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our partners may become involved in interference proceedings in the U.S. Patent and Trademark Office, or other proceedings in other jurisdictions, to determine the priority, validity or enforceability of our patents or our partners&#8217; patents related to our collaborations. For example, as a result of one such proceeding, in March 2023 the Opposition Division of the European Patent Office revoked one of Janssen&#8217;s co-formulation patents for DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (daratumumab) SC. In addition, costly litigation could be necessary to protect our patent position. Successful challenges to the priority, validity or enforceability of our or our partners&#8217; patents could have a material adverse effect on our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trademarks to protect the names of our products (e.g. Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recombinant). We may not be able to obtain trademark protection for any proposed product names we select. In addition, product names for pharmaceutical products must be approved by health regulatory authorities such as the FDA in addition to meeting the legal standards required for trademark protection and product names we propose may not be timely approved by regulatory agencies which may delay product launch. In addition, our trademarks may be challenged by others. If we enforce our trademarks against third parties, such enforcement proceedings may be expensive.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secrets, unpatented proprietary know-how and continuing technological innovation that we seek to protect with confidentiality agreements with employees, consultants and others with whom we discuss our business. Disputes may arise concerning the ownership of intellectual property or the applicability or enforceability of these agreements, and we might not be able to resolve these disputes in our favor.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to protecting our own intellectual property rights, third parties may assert patent, trademark or copyright infringement or other intellectual property claims against us. If we become involved in any intellectual property litigation, we may be required to pay substantial damages, including but not limited to treble damages, attorneys&#8217; fees and costs, for past infringement if it is ultimately determined that our products infringe a third-party&#8217;s intellectual property rights. Even if infringement claims against us are without merit, defending a lawsuit takes significant time, may be expensive and may divert management&#8217;s attention from other business concerns. Further, we may be stopped from developing, manufacturing or selling our products until we obtain a license from the owner of the relevant technology or other intellectual property rights. If such a license is available at all, it may require us to pay substantial royalties or other fees.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur significant liability if it is determined that we are promoting or have in the past promoted the &#8220;off-label&#8221; use of drugs or medical devices, or otherwise promoted or marketed approved products in a manner inconsistent with the FDA&#8217;s requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and certain other jurisdictions, companies may not promote drugs or medical devices for &#8220;off-label&#8221; uses, that is, uses that are not described in the product&#8217;s labeling and that differ from those that were approved or cleared by the FDA or other foreign regulatory agencies. However, physicians and other healthcare practitioners may prescribe drug products and use medical devices for off-label or unapproved uses, and such uses are common across some medical specialties. Although the FDA does not regulate a physician&#8217;s choice of medications, treatments or product uses, the Federal Food, Drug and Cosmetic Act and FDA regulations significantly restrict permissible communications on the subject of off-label uses of drug products and medical devices by pharmaceutical and medical device companies. As the sponsors of FDA approved products, we and our partners will not only be responsible for the actions of the companies but also can be held liable for the actions of employees </span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and contractors, requiring that all employees and contractors engaging in regulated functions, such as product promotion, be adequately trained and monitored, which requires time and monetary expenditures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA determines that a company has improperly promoted a product &#8220;off label&#8221; or otherwise not in accordance with the agency&#8217;s promotional requirements, the FDA may issue a warning letter or seek other enforcement action to limit or restrict certain promotional activities or materials or seek to have product withdrawn from the market or seize product, among other enforcement requirements. In addition, a company that is found to have improperly promoted off-label uses may be subject to significant liability, including civil fines, criminal fines and penalties, civil damages and exclusion from federal funded healthcare programs such as Medicare and Medicaid and/or government contracting, consent decrees and corporate integrity agreements, as well as potential liability under the federal FCA and applicable state false claims acts. Conduct giving rise to such liability could also form the basis for private civil litigation by third-party payers or other persons allegedly harmed by such conduct.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, in addition to the regulatory restrictions on off-label promotion, there are other FDA restrictions on and requirements concerning product promotion and advertising, such as requirements that such communications be truthful and non-misleading and adequately supported. The FDA also has requirements concerning the distribution of drug samples. The FDA and other authorities may take the position that we are not in compliance with promotional, advertising, and marketing requirements, and, if such non-compliance is proven, we may be subject to significant liability, including but not limited to administrative, civil and criminal penalties and fines, in addition to regulatory enforcement actions.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">For certain of our products, we and our independent contractors, distributors, prescribers, and dispensers are required to comply with regulatory requirements related to controlled substances, which will require the expenditure of additional time and will incur additional expenses to maintain compliance and may subject us to additional penalties for noncompliance, which could inhibit successful commercialization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products are controlled substances and accordingly, we, and our contractors, distributors, prescribers, and dispensers must comply with Federal controlled substances laws and regulations, enforced by the U.S. Drug Enforcement Administration (&#8220;DEA&#8221;), as well as state-controlled substances laws and regulations enforced by state authorities. These requirements include, but are not limited to, registration, security, recordkeeping, reporting, storage, distribution, importation, exportation, inventory, and other requirements. These requirements are enforced by the DEA through periodic inspections. Not only must continuous controlled substance registration be maintained, but compliance with the applicable controlled substance requirements will require significant efforts and expenditures, which could also inhibit successful commercialization. These compliance requirements also add complexity to the distribution, prescribing and dispensing of certain of our products that may also impact commercialization, including the establishment of anti-diversion procedures. If we and our contractors, distributors, prescribers, and dispensers do not comply with the applicable controlled substance requirements, we or they may be subject to administrative, civil or criminal enforcement, including civil penalties, refusals to renew necessary registrations, revocation of registrations, criminal proceedings, or consent decrees.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent protection for biotechnology inventions and for inventions generally is subject to significant scrutiny if patent laws or the interpretation of patent laws change, our business may be adversely impacted because we may lose the ability to enforce our intellectual property rights against competitors develop and commercialize products based on our discoveries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent protection for protein-based therapeutic products is highly uncertain and involves complex legal and factual questions. In recent years, there have been significant changes in patent law, including the legal standards that govern the scope of protein and biotechnology patents. Standards for patentability of full-length and partial genes, and their corresponding proteins, are changing. Recent court decisions have made it more difficult to obtain patents, by making it more difficult to satisfy the patentable subject matter requirement and the requirement of non-obviousness, have decreased the availability of injunctions against infringers, and have increased the likelihood of challenging the validity of a patent through a declaratory judgment action. Taken together, these decisions could make it more difficult and costly for us to obtain, license and enforce our patents. In addition, the Leahy-Smith America Invents Act (HR 1249) was signed into law in September 2011, which among other changes to the U.S. patent laws, changes patent priority from &#8220;first to invent&#8221; to &#8220;first to file,&#8221; implements a post-grant opposition system for patents and provides for a prior user defense to infringement. These judicial and legislative changes have introduced significant uncertainty in the patent law landscape and may potentially negatively impact our ability to procure, maintain and enforce patents to provide exclusivity for our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also have been, and continue to be, policy discussions concerning the scope of patent protection awarded to biotechnology inventions. Social and political opposition to biotechnology patents may lead to narrower patent protection within the biotechnology industry. Social and political opposition to patents on genes and proteins and recent court decisions concerning patentability of isolated genes may lead to narrower patent protection, or narrower claim interpretation, for isolated genes, their corresponding proteins and inventions related to their use, formulation and manufacture. Patent protection relating to biotechnology products is also subject to a great deal of uncertainty outside the U.S., and patent laws are evolving and undergoing revision in many countries. Changes in, or different interpretations of, patent laws worldwide may result in our </span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inability to obtain or enforce patents, and may allow others to use our discoveries to develop and commercialize competitive products, which would impair our business.</span></div><div style="margin-top:6pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party reimbursement and customer contracts are not available, our proprietary and partnered products may not be accepted in the market resulting in commercial performance below that which was expected or projected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our partners&#8217; ability to earn sufficient returns on proprietary and partnered products will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, managed care organizations and other healthcare providers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers are increasingly attempting to limit both the coverage and the level of reimbursement of new drug products to contain costs. Consequently, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. Third-party payers may not establish adequate levels of reimbursement for the products that we and our partners commercialize, which could limit their market acceptance and result in a material adverse effect on our revenues and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer contracts, such as with group purchasing organizations and hospital formularies, will often not offer contract or formulary status without either the lowest price or substantial proven clinical differentiation. If, for example, Hylenex is compared to animal-derived hyaluronidases by these entities, it is possible that neither of these conditions will be met, which could limit market acceptance and result in a material adverse effect on our revenues and financial condition.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The rising cost of healthcare and related pharmaceutical product pricing has led to cost containment pressures from third-party payers as well as changes in federal coverage and reimbursement policies and practices that could cause us and our partners to sell our products at lower prices, and impact access to our and our partners&#8217; products, resulting in less revenue to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of our proprietary or partnered products that have been, or in the future are, approved by the FDA may be purchased or reimbursed by state and federal government authorities, private health insurers and other organizations, such as health maintenance organizations and managed care organizations. Such third-party payers increasingly challenge pharmaceutical product pricing. The trend toward managed healthcare in the U.S., the growth of such organizations, and various legislative proposals and enactments to reform healthcare and government insurance programs, including the Medicare Prescription Drug Modernization Act of 2003 and the Affordable Care Act of 2010 (ACA), could significantly influence the manner in which pharmaceutical products are prescribed and purchased, resulting in lower prices and/or a reduction in demand. Such cost containment measures and healthcare reforms could adversely affect our ability to sell our product and our partners&#8217; ability to sell their products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., our business may be impacted by changes in federal reimbursement policy resulting from executive actions, federal regulations, or federal demonstration projects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal administration and/or agencies, such as the Centers for Medicare &amp; Medicaid Services, or CMS, have announced a number of demonstration projects, recommendations and proposals to implement various elements described in the drug pricing blueprint. CMS, the federal agency responsible for administering Medicare and overseeing state Medicaid programs and Health Insurance Marketplaces, has substantial power to implement policy changes or demonstration projects that can quickly and significantly affect how drugs, including our products, are covered and reimbursed. For example, in November 2020, former President Trump announced the interim final rule to implement the Most Favored Nations drug pricing model seeking to tie Medicare payment rates to an international index price. This final rule was subsequently rescinded by CMS. Additionally, a number of Congressional committees have also held hearings and evaluated proposed legislation on drug pricing and payment policy which may affect our business. For example, in July 2019, the Senate Finance Committee advanced a bill that in part would penalize pharmaceutical manufacturers for increasing drug list prices covered by Medicare Part B and Part D, faster than the rate of inflation, and cap out-of-pocket expenses for Medicare Part D beneficiaries. Several other proposals have been introduced that, if enacted and implemented, could affect access to and sales of our and our partners&#8217; products, allow the federal government to engage in price negotiations on certain drugs, and allow importation of prescription medication from Canada or other countries. For example, in August 2022, &#8220;The Inflation Reduction Act of 2022&#8221; was enacted which will, among other things, allow and require the federal government to negotiate prices for some drugs covered under Medicare Part B and Part D, require drug companies to pay rebates to Medicare if prices rise faster than inflation for drugs used by Medicare beneficiaries and cap out-of-pocket spending for individuals enrolled in Medicare Part D.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this dynamic environment, we are unable to predict which or how many federal policy, legislative or regulatory changes may ultimately be enacted. To the extent federal government initiatives decrease or modify the coverage or reimbursement available for our or our partners&#8217; products, limit or impact our decisions regarding the pricing of biopharmaceutical products or otherwise reduce the use of our or our partners&#8217; U.S. products, such actions could have a material adverse effect on our business and results of operations. </span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, individual states are considering proposed legislation and have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payers or other restrictions could negatively and materially impact our revenues and financial condition. We anticipate that we will encounter similar regulatory and legislative issues in most other countries outside the U.S.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, private payers in the U.S., including insurers, pharmacy benefit managers (PBMs), integrated healthcare delivery systems, and group purchasing organizations, are continuously seeking ways to reduce drug costs. Many payers have developed and continue to develop ways to shift a greater portion of drug costs to patients through, for example, limited benefit plan designs, high deductible plans and higher co-pay or coinsurance obligations. Consolidation in the payer space has also resulted in a few large PBMs and insurers which place greater pressure on pricing and utilization negotiations for our and our partners&#8217; products in the U.S., increasing the need for higher discounts and rebates and limiting patient access and utilization. Ultimately, additional discounts, rebates and other price reductions, fees, coverage and plan changes, or exclusions imposed by these private payers on our and our partners&#8217; products could have an adverse event on product sales, our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help patients afford certain of our products, we offer discount, rebate, and co-pay coupon programs. CMS recently has issued a regulation imposing additional obligations on manufacturers in order to continue excluding such programs from government pricing calculations to avoid payment of increased Medicaid rebates. In recent years, other pharmaceutical manufacturers have been named in class action lawsuits challenging the legality of their co-pay programs under a variety of federal and state laws. Our co-pay coupon programs could become the target of similar lawsuits or insurer actions. It is possible that the outcome of litigation against other manufacturers, changes in insurer policies regarding co-pay coupons, and/or the introduction and enactment of new legislation or regulatory action could restrict or otherwise negatively affect these programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face risks relating to the reporting of pricing data that affects the reimbursement of and discounts provided for our products. Government price reporting regulations are complex and may require a manufacturer to update certain previously submitted data. If our submitted pricing data are incorrect, we may become subject to substantial fines and penalties or other government enforcement actions, which could have a material adverse effect on our business and results of operations. In addition, as a result of restating previously reported price data, we also may be required to pay additional rebates and provide additional discounts.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition and rapid technological change that could result in the development of products by others that are competitive with our proprietary and partnered products, including those under development.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary and partnered products have numerous competitors in the U.S. and abroad including, among others, major pharmaceutical and specialized biotechnology firms, universities and other research institutions that have developed competing products. Many of these competitors have substantially more resources and product development, manufacturing and marketing experience and capabilities than we do. The competitors for Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recombinant include, but are not limited to, Bausch Health Companies, Inc.&#8217;s FDA-approved product, Vitrase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an ovine (ram) hyaluronidase, and Amphastar Pharmaceuticals, Inc.&#8217;s product, Amphadase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a bovine (bull) hyaluronidase. For our ENHANZE technology, such competitors may include major pharmaceutical and specialized biotechnology firms. These competitors may develop technologies and products that are more effective, safer, or less costly than our current or future proprietary and partnered products and product candidates or that could render our and our partners&#8217; products, technologies and product candidates obsolete or noncompetitive.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risks</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to attract, hire and retain key personnel our business could be negatively affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on the performance of key employees with relevant experience. We depend substantially on our ability to hire, train, motivate and retain high quality personnel. If we are unable to identify, hire and retain qualified personnel, our ability to support current and future alliances with strategic partners could be adversely impacted. Our use of domestic and international third-party contractors, consultants and staffing agencies also subjects us to potential co-employment liability claims.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, if we were to lose key personnel, we may lose some portion of our institutional knowledge and technical know-how, potentially causing a disruption or delay in one or more of our partnered development programs until adequate replacement personnel could be hired and trained. In addition, we do not have key person life insurance policies on the lives of any of our employees which would help cover the cost of associated with the loss of key employees.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, including laboratories, offices and other research facilities, are headquartered in San Diego, California. We have additional facilities in Ewing, New Jersey and Minnetonka, Minnesota. We depend on our facilities and on our collaborators, contractors and vendors for the continued operation of our business. Natural disasters or other catastrophic events, pandemics, interruptions in the supply of natural resources, political and governmental changes, wildfires and other fires, tornadoes, floods, explosions, actions of animal rights activists, earthquakes and civil unrest could disrupt our operations or those of our partners, contractors and vendors. Even though we believe we carry commercially reasonable business interruption and liability insurance, and our contractors may carry liability insurance that protect us in certain events, we may suffer losses as a result of business interruptions that exceed the coverage available under our and our contractors&#8217; insurance policies or for which we or our contractors do not have coverage. Any natural disaster or catastrophic event could have a significant negative impact on our operations and financial results. Moreover, any such event could delay our partners&#8217; research and development programs.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cyberattacks, security breaches or system breakdowns may disrupt our operations and harm our operating results and reputation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners are subject to increasingly sophisticated attempts to gain unauthorized access to our information technology storage and access systems and are devoting resources to protect against such intrusion. Cyberattacks could render us or our partners unable to utilize key systems or access important data needed to operate our business.&#160;The wrongful use, theft, deliberate sabotage or any other type of security breach with respect to any of our or any of our vendors and partners&#8217; information technology storage and access systems could result in the breakdown or other service interruption, or the disruption of our ability to use such systems or disclosure or dissemination of proprietary and confidential information that is electronically stored, including intellectual property, trade secrets, financial information, regulatory information, strategic plans, sales trends and forecasts, litigation materials or personal information belonging to us, our staff, our patients, customers and/or other business partners which could result in a material adverse impact on our business, operating results and financial condition. We continue to invest in monitoring, and other security and data recovery measures to protect our critical and sensitive data and systems. However, these may not be adequate to prevent or fully recover systems or data from all breakdowns, service interruptions, attacks or breaches of our systems. In addition, our cybersecurity insurance may not be sufficient to cover us against liability related to any such breaches. Furthermore, any physical break-in or trespass of our facilities could result in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data or damage to our research and development equipment and assets. Such adverse effects could be material and irrevocable to our business, operating results, financial condition and reputation.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.52pt">Quantitative and Qualitative Disclosures About Market Risk </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our market risks during the quarter ended March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, our cash equivalents and marketable securities consisted of investments in money market funds, asset-backed securities, U.S. Treasury securities, corporate debt securities, agency bonds and commercial paper. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. Some of the financial instruments that we invest in could be subject to market risk. This means that a change in prevailing interest rates may cause the value of the instruments to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of that security may decline. Based on our current investment portfolio as of March&#160;31, 2023, we do not believe that our results of operations would be materially impacted by an immediate change of 10% in interest rates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not hold or issue derivatives, derivative commodity instruments or other financial instruments for speculative trading purposes. Further, we do not believe our cash, cash equivalents and marketable securities have significant risk of default or illiquidity. We made this determination based on discussions with our investment advisors and a review of our holdings. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. All of our cash equivalents and marketable securities are recorded at fair market value.</span></div><div id="i2807c465c47449f58323217d8928fdb2_109"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.52pt">Controls and Procedures</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the timelines specified in the Securities and Exchange Commission&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decision regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our internal control over financial reporting that occurred during the quarter ended March&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="i2807c465c47449f58323217d8928fdb2_115"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.52pt">Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our condensed consolidated statements of income and balance sheets. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in our opinion, individually or in the aggregate, would have a material adverse effect on our condensed consolidated statements of income or balance sheets.</span></div><div id="i2807c465c47449f58323217d8928fdb2_118"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.3pt">Risk Factors </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have provided updated Risk Factors in the section labeled &#8220;Risk Factors&#8221; in Part I, Item 2, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. We do not believe the updates have materially changed the type or magnitude of risks we face in comparison to the disclosure provided in our most recent Annual Report on Form 10-K.</span></div><div id="i2807c465c47449f58323217d8928fdb2_121"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.52pt">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below sets forth information regarding repurchases of our common stock during the three months ended March&#160;31, 2023:</span></div><div style="margin-top:11pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:41.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.557%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.557%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.557%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Price paid per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares That May Yet  Be Purchased under the Programs (thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023 &#8211; January 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February  1, 2023 &#8211; February 28, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023 &#8211;  March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,128,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,128,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,165,258&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,165,258&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-indent:38.25pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2021, the Board of Directors authorized a capital return program to repurchase up to $750.0 million of outstanding stock over a three-year period. </span></div><div id="i2807c465c47449f58323217d8928fdb2_124"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.52pt">Defaults Upon Senior Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i2807c465c47449f58323217d8928fdb2_127"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.52pt">Mine Safety Disclosures</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i2807c465c47449f58323217d8928fdb2_130"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.52pt">Other Information</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.52pt">Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903619000019/exhibit31.htm">Amended and Restated Certificate of Incorporation</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903619000019/exhibit31.htm"> of Halozyme Therapeutics, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903619000019/exhibit31.htm"> (</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903619000019/exhibit31.htm">filed as Exhibit 3.1 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903619000019/exhibit31.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903619000019/exhibit31.htm">s Form 8-K filed May</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903619000019/exhibit31.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903619000019/exhibit31.htm">3, 2019 and inco</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903619000019/exhibit31.htm">rporated herein by reference</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903619000019/exhibit31.htm">)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">Bylaws, as amended (</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">filed as Exhibit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">3.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm"> to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">s Form 8-K filed December 10, 2021 and inc</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">orporated herein by reference</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex41.htm">Indenture, dated March 1, 2021, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex41.htm"> (</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">filed as Exhibit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">.1 to the Company&#8217;s Form 8-K filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm"> 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm"> and incorporated herein by reference</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex41.htm">)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex42.htm">Form of Note, dated March 1, 2021, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex42.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex42.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">filed as Exhibit 4.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm"> to the Company&#8217;s Form 8-K filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm"> and incorporated herein by reference</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex42.htm">)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex41.htm">Indenture, dated August 18, 2022, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex41.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">filed as Exhibit 4.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm"> to the Company&#8217;s Form 8-K filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm"> 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm"> and incorporated herein by reference</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex41.htm">)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex41.htm">Form of Note, dated August 18, 2022, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex41.htm">(included within Exhibit 4.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex41.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex41.htm">) (</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">filed as Exhibit 4.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm"> to the Company&#8217;s Form 8-K filed August 18, 2022 and incorporated herein by reference</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522224202/d391138dex41.htm">)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101-amendmentno2tocredit.htm">Amendment No. 2 to the Credit Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filed herewith)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex31110qq12023.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filed herewith)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex31210qq12023.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (filed herewith)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex3210qq12023.htm">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (furnished herewith)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instance Document - the instance document does not appear in the interactive Data File because its XBRL tags are embedded within the Inline XBRL document (filed herewith)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline Taxonomy Extension Schema Document (filed herewith)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline Taxonomy Extension Calculation Linkbase Document (filed herewith)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline Taxonomy Extension Definition Linkbase Document (filed herewith)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline Taxonomy Extension Label Linkbase Document (filed herewith)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline Taxonomy Extension Presentation Linkbase Document (filed herewith)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) (filed herewith)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.478%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="i2807c465c47449f58323217d8928fdb2_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.210%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Halozyme Therapeutics, Inc.,<br/>a Delaware corporation</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Helen I. Torley, M.B. Ch.B., M.R.C.P.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helen I. Torley, M.B. Ch.B., M.R.C.P.<br/>President and Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Nicole LaBrosse</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicole LaBrosse<br/>Senior Vice President and Chief Financial Officer<br/>(Principal Financial and Accounting Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex101-amendmentno2tocredit.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i090b04bc370c4950a3d9f1df1fa745b5_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDMENT NO. 2 TO THE CREDIT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AMENDMENT NO. 2 to the CREDIT AGREEMENT, dated as of March 1, 2023 (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), is made by and among HALOZYME THERAPEUTICS, INC., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and BANK OF AMERICA, N.A., as administrative agent (in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, reference is hereby made to the Credit Agreement, dated as of May 24, 2022 (as amended by Amendment No. 1, dated as of August 18, 2022, and as further amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with the terms thereof prior to the date hereof, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), among the Borrower, the Guarantors from time to time party thereto, the Administrative Agent, the Swing Line Lender, each Lender and L&#47;C Issuer from time to time party thereto&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Credit Agreement provides that if the Administrative Agent and the Borrower acting together identify any ambiguity, omission, mistake, typographical error or other defect in any provision of the Credit Agreement, then the Administrative Agent and the Borrower shall be permitted to amend, modify or supplement such provision to cure such ambiguity, omission, mistake, typographical error or other defect, and such amendment shall become effective without any further action or consent of any other party to the Credit Agreement&#59; and </font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Administrative Agent and the Borrower desire to amend the Credit Agreement in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> as further described herein&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in consideration of the premises and agreements, provisions and covenants herein contained, the parties hereto agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.81pt">Defined Terms&#59; References</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unless otherwise specifically defined herein, each term used herein which is defined in the Credit Agreement has the meaning assigned to such term in the Credit Agreement.  Each reference to &#8220;hereof&#8221;, &#8220;hereunder&#8221;, &#8220;herein&#8221; and &#8220;hereby&#8221; and each other similar reference and each reference to &#8220;this Agreement&#8221; and each other similar reference contained in the Credit Agreement shall, after this Amendment becomes effective, refer to the Credit Agreement as amended hereby.  This Amendment is a &#8220;Loan Document&#8221; as defined under the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.81pt">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions to effectiveness set forth in Section 3 hereof, the Credit Agreement is hereby amended as follows&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The definition of &#8220;Hedge Bank&#8221; in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Credit Agreement is hereby amended &#160;&#160;&#160;&#160;and restated as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Hedge Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Person that, at the time it enters into any Swap Contract permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> is the Administrative Agent, a Lender or an Affiliate of a Lender or Administrative Agent, in its capacity as a party to such Swap Contracts.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (b) &#160;&#160;&#160;&#160;The definition of &#8220;Secured Hedge Agreement&#8221; in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Credit Agreement is hereby amended and restated as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Secured Hedge Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Swap Contract permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Article VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that is entered into by and between any Loan Party or Subsidiary of a Loan Party and any Hedge Bank.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.81pt">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Amendment shall become effective on the date that the Administrative Agent shall have received this Amendment, duly executed by the Borrower and the Administrative Agent.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page to Amendment No. 2 to the Credit Agreement&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.81pt">Amendment, Modification and Waiver.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">After the effectiveness hereof, this Amendment may not be amended, modified or waived except in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.81pt">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Amendment, the Credit Agreement and the other Loan Documents constitute the entire agreement among the parties hereto with respect to the subject matter hereof and thereof and supersede all other prior agreements and understandings, both written and verbal, among the parties hereto with respect to the subject matter hereof.  Except as expressly set forth herein, this Amendment shall not by implication or otherwise limit, impair, constitute a waiver of, or otherwise affect the rights and remedies of any party under, the Credit Agreement, nor alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement, all of which are ratified and affirmed in all respects and shall continue in full force and effect.  It is understood and agreed that each reference in each Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Document to the Credit Agreement, whether direct or indirect, shall hereafter be deemed to be a reference to the Credit Agreement as amended hereby and that this Amendment is a Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Document.  This Amendment shall not constitute a novation of the Credit Agreement or any other Loan Document.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.81pt">GOVERNING LAW&#59; JURISDICTION&#59; WAIVER OF JURY TRIAL&#59; ETC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Credit Agreement is hereby incorporated </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and shall apply hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.81pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If any provision of this Amendment is held to be illegal, invalid or unenforceable, the legality, validity and enforceability of the remaining provisions of this Amendment shall not be affected or impaired thereby.  The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.81pt">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Amendment may be executed in counterparts, each of which shall be an original, but all of which taken together shall constitute the same instrument.  Delivery of an executed counterpart of this Amendment by facsimile or other electronic means, including by email with a &#8220;pdf&#8221; copy thereof attached, shall constitute an original for purposes hereof. The words &#8220;execution,&#8221; &#8220;signed,&#8221; &#8220;signature&#8221; and words of like import in this Amendment relating to the execution and delivery of this Amendment shall be deemed to include electronic signatures, which shall be of the same legal effect, validity or enforceability as a manually executed signature to the extent and as provided in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.81pt">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The headings of this Amendment are for purposes of reference only and shall not limit or otherwise affect the meaning hereof.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Remainder of Page Intentionally Left Blank&#93;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their respective authorized officers as of the day and year first above written.</font></div><div style="margin-top:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HALOZYME THERAPEUTICS, INC., as Borrower</font></div><div style="margin-bottom:24pt;margin-top:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br>&#160;&#160;&#160;&#160;Name&#58; Nicole LaBrosse<br>&#160;&#160;&#160;&#160;Title&#58; &#160;&#160;&#160;&#160;Senior Vice President, CFO</font></div><div style="margin-bottom:24pt;margin-top:24pt;padding-left:216pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page to Amendment No. 2 to the Credit Agreement&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:216pt;padding-right:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BANK OF AMERICA, N.A., as Administrative Agent<br></font></div><div style="margin-top:12pt;padding-left:216pt;padding-right:-36pt"><font><br></font></div><div style="padding-left:234pt;padding-right:-49.7pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br>Name&#58;</font></div><div style="padding-left:234pt;padding-right:-49.7pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Title&#58;   <br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page to Amendment No. 2 to the Credit Agreement&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex31110qq12023.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ieec37be8bdc24ff2911573ef9bc3dace_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Helen I. Torley, M.B. Ch.B., M.R.C.P., Chief Executive Officer of Halozyme Therapeutics, Inc. certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">I have reviewed this Quarterly Report on Form 10-Q of Halozyme Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.773%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Helen I. Torley, M.B. Ch.B., M.R.C.P.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helen I. Torley, M.B. Ch.B., M.R.C.P</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex31210qq12023.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie4a6ba5cd37d42c2921707f1f6c675d6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Nicole LaBrosse, Chief Financial Officer of Halozyme Therapeutics, Inc. certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">I have reviewed this Quarterly Report on Form 10-Q of Halozyme Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Nicole LaBrosse</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicole LaBrosse</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>ex3210qq12023.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i369febb41fed451998d818485c347d96_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Halozyme Therapeutics, Inc. (the &#8220;Registrant&#8221;) on Form 10-Q for the quarter ended March&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Helen I. Torley, M.B. Ch.B., M.R.C.P., Chief Executive Officer of the Registrant, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.773%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Helen I. Torley, M.B. Ch.B., M.R.C.P.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helen I. Torley, M.B. Ch.B., M.R.C.P.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Halozyme Therapeutics, Inc. (the &#8220;Registrant&#8221;) on Form 10-Q for the quarter ended March&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Nicole LaBrosse, Chief Financial Officer of the Registrant, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.774%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Nicole LaBrosse</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicole LaBrosse</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>halo-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5667a7fc-e0e0-4ae8-9db7-13762e0ab1e4,g:df8c4c1a-0af9-473f-aa3c-bddd63ebeeb8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:halo="http://www.halozyme.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.halozyme.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.halozyme.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncomeUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBusiness" roleURI="http://www.halozyme.com/role/OrganizationandBusiness">
        <link:definition>0000008 - Disclosure - Organization and Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombination" roleURI="http://www.halozyme.com/role/BusinessCombination">
        <link:definition>0000010 - Disclosure - Business Combination</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.halozyme.com/role/FairValueMeasurement">
        <link:definition>0000011 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.halozyme.com/role/Revenue">
        <link:definition>0000012 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItems" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItems">
        <link:definition>0000013 - Disclosure - Certain Balance Sheet Items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000014 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNet" roleURI="http://www.halozyme.com/role/LongTermDebtNet">
        <link:definition>0000015 - Disclosure - Long-Term Debt, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensation" roleURI="http://www.halozyme.com/role/SharebasedCompensation">
        <link:definition>0000016 - Disclosure - Share-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.halozyme.com/role/StockholdersEquity">
        <link:definition>0000017 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomepershare" roleURI="http://www.halozyme.com/role/NetIncomepershare">
        <link:definition>0000018 - Disclosure - Net Income per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.halozyme.com/role/CommitmentsandContingencies">
        <link:definition>0000019 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationTables" roleURI="http://www.halozyme.com/role/BusinessCombinationTables">
        <link:definition>0000021 - Disclosure - Business Combination (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.halozyme.com/role/FairValueMeasurementTables">
        <link:definition>0000022 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.halozyme.com/role/RevenueTables">
        <link:definition>0000023 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsTables" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsTables">
        <link:definition>0000024 - Disclosure - Certain Balance Sheet Items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>0000025 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetTables" roleURI="http://www.halozyme.com/role/LongTermDebtNetTables">
        <link:definition>0000026 - Disclosure - Long-Term Debt, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationTables" roleURI="http://www.halozyme.com/role/SharebasedCompensationTables">
        <link:definition>0000027 - Disclosure - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.halozyme.com/role/StockholdersEquityTables">
        <link:definition>0000028 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareTables" roleURI="http://www.halozyme.com/role/EarningspershareTables">
        <link:definition>0000029 - Disclosure - Earnings per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBusinessDetails" roleURI="http://www.halozyme.com/role/OrganizationandBusinessDetails">
        <link:definition>0000030 - Disclosure - Organization and Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRestrictedCashDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails">
        <link:definition>0000031 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesLeasesDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails">
        <link:definition>0000032 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails">
        <link:definition>0000033 - Disclosure - Summary of Significant Accounting Policies - Revenue and Cost of Product Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails">
        <link:definition>0000034 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSegmentInformationDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails">
        <link:definition>0000035 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationNarrativeDetails" roleURI="http://www.halozyme.com/role/BusinessCombinationNarrativeDetails">
        <link:definition>0000036 - Disclosure - Business Combination - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationPurchaseConsiderationDetails" roleURI="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails">
        <link:definition>0000037 - Disclosure - Business Combination -Purchase Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>0000038 - Disclosure - Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationIntangibleAssetsAcquiredDetails" roleURI="http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails">
        <link:definition>0000039 - Disclosure - Business Combination - Intangible Assets Acquired (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" roleURI="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails">
        <link:definition>0000040 - Disclosure - Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementNarrativeDetails" roleURI="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails">
        <link:definition>0000041 - Disclosure - Fair Value Measurement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails" roleURI="http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails">
        <link:definition>0000042 - Disclosure - Fair Value Measurement - Contractual Maturities of Available for Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>0000043 - Disclosure - Fair Value Measurement - Assets Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregatedRevenuesDetails" roleURI="http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails">
        <link:definition>0000044 - Disclosure - Revenue - Disaggregated Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails" roleURI="http://www.halozyme.com/role/RevenueNarrativeDetails">
        <link:definition>0000045 - Disclosure - Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails" roleURI="http://www.halozyme.com/role/RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails">
        <link:definition>0000046 - Disclosure - Revenue - Accounts Receivable, net and Deferred Revenues from Contracts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdditionalRevenueInformationDetails" roleURI="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails">
        <link:definition>0000047 - Disclosure - Revenue - Additional Revenue Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdditionalRevenueInformationDetails_1" roleURI="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails_1">
        <link:definition>0000047 - Disclosure - Revenue - Additional Revenue Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsAccountsReceivablenetDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails">
        <link:definition>0000048 - Disclosure - Certain Balance Sheet Items - Accounts Receivable, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsInventoriesDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails">
        <link:definition>0000049 - Disclosure - Certain Balance Sheet Items - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails">
        <link:definition>0000050 - Disclosure - Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1">
        <link:definition>0000050 - Disclosure - Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPropertyandEquipmentnetDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails">
        <link:definition>0000051 - Disclosure - Certain Balance Sheet Items - Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsAccruedExpensesDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails">
        <link:definition>0000052 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsAccruedExpensesDetails_1" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1">
        <link:definition>0000052 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsAdditionalDetails" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails">
        <link:definition>0000053 - Disclosure - Goodwill and Intangible Assets - Additional (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsGoodwillRollforwardDetails" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails">
        <link:definition>0000054 - Disclosure - Goodwill and Intangible Assets - Goodwill Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsIntangibleAssetsDetails" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails">
        <link:definition>0000055 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsFutureAmortizationDetails" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails">
        <link:definition>0000056 - Disclosure - Goodwill and Intangible Assets -Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetNarrativeDetails" roleURI="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails">
        <link:definition>0000057 - Disclosure - Long-Term Debt, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetCarryingAmountofConvertibleNotesDetails" roleURI="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails">
        <link:definition>0000058 - Disclosure - Long-Term Debt, Net - Carrying Amount of Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetComponentsofInterestExpenseDetails" roleURI="http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails">
        <link:definition>0000059 - Disclosure - Long-Term Debt, Net - Components of Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationSharebasedCompensationExpenseDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails">
        <link:definition>0000060 - Disclosure - Share-based Compensation - Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationNarrativeDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails">
        <link:definition>0000061 - Disclosure - Share-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails">
        <link:definition>0000062 - Disclosure - Share-based Compensation - Assumptions Used in the Black-Scholes Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails">
        <link:definition>0000063 - Disclosure - Share-based Compensation - Unrecognized Estimated Compensation Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>0000064 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityShareRepurchaseActivityDetails" roleURI="http://www.halozyme.com/role/StockholdersEquityShareRepurchaseActivityDetails">
        <link:definition>0000065 - Disclosure - Stockholders' Equity - Share Repurchase Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareComputationDetails" roleURI="http://www.halozyme.com/role/EarningspershareComputationDetails">
        <link:definition>0000066 - Disclosure - Earnings per share - Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningspershareAntidilutiveSecuritiesDetails" roleURI="http://www.halozyme.com/role/EarningspershareAntidilutiveSecuritiesDetails">
        <link:definition>0000067 - Disclosure - Earnings per share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="halo_PaymentForCappedCallTransactions" abstract="false" name="PaymentForCappedCallTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_LicenseFeesAndEventBasedMember" abstract="true" name="LicenseFeesAndEventBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" abstract="false" name="ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" abstract="false" name="PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_Accountsreceivablefromproductsales" abstract="false" name="Accountsreceivablefromproductsales" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_DebtInstrumentInterestPeriodThreeMember" abstract="true" name="DebtInstrumentInterestPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_JanssenMember" abstract="true" name="JanssenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_RocheMember" abstract="true" name="RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_SalesbasedmilestoneMember" abstract="true" name="SalesbasedmilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ShareBasedCompensationAwardsVestedMember" abstract="true" name="ShareBasedCompensationAwardsVestedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" abstract="true" name="ScheduleofSharebasedCompensationArrangementsValuationInputsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_TermLoanFacilityMember" abstract="true" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_Accruedmanufacturingexpenses" abstract="false" name="Accruedmanufacturingexpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_Accountsreceivablefromroyalties" abstract="false" name="Accountsreceivablefromroyalties" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_DebtInstrumentInterestPeriodOneMember" abstract="true" name="DebtInstrumentInterestPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" abstract="false" name="SaleOfStockPremiumOverLastReportedSalePricePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="halo_OperatingLeaseAccretionOfLiability" abstract="false" name="OperatingLeaseAccretionOfLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_RoyaltiesReceivedNumberOfProductsSold" abstract="false" name="RoyaltiesReceivedNumberOfProductsSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="halo_OthercollaboratorsMember" abstract="true" name="OthercollaboratorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DebtInstrumentCapCallTransactionCapPricePerShare" abstract="false" name="DebtInstrumentCapCallTransactionCapPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="halo_DebtInstrumentInterestPeriodTwoMember" abstract="true" name="DebtInstrumentInterestPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_A2021ESPPPlanMember" abstract="true" name="A2021ESPPPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ComputerAndOfficeEquipmentMember" abstract="true" name="ComputerAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_TreasuryStockAcquiredFeeCostPerShare" abstract="false" name="TreasuryStockAcquiredFeeCostPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" abstract="false" name="DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="halo_DevelopmentFeesMember" abstract="true" name="DevelopmentFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_BulkrHuPH20Member" abstract="true" name="BulkrHuPH20Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ResearchEquipmentMember" abstract="true" name="ResearchEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_VariableRateComponentTwoMember" abstract="true" name="VariableRateComponentTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_BusinessCombinationConsiderationTransferredBonusAwards" abstract="false" name="BusinessCombinationConsiderationTransferredBonusAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock" abstract="false" name="GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="halo_VariableRateComponentDomain" abstract="true" name="VariableRateComponentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AccruedLiabilitiesNoncurrent" abstract="false" name="AccruedLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_TLANDOProductRightsMember" abstract="true" name="TLANDOProductRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AnnualInterestPaymentPeriodDomain" abstract="true" name="AnnualInterestPaymentPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_A1.25ConvertibleSeniorNotesdue2024Member" abstract="true" name="A1.25ConvertibleSeniorNotesdue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_VariableRateComponentAxis" abstract="true" name="VariableRateComponentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="halo_UpfrontfeesMember" abstract="true" name="UpfrontfeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_A025ConvertibleSeniorNotesDue2027Member" abstract="true" name="A025ConvertibleSeniorNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_BaxaltaMember" abstract="true" name="BaxaltaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_CollaborativeAgreementsMember" abstract="true" name="CollaborativeAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AntaresPharmaIncMember" abstract="true" name="AntaresPharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DebtInstrumentInterestPeriodFourMember" abstract="true" name="DebtInstrumentInterestPeriodFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" abstract="true" name="ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="halo_ProprietaryProductsSalesMember" abstract="true" name="ProprietaryProductsSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" abstract="false" name="AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_RoyaltiesReceivedNumberOfCollaborators" abstract="false" name="RoyaltiesReceivedNumberOfCollaborators" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="halo_XYOSTEDProprietaryProductMember" abstract="true" name="XYOSTEDProprietaryProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_Accountsreceivablefromproductsalestocollaborators" abstract="false" name="Accountsreceivablefromproductsalestocollaborators" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_ManufacturingEquipmentMember" abstract="true" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_Accountsreceivablefromcollaborators" abstract="false" name="Accountsreceivablefromcollaborators" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_VariableRateComponentOneMember" abstract="true" name="VariableRateComponentOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AnnualInterestPaymentPeriodAxis" abstract="true" name="AnnualInterestPaymentPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="halo_A100ConvertibleSeniorNotesDue2028Member" abstract="true" name="A100ConvertibleSeniorNotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_RestrictStockUnitsPerformanceSharesAndESPPMember" abstract="true" name="RestrictStockUnitsPerformanceSharesAndESPPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AllowanceforDistributionFeesandDiscounts" abstract="false" name="AllowanceforDistributionFeesandDiscounts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" abstract="false" name="RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="halo_DevicePartneredProductsMember" abstract="true" name="DevicePartneredProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_RSURSAandPRSUawardsMember" abstract="true" name="RSURSAandPRSUawardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ShareBasedCompensationAwardUnvestedMember" abstract="true" name="ShareBasedCompensationAwardUnvestedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DeviceLicensingAndDevelopmentMember" abstract="true" name="DeviceLicensingAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="halo_DeferredRentPayments" abstract="false" name="DeferredRentPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AutoInjectorTechnologyPlatformMember" abstract="true" name="AutoInjectorTechnologyPlatformMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>halo-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5667a7fc-e0e0-4ae8-9db7-13762e0ab1e4,g:df8c4c1a-0af9-473f-aa3c-bddd63ebeeb8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="halo-20230331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3bbb9015-ed07-4bb9-b17b-1b5cab9b71c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e1009261-4d4d-4c24-ae1c-c156b4c8b902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3bbb9015-ed07-4bb9-b17b-1b5cab9b71c9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e1009261-4d4d-4c24-ae1c-c156b4c8b902" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c9aae8c5-48ff-4797-a1b0-27d6d465e720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3bbb9015-ed07-4bb9-b17b-1b5cab9b71c9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c9aae8c5-48ff-4797-a1b0-27d6d465e720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b06a8cb3-09ce-495f-8b4c-cbaea68ab527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3bbb9015-ed07-4bb9-b17b-1b5cab9b71c9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b06a8cb3-09ce-495f-8b4c-cbaea68ab527" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4d78b425-7f82-456a-9c71-49b4dc4c4ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3bbb9015-ed07-4bb9-b17b-1b5cab9b71c9" xlink:to="loc_us-gaap_InventoryNet_4d78b425-7f82-456a-9c71-49b4dc4c4ab6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33f7f02a-efd5-4baf-af1b-e0d5fb4b68a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3bbb9015-ed07-4bb9-b17b-1b5cab9b71c9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33f7f02a-efd5-4baf-af1b-e0d5fb4b68a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7e1c3965-175e-4641-8677-9b49c55132c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b62ae46d-c40d-4ca8-be6f-295172c31479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7e1c3965-175e-4641-8677-9b49c55132c0" xlink:to="loc_us-gaap_AccountsPayableCurrent_b62ae46d-c40d-4ca8-be6f-295172c31479" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d8024e13-0e1d-448d-9322-f852bc800ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7e1c3965-175e-4641-8677-9b49c55132c0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d8024e13-0e1d-448d-9322-f852bc800ec2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_3940c814-8555-40d3-be91-7a66b5dd042c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7e1c3965-175e-4641-8677-9b49c55132c0" xlink:to="loc_us-gaap_DeferredRevenueCurrent_3940c814-8555-40d3-be91-7a66b5dd042c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d38e8dfc-8029-41c7-91a2-0574ebea5bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7e1c3965-175e-4641-8677-9b49c55132c0" xlink:to="loc_us-gaap_LongTermDebtCurrent_d38e8dfc-8029-41c7-91a2-0574ebea5bd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_13575aef-a984-4cab-843f-621859ab991c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0357f7f6-da70-44bb-a7f2-a4e327619c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13575aef-a984-4cab-843f-621859ab991c" xlink:to="loc_us-gaap_AssetsCurrent_0357f7f6-da70-44bb-a7f2-a4e327619c23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_75048ac7-3993-4a4f-b04c-c22e5f50638f" xlink:href="halo-20230331.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13575aef-a984-4cab-843f-621859ab991c" xlink:to="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_75048ac7-3993-4a4f-b04c-c22e5f50638f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_8d7cc377-0a8b-4d4d-be6f-c9d97ce329bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13575aef-a984-4cab-843f-621859ab991c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_8d7cc377-0a8b-4d4d-be6f-c9d97ce329bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1f6d5bc2-169a-4e4e-b0ef-187808b99d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13575aef-a984-4cab-843f-621859ab991c" xlink:to="loc_us-gaap_Goodwill_1f6d5bc2-169a-4e4e-b0ef-187808b99d6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ad54d33b-9434-428b-aefc-8854ca698522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13575aef-a984-4cab-843f-621859ab991c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ad54d33b-9434-428b-aefc-8854ca698522" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_a2a8ca14-fa5c-4561-9c32-65a5de70592f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13575aef-a984-4cab-843f-621859ab991c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_a2a8ca14-fa5c-4561-9c32-65a5de70592f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_9c2f8813-4e7b-464c-bb86-0d93d907e1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13575aef-a984-4cab-843f-621859ab991c" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_9c2f8813-4e7b-464c-bb86-0d93d907e1e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_735c6599-d4b7-407a-9893-55b8013c0853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c4db5601-78a5-4b0f-ac1f-30dddddb4361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_735c6599-d4b7-407a-9893-55b8013c0853" xlink:to="loc_us-gaap_PreferredStockValue_c4db5601-78a5-4b0f-ac1f-30dddddb4361" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d8518e3c-ac5d-4e87-9b01-d6a1070c91c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_735c6599-d4b7-407a-9893-55b8013c0853" xlink:to="loc_us-gaap_CommonStockValue_d8518e3c-ac5d-4e87-9b01-d6a1070c91c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0e294519-3424-4d82-a276-d01a30b19df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_735c6599-d4b7-407a-9893-55b8013c0853" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0e294519-3424-4d82-a276-d01a30b19df8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c25aca97-8e36-4c87-b43f-563b1b8adc07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_735c6599-d4b7-407a-9893-55b8013c0853" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c25aca97-8e36-4c87-b43f-563b1b8adc07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_09d5548e-601a-4280-85df-f9fa6c9b238f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_735c6599-d4b7-407a-9893-55b8013c0853" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_09d5548e-601a-4280-85df-f9fa6c9b238f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2fae777f-145a-4bfe-b5e5-016977ce3f73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_f07a3bb1-8d6c-46ad-8fa1-343b98e189ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2fae777f-145a-4bfe-b5e5-016977ce3f73" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_f07a3bb1-8d6c-46ad-8fa1-343b98e189ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0ad8325f-8d23-4387-984b-915a50d87d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2fae777f-145a-4bfe-b5e5-016977ce3f73" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0ad8325f-8d23-4387-984b-915a50d87d06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1ad94121-e5c8-46ce-9017-15f2a603f2db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2fae777f-145a-4bfe-b5e5-016977ce3f73" xlink:to="loc_us-gaap_LiabilitiesCurrent_1ad94121-e5c8-46ce-9017-15f2a603f2db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1da58245-43a2-4277-9534-aa2db60a6f04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2fae777f-145a-4bfe-b5e5-016977ce3f73" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1da58245-43a2-4277-9534-aa2db60a6f04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2e7a211c-6f9e-4819-83b3-0b3257934e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2fae777f-145a-4bfe-b5e5-016977ce3f73" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2e7a211c-6f9e-4819-83b3-0b3257934e07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b77d8160-5fbf-485f-bd05-34dbd9008fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_186dd6b7-a330-4920-b060-867b1c5a000c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b77d8160-5fbf-485f-bd05-34dbd9008fc1" xlink:to="loc_us-gaap_Liabilities_186dd6b7-a330-4920-b060-867b1c5a000c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e2b3f4b0-79a2-4a3a-8a44-60102bf81e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b77d8160-5fbf-485f-bd05-34dbd9008fc1" xlink:to="loc_us-gaap_StockholdersEquity_e2b3f4b0-79a2-4a3a-8a44-60102bf81e17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_98899281-ba84-42cd-9d1f-750f3f51ebba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b77d8160-5fbf-485f-bd05-34dbd9008fc1" xlink:to="loc_us-gaap_CommitmentsAndContingencies_98899281-ba84-42cd-9d1f-750f3f51ebba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="halo-20230331.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_78cc209f-6e0d-45cd-9ddd-7ecc0df79def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3a560358-227a-4d2f-b2a6-056f56c0143d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_78cc209f-6e0d-45cd-9ddd-7ecc0df79def" xlink:to="loc_us-gaap_CostsAndExpenses_3a560358-227a-4d2f-b2a6-056f56c0143d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_422860e7-0d42-4bc7-99fc-1758fc55164b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_78cc209f-6e0d-45cd-9ddd-7ecc0df79def" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_422860e7-0d42-4bc7-99fc-1758fc55164b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_38488078-626c-4fa0-ab8f-89d453afad5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0f8d274f-5396-4780-8d57-23c704ebe3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_38488078-626c-4fa0-ab8f-89d453afad5d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0f8d274f-5396-4780-8d57-23c704ebe3ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fc81183d-103f-4b6a-ad1e-0755a858e78c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_38488078-626c-4fa0-ab8f-89d453afad5d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fc81183d-103f-4b6a-ad1e-0755a858e78c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_800ead1e-c25f-4a3d-b592-0deddf5c19e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bc3db416-f5fe-4ad7-aad4-52aab6e5660d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_800ead1e-c25f-4a3d-b592-0deddf5c19e3" xlink:to="loc_us-gaap_OperatingIncomeLoss_bc3db416-f5fe-4ad7-aad4-52aab6e5660d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_84a51a7e-bbbd-4cea-b1fa-d2f645d3abc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_800ead1e-c25f-4a3d-b592-0deddf5c19e3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_84a51a7e-bbbd-4cea-b1fa-d2f645d3abc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2ff35559-69c8-4538-82b9-fe75882572e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_800ead1e-c25f-4a3d-b592-0deddf5c19e3" xlink:to="loc_us-gaap_InterestExpense_2ff35559-69c8-4538-82b9-fe75882572e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c6e28940-7461-49bb-92a5-c51edee12a68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c5407e3a-590b-4279-8066-875c59257bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c6e28940-7461-49bb-92a5-c51edee12a68" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c5407e3a-590b-4279-8066-875c59257bb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e1fe1d98-0a2b-4c94-a590-6edaeb05d0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c6e28940-7461-49bb-92a5-c51edee12a68" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e1fe1d98-0a2b-4c94-a590-6edaeb05d0b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6a2f451e-47cc-4610-802c-7cc72ac760e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c6e28940-7461-49bb-92a5-c51edee12a68" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6a2f451e-47cc-4610-802c-7cc72ac760e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ee32e896-a428-4b71-8521-597f2f4db974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c6e28940-7461-49bb-92a5-c51edee12a68" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ee32e896-a428-4b71-8521-597f2f4db974" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="halo-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d92d345e-d937-4c87-bcc5-7c2c251ecbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b1f01a6b-d1cf-4a73-b935-64eb7d96f5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d92d345e-d937-4c87-bcc5-7c2c251ecbd2" xlink:to="loc_us-gaap_NetIncomeLoss_b1f01a6b-d1cf-4a73-b935-64eb7d96f5e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b8d2e891-376d-4199-bb58-c338b033e379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d92d345e-d937-4c87-bcc5-7c2c251ecbd2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b8d2e891-376d-4199-bb58-c338b033e379" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_298a0962-489b-451c-9155-fece12d564b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d92d345e-d937-4c87-bcc5-7c2c251ecbd2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_298a0962-489b-451c-9155-fece12d564b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="halo-20230331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13f20ae2-42ec-4ed4-b0ec-633d3d5284bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_98a1fd09-18d0-4cc7-9aba-1f9ce74d292c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13f20ae2-42ec-4ed4-b0ec-633d3d5284bf" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_98a1fd09-18d0-4cc7-9aba-1f9ce74d292c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_cc33348f-ca70-43b1-a958-f31002cc9efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13f20ae2-42ec-4ed4-b0ec-633d3d5284bf" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_cc33348f-ca70-43b1-a958-f31002cc9efd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8fd3bd5e-05fb-496d-ba80-173995860573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_13f20ae2-42ec-4ed4-b0ec-633d3d5284bf" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8fd3bd5e-05fb-496d-ba80-173995860573" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_878b9825-fb00-4bef-b193-9b3572d1c983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3133e5f8-7373-425a-bc26-7714430c53c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_878b9825-fb00-4bef-b193-9b3572d1c983" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3133e5f8-7373-425a-bc26-7714430c53c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_33480125-e674-41b5-87af-05e3c1f896da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_878b9825-fb00-4bef-b193-9b3572d1c983" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_33480125-e674-41b5-87af-05e3c1f896da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7628bac7-1d80-4278-bcdc-76f61d14affd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_878b9825-fb00-4bef-b193-9b3572d1c983" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7628bac7-1d80-4278-bcdc-76f61d14affd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4ba482f6-f120-4f2b-985c-4fed68a94215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_c630c879-cafc-41aa-ae36-e7e827a63c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4ba482f6-f120-4f2b-985c-4fed68a94215" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_c630c879-cafc-41aa-ae36-e7e827a63c4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_adb2153e-96f9-468d-a87f-638341365df4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4ba482f6-f120-4f2b-985c-4fed68a94215" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_adb2153e-96f9-468d-a87f-638341365df4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_7d126ceb-4753-47d3-86cc-a932666a35fd" xlink:href="halo-20230331.xsd#halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4ba482f6-f120-4f2b-985c-4fed68a94215" xlink:to="loc_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_7d126ceb-4753-47d3-86cc-a932666a35fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daf6d915-4c0a-4ee2-adb3-be0baec211d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1a5f0318-f1ec-4417-9fe4-a688c145a928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daf6d915-4c0a-4ee2-adb3-be0baec211d8" xlink:to="loc_us-gaap_NetIncomeLoss_1a5f0318-f1ec-4417-9fe4-a688c145a928" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f9cbf6f1-0e01-40df-b196-4252ccf5bc29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daf6d915-4c0a-4ee2-adb3-be0baec211d8" xlink:to="loc_us-gaap_ShareBasedCompensation_f9cbf6f1-0e01-40df-b196-4252ccf5bc29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3276c54a-c62b-44bf-8a17-5d8b279448e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daf6d915-4c0a-4ee2-adb3-be0baec211d8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3276c54a-c62b-44bf-8a17-5d8b279448e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_6cf1e7a0-8cc6-4d99-8e2c-1de5657860a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daf6d915-4c0a-4ee2-adb3-be0baec211d8" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_6cf1e7a0-8cc6-4d99-8e2c-1de5657860a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_7b837e50-35f1-4229-a98c-01be9c25347f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daf6d915-4c0a-4ee2-adb3-be0baec211d8" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_7b837e50-35f1-4229-a98c-01be9c25347f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_36fe687e-2400-47e7-9f3c-f0979abab274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daf6d915-4c0a-4ee2-adb3-be0baec211d8" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_36fe687e-2400-47e7-9f3c-f0979abab274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7c0758cc-3c41-4f3f-8ac8-0b24685c2f47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daf6d915-4c0a-4ee2-adb3-be0baec211d8" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7c0758cc-3c41-4f3f-8ac8-0b24685c2f47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredRentPayments_ec3b98dc-2ff5-4373-9f7f-2978c3bfdc1a" xlink:href="halo-20230331.xsd#halo_DeferredRentPayments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daf6d915-4c0a-4ee2-adb3-be0baec211d8" xlink:to="loc_halo_DeferredRentPayments_ec3b98dc-2ff5-4373-9f7f-2978c3bfdc1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1a2ef663-422a-4d4a-a8e1-cf251284466d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daf6d915-4c0a-4ee2-adb3-be0baec211d8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1a2ef663-422a-4d4a-a8e1-cf251284466d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1e9b4179-ea6f-4cdf-8c9b-1834c395dcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daf6d915-4c0a-4ee2-adb3-be0baec211d8" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1e9b4179-ea6f-4cdf-8c9b-1834c395dcd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bec7c9f2-bf10-4bfc-bd68-efc2b6c400ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daf6d915-4c0a-4ee2-adb3-be0baec211d8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bec7c9f2-bf10-4bfc-bd68-efc2b6c400ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9962332f-8a6a-4b31-98c1-e7a5248b1dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daf6d915-4c0a-4ee2-adb3-be0baec211d8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9962332f-8a6a-4b31-98c1-e7a5248b1dfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_e11b3a81-84b0-459d-8fe6-5f42081bd8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daf6d915-4c0a-4ee2-adb3-be0baec211d8" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_e11b3a81-84b0-459d-8fe6-5f42081bd8f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4cfb1860-de26-4b6e-a984-80e5b84a363f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_daf6d915-4c0a-4ee2-adb3-be0baec211d8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4cfb1860-de26-4b6e-a984-80e5b84a363f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#BusinessCombinationPurchaseConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_bd9c2d4f-48cb-4b10-b390-96d85869c270" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_59c3ff14-22cc-46cd-85ba-df918b04b8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_bd9c2d4f-48cb-4b10-b390-96d85869c270" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_59c3ff14-22cc-46cd-85ba-df918b04b8cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_b8cbbcfd-35f3-4d38-8192-f7bd223a9147" xlink:href="halo-20230331.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_bd9c2d4f-48cb-4b10-b390-96d85869c270" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_b8cbbcfd-35f3-4d38-8192-f7bd223a9147" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_2cf8c04a-08a1-47fb-bb79-5c837faad968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_bd9c2d4f-48cb-4b10-b390-96d85869c270" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_2cf8c04a-08a1-47fb-bb79-5c837faad968" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_4e4416c5-052e-467e-8c23-430890bd375d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_bd9c2d4f-48cb-4b10-b390-96d85869c270" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_4e4416c5-052e-467e-8c23-430890bd375d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards_b2058c5a-a93e-4a6a-a44c-b1705b8c43cc" xlink:href="halo-20230331.xsd#halo_BusinessCombinationConsiderationTransferredBonusAwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_bd9c2d4f-48cb-4b10-b390-96d85869c270" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards_b2058c5a-a93e-4a6a-a44c-b1705b8c43cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8bdc2cd0-021c-4d2d-8a59-64c910b08d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d84a9cd2-4033-45d7-80a3-76315b146f30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8bdc2cd0-021c-4d2d-8a59-64c910b08d4d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d84a9cd2-4033-45d7-80a3-76315b146f30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_0fa47ca8-2fab-4efc-9752-c16e089d7ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8bdc2cd0-021c-4d2d-8a59-64c910b08d4d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_0fa47ca8-2fab-4efc-9752-c16e089d7ae3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_b473b4d2-5052-49a4-832e-2122d5830847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8bdc2cd0-021c-4d2d-8a59-64c910b08d4d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_b473b4d2-5052-49a4-832e-2122d5830847" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9a17a7f2-7fa0-41cf-991b-aad16afd09cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8bdc2cd0-021c-4d2d-8a59-64c910b08d4d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9a17a7f2-7fa0-41cf-991b-aad16afd09cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_e24772a3-208b-412a-964c-6471413edd99" xlink:href="halo-20230331.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8bdc2cd0-021c-4d2d-8a59-64c910b08d4d" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_e24772a3-208b-412a-964c-6471413edd99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_80ee41fd-b557-4dcc-8c04-da0940f3c143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8bdc2cd0-021c-4d2d-8a59-64c910b08d4d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_80ee41fd-b557-4dcc-8c04-da0940f3c143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_64dde82d-430f-4546-8b20-116859a19f63" xlink:href="halo-20230331.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8bdc2cd0-021c-4d2d-8a59-64c910b08d4d" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_64dde82d-430f-4546-8b20-116859a19f63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_58959164-a549-4112-8918-1c1fc2e06f00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8bdc2cd0-021c-4d2d-8a59-64c910b08d4d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_58959164-a549-4112-8918-1c1fc2e06f00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_e4eb317d-05da-402b-ad21-7f343b34e96d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8bdc2cd0-021c-4d2d-8a59-64c910b08d4d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_e4eb317d-05da-402b-ad21-7f343b34e96d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_002a9c73-0cb4-4d35-bffa-6d909aef385c" xlink:href="halo-20230331.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8bdc2cd0-021c-4d2d-8a59-64c910b08d4d" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_002a9c73-0cb4-4d35-bffa-6d909aef385c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7c39a078-525b-44c9-951f-af7a258b6b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8bdc2cd0-021c-4d2d-8a59-64c910b08d4d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7c39a078-525b-44c9-951f-af7a258b6b45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_aa99c2f0-d1c3-4dca-a5cb-a62689af7296" xlink:href="halo-20230331.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8bdc2cd0-021c-4d2d-8a59-64c910b08d4d" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_aa99c2f0-d1c3-4dca-a5cb-a62689af7296" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7ee43b34-0023-4cb5-af14-c7ce9a180e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_073fb368-aace-4590-897c-e65941a9d84a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7ee43b34-0023-4cb5-af14-c7ce9a180e1f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_073fb368-aace-4590-897c-e65941a9d84a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_653933c6-2ed1-402f-9f55-a279d81d138d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7ee43b34-0023-4cb5-af14-c7ce9a180e1f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_653933c6-2ed1-402f-9f55-a279d81d138d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a85724b3-ccaf-4b1b-b64d-eaa42de00b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7ee43b34-0023-4cb5-af14-c7ce9a180e1f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a85724b3-ccaf-4b1b-b64d-eaa42de00b79" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e7345c7d-ff68-429f-a0b4-192ef113f3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_dab3722b-4cf9-4fcb-8cdc-5ce172723135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e7345c7d-ff68-429f-a0b4-192ef113f3c9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_dab3722b-4cf9-4fcb-8cdc-5ce172723135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8ce335fd-5bba-456d-9490-5b6c694ba336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e7345c7d-ff68-429f-a0b4-192ef113f3c9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8ce335fd-5bba-456d-9490-5b6c694ba336" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e65a50e6-fb4d-4462-bce7-d431a4cbdeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a7f16721-3aa7-42aa-857b-c1bf85bf14c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_e65a50e6-fb4d-4462-bce7-d431a4cbdeaa" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a7f16721-3aa7-42aa-857b-c1bf85bf14c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_583bcbeb-339c-42ef-a9e4-e02a279d7ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_e65a50e6-fb4d-4462-bce7-d431a4cbdeaa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_583bcbeb-339c-42ef-a9e4-e02a279d7ce7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#CertainBalanceSheetItemsAccountsReceivablenetDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_e979e1c4-bbb9-413e-a7ca-a966fa7c68d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromproductsalestocollaborators_ea4dbb7d-7982-40bb-96c4-94087bfaef5a" xlink:href="halo-20230331.xsd#halo_Accountsreceivablefromproductsalestocollaborators"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent_e979e1c4-bbb9-413e-a7ca-a966fa7c68d0" xlink:to="loc_halo_Accountsreceivablefromproductsalestocollaborators_ea4dbb7d-7982-40bb-96c4-94087bfaef5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromcollaborators_03f74912-0b4a-4f9f-8eb9-f69743c9d0a6" xlink:href="halo-20230331.xsd#halo_Accountsreceivablefromcollaborators"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent_e979e1c4-bbb9-413e-a7ca-a966fa7c68d0" xlink:to="loc_halo_Accountsreceivablefromcollaborators_03f74912-0b4a-4f9f-8eb9-f69743c9d0a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromroyalties_440a83d6-d7e8-4c73-9a0b-79833aa5dfb6" xlink:href="halo-20230331.xsd#halo_Accountsreceivablefromroyalties"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent_e979e1c4-bbb9-413e-a7ca-a966fa7c68d0" xlink:to="loc_halo_Accountsreceivablefromroyalties_440a83d6-d7e8-4c73-9a0b-79833aa5dfb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromproductsales_4c052196-7c62-4b0d-b0aa-465d9761314c" xlink:href="halo-20230331.xsd#halo_Accountsreceivablefromproductsales"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent_e979e1c4-bbb9-413e-a7ca-a966fa7c68d0" xlink:to="loc_halo_Accountsreceivablefromproductsales_4c052196-7c62-4b0d-b0aa-465d9761314c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_c855724a-e703-4946-966f-317400f52a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent_e979e1c4-bbb9-413e-a7ca-a966fa7c68d0" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_c855724a-e703-4946-966f-317400f52a5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1dcd8cc0-6fb5-494e-a8af-7380c1247cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_f762eb32-0b6e-4259-ad9b-a982a0ced7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_1dcd8cc0-6fb5-494e-a8af-7380c1247cc8" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_f762eb32-0b6e-4259-ad9b-a982a0ced7a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AllowanceforDistributionFeesandDiscounts_ba29756c-60f3-4fd4-b73a-09fcbe4ddd91" xlink:href="halo-20230331.xsd#halo_AllowanceforDistributionFeesandDiscounts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_1dcd8cc0-6fb5-494e-a8af-7380c1247cc8" xlink:to="loc_halo_AllowanceforDistributionFeesandDiscounts_ba29756c-60f3-4fd4-b73a-09fcbe4ddd91" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#CertainBalanceSheetItemsInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_adcc2ce4-3744-4c81-8523-73ac5c890461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_7e71306d-313b-4ffa-9ac8-414b2adedb13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_adcc2ce4-3744-4c81-8523-73ac5c890461" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_7e71306d-313b-4ffa-9ac8-414b2adedb13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_35ffe2f2-e6d2-4845-89b1-a17eb67908fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_adcc2ce4-3744-4c81-8523-73ac5c890461" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_35ffe2f2-e6d2-4845-89b1-a17eb67908fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_475fb6cf-c0fd-4a34-812b-f18b8ed13bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_adcc2ce4-3744-4c81-8523-73ac5c890461" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_475fb6cf-c0fd-4a34-812b-f18b8ed13bcb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_2f157ef8-ec1c-4fa0-ab27-ef27ed0151eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_b3a7f70f-e6b2-428b-ba1d-b85fa1260358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_2f157ef8-ec1c-4fa0-ab27-ef27ed0151eb" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_b3a7f70f-e6b2-428b-ba1d-b85fa1260358" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_d208ea22-c880-40b9-9ef3-5ef56b069f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_2f157ef8-ec1c-4fa0-ab27-ef27ed0151eb" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_d208ea22-c880-40b9-9ef3-5ef56b069f1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_2380580e-3ef1-4552-98d0-534afe16d629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_2f157ef8-ec1c-4fa0-ab27-ef27ed0151eb" xlink:to="loc_us-gaap_OtherAssets_2380580e-3ef1-4552-98d0-534afe16d629" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1" xlink:type="simple" xlink:href="halo-20230331.xsd#CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_18561281-f7ea-4111-9449-ba703f412e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_f1b19f83-b528-4e4e-b849-190d5b62d123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_18561281-f7ea-4111-9449-ba703f412e72" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_f1b19f83-b528-4e4e-b849-190d5b62d123" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6d947aaa-034b-4467-a93b-be3b0c0ebd84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_18561281-f7ea-4111-9449-ba703f412e72" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6d947aaa-034b-4467-a93b-be3b0c0ebd84" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#CertainBalanceSheetItemsPropertyandEquipmentnetDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3c909ea6-1a17-4c75-951e-17015b78a059" xlink:href="halo-20230331.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ecd5a86d-9eba-4e80-a3d2-381745796116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3c909ea6-1a17-4c75-951e-17015b78a059" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ecd5a86d-9eba-4e80-a3d2-381745796116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_18d38d4a-4dcd-48ca-931a-978f1d7ad026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3c909ea6-1a17-4c75-951e-17015b78a059" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_18d38d4a-4dcd-48ca-931a-978f1d7ad026" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_99da4c01-4855-459a-966e-cc4c173ab9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7dc2df52-5a56-4bbb-8a3d-347419cb6fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_99da4c01-4855-459a-966e-cc4c173ab9fb" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7dc2df52-5a56-4bbb-8a3d-347419cb6fd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ce885339-df30-49d1-863a-56f88c580bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_99da4c01-4855-459a-966e-cc4c173ab9fb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ce885339-df30-49d1-863a-56f88c580bbc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#CertainBalanceSheetItemsAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_daf4fc17-e9ab-4e94-9098-b90a4a63ed8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_36f16450-4675-40e2-bc6c-8b2ec76adbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_daf4fc17-e9ab-4e94-9098-b90a4a63ed8e" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_36f16450-4675-40e2-bc6c-8b2ec76adbbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_20f73e65-88d3-4e34-a824-c39c6000725f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_daf4fc17-e9ab-4e94-9098-b90a4a63ed8e" xlink:to="loc_us-gaap_OperatingLeaseLiability_20f73e65-88d3-4e34-a824-c39c6000725f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accruedmanufacturingexpenses_f6248dca-46dd-4e62-9c3e-5da4d447f7ab" xlink:href="halo-20230331.xsd#halo_Accruedmanufacturingexpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_daf4fc17-e9ab-4e94-9098-b90a4a63ed8e" xlink:to="loc_halo_Accruedmanufacturingexpenses_f6248dca-46dd-4e62-9c3e-5da4d447f7ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_290f0247-447c-469e-8172-fd7c6a1bdc64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_daf4fc17-e9ab-4e94-9098-b90a4a63ed8e" xlink:to="loc_us-gaap_TaxesPayableCurrent_290f0247-447c-469e-8172-fd7c6a1bdc64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_285ada1c-e8c5-489b-aac2-7fb1380d26a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_daf4fc17-e9ab-4e94-9098-b90a4a63ed8e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_285ada1c-e8c5-489b-aac2-7fb1380d26a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ee8c4f2f-820c-4acc-b62c-13c05f160b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_daf4fc17-e9ab-4e94-9098-b90a4a63ed8e" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ee8c4f2f-820c-4acc-b62c-13c05f160b73" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1" xlink:type="simple" xlink:href="halo-20230331.xsd#CertainBalanceSheetItemsAccruedExpensesDetails_1"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_9fb859cb-9b71-480a-96ce-e06ea6eaedb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccruedLiabilitiesNoncurrent_b5b64b6b-c342-438d-8df5-753fec835afe" xlink:href="halo-20230331.xsd#halo_AccruedLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_9fb859cb-9b71-480a-96ce-e06ea6eaedb8" xlink:to="loc_halo_AccruedLiabilitiesNoncurrent_b5b64b6b-c342-438d-8df5-753fec835afe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_90a33359-cfb3-4fe2-a8a7-d3c617d34e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_9fb859cb-9b71-480a-96ce-e06ea6eaedb8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_90a33359-cfb3-4fe2-a8a7-d3c617d34e89" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9d539482-2459-4a43-ba15-e6f0a80804d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_196f8f0b-f4ff-4c8a-8312-bcd75d6c84d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9d539482-2459-4a43-ba15-e6f0a80804d4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_196f8f0b-f4ff-4c8a-8312-bcd75d6c84d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_adfb0044-917e-4451-ad88-65a71f7337fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9d539482-2459-4a43-ba15-e6f0a80804d4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_adfb0044-917e-4451-ad88-65a71f7337fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#GoodwillandIntangibleAssetsFutureAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b6cdecf7-5022-4ac6-a5db-56a0786ff5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_260f2cd1-6ebf-455e-9c18-398c49636468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b6cdecf7-5022-4ac6-a5db-56a0786ff5c0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_260f2cd1-6ebf-455e-9c18-398c49636468" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ff51533d-0982-4e14-97bf-5b2b4c6a11da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b6cdecf7-5022-4ac6-a5db-56a0786ff5c0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ff51533d-0982-4e14-97bf-5b2b4c6a11da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6e6fdd7b-8e55-4129-a07e-9d2c2e4e5924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b6cdecf7-5022-4ac6-a5db-56a0786ff5c0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6e6fdd7b-8e55-4129-a07e-9d2c2e4e5924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e5a1df14-0bc1-4245-8f26-69b3eaf0c9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b6cdecf7-5022-4ac6-a5db-56a0786ff5c0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e5a1df14-0bc1-4245-8f26-69b3eaf0c9d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour_77a64d2e-4789-4754-a839-79e22877f2ff" xlink:href="halo-20230331.xsd#halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b6cdecf7-5022-4ac6-a5db-56a0786ff5c0" xlink:to="loc_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour_77a64d2e-4789-4754-a839-79e22877f2ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_aec9497c-11a0-4548-abec-e77f754a7989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b6cdecf7-5022-4ac6-a5db-56a0786ff5c0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_aec9497c-11a0-4548-abec-e77f754a7989" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#LongTermDebtNetCarryingAmountofConvertibleNotesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d6f98071-1196-4e4c-93b3-be1d94986301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_52427b1b-6cf3-4400-9ace-5ead635dc5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d6f98071-1196-4e4c-93b3-be1d94986301" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_52427b1b-6cf3-4400-9ace-5ead635dc5b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_e01d23b3-4324-40d0-afca-900578960ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d6f98071-1196-4e4c-93b3-be1d94986301" xlink:to="loc_us-gaap_LongTermDebtCurrent_e01d23b3-4324-40d0-afca-900578960ecc" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>halo-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5667a7fc-e0e0-4ae8-9db7-13762e0ab1e4,g:df8c4c1a-0af9-473f-aa3c-bddd63ebeeb8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="halo-20230331.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended" id="idd22126c73b64c0e95b382502be3dc5b_CondensedConsolidatedStatementsofIncomeUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_46370f0d-9897-4945-9312-3ab2c273cd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_RevenuesAbstract_46370f0d-9897-4945-9312-3ab2c273cd0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e842bb87-96e8-4938-8728-06429aae1c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_46370f0d-9897-4945-9312-3ab2c273cd0b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e842bb87-96e8-4938-8728-06429aae1c97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_3048cea7-0867-4d65-a52f-5bc15eac2800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_3048cea7-0867-4d65-a52f-5bc15eac2800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_af717539-232e-4793-85c0-879e238110f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3048cea7-0867-4d65-a52f-5bc15eac2800" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_af717539-232e-4793-85c0-879e238110f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_fbbd923b-afc5-46c9-af1e-dea33978276c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3048cea7-0867-4d65-a52f-5bc15eac2800" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_fbbd923b-afc5-46c9-af1e-dea33978276c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_284cdc16-b491-40a6-9b76-4c658de3dd41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3048cea7-0867-4d65-a52f-5bc15eac2800" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_284cdc16-b491-40a6-9b76-4c658de3dd41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_886bd78f-275b-4eab-9a21-2eb4b44e0c47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3048cea7-0867-4d65-a52f-5bc15eac2800" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_886bd78f-275b-4eab-9a21-2eb4b44e0c47" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b2372d51-cf6f-4821-b104-33dee45838a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3048cea7-0867-4d65-a52f-5bc15eac2800" xlink:to="loc_us-gaap_CostsAndExpenses_b2372d51-cf6f-4821-b104-33dee45838a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6bd7af4d-92ad-4ee5-b84d-4743eaddec59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_OperatingIncomeLoss_6bd7af4d-92ad-4ee5-b84d-4743eaddec59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_7e24013f-4727-4cd4-9d7d-5b3c8caf730d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_7e24013f-4727-4cd4-9d7d-5b3c8caf730d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0632bbc0-528c-4440-956c-efb345e53942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_7e24013f-4727-4cd4-9d7d-5b3c8caf730d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0632bbc0-528c-4440-956c-efb345e53942" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4926db32-3c1f-4f0d-9145-4a70f978db34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_7e24013f-4727-4cd4-9d7d-5b3c8caf730d" xlink:to="loc_us-gaap_InterestExpense_4926db32-3c1f-4f0d-9145-4a70f978db34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_daf653a3-573f-436c-9554-4d14c99c63e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_daf653a3-573f-436c-9554-4d14c99c63e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2b10efd9-69a2-45e9-8582-88d66afe1ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2b10efd9-69a2-45e9-8582-88d66afe1ce0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0933482c-f0d5-4409-8343-bd0533a12c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_NetIncomeLoss_0933482c-f0d5-4409-8343-bd0533a12c3d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_bd0985d8-ba8c-4bb7-8565-b3e0d564dfe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_EarningsPerShareAbstract_bd0985d8-ba8c-4bb7-8565-b3e0d564dfe0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4dafc820-7fbe-458a-b96d-1692facc33a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bd0985d8-ba8c-4bb7-8565-b3e0d564dfe0" xlink:to="loc_us-gaap_EarningsPerShareBasic_4dafc820-7fbe-458a-b96d-1692facc33a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9d1a493a-2625-409b-914d-3388dcbe287b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bd0985d8-ba8c-4bb7-8565-b3e0d564dfe0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9d1a493a-2625-409b-914d-3388dcbe287b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2cd71332-9d77-45d5-8c79-2a821906a7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2cd71332-9d77-45d5-8c79-2a821906a7a9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_071240ba-0aaf-4813-bd4c-7e06acabb7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2cd71332-9d77-45d5-8c79-2a821906a7a9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_071240ba-0aaf-4813-bd4c-7e06acabb7c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e35a2a6-135a-422d-adbd-ce1a6a7c258b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2cd71332-9d77-45d5-8c79-2a821906a7a9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e35a2a6-135a-422d-adbd-ce1a6a7c258b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_42f4d7dc-33a4-4d64-9c6c-9b2c637c254f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_StatementTable_42f4d7dc-33a4-4d64-9c6c-9b2c637c254f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_647eb7a2-53f2-41fb-b15b-90dbc96e7eec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_42f4d7dc-33a4-4d64-9c6c-9b2c637c254f" xlink:to="loc_srt_ProductOrServiceAxis_647eb7a2-53f2-41fb-b15b-90dbc96e7eec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_647eb7a2-53f2-41fb-b15b-90dbc96e7eec_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_647eb7a2-53f2-41fb-b15b-90dbc96e7eec" xlink:to="loc_srt_ProductsAndServicesDomain_647eb7a2-53f2-41fb-b15b-90dbc96e7eec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4743d4a6-3e75-40fb-82e8-42f829f0b357" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_647eb7a2-53f2-41fb-b15b-90dbc96e7eec" xlink:to="loc_srt_ProductsAndServicesDomain_4743d4a6-3e75-40fb-82e8-42f829f0b357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_c36cdd88-8ccb-4857-bd2c-49728e013873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4743d4a6-3e75-40fb-82e8-42f829f0b357" xlink:to="loc_us-gaap_RoyaltyMember_c36cdd88-8ccb-4857-bd2c-49728e013873" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f2903ae4-3613-40ba-9cf9-9d2bf52edecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4743d4a6-3e75-40fb-82e8-42f829f0b357" xlink:to="loc_us-gaap_ProductMember_f2903ae4-3613-40ba-9cf9-9d2bf52edecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember_0a5bff1e-4a66-43e6-a0bf-cecd876c9302" xlink:href="halo-20230331.xsd#halo_CollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4743d4a6-3e75-40fb-82e8-42f829f0b357" xlink:to="loc_halo_CollaborativeAgreementsMember_0a5bff1e-4a66-43e6-a0bf-cecd876c9302" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="halo-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended" id="i895c10ee1b84406da7b9d713697c367b_CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_38dcb873-410b-4704-87c9-9f344fd8fc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_38dcb873-410b-4704-87c9-9f344fd8fc76" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_2bac6292-5dc6-4783-b054-6e7066d4035e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_SharesOutstanding_2bac6292-5dc6-4783-b054-6e7066d4035e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e40aacb8-6255-434c-956d-6abf2afa5a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_StockholdersEquity_e40aacb8-6255-434c-956d-6abf2afa5a59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_86405722-b0cd-40ee-9e35-c9b789950f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_86405722-b0cd-40ee-9e35-c9b789950f3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_214e34ad-8aa0-438b-abcf-f022655b2618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_214e34ad-8aa0-438b-abcf-f022655b2618" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ca0978cf-3dda-4b21-9773-d063a662a1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ca0978cf-3dda-4b21-9773-d063a662a1bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6d545db5-effd-4fb9-8359-5a75625b96aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6d545db5-effd-4fb9-8359-5a75625b96aa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_00a6596e-e00a-4a06-88c2-165a84d61276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_00a6596e-e00a-4a06-88c2-165a84d61276" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_8f503721-8866-47d1-98bc-9b4971a91b22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_8f503721-8866-47d1-98bc-9b4971a91b22" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_68fd6ec5-dfca-4fd5-b731-d07863e0a86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_68fd6ec5-dfca-4fd5-b731-d07863e0a86c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_2baacb51-c412-4443-b1d4-5fae3f2100c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_2baacb51-c412-4443-b1d4-5fae3f2100c7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4c0c078e-e6d0-44a7-85bd-d82f3ef51a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_NetIncomeLoss_4c0c078e-e6d0-44a7-85bd-d82f3ef51a54" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_cb4efad9-9e4e-4e09-9149-838f099bac22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_98f48a51-9449-4438-9061-e428bdbe038e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_108abcbc-ddf8-46cd-83fc-699acb133ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_38dcb873-410b-4704-87c9-9f344fd8fc76" xlink:to="loc_us-gaap_StatementTable_108abcbc-ddf8-46cd-83fc-699acb133ba8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6cc35acc-cd7e-4a26-94ac-6c49cfc04255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_108abcbc-ddf8-46cd-83fc-699acb133ba8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6cc35acc-cd7e-4a26-94ac-6c49cfc04255" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6cc35acc-cd7e-4a26-94ac-6c49cfc04255_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6cc35acc-cd7e-4a26-94ac-6c49cfc04255" xlink:to="loc_us-gaap_EquityComponentDomain_6cc35acc-cd7e-4a26-94ac-6c49cfc04255_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e1cb8a80-e966-4c5a-b58e-978b97589c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6cc35acc-cd7e-4a26-94ac-6c49cfc04255" xlink:to="loc_us-gaap_EquityComponentDomain_e1cb8a80-e966-4c5a-b58e-978b97589c3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d6e5bd81-a695-4be2-8f95-d188f885d1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e1cb8a80-e966-4c5a-b58e-978b97589c3d" xlink:to="loc_us-gaap_CommonStockMember_d6e5bd81-a695-4be2-8f95-d188f885d1af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5f4ab508-3638-48e2-b841-46d22c4fa508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e1cb8a80-e966-4c5a-b58e-978b97589c3d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5f4ab508-3638-48e2-b841-46d22c4fa508" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e45fff02-e32a-4c73-825a-2997558d1859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e1cb8a80-e966-4c5a-b58e-978b97589c3d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e45fff02-e32a-4c73-825a-2997558d1859" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e5ad48d9-25e6-4fa4-9d92-6f903d69cf71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e1cb8a80-e966-4c5a-b58e-978b97589c3d" xlink:to="loc_us-gaap_RetainedEarningsMember_e5ad48d9-25e6-4fa4-9d92-6f903d69cf71" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/OrganizationandBusinessDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#OrganizationandBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/OrganizationandBusinessDetails" xlink:type="extended" id="ice859c1501764cafbda4be49657ca971_OrganizationandBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b76e73b8-502a-448b-8bad-7bc0c9fa564b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RoyaltiesReceivedNumberOfCollaborators_1b181bfb-8bd5-4a91-bf53-d4e407287519" xlink:href="halo-20230331.xsd#halo_RoyaltiesReceivedNumberOfCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b76e73b8-502a-448b-8bad-7bc0c9fa564b" xlink:to="loc_halo_RoyaltiesReceivedNumberOfCollaborators_1b181bfb-8bd5-4a91-bf53-d4e407287519" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RoyaltiesReceivedNumberOfProductsSold_878daae8-96bf-43b6-a286-9d9840ff93fc" xlink:href="halo-20230331.xsd#halo_RoyaltiesReceivedNumberOfProductsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b76e73b8-502a-448b-8bad-7bc0c9fa564b" xlink:to="loc_halo_RoyaltiesReceivedNumberOfProductsSold_878daae8-96bf-43b6-a286-9d9840ff93fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6d203d3-a0f1-4248-8cd1-41c9b23f7bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b76e73b8-502a-448b-8bad-7bc0c9fa564b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6d203d3-a0f1-4248-8cd1-41c9b23f7bf6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d6d29895-c2f0-410d-8810-445c1d07de94" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6d203d3-a0f1-4248-8cd1-41c9b23f7bf6" xlink:to="loc_srt_CounterpartyNameAxis_d6d29895-c2f0-410d-8810-445c1d07de94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6d29895-c2f0-410d-8810-445c1d07de94_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d6d29895-c2f0-410d-8810-445c1d07de94" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6d29895-c2f0-410d-8810-445c1d07de94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5e22711-57c2-486f-8f5f-f307ba4cb936" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d6d29895-c2f0-410d-8810-445c1d07de94" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5e22711-57c2-486f-8f5f-f307ba4cb936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BaxaltaMember_0a032169-51e8-4cbc-9582-d3b67b25a1e9" xlink:href="halo-20230331.xsd#halo_BaxaltaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5e22711-57c2-486f-8f5f-f307ba4cb936" xlink:to="loc_halo_BaxaltaMember_0a032169-51e8-4cbc-9582-d3b67b25a1e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RocheMember_4ae28c42-c93b-4aca-adcf-600dda1270be" xlink:href="halo-20230331.xsd#halo_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5e22711-57c2-486f-8f5f-f307ba4cb936" xlink:to="loc_halo_RocheMember_4ae28c42-c93b-4aca-adcf-600dda1270be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_JanssenMember_2a2f5a80-6ba5-4cd5-a429-ffb6f4050077" xlink:href="halo-20230331.xsd#halo_JanssenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5e22711-57c2-486f-8f5f-f307ba4cb936" xlink:to="loc_halo_JanssenMember_2a2f5a80-6ba5-4cd5-a429-ffb6f4050077" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#SummaryofSignificantAccountingPoliciesLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="extended" id="i6fa31a153fd54cf9bc8892080e8ed0bb_SummaryofSignificantAccountingPoliciesLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f23826cb-cdf3-458b-9834-63b1920fa1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_49a100f4-38ae-4d30-b799-504233b97ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f23826cb-cdf3-458b-9834-63b1920fa1bb" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_49a100f4-38ae-4d30-b799-504233b97ae1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f97894cb-c6f1-4ebc-8580-8b09d9436fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f23826cb-cdf3-458b-9834-63b1920fa1bb" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f97894cb-c6f1-4ebc-8580-8b09d9436fa0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0e063398-a04d-4e04-8099-6c7674d8f925" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f97894cb-c6f1-4ebc-8580-8b09d9436fa0" xlink:to="loc_srt_RangeAxis_0e063398-a04d-4e04-8099-6c7674d8f925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0e063398-a04d-4e04-8099-6c7674d8f925_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0e063398-a04d-4e04-8099-6c7674d8f925" xlink:to="loc_srt_RangeMember_0e063398-a04d-4e04-8099-6c7674d8f925_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eaebdf76-d47a-408d-80f6-58f26de9eb33" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0e063398-a04d-4e04-8099-6c7674d8f925" xlink:to="loc_srt_RangeMember_eaebdf76-d47a-408d-80f6-58f26de9eb33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0a4b3131-d347-4560-bec5-5d3b4be48313" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eaebdf76-d47a-408d-80f6-58f26de9eb33" xlink:to="loc_srt_MinimumMember_0a4b3131-d347-4560-bec5-5d3b4be48313" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_609b6256-576d-47ab-8c9e-8e9262abb806" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eaebdf76-d47a-408d-80f6-58f26de9eb33" xlink:to="loc_srt_MaximumMember_609b6256-576d-47ab-8c9e-8e9262abb806" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationNarrativeDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#BusinessCombinationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/BusinessCombinationNarrativeDetails" xlink:type="extended" id="i4dde83de00e547ba867737e330017683_BusinessCombinationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_af6f5d1d-2fa7-492d-99e1-5d9a8a0e7f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_af6f5d1d-2fa7-492d-99e1-5d9a8a0e7f54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_7b034a7d-d890-4632-ab1f-2067bdb1a9ca" xlink:href="halo-20230331.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_7b034a7d-d890-4632-ab1f-2067bdb1a9ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_74ec1c0f-dc8c-440d-b07b-412a2b49b452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_74ec1c0f-dc8c-440d-b07b-412a2b49b452" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_f08f31c7-5753-4306-9c05-3015e5ddee3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_f08f31c7-5753-4306-9c05-3015e5ddee3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_14b841f4-a5be-44eb-9f51-12bdd658d8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_14b841f4-a5be-44eb-9f51-12bdd658d8f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b56970c6-23aa-4ba5-b423-32eaa97d07db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b56970c6-23aa-4ba5-b423-32eaa97d07db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6df60ac5-c9fc-4b9c-8856-46e35f30fdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6df60ac5-c9fc-4b9c-8856-46e35f30fdc5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense_d9d87d5e-5dce-4767-90b0-05fefefa4ec6" xlink:href="halo-20230331.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense_d9d87d5e-5dce-4767-90b0-05fefefa4ec6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet_2b0eb114-82ab-4ffa-a87e-9e32b865a450" xlink:href="halo-20230331.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet_2b0eb114-82ab-4ffa-a87e-9e32b865a450" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_b55f3f1b-fe6f-400f-a134-dac20d138318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_b55f3f1b-fe6f-400f-a134-dac20d138318" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c219a245-7a79-483f-b425-dae0ca564c63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c219a245-7a79-483f-b425-dae0ca564c63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b5cf7939-c8d7-4544-910f-6b1ba5345626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c219a245-7a79-483f-b425-dae0ca564c63" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b5cf7939-c8d7-4544-910f-6b1ba5345626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5cf7939-c8d7-4544-910f-6b1ba5345626_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b5cf7939-c8d7-4544-910f-6b1ba5345626" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5cf7939-c8d7-4544-910f-6b1ba5345626_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f6e1043-43e8-411f-8f8a-f95a6000423b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b5cf7939-c8d7-4544-910f-6b1ba5345626" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f6e1043-43e8-411f-8f8a-f95a6000423b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_fb516a25-f866-4a84-b4e9-bb22fc43b4f9" xlink:href="halo-20230331.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f6e1043-43e8-411f-8f8a-f95a6000423b" xlink:to="loc_halo_AntaresPharmaIncMember_fb516a25-f866-4a84-b4e9-bb22fc43b4f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c69c4419-716d-49cf-89d3-1853f55826ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c219a245-7a79-483f-b425-dae0ca564c63" xlink:to="loc_us-gaap_DebtInstrumentAxis_c69c4419-716d-49cf-89d3-1853f55826ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c69c4419-716d-49cf-89d3-1853f55826ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c69c4419-716d-49cf-89d3-1853f55826ff" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c69c4419-716d-49cf-89d3-1853f55826ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_19b74c46-964e-4d96-bab3-0b4987c6ea7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c69c4419-716d-49cf-89d3-1853f55826ff" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_19b74c46-964e-4d96-bab3-0b4987c6ea7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TermLoanFacilityMember_f08181fe-999e-45c2-9f05-47e31a1cab18" xlink:href="halo-20230331.xsd#halo_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_19b74c46-964e-4d96-bab3-0b4987c6ea7a" xlink:to="loc_halo_TermLoanFacilityMember_f08181fe-999e-45c2-9f05-47e31a1cab18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_76af8dbe-e482-4d95-9e2f-3987012dd175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c219a245-7a79-483f-b425-dae0ca564c63" xlink:to="loc_us-gaap_CreditFacilityAxis_76af8dbe-e482-4d95-9e2f-3987012dd175" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_76af8dbe-e482-4d95-9e2f-3987012dd175_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_76af8dbe-e482-4d95-9e2f-3987012dd175" xlink:to="loc_us-gaap_CreditFacilityDomain_76af8dbe-e482-4d95-9e2f-3987012dd175_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_bb68eb83-070b-4d92-9c47-8d3c47b7c0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_76af8dbe-e482-4d95-9e2f-3987012dd175" xlink:to="loc_us-gaap_CreditFacilityDomain_bb68eb83-070b-4d92-9c47-8d3c47b7c0f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_8be3ba33-aac4-4846-82ab-9abed2eaa3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_bb68eb83-070b-4d92-9c47-8d3c47b7c0f9" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_8be3ba33-aac4-4846-82ab-9abed2eaa3ce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#BusinessCombinationPurchaseConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails" xlink:type="extended" id="ib0961cce302b4d229b1c65acd3d0b310_BusinessCombinationPurchaseConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a2986641-79c5-46c0-b7b5-1d448924b1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e9a80547-7232-44c9-8827-3604e8d466d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2986641-79c5-46c0-b7b5-1d448924b1af" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e9a80547-7232-44c9-8827-3604e8d466d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_f83c5386-3d8c-4794-8325-d3cd1fdde7b7" xlink:href="halo-20230331.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2986641-79c5-46c0-b7b5-1d448924b1af" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_f83c5386-3d8c-4794-8325-d3cd1fdde7b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_af972991-15d3-431c-baa3-e825da0d6779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2986641-79c5-46c0-b7b5-1d448924b1af" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_af972991-15d3-431c-baa3-e825da0d6779" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a3c2a151-2319-4b3e-a4f3-cbe04146b96d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2986641-79c5-46c0-b7b5-1d448924b1af" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a3c2a151-2319-4b3e-a4f3-cbe04146b96d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards_a545fce0-cb37-4a55-9752-dddc15e72690" xlink:href="halo-20230331.xsd#halo_BusinessCombinationConsiderationTransferredBonusAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2986641-79c5-46c0-b7b5-1d448924b1af" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards_a545fce0-cb37-4a55-9752-dddc15e72690" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_33608f77-2b81-48dc-9647-037360c4ffb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2986641-79c5-46c0-b7b5-1d448924b1af" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_33608f77-2b81-48dc-9647-037360c4ffb5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_e44b7112-117b-4afd-9411-97256d8b389d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2986641-79c5-46c0-b7b5-1d448924b1af" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_e44b7112-117b-4afd-9411-97256d8b389d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b08f06c1-2cd6-42d9-bc51-feb9075e41e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2986641-79c5-46c0-b7b5-1d448924b1af" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b08f06c1-2cd6-42d9-bc51-feb9075e41e1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_19b67ada-9d22-4ec8-8519-be8f1c76e458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b08f06c1-2cd6-42d9-bc51-feb9075e41e1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_19b67ada-9d22-4ec8-8519-be8f1c76e458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19b67ada-9d22-4ec8-8519-be8f1c76e458_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_19b67ada-9d22-4ec8-8519-be8f1c76e458" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19b67ada-9d22-4ec8-8519-be8f1c76e458_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06a1a895-260a-4050-8836-e25b4f41745e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_19b67ada-9d22-4ec8-8519-be8f1c76e458" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06a1a895-260a-4050-8836-e25b4f41745e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_7a1bd1fd-e029-4f88-b24b-9483a5410619" xlink:href="halo-20230331.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06a1a895-260a-4050-8836-e25b4f41745e" xlink:to="loc_halo_AntaresPharmaIncMember_7a1bd1fd-e029-4f88-b24b-9483a5410619" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_bb753b7e-2be8-4a7f-a857-87ceb2b3a99a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b08f06c1-2cd6-42d9-bc51-feb9075e41e1" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_bb753b7e-2be8-4a7f-a857-87ceb2b3a99a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_bb753b7e-2be8-4a7f-a857-87ceb2b3a99a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_bb753b7e-2be8-4a7f-a857-87ceb2b3a99a" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_bb753b7e-2be8-4a7f-a857-87ceb2b3a99a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_34680769-b56a-448f-88e3-60989a0174bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_bb753b7e-2be8-4a7f-a857-87ceb2b3a99a" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_34680769-b56a-448f-88e3-60989a0174bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationAwardsVestedMember_02701118-d415-494e-91fb-e8cf1f9c5686" xlink:href="halo-20230331.xsd#halo_ShareBasedCompensationAwardsVestedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_34680769-b56a-448f-88e3-60989a0174bd" xlink:to="loc_halo_ShareBasedCompensationAwardsVestedMember_02701118-d415-494e-91fb-e8cf1f9c5686" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationAwardUnvestedMember_1c9a3c38-dd90-4526-b75b-f06585d09c6b" xlink:href="halo-20230331.xsd#halo_ShareBasedCompensationAwardUnvestedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_34680769-b56a-448f-88e3-60989a0174bd" xlink:to="loc_halo_ShareBasedCompensationAwardUnvestedMember_1c9a3c38-dd90-4526-b75b-f06585d09c6b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i61160262581345bf90376b1aa948415a_BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f7803aeb-e651-49cb-bcdb-e731db59d7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3d4a0c22-e11e-4ff9-a856-590ddce8a439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7803aeb-e651-49cb-bcdb-e731db59d7c5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3d4a0c22-e11e-4ff9-a856-590ddce8a439" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_ad7c8692-e99f-42e7-9496-674254276379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7803aeb-e651-49cb-bcdb-e731db59d7c5" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_ad7c8692-e99f-42e7-9496-674254276379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7803aeb-e651-49cb-bcdb-e731db59d7c5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_a2417859-f6da-4796-a144-7616e9ffe192" xlink:href="halo-20230331.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_a2417859-f6da-4796-a144-7616e9ffe192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_ef497496-88e1-43b9-a411-e9b90f738b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_ef497496-88e1-43b9-a411-e9b90f738b0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_f51e30f5-ece8-48d9-9d03-81d1026e5fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_f51e30f5-ece8-48d9-9d03-81d1026e5fd7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9b721406-6e14-4554-bf44-6ba81e69f86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9b721406-6e14-4554-bf44-6ba81e69f86d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_eb3964d1-4eba-4e40-91fd-1735762b533b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_eb3964d1-4eba-4e40-91fd-1735762b533b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_52554f4b-34c7-48ec-a5cf-c25bc10b2daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_52554f4b-34c7-48ec-a5cf-c25bc10b2daf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_6b620a25-15a1-4896-aa13-d76183817aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_6b620a25-15a1-4896-aa13-d76183817aca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_c9ef993f-fe2c-47fa-8e03-ccd105facff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_c9ef993f-fe2c-47fa-8e03-ccd105facff6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7803aeb-e651-49cb-bcdb-e731db59d7c5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5aba814b-b9c3-4d56-a783-a60140bfb819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5aba814b-b9c3-4d56-a783-a60140bfb819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense_12d2c6fa-2759-4619-986c-ae9e619e27c9" xlink:href="halo-20230331.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense_12d2c6fa-2759-4619-986c-ae9e619e27c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_e90f3a3c-c225-47c2-b470-d1ce542314de" xlink:href="halo-20230331.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_e90f3a3c-c225-47c2-b470-d1ce542314de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_179e3517-bba8-462f-8a77-b8dd8c7a7070" xlink:href="halo-20230331.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_179e3517-bba8-462f-8a77-b8dd8c7a7070" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_cd5b4eb6-70e9-4aa9-b3ba-96f7438d0bcc" xlink:href="halo-20230331.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_cd5b4eb6-70e9-4aa9-b3ba-96f7438d0bcc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet_db266ab8-87a0-4fb5-84a7-a22c11c59518" xlink:href="halo-20230331.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet_db266ab8-87a0-4fb5-84a7-a22c11c59518" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_257464af-fe0e-433d-b63e-139c58623618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_257464af-fe0e-433d-b63e-139c58623618" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities_72eda97a-4189-451f-ba8a-594cca061311" xlink:href="halo-20230331.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities_72eda97a-4189-451f-ba8a-594cca061311" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_c4a5c083-29bb-4224-8c9b-1e9671a2f16d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_c4a5c083-29bb-4224-8c9b-1e9671a2f16d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill_a94431ba-37eb-4340-a3fe-fbb2be9ea365" xlink:href="halo-20230331.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill_a94431ba-37eb-4340-a3fe-fbb2be9ea365" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ed4a16c2-4e32-4bce-aafc-477fdd9366ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7803aeb-e651-49cb-bcdb-e731db59d7c5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ed4a16c2-4e32-4bce-aafc-477fdd9366ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_a5926c97-0e88-4209-8a35-03d99767f0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7803aeb-e651-49cb-bcdb-e731db59d7c5" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_a5926c97-0e88-4209-8a35-03d99767f0ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c7dbd2ee-9350-43e7-ad2c-d6ee5e9f51c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7803aeb-e651-49cb-bcdb-e731db59d7c5" xlink:to="loc_us-gaap_Goodwill_c7dbd2ee-9350-43e7-ad2c-d6ee5e9f51c8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_74256c2d-3642-4560-85dc-ce666295da87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7803aeb-e651-49cb-bcdb-e731db59d7c5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_74256c2d-3642-4560-85dc-ce666295da87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4d23c83b-26a5-4349-8cd1-a4350e54e41d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_74256c2d-3642-4560-85dc-ce666295da87" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4d23c83b-26a5-4349-8cd1-a4350e54e41d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d23c83b-26a5-4349-8cd1-a4350e54e41d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4d23c83b-26a5-4349-8cd1-a4350e54e41d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d23c83b-26a5-4349-8cd1-a4350e54e41d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d8f3dda-faeb-4d33-a992-3e4d44a73532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4d23c83b-26a5-4349-8cd1-a4350e54e41d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d8f3dda-faeb-4d33-a992-3e4d44a73532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_78bf5205-346c-4379-bacd-af6fc2854a29" xlink:href="halo-20230331.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d8f3dda-faeb-4d33-a992-3e4d44a73532" xlink:to="loc_halo_AntaresPharmaIncMember_78bf5205-346c-4379-bacd-af6fc2854a29" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#BusinessCombinationIntangibleAssetsAcquiredDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails" xlink:type="extended" id="i0bdc1ad6a877457fb90b8184be5f9f2a_BusinessCombinationIntangibleAssetsAcquiredDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_200bd14a-758a-41f6-ab2f-2ab26bdf9a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_55b64bcf-8aa6-4e45-911c-7a26719af3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_200bd14a-758a-41f6-ab2f-2ab26bdf9a34" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_55b64bcf-8aa6-4e45-911c-7a26719af3b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c43444ac-5961-49ea-9777-c77326b9b830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_200bd14a-758a-41f6-ab2f-2ab26bdf9a34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c43444ac-5961-49ea-9777-c77326b9b830" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_dc0c3a7d-64f2-477d-a534-348d190eb4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_200bd14a-758a-41f6-ab2f-2ab26bdf9a34" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_dc0c3a7d-64f2-477d-a534-348d190eb4c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_fb8f68cc-74cb-4f40-b249-9d2b7dbe1cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_200bd14a-758a-41f6-ab2f-2ab26bdf9a34" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_fb8f68cc-74cb-4f40-b249-9d2b7dbe1cea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1c4e27fd-c0bd-4668-9a92-09f8b1935c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_200bd14a-758a-41f6-ab2f-2ab26bdf9a34" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1c4e27fd-c0bd-4668-9a92-09f8b1935c7d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8488a70a-1434-4419-a669-f96052f2b6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1c4e27fd-c0bd-4668-9a92-09f8b1935c7d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8488a70a-1434-4419-a669-f96052f2b6b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8488a70a-1434-4419-a669-f96052f2b6b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8488a70a-1434-4419-a669-f96052f2b6b7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8488a70a-1434-4419-a669-f96052f2b6b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_465fc0ca-3210-4a34-bb3f-d1d39983cb59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8488a70a-1434-4419-a669-f96052f2b6b7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_465fc0ca-3210-4a34-bb3f-d1d39983cb59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_953f4c9d-4e17-4f78-8c8d-8255f39badb3" xlink:href="halo-20230331.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_465fc0ca-3210-4a34-bb3f-d1d39983cb59" xlink:to="loc_halo_AntaresPharmaIncMember_953f4c9d-4e17-4f78-8c8d-8255f39badb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2123162a-3f42-4510-b6bd-4daf1ceda135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1c4e27fd-c0bd-4668-9a92-09f8b1935c7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2123162a-3f42-4510-b6bd-4daf1ceda135" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2123162a-3f42-4510-b6bd-4daf1ceda135_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2123162a-3f42-4510-b6bd-4daf1ceda135" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2123162a-3f42-4510-b6bd-4daf1ceda135_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c874cc60-5aa5-4920-b67c-a0e5e5f06615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2123162a-3f42-4510-b6bd-4daf1ceda135" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c874cc60-5aa5-4920-b67c-a0e5e5f06615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AutoInjectorTechnologyPlatformMember_1f24ffa2-efe2-4773-9011-0ea72f703679" xlink:href="halo-20230331.xsd#halo_AutoInjectorTechnologyPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c874cc60-5aa5-4920-b67c-a0e5e5f06615" xlink:to="loc_halo_AutoInjectorTechnologyPlatformMember_1f24ffa2-efe2-4773-9011-0ea72f703679" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_XYOSTEDProprietaryProductMember_e6bedb4b-5018-49f1-a2eb-cbef717b466c" xlink:href="halo-20230331.xsd#halo_XYOSTEDProprietaryProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c874cc60-5aa5-4920-b67c-a0e5e5f06615" xlink:to="loc_halo_XYOSTEDProprietaryProductMember_e6bedb4b-5018-49f1-a2eb-cbef717b466c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TLANDOProductRightsMember_7a51e6aa-2369-40d7-80af-edd8e697bd27" xlink:href="halo-20230331.xsd#halo_TLANDOProductRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c874cc60-5aa5-4920-b67c-a0e5e5f06615" xlink:to="loc_halo_TLANDOProductRightsMember_7a51e6aa-2369-40d7-80af-edd8e697bd27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_78498e82-d2dd-4acb-aeb2-c6dc70b74893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1c4e27fd-c0bd-4668-9a92-09f8b1935c7d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_78498e82-d2dd-4acb-aeb2-c6dc70b74893" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_78498e82-d2dd-4acb-aeb2-c6dc70b74893_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_78498e82-d2dd-4acb-aeb2-c6dc70b74893" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_78498e82-d2dd-4acb-aeb2-c6dc70b74893_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7cd42138-4dcd-475c-ba99-16ace53b55c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_78498e82-d2dd-4acb-aeb2-c6dc70b74893" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7cd42138-4dcd-475c-ba99-16ace53b55c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_18c9a92f-61f5-4f67-813b-6593d2d6c8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7cd42138-4dcd-475c-ba99-16ace53b55c0" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_18c9a92f-61f5-4f67-813b-6593d2d6c8d7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="extended" id="iae0357229832476bb78aaeff4402d493_FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d75ccf-d6c5-4f1e-8035-df6deb401f03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a931d007-5400-40a5-a3f5-f3b0ca42be23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d75ccf-d6c5-4f1e-8035-df6deb401f03" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a931d007-5400-40a5-a3f5-f3b0ca42be23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b88ebcb9-83a6-4a60-99fc-994805e52316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d75ccf-d6c5-4f1e-8035-df6deb401f03" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b88ebcb9-83a6-4a60-99fc-994805e52316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a602c9da-76eb-4afa-b24f-9286c714ac5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d75ccf-d6c5-4f1e-8035-df6deb401f03" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a602c9da-76eb-4afa-b24f-9286c714ac5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4be57881-7897-4bba-bbba-2355c1f7356f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d75ccf-d6c5-4f1e-8035-df6deb401f03" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4be57881-7897-4bba-bbba-2355c1f7356f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e368a2e8-9aa8-4baa-923c-d977aa1a05f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d75ccf-d6c5-4f1e-8035-df6deb401f03" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e368a2e8-9aa8-4baa-923c-d977aa1a05f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ce4891f3-a310-4b99-8720-a3ac32957d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e368a2e8-9aa8-4baa-923c-d977aa1a05f0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ce4891f3-a310-4b99-8720-a3ac32957d92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce4891f3-a310-4b99-8720-a3ac32957d92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ce4891f3-a310-4b99-8720-a3ac32957d92" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce4891f3-a310-4b99-8720-a3ac32957d92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeacd4c5-c5c2-4954-886a-e68f54ce4d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ce4891f3-a310-4b99-8720-a3ac32957d92" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeacd4c5-c5c2-4954-886a-e68f54ce4d4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_8354240a-01dd-4424-b83e-2ec40da61a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeacd4c5-c5c2-4954-886a-e68f54ce4d4f" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_8354240a-01dd-4424-b83e-2ec40da61a09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3f1b7cd6-ce47-4470-bbc0-ed4e3636aa48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeacd4c5-c5c2-4954-886a-e68f54ce4d4f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3f1b7cd6-ce47-4470-bbc0-ed4e3636aa48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_089302bb-d42b-4f1a-81ed-9d7e52829230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeacd4c5-c5c2-4954-886a-e68f54ce4d4f" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_089302bb-d42b-4f1a-81ed-9d7e52829230" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_571524f2-fcf6-435a-8b4a-1008e8daa733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeacd4c5-c5c2-4954-886a-e68f54ce4d4f" xlink:to="loc_us-gaap_CommercialPaperMember_571524f2-fcf6-435a-8b4a-1008e8daa733" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_e4587129-bfd4-47c1-9cfc-0b36687fcf04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeacd4c5-c5c2-4954-886a-e68f54ce4d4f" xlink:to="loc_us-gaap_AgencySecuritiesMember_e4587129-bfd4-47c1-9cfc-0b36687fcf04" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended" id="iefe548bebdbb4fe2b8b60b14d6b89ef4_FairValueMeasurementNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b82047aa-fe4b-4caf-8405-7964772bde9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_026046ac-6287-44b7-b503-fab945aebba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b82047aa-fe4b-4caf-8405-7964772bde9d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_026046ac-6287-44b7-b503-fab945aebba6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_8862b3b6-1d11-4037-8374-5692dbf33ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b82047aa-fe4b-4caf-8405-7964772bde9d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_8862b3b6-1d11-4037-8374-5692dbf33ccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9744c44-1711-4480-b5ff-728da5088a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b82047aa-fe4b-4caf-8405-7964772bde9d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9744c44-1711-4480-b5ff-728da5088a9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_17aae73b-8db8-484e-ac01-0c478343047f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b82047aa-fe4b-4caf-8405-7964772bde9d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_17aae73b-8db8-484e-ac01-0c478343047f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6a0d6ac5-650d-4397-ba2b-f52c854ff1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b82047aa-fe4b-4caf-8405-7964772bde9d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6a0d6ac5-650d-4397-ba2b-f52c854ff1ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a33048f2-ef2b-45ef-8f7a-cd4d4c736163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b82047aa-fe4b-4caf-8405-7964772bde9d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a33048f2-ef2b-45ef-8f7a-cd4d4c736163" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e864dcbd-509d-4b4a-8817-e25d395eee16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b82047aa-fe4b-4caf-8405-7964772bde9d" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e864dcbd-509d-4b4a-8817-e25d395eee16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4954b14b-effb-455d-9c9a-618775fb3f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e864dcbd-509d-4b4a-8817-e25d395eee16" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4954b14b-effb-455d-9c9a-618775fb3f27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4954b14b-effb-455d-9c9a-618775fb3f27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4954b14b-effb-455d-9c9a-618775fb3f27" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4954b14b-effb-455d-9c9a-618775fb3f27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5681d818-1f56-4b4b-9bce-e7cd03227672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4954b14b-effb-455d-9c9a-618775fb3f27" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5681d818-1f56-4b4b-9bce-e7cd03227672" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fc76e332-0daa-4ecf-8635-6c719b633c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5681d818-1f56-4b4b-9bce-e7cd03227672" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fc76e332-0daa-4ecf-8635-6c719b633c1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1adabcc7-b6bd-4bd8-ad87-49d271b90d00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e864dcbd-509d-4b4a-8817-e25d395eee16" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1adabcc7-b6bd-4bd8-ad87-49d271b90d00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1adabcc7-b6bd-4bd8-ad87-49d271b90d00_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1adabcc7-b6bd-4bd8-ad87-49d271b90d00" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1adabcc7-b6bd-4bd8-ad87-49d271b90d00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68ac385f-08cf-460f-86bb-9c1a42cc0c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1adabcc7-b6bd-4bd8-ad87-49d271b90d00" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68ac385f-08cf-460f-86bb-9c1a42cc0c25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_c7b11df1-5ca8-4255-9d4d-4dfbf6fd64bf" xlink:href="halo-20230331.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68ac385f-08cf-460f-86bb-9c1a42cc0c25" xlink:to="loc_halo_AntaresPharmaIncMember_c7b11df1-5ca8-4255-9d4d-4dfbf6fd64bf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="if564570c4c004c22832bbc8013c9bfde_FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_045d776a-4089-4b44-a64d-c3907a7dc8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9aabddef-037e-4a51-8b81-f41a6c0dafa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_045d776a-4089-4b44-a64d-c3907a7dc8f1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9aabddef-037e-4a51-8b81-f41a6c0dafa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_15a09eac-19ac-495d-a0af-c53d8ab7225b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_045d776a-4089-4b44-a64d-c3907a7dc8f1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_15a09eac-19ac-495d-a0af-c53d8ab7225b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a89dcf6a-9084-4c33-a756-18174a9d6978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_045d776a-4089-4b44-a64d-c3907a7dc8f1" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a89dcf6a-9084-4c33-a756-18174a9d6978" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ce33b509-3f40-4ac5-bfed-de5a1e1c1be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_045d776a-4089-4b44-a64d-c3907a7dc8f1" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ce33b509-3f40-4ac5-bfed-de5a1e1c1be3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_202114ec-8f41-4059-94cb-cf6c43d88b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ce33b509-3f40-4ac5-bfed-de5a1e1c1be3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_202114ec-8f41-4059-94cb-cf6c43d88b08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_202114ec-8f41-4059-94cb-cf6c43d88b08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_202114ec-8f41-4059-94cb-cf6c43d88b08" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_202114ec-8f41-4059-94cb-cf6c43d88b08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_981d1f2b-6396-4579-8406-e12df5c7a811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_202114ec-8f41-4059-94cb-cf6c43d88b08" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_981d1f2b-6396-4579-8406-e12df5c7a811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cd9cbab4-d822-40df-8cd1-3f2191ec5d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_981d1f2b-6396-4579-8406-e12df5c7a811" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cd9cbab4-d822-40df-8cd1-3f2191ec5d3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b55639ea-f8f2-4a14-afe2-d5afa329ff9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_981d1f2b-6396-4579-8406-e12df5c7a811" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b55639ea-f8f2-4a14-afe2-d5afa329ff9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_757bfc78-25b3-4696-874a-21cd33188a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_981d1f2b-6396-4579-8406-e12df5c7a811" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_757bfc78-25b3-4696-874a-21cd33188a4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_a12dec09-aa3c-4b29-a61a-123e9b327b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ce33b509-3f40-4ac5-bfed-de5a1e1c1be3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_a12dec09-aa3c-4b29-a61a-123e9b327b9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a12dec09-aa3c-4b29-a61a-123e9b327b9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a12dec09-aa3c-4b29-a61a-123e9b327b9b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a12dec09-aa3c-4b29-a61a-123e9b327b9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9dffc669-c829-44b5-9454-fd713de39a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a12dec09-aa3c-4b29-a61a-123e9b327b9b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9dffc669-c829-44b5-9454-fd713de39a12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_55ce983d-1c91-4463-af37-d11a48ff2ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9dffc669-c829-44b5-9454-fd713de39a12" xlink:to="loc_us-gaap_MoneyMarketFundsMember_55ce983d-1c91-4463-af37-d11a48ff2ef8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_f4fc1fae-aa60-45c1-be49-2cb34d62e390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9dffc669-c829-44b5-9454-fd713de39a12" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_f4fc1fae-aa60-45c1-be49-2cb34d62e390" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a25a4bbb-772c-4076-8996-98aed026adce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ce33b509-3f40-4ac5-bfed-de5a1e1c1be3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a25a4bbb-772c-4076-8996-98aed026adce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a25a4bbb-772c-4076-8996-98aed026adce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a25a4bbb-772c-4076-8996-98aed026adce" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a25a4bbb-772c-4076-8996-98aed026adce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_395f518c-fd5a-48ab-971b-e5673b1769b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a25a4bbb-772c-4076-8996-98aed026adce" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_395f518c-fd5a-48ab-971b-e5673b1769b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_e31514e4-454c-4516-b68b-de8d44cede27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_395f518c-fd5a-48ab-971b-e5673b1769b5" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_e31514e4-454c-4516-b68b-de8d44cede27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_083b6428-7b49-431b-b8be-c317cbe4fa31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_395f518c-fd5a-48ab-971b-e5673b1769b5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_083b6428-7b49-431b-b8be-c317cbe4fa31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_51fc4660-a2ff-4e67-a223-6fb0873c9a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_395f518c-fd5a-48ab-971b-e5673b1769b5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_51fc4660-a2ff-4e67-a223-6fb0873c9a9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_c77c229b-e67a-4be3-a2ab-1bd640ac9903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_395f518c-fd5a-48ab-971b-e5673b1769b5" xlink:to="loc_us-gaap_AgencySecuritiesMember_c77c229b-e67a-4be3-a2ab-1bd640ac9903" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_cc620b79-7cc3-4b6d-8398-cafa607ef398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_395f518c-fd5a-48ab-971b-e5673b1769b5" xlink:to="loc_us-gaap_CommercialPaperMember_cc620b79-7cc3-4b6d-8398-cafa607ef398" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#RevenueDisaggregatedRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails" xlink:type="extended" id="i0328a61e056744d78771bb4bbe2421b8_RevenueDisaggregatedRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a1f598a6-9fa9-4388-811d-5dbd42a33eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6cea62d-8689-4af0-981a-b1fd68888d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a1f598a6-9fa9-4388-811d-5dbd42a33eb9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6cea62d-8689-4af0-981a-b1fd68888d47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_06be638e-c69a-4fe1-bbd3-b1919eb24574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a1f598a6-9fa9-4388-811d-5dbd42a33eb9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_06be638e-c69a-4fe1-bbd3-b1919eb24574" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6a01e4d9-1838-4060-8811-717804e4cc4b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_06be638e-c69a-4fe1-bbd3-b1919eb24574" xlink:to="loc_srt_ProductOrServiceAxis_6a01e4d9-1838-4060-8811-717804e4cc4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6a01e4d9-1838-4060-8811-717804e4cc4b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6a01e4d9-1838-4060-8811-717804e4cc4b" xlink:to="loc_srt_ProductsAndServicesDomain_6a01e4d9-1838-4060-8811-717804e4cc4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f80cd44b-871d-4322-863c-d464d196ea81" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6a01e4d9-1838-4060-8811-717804e4cc4b" xlink:to="loc_srt_ProductsAndServicesDomain_f80cd44b-871d-4322-863c-d464d196ea81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_be5c87dc-035d-4f74-92d2-380b8369c43c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f80cd44b-871d-4322-863c-d464d196ea81" xlink:to="loc_us-gaap_RoyaltyMember_be5c87dc-035d-4f74-92d2-380b8369c43c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0f78d280-5b09-4e6f-93d9-aab1f7d761cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f80cd44b-871d-4322-863c-d464d196ea81" xlink:to="loc_us-gaap_ProductMember_0f78d280-5b09-4e6f-93d9-aab1f7d761cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BulkrHuPH20Member_82645d81-54b4-497d-92e5-7103a86aaa05" xlink:href="halo-20230331.xsd#halo_BulkrHuPH20Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_0f78d280-5b09-4e6f-93d9-aab1f7d761cc" xlink:to="loc_halo_BulkrHuPH20Member_82645d81-54b4-497d-92e5-7103a86aaa05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProprietaryProductsSalesMember_938b52aa-ec81-43b0-9407-c0d575b4bb4f" xlink:href="halo-20230331.xsd#halo_ProprietaryProductsSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_0f78d280-5b09-4e6f-93d9-aab1f7d761cc" xlink:to="loc_halo_ProprietaryProductsSalesMember_938b52aa-ec81-43b0-9407-c0d575b4bb4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevicePartneredProductsMember_39251794-dc02-41e9-9264-73cb2840f2bd" xlink:href="halo-20230331.xsd#halo_DevicePartneredProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_0f78d280-5b09-4e6f-93d9-aab1f7d761cc" xlink:to="loc_halo_DevicePartneredProductsMember_39251794-dc02-41e9-9264-73cb2840f2bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember_bb952b8c-6471-4786-b7da-5ba5bb3ca2ac" xlink:href="halo-20230331.xsd#halo_CollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f80cd44b-871d-4322-863c-d464d196ea81" xlink:to="loc_halo_CollaborativeAgreementsMember_bb952b8c-6471-4786-b7da-5ba5bb3ca2ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_UpfrontfeesMember_207c2fa5-8c52-4a36-95d1-d0a428ca0e8b" xlink:href="halo-20230331.xsd#halo_UpfrontfeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsMember_bb952b8c-6471-4786-b7da-5ba5bb3ca2ac" xlink:to="loc_halo_UpfrontfeesMember_207c2fa5-8c52-4a36-95d1-d0a428ca0e8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevelopmentFeesMember_e0701b8d-736e-4d01-806b-8e9a7598e303" xlink:href="halo-20230331.xsd#halo_DevelopmentFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsMember_bb952b8c-6471-4786-b7da-5ba5bb3ca2ac" xlink:to="loc_halo_DevelopmentFeesMember_e0701b8d-736e-4d01-806b-8e9a7598e303" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_SalesbasedmilestoneMember_a92350ea-8da7-4192-8bb4-51d2ed327410" xlink:href="halo-20230331.xsd#halo_SalesbasedmilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsMember_bb952b8c-6471-4786-b7da-5ba5bb3ca2ac" xlink:to="loc_halo_SalesbasedmilestoneMember_a92350ea-8da7-4192-8bb4-51d2ed327410" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeviceLicensingAndDevelopmentMember_20ff443e-e841-47ef-916f-4f80903e5350" xlink:href="halo-20230331.xsd#halo_DeviceLicensingAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsMember_bb952b8c-6471-4786-b7da-5ba5bb3ca2ac" xlink:to="loc_halo_DeviceLicensingAndDevelopmentMember_20ff443e-e841-47ef-916f-4f80903e5350" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#RevenueNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/RevenueNarrativeDetails" xlink:type="extended" id="ie0e80b9ffc984c99a79015811b9cd500_RevenueNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b87a7558-00db-46e2-87c2-99194be6148f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d554e089-9126-4678-b84b-d4f65488e21e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b87a7558-00db-46e2-87c2-99194be6148f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d554e089-9126-4678-b84b-d4f65488e21e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6b660d65-7eca-42a4-9588-f0f5ca79a09c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b87a7558-00db-46e2-87c2-99194be6148f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6b660d65-7eca-42a4-9588-f0f5ca79a09c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_199d1f97-5a12-46e3-b31a-a4ed51062c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b87a7558-00db-46e2-87c2-99194be6148f" xlink:to="loc_us-gaap_DeferredRevenue_199d1f97-5a12-46e3-b31a-a4ed51062c48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_bdfcdca7-02ee-4be7-9173-4362b4533d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b87a7558-00db-46e2-87c2-99194be6148f" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_bdfcdca7-02ee-4be7-9173-4362b4533d90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_a895ef2a-3dbb-4bfc-89b6-e3676552a68f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b87a7558-00db-46e2-87c2-99194be6148f" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_a895ef2a-3dbb-4bfc-89b6-e3676552a68f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_c6acf4d3-8165-4fde-a312-ed57ee272e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b87a7558-00db-46e2-87c2-99194be6148f" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_c6acf4d3-8165-4fde-a312-ed57ee272e2c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_590d2bb5-8144-4c68-889d-854802acd60d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b87a7558-00db-46e2-87c2-99194be6148f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_590d2bb5-8144-4c68-889d-854802acd60d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d01298bf-b3c5-4862-af64-6fb189d89312" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_590d2bb5-8144-4c68-889d-854802acd60d" xlink:to="loc_srt_ProductOrServiceAxis_d01298bf-b3c5-4862-af64-6fb189d89312" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d01298bf-b3c5-4862-af64-6fb189d89312_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d01298bf-b3c5-4862-af64-6fb189d89312" xlink:to="loc_srt_ProductsAndServicesDomain_d01298bf-b3c5-4862-af64-6fb189d89312_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_679f847d-33a9-41b9-9426-5efbd2789bdb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d01298bf-b3c5-4862-af64-6fb189d89312" xlink:to="loc_srt_ProductsAndServicesDomain_679f847d-33a9-41b9-9426-5efbd2789bdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LicenseFeesAndEventBasedMember_fbcba8c2-154a-4c21-9376-a88a027fc76b" xlink:href="halo-20230331.xsd#halo_LicenseFeesAndEventBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_679f847d-33a9-41b9-9426-5efbd2789bdb" xlink:to="loc_halo_LicenseFeesAndEventBasedMember_fbcba8c2-154a-4c21-9376-a88a027fc76b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3a7bd753-677e-4d56-b39f-592fb5497c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_679f847d-33a9-41b9-9426-5efbd2789bdb" xlink:to="loc_us-gaap_ProductMember_3a7bd753-677e-4d56-b39f-592fb5497c3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_401f592a-8caa-45e0-b696-dbc0067ebd73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_590d2bb5-8144-4c68-889d-854802acd60d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_401f592a-8caa-45e0-b696-dbc0067ebd73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_401f592a-8caa-45e0-b696-dbc0067ebd73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_401f592a-8caa-45e0-b696-dbc0067ebd73" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_401f592a-8caa-45e0-b696-dbc0067ebd73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_323e77e8-4559-401a-9b68-81003cdc6cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_401f592a-8caa-45e0-b696-dbc0067ebd73" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_323e77e8-4559-401a-9b68-81003cdc6cdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OthercollaboratorsMember_d36b6ced-f223-46e2-89a6-975a1b4012c2" xlink:href="halo-20230331.xsd#halo_OthercollaboratorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_323e77e8-4559-401a-9b68-81003cdc6cdb" xlink:to="loc_halo_OthercollaboratorsMember_d36b6ced-f223-46e2-89a6-975a1b4012c2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#RevenueAdditionalRevenueInformationDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails" xlink:type="extended" id="i7a96b5acb18b4eb8bb2599aae5456390_RevenueAdditionalRevenueInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f37db388-3f71-421d-bc27-4105ab6cb346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_889b274f-f142-480d-9938-b6d6a05123fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f37db388-3f71-421d-bc27-4105ab6cb346" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_889b274f-f142-480d-9938-b6d6a05123fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_106b2f84-57ee-4df3-a710-2fef16d976af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f37db388-3f71-421d-bc27-4105ab6cb346" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_106b2f84-57ee-4df3-a710-2fef16d976af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d1625c6e-d742-4332-ae85-9c0153dd61a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f37db388-3f71-421d-bc27-4105ab6cb346" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d1625c6e-d742-4332-ae85-9c0153dd61a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_6c8e9cd0-7885-4442-bea7-b31c4006a8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d1625c6e-d742-4332-ae85-9c0153dd61a7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_6c8e9cd0-7885-4442-bea7-b31c4006a8cb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails_1" xlink:type="simple" xlink:href="halo-20230331.xsd#RevenueAdditionalRevenueInformationDetails_1"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails_1" xlink:type="extended" id="ifd9273bbef4243bdabc698c0fbbcf70d_RevenueAdditionalRevenueInformationDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f37db388-3f71-421d-bc27-4105ab6cb346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_889b274f-f142-480d-9938-b6d6a05123fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f37db388-3f71-421d-bc27-4105ab6cb346" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_889b274f-f142-480d-9938-b6d6a05123fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_106b2f84-57ee-4df3-a710-2fef16d976af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f37db388-3f71-421d-bc27-4105ab6cb346" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_106b2f84-57ee-4df3-a710-2fef16d976af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d1625c6e-d742-4332-ae85-9c0153dd61a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f37db388-3f71-421d-bc27-4105ab6cb346" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d1625c6e-d742-4332-ae85-9c0153dd61a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" xlink:type="extended" id="i88f3d6b0d70745e19fa766732754460d_CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0ca1f0c7-290a-4cf7-b5b4-531693cbd3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_ca857109-b8de-4076-9619-238e285b1d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0ca1f0c7-290a-4cf7-b5b4-531693cbd3d7" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_ca857109-b8de-4076-9619-238e285b1d6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_18c9ff00-445e-4d60-87ff-4afc69760c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0ca1f0c7-290a-4cf7-b5b4-531693cbd3d7" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_18c9ff00-445e-4d60-87ff-4afc69760c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_1a052bd2-2fa0-4e52-88d5-7186898a23af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0ca1f0c7-290a-4cf7-b5b4-531693cbd3d7" xlink:to="loc_us-gaap_OtherAssets_1a052bd2-2fa0-4e52-88d5-7186898a23af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_af0fb129-b172-4610-93d4-29a35ac1ba3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0ca1f0c7-290a-4cf7-b5b4-531693cbd3d7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_af0fb129-b172-4610-93d4-29a35ac1ba3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_04b94550-d482-4ddf-a4f3-7743d29070e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0ca1f0c7-290a-4cf7-b5b4-531693cbd3d7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_04b94550-d482-4ddf-a4f3-7743d29070e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bd142d80-6b2e-4d93-821f-5908903ca41d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0ca1f0c7-290a-4cf7-b5b4-531693cbd3d7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bd142d80-6b2e-4d93-821f-5908903ca41d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6528bc71-f356-413d-a365-a9de24e4e93e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0ca1f0c7-290a-4cf7-b5b4-531693cbd3d7" xlink:to="loc_us-gaap_StatementTable_6528bc71-f356-413d-a365-a9de24e4e93e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_428827cb-553c-44d0-bb9e-998918892b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6528bc71-f356-413d-a365-a9de24e4e93e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_428827cb-553c-44d0-bb9e-998918892b11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_428827cb-553c-44d0-bb9e-998918892b11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_428827cb-553c-44d0-bb9e-998918892b11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_428827cb-553c-44d0-bb9e-998918892b11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7675f8c7-a1c1-4f4f-863d-0f0b497cc3db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_428827cb-553c-44d0-bb9e-998918892b11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7675f8c7-a1c1-4f4f-863d-0f0b497cc3db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ComputerAndOfficeEquipmentMember_18cad97f-4876-4c62-850e-b6c873388f2f" xlink:href="halo-20230331.xsd#halo_ComputerAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7675f8c7-a1c1-4f4f-863d-0f0b497cc3db" xlink:to="loc_halo_ComputerAndOfficeEquipmentMember_18cad97f-4876-4c62-850e-b6c873388f2f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#CertainBalanceSheetItemsPropertyandEquipmentnetDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails" xlink:type="extended" id="icf513a4c82494315bf4029154c439f42_CertainBalanceSheetItemsPropertyandEquipmentnetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79d7b825-5aee-4ca8-b7ec-4515306e6357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_053e5a6a-2387-40e3-86b2-ae4e33083407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79d7b825-5aee-4ca8-b7ec-4515306e6357" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_053e5a6a-2387-40e3-86b2-ae4e33083407" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ebbae123-a794-41b7-9229-27d7c119a605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79d7b825-5aee-4ca8-b7ec-4515306e6357" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ebbae123-a794-41b7-9229-27d7c119a605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b5de3cc4-f972-4491-9f1a-c1381d07e96b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79d7b825-5aee-4ca8-b7ec-4515306e6357" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b5de3cc4-f972-4491-9f1a-c1381d07e96b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b9db2933-8789-4ba6-ad61-29851d038b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79d7b825-5aee-4ca8-b7ec-4515306e6357" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b9db2933-8789-4ba6-ad61-29851d038b16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d5fd8fc3-6f31-46c7-b890-e0a1cd94d9c5" xlink:href="halo-20230331.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79d7b825-5aee-4ca8-b7ec-4515306e6357" xlink:to="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d5fd8fc3-6f31-46c7-b890-e0a1cd94d9c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_59facd8d-5bd1-40b6-9266-f4f4682043dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79d7b825-5aee-4ca8-b7ec-4515306e6357" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_59facd8d-5bd1-40b6-9266-f4f4682043dd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_7d678001-020c-4b6c-a5dd-a940da34e929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79d7b825-5aee-4ca8-b7ec-4515306e6357" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_7d678001-020c-4b6c-a5dd-a940da34e929" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a26415f-7ec7-490c-b402-1650e415f50c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79d7b825-5aee-4ca8-b7ec-4515306e6357" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a26415f-7ec7-490c-b402-1650e415f50c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_be8d2a4a-86f9-4144-925b-f2492aa61a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a26415f-7ec7-490c-b402-1650e415f50c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_be8d2a4a-86f9-4144-925b-f2492aa61a70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be8d2a4a-86f9-4144-925b-f2492aa61a70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_be8d2a4a-86f9-4144-925b-f2492aa61a70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be8d2a4a-86f9-4144-925b-f2492aa61a70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2e5f2061-dc0a-4b42-878e-916c7b111583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_be8d2a4a-86f9-4144-925b-f2492aa61a70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2e5f2061-dc0a-4b42-878e-916c7b111583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ResearchEquipmentMember_02337395-a03f-494f-9db8-e9110cf7c98f" xlink:href="halo-20230331.xsd#halo_ResearchEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2e5f2061-dc0a-4b42-878e-916c7b111583" xlink:to="loc_halo_ResearchEquipmentMember_02337395-a03f-494f-9db8-e9110cf7c98f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ManufacturingEquipmentMember_ab8ca9f1-c65c-4b8b-97a7-fb2e3a5377dd" xlink:href="halo-20230331.xsd#halo_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2e5f2061-dc0a-4b42-878e-916c7b111583" xlink:to="loc_halo_ManufacturingEquipmentMember_ab8ca9f1-c65c-4b8b-97a7-fb2e3a5377dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ComputerAndOfficeEquipmentMember_61449967-62c8-423c-8633-3f47191f0edd" xlink:href="halo-20230331.xsd#halo_ComputerAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2e5f2061-dc0a-4b42-878e-916c7b111583" xlink:to="loc_halo_ComputerAndOfficeEquipmentMember_61449967-62c8-423c-8633-3f47191f0edd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4303a64e-1309-4707-9657-2021ac049315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2e5f2061-dc0a-4b42-878e-916c7b111583" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4303a64e-1309-4707-9657-2021ac049315" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#GoodwillandIntangibleAssetsAdditionalDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails" xlink:type="extended" id="i560d53653c6b4e59a595421be374424f_GoodwillandIntangibleAssetsAdditionalDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_285569da-eb11-4e5d-922c-95af874633b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8290c5ab-3523-4071-a2f0-83a59b47690a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_285569da-eb11-4e5d-922c-95af874633b0" xlink:to="loc_us-gaap_Goodwill_8290c5ab-3523-4071-a2f0-83a59b47690a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4d1a39f5-6c39-4684-8bf7-70c50d858736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_285569da-eb11-4e5d-922c-95af874633b0" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4d1a39f5-6c39-4684-8bf7-70c50d858736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_72f8d08e-af47-491d-847e-c95c6434001b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_285569da-eb11-4e5d-922c-95af874633b0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_72f8d08e-af47-491d-847e-c95c6434001b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4f221024-03fa-4245-b002-3e2e764b7bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_72f8d08e-af47-491d-847e-c95c6434001b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4f221024-03fa-4245-b002-3e2e764b7bbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f221024-03fa-4245-b002-3e2e764b7bbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4f221024-03fa-4245-b002-3e2e764b7bbb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f221024-03fa-4245-b002-3e2e764b7bbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dec2841f-d745-47bb-8a94-4ca24075f5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4f221024-03fa-4245-b002-3e2e764b7bbb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dec2841f-d745-47bb-8a94-4ca24075f5fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_626fc621-fd47-4ac0-a668-f46400dca69b" xlink:href="halo-20230331.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dec2841f-d745-47bb-8a94-4ca24075f5fa" xlink:to="loc_halo_AntaresPharmaIncMember_626fc621-fd47-4ac0-a668-f46400dca69b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6287d22f-4454-4dec-9327-e4a555377d14" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_72f8d08e-af47-491d-847e-c95c6434001b" xlink:to="loc_srt_RangeAxis_6287d22f-4454-4dec-9327-e4a555377d14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6287d22f-4454-4dec-9327-e4a555377d14_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6287d22f-4454-4dec-9327-e4a555377d14" xlink:to="loc_srt_RangeMember_6287d22f-4454-4dec-9327-e4a555377d14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6f5dd027-0bc6-4b24-b2b7-6e8036cfd9d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6287d22f-4454-4dec-9327-e4a555377d14" xlink:to="loc_srt_RangeMember_6f5dd027-0bc6-4b24-b2b7-6e8036cfd9d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_65ec7bd4-7846-4664-8819-12bfa6913047" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6f5dd027-0bc6-4b24-b2b7-6e8036cfd9d1" xlink:to="loc_srt_MinimumMember_65ec7bd4-7846-4664-8819-12bfa6913047" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a4d14237-a4ef-4678-8e80-3e11d8349941" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6f5dd027-0bc6-4b24-b2b7-6e8036cfd9d1" xlink:to="loc_srt_MaximumMember_a4d14237-a4ef-4678-8e80-3e11d8349941" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended" id="i831542d7c0dd450fb5fb80cd37cff7af_GoodwillandIntangibleAssetsIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_56581cea-fb0c-4756-9fee-0f8ceff9f596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_7376c668-7e9d-4d70-8ffe-8cc08b3023e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_56581cea-fb0c-4756-9fee-0f8ceff9f596" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_7376c668-7e9d-4d70-8ffe-8cc08b3023e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e4b44b7a-bb6a-4c67-9ce7-6b252cc66325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_56581cea-fb0c-4756-9fee-0f8ceff9f596" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e4b44b7a-bb6a-4c67-9ce7-6b252cc66325" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3cf35f51-5a07-42db-8b34-7e3d2eb06843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_56581cea-fb0c-4756-9fee-0f8ceff9f596" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3cf35f51-5a07-42db-8b34-7e3d2eb06843" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eec35d2d-7c23-47b0-90c3-653c21fca00c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_56581cea-fb0c-4756-9fee-0f8ceff9f596" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eec35d2d-7c23-47b0-90c3-653c21fca00c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_01c6462f-3f98-41fd-a174-39583b41d169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_56581cea-fb0c-4756-9fee-0f8ceff9f596" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_01c6462f-3f98-41fd-a174-39583b41d169" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0f886ce4-1f8c-4ca3-9986-79a35ee8ad46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_56581cea-fb0c-4756-9fee-0f8ceff9f596" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0f886ce4-1f8c-4ca3-9986-79a35ee8ad46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_87346687-eb72-4f86-8335-d7058dfac932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_56581cea-fb0c-4756-9fee-0f8ceff9f596" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_87346687-eb72-4f86-8335-d7058dfac932" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_14992bc4-7967-43b2-8eab-53ae94ba368f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_87346687-eb72-4f86-8335-d7058dfac932" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_14992bc4-7967-43b2-8eab-53ae94ba368f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_14992bc4-7967-43b2-8eab-53ae94ba368f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_14992bc4-7967-43b2-8eab-53ae94ba368f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_14992bc4-7967-43b2-8eab-53ae94ba368f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4387abb1-c096-4a44-b566-b89377ff9ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_14992bc4-7967-43b2-8eab-53ae94ba368f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4387abb1-c096-4a44-b566-b89377ff9ec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AutoInjectorTechnologyPlatformMember_c537d319-cc8a-495c-bdc3-8b899cc96d1e" xlink:href="halo-20230331.xsd#halo_AutoInjectorTechnologyPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4387abb1-c096-4a44-b566-b89377ff9ec2" xlink:to="loc_halo_AutoInjectorTechnologyPlatformMember_c537d319-cc8a-495c-bdc3-8b899cc96d1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_XYOSTEDProprietaryProductMember_404c67e1-8df6-4927-8972-32417cac035a" xlink:href="halo-20230331.xsd#halo_XYOSTEDProprietaryProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4387abb1-c096-4a44-b566-b89377ff9ec2" xlink:to="loc_halo_XYOSTEDProprietaryProductMember_404c67e1-8df6-4927-8972-32417cac035a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TLANDOProductRightsMember_b77d06fb-273f-4778-aceb-3489366682d6" xlink:href="halo-20230331.xsd#halo_TLANDOProductRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4387abb1-c096-4a44-b566-b89377ff9ec2" xlink:to="loc_halo_TLANDOProductRightsMember_b77d06fb-273f-4778-aceb-3489366682d6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#LongTermDebtNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails" xlink:type="extended" id="id960008d749648ebbcfa828e23d7b70c_LongTermDebtNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36f435d2-67cd-415d-8317-9f000630a6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36f435d2-67cd-415d-8317-9f000630a6ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fdb6cb6e-3aaa-4901-95f9-eed4910a5aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fdb6cb6e-3aaa-4901-95f9-eed4910a5aee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_4576cf3e-ad52-4950-9a5c-019d93a741ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_4576cf3e-ad52-4950-9a5c-019d93a741ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_5b18901f-aa2b-4dab-b918-afefdaf91bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_5b18901f-aa2b-4dab-b918-afefdaf91bd7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3699909e-7127-48fd-8e9a-d50b4cb27323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3699909e-7127-48fd-8e9a-d50b4cb27323" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_c0925f67-2807-4fad-8fc7-ea39b681e8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_c0925f67-2807-4fad-8fc7-ea39b681e8a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_be24a0a4-b039-4ad9-a6bd-15342100105f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_be24a0a4-b039-4ad9-a6bd-15342100105f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2a851b97-033c-4c56-bc0a-2ee89e7ee85a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2a851b97-033c-4c56-bc0a-2ee89e7ee85a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_daf6e700-b11f-4f84-84e0-a74de15e630b" xlink:href="halo-20230331.xsd#halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_daf6e700-b11f-4f84-84e0-a74de15e630b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_0ad8468e-7b29-409c-8e62-4d375b701d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_0ad8468e-7b29-409c-8e62-4d375b701d94" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_329cf5e9-f2bd-44ab-94b1-050a40497c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_329cf5e9-f2bd-44ab-94b1-050a40497c8c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentCapCallTransactionCapPricePerShare_e7bae0cb-fe44-4a2a-afa3-0384f1c7d275" xlink:href="halo-20230331.xsd#halo_DebtInstrumentCapCallTransactionCapPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_halo_DebtInstrumentCapCallTransactionCapPricePerShare_e7bae0cb-fe44-4a2a-afa3-0384f1c7d275" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_5405a6e2-8732-4843-833c-148b1623ed0e" xlink:href="halo-20230331.xsd#halo_SaleOfStockPremiumOverLastReportedSalePricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_5405a6e2-8732-4843-833c-148b1623ed0e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b945437d-5fb9-4648-9d8f-4a74381c7437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b945437d-5fb9-4648-9d8f-4a74381c7437" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PaymentForCappedCallTransactions_26bf8e23-136e-484d-a52e-e40865d4903f" xlink:href="halo-20230331.xsd#halo_PaymentForCappedCallTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_halo_PaymentForCappedCallTransactions_26bf8e23-136e-484d-a52e-e40865d4903f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_00a25dd6-74b5-4992-954a-6bbfcb817f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_00a25dd6-74b5-4992-954a-6bbfcb817f68" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_fc6ea165-3647-4beb-85e7-84eb5578e8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_fc6ea165-3647-4beb-85e7-84eb5578e8d9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_cc1a0463-8414-4c89-bfeb-45293e95ff20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_cc1a0463-8414-4c89-bfeb-45293e95ff20" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_5f2a50f6-b3d6-42ed-82d9-b6992c10fd86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_5f2a50f6-b3d6-42ed-82d9-b6992c10fd86" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f4aaae3f-37a7-4c66-88ed-beb1405bb379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f4aaae3f-37a7-4c66-88ed-beb1405bb379" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_3acfd785-4320-4703-8811-7e98bfbd7f47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_3acfd785-4320-4703-8811-7e98bfbd7f47" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_16d28c83-c143-4d77-a176-2e6791f2a411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_16d28c83-c143-4d77-a176-2e6791f2a411" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_b6e51940-eab0-4f23-9d8c-f1a3baec85ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_b6e51940-eab0-4f23-9d8c-f1a3baec85ec" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_deed3915-03ae-4574-a9bc-b5e90488dadb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_deed3915-03ae-4574-a9bc-b5e90488dadb" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_dc6dc408-b384-426e-9833-236024dae4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_dc6dc408-b384-426e-9833-236024dae4b2" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_db4b4e19-1b85-4271-93bb-acba9f11fccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:to="loc_us-gaap_DebtInstrumentAxis_db4b4e19-1b85-4271-93bb-acba9f11fccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_db4b4e19-1b85-4271-93bb-acba9f11fccf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_db4b4e19-1b85-4271-93bb-acba9f11fccf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_db4b4e19-1b85-4271-93bb-acba9f11fccf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_25b40c46-cfa2-410e-aa60-51a12019de00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_db4b4e19-1b85-4271-93bb-acba9f11fccf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_25b40c46-cfa2-410e-aa60-51a12019de00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member_34835781-4caf-49fe-ab18-ac3541c1000e" xlink:href="halo-20230331.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25b40c46-cfa2-410e-aa60-51a12019de00" xlink:to="loc_halo_A100ConvertibleSeniorNotesDue2028Member_34835781-4caf-49fe-ab18-ac3541c1000e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_a90663d3-e167-4552-a996-16bddb6ec717" xlink:href="halo-20230331.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25b40c46-cfa2-410e-aa60-51a12019de00" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_a90663d3-e167-4552-a996-16bddb6ec717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_44f42410-8eb1-49c7-bc6d-5ffa60823f9e" xlink:href="halo-20230331.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25b40c46-cfa2-410e-aa60-51a12019de00" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_44f42410-8eb1-49c7-bc6d-5ffa60823f9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CreditAgreementMember_6356c93e-3965-44a1-bb8f-f28b54c78cd3" xlink:href="halo-20230331.xsd#halo_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25b40c46-cfa2-410e-aa60-51a12019de00" xlink:to="loc_halo_CreditAgreementMember_6356c93e-3965-44a1-bb8f-f28b54c78cd3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_183b6b71-21b7-4254-9920-193dec8ad658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_183b6b71-21b7-4254-9920-193dec8ad658" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_183b6b71-21b7-4254-9920-193dec8ad658_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_183b6b71-21b7-4254-9920-193dec8ad658" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_183b6b71-21b7-4254-9920-193dec8ad658_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_58942cdc-c400-40f0-a393-163201884986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_183b6b71-21b7-4254-9920-193dec8ad658" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_58942cdc-c400-40f0-a393-163201884986" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_3cbb72c5-5f0c-4278-ac61-cbee14601037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_58942cdc-c400-40f0-a393-163201884986" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_3cbb72c5-5f0c-4278-ac61-cbee14601037" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_5e477687-aaeb-4489-87a2-dc70d7244589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_58942cdc-c400-40f0-a393-163201884986" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_5e477687-aaeb-4489-87a2-dc70d7244589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9140de34-282a-4da7-bc4a-11a198cca7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9140de34-282a-4da7-bc4a-11a198cca7e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9140de34-282a-4da7-bc4a-11a198cca7e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9140de34-282a-4da7-bc4a-11a198cca7e3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9140de34-282a-4da7-bc4a-11a198cca7e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_57bc2de4-0fe6-4646-9d19-af97f6a932cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9140de34-282a-4da7-bc4a-11a198cca7e3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_57bc2de4-0fe6-4646-9d19-af97f6a932cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_52c63fd5-1d46-417e-a9c9-c7b455cf6345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_57bc2de4-0fe6-4646-9d19-af97f6a932cf" xlink:to="loc_us-gaap_ConvertibleDebtMember_52c63fd5-1d46-417e-a9c9-c7b455cf6345" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_6cae7ce7-5721-4e93-a178-6ca4d1ba759c" xlink:href="halo-20230331.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_57bc2de4-0fe6-4646-9d19-af97f6a932cf" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_6cae7ce7-5721-4e93-a178-6ca4d1ba759c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TermLoanFacilityMember_7e5c5323-65ff-4bc9-b3a7-31b8c5edf2bc" xlink:href="halo-20230331.xsd#halo_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_57bc2de4-0fe6-4646-9d19-af97f6a932cf" xlink:to="loc_halo_TermLoanFacilityMember_7e5c5323-65ff-4bc9-b3a7-31b8c5edf2bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_36bafc1c-1eac-4337-ae3d-b3c9ffa78840" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:to="loc_srt_RangeAxis_36bafc1c-1eac-4337-ae3d-b3c9ffa78840" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_36bafc1c-1eac-4337-ae3d-b3c9ffa78840_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_36bafc1c-1eac-4337-ae3d-b3c9ffa78840" xlink:to="loc_srt_RangeMember_36bafc1c-1eac-4337-ae3d-b3c9ffa78840_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1b136e43-13b0-4463-9dc9-564c68ba684c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_36bafc1c-1eac-4337-ae3d-b3c9ffa78840" xlink:to="loc_srt_RangeMember_1b136e43-13b0-4463-9dc9-564c68ba684c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_afe5dc67-e7c9-46ba-ab5a-1a5931b02383" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1b136e43-13b0-4463-9dc9-564c68ba684c" xlink:to="loc_srt_MinimumMember_afe5dc67-e7c9-46ba-ab5a-1a5931b02383" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_38d5091d-e7e6-4c75-b0c9-2f61ac5a2205" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1b136e43-13b0-4463-9dc9-564c68ba684c" xlink:to="loc_srt_MaximumMember_38d5091d-e7e6-4c75-b0c9-2f61ac5a2205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_189cf13c-fc37-4e43-a470-d3c45a13edd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:to="loc_us-gaap_VariableRateAxis_189cf13c-fc37-4e43-a470-d3c45a13edd7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_189cf13c-fc37-4e43-a470-d3c45a13edd7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_189cf13c-fc37-4e43-a470-d3c45a13edd7" xlink:to="loc_us-gaap_VariableRateDomain_189cf13c-fc37-4e43-a470-d3c45a13edd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7875bda9-4797-456a-9d0d-238da55f9881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_189cf13c-fc37-4e43-a470-d3c45a13edd7" xlink:to="loc_us-gaap_VariableRateDomain_7875bda9-4797-456a-9d0d-238da55f9881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_abca0c93-f289-4424-b34c-55d977b5b7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_7875bda9-4797-456a-9d0d-238da55f9881" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_abca0c93-f289-4424-b34c-55d977b5b7c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_31fe183f-a706-4fa2-a200-fc44ec99f3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_7875bda9-4797-456a-9d0d-238da55f9881" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_31fe183f-a706-4fa2-a200-fc44ec99f3ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_51e39d75-4564-4e2a-a55c-be165f187d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_7875bda9-4797-456a-9d0d-238da55f9881" xlink:to="loc_us-gaap_BaseRateMember_51e39d75-4564-4e2a-a55c-be165f187d25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_1ff66883-5283-4420-99bc-6954777d399c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:to="loc_us-gaap_CreditFacilityAxis_1ff66883-5283-4420-99bc-6954777d399c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1ff66883-5283-4420-99bc-6954777d399c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1ff66883-5283-4420-99bc-6954777d399c" xlink:to="loc_us-gaap_CreditFacilityDomain_1ff66883-5283-4420-99bc-6954777d399c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ac0254b9-6d61-4d69-b65c-c2c1b58c693f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1ff66883-5283-4420-99bc-6954777d399c" xlink:to="loc_us-gaap_CreditFacilityDomain_ac0254b9-6d61-4d69-b65c-c2c1b58c693f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_2c7aa166-fba7-4b30-8687-18c701f26e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_ac0254b9-6d61-4d69-b65c-c2c1b58c693f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_2c7aa166-fba7-4b30-8687-18c701f26e2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodAxis_c6e890e5-da34-47ae-b383-25b6c403f9a2" xlink:href="halo-20230331.xsd#halo_AnnualInterestPaymentPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:to="loc_halo_AnnualInterestPaymentPeriodAxis_c6e890e5-da34-47ae-b383-25b6c403f9a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodDomain_c6e890e5-da34-47ae-b383-25b6c403f9a2_default" xlink:href="halo-20230331.xsd#halo_AnnualInterestPaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_halo_AnnualInterestPaymentPeriodAxis_c6e890e5-da34-47ae-b383-25b6c403f9a2" xlink:to="loc_halo_AnnualInterestPaymentPeriodDomain_c6e890e5-da34-47ae-b383-25b6c403f9a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodDomain_bb8a62b1-d970-44c8-8620-4bf37da30190" xlink:href="halo-20230331.xsd#halo_AnnualInterestPaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_halo_AnnualInterestPaymentPeriodAxis_c6e890e5-da34-47ae-b383-25b6c403f9a2" xlink:to="loc_halo_AnnualInterestPaymentPeriodDomain_bb8a62b1-d970-44c8-8620-4bf37da30190" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodOneMember_e1cbe51d-d200-40bc-92b0-14a83386a0e5" xlink:href="halo-20230331.xsd#halo_DebtInstrumentInterestPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_bb8a62b1-d970-44c8-8620-4bf37da30190" xlink:to="loc_halo_DebtInstrumentInterestPeriodOneMember_e1cbe51d-d200-40bc-92b0-14a83386a0e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodTwoMember_8f12ea78-f7de-40f9-8380-18543cc2a678" xlink:href="halo-20230331.xsd#halo_DebtInstrumentInterestPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_bb8a62b1-d970-44c8-8620-4bf37da30190" xlink:to="loc_halo_DebtInstrumentInterestPeriodTwoMember_8f12ea78-f7de-40f9-8380-18543cc2a678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodThreeMember_110a6e19-3fd9-40df-8956-63620b9c0f85" xlink:href="halo-20230331.xsd#halo_DebtInstrumentInterestPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_bb8a62b1-d970-44c8-8620-4bf37da30190" xlink:to="loc_halo_DebtInstrumentInterestPeriodThreeMember_110a6e19-3fd9-40df-8956-63620b9c0f85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodFourMember_0fa4131b-cb3b-4fbd-a7b5-0b2916d172c7" xlink:href="halo-20230331.xsd#halo_DebtInstrumentInterestPeriodFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_bb8a62b1-d970-44c8-8620-4bf37da30190" xlink:to="loc_halo_DebtInstrumentInterestPeriodFourMember_0fa4131b-cb3b-4fbd-a7b5-0b2916d172c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentAxis_bf544222-e65f-49c4-aa3d-7cb864f7bcdc" xlink:href="halo-20230331.xsd#halo_VariableRateComponentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:to="loc_halo_VariableRateComponentAxis_bf544222-e65f-49c4-aa3d-7cb864f7bcdc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentDomain_bf544222-e65f-49c4-aa3d-7cb864f7bcdc_default" xlink:href="halo-20230331.xsd#halo_VariableRateComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_halo_VariableRateComponentAxis_bf544222-e65f-49c4-aa3d-7cb864f7bcdc" xlink:to="loc_halo_VariableRateComponentDomain_bf544222-e65f-49c4-aa3d-7cb864f7bcdc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentDomain_b2c99a77-b9e0-4052-bea2-8c794f26fa3f" xlink:href="halo-20230331.xsd#halo_VariableRateComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_halo_VariableRateComponentAxis_bf544222-e65f-49c4-aa3d-7cb864f7bcdc" xlink:to="loc_halo_VariableRateComponentDomain_b2c99a77-b9e0-4052-bea2-8c794f26fa3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentOneMember_698e4984-287a-4680-a35f-f5418c132b33" xlink:href="halo-20230331.xsd#halo_VariableRateComponentOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_VariableRateComponentDomain_b2c99a77-b9e0-4052-bea2-8c794f26fa3f" xlink:to="loc_halo_VariableRateComponentOneMember_698e4984-287a-4680-a35f-f5418c132b33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentTwoMember_603d72c8-56d9-4494-929d-6e89a9fe8434" xlink:href="halo-20230331.xsd#halo_VariableRateComponentTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_VariableRateComponentDomain_b2c99a77-b9e0-4052-bea2-8c794f26fa3f" xlink:to="loc_halo_VariableRateComponentTwoMember_603d72c8-56d9-4494-929d-6e89a9fe8434" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#LongTermDebtNetCarryingAmountofConvertibleNotesDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails" xlink:type="extended" id="ib367cf60863e488a9b2317a7b64a19a8_LongTermDebtNetCarryingAmountofConvertibleNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6519217f-b7fe-4354-a6ef-c40e0a3fd6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fe76a1cb-9485-40e5-bad1-1fe9137f6519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6519217f-b7fe-4354-a6ef-c40e0a3fd6ab" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fe76a1cb-9485-40e5-bad1-1fe9137f6519" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_266fe398-c91e-412e-874e-a2734931ff63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6519217f-b7fe-4354-a6ef-c40e0a3fd6ab" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_266fe398-c91e-412e-874e-a2734931ff63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_88e9fbe8-578b-41e6-89f1-cde56befb145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6519217f-b7fe-4354-a6ef-c40e0a3fd6ab" xlink:to="loc_us-gaap_LongTermDebtCurrent_88e9fbe8-578b-41e6-89f1-cde56befb145" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_97040b99-fe0b-40a5-84f6-718d15bb9498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6519217f-b7fe-4354-a6ef-c40e0a3fd6ab" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_97040b99-fe0b-40a5-84f6-718d15bb9498" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b0103be9-d661-4df7-946d-79862156011d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6519217f-b7fe-4354-a6ef-c40e0a3fd6ab" xlink:to="loc_us-gaap_LongTermDebt_b0103be9-d661-4df7-946d-79862156011d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_cf9b3288-eae9-4960-9bc7-665a02dd6c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6519217f-b7fe-4354-a6ef-c40e0a3fd6ab" xlink:to="loc_us-gaap_DebtInstrumentFairValue_cf9b3288-eae9-4960-9bc7-665a02dd6c8a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_34579582-549b-41c7-af5d-7ddc3a2b3128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6519217f-b7fe-4354-a6ef-c40e0a3fd6ab" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_34579582-549b-41c7-af5d-7ddc3a2b3128" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_55b1b0fb-de3a-4165-a943-5cafbe3f1ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6519217f-b7fe-4354-a6ef-c40e0a3fd6ab" xlink:to="loc_us-gaap_DebtInstrumentTable_55b1b0fb-de3a-4165-a943-5cafbe3f1ba7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_90699959-ef11-4e47-baca-d0a1e4ead923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_55b1b0fb-de3a-4165-a943-5cafbe3f1ba7" xlink:to="loc_us-gaap_DebtInstrumentAxis_90699959-ef11-4e47-baca-d0a1e4ead923" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_90699959-ef11-4e47-baca-d0a1e4ead923_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_90699959-ef11-4e47-baca-d0a1e4ead923" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_90699959-ef11-4e47-baca-d0a1e4ead923_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dbea2308-45cc-4dbd-a4e0-ee13094ef655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_90699959-ef11-4e47-baca-d0a1e4ead923" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dbea2308-45cc-4dbd-a4e0-ee13094ef655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_4971527b-cc70-44f5-a321-abeebf693cae" xlink:href="halo-20230331.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbea2308-45cc-4dbd-a4e0-ee13094ef655" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_4971527b-cc70-44f5-a321-abeebf693cae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_19252e69-c483-4a31-8cb5-85f1688fb99b" xlink:href="halo-20230331.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbea2308-45cc-4dbd-a4e0-ee13094ef655" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_19252e69-c483-4a31-8cb5-85f1688fb99b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member_7114d8fe-354d-4d36-a83a-243790ce061a" xlink:href="halo-20230331.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbea2308-45cc-4dbd-a4e0-ee13094ef655" xlink:to="loc_halo_A100ConvertibleSeniorNotesDue2028Member_7114d8fe-354d-4d36-a83a-243790ce061a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#LongTermDebtNetComponentsofInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails" xlink:type="extended" id="i52bc99664aeb4bbaa653f690639403c2_LongTermDebtNetComponentsofInterestExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7c4a723e-c4ae-4458-9a53-a25213d3b637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_c8b5bdef-e8c1-43aa-b020-925bbe253a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7c4a723e-c4ae-4458-9a53-a25213d3b637" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_c8b5bdef-e8c1-43aa-b020-925bbe253a81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_13a8f0d9-c6bd-4bae-a7b2-6d706640c536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7c4a723e-c4ae-4458-9a53-a25213d3b637" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_13a8f0d9-c6bd-4bae-a7b2-6d706640c536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_6118085f-176a-495b-8d07-44032460ecda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7c4a723e-c4ae-4458-9a53-a25213d3b637" xlink:to="loc_us-gaap_InterestExpenseDebt_6118085f-176a-495b-8d07-44032460ecda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_ef3dce4c-df79-4819-8ca9-061c83116ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7c4a723e-c4ae-4458-9a53-a25213d3b637" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_ef3dce4c-df79-4819-8ca9-061c83116ba8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_adacaa54-0110-4b14-8852-821899cee7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7c4a723e-c4ae-4458-9a53-a25213d3b637" xlink:to="loc_us-gaap_DebtInstrumentTable_adacaa54-0110-4b14-8852-821899cee7ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6a2962df-3477-4dde-99a1-9fbc135de590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_adacaa54-0110-4b14-8852-821899cee7ff" xlink:to="loc_us-gaap_DebtInstrumentAxis_6a2962df-3477-4dde-99a1-9fbc135de590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6a2962df-3477-4dde-99a1-9fbc135de590_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6a2962df-3477-4dde-99a1-9fbc135de590" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6a2962df-3477-4dde-99a1-9fbc135de590_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b72347e9-2457-452c-be3a-0034a84bfabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6a2962df-3477-4dde-99a1-9fbc135de590" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b72347e9-2457-452c-be3a-0034a84bfabd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_3092f159-a28d-4e2a-8060-59cca84d3b5a" xlink:href="halo-20230331.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b72347e9-2457-452c-be3a-0034a84bfabd" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_3092f159-a28d-4e2a-8060-59cca84d3b5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_9729f3e2-f047-4998-9957-38c58585001b" xlink:href="halo-20230331.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b72347e9-2457-452c-be3a-0034a84bfabd" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_9729f3e2-f047-4998-9957-38c58585001b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member_744a4234-53e3-4c49-a2bb-5b35e541873c" xlink:href="halo-20230331.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b72347e9-2457-452c-be3a-0034a84bfabd" xlink:to="loc_halo_A100ConvertibleSeniorNotesDue2028Member_744a4234-53e3-4c49-a2bb-5b35e541873c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cbd6f2e7-e67e-4ac5-aa0a-95624805121e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_adacaa54-0110-4b14-8852-821899cee7ff" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cbd6f2e7-e67e-4ac5-aa0a-95624805121e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cbd6f2e7-e67e-4ac5-aa0a-95624805121e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cbd6f2e7-e67e-4ac5-aa0a-95624805121e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cbd6f2e7-e67e-4ac5-aa0a-95624805121e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d96cf275-b742-4c32-8d02-af864f0b6079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cbd6f2e7-e67e-4ac5-aa0a-95624805121e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d96cf275-b742-4c32-8d02-af864f0b6079" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_081ce9c3-d2b4-42e2-bffa-629b53601015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d96cf275-b742-4c32-8d02-af864f0b6079" xlink:to="loc_us-gaap_ConvertibleDebtMember_081ce9c3-d2b4-42e2-bffa-629b53601015" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#SharebasedCompensationSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails" xlink:type="extended" id="ia13ea77cafd642e7af07c73efbaa5498_SharebasedCompensationSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_90921ba3-cf47-4e95-a2e9-3500e7dba21c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_48a9c61f-0253-490a-8fc7-46b45144cb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_90921ba3-cf47-4e95-a2e9-3500e7dba21c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_48a9c61f-0253-490a-8fc7-46b45144cb4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_546004c9-da90-4ee4-9532-0838e9ed42e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_90921ba3-cf47-4e95-a2e9-3500e7dba21c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_546004c9-da90-4ee4-9532-0838e9ed42e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f3419ee3-0331-49ac-8e60-dcbce9a5414b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_546004c9-da90-4ee4-9532-0838e9ed42e8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f3419ee3-0331-49ac-8e60-dcbce9a5414b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f3419ee3-0331-49ac-8e60-dcbce9a5414b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f3419ee3-0331-49ac-8e60-dcbce9a5414b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f3419ee3-0331-49ac-8e60-dcbce9a5414b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8f91af6d-c794-44f0-98ff-63b188da5566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f3419ee3-0331-49ac-8e60-dcbce9a5414b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8f91af6d-c794-44f0-98ff-63b188da5566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_516fdf55-da9e-4c0b-ab72-9fc8d200c3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8f91af6d-c794-44f0-98ff-63b188da5566" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_516fdf55-da9e-4c0b-ab72-9fc8d200c3fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_36a9e418-94af-43d5-a992-0a37d918b0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8f91af6d-c794-44f0-98ff-63b188da5566" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_36a9e418-94af-43d5-a992-0a37d918b0ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2047cfe3-6dd9-4102-a5d0-824e33737f31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_546004c9-da90-4ee4-9532-0838e9ed42e8" xlink:to="loc_us-gaap_AwardTypeAxis_2047cfe3-6dd9-4102-a5d0-824e33737f31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2047cfe3-6dd9-4102-a5d0-824e33737f31_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2047cfe3-6dd9-4102-a5d0-824e33737f31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2047cfe3-6dd9-4102-a5d0-824e33737f31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f5d29ff-50cd-4ed3-adc8-77c5fc2c37ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2047cfe3-6dd9-4102-a5d0-824e33737f31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f5d29ff-50cd-4ed3-adc8-77c5fc2c37ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_159c7b7f-957f-448d-95e5-b5c58ad32b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f5d29ff-50cd-4ed3-adc8-77c5fc2c37ba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_159c7b7f-957f-448d-95e5-b5c58ad32b46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember_fce3b7fc-1ae3-497c-883d-47a7d98e6e02" xlink:href="halo-20230331.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f5d29ff-50cd-4ed3-adc8-77c5fc2c37ba" xlink:to="loc_halo_RSURSAandPRSUawardsMember_fce3b7fc-1ae3-497c-883d-47a7d98e6e02" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#SharebasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails" xlink:type="extended" id="i31d8f851fed348259ad20c48fa7ee267_SharebasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa76e760-10da-4341-b860-f8fac7c6e812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c05a0137-33c3-4777-a45d-76bef52bd87e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa76e760-10da-4341-b860-f8fac7c6e812" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c05a0137-33c3-4777-a45d-76bef52bd87e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_40402d99-8a03-4586-b4c0-35dfb784824c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa76e760-10da-4341-b860-f8fac7c6e812" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_40402d99-8a03-4586-b4c0-35dfb784824c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_e123a824-d984-42da-a4e7-9da407c1e13b" xlink:href="halo-20230331.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa76e760-10da-4341-b860-f8fac7c6e812" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_e123a824-d984-42da-a4e7-9da407c1e13b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_a10bf97a-1649-4baf-8bd1-e0270c0e7d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa76e760-10da-4341-b860-f8fac7c6e812" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_a10bf97a-1649-4baf-8bd1-e0270c0e7d67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_5b30830c-2197-45a7-85ae-7aaf35bb0092" xlink:href="halo-20230331.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa76e760-10da-4341-b860-f8fac7c6e812" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_5b30830c-2197-45a7-85ae-7aaf35bb0092" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8722d938-5cc0-45c2-98a3-dee8a316e3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa76e760-10da-4341-b860-f8fac7c6e812" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8722d938-5cc0-45c2-98a3-dee8a316e3a5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_368dcc7e-2d71-4c7c-931a-708b5f3b11f3" xlink:href="halo-20230331.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa76e760-10da-4341-b860-f8fac7c6e812" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_368dcc7e-2d71-4c7c-931a-708b5f3b11f3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a3656a9-895a-452d-ba0c-3c3265d8cb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa76e760-10da-4341-b860-f8fac7c6e812" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a3656a9-895a-452d-ba0c-3c3265d8cb1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_92a7b95c-c9d9-408a-a130-24dbcb51c19e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a3656a9-895a-452d-ba0c-3c3265d8cb1e" xlink:to="loc_us-gaap_AwardTypeAxis_92a7b95c-c9d9-408a-a130-24dbcb51c19e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92a7b95c-c9d9-408a-a130-24dbcb51c19e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_92a7b95c-c9d9-408a-a130-24dbcb51c19e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92a7b95c-c9d9-408a-a130-24dbcb51c19e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd0bf22c-de7d-401d-8038-99b139e60340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_92a7b95c-c9d9-408a-a130-24dbcb51c19e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd0bf22c-de7d-401d-8038-99b139e60340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_14c844a5-f5fb-42de-a3e9-c7442061d207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd0bf22c-de7d-401d-8038-99b139e60340" xlink:to="loc_us-gaap_EmployeeStockOptionMember_14c844a5-f5fb-42de-a3e9-c7442061d207" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember_0b9494ff-284b-4ebc-8535-8020135a3fee" xlink:href="halo-20230331.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd0bf22c-de7d-401d-8038-99b139e60340" xlink:to="loc_halo_RSURSAandPRSUawardsMember_0b9494ff-284b-4ebc-8535-8020135a3fee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a0c5ea01-9664-4b92-b4ae-0c66cb932f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd0bf22c-de7d-401d-8038-99b139e60340" xlink:to="loc_us-gaap_EmployeeStockMember_a0c5ea01-9664-4b92-b4ae-0c66cb932f86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a2e02124-2325-4e13-abe9-a1140d086a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a3656a9-895a-452d-ba0c-3c3265d8cb1e" xlink:to="loc_us-gaap_PlanNameAxis_a2e02124-2325-4e13-abe9-a1140d086a7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a2e02124-2325-4e13-abe9-a1140d086a7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_a2e02124-2325-4e13-abe9-a1140d086a7e" xlink:to="loc_us-gaap_PlanNameDomain_a2e02124-2325-4e13-abe9-a1140d086a7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_186cb3e3-40de-4db1-8c18-d94567f532c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_a2e02124-2325-4e13-abe9-a1140d086a7e" xlink:to="loc_us-gaap_PlanNameDomain_186cb3e3-40de-4db1-8c18-d94567f532c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2021ESPPPlanMember_5cad7b96-bfe6-46f0-b372-a413ca418294" xlink:href="halo-20230331.xsd#halo_A2021ESPPPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_186cb3e3-40de-4db1-8c18-d94567f532c9" xlink:to="loc_halo_A2021ESPPPlanMember_5cad7b96-bfe6-46f0-b372-a413ca418294" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails" xlink:type="extended" id="icc8f65b8b8b74c2a8acb0d6db8baefff_SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails">
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_38ef9a57-f851-416c-be68-69e62e5ecdd6" xlink:href="halo-20230331.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_622d0e10-411d-4945-91b1-40001edebff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_38ef9a57-f851-416c-be68-69e62e5ecdd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_622d0e10-411d-4945-91b1-40001edebff7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9219312f-66e1-4411-aed9-d6252e4c3e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_38ef9a57-f851-416c-be68-69e62e5ecdd6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9219312f-66e1-4411-aed9-d6252e4c3e7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_298834ea-dfe0-4f1f-a8ea-bbba8920728a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_38ef9a57-f851-416c-be68-69e62e5ecdd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_298834ea-dfe0-4f1f-a8ea-bbba8920728a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a4f277c1-32a7-49cd-82fd-7df379b9a7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_38ef9a57-f851-416c-be68-69e62e5ecdd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a4f277c1-32a7-49cd-82fd-7df379b9a7b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_485e29d5-4fc6-4cea-a2c1-53a443413b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_38ef9a57-f851-416c-be68-69e62e5ecdd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_485e29d5-4fc6-4cea-a2c1-53a443413b42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_e2ed7581-b191-44a7-a0d8-15a1e0ebc095" xlink:href="halo-20230331.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_38ef9a57-f851-416c-be68-69e62e5ecdd6" xlink:to="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_e2ed7581-b191-44a7-a0d8-15a1e0ebc095" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bfc61a6a-18f3-42a8-ae19-dc42d8fb901f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_e2ed7581-b191-44a7-a0d8-15a1e0ebc095" xlink:to="loc_srt_RangeAxis_bfc61a6a-18f3-42a8-ae19-dc42d8fb901f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bfc61a6a-18f3-42a8-ae19-dc42d8fb901f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bfc61a6a-18f3-42a8-ae19-dc42d8fb901f" xlink:to="loc_srt_RangeMember_bfc61a6a-18f3-42a8-ae19-dc42d8fb901f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ad920f7c-782c-4311-ba53-47c53c02a9b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bfc61a6a-18f3-42a8-ae19-dc42d8fb901f" xlink:to="loc_srt_RangeMember_ad920f7c-782c-4311-ba53-47c53c02a9b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3a134250-ae9b-4b9e-aed5-7ac9eaf3c239" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ad920f7c-782c-4311-ba53-47c53c02a9b0" xlink:to="loc_srt_MinimumMember_3a134250-ae9b-4b9e-aed5-7ac9eaf3c239" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_34d68ae3-1e7c-4d9c-b115-6f43167b6cc0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ad920f7c-782c-4311-ba53-47c53c02a9b0" xlink:to="loc_srt_MaximumMember_34d68ae3-1e7c-4d9c-b115-6f43167b6cc0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails" xlink:type="extended" id="idc93ed1354ad4f2d9c4b38cbbc1348cd_SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40dbca22-08d8-4c01-815e-65354cf4e4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_84cc2945-c95c-4717-bfe4-36075e776d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40dbca22-08d8-4c01-815e-65354cf4e4c4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_84cc2945-c95c-4717-bfe4-36075e776d78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b7469df6-530b-4cb2-bff4-cd83e61befa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40dbca22-08d8-4c01-815e-65354cf4e4c4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b7469df6-530b-4cb2-bff4-cd83e61befa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53a22764-ec24-41b1-8275-8ba910157f18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40dbca22-08d8-4c01-815e-65354cf4e4c4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53a22764-ec24-41b1-8275-8ba910157f18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6f6b135d-d3c7-44b7-b233-7c3216eec657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53a22764-ec24-41b1-8275-8ba910157f18" xlink:to="loc_us-gaap_AwardTypeAxis_6f6b135d-d3c7-44b7-b233-7c3216eec657" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f6b135d-d3c7-44b7-b233-7c3216eec657_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6f6b135d-d3c7-44b7-b233-7c3216eec657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f6b135d-d3c7-44b7-b233-7c3216eec657_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e7df95a-efa2-4873-8a7e-82e175b18902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6f6b135d-d3c7-44b7-b233-7c3216eec657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e7df95a-efa2-4873-8a7e-82e175b18902" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_78a4eaf0-b289-4032-bac4-5c4f4b1b6692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e7df95a-efa2-4873-8a7e-82e175b18902" xlink:to="loc_us-gaap_EmployeeStockOptionMember_78a4eaf0-b289-4032-bac4-5c4f4b1b6692" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9acc9a61-bfd0-4d3e-bd9e-ffb5b23c85b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e7df95a-efa2-4873-8a7e-82e175b18902" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9acc9a61-bfd0-4d3e-bd9e-ffb5b23c85b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_c8166f0d-6ab1-48c5-86b6-f570485df186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e7df95a-efa2-4873-8a7e-82e175b18902" xlink:to="loc_us-gaap_PerformanceSharesMember_c8166f0d-6ab1-48c5-86b6-f570485df186" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_471d9018-dc46-480c-85fe-e96174f15c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e7df95a-efa2-4873-8a7e-82e175b18902" xlink:to="loc_us-gaap_EmployeeStockMember_471d9018-dc46-480c-85fe-e96174f15c91" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i347936400cc4481cb0410ed431d0c2db_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c996231-ddac-40e0-9c9d-28c8001b014d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c996231-ddac-40e0-9c9d-28c8001b014d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5ffd18a7-0a2f-421f-a0ad-06f25258bbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5ffd18a7-0a2f-421f-a0ad-06f25258bbe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7932f2f3-48cc-4e48-bdc6-fed465a0e9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7932f2f3-48cc-4e48-bdc6-fed465a0e9e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3d4c98a1-8b0c-4445-9b9e-1d292c137091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3d4c98a1-8b0c-4445-9b9e-1d292c137091" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_aa714793-82e6-403a-8065-9507454ef3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_aa714793-82e6-403a-8065-9507454ef3ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_499d3622-ada5-4b02-92b9-107cb9e210ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_499d3622-ada5-4b02-92b9-107cb9e210ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_21e729ac-9acb-432c-af53-a73fd1d54187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_21e729ac-9acb-432c-af53-a73fd1d54187" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_659705a3-4a5f-4b2d-ab78-15eacf0056cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_659705a3-4a5f-4b2d-ab78-15eacf0056cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_92a90b54-e10c-4022-a70b-bb511f68bfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_92a90b54-e10c-4022-a70b-bb511f68bfaa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_04cb291a-d47d-4d1a-9ebc-5e004666d648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_04cb291a-d47d-4d1a-9ebc-5e004666d648" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2833ced7-7348-472d-b28c-09f3b75310a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2833ced7-7348-472d-b28c-09f3b75310a0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_351178a4-1206-4fcb-a5e4-0a99d3a797c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_351178a4-1206-4fcb-a5e4-0a99d3a797c9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_88b7db2f-37ac-4d61-9a2d-2c2cb4e0ad44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_88b7db2f-37ac-4d61-9a2d-2c2cb4e0ad44" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4a1e7213-d71b-4b60-ae1a-44b8e16a4ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4a1e7213-d71b-4b60-ae1a-44b8e16a4ce0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bd25fb0-1762-4e8f-95dc-2be68eb237c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c996231-ddac-40e0-9c9d-28c8001b014d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bd25fb0-1762-4e8f-95dc-2be68eb237c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_89c2f38f-7aef-413c-9553-bd0db045077e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bd25fb0-1762-4e8f-95dc-2be68eb237c1" xlink:to="loc_us-gaap_AwardTypeAxis_89c2f38f-7aef-413c-9553-bd0db045077e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89c2f38f-7aef-413c-9553-bd0db045077e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_89c2f38f-7aef-413c-9553-bd0db045077e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89c2f38f-7aef-413c-9553-bd0db045077e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_451be06c-60d8-4929-bcfb-e40c524182ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_89c2f38f-7aef-413c-9553-bd0db045077e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_451be06c-60d8-4929-bcfb-e40c524182ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_76adb3d3-b25d-4e0e-9f85-78a6b727e7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_451be06c-60d8-4929-bcfb-e40c524182ef" xlink:to="loc_us-gaap_EmployeeStockOptionMember_76adb3d3-b25d-4e0e-9f85-78a6b727e7a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f5031624-990e-4a81-a4a0-a4e7e9c019e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_451be06c-60d8-4929-bcfb-e40c524182ef" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f5031624-990e-4a81-a4a0-a4e7e9c019e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_StockOptionsAndRestrictedStockUnitsMember_4e0ae5ac-712e-450e-a3bd-7e4e7eb9e06d" xlink:href="halo-20230331.xsd#halo_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_451be06c-60d8-4929-bcfb-e40c524182ef" xlink:to="loc_halo_StockOptionsAndRestrictedStockUnitsMember_4e0ae5ac-712e-450e-a3bd-7e4e7eb9e06d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/EarningspershareComputationDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#EarningspershareComputationDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/EarningspershareComputationDetails" xlink:type="extended" id="i697a2d80d3a5480fa8d37684206fa002_EarningspershareComputationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_8eccf9a7-822a-4b86-8b14-fb8ec4886f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ff96eff2-0de8-45d6-9343-1def19c17924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8eccf9a7-822a-4b86-8b14-fb8ec4886f78" xlink:to="loc_us-gaap_NetIncomeLoss_ff96eff2-0de8-45d6-9343-1def19c17924" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1923d577-6a7b-4c81-bc52-64380f8c70de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8eccf9a7-822a-4b86-8b14-fb8ec4886f78" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1923d577-6a7b-4c81-bc52-64380f8c70de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ea3500a6-909b-4c3a-9373-8fe651ae8aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8eccf9a7-822a-4b86-8b14-fb8ec4886f78" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ea3500a6-909b-4c3a-9373-8fe651ae8aba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ebe923fb-cbb1-4b62-a24b-c8b6bfc1d37c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8eccf9a7-822a-4b86-8b14-fb8ec4886f78" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ebe923fb-cbb1-4b62-a24b-c8b6bfc1d37c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_b451b94a-b101-4628-9671-a57a8e09f3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8eccf9a7-822a-4b86-8b14-fb8ec4886f78" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_b451b94a-b101-4628-9671-a57a8e09f3b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4820c525-676a-400d-94f2-b1b43a37496a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_b451b94a-b101-4628-9671-a57a8e09f3b3" xlink:to="loc_us-gaap_EarningsPerShareBasic_4820c525-676a-400d-94f2-b1b43a37496a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0ce8b3d3-28e9-4fc3-ac0c-0a65a6bb0e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_b451b94a-b101-4628-9671-a57a8e09f3b3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0ce8b3d3-28e9-4fc3-ac0c-0a65a6bb0e86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_785563b2-aab1-4d27-9b9c-808fbc776579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8eccf9a7-822a-4b86-8b14-fb8ec4886f78" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_785563b2-aab1-4d27-9b9c-808fbc776579" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_628c0e5b-06af-4cfb-8432-cce76cff9bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_785563b2-aab1-4d27-9b9c-808fbc776579" xlink:to="loc_us-gaap_AwardTypeAxis_628c0e5b-06af-4cfb-8432-cce76cff9bac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_628c0e5b-06af-4cfb-8432-cce76cff9bac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_628c0e5b-06af-4cfb-8432-cce76cff9bac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_628c0e5b-06af-4cfb-8432-cce76cff9bac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9dbf249-7408-4f38-9896-d70b2a1f175f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_628c0e5b-06af-4cfb-8432-cce76cff9bac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9dbf249-7408-4f38-9896-d70b2a1f175f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_25c507ad-0100-4ee1-8d97-8b3c5d4e46f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9dbf249-7408-4f38-9896-d70b2a1f175f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_25c507ad-0100-4ee1-8d97-8b3c5d4e46f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RestrictStockUnitsPerformanceSharesAndESPPMember_bc87580b-2aa4-49b0-bb45-902a1f231f46" xlink:href="halo-20230331.xsd#halo_RestrictStockUnitsPerformanceSharesAndESPPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9dbf249-7408-4f38-9896-d70b2a1f175f" xlink:to="loc_halo_RestrictStockUnitsPerformanceSharesAndESPPMember_bc87580b-2aa4-49b0-bb45-902a1f231f46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f3fa9cfa-912d-4213-8d52-efa3a96d7275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_785563b2-aab1-4d27-9b9c-808fbc776579" xlink:to="loc_us-gaap_DebtInstrumentAxis_f3fa9cfa-912d-4213-8d52-efa3a96d7275" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f3fa9cfa-912d-4213-8d52-efa3a96d7275_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f3fa9cfa-912d-4213-8d52-efa3a96d7275" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f3fa9cfa-912d-4213-8d52-efa3a96d7275_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_654fc32d-cf11-4512-9e8e-0ae179a6b9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f3fa9cfa-912d-4213-8d52-efa3a96d7275" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_654fc32d-cf11-4512-9e8e-0ae179a6b9cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_a64c0d41-3765-4c7e-bc32-7b4e52520c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_654fc32d-cf11-4512-9e8e-0ae179a6b9cd" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_a64c0d41-3765-4c7e-bc32-7b4e52520c01" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>halo-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5667a7fc-e0e0-4ae8-9db7-13762e0ab1e4,g:df8c4c1a-0af9-473f-aa3c-bddd63ebeeb8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_halo_DeferredRentPayments_1e4c4325-e8f5-4fa1-bdb5-bbb20b87c69b_negatedTerseLabel_en-US" xlink:label="lab_halo_DeferredRentPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease payments recognized (deferred)</link:label>
    <link:label id="lab_halo_DeferredRentPayments_label_en-US" xlink:label="lab_halo_DeferredRentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Payments</link:label>
    <link:label id="lab_halo_DeferredRentPayments_documentation_en-US" xlink:label="lab_halo_DeferredRentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredRentPayments" xlink:href="halo-20230331.xsd#halo_DeferredRentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DeferredRentPayments" xlink:to="lab_halo_DeferredRentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0af95448-7d44-44fd-ac66-976d188652be_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_74457e5e-c4e8-463a-b2a5-1e6cd9d591cd_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Contract with Customer Liability</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_label_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Contract with Customer Liability</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_documentation_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Contract with Customer Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" xlink:href="halo-20230331.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" xlink:to="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_5c55842b-d3f5-4903-aefe-7d94a0be7e28_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share repurchases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_fc99316b-ae80-4e51-8dde-1008bb6f8d37_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_cbc0ae1b-0501-4724-a223-16fd523c680e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_d2a225b7-1bf8-4559-a9d5-0f5b80904a1f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_560aec85-5700-40bb-bba8-e30132c5dbb5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ca0eef4e-54dd-4e56-8603-893a8dd255f8_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4385429d-d8bc-4afc-be4e-97f827c79e78_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2170b7b0-743e-4156-a1b1-d592e20cc9bf_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_50020296-1fc3-455b-a34c-494eb607f1b5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use of assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_041bc9fd-8e1f-4e60-989a-188d7199aa0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5a7b203d-6c27-49e0-a28d-af76c294761f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_4ddb20a4-9478-4a5e-b83a-547cd55b25e3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_1acfae45-788d-45d5-b1f4-9b546f719f5f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and payroll taxes</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_507247dc-54ca-410d-9177-ba77b00d291e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4208d9d2-94b6-4532-abd6-70d20dab2ffa_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2ff186e0-caa8-4c80-a40a-fd3d464b0f90_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_fa3a910d-237e-4632-b245-91adfb2e7f37_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a498524e-43b9-47fc-9c32-74187a644270_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_5f42981c-c81b-4368-bb19-4f1a89cba0b8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ComputerAndOfficeEquipmentMember_7fbdbd8f-bc30-4545-8863-a25f72662714_terseLabel_en-US" xlink:label="lab_halo_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and office equipment</link:label>
    <link:label id="lab_halo_ComputerAndOfficeEquipmentMember_label_en-US" xlink:label="lab_halo_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and Office Equipment [Member]</link:label>
    <link:label id="lab_halo_ComputerAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_halo_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and office equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ComputerAndOfficeEquipmentMember" xlink:href="halo-20230331.xsd#halo_ComputerAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ComputerAndOfficeEquipmentMember" xlink:to="lab_halo_ComputerAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_13f57525-242e-4991-ace2-6c9977a12869_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, convertible, conversion price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_23473a3e-c035-4d8c-ab31-fb7d479faea8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_730e1af5-855c-49e4-9ded-9598a9145833_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_c4189cb5-8fa5-443f-8eb4-a809cf1d96a3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accounts receivable, deferred revenues from contracts with customers, and amounts under collaborative agreements included in transaction price</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_5adb1abc-876b-4791-8d89-301b79c0a45f_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3c7fac82-f3f0-415b-93b8-6938884c957b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_05bc6828-03b9-4f1b-aedf-b9a07a63614c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb891675-6d71-4e09-ae62-288f418142d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0305ba66-b67a-4b68-8cf3-3e3fbc3cf1f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e8414e65-015d-4702-900f-4623e09cc355_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_5e17d70f-b2ff-4366-ba39-d7f0798844e8_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_88f3dd5c-8a27-4ef4-9493-d9dc11774ec6_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_b7c60d6d-e20c-42d3-ba94-fbcfb5d9a731_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contribution amount</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_label_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:href="halo-20230331.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:to="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e8a1a7d1-c035-4db2-a95e-cdb0af245ba4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_521699ec-2d92-4f38-8c53-1aee31abe3ad_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1a2945b9-61c2-4118-8e6d-29f297c07b27_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of available-for-sale marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_StockOptionsAndRestrictedStockUnitsMember_b0e68aee-0059-4c88-98d4-286d7e08e895_terseLabel_en-US" xlink:label="lab_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and restricted units</link:label>
    <link:label id="lab_halo_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_halo_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:href="halo-20230331.xsd#halo_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_01d04008-0a75-469e-b647-97c1813c7a22_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_48d9a165-2120-489a-b11d-452ac2b0b6ac_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_dbb065d8-304b-4420-93ca-b74cd1f14738_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_99076bca-2737-49d6-b199-d3f3baee1309_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_39f2520a-c48e-4f94-bd8d-65ccf3a34d8f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_cd0a37ed-99f2-438c-878e-cde3cb4f4a70_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_93771b84-47da-459f-9178-70ec559fb186_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_d1c40a4a-6c14-456c-8eb8-94a922e8cd84_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average useful life (in years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7f25548a-e097-42ba-9e23-958bd067c619_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive shares excluded from per share calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_OperatingLeaseAccretionOfLiability_93f61efb-ca15-470f-a120-9dacc3b228f0_terseLabel_en-US" xlink:label="lab_halo_OperatingLeaseAccretionOfLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense associated with accretion of lease liabilities</link:label>
    <link:label id="lab_halo_OperatingLeaseAccretionOfLiability_label_en-US" xlink:label="lab_halo_OperatingLeaseAccretionOfLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Accretion Of Liability</link:label>
    <link:label id="lab_halo_OperatingLeaseAccretionOfLiability_documentation_en-US" xlink:label="lab_halo_OperatingLeaseAccretionOfLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Accretion Of Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OperatingLeaseAccretionOfLiability" xlink:href="halo-20230331.xsd#halo_OperatingLeaseAccretionOfLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_OperatingLeaseAccretionOfLiability" xlink:to="lab_halo_OperatingLeaseAccretionOfLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_40a483ac-a083-4f27-b5fd-02575b648a7e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a9f12d50-bad7-402a-97f9-2f1b825ede0b_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_be3c592a-0695-48cc-ad93-00c0c420490a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_c7f7af1b-f7d4-47aa-b884-90910ccdeaa9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents and Marketable Securities and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_0c8d3dd5-6138-40e9-a000-1c742711bf83_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DevicePartneredProductsMember_8c54bf4c-b6c1-4e1c-9a06-6ae7f3e67ef5_terseLabel_en-US" xlink:label="lab_halo_DevicePartneredProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Partnered Products</link:label>
    <link:label id="lab_halo_DevicePartneredProductsMember_label_en-US" xlink:label="lab_halo_DevicePartneredProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Partnered Products [Member]</link:label>
    <link:label id="lab_halo_DevicePartneredProductsMember_documentation_en-US" xlink:label="lab_halo_DevicePartneredProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Partnered Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevicePartneredProductsMember" xlink:href="halo-20230331.xsd#halo_DevicePartneredProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DevicePartneredProductsMember" xlink:to="lab_halo_DevicePartneredProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_ae981a97-07e7-4efc-97d7-6368aaf51304_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_5cae3485-118f-4405-9d8d-e661b8e9dbe5_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_eab57666-6824-4980-9adc-5cbbbbe00cba_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_CreditAgreementMember_11826b3c-0345-49d1-a25d-0d1d21d419e9_terseLabel_en-US" xlink:label="lab_halo_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_halo_CreditAgreementMember_label_en-US" xlink:label="lab_halo_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_halo_CreditAgreementMember_documentation_en-US" xlink:label="lab_halo_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CreditAgreementMember" xlink:href="halo-20230331.xsd#halo_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_CreditAgreementMember" xlink:to="lab_halo_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_b1beb5e7-3033-44ca-91bc-d33d15a78530_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued for conversion of debt instrument (shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a95f1a81-d4b5-4436-b2d8-4cf173fd14f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodAxis_09117be3-f2d1-4713-9373-90e7b9a0a10c_terseLabel_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Interest Payment Period [Axis]</link:label>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodAxis_label_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Interest Payment Period [Axis]</link:label>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodAxis_documentation_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Interest Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodAxis" xlink:href="halo-20230331.xsd#halo_AnnualInterestPaymentPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AnnualInterestPaymentPeriodAxis" xlink:to="lab_halo_AnnualInterestPaymentPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_2074da92-d994-4d8c-a864-289246727aca_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_9603d35f-9be1-4f1f-8151-805db467a5d8_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_d84a515c-08a7-4e18-a62e-b55b55f35fe3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of contractual maturities of available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ResearchEquipmentMember_b7e4c800-ee21-4cfc-88a6-53953638216e_terseLabel_en-US" xlink:label="lab_halo_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research equipment</link:label>
    <link:label id="lab_halo_ResearchEquipmentMember_label_en-US" xlink:label="lab_halo_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Equipment [Member]</link:label>
    <link:label id="lab_halo_ResearchEquipmentMember_documentation_en-US" xlink:label="lab_halo_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ResearchEquipmentMember" xlink:href="halo-20230331.xsd#halo_ResearchEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ResearchEquipmentMember" xlink:to="lab_halo_ResearchEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_82df731c-5e0c-439a-a965-ff35aae43e4d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_b206550d-2478-4d5c-bc45-7c293c2f5e0a_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_13975af2-a075-4c46-85fe-aa7e446a4b57_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_TLANDOProductRightsMember_a48d6780-90bd-4257-b9a3-37049fb550ee_terseLabel_en-US" xlink:label="lab_halo_TLANDOProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TLANDO, Product Rights [Member]</link:label>
    <link:label id="lab_halo_TLANDOProductRightsMember_label_en-US" xlink:label="lab_halo_TLANDOProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TLANDO, Product Rights [Member]</link:label>
    <link:label id="lab_halo_TLANDOProductRightsMember_documentation_en-US" xlink:label="lab_halo_TLANDOProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TLANDO, Product Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TLANDOProductRightsMember" xlink:href="halo-20230331.xsd#halo_TLANDOProductRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_TLANDOProductRightsMember" xlink:to="lab_halo_TLANDOProductRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_42ac24a4-7fdd-4246-bb51-7d770b4ec261_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options and restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_dd68dfd6-d6d2-42ed-a9cc-150dc2eab13e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_7b5e5a8d-be5b-4d26-a730-ac029c0f98db_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible, threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_0894b6e8-a1d5-4ed9-ac9d-5c0533ba14d0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0eabef39-8fc7-4742-839d-84592a7743b1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b4e4be64-a80e-4ea6-bf88-dd2b2f504576_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_f5aafe5d-75e6-486b-9392-07e781407cde_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of outstanding notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ManufacturingEquipmentMember_91e0bc86-9eb2-4227-baa4-9480b7d81772_terseLabel_en-US" xlink:label="lab_halo_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_halo_ManufacturingEquipmentMember_label_en-US" xlink:label="lab_halo_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_halo_ManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_halo_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ManufacturingEquipmentMember" xlink:href="halo-20230331.xsd#halo_ManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ManufacturingEquipmentMember" xlink:to="lab_halo_ManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d39b95e4-6e68-48e4-9b4b-accdeea330e0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_07077431-165c-4f31-ad40-9bef76f4fd59_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for the induced conversion related to convertible notes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_1bb9b9db-7654-473c-9693-c50656146209_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_299276b9-a006-4e91-89fd-bbd889dc7e16_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net and other contract assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f8f875f3-a6f8-4cce-a689-4434a804009c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts accrued for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_7c6b2025-e324-4922-bf5a-3535cf516698_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_10df40a9-293f-4f70-abcf-b35b90030d0e_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_941dba1d-2536-49a4-a45c-e5ecd8e7f651_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee subscription rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice_9905fc92-7c87-4687-b412-f1f0bcd0f9aa_terseLabel_en-US" xlink:label="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of contract termination by written notice</link:label>
    <link:label id="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice_label_en-US" xlink:label="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Period Of Termination By Written Notice</link:label>
    <link:label id="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice_documentation_en-US" xlink:label="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Period Of Termination By Written Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" xlink:href="halo-20230331.xsd#halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" xlink:to="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_b0ad6928-28be-44ae-b17f-8eff89f03186_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_90d8f023-90ce-4b7f-a149-0487a7a5f304_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_8f19cc4d-8330-40e5-b728-0560a349e804_verboseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs withheld to pay for minimum withholding taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4b94c0e7-9531-4ea0-98d2-80781e4e83a4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4a16b000-1cc5-42f2-a7f0-ddfe5f6d646b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_VariableRateComponentTwoMember_cf72e17a-239c-4f1c-9e9b-aa34b0f16db7_terseLabel_en-US" xlink:label="lab_halo_VariableRateComponentTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component Two</link:label>
    <link:label id="lab_halo_VariableRateComponentTwoMember_label_en-US" xlink:label="lab_halo_VariableRateComponentTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component Two [Member]</link:label>
    <link:label id="lab_halo_VariableRateComponentTwoMember_documentation_en-US" xlink:label="lab_halo_VariableRateComponentTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentTwoMember" xlink:href="halo-20230331.xsd#halo_VariableRateComponentTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_VariableRateComponentTwoMember" xlink:to="lab_halo_VariableRateComponentTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_1e743f4f-37a0-4dd2-9907-b2b89d850b19_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_8dc6192b-2cad-4297-bd9a-abc1a315d8c7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RoyaltiesReceivedNumberOfCollaborators_e12786a9-1c78-4000-98a2-e83c8491f8a1_terseLabel_en-US" xlink:label="lab_halo_RoyaltiesReceivedNumberOfCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties received, number of collaborators</link:label>
    <link:label id="lab_halo_RoyaltiesReceivedNumberOfCollaborators_label_en-US" xlink:label="lab_halo_RoyaltiesReceivedNumberOfCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Received, Number of Collaborators</link:label>
    <link:label id="lab_halo_RoyaltiesReceivedNumberOfCollaborators_documentation_en-US" xlink:label="lab_halo_RoyaltiesReceivedNumberOfCollaborators" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Received, Number of Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RoyaltiesReceivedNumberOfCollaborators" xlink:href="halo-20230331.xsd#halo_RoyaltiesReceivedNumberOfCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RoyaltiesReceivedNumberOfCollaborators" xlink:to="lab_halo_RoyaltiesReceivedNumberOfCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6d7fb400-5f52-4901-a920-1e4a36559fd9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_7422fe8d-d7c7-4cbd-af2d-c34ee48d69e3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_96e6bf68-28af-4b52-8eda-3dce036e0a98_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5fb7bc19-234e-402f-b172-73503a3dc81e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodFourMember_9037efea-1c5e-48a9-b5c8-35cdc525befb_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year four</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodFourMember_label_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period Four [Member]</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodFourMember_documentation_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodFourMember" xlink:href="halo-20230331.xsd#halo_DebtInstrumentInterestPeriodFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentInterestPeriodFourMember" xlink:to="lab_halo_DebtInstrumentInterestPeriodFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_b37abece-253d-4f1a-a02b-a2fc503338ca_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash acquired</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_86f39d85-e48d-4b32-b470-9b24e0085044_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ed5edd6b-e5ee-43f7-ba68-c8180fb8d78b_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Total</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_d2471a32-7a2b-42f9-9fa9-8394c01a30a6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_847cecce-862e-4a41-ab14-e434c714bf7a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid manufacturing expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_9152c45e-1bce-4c80-9077-b2195227f942_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of disaggregation of revenues</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_1488b4ec-70eb-4284-80bf-4b910dfd40e3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_82a3d6fc-6a4c-4dcf-9ba4-369833e356de_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_82e93a00-7827-4aaa-afdf-01913e226966_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of convertible debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_c0a8e08a-e3df-442f-928e-604c5171a214_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_25972964-d6f8-4686-86b4-e618340ca393_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts related to leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_Accountsreceivablefromcollaborators_f3068eca-c7e3-4d58-9037-b22943b07e6f_terseLabel_en-US" xlink:label="lab_halo_Accountsreceivablefromcollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from revenues under collaborative agreements</link:label>
    <link:label id="lab_halo_Accountsreceivablefromcollaborators_label_en-US" xlink:label="lab_halo_Accountsreceivablefromcollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from collaborators</link:label>
    <link:label id="lab_halo_Accountsreceivablefromcollaborators_documentation_en-US" xlink:label="lab_halo_Accountsreceivablefromcollaborators" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due from collaborators, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromcollaborators" xlink:href="halo-20230331.xsd#halo_Accountsreceivablefromcollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accountsreceivablefromcollaborators" xlink:to="lab_halo_Accountsreceivablefromcollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_296b7409-4d37-41fa-aae5-99557e9eceec_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_0068190d-c48b-4f94-ac8f-2bb62d367e9f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_11d0a325-06c1-43eb-8e3c-0e4059a89667_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_a87a1e81-57fc-41c2-9f48-f7587a802173_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_a7753896-893a-4b96-aa82-d8c0ddd51862_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_a015378b-e254-4402-b2fb-4d4a4b36f698_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_3c492312-1c03-444c-b59d-d2d2bfd88b2d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_9e5ea212-5d11-434c-a31b-db0dde855eb4_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_UpfrontfeesMember_30f8d9f8-b8e8-4ae9-99f0-cc5b6fde0aa2_terseLabel_en-US" xlink:label="lab_halo_UpfrontfeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront License Fees</link:label>
    <link:label id="lab_halo_UpfrontfeesMember_label_en-US" xlink:label="lab_halo_UpfrontfeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront fees [Member]</link:label>
    <link:label id="lab_halo_UpfrontfeesMember_documentation_en-US" xlink:label="lab_halo_UpfrontfeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_UpfrontfeesMember" xlink:href="halo-20230331.xsd#halo_UpfrontfeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_UpfrontfeesMember" xlink:to="lab_halo_UpfrontfeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_78d99e95-a3c5-40d9-b020-646375a6f70c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c7ceda8d-b293-4f13-a53a-0e8048027fb6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8ff26c63-237b-4ec8-9a74-ebbeec8067d8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_168724a9-8e6f-4d36-b1ad-3b0bacfaf4e1_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Contract with Customer Liability</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_label_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Contract with Customer Liability</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_documentation_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Contract with Customer Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" xlink:href="halo-20230331.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" xlink:to="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ee7a7757-ff00-4616-bbfa-6a038f74f06f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_7088ddb8-d103-4607-ac07-695b82c389c0_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_05d92591-c93f-44e0-a48c-165df0343bc8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b31c81fa-6f1a-4a49-ad77-2924a6e85c58_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_d6871617-6dfe-4cae-b7c6-ea5cb6b7b210_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BaxaltaMember_a2e0dcff-4d88-4d5c-985f-d77b29dde197_terseLabel_en-US" xlink:label="lab_halo_BaxaltaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta</link:label>
    <link:label id="lab_halo_BaxaltaMember_label_en-US" xlink:label="lab_halo_BaxaltaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta [Member]</link:label>
    <link:label id="lab_halo_BaxaltaMember_documentation_en-US" xlink:label="lab_halo_BaxaltaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BaxaltaMember" xlink:href="halo-20230331.xsd#halo_BaxaltaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BaxaltaMember" xlink:to="lab_halo_BaxaltaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_bbc82803-85cf-47ec-be32-df2acf9042a6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6d65e5f4-7b37-4d7a-a4f8-59a6d72c90a9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options weighted average exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_dfccfbaf-8b43-4db5-b064-d6cd558af90f_terseLabel_en-US" xlink:label="lab_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement</link:label>
    <link:label id="lab_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_label_en-US" xlink:label="lab_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From (Payments) for Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:label id="lab_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_documentation_en-US" xlink:label="lab_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From (Payments) for Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" xlink:href="halo-20230331.xsd#halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" xlink:to="lab_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_1063cfe2-8855-4ee8-8602-fa27338c5584_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b5fa5d1d-fc82-4a91-8a9a-a130db6a6f3e_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_24678246-a5bb-4a15-9b49-cacd98330895_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_cdc7c695-a594-41fb-accd-ec576f73fff2_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_e4b85777-2464-444c-9ce9-e4ec14fa48b9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_93807169-84b5-4b41-9502-c2e1692e737a_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average price paid per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_LicenseFeesAndEventBasedMember_621b1b95-5361-422c-b022-102279087727_terseLabel_en-US" xlink:label="lab_halo_LicenseFeesAndEventBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees And Event-Based</link:label>
    <link:label id="lab_halo_LicenseFeesAndEventBasedMember_label_en-US" xlink:label="lab_halo_LicenseFeesAndEventBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees And Event-Based [Member]</link:label>
    <link:label id="lab_halo_LicenseFeesAndEventBasedMember_documentation_en-US" xlink:label="lab_halo_LicenseFeesAndEventBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees And Event-Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LicenseFeesAndEventBasedMember" xlink:href="halo-20230331.xsd#halo_LicenseFeesAndEventBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_LicenseFeesAndEventBasedMember" xlink:to="lab_halo_LicenseFeesAndEventBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d4bd0eeb-e342-4ec6-9504-de0b1da6844d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1b3387b3-a6fe-4590-8a1e-f32d1e1dd8df_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b08d5f0c-3eaa-4146-83ef-dff9c136e661_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock and performance stock units, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_931756bd-02eb-4673-80d9-8cc304a79f75_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current portion</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_38950048-8c99-4dc9-8355-0b69f6df2eb0_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_cc430807-c33f-4993-8547-da93302a0fac_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3fa83852-53a0-44ab-ac52-fd37f52bbda8_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in amount of contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_ed6f34fb-23f2-41fa-8bf3-6f9ee0a261c5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_74eeac16-df3a-456d-ab11-39902103c4ef_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9fd2c70c-1d08-43c1-b8da-fdcefa4b5040_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_06bf680a-e244-4952-8e61-2e4e4c2af598_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill_cd9da7e5-27b0-45b1-af16-460ca3e6d6b4_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net assets Acquired, Excluding Goodwill</link:label>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill_label_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net assets Acquired, Excluding Goodwill</link:label>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill_documentation_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net assets Acquired, Excluding Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill" xlink:href="halo-20230331.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill" xlink:to="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_bfb0b1b3-59ac-484e-ac71-44d43271322b_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_fe176cc9-591c-44d8-92db-ebacbcd38982_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_025b717d-2e10-4e3d-806e-532167802301_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b29bca0c-d4cd-4b8e-bd7d-985d0c8cc007_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_ebf3c68e-959d-45c7-a4e2-cabf17c72c35_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1d5918d4-7223-47f5-a506-bbaa1d666862_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b06fef6d-0a26-4b6f-97fc-631db71b47aa_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_6f7065f6-b5c8-4d02-9688-11a4461a8bf1_terseLabel_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</link:label>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_label_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</link:label>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_documentation_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:href="halo-20230331.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:to="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a20ddef2-9ce0-4430-b8bc-43a8735fcd05_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_638ce988-1836-4083-b218-59b9863408f1_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_c0bb5473-cf2d-4b33-aff2-5f9483eebeb2_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2d63e0ea-d647-438d-8726-18f3b0b98f3f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2fa28f93-e5ed-4248-aef6-752aa21ceac1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense_b46328a3-d4f4-4572-aec7-2c52d5667fb1_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, provisional information, initial accounting incomplete, adjustment, accrued expense</link:label>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense_label_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, provisional information, initial accounting incomplete, adjustment, accrued expense</link:label>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense_documentation_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, provisional information, initial accounting incomplete, adjustment, accrued expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense" xlink:href="halo-20230331.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense" xlink:to="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_8356d877-0acf-48a3-a0d7-dcb11b46cd5a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_46e8720b-337d-4223-8836-dc46bbeee048_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_701f1485-e721-42fa-af30-91c3dc4f29bf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_82dcbf33-da67-4f79-976e-d5cc8b005a59_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_7870eb2e-a024-4562-8e16-8aecdb5737fb_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ef33f58f-7553-4e29-a36b-5184e357e13e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_6dd8c274-9a8f-4551-abb9-574b002064e1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2fe1d377-c5cc-468a-9671-7f446e7a7418_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_292b49ef-b4bc-43ce-9525-11cb5f1b4d2a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Weighted-Average Recognition Period (years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_b97926ed-0816-44e8-a772-08079cf79ea7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustment</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_503d565f-2986-4d82-a72f-c4606220f71a_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_85b259f3-e578-4e40-9edd-b3f54e9d7ad9_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_1beda2e5-729e-4581-9c02-d27a544df065_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 12)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodTwoMember_bb6da6c6-a41e-48d4-af7a-82aba84b811a_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year two</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodTwoMember_label_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period two [Member]</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodTwoMember_documentation_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodTwoMember" xlink:href="halo-20230331.xsd#halo_DebtInstrumentInterestPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentInterestPeriodTwoMember" xlink:to="lab_halo_DebtInstrumentInterestPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4d8a0ed4-03a1-47dd-b36c-105542c63623_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_c7bee1ae-4d4f-4b7a-a6e1-314d0a5238c8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9e49ff72-40e6-415b-b79e-fd49e96c25e8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_9d84a9f4-6bb9-4357-b9aa-e02dc0996b26_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance cost</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7b7da7cf-351e-41fe-91af-5b768a6d6fca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assumptions used in Black-Scholes model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_PaymentForCappedCallTransactions_11f4c1fe-be85-4518-a282-62b7db756c72_terseLabel_en-US" xlink:label="lab_halo_PaymentForCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for capped calls</link:label>
    <link:label id="lab_halo_PaymentForCappedCallTransactions_label_en-US" xlink:label="lab_halo_PaymentForCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Capped Call Transactions</link:label>
    <link:label id="lab_halo_PaymentForCappedCallTransactions_documentation_en-US" xlink:label="lab_halo_PaymentForCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Capped Call Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PaymentForCappedCallTransactions" xlink:href="halo-20230331.xsd#halo_PaymentForCappedCallTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_PaymentForCappedCallTransactions" xlink:to="lab_halo_PaymentForCappedCallTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4796bbaf-ba65-4139-8ab9-78f62607cfc8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_A100ConvertibleSeniorNotesDue2028Member_3d14281b-1437-40cd-bc38-664f3b12284a_terseLabel_en-US" xlink:label="lab_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.00% Convertible Senior Notes due 2028</link:label>
    <link:label id="lab_halo_A100ConvertibleSeniorNotesDue2028Member_label_en-US" xlink:label="lab_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.00% Convertible Senior Notes due 2028 [Member]</link:label>
    <link:label id="lab_halo_A100ConvertibleSeniorNotesDue2028Member_documentation_en-US" xlink:label="lab_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.00% Convertible Senior Notes due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:href="halo-20230331.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:to="lab_halo_A100ConvertibleSeniorNotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_JanssenMember_574cd828-fafe-4a1f-8c5d-b42e6070a385_terseLabel_en-US" xlink:label="lab_halo_JanssenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_halo_JanssenMember_label_en-US" xlink:label="lab_halo_JanssenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen [Member]</link:label>
    <link:label id="lab_halo_JanssenMember_documentation_en-US" xlink:label="lab_halo_JanssenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_JanssenMember" xlink:href="halo-20230331.xsd#halo_JanssenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_JanssenMember" xlink:to="lab_halo_JanssenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b0761f97-b003-4951-8ff4-34f8d32048a6_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential common stock outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_460155eb-b332-49de-9ddd-c8ad912ecd61_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_2e6ed47e-d807-40ed-93c6-766c7b3a0344_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_VariableRateComponentAxis_c6bad0db-c17e-4c4a-80ad-2e6f99460c2e_terseLabel_en-US" xlink:label="lab_halo_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Axis]</link:label>
    <link:label id="lab_halo_VariableRateComponentAxis_label_en-US" xlink:label="lab_halo_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Axis]</link:label>
    <link:label id="lab_halo_VariableRateComponentAxis_documentation_en-US" xlink:label="lab_halo_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentAxis" xlink:href="halo-20230331.xsd#halo_VariableRateComponentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_VariableRateComponentAxis" xlink:to="lab_halo_VariableRateComponentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_ff145030-a0e5-4967-8556-f5506d7f9892_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_3658cefd-9708-4b1f-8905-b65f30173279_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RocheMember_f3f0030b-da30-4519-9250-aa236a310a0e_terseLabel_en-US" xlink:label="lab_halo_RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_halo_RocheMember_label_en-US" xlink:label="lab_halo_RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_halo_RocheMember_documentation_en-US" xlink:label="lab_halo_RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RocheMember" xlink:href="halo-20230331.xsd#halo_RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RocheMember" xlink:to="lab_halo_RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_22934624-8ab8-4b0b-ba83-7fa274826b2d_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Short-Term Investments</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_label_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Short-Term Investments</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_documentation_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" xlink:href="halo-20230331.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" xlink:to="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e06876cf-7a97-478b-a11f-569914f3cecc_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d2f156e8-0716-4ebc-9810-f3d95c9227d5_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other assets, current</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_3e223301-05ca-474d-b573-841bb720c573_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_02f953a8-d228-40fb-8839-982b9ea7f29d_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b0c2f857-c20d-4bd7-b9d4-375116fe0124_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a0397f53-431e-44f4-962c-de97beec56b1_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses, current</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ec5383a4-0617-4ee5-8400-98fa51137c02_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3770cf75-592c-4c70-8058-292a052a5325_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_9cb1bbe5-7c1c-4cf8-9cd9-6c5a9d0b08bc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ed6149f5-dd4f-4c7e-8032-7cb582b5644f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_855c81f6-c32a-4ea9-bacd-d7c5efae64aa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_21256604-1ed7-40d2-b1c9-5e6f9daff192_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_OthercollaboratorsMember_b62f2858-17cd-448b-872c-878d0776d657_terseLabel_en-US" xlink:label="lab_halo_OthercollaboratorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other collaborators</link:label>
    <link:label id="lab_halo_OthercollaboratorsMember_label_en-US" xlink:label="lab_halo_OthercollaboratorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other collaborators [Member]</link:label>
    <link:label id="lab_halo_OthercollaboratorsMember_documentation_en-US" xlink:label="lab_halo_OthercollaboratorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other collaborators [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OthercollaboratorsMember" xlink:href="halo-20230331.xsd#halo_OthercollaboratorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_OthercollaboratorsMember" xlink:to="lab_halo_OthercollaboratorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_cf534a9d-42c9-4eeb-9463-3026bd035bcb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_efb5e9d0-62d6-43f9-9e60-912cfcec233d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_31842c65-ebe9-4686-a1f1-5602ff428f86_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_0e1e1bba-8738-47b1-8da6-f206dad4ffb7_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_96045d32-ba10-4f7f-9e43-a56602750268_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3aa0337d-2094-49bf-b109-cbfbfea4b853_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_1a5eecc4-89c5-4728-b3ab-b2808788eab6_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, period</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Period in Force</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:to="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ae3d97f-0de4-4c4b-966a-7baf5f56879f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_74c0773d-1826-4064-8b10-b9f033eb2178_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year but within five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_761b2feb-b164-408b-9c3e-f2fb30f2fe45_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0b31a9f4-cc7f-4aae-a3b9-7bca909c335c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss position of debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_59f9a15a-b550-4651-8a6b-27397aba6fef_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1045e943-1bda-4e22-9afd-520c6a30b3a9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour_e5abc2c5-d182-41c2-b3a9-212e39c046f1_terseLabel_en-US" xlink:label="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour_label_en-US" xlink:label="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Yea, After Year Four</link:label>
    <link:label id="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour_documentation_en-US" xlink:label="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Yea, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour" xlink:href="halo-20230331.xsd#halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour" xlink:to="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d9e02ed8-8f49-412c-abfa-c3ed3283acfe_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodOneMember_00c247e2-ae75-44bd-8eec-2d98273b2654_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year one</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodOneMember_label_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period One [Member]</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodOneMember_documentation_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodOneMember" xlink:href="halo-20230331.xsd#halo_DebtInstrumentInterestPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentInterestPeriodOneMember" xlink:to="lab_halo_DebtInstrumentInterestPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_59d893bf-fe88-4309-b213-7aeaed7bb1f6_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_77de93ee-86b6-48da-81c8-96064dc9462a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_66617fa7-281e-4875-b19f-b6c85c800d7f_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7c196309-c80f-4724-99d8-74de3d6665a1_verboseLabel_en-US" xlink:label="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_506ccdb5-a7ba-4a26-af4b-9cb74520698d_totalLabel_en-US" xlink:label="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:label id="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_documentation_en-US" xlink:label="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="halo-20230331.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_57e59400-5baa-4458-9fd8-ecc8aefb8a27_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_8d51e373-340a-4428-a74f-0ac94b248e7a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_d20f5bba-d7d4-4224-b3ad-92c077b38f81_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_A025ConvertibleSeniorNotesDue2027Member_0a076500-036e-4d4e-ad39-2e1b305fc99b_terseLabel_en-US" xlink:label="lab_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.25% Convertible Senior Notes due 2027</link:label>
    <link:label id="lab_halo_A025ConvertibleSeniorNotesDue2027Member_label_en-US" xlink:label="lab_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.25% Convertible Senior Notes due 2027 [Member]</link:label>
    <link:label id="lab_halo_A025ConvertibleSeniorNotesDue2027Member_documentation_en-US" xlink:label="lab_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.25% Convertible Senior Notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:href="halo-20230331.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:to="lab_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock_cb0b89e2-19c9-4247-bddf-13315cd5e62e_terseLabel_en-US" xlink:label="lab_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets and Other Long-Lived Assets</link:label>
    <link:label id="lab_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets and Other Long-Lived Assets Policy [Policy Text Block]</link:label>
    <link:label id="lab_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets and Other Long-Lived Assets Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock" xlink:href="halo-20230331.xsd#halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock" xlink:to="lab_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_56f6e180-7766-459b-a99c-6a81fbb766ca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c3a668e-df9d-4c8a-872c-3a3c26b9c7a2_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3eb6efc6-5aa2-46a1-95a6-2c752137e402_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_aeed4cdc-7eb1-431b-8cb0-472d05447c0c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_04500b1a-6f50-4ae2-a782-a9a574fa526c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for conversion of 2024 Convertible Notes</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_704fda38-b544-49da-8339-96af1ca67c02_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_97897321-aef1-46d8-be0f-23b4e37bf70c_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration for Antares equity compensation awards</link:label>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_label_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issuable, Equity Compensation Awards</link:label>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_documentation_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issuable, Equity Compensation Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" xlink:href="halo-20230331.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" xlink:to="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_3c3b3cd6-fc83-41aa-8b29-5d6ba23f5d49_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_c8033169-1972-4c59-b8d8-fb59f683fb0d_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_5281f3a6-03c3-4335-b8c6-d79a6410eaa8_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_2e2dca12-18cb-466d-88b3-8a7e1ed93232_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InducedConversionOfConvertibleDebtExpense_2e875afc-00a2-4846-bd26-f18502133b9b_terseLabel_en-US" xlink:label="lab_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Induced conversion expense related to convertible notes</link:label>
    <link:label id="lab_us-gaap_InducedConversionOfConvertibleDebtExpense_label_en-US" xlink:label="lab_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Induced Conversion of Convertible Debt Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:to="lab_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c699e0af-5279-49d5-ba80-a9467d8a20c9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a0e71beb-df12-4c61-8e95-642bb3ece660_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodThreeMember_cf8c8de9-410c-4268-a4b8-b39361305171_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year three</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodThreeMember_label_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period Three [Member]</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodThreeMember_documentation_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodThreeMember" xlink:href="halo-20230331.xsd#halo_DebtInstrumentInterestPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentInterestPeriodThreeMember" xlink:to="lab_halo_DebtInstrumentInterestPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9b8c46f6-0d4b-4d5f-8910-823b666197c0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17110795-1b1a-4038-a20f-829ee6c4aad8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_5aaf7498-f31f-48e6-ac72-0563afbfa256_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_cba0ea10-1fdf-4eb1-b2e5-b5220fe33a03_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_84370003-2490-4813-801d-a5b8ef2e65af_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_fe8eac78-7f3a-4599-b675-a37462d9a989_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5fb6c961-a3a7-48f4-a150-06cadbd66d68_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b0d0d71a-5475-4512-adc7-8a9524dc75c8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b2e88688-2b23-4478-95d7-f11563cddbef_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_82cdac25-f1bd-4396-a83d-5a7fd142499f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationAwardsVestedMember_d1fbdca2-48e7-4c0a-aed0-500d758a515e_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationAwardsVestedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Compensation Awards, Vested</link:label>
    <link:label id="lab_halo_ShareBasedCompensationAwardsVestedMember_label_en-US" xlink:label="lab_halo_ShareBasedCompensationAwardsVestedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Awards, Vested [Member]</link:label>
    <link:label id="lab_halo_ShareBasedCompensationAwardsVestedMember_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationAwardsVestedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Awards, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationAwardsVestedMember" xlink:href="halo-20230331.xsd#halo_ShareBasedCompensationAwardsVestedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationAwardsVestedMember" xlink:to="lab_halo_ShareBasedCompensationAwardsVestedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_e5baff35-3844-4903-b950-3ec4ebfc4144_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount paid for conversion of debt instrument</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_37ee7e45-f60a-4ed3-9d42-a1ddf13a80cd_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible, threshold consecutive business days</link:label>
    <link:label id="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_label_en-US" xlink:label="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Business Days</link:label>
    <link:label id="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_documentation_en-US" xlink:label="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Business Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" xlink:href="halo-20230331.xsd#halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" xlink:to="lab_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AutoInjectorTechnologyPlatformMember_c7264f43-e5f0-42ab-89eb-a0fcaa4eeec1_terseLabel_en-US" xlink:label="lab_halo_AutoInjectorTechnologyPlatformMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auto Injector Technology Platform [Member]</link:label>
    <link:label id="lab_halo_AutoInjectorTechnologyPlatformMember_label_en-US" xlink:label="lab_halo_AutoInjectorTechnologyPlatformMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auto Injector Technology Platform [Member]</link:label>
    <link:label id="lab_halo_AutoInjectorTechnologyPlatformMember_documentation_en-US" xlink:label="lab_halo_AutoInjectorTechnologyPlatformMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auto Injector Technology Platform</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AutoInjectorTechnologyPlatformMember" xlink:href="halo-20230331.xsd#halo_AutoInjectorTechnologyPlatformMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AutoInjectorTechnologyPlatformMember" xlink:to="lab_halo_AutoInjectorTechnologyPlatformMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_5c33df17-5812-4ae7-a0ef-54e0d1c19688_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_12cb4fb2-debc-4fd4-96e9-06cade666bcf_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_2e80a259-11ae-4d5f-bbc8-8ecba4ec05ec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b3f2cf9b-887c-4945-82dd-523eadbc7a34_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1f1a37f4-98d3-488d-ae52-b77d81a003df_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity (deficit) (textual)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_aa1cdc48-45e1-4f74-9169-ada4d26d984d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_e8b0e38a-138d-48c3-961f-794518aa792a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_ac6dc8e8-a820-4214-8384-cbaedf7c0652_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_fcd297e6-07f8-470d-98c8-ac0132707c74_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_36b45845-879c-4c4d-bb78-d08c43a58c04_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a536ebc5-ecd1-4536-b69f-6e81f8145e64_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rates</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_SalesbasedmilestoneMember_ccbd0a9a-9134-4936-b65a-15ea8d9e8028_terseLabel_en-US" xlink:label="lab_halo_SalesbasedmilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestone</link:label>
    <link:label id="lab_halo_SalesbasedmilestoneMember_label_en-US" xlink:label="lab_halo_SalesbasedmilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestone [Member]</link:label>
    <link:label id="lab_halo_SalesbasedmilestoneMember_documentation_en-US" xlink:label="lab_halo_SalesbasedmilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_SalesbasedmilestoneMember" xlink:href="halo-20230331.xsd#halo_SalesbasedmilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_SalesbasedmilestoneMember" xlink:to="lab_halo_SalesbasedmilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6c1a3357-194b-45ee-bc1a-a1fb0aee55d5_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a906d41c-5fd9-4f63-808a-7309ddb1d499_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards_06e22fbb-7b5e-4772-94b4-615701437b1f_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Bonus Awards</link:label>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards_label_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Bonus Awards</link:label>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards_documentation_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Bonus Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards" xlink:href="halo-20230331.xsd#halo_BusinessCombinationConsiderationTransferredBonusAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards" xlink:to="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_14b178e4-6217-45ce-82ff-8d639771b2cf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_TermLoanFacilityMember_29666f2c-0071-4aac-8ac9-4562699c3041_terseLabel_en-US" xlink:label="lab_halo_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_halo_TermLoanFacilityMember_label_en-US" xlink:label="lab_halo_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_halo_TermLoanFacilityMember_documentation_en-US" xlink:label="lab_halo_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TermLoanFacilityMember" xlink:href="halo-20230331.xsd#halo_TermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_TermLoanFacilityMember" xlink:to="lab_halo_TermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d558860f-4fb8-4610-9d37-aefcf712ed18_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_1440493e-b010-4d0b-bd93-32aa51fd3af8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_42337425-ed62-47c7-bb61-d9726f305f88_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_47f10337-4fc4-455e-b6f9-32846b69227e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_a67a3ecd-4109-4c61-8ea4-78dfb15f1752_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_8f2ce9bc-38c9-4fcc-b9ea-9f84ac13f568_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period (in months)</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_label_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:href="halo-20230331.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_4e4ea35a-6243-462c-bf59-efa4847763f7_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_22234ec0-eb97-4ced-9b6d-5d6698227385_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f24268ed-b065-4952-b0d0-bacaa43d8d19_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_8216eebf-9b35-4411-9edb-86ba5087f5b5_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a32e611a-c961-4039-86c3-0f0e9dd0b87d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_a0eb6f07-2f3f-4f5d-bb88-a64135d8fa60_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amortization per period of debt discount (in years):</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_8d33b190-cbbe-4c3b-a0d5-6923ab22a47e_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from stock options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_de4c7d77-a0a6-421b-a30d-fd10b32a7ed8_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATRS-1902 (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eb59f879-7b00-47f3-a93b-810f02404420_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_fefd3698-2ba6-47ff-b6aa-ffa7ee551eca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_6e4a104b-1ca4-490a-9123-66f72339ccf7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8acca9ad-9273-4fb8-8b42-5fc47fcffa47_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net and contract assets</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_dfa93281-b0de-4600-ba1d-52ea35c68f8d_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts receivable, net and contract assets</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_50956341-1f82-4f41-a280-f6ed4706c309_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_957a1383-0f7e-4b6c-a88e-7ea41afcec18_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_be516b61-7332-4274-b353-efdf714ef8ab_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_fdb7b5d0-a613-4fcc-8bfd-702b79c9cc36_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_17297e3c-4be6-452e-b97a-62856388d8d5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_f71de435-190d-43c8-b833-1e5ba9870129_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_1f94bb4f-f44a-4aee-8435-8d33b21ca17f_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_947ebb32-b7cc-4a9f-a47c-e6cc061ce857_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7694521d-bec8-435e-b99a-0bb819838759_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_3c5972e3-7c86-462a-adf1-40f2a06309e7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_21e87deb-5cc6-42aa-a951-1ab8b58edd71_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_ac6ac41d-d0ed-4e0f-be88-824148cf4cd7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_12514b8e-b5da-4f2e-8820-42666d90d41f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_315dce66-acfe-428b-86a6-5fb46c747aa4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_9ece7798-7c13-423d-9048-717deba32164_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8f7b3365-f400-4586-90c9-8b9663646fac_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_680968fa-8544-487f-85da-2a37a8831205_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_b880e5a7-a7ff-47f9-b380-dfa1f378ba3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Indefinite-lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_844e89cf-d6b5-472d-ac26-2f5e59284825_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_CollaborativeAgreementsMember_34498fc7-6248-4974-a265-e38381aa9a12_terseLabel_en-US" xlink:label="lab_halo_CollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues under collaborative agreements</link:label>
    <link:label id="lab_halo_CollaborativeAgreementsMember_b89dfde7-a241-479b-b27b-b7900ee1f54b_verboseLabel_en-US" xlink:label="lab_halo_CollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_halo_CollaborativeAgreementsMember_label_en-US" xlink:label="lab_halo_CollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements [Member]</link:label>
    <link:label id="lab_halo_CollaborativeAgreementsMember_documentation_en-US" xlink:label="lab_halo_CollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember" xlink:href="halo-20230331.xsd#halo_CollaborativeAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_CollaborativeAgreementsMember" xlink:to="lab_halo_CollaborativeAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b5e509cc-21b6-447a-bfe6-c4a0f8a81e9a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a5071e6a-7824-4c2e-9459-21bdcc2b2e33_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_dcb586d2-3f9b-4bcd-b59d-08776ae56ba3_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Number of Shares Purchased (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_TreasuryStockAcquiredFeeCostPerShare_af6f1e3b-d3fc-42aa-ab4b-e6db6b22b02d_terseLabel_en-US" xlink:label="lab_halo_TreasuryStockAcquiredFeeCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee per share (usd per share)</link:label>
    <link:label id="lab_halo_TreasuryStockAcquiredFeeCostPerShare_label_en-US" xlink:label="lab_halo_TreasuryStockAcquiredFeeCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Fee Cost Per Share</link:label>
    <link:label id="lab_halo_TreasuryStockAcquiredFeeCostPerShare_documentation_en-US" xlink:label="lab_halo_TreasuryStockAcquiredFeeCostPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Fee Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TreasuryStockAcquiredFeeCostPerShare" xlink:href="halo-20230331.xsd#halo_TreasuryStockAcquiredFeeCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_TreasuryStockAcquiredFeeCostPerShare" xlink:to="lab_halo_TreasuryStockAcquiredFeeCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_a7e002f0-a94a-40a8-a793-e92d802187d1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_2b532c8f-48d2-4c33-8b2a-b7fe86226521_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_402901b4-72d2-4627-a8af-c2c8169638bd_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_384dd6f7-b825-4b04-b6e6-c6d2299f6dc9_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_2e483838-3597-4369-8093-aef6ad9ede0c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_27b332db-1ee2-430d-8702-6d9980aa6401_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ba2084e1-212a-49cb-9cb2-202e8c4d59df_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_7baf375f-5fa1-4af5-a2ea-7c8d9d47e0cf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2447c9b4-f9f0-49d9-8aeb-33fc9e025929_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4fe9c35f-8f12-44aa-ab4b-741d64cd8af9_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_63577beb-d26f-4a87-bd83-840aabd43afd_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_4924531a-584f-4d05-9b51-fcd453f575b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share-based compensation expense by type</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_fcdb19bc-64fd-49df-95a7-495c695c1a91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_ef467fa2-46e1-4a79-8bcb-7b3745ef1dbc_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_8df91f14-71e2-4ee6-a335-43b89eb15619_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_VariableRateComponentOneMember_bb6b0891-72de-46ea-b0a2-419a1b333400_terseLabel_en-US" xlink:label="lab_halo_VariableRateComponentOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component One</link:label>
    <link:label id="lab_halo_VariableRateComponentOneMember_label_en-US" xlink:label="lab_halo_VariableRateComponentOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component One [Member]</link:label>
    <link:label id="lab_halo_VariableRateComponentOneMember_documentation_en-US" xlink:label="lab_halo_VariableRateComponentOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentOneMember" xlink:href="halo-20230331.xsd#halo_VariableRateComponentOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_VariableRateComponentOneMember" xlink:to="lab_halo_VariableRateComponentOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d6fca52a-6ec4-4604-995e-6901923f9971_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_282a772e-3eb9-4afb-acb4-c1b6cc73ddb4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP purchase price of common stock, percent of market price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4909c529-9237-4267-8785-00988f8e9838_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_e10193b6-6948-48d7-8504-37734c29a66d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_74e4498c-bf7e-42ce-aa0a-b5267b5f4493_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c2094420-b452-4503-963f-9dd461daf857_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market value of gross unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b1b7ef21-f68f-42de-b981-29c444c90576_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e9f54544-91f2-45e5-9bd3-bb8efc57f315_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6221c307-0226-4bcb-9c13-1969960b924b_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d05a6777-a893-42bb-9b16-1190004399f9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bbfeabc5-4887-44da-b555-e3071a54e749_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of numerators and denominators of basic and diluted computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_1df5ded6-4769-4450-bb77-364acb866916_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_76dabf31-0371-431e-85c5-6e3480bed44b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible, threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8c8baf26-c940-424c-ae03-c9703c11549f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_ae7bcf19-e559-4fd3-a937-1c8c660e22b8_terseLabel_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency Securities</link:label>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AgencySecuritiesMember" xlink:to="lab_us-gaap_AgencySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6b25ac8f-d5b2-44ad-bea3-933fb12edbdb_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8551fdb2-437e-40e3-9f54-3d15f7870a2d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_ef8b1f04-bbc3-47f5-ac73-952d8515d97b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_8426f978-fae1-4282-92e9-f6366e9c1221_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_48f42885-e8b8-42ef-a629-447eea5d7c3d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_aa3fdc36-99f2-415f-aa46-fcb3435a0ea4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_bdb4d599-38a9-44f3-af7d-d5abdff3c786_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of 2024 Convertible Notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7287f218-017a-4ab3-93a1-c240bea54738_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_48585eda-823d-4953-b041-d60c6076c9da_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_c356ace7-77af-4ab1-b171-9cf1e5b89d6c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Balance Sheet Items</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_e26aba30-9898-453e-acce-d8faa1d0846a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_fea5a197-4bb5-4c18-a3fa-35df9df6bc73_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accounts receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_5b1171c1-38e2-4b30-91d1-ab955d7f66eb_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_45463b00-d34a-41f3-8cfa-d7abfc0dea78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Long-term portion</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_c0e183e3-13ea-4de3-b1b7-4ae3f43903c7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4edfab1a-e037-4dd2-8396-a881fc108911_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_1f36fbff-0c5b-4c59-90ec-1bbe71a807f4_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_fe9814b1-5a94-4477-8177-338cd69b0df2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product returns and sales allowance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_c4289f48-4986-4b03-8c78-ddfc779fe2f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of unrecognized estimated compensation cost by type</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_15611052-63ec-4efe-ba90-d0bd91514ed4_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_aa77abc3-0c59-4d01-8f62-64c2551cbeb7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, remaining performance obligation, expected timing</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff13968d-a453-478e-841e-15ee21c401bf_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_952022ae-8fd6-444f-9923-04bf2e978089_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_4fe64063-a8c5-443d-bde0-b5c63050a23d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0a4f133d-0ece-4976-a2df-66870d54256c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities_852a15e1-7c72-47fa-91c9-aa1ef55bea00_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other long-term liabilities</link:label>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities_label_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other long-term liabilities</link:label>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities_documentation_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other long-term liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities" xlink:href="halo-20230331.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities" xlink:to="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_72219d4b-a66b-4517-8677-ea6ff93a8645_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_4e957fd8-4b0c-4cfc-936c-df2809c68e3f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenders fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee960d4c-676d-42b3-a581-eab222ee2653_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6e825651-f51a-41a8-8251-ae00cbf0d8bb_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding for basic net income (loss) per share (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8d45943b-8b86-4ab4-8310-6e0455bcce3e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_5ade5282-8191-4d17-b98f-84dd217af266_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_e7833269-fbc4-44fb-bc3d-7c9ddce0a9bb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_1af210ff-5a08-4c75-9a4d-3b1c1df90778_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum employee subscription rate</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:href="halo-20230331.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:to="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_3ff4aa8a-959f-449d-8cab-4ad932780225_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_9f6207bc-1207-42aa-8fe3-d1895e05837f_terseLabel_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_label_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:to="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a75befe0-a07a-4bee-9d00-f141a07814e8_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_383d1bf7-641d-4823-a965-a24c72a76302_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_e349b1c6-be01-45ac-989e-6caaf906a3a3_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_7d75fa26-08ca-429d-afc0-340b233f5740_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_label_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_documentation_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" xlink:href="halo-20230331.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" xlink:to="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_b24ac64a-2bc9-4eee-90e8-56fb4eae553a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b2da1bd8-b51d-4c1f-857b-04c3c05032d7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8c977e1b-f253-47f3-a314-ae75ab697ad3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for the induced conversion related to convertible notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_db1cbdef-d43e-4ebe-a3fc-c599a9ddc17d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_23663c36-eb6b-4771-81ae-29ced119424b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_bf555164-01a3-4526-b922-e49883abb133_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_675cd9a4-9e73-468a-8610-7f73ade875c6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_84f98e7f-3496-4740-92b5-814d6b47f3c0_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_7ffebb7e-b75f-4032-9099-6cd6805a31d7_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_23fe70f4-ca80-42ce-b56f-663032e476c1_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_e890f73c-ee87-49e6-ac9a-7296c0c97f34_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_aa9f1536-ab72-4c84-86fa-3d8a3380d107_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_b4bdec0b-c18f-4771-8fc5-b34ec0d3b5a2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from revolving credit facilities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_6654b0ce-6e51-4a5c-bace-b9342764d453_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_69781d83-07d7-48d4-8549-a867a1b37ec9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from convertible debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_60ce2796-b6a0-4d74-9292-573d03ba60ac_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_801a4bfe-cc30-4a1e-8637-4d4bf10ded74_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_65ce3e1f-bb3d-4b83-a382-da8be4c9830f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_8e163590-db49-4c3f-bb94-796bc7ba8844_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_80f800f1-4883-43ce-9295-1dda95e1715e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DevelopmentFeesMember_3fd83113-921b-4060-854a-d163784102ae_terseLabel_en-US" xlink:label="lab_halo_DevelopmentFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Event-Based Development Fees</link:label>
    <link:label id="lab_halo_DevelopmentFeesMember_label_en-US" xlink:label="lab_halo_DevelopmentFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Fees [Member]</link:label>
    <link:label id="lab_halo_DevelopmentFeesMember_documentation_en-US" xlink:label="lab_halo_DevelopmentFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevelopmentFeesMember" xlink:href="halo-20230331.xsd#halo_DevelopmentFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DevelopmentFeesMember" xlink:to="lab_halo_DevelopmentFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d201fd3e-c1e9-438b-9637-6719827b3299_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5f2bbe1a-4d9c-41ca-b4c8-8794d40fa6f3_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_d9fc46de-400a-4aac-994d-969eca312d74_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_fda4e76a-2634-4f5d-8030-91343ff727ef_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_75a0c63d-bae5-49f5-921e-b024a7f2b951_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_a3f86f6e-2974-4931-a0a8-148db44fd5b2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total coupon interest</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e5a6495b-a850-4b28-97e9-055dde907f95_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period, shares, restricted stock award, net of forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_Accountsreceivablefromroyalties_363dcc23-9c54-42e6-821f-3ce915ee26fc_terseLabel_en-US" xlink:label="lab_halo_Accountsreceivablefromroyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from royalty payments</link:label>
    <link:label id="lab_halo_Accountsreceivablefromroyalties_label_en-US" xlink:label="lab_halo_Accountsreceivablefromroyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from royalties</link:label>
    <link:label id="lab_halo_Accountsreceivablefromroyalties_documentation_en-US" xlink:label="lab_halo_Accountsreceivablefromroyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due from royalties, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromroyalties" xlink:href="halo-20230331.xsd#halo_Accountsreceivablefromroyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accountsreceivablefromroyalties" xlink:to="lab_halo_Accountsreceivablefromroyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_401e78d0-58a9-4973-9a59-8903a8d4a943_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_af0aea27-4d04-429f-ac13-219e6bb8ce1d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2acc31f4-5340-489b-b447-cbf7a72385bb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_456f9b27-4d3c-4c59-bc1d-e5401de338e1_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_94886f12-99cc-4ae3-af5c-38398958c56d_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_085c6947-9750-4756-b1b0-721fd630df20_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationAwardUnvestedMember_0a23de3e-3567-4758-bece-6793bad64584_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationAwardUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Compensation Award, Unvested</link:label>
    <link:label id="lab_halo_ShareBasedCompensationAwardUnvestedMember_label_en-US" xlink:label="lab_halo_ShareBasedCompensationAwardUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Unvested [Member]</link:label>
    <link:label id="lab_halo_ShareBasedCompensationAwardUnvestedMember_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationAwardUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Unvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationAwardUnvestedMember" xlink:href="halo-20230331.xsd#halo_ShareBasedCompensationAwardUnvestedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationAwardUnvestedMember" xlink:to="lab_halo_ShareBasedCompensationAwardUnvestedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_f5a54a56-d14a-4c5f-9d7f-b67c56e8e506_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_Accountsreceivablefromproductsalestocollaborators_5a930785-4035-44eb-9671-ec861eb2e850_terseLabel_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsalestocollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from product sales to partners</link:label>
    <link:label id="lab_halo_Accountsreceivablefromproductsalestocollaborators_label_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsalestocollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from product sales to collaborators</link:label>
    <link:label id="lab_halo_Accountsreceivablefromproductsalestocollaborators_documentation_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsalestocollaborators" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from product sales to collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromproductsalestocollaborators" xlink:href="halo-20230331.xsd#halo_Accountsreceivablefromproductsalestocollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accountsreceivablefromproductsalestocollaborators" xlink:to="lab_halo_Accountsreceivablefromproductsalestocollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_6e2523cf-1064-44a0-9fef-10c4573cfa65_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_16692c4f-c4d7-482e-92c0-b8bfefecc6d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5ea9f0da-d862-42ea-b6a7-b97dc121c795_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_e61bd056-b6ee-4026-96fb-5f5ad84a1eba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_6e58069d-d16b-40ec-b8a8-9aec94312d7b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DeviceLicensingAndDevelopmentMember_458d36c3-b48b-40f0-bcbb-11275e302816_terseLabel_en-US" xlink:label="lab_halo_DeviceLicensingAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Licensing and development revenue</link:label>
    <link:label id="lab_halo_DeviceLicensingAndDevelopmentMember_label_en-US" xlink:label="lab_halo_DeviceLicensingAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Licensing and Development [Member]</link:label>
    <link:label id="lab_halo_DeviceLicensingAndDevelopmentMember_documentation_en-US" xlink:label="lab_halo_DeviceLicensingAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Licensing and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeviceLicensingAndDevelopmentMember" xlink:href="halo-20230331.xsd#halo_DeviceLicensingAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DeviceLicensingAndDevelopmentMember" xlink:to="lab_halo_DeviceLicensingAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_9de455e3-291a-41b2-a56e-923c4e384976_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ProprietaryProductsSalesMember_5a406142-d5cb-4b5b-94cb-34aab749979e_terseLabel_en-US" xlink:label="lab_halo_ProprietaryProductsSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proprietary Products Sales</link:label>
    <link:label id="lab_halo_ProprietaryProductsSalesMember_label_en-US" xlink:label="lab_halo_ProprietaryProductsSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proprietary Products Sales [Member]</link:label>
    <link:label id="lab_halo_ProprietaryProductsSalesMember_documentation_en-US" xlink:label="lab_halo_ProprietaryProductsSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proprietary Products Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProprietaryProductsSalesMember" xlink:href="halo-20230331.xsd#halo_ProprietaryProductsSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ProprietaryProductsSalesMember" xlink:to="lab_halo_ProprietaryProductsSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_4e747960-f31c-4689-acd7-ac1b82f13b39_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4f41f353-b31f-4643-b05f-d3c75d3079ef_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8173eac7-7ad5-4271-9ee1-0a4c3d21e378_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_ef105356-c537-4716-961b-6edbef65dbe1_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_XYOSTEDProprietaryProductMember_cea0f25e-7800-433c-90a3-a82b234d2619_terseLabel_en-US" xlink:label="lab_halo_XYOSTEDProprietaryProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XYOSTED Proprietary Product [Member]</link:label>
    <link:label id="lab_halo_XYOSTEDProprietaryProductMember_label_en-US" xlink:label="lab_halo_XYOSTEDProprietaryProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XYOSTED Proprietary Product [Member]</link:label>
    <link:label id="lab_halo_XYOSTEDProprietaryProductMember_documentation_en-US" xlink:label="lab_halo_XYOSTEDProprietaryProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XYOSTED Proprietary Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_XYOSTEDProprietaryProductMember" xlink:href="halo-20230331.xsd#halo_XYOSTEDProprietaryProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_XYOSTEDProprietaryProductMember" xlink:to="lab_halo_XYOSTEDProprietaryProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0f26c29e-1497-48ed-bd43-aa2068cf7862_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of loss positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_e953da63-69f0-4a0e-bd49-58c0899561e8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_90e1ef42-299d-4017-a1f2-0be3d0494a70_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, excluding current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare_12451c5e-4a90-494b-ad5a-6bd17eb5c7d4_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap call transaction, cap price per share (in usd per share)</link:label>
    <link:label id="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare_label_en-US" xlink:label="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Cap Call Transaction, Cap Price Per Share</link:label>
    <link:label id="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare_documentation_en-US" xlink:label="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Cap Call Transaction, Cap Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:href="halo-20230331.xsd#halo_DebtInstrumentCapCallTransactionCapPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:to="lab_halo_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_63a9112c-3317-4dd3-9aba-c212eea1067a_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_80eea9c5-b942-448b-b2e4-c30c6cf3fde4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_3a24082a-ed5c-4a5f-9c28-a112730c3652_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, cash paid per acquiree share (in usd per share)</link:label>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_label_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share</link:label>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_documentation_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" xlink:href="halo-20230331.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" xlink:to="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RoyaltiesReceivedNumberOfProductsSold_875845dd-5b40-43e7-aa4f-1fd7ba062fc7_terseLabel_en-US" xlink:label="lab_halo_RoyaltiesReceivedNumberOfProductsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">royalties received, number of products sold</link:label>
    <link:label id="lab_halo_RoyaltiesReceivedNumberOfProductsSold_label_en-US" xlink:label="lab_halo_RoyaltiesReceivedNumberOfProductsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Received, Number of Products Sold</link:label>
    <link:label id="lab_halo_RoyaltiesReceivedNumberOfProductsSold_documentation_en-US" xlink:label="lab_halo_RoyaltiesReceivedNumberOfProductsSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Received, Number of Products Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RoyaltiesReceivedNumberOfProductsSold" xlink:href="halo-20230331.xsd#halo_RoyaltiesReceivedNumberOfProductsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RoyaltiesReceivedNumberOfProductsSold" xlink:to="lab_halo_RoyaltiesReceivedNumberOfProductsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_6b74cdc6-1efd-45c4-8cee-dfb74d05034d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_81bb7010-dd0b-45c1-985c-0a0ccba7b979_terseLabel_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</link:label>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_label_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</link:label>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_documentation_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:href="halo-20230331.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:to="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c6d276b3-9df9-4fbe-9272-1e3a96ccb136_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RSURSAandPRSUawardsMember_3a9ec828-fe22-4b7e-8b16-757d6da7e593_verboseLabel_en-US" xlink:label="lab_halo_RSURSAandPRSUawardsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs, PSUs and ESPP</link:label>
    <link:label id="lab_halo_RSURSAandPRSUawardsMember_label_en-US" xlink:label="lab_halo_RSURSAandPRSUawardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU, RSA, and PRSU awards [Member]</link:label>
    <link:label id="lab_halo_RSURSAandPRSUawardsMember_documentation_en-US" xlink:label="lab_halo_RSURSAandPRSUawardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit, Restricted Stock Awards, and Performance Restricted Stock Unit awards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember" xlink:href="halo-20230331.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RSURSAandPRSUawardsMember" xlink:to="lab_halo_RSURSAandPRSUawardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d5a6e0f6-78da-4c31-8ab1-5f7ca3f39f87_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_ae5d383a-65af-4470-a708-266b223defa9_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts receivable and contract assets</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_f3c6db16-c644-496f-b0c9-c67bcd5a7ac7_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of (premium) discounts on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_b3a132ea-6429-45aa-aa8c-b0d83fde2f62_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AntaresPharmaIncMember_4cef40b6-4e2a-4c31-ad69-8d40b872f2e5_terseLabel_en-US" xlink:label="lab_halo_AntaresPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antares Pharma, Inc</link:label>
    <link:label id="lab_halo_AntaresPharmaIncMember_label_en-US" xlink:label="lab_halo_AntaresPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antares Pharma, Inc [Member]</link:label>
    <link:label id="lab_halo_AntaresPharmaIncMember_documentation_en-US" xlink:label="lab_halo_AntaresPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antares Pharma, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember" xlink:href="halo-20230331.xsd#halo_AntaresPharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AntaresPharmaIncMember" xlink:to="lab_halo_AntaresPharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0387b162-3df3-4213-a2cf-acb20abdce8f_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_d51bbd50-c58b-4ba8-8a39-1b35c01809c1_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_819e86c9-9f29-478f-9b19-7f3f2fe42e93_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_571a8010-eea3-4b8a-8bcf-039151637a15_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2f6ea1c9-37e5-41be-b6b8-669b3e694de2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_98558407-1d1a-4753-9f31-29b2a1bfed3a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets_6597f503-39cb-4bc7-96d4-bd7f56688720_terseLabel_en-US" xlink:label="lab_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets_label_en-US" xlink:label="lab_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current, excluding Other Contract Assets</link:label>
    <link:label id="lab_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets_documentation_en-US" xlink:label="lab_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current, excluding Other Contract Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" xlink:href="halo-20230331.xsd#halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" xlink:to="lab_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_b84caf6b-c664-48b2-9eca-326c1d7b6ec7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_e92e4017-3fc2-4469-8bf2-e23a2c28a513_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_2e8363ad-40c7-4e64-9392-da356d994a80_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_646d80df-2545-4eaf-a121-80197a8fb7f7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8eee31a9-2e66-4d9e-aec2-c7684452ed7c_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_3abfbad0-9b1a-426b-9991-5485b922da4b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_85ac7264-6b0b-42bc-8831-0c2e282d2c47_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5828394a-51da-4052-930f-40909e247704_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ffade773-2c22-4fda-9c8c-47c7798ce9a1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_e757f30e-c0ca-4b04-8f46-7be15b737d1a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_f117eb7b-2814-490a-b4b3-bdf1af8558ac_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_959f06c9-54a7-42d9-9a2d-e0e60c8b8481_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet_39a86626-17a0-473f-b513-9d7382b5f40d_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred tax liabilities, net</link:label>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet_label_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred tax liabilities, net</link:label>
    <link:label id="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet_documentation_en-US" xlink:label="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred tax liabilities, net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet" xlink:href="halo-20230331.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet" xlink:to="lab_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6f479d7e-1a09-4fab-8f1a-331fba6589d2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_16627c0d-bde7-4c12-a947-b0fecbdf0ebe_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_55d558b2-f4dd-4426-8f3f-0bf723873148_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock issued as a result of stock option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_fa4606b9-9463-40dc-9238-511f160f38f8_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue and Cost of Product Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_16fa1778-ae72-480d-9194-f8261c6df259_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_83fe5aef-fabf-471f-97e8-35a6a69e5755_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding for diluted net income (loss) per share (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_c1a5ab43-e23f-4826-9f49-e82a79324434_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_650a9fb0-47ba-4018-9ebf-2f26fd3598f2_terseLabel_en-US" xlink:label="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock premium over last reported sale price, percentage</link:label>
    <link:label id="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_label_en-US" xlink:label="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock Premium Over Last Reported Sale Price, Percentage</link:label>
    <link:label id="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_documentation_en-US" xlink:label="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock Premium Over Last Reported Sale Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" xlink:href="halo-20230331.xsd#halo_SaleOfStockPremiumOverLastReportedSalePricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" xlink:to="lab_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AccruedLiabilitiesNoncurrent_11d8cdaf-5e22-4275-b9fb-19173e31d949_negatedTerseLabel_en-US" xlink:label="lab_halo_AccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less long-term portion</link:label>
    <link:label id="lab_halo_AccruedLiabilitiesNoncurrent_label_en-US" xlink:label="lab_halo_AccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Noncurrent</link:label>
    <link:label id="lab_halo_AccruedLiabilitiesNoncurrent_documentation_en-US" xlink:label="lab_halo_AccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccruedLiabilitiesNoncurrent" xlink:href="halo-20230331.xsd#halo_AccruedLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AccruedLiabilitiesNoncurrent" xlink:to="lab_halo_AccruedLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_a04f2220-1f04-49b0-b052-9a20ebce1520_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_1c48c970-f478-4f2f-8a78-17b15a93c1a2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_6a1f22e3-408d-461f-879d-fa4fb359e8fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4ea9de6c-01a8-4088-b329-3a3dd9661b84_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4474a89b-dbab-42ac-a496-68983630c797_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f7d25ccc-f337-4844-b82c-670f767dc4be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_8b704800-b5af-4195-89be-60c73b89dece_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_48cb5855-46f3-4587-9722-a0159b91730a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AllowanceforDistributionFeesandDiscounts_b4da7d59-e75f-4750-b1fd-e7423386d970_negatedTerseLabel_en-US" xlink:label="lab_halo_AllowanceforDistributionFeesandDiscounts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for distribution fees and discounts</link:label>
    <link:label id="lab_halo_AllowanceforDistributionFeesandDiscounts_label_en-US" xlink:label="lab_halo_AllowanceforDistributionFeesandDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Distribution Fees and Discounts</link:label>
    <link:label id="lab_halo_AllowanceforDistributionFeesandDiscounts_documentation_en-US" xlink:label="lab_halo_AllowanceforDistributionFeesandDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Discount and Distribution Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AllowanceforDistributionFeesandDiscounts" xlink:href="halo-20230331.xsd#halo_AllowanceforDistributionFeesandDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AllowanceforDistributionFeesandDiscounts" xlink:to="lab_halo_AllowanceforDistributionFeesandDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_63784dae-0d7f-4073-a2df-f559d5d7380c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_6c12862f-cf69-47c6-9224-dfc2e4cb8728_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_be4be277-e200-4383-ad23-47c458897f9e_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b0748c49-e23b-4e5b-a5b3-554fc2cf08d4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2883195b-88a2-4bd9-bc60-94184799c1a6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_28b17f1f-b3d3-4d2f-b085-92ce676f53bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7b34b5bc-c940-4854-8cca-a55865927763_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_eec251ab-d8cb-4947-889f-4b881277c0b9_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_69e3bd87-a4a9-4009-9e5c-24c7a7b6b2f1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_aab92c7f-8ba0-4393-970e-96bf9aaecbf0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3aa40680-92dc-4cb6-9a47-912616896cef_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for tax withholding for restricted stock units vested, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_adc8b9fa-ba06-49a3-904a-8f03889c460c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_A2021ESPPPlanMember_f00ce823-f832-480a-83ba-bfb0faa22d58_terseLabel_en-US" xlink:label="lab_halo_A2021ESPPPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 ESPP Plan</link:label>
    <link:label id="lab_halo_A2021ESPPPlanMember_label_en-US" xlink:label="lab_halo_A2021ESPPPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 ESPP Plan [Member]</link:label>
    <link:label id="lab_halo_A2021ESPPPlanMember_documentation_en-US" xlink:label="lab_halo_A2021ESPPPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 ESPP Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2021ESPPPlanMember" xlink:href="halo-20230331.xsd#halo_A2021ESPPPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A2021ESPPPlanMember" xlink:to="lab_halo_A2021ESPPPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_VariableRateComponentDomain_621f246f-6a4f-456d-afd6-5e93df4fd19b_terseLabel_en-US" xlink:label="lab_halo_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:label id="lab_halo_VariableRateComponentDomain_label_en-US" xlink:label="lab_halo_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:label id="lab_halo_VariableRateComponentDomain_documentation_en-US" xlink:label="lab_halo_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentDomain" xlink:href="halo-20230331.xsd#halo_VariableRateComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_VariableRateComponentDomain" xlink:to="lab_halo_VariableRateComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RestrictStockUnitsPerformanceSharesAndESPPMember_136aeab7-5826-42b0-b13f-5ed80c6eb28d_terseLabel_en-US" xlink:label="lab_halo_RestrictStockUnitsPerformanceSharesAndESPPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs, PSUs and ESPP</link:label>
    <link:label id="lab_halo_RestrictStockUnitsPerformanceSharesAndESPPMember_label_en-US" xlink:label="lab_halo_RestrictStockUnitsPerformanceSharesAndESPPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrict Stock Units, Performance Shares and ESPP [Member]</link:label>
    <link:label id="lab_halo_RestrictStockUnitsPerformanceSharesAndESPPMember_documentation_en-US" xlink:label="lab_halo_RestrictStockUnitsPerformanceSharesAndESPPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrict Stock Units, Performance Shares and ESPP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RestrictStockUnitsPerformanceSharesAndESPPMember" xlink:href="halo-20230331.xsd#halo_RestrictStockUnitsPerformanceSharesAndESPPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RestrictStockUnitsPerformanceSharesAndESPPMember" xlink:to="lab_halo_RestrictStockUnitsPerformanceSharesAndESPPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BulkrHuPH20Member_0ebfa2d9-5c61-41e0-aadc-9c423644a166_terseLabel_en-US" xlink:label="lab_halo_BulkrHuPH20Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bulk rHuPH20</link:label>
    <link:label id="lab_halo_BulkrHuPH20Member_label_en-US" xlink:label="lab_halo_BulkrHuPH20Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bulk rHuPH20 [Member]</link:label>
    <link:label id="lab_halo_BulkrHuPH20Member_documentation_en-US" xlink:label="lab_halo_BulkrHuPH20Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bulk rHuPH20 for use in collaboration products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BulkrHuPH20Member" xlink:href="halo-20230331.xsd#halo_BulkrHuPH20Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BulkrHuPH20Member" xlink:to="lab_halo_BulkrHuPH20Member" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_Accruedmanufacturingexpenses_a15e9e6d-5f4f-4cba-9c3d-62015a0998ef_terseLabel_en-US" xlink:label="lab_halo_Accruedmanufacturingexpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued outsourced manufacturing expenses</link:label>
    <link:label id="lab_halo_Accruedmanufacturingexpenses_label_en-US" xlink:label="lab_halo_Accruedmanufacturingexpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued manufacturing expenses</link:label>
    <link:label id="lab_halo_Accruedmanufacturingexpenses_documentation_en-US" xlink:label="lab_halo_Accruedmanufacturingexpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued manufacturing expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accruedmanufacturingexpenses" xlink:href="halo-20230331.xsd#halo_Accruedmanufacturingexpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accruedmanufacturingexpenses" xlink:to="lab_halo_Accruedmanufacturingexpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f2b9df31-406f-45d0-abcd-f2ddaee87258_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_2764aa05-871b-4823-bec9-e80c5744b634_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bc6861d1-8343-4299-802b-24158b277f66_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_25a99484-12c8-4f0c-b9a2-7c447a9e2be0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodDomain_08bf2080-9943-40cd-96c9-66d77055e625_terseLabel_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Interest Payment Period [Domain]</link:label>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodDomain_label_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Interest Payment Period [Domain]</link:label>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodDomain_documentation_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Interest Payment Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodDomain" xlink:href="halo-20230331.xsd#halo_AnnualInterestPaymentPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain" xlink:to="lab_halo_AnnualInterestPaymentPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_f6d4697e-bae7-412d-b42c-93a355e06135_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6872f5ea-9ebd-4ab0-bbf1-71490cd43c98_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_bdb92dce-c2c9-4310-b182-223767f7b406_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8bc601b2-a8f7-47bf-b265-d82de2e803dc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ef2bfd35-4e07-4ba3-b48b-a3d8c284f967_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_131735ee-3fe0-46d8-8138-515f4fca5188_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4c42f558-d5b2-460d-8ce3-33ef9a45910e_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption and Pending Adoption of Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member_9ccbda1d-a754-433b-a07e-f317c60a6f10_terseLabel_en-US" xlink:label="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% Convertible Senior Notes due 2024</link:label>
    <link:label id="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member_label_en-US" xlink:label="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% Convertible Senior Notes due 2024 [Member]</link:label>
    <link:label id="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member_documentation_en-US" xlink:label="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% Convertible Senior Notes due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:href="halo-20230331.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:to="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1a54d55a-1002-4f12-83f4-bda57a7136da_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_34e4ebef-90fd-4c5a-895f-f54b002d6257_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c1d44547-0733-49d8-8dd8-494d7574a563_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_401ca95f-3aa1-42a2-acd9-22a86738a233_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_31f9e868-04d0-4157-87c3-8a76d8c1c776_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_6bede8f4-f9b7-4050-b4d9-e16dd588a6a8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_90ac7f38-febc-4e59-bd8d-5a435a8e9ef3_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_8448539e-baf3-4a38-ae48-76de9129f594_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_1918c9c9-56d1-445f-b7a6-7632a9eae405_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_ee44bf87-ba31-4d51-bbe6-9a6fd047c614_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Ending Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenue_66789636-7ea5-483f-8652-05bbda2177da_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue" xlink:to="lab_us-gaap_DeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_c34974eb-f1de-4977-af9a-2266d84a8762_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_Accountsreceivablefromproductsales_0d8b5b12-8e56-47dc-aca2-8222983af112_terseLabel_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from other product sales</link:label>
    <link:label id="lab_halo_Accountsreceivablefromproductsales_label_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from product sales</link:label>
    <link:label id="lab_halo_Accountsreceivablefromproductsales_documentation_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from product sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromproductsales" xlink:href="halo-20230331.xsd#halo_Accountsreceivablefromproductsales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accountsreceivablefromproductsales" xlink:to="lab_halo_Accountsreceivablefromproductsales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_99a26d78-097c-4805-b3e7-285f22eae8f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_3561f041-2b4b-4d6e-a1d2-de3a172d758e_verboseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8c2f91d-ed1d-4f1f-bb6c-6ad2a4dd2ace_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_49972250-57bf-4158-927f-adc806277cb7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_c4188fde-a91a-4cee-8fc5-8b5077f1c49e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_e1ea488f-8075-4efc-9928-b9690c0fffed_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_d6806a59-8433-41bf-aaa3-e3ff89dd5c53_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_7deaa810-c73b-47ae-a5c9-5632eb2088d1_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1ebd4bb1-ddb3-43b3-a058-85fe9a8ba9a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2b31a95-3dfe-4e49-a316-71dae5d17186_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_31587203-a542-4088-87ec-fe4f2d127bc0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>halo-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5667a7fc-e0e0-4ae8-9db7-13762e0ab1e4,g:df8c4c1a-0af9-473f-aa3c-bddd63ebeeb8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.halozyme.com/role/CoverPage" xlink:type="simple" xlink:href="halo-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_80e663ba-002a-4e2e-9376-77d04b4387d9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_DocumentType_80e663ba-002a-4e2e-9376-77d04b4387d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_a7fa2dd6-7ce8-4dd8-a3d3-5792ae9d7f43" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_DocumentQuarterlyReport_a7fa2dd6-7ce8-4dd8-a3d3-5792ae9d7f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3b80b6f5-8a73-412a-872e-18580879222c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_DocumentPeriodEndDate_3b80b6f5-8a73-412a-872e-18580879222c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_40de159a-97a1-4f64-abcb-dc3d004086fa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_DocumentTransitionReport_40de159a-97a1-4f64-abcb-dc3d004086fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9d04e610-521f-4a2c-bb0d-80fb9730bd13" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_EntityFileNumber_9d04e610-521f-4a2c-bb0d-80fb9730bd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ffc68a10-7339-45df-8831-b4e93e166f2d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_EntityRegistrantName_ffc68a10-7339-45df-8831-b4e93e166f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c18830f3-8691-4732-89b9-228d2475327c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c18830f3-8691-4732-89b9-228d2475327c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a2127e2c-99f2-4efe-ad54-19ef72441d0f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_EntityTaxIdentificationNumber_a2127e2c-99f2-4efe-ad54-19ef72441d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_26febc81-fc3f-4abd-8dda-5d60c5d90802" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_EntityAddressAddressLine1_26febc81-fc3f-4abd-8dda-5d60c5d90802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_fbf8be1b-441d-47a1-b73c-8eb62a7f73c4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_EntityAddressCityOrTown_fbf8be1b-441d-47a1-b73c-8eb62a7f73c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8b9db3d4-1ea5-423e-88f5-7614fa40f881" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_EntityAddressStateOrProvince_8b9db3d4-1ea5-423e-88f5-7614fa40f881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c6827b57-d5a7-4354-bc87-7689f8de45f5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_EntityAddressPostalZipCode_c6827b57-d5a7-4354-bc87-7689f8de45f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_36ea3460-7bc2-4ee3-9cc4-31edef6ec5ae" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_CityAreaCode_36ea3460-7bc2-4ee3-9cc4-31edef6ec5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1051bc74-750a-428a-b9a0-6b48a77a8db5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_LocalPhoneNumber_1051bc74-750a-428a-b9a0-6b48a77a8db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3b6a5fdd-9f1a-423d-8791-c9128bcc064a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_Security12bTitle_3b6a5fdd-9f1a-423d-8791-c9128bcc064a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_cd9b7bcb-195b-4a04-b789-5d4bc97bb635" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_TradingSymbol_cd9b7bcb-195b-4a04-b789-5d4bc97bb635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2390b470-556d-404e-a264-65c5cc4b5a4b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_SecurityExchangeName_2390b470-556d-404e-a264-65c5cc4b5a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_27fc699e-e34b-40a7-b284-664d9f1adb5e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_EntityCurrentReportingStatus_27fc699e-e34b-40a7-b284-664d9f1adb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ceb75a92-5ea6-45c9-8d7a-59436bb46fc7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_EntityInteractiveDataCurrent_ceb75a92-5ea6-45c9-8d7a-59436bb46fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f50a1cce-f3f7-40cf-a3f2-3d9b46cb3e74" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_EntitySmallBusiness_f50a1cce-f3f7-40cf-a3f2-3d9b46cb3e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f6579e3e-d028-4a18-9e2b-823839c5231a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_EntityEmergingGrowthCompany_f6579e3e-d028-4a18-9e2b-823839c5231a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4fb9f89c-b153-46d7-ab8a-a6c6c0d01588" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_EntityShellCompany_4fb9f89c-b153-46d7-ab8a-a6c6c0d01588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6f40a7cb-0ee2-4d81-87b7-232c3ca20c37" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6f40a7cb-0ee2-4d81-87b7-232c3ca20c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_89e5c678-5ed1-4978-b4a1-9cb792f17e72" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_EntityCentralIndexKey_89e5c678-5ed1-4978-b4a1-9cb792f17e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f6823231-c0ed-4742-bf30-a37c0928b1eb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_AmendmentFlag_f6823231-c0ed-4742-bf30-a37c0928b1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_7f2a647a-8aae-4bb4-9ae0-e1823944f5a1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_DocumentFiscalYearFocus_7f2a647a-8aae-4bb4-9ae0-e1823944f5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d9b3ef20-bc6b-405b-9c6d-d8a3cd8bf607" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d9b3ef20-bc6b-405b-9c6d-d8a3cd8bf607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_31ac8ab3-16d6-46b8-85a2-128226a3701f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_CurrentFiscalYearEndDate_31ac8ab3-16d6-46b8-85a2-128226a3701f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a5b98c50-9723-44fa-91ff-9a6c5da39ddd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_358698e0-0f7d-4cec-982d-e340b83523d3" xlink:to="loc_dei_EntityFilerCategory_a5b98c50-9723-44fa-91ff-9a6c5da39ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="halo-20230331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7b0d6251-98af-4eb6-9782-38f091733a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0a4d3293-d429-403f-b301-c3fb10e3445f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7b0d6251-98af-4eb6-9782-38f091733a81" xlink:to="loc_us-gaap_AssetsAbstract_0a4d3293-d429-403f-b301-c3fb10e3445f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_af56ab27-85cc-43ff-82ec-9e6f5b877ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a4d3293-d429-403f-b301-c3fb10e3445f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_af56ab27-85cc-43ff-82ec-9e6f5b877ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_859b0851-8a6a-4d53-9819-c13e34421f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af56ab27-85cc-43ff-82ec-9e6f5b877ca5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_859b0851-8a6a-4d53-9819-c13e34421f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_431ba27b-cec8-4b28-a9f2-31edadb644e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af56ab27-85cc-43ff-82ec-9e6f5b877ca5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_431ba27b-cec8-4b28-a9f2-31edadb644e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c75fa753-8fec-43f7-8743-64390cd0f1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af56ab27-85cc-43ff-82ec-9e6f5b877ca5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c75fa753-8fec-43f7-8743-64390cd0f1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_06020612-1ea2-4644-bd00-dee509031d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af56ab27-85cc-43ff-82ec-9e6f5b877ca5" xlink:to="loc_us-gaap_InventoryNet_06020612-1ea2-4644-bd00-dee509031d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_543e7cef-920e-4a8e-be06-9b3fcbd08778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af56ab27-85cc-43ff-82ec-9e6f5b877ca5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_543e7cef-920e-4a8e-be06-9b3fcbd08778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d2a86b67-ab59-4d73-b8ba-bf36a8dcace2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af56ab27-85cc-43ff-82ec-9e6f5b877ca5" xlink:to="loc_us-gaap_AssetsCurrent_d2a86b67-ab59-4d73-b8ba-bf36a8dcace2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_346fe2c8-d69a-40b2-8196-4af47b81a6e6" xlink:href="halo-20230331.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a4d3293-d429-403f-b301-c3fb10e3445f" xlink:to="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_346fe2c8-d69a-40b2-8196-4af47b81a6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_cfb078d9-4609-407f-8e1e-bf64456cab7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a4d3293-d429-403f-b301-c3fb10e3445f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_cfb078d9-4609-407f-8e1e-bf64456cab7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7835f688-08f6-4b29-84af-de35c30cdaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a4d3293-d429-403f-b301-c3fb10e3445f" xlink:to="loc_us-gaap_Goodwill_7835f688-08f6-4b29-84af-de35c30cdaf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_58533388-3f8d-410b-84cc-152fc7f1d354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a4d3293-d429-403f-b301-c3fb10e3445f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_58533388-3f8d-410b-84cc-152fc7f1d354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_64928894-b0e2-45f6-badd-0a2a1a0be1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a4d3293-d429-403f-b301-c3fb10e3445f" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_64928894-b0e2-45f6-badd-0a2a1a0be1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ffeef254-da3c-43c2-83d9-75c15decc4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a4d3293-d429-403f-b301-c3fb10e3445f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ffeef254-da3c-43c2-83d9-75c15decc4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_138cfb29-2fad-4a3b-b64f-afcf8f300a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a4d3293-d429-403f-b301-c3fb10e3445f" xlink:to="loc_us-gaap_Assets_138cfb29-2fad-4a3b-b64f-afcf8f300a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4bd71e0d-b591-4b33-9784-4a0b16e11b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7b0d6251-98af-4eb6-9782-38f091733a81" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4bd71e0d-b591-4b33-9784-4a0b16e11b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_16539ebc-97e7-462b-8042-be68ced0dbec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4bd71e0d-b591-4b33-9784-4a0b16e11b4b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_16539ebc-97e7-462b-8042-be68ced0dbec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_514e44cf-1fc9-497f-acf9-4ccf645bb14d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16539ebc-97e7-462b-8042-be68ced0dbec" xlink:to="loc_us-gaap_AccountsPayableCurrent_514e44cf-1fc9-497f-acf9-4ccf645bb14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1f235e08-891b-410a-ab91-0faf4aa09672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16539ebc-97e7-462b-8042-be68ced0dbec" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1f235e08-891b-410a-ab91-0faf4aa09672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_46194e42-19c9-4216-a727-f7162b5b2b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16539ebc-97e7-462b-8042-be68ced0dbec" xlink:to="loc_us-gaap_DeferredRevenueCurrent_46194e42-19c9-4216-a727-f7162b5b2b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_e4b4c2a8-b338-4596-a2ed-a33f66ff84cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16539ebc-97e7-462b-8042-be68ced0dbec" xlink:to="loc_us-gaap_LongTermDebtCurrent_e4b4c2a8-b338-4596-a2ed-a33f66ff84cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_37c9b4c9-ff7e-4b92-a04a-a35861a936e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16539ebc-97e7-462b-8042-be68ced0dbec" xlink:to="loc_us-gaap_LiabilitiesCurrent_37c9b4c9-ff7e-4b92-a04a-a35861a936e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_74ce95dd-1b36-442d-9ec6-245262ca41d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4bd71e0d-b591-4b33-9784-4a0b16e11b4b" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_74ce95dd-1b36-442d-9ec6-245262ca41d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e39af736-52d4-4ec7-acc6-cad30b189000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4bd71e0d-b591-4b33-9784-4a0b16e11b4b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e39af736-52d4-4ec7-acc6-cad30b189000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d14e7b8d-21b6-4267-8f43-383c0bb6235d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4bd71e0d-b591-4b33-9784-4a0b16e11b4b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d14e7b8d-21b6-4267-8f43-383c0bb6235d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7e56e775-da63-4fcf-bfbf-5068f1af34be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4bd71e0d-b591-4b33-9784-4a0b16e11b4b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7e56e775-da63-4fcf-bfbf-5068f1af34be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5f711907-2529-430d-9572-61416ad6c739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4bd71e0d-b591-4b33-9784-4a0b16e11b4b" xlink:to="loc_us-gaap_Liabilities_5f711907-2529-430d-9572-61416ad6c739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_34f5c24f-31c4-4e78-8ee1-9f9ae7ac1e20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4bd71e0d-b591-4b33-9784-4a0b16e11b4b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_34f5c24f-31c4-4e78-8ee1-9f9ae7ac1e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e1e10f1f-0632-47ca-aeb1-7f987be8c038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4bd71e0d-b591-4b33-9784-4a0b16e11b4b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e1e10f1f-0632-47ca-aeb1-7f987be8c038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_dabf31f7-538b-4da9-bf8c-5a80886ebe04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e1e10f1f-0632-47ca-aeb1-7f987be8c038" xlink:to="loc_us-gaap_PreferredStockValue_dabf31f7-538b-4da9-bf8c-5a80886ebe04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5a4a597a-4cb6-4d3f-afef-96d704e90fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e1e10f1f-0632-47ca-aeb1-7f987be8c038" xlink:to="loc_us-gaap_CommonStockValue_5a4a597a-4cb6-4d3f-afef-96d704e90fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_079d4625-0c06-4c98-8a48-eddc61bcc2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e1e10f1f-0632-47ca-aeb1-7f987be8c038" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_079d4625-0c06-4c98-8a48-eddc61bcc2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b3443e4b-0ea1-4725-99d0-b082a3cc6436" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e1e10f1f-0632-47ca-aeb1-7f987be8c038" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b3443e4b-0ea1-4725-99d0-b082a3cc6436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b5e63435-0954-4804-a81f-9d9d61e3ad6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e1e10f1f-0632-47ca-aeb1-7f987be8c038" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b5e63435-0954-4804-a81f-9d9d61e3ad6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1a69fd26-f8be-4c3d-a617-9b8f26284866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e1e10f1f-0632-47ca-aeb1-7f987be8c038" xlink:to="loc_us-gaap_StockholdersEquity_1a69fd26-f8be-4c3d-a617-9b8f26284866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_28632300-c38e-4019-8b3c-40b38ad6f9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4bd71e0d-b591-4b33-9784-4a0b16e11b4b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_28632300-c38e-4019-8b3c-40b38ad6f9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="halo-20230331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_144f14b6-51be-4000-b947-98ac1c5737a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8f7a2e7a-252a-4c7d-a38e-9fd518526c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_144f14b6-51be-4000-b947-98ac1c5737a6" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8f7a2e7a-252a-4c7d-a38e-9fd518526c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c39b8556-7d54-4c12-a9be-654128b53f92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_144f14b6-51be-4000-b947-98ac1c5737a6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c39b8556-7d54-4c12-a9be-654128b53f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9210dec3-eca5-467c-b222-b603c92f7821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_144f14b6-51be-4000-b947-98ac1c5737a6" xlink:to="loc_us-gaap_PreferredStockSharesIssued_9210dec3-eca5-467c-b222-b603c92f7821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a56b8fef-dfe4-4045-9c81-94ca4d726234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_144f14b6-51be-4000-b947-98ac1c5737a6" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a56b8fef-dfe4-4045-9c81-94ca4d726234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_141de7e3-0a26-4cda-8adb-3f912cdd13ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_144f14b6-51be-4000-b947-98ac1c5737a6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_141de7e3-0a26-4cda-8adb-3f912cdd13ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b85857ef-654c-4f87-8fdd-a69a1108bbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_144f14b6-51be-4000-b947-98ac1c5737a6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b85857ef-654c-4f87-8fdd-a69a1108bbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_fb792dec-130c-483c-83d3-6e70ed13dcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_144f14b6-51be-4000-b947-98ac1c5737a6" xlink:to="loc_us-gaap_CommonStockSharesIssued_fb792dec-130c-483c-83d3-6e70ed13dcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_93d87813-95de-4e14-ad0b-4bfab6588168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_144f14b6-51be-4000-b947-98ac1c5737a6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_93d87813-95de-4e14-ad0b-4bfab6588168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="halo-20230331.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_52accbc1-00df-42ad-ac03-3738128c9486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_42f4d7dc-33a4-4d64-9c6c-9b2c637c254f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_52accbc1-00df-42ad-ac03-3738128c9486" xlink:to="loc_us-gaap_StatementTable_42f4d7dc-33a4-4d64-9c6c-9b2c637c254f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_647eb7a2-53f2-41fb-b15b-90dbc96e7eec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42f4d7dc-33a4-4d64-9c6c-9b2c637c254f" xlink:to="loc_srt_ProductOrServiceAxis_647eb7a2-53f2-41fb-b15b-90dbc96e7eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4743d4a6-3e75-40fb-82e8-42f829f0b357" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_647eb7a2-53f2-41fb-b15b-90dbc96e7eec" xlink:to="loc_srt_ProductsAndServicesDomain_4743d4a6-3e75-40fb-82e8-42f829f0b357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_c36cdd88-8ccb-4857-bd2c-49728e013873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4743d4a6-3e75-40fb-82e8-42f829f0b357" xlink:to="loc_us-gaap_RoyaltyMember_c36cdd88-8ccb-4857-bd2c-49728e013873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f2903ae4-3613-40ba-9cf9-9d2bf52edecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4743d4a6-3e75-40fb-82e8-42f829f0b357" xlink:to="loc_us-gaap_ProductMember_f2903ae4-3613-40ba-9cf9-9d2bf52edecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember_0a5bff1e-4a66-43e6-a0bf-cecd876c9302" xlink:href="halo-20230331.xsd#halo_CollaborativeAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4743d4a6-3e75-40fb-82e8-42f829f0b357" xlink:to="loc_halo_CollaborativeAgreementsMember_0a5bff1e-4a66-43e6-a0bf-cecd876c9302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42f4d7dc-33a4-4d64-9c6c-9b2c637c254f" xlink:to="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_46370f0d-9897-4945-9312-3ab2c273cd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_RevenuesAbstract_46370f0d-9897-4945-9312-3ab2c273cd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e842bb87-96e8-4938-8728-06429aae1c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_46370f0d-9897-4945-9312-3ab2c273cd0b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e842bb87-96e8-4938-8728-06429aae1c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_3048cea7-0867-4d65-a52f-5bc15eac2800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_3048cea7-0867-4d65-a52f-5bc15eac2800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_af717539-232e-4793-85c0-879e238110f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3048cea7-0867-4d65-a52f-5bc15eac2800" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_af717539-232e-4793-85c0-879e238110f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_fbbd923b-afc5-46c9-af1e-dea33978276c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3048cea7-0867-4d65-a52f-5bc15eac2800" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_fbbd923b-afc5-46c9-af1e-dea33978276c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_284cdc16-b491-40a6-9b76-4c658de3dd41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3048cea7-0867-4d65-a52f-5bc15eac2800" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_284cdc16-b491-40a6-9b76-4c658de3dd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_886bd78f-275b-4eab-9a21-2eb4b44e0c47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3048cea7-0867-4d65-a52f-5bc15eac2800" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_886bd78f-275b-4eab-9a21-2eb4b44e0c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b2372d51-cf6f-4821-b104-33dee45838a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3048cea7-0867-4d65-a52f-5bc15eac2800" xlink:to="loc_us-gaap_CostsAndExpenses_b2372d51-cf6f-4821-b104-33dee45838a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6bd7af4d-92ad-4ee5-b84d-4743eaddec59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_OperatingIncomeLoss_6bd7af4d-92ad-4ee5-b84d-4743eaddec59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_7e24013f-4727-4cd4-9d7d-5b3c8caf730d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_7e24013f-4727-4cd4-9d7d-5b3c8caf730d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0632bbc0-528c-4440-956c-efb345e53942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_7e24013f-4727-4cd4-9d7d-5b3c8caf730d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0632bbc0-528c-4440-956c-efb345e53942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4926db32-3c1f-4f0d-9145-4a70f978db34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_7e24013f-4727-4cd4-9d7d-5b3c8caf730d" xlink:to="loc_us-gaap_InterestExpense_4926db32-3c1f-4f0d-9145-4a70f978db34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_daf653a3-573f-436c-9554-4d14c99c63e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_daf653a3-573f-436c-9554-4d14c99c63e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2b10efd9-69a2-45e9-8582-88d66afe1ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2b10efd9-69a2-45e9-8582-88d66afe1ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0933482c-f0d5-4409-8343-bd0533a12c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_NetIncomeLoss_0933482c-f0d5-4409-8343-bd0533a12c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_bd0985d8-ba8c-4bb7-8565-b3e0d564dfe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_EarningsPerShareAbstract_bd0985d8-ba8c-4bb7-8565-b3e0d564dfe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4dafc820-7fbe-458a-b96d-1692facc33a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bd0985d8-ba8c-4bb7-8565-b3e0d564dfe0" xlink:to="loc_us-gaap_EarningsPerShareBasic_4dafc820-7fbe-458a-b96d-1692facc33a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9d1a493a-2625-409b-914d-3388dcbe287b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bd0985d8-ba8c-4bb7-8565-b3e0d564dfe0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9d1a493a-2625-409b-914d-3388dcbe287b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2cd71332-9d77-45d5-8c79-2a821906a7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cffee252-3a4d-46d0-ad6f-6cd166998479" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2cd71332-9d77-45d5-8c79-2a821906a7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_071240ba-0aaf-4813-bd4c-7e06acabb7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2cd71332-9d77-45d5-8c79-2a821906a7a9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_071240ba-0aaf-4813-bd4c-7e06acabb7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e35a2a6-135a-422d-adbd-ce1a6a7c258b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2cd71332-9d77-45d5-8c79-2a821906a7a9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e35a2a6-135a-422d-adbd-ce1a6a7c258b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="halo-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c325000c-cff8-4ba8-b336-9922388eca81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_84802887-9c35-40e7-9bae-4604c26c5538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c325000c-cff8-4ba8-b336-9922388eca81" xlink:to="loc_us-gaap_NetIncomeLoss_84802887-9c35-40e7-9bae-4604c26c5538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7f56120d-48ec-4dd6-b12f-a6d1f800b919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c325000c-cff8-4ba8-b336-9922388eca81" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7f56120d-48ec-4dd6-b12f-a6d1f800b919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_49646b4e-b54a-4987-a5f7-84d27ce0176c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7f56120d-48ec-4dd6-b12f-a6d1f800b919" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_49646b4e-b54a-4987-a5f7-84d27ce0176c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_ec7887c9-5483-48ec-94b8-bf5292fa4362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7f56120d-48ec-4dd6-b12f-a6d1f800b919" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_ec7887c9-5483-48ec-94b8-bf5292fa4362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_df6efa56-8f2e-45bc-bd95-0404e60e5414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c325000c-cff8-4ba8-b336-9922388eca81" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_df6efa56-8f2e-45bc-bd95-0404e60e5414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="halo-20230331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3affebf6-a66a-4228-9ebc-011f10b56761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d7e8b8e0-7bfa-4109-a1b2-07152a31feaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3affebf6-a66a-4228-9ebc-011f10b56761" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d7e8b8e0-7bfa-4109-a1b2-07152a31feaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6231e0e6-357d-4dd7-9741-a23dd81008b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d7e8b8e0-7bfa-4109-a1b2-07152a31feaa" xlink:to="loc_us-gaap_NetIncomeLoss_6231e0e6-357d-4dd7-9741-a23dd81008b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6461f1c9-de5f-4878-a5e4-c769c6ddf139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d7e8b8e0-7bfa-4109-a1b2-07152a31feaa" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6461f1c9-de5f-4878-a5e4-c769c6ddf139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0fe959a7-56bd-40ca-bafa-84e6912bc5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6461f1c9-de5f-4878-a5e4-c769c6ddf139" xlink:to="loc_us-gaap_ShareBasedCompensation_0fe959a7-56bd-40ca-bafa-84e6912bc5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_24722f0a-3b4d-4211-82da-0ea77e416fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6461f1c9-de5f-4878-a5e4-c769c6ddf139" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_24722f0a-3b4d-4211-82da-0ea77e416fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_572bbd9d-00ff-4f35-bebf-3c3fda5264e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6461f1c9-de5f-4878-a5e4-c769c6ddf139" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_572bbd9d-00ff-4f35-bebf-3c3fda5264e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_aed0a8bd-c4bb-4ca4-87fc-37d073874366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6461f1c9-de5f-4878-a5e4-c769c6ddf139" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_aed0a8bd-c4bb-4ca4-87fc-37d073874366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_abf230bb-6176-4f8c-b660-559faf4cb579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6461f1c9-de5f-4878-a5e4-c769c6ddf139" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_abf230bb-6176-4f8c-b660-559faf4cb579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8cca2d07-78aa-4b12-ad4e-1bb8f2bc2ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6461f1c9-de5f-4878-a5e4-c769c6ddf139" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8cca2d07-78aa-4b12-ad4e-1bb8f2bc2ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3bed4732-138c-436d-8036-86b793da3328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6461f1c9-de5f-4878-a5e4-c769c6ddf139" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3bed4732-138c-436d-8036-86b793da3328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredRentPayments_fca4530c-49f5-4ab2-beff-2cc472d9a3da" xlink:href="halo-20230331.xsd#halo_DeferredRentPayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6461f1c9-de5f-4878-a5e4-c769c6ddf139" xlink:to="loc_halo_DeferredRentPayments_fca4530c-49f5-4ab2-beff-2cc472d9a3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_7830c4eb-0c2a-463f-8e14-342b75c6efae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6461f1c9-de5f-4878-a5e4-c769c6ddf139" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_7830c4eb-0c2a-463f-8e14-342b75c6efae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_18b571ea-7b62-4171-bf9e-ac050b1bd41c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6461f1c9-de5f-4878-a5e4-c769c6ddf139" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_18b571ea-7b62-4171-bf9e-ac050b1bd41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cce8f168-7597-46f7-99a4-18c5a0e36ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_18b571ea-7b62-4171-bf9e-ac050b1bd41c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cce8f168-7597-46f7-99a4-18c5a0e36ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c912264e-ee68-4aa8-97dd-6748f3dccbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_18b571ea-7b62-4171-bf9e-ac050b1bd41c" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c912264e-ee68-4aa8-97dd-6748f3dccbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_77117e08-c630-47c3-9852-cdb1b3c5f0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_18b571ea-7b62-4171-bf9e-ac050b1bd41c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_77117e08-c630-47c3-9852-cdb1b3c5f0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4ae70b32-31e1-422e-a74a-8bda1d2ef169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_18b571ea-7b62-4171-bf9e-ac050b1bd41c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4ae70b32-31e1-422e-a74a-8bda1d2ef169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a6f8398-8ffa-4d33-8d3f-510b6dd4ebea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d7e8b8e0-7bfa-4109-a1b2-07152a31feaa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a6f8398-8ffa-4d33-8d3f-510b6dd4ebea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d4f489b5-89a5-425f-b7e1-cdced1497588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3affebf6-a66a-4228-9ebc-011f10b56761" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d4f489b5-89a5-425f-b7e1-cdced1497588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5ba3b57c-16db-4b64-a9fa-159fa561ce78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d4f489b5-89a5-425f-b7e1-cdced1497588" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5ba3b57c-16db-4b64-a9fa-159fa561ce78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d64863f4-fa8f-44ba-b9ac-d7221a66af09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d4f489b5-89a5-425f-b7e1-cdced1497588" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d64863f4-fa8f-44ba-b9ac-d7221a66af09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b7760ec8-e386-42a4-8a94-634988457081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d4f489b5-89a5-425f-b7e1-cdced1497588" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b7760ec8-e386-42a4-8a94-634988457081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dce43949-d532-4ed0-b07f-356124b3d401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d4f489b5-89a5-425f-b7e1-cdced1497588" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dce43949-d532-4ed0-b07f-356124b3d401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a64eea9-e5a7-4ded-bea1-d4251904e9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3affebf6-a66a-4228-9ebc-011f10b56761" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a64eea9-e5a7-4ded-bea1-d4251904e9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_be5730b7-8740-4fc6-909c-57846e5b6fca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a64eea9-e5a7-4ded-bea1-d4251904e9c7" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_be5730b7-8740-4fc6-909c-57846e5b6fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c70d6590-12d7-4fb3-92bd-ca1755a552e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a64eea9-e5a7-4ded-bea1-d4251904e9c7" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c70d6590-12d7-4fb3-92bd-ca1755a552e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_ce73fe8c-c537-421a-8112-a941447cf29e" xlink:href="halo-20230331.xsd#halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a64eea9-e5a7-4ded-bea1-d4251904e9c7" xlink:to="loc_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_ce73fe8c-c537-421a-8112-a941447cf29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6dbcca82-13ef-4be3-b001-f9adeb338440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a64eea9-e5a7-4ded-bea1-d4251904e9c7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6dbcca82-13ef-4be3-b001-f9adeb338440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8509c5ed-3507-4a86-8a24-4ea4e2860325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3affebf6-a66a-4228-9ebc-011f10b56761" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8509c5ed-3507-4a86-8a24-4ea4e2860325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_daec057f-25ba-418c-a31c-a07560303550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3affebf6-a66a-4228-9ebc-011f10b56761" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_daec057f-25ba-418c-a31c-a07560303550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1bdbf50e-aa80-4fd3-8551-4a870137ec7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3affebf6-a66a-4228-9ebc-011f10b56761" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1bdbf50e-aa80-4fd3-8551-4a870137ec7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_99d0ca50-3d21-4236-883a-57caa764897f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3affebf6-a66a-4228-9ebc-011f10b56761" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_99d0ca50-3d21-4236-883a-57caa764897f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5f22595a-40e0-4ffb-9825-4b5d78650b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_99d0ca50-3d21-4236-883a-57caa764897f" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5f22595a-40e0-4ffb-9825-4b5d78650b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_17eb3ee0-3e1c-461c-9927-8500be6f620b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_99d0ca50-3d21-4236-883a-57caa764897f" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_17eb3ee0-3e1c-461c-9927-8500be6f620b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_811db16e-fd11-40ca-85b8-2f5d87781423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_99d0ca50-3d21-4236-883a-57caa764897f" xlink:to="loc_us-gaap_StockIssued1_811db16e-fd11-40ca-85b8-2f5d87781423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="halo-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_48e023e0-5968-4323-b1a6-8678045246ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_108abcbc-ddf8-46cd-83fc-699acb133ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_48e023e0-5968-4323-b1a6-8678045246ee" xlink:to="loc_us-gaap_StatementTable_108abcbc-ddf8-46cd-83fc-699acb133ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6cc35acc-cd7e-4a26-94ac-6c49cfc04255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_108abcbc-ddf8-46cd-83fc-699acb133ba8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6cc35acc-cd7e-4a26-94ac-6c49cfc04255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e1cb8a80-e966-4c5a-b58e-978b97589c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6cc35acc-cd7e-4a26-94ac-6c49cfc04255" xlink:to="loc_us-gaap_EquityComponentDomain_e1cb8a80-e966-4c5a-b58e-978b97589c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d6e5bd81-a695-4be2-8f95-d188f885d1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e1cb8a80-e966-4c5a-b58e-978b97589c3d" xlink:to="loc_us-gaap_CommonStockMember_d6e5bd81-a695-4be2-8f95-d188f885d1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5f4ab508-3638-48e2-b841-46d22c4fa508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e1cb8a80-e966-4c5a-b58e-978b97589c3d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5f4ab508-3638-48e2-b841-46d22c4fa508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e45fff02-e32a-4c73-825a-2997558d1859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e1cb8a80-e966-4c5a-b58e-978b97589c3d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e45fff02-e32a-4c73-825a-2997558d1859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e5ad48d9-25e6-4fa4-9d92-6f903d69cf71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e1cb8a80-e966-4c5a-b58e-978b97589c3d" xlink:to="loc_us-gaap_RetainedEarningsMember_e5ad48d9-25e6-4fa4-9d92-6f903d69cf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_38dcb873-410b-4704-87c9-9f344fd8fc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_108abcbc-ddf8-46cd-83fc-699acb133ba8" xlink:to="loc_us-gaap_StatementLineItems_38dcb873-410b-4704-87c9-9f344fd8fc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_38dcb873-410b-4704-87c9-9f344fd8fc76" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_2bac6292-5dc6-4783-b054-6e7066d4035e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_SharesOutstanding_2bac6292-5dc6-4783-b054-6e7066d4035e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e40aacb8-6255-434c-956d-6abf2afa5a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_StockholdersEquity_e40aacb8-6255-434c-956d-6abf2afa5a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_86405722-b0cd-40ee-9e35-c9b789950f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_86405722-b0cd-40ee-9e35-c9b789950f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_214e34ad-8aa0-438b-abcf-f022655b2618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_214e34ad-8aa0-438b-abcf-f022655b2618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ca0978cf-3dda-4b21-9773-d063a662a1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ca0978cf-3dda-4b21-9773-d063a662a1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6d545db5-effd-4fb9-8359-5a75625b96aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6d545db5-effd-4fb9-8359-5a75625b96aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_00a6596e-e00a-4a06-88c2-165a84d61276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_00a6596e-e00a-4a06-88c2-165a84d61276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_8f503721-8866-47d1-98bc-9b4971a91b22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_8f503721-8866-47d1-98bc-9b4971a91b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_68fd6ec5-dfca-4fd5-b731-d07863e0a86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_68fd6ec5-dfca-4fd5-b731-d07863e0a86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_2baacb51-c412-4443-b1d4-5fae3f2100c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_2baacb51-c412-4443-b1d4-5fae3f2100c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4c0c078e-e6d0-44a7-85bd-d82f3ef51a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_NetIncomeLoss_4c0c078e-e6d0-44a7-85bd-d82f3ef51a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_cb4efad9-9e4e-4e09-9149-838f099bac22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_SharesOutstanding_cb4efad9-9e4e-4e09-9149-838f099bac22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_98f48a51-9449-4438-9061-e428bdbe038e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a45a7f7-4e1a-4192-98fa-7959cba0e91c" xlink:to="loc_us-gaap_StockholdersEquity_98f48a51-9449-4438-9061-e428bdbe038e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/OrganizationandBusiness" xlink:type="simple" xlink:href="halo-20230331.xsd#OrganizationandBusiness"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/OrganizationandBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e60d57e4-12bf-4ccf-9aa6-d41914962080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_0b468a2e-49d5-4da9-bd99-af37f3823c53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e60d57e4-12bf-4ccf-9aa6-d41914962080" xlink:to="loc_us-gaap_NatureOfOperations_0b468a2e-49d5-4da9-bd99-af37f3823c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="halo-20230331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cb2c96f4-73d0-4a41-aaac-baa058ccf86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2211c95c-4a20-484a-9cb9-b16ddd4e83f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb2c96f4-73d0-4a41-aaac-baa058ccf86d" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2211c95c-4a20-484a-9cb9-b16ddd4e83f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombination" xlink:type="simple" xlink:href="halo-20230331.xsd#BusinessCombination"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombination" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b4fb1bb5-98df-4f5c-af0f-82a5f7a27248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_11c5d115-8ea4-4ef8-b46d-c96b7073c621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b4fb1bb5-98df-4f5c-af0f-82a5f7a27248" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_11c5d115-8ea4-4ef8-b46d-c96b7073c621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="halo-20230331.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cfecc803-0013-4f08-8a6d-2a2f90deb498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ec386c88-b155-4060-9555-09beb02a1fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cfecc803-0013-4f08-8a6d-2a2f90deb498" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ec386c88-b155-4060-9555-09beb02a1fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/Revenue" xlink:type="simple" xlink:href="halo-20230331.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5b73960b-860f-46c4-9b88-25fabf0d563a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_553f0a70-6a64-4204-ac42-932f5fe9f494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5b73960b-860f-46c4-9b88-25fabf0d563a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_553f0a70-6a64-4204-ac42-932f5fe9f494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItems" xlink:type="simple" xlink:href="halo-20230331.xsd#CertainBalanceSheetItems"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItems" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_09d3c70b-bc73-43c1-99b3-2d9aa23e4ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_9ae3184d-fbd1-4dc0-98d2-129267d360c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_09d3c70b-bc73-43c1-99b3-2d9aa23e4ca8" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_9ae3184d-fbd1-4dc0-98d2-129267d360c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="halo-20230331.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_be0b26b9-7831-4edd-9b6d-5e73dc09bb94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_6f4e015b-e336-4fc9-b663-077af844b429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_be0b26b9-7831-4edd-9b6d-5e73dc09bb94" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_6f4e015b-e336-4fc9-b663-077af844b429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNet" xlink:type="simple" xlink:href="halo-20230331.xsd#LongTermDebtNet"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e1f39598-f677-4ef7-b4d4-053560f9539d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_36f23382-ea35-4949-aa18-382deb43d335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e1f39598-f677-4ef7-b4d4-053560f9539d" xlink:to="loc_us-gaap_LongTermDebtTextBlock_36f23382-ea35-4949-aa18-382deb43d335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensation" xlink:type="simple" xlink:href="halo-20230331.xsd#SharebasedCompensation"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_d9c1c903-0cde-408b-b25c-7b4924323b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6289a6fd-7343-4924-b07f-4971e5af4e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_d9c1c903-0cde-408b-b25c-7b4924323b99" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6289a6fd-7343-4924-b07f-4971e5af4e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/StockholdersEquity" xlink:type="simple" xlink:href="halo-20230331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_68e0ccac-34a2-48eb-97f7-7171c6af320e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0eaa4ed9-0132-4873-82ec-7e55fb265717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_68e0ccac-34a2-48eb-97f7-7171c6af320e" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0eaa4ed9-0132-4873-82ec-7e55fb265717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/NetIncomepershare" xlink:type="simple" xlink:href="halo-20230331.xsd#NetIncomepershare"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/NetIncomepershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4d2be8f5-093a-446f-b7b2-35f06a467df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_11cf2660-3cb7-49d7-9b98-5937b0636f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4d2be8f5-093a-446f-b7b2-35f06a467df1" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_11cf2660-3cb7-49d7-9b98-5937b0636f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="halo-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_57c2e4d3-0d07-4d34-b41e-5c9f1eec9564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1ea2377a-8647-4c4c-bbc6-16963a72b4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_57c2e4d3-0d07-4d34-b41e-5c9f1eec9564" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1ea2377a-8647-4c4c-bbc6-16963a72b4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="halo-20230331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5adb13f2-f088-4336-9557-c846da31c91d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_75cbc88b-cba8-4b26-a32b-423cbbca1420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adb13f2-f088-4336-9557-c846da31c91d" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_75cbc88b-cba8-4b26-a32b-423cbbca1420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_f17cb521-08c3-40ae-b10a-52a0feefb7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adb13f2-f088-4336-9557-c846da31c91d" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_f17cb521-08c3-40ae-b10a-52a0feefb7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_6cdbf441-6c30-4d93-bd32-2dfef3e349c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adb13f2-f088-4336-9557-c846da31c91d" xlink:to="loc_us-gaap_UseOfEstimates_6cdbf441-6c30-4d93-bd32-2dfef3e349c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_8bd1547c-ffea-4eca-8c92-e1a1170defd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adb13f2-f088-4336-9557-c846da31c91d" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_8bd1547c-ffea-4eca-8c92-e1a1170defd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_6dc87f10-df70-4bac-873c-eec08b82c4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adb13f2-f088-4336-9557-c846da31c91d" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_6dc87f10-df70-4bac-873c-eec08b82c4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_f4dfd3b8-5272-4c73-bebc-737a0e58f7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adb13f2-f088-4336-9557-c846da31c91d" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_f4dfd3b8-5272-4c73-bebc-737a0e58f7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_ffe76e5c-28db-415d-a88a-60db0ec9518c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adb13f2-f088-4336-9557-c846da31c91d" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_ffe76e5c-28db-415d-a88a-60db0ec9518c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_343982ca-1728-460e-951e-ba9c55a78e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adb13f2-f088-4336-9557-c846da31c91d" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_343982ca-1728-460e-951e-ba9c55a78e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock_eee9f843-43f8-47d2-9e78-3f9740795000" xlink:href="halo-20230331.xsd#halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adb13f2-f088-4336-9557-c846da31c91d" xlink:to="loc_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock_eee9f843-43f8-47d2-9e78-3f9740795000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_432df605-0373-46f3-a749-a03b57ecb68d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adb13f2-f088-4336-9557-c846da31c91d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_432df605-0373-46f3-a749-a03b57ecb68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_a6688c4a-1b78-4b85-ac1e-4b6adeee0356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adb13f2-f088-4336-9557-c846da31c91d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_a6688c4a-1b78-4b85-ac1e-4b6adeee0356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_013fa223-2801-4208-9305-3d0ddb48fb46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adb13f2-f088-4336-9557-c846da31c91d" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_013fa223-2801-4208-9305-3d0ddb48fb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_ffabc7c8-f282-439d-99dd-526f63c34c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adb13f2-f088-4336-9557-c846da31c91d" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_ffabc7c8-f282-439d-99dd-526f63c34c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_bff80013-02ec-421a-8ea0-53c9fcd12540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adb13f2-f088-4336-9557-c846da31c91d" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_bff80013-02ec-421a-8ea0-53c9fcd12540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ce636b97-5ad1-426e-ada4-0a82c9074fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5adb13f2-f088-4336-9557-c846da31c91d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ce636b97-5ad1-426e-ada4-0a82c9074fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationTables" xlink:type="simple" xlink:href="halo-20230331.xsd#BusinessCombinationTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a10c57d9-a568-4ed9-b881-2a5fc3d4ceb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_b1805a7a-8da8-43a1-84f9-ee8df65d5e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a10c57d9-a568-4ed9-b881-2a5fc3d4ceb7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_b1805a7a-8da8-43a1-84f9-ee8df65d5e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_10ae4cdd-05a7-4dd5-bdca-59b7571af1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a10c57d9-a568-4ed9-b881-2a5fc3d4ceb7" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_10ae4cdd-05a7-4dd5-bdca-59b7571af1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_008fa0a5-6c69-4f65-8297-fdce3fe75d51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a10c57d9-a568-4ed9-b881-2a5fc3d4ceb7" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_008fa0a5-6c69-4f65-8297-fdce3fe75d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_9e163dc5-600d-499b-82c5-60a93dcadea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a10c57d9-a568-4ed9-b881-2a5fc3d4ceb7" xlink:to="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_9e163dc5-600d-499b-82c5-60a93dcadea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="halo-20230331.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_90857f5f-5d26-47c1-8bd1-7717445c26fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_e9f83e20-589c-47a9-95a5-e46eb758f764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_90857f5f-5d26-47c1-8bd1-7717445c26fd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_e9f83e20-589c-47a9-95a5-e46eb758f764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_750838b1-f1a0-4e54-ac18-3a008c0d4f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_90857f5f-5d26-47c1-8bd1-7717445c26fd" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_750838b1-f1a0-4e54-ac18-3a008c0d4f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_70d7d0ae-afa3-4dd3-8e42-8994126bffed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_90857f5f-5d26-47c1-8bd1-7717445c26fd" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_70d7d0ae-afa3-4dd3-8e42-8994126bffed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueTables" xlink:type="simple" xlink:href="halo-20230331.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b78cc064-636b-4b48-8879-12fd39cafe16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4fd927e3-2c6a-4b29-9289-1ebcd1afa1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b78cc064-636b-4b48-8879-12fd39cafe16" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4fd927e3-2c6a-4b29-9289-1ebcd1afa1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_422f7cb5-cce1-4267-b8e4-88a1a7beb6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b78cc064-636b-4b48-8879-12fd39cafe16" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_422f7cb5-cce1-4267-b8e4-88a1a7beb6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsTables" xlink:type="simple" xlink:href="halo-20230331.xsd#CertainBalanceSheetItemsTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6f5056f5-ac93-4400-b527-88f649cc1882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_4b15ba73-1ecf-441d-8b36-d29b0eea55c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6f5056f5-ac93-4400-b527-88f649cc1882" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_4b15ba73-1ecf-441d-8b36-d29b0eea55c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_04d11d6e-d464-4090-af39-c3f14ffa2f11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6f5056f5-ac93-4400-b527-88f649cc1882" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_04d11d6e-d464-4090-af39-c3f14ffa2f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_8ad2bc3c-71a0-4ad5-a0c7-76b81fe63736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6f5056f5-ac93-4400-b527-88f649cc1882" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_8ad2bc3c-71a0-4ad5-a0c7-76b81fe63736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2fbfb7ed-41ad-4268-a2f0-e8bac7511af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6f5056f5-ac93-4400-b527-88f649cc1882" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2fbfb7ed-41ad-4268-a2f0-e8bac7511af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_bc4a34cb-21b5-4256-8340-518d1bd56aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6f5056f5-ac93-4400-b527-88f649cc1882" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_bc4a34cb-21b5-4256-8340-518d1bd56aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="halo-20230331.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1f24cd28-3a0d-4507-8911-a8a0ec29d6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ba093d40-b8bd-4595-97a9-b39351c904aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1f24cd28-3a0d-4507-8911-a8a0ec29d6f1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ba093d40-b8bd-4595-97a9-b39351c904aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_543eac63-4cd7-4040-a185-f97825e390b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1f24cd28-3a0d-4507-8911-a8a0ec29d6f1" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_543eac63-4cd7-4040-a185-f97825e390b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_d6245490-e01c-48ff-9e84-cf8dffc3f54b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1f24cd28-3a0d-4507-8911-a8a0ec29d6f1" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_d6245490-e01c-48ff-9e84-cf8dffc3f54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetTables" xlink:type="simple" xlink:href="halo-20230331.xsd#LongTermDebtNetTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3f262b01-a504-4f0a-82b7-cfa35e7dbb95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_02569867-9f68-4f85-90bc-71b2587ecf4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3f262b01-a504-4f0a-82b7-cfa35e7dbb95" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_02569867-9f68-4f85-90bc-71b2587ecf4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_9cf19847-fc44-455b-bc40-1e8b80b60d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3f262b01-a504-4f0a-82b7-cfa35e7dbb95" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_9cf19847-fc44-455b-bc40-1e8b80b60d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationTables" xlink:type="simple" xlink:href="halo-20230331.xsd#SharebasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_e955763a-96fd-4374-85e4-168ccd3eb59b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_88925aa6-86aa-4f40-8e88-a59b721fcef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_e955763a-96fd-4374-85e4-168ccd3eb59b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_88925aa6-86aa-4f40-8e88-a59b721fcef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2e93c850-d087-4a27-a7da-9d79cb8fd1df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_e955763a-96fd-4374-85e4-168ccd3eb59b" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2e93c850-d087-4a27-a7da-9d79cb8fd1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_406655a9-ff2d-4801-a818-cdb7aeba85d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_e955763a-96fd-4374-85e4-168ccd3eb59b" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_406655a9-ff2d-4801-a818-cdb7aeba85d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_d1ccbd4e-1cd2-4d59-a984-82ddc0013572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_e955763a-96fd-4374-85e4-168ccd3eb59b" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_d1ccbd4e-1cd2-4d59-a984-82ddc0013572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="halo-20230331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4feb122a-0752-4c82-a8db-3cea5b36d0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_7b78a2c4-9a32-4770-b3a8-276e07eaec85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4feb122a-0752-4c82-a8db-3cea5b36d0aa" xlink:to="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_7b78a2c4-9a32-4770-b3a8-276e07eaec85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/EarningspershareTables" xlink:type="simple" xlink:href="halo-20230331.xsd#EarningspershareTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/EarningspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_405954a4-c66e-4998-a524-8f7462a815d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0b71827c-c510-4f3a-b685-4c7f99c5a3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_405954a4-c66e-4998-a524-8f7462a815d0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0b71827c-c510-4f3a-b685-4c7f99c5a3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7aaf429f-8a96-447f-9aa2-3a08d11cccf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_405954a4-c66e-4998-a524-8f7462a815d0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7aaf429f-8a96-447f-9aa2-3a08d11cccf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/OrganizationandBusinessDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#OrganizationandBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/OrganizationandBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0d502396-d44a-4b57-9ab2-98caa06fa6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6d203d3-a0f1-4248-8cd1-41c9b23f7bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0d502396-d44a-4b57-9ab2-98caa06fa6a0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6d203d3-a0f1-4248-8cd1-41c9b23f7bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d6d29895-c2f0-410d-8810-445c1d07de94" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6d203d3-a0f1-4248-8cd1-41c9b23f7bf6" xlink:to="loc_srt_CounterpartyNameAxis_d6d29895-c2f0-410d-8810-445c1d07de94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5e22711-57c2-486f-8f5f-f307ba4cb936" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d6d29895-c2f0-410d-8810-445c1d07de94" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5e22711-57c2-486f-8f5f-f307ba4cb936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BaxaltaMember_0a032169-51e8-4cbc-9582-d3b67b25a1e9" xlink:href="halo-20230331.xsd#halo_BaxaltaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5e22711-57c2-486f-8f5f-f307ba4cb936" xlink:to="loc_halo_BaxaltaMember_0a032169-51e8-4cbc-9582-d3b67b25a1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RocheMember_4ae28c42-c93b-4aca-adcf-600dda1270be" xlink:href="halo-20230331.xsd#halo_RocheMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5e22711-57c2-486f-8f5f-f307ba4cb936" xlink:to="loc_halo_RocheMember_4ae28c42-c93b-4aca-adcf-600dda1270be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_JanssenMember_2a2f5a80-6ba5-4cd5-a429-ffb6f4050077" xlink:href="halo-20230331.xsd#halo_JanssenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5e22711-57c2-486f-8f5f-f307ba4cb936" xlink:to="loc_halo_JanssenMember_2a2f5a80-6ba5-4cd5-a429-ffb6f4050077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b76e73b8-502a-448b-8bad-7bc0c9fa564b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b6d203d3-a0f1-4248-8cd1-41c9b23f7bf6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b76e73b8-502a-448b-8bad-7bc0c9fa564b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RoyaltiesReceivedNumberOfCollaborators_1b181bfb-8bd5-4a91-bf53-d4e407287519" xlink:href="halo-20230331.xsd#halo_RoyaltiesReceivedNumberOfCollaborators"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b76e73b8-502a-448b-8bad-7bc0c9fa564b" xlink:to="loc_halo_RoyaltiesReceivedNumberOfCollaborators_1b181bfb-8bd5-4a91-bf53-d4e407287519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RoyaltiesReceivedNumberOfProductsSold_878daae8-96bf-43b6-a286-9d9840ff93fc" xlink:href="halo-20230331.xsd#halo_RoyaltiesReceivedNumberOfProductsSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b76e73b8-502a-448b-8bad-7bc0c9fa564b" xlink:to="loc_halo_RoyaltiesReceivedNumberOfProductsSold_878daae8-96bf-43b6-a286-9d9840ff93fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#SummaryofSignificantAccountingPoliciesRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8f7032c4-30b1-412b-b972-d0eaff3f6476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_fe2d2698-b3a0-4fb0-861f-a695a8ca6bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f7032c4-30b1-412b-b972-d0eaff3f6476" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_fe2d2698-b3a0-4fb0-861f-a695a8ca6bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#SummaryofSignificantAccountingPoliciesLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9c2cf9a4-ab1e-48e7-b7b7-56cc57fb88b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f97894cb-c6f1-4ebc-8580-8b09d9436fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9c2cf9a4-ab1e-48e7-b7b7-56cc57fb88b7" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f97894cb-c6f1-4ebc-8580-8b09d9436fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0e063398-a04d-4e04-8099-6c7674d8f925" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f97894cb-c6f1-4ebc-8580-8b09d9436fa0" xlink:to="loc_srt_RangeAxis_0e063398-a04d-4e04-8099-6c7674d8f925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eaebdf76-d47a-408d-80f6-58f26de9eb33" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0e063398-a04d-4e04-8099-6c7674d8f925" xlink:to="loc_srt_RangeMember_eaebdf76-d47a-408d-80f6-58f26de9eb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0a4b3131-d347-4560-bec5-5d3b4be48313" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eaebdf76-d47a-408d-80f6-58f26de9eb33" xlink:to="loc_srt_MinimumMember_0a4b3131-d347-4560-bec5-5d3b4be48313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_609b6256-576d-47ab-8c9e-8e9262abb806" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eaebdf76-d47a-408d-80f6-58f26de9eb33" xlink:to="loc_srt_MaximumMember_609b6256-576d-47ab-8c9e-8e9262abb806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f23826cb-cdf3-458b-9834-63b1920fa1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f97894cb-c6f1-4ebc-8580-8b09d9436fa0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_f23826cb-cdf3-458b-9834-63b1920fa1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_49a100f4-38ae-4d30-b799-504233b97ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f23826cb-cdf3-458b-9834-63b1920fa1bb" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_49a100f4-38ae-4d30-b799-504233b97ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_acac7b10-359e-497e-afff-009aed5a0234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice_f75a2046-ffb9-4fb2-a49c-b46fa09e7945" xlink:href="halo-20230331.xsd#halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_acac7b10-359e-497e-afff-009aed5a0234" xlink:to="loc_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice_f75a2046-ffb9-4fb2-a49c-b46fa09e7945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#SummaryofSignificantAccountingPoliciesIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9cada11b-b2d7-405c-8897-cf6cce172a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_16212a82-56e5-4175-9ffb-2c1f0426ab7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9cada11b-b2d7-405c-8897-cf6cce172a9b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_16212a82-56e5-4175-9ffb-2c1f0426ab7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7117bb6f-a4a1-4774-ad64-c282f0c59969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9cada11b-b2d7-405c-8897-cf6cce172a9b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7117bb6f-a4a1-4774-ad64-c282f0c59969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3f31892d-576b-4730-9d0f-ce516687dd49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6b82d39f-13be-4dc6-8db5-b1d92cf1e4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f31892d-576b-4730-9d0f-ce516687dd49" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6b82d39f-13be-4dc6-8db5-b1d92cf1e4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationNarrativeDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#BusinessCombinationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c631b773-6d96-45ca-9c91-3326ee3b9d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c219a245-7a79-483f-b425-dae0ca564c63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c631b773-6d96-45ca-9c91-3326ee3b9d42" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c219a245-7a79-483f-b425-dae0ca564c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b5cf7939-c8d7-4544-910f-6b1ba5345626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c219a245-7a79-483f-b425-dae0ca564c63" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b5cf7939-c8d7-4544-910f-6b1ba5345626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f6e1043-43e8-411f-8f8a-f95a6000423b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b5cf7939-c8d7-4544-910f-6b1ba5345626" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f6e1043-43e8-411f-8f8a-f95a6000423b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_fb516a25-f866-4a84-b4e9-bb22fc43b4f9" xlink:href="halo-20230331.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f6e1043-43e8-411f-8f8a-f95a6000423b" xlink:to="loc_halo_AntaresPharmaIncMember_fb516a25-f866-4a84-b4e9-bb22fc43b4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c69c4419-716d-49cf-89d3-1853f55826ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c219a245-7a79-483f-b425-dae0ca564c63" xlink:to="loc_us-gaap_DebtInstrumentAxis_c69c4419-716d-49cf-89d3-1853f55826ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_19b74c46-964e-4d96-bab3-0b4987c6ea7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c69c4419-716d-49cf-89d3-1853f55826ff" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_19b74c46-964e-4d96-bab3-0b4987c6ea7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TermLoanFacilityMember_f08181fe-999e-45c2-9f05-47e31a1cab18" xlink:href="halo-20230331.xsd#halo_TermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_19b74c46-964e-4d96-bab3-0b4987c6ea7a" xlink:to="loc_halo_TermLoanFacilityMember_f08181fe-999e-45c2-9f05-47e31a1cab18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_76af8dbe-e482-4d95-9e2f-3987012dd175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c219a245-7a79-483f-b425-dae0ca564c63" xlink:to="loc_us-gaap_CreditFacilityAxis_76af8dbe-e482-4d95-9e2f-3987012dd175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_bb68eb83-070b-4d92-9c47-8d3c47b7c0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_76af8dbe-e482-4d95-9e2f-3987012dd175" xlink:to="loc_us-gaap_CreditFacilityDomain_bb68eb83-070b-4d92-9c47-8d3c47b7c0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_8be3ba33-aac4-4846-82ab-9abed2eaa3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_bb68eb83-070b-4d92-9c47-8d3c47b7c0f9" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_8be3ba33-aac4-4846-82ab-9abed2eaa3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c219a245-7a79-483f-b425-dae0ca564c63" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_af6f5d1d-2fa7-492d-99e1-5d9a8a0e7f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_af6f5d1d-2fa7-492d-99e1-5d9a8a0e7f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_7b034a7d-d890-4632-ab1f-2067bdb1a9ca" xlink:href="halo-20230331.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_7b034a7d-d890-4632-ab1f-2067bdb1a9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_74ec1c0f-dc8c-440d-b07b-412a2b49b452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_74ec1c0f-dc8c-440d-b07b-412a2b49b452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_f08f31c7-5753-4306-9c05-3015e5ddee3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_f08f31c7-5753-4306-9c05-3015e5ddee3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_14b841f4-a5be-44eb-9f51-12bdd658d8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_14b841f4-a5be-44eb-9f51-12bdd658d8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b56970c6-23aa-4ba5-b423-32eaa97d07db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b56970c6-23aa-4ba5-b423-32eaa97d07db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6df60ac5-c9fc-4b9c-8856-46e35f30fdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6df60ac5-c9fc-4b9c-8856-46e35f30fdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense_d9d87d5e-5dce-4767-90b0-05fefefa4ec6" xlink:href="halo-20230331.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense_d9d87d5e-5dce-4767-90b0-05fefefa4ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet_2b0eb114-82ab-4ffa-a87e-9e32b865a450" xlink:href="halo-20230331.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet_2b0eb114-82ab-4ffa-a87e-9e32b865a450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_b55f3f1b-fe6f-400f-a134-dac20d138318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3fb97cdc-f5aa-4982-9857-499dc2095925" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_b55f3f1b-fe6f-400f-a134-dac20d138318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#BusinessCombinationPurchaseConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9e0971bb-98f1-43bd-bf85-2b627229bfd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b08f06c1-2cd6-42d9-bc51-feb9075e41e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9e0971bb-98f1-43bd-bf85-2b627229bfd2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b08f06c1-2cd6-42d9-bc51-feb9075e41e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_19b67ada-9d22-4ec8-8519-be8f1c76e458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b08f06c1-2cd6-42d9-bc51-feb9075e41e1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_19b67ada-9d22-4ec8-8519-be8f1c76e458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06a1a895-260a-4050-8836-e25b4f41745e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_19b67ada-9d22-4ec8-8519-be8f1c76e458" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06a1a895-260a-4050-8836-e25b4f41745e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_7a1bd1fd-e029-4f88-b24b-9483a5410619" xlink:href="halo-20230331.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06a1a895-260a-4050-8836-e25b4f41745e" xlink:to="loc_halo_AntaresPharmaIncMember_7a1bd1fd-e029-4f88-b24b-9483a5410619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_bb753b7e-2be8-4a7f-a857-87ceb2b3a99a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b08f06c1-2cd6-42d9-bc51-feb9075e41e1" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_bb753b7e-2be8-4a7f-a857-87ceb2b3a99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_34680769-b56a-448f-88e3-60989a0174bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_bb753b7e-2be8-4a7f-a857-87ceb2b3a99a" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_34680769-b56a-448f-88e3-60989a0174bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationAwardsVestedMember_02701118-d415-494e-91fb-e8cf1f9c5686" xlink:href="halo-20230331.xsd#halo_ShareBasedCompensationAwardsVestedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_34680769-b56a-448f-88e3-60989a0174bd" xlink:to="loc_halo_ShareBasedCompensationAwardsVestedMember_02701118-d415-494e-91fb-e8cf1f9c5686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationAwardUnvestedMember_1c9a3c38-dd90-4526-b75b-f06585d09c6b" xlink:href="halo-20230331.xsd#halo_ShareBasedCompensationAwardUnvestedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_34680769-b56a-448f-88e3-60989a0174bd" xlink:to="loc_halo_ShareBasedCompensationAwardUnvestedMember_1c9a3c38-dd90-4526-b75b-f06585d09c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a2986641-79c5-46c0-b7b5-1d448924b1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b08f06c1-2cd6-42d9-bc51-feb9075e41e1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a2986641-79c5-46c0-b7b5-1d448924b1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e9a80547-7232-44c9-8827-3604e8d466d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2986641-79c5-46c0-b7b5-1d448924b1af" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_e9a80547-7232-44c9-8827-3604e8d466d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_f83c5386-3d8c-4794-8325-d3cd1fdde7b7" xlink:href="halo-20230331.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2986641-79c5-46c0-b7b5-1d448924b1af" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_f83c5386-3d8c-4794-8325-d3cd1fdde7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_af972991-15d3-431c-baa3-e825da0d6779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2986641-79c5-46c0-b7b5-1d448924b1af" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_af972991-15d3-431c-baa3-e825da0d6779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a3c2a151-2319-4b3e-a4f3-cbe04146b96d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2986641-79c5-46c0-b7b5-1d448924b1af" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a3c2a151-2319-4b3e-a4f3-cbe04146b96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards_a545fce0-cb37-4a55-9752-dddc15e72690" xlink:href="halo-20230331.xsd#halo_BusinessCombinationConsiderationTransferredBonusAwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2986641-79c5-46c0-b7b5-1d448924b1af" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards_a545fce0-cb37-4a55-9752-dddc15e72690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_33608f77-2b81-48dc-9647-037360c4ffb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2986641-79c5-46c0-b7b5-1d448924b1af" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_33608f77-2b81-48dc-9647-037360c4ffb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_e44b7112-117b-4afd-9411-97256d8b389d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a2986641-79c5-46c0-b7b5-1d448924b1af" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_e44b7112-117b-4afd-9411-97256d8b389d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_fb3cdc35-8ec6-41ea-a622-ce1b0d0fc8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_74256c2d-3642-4560-85dc-ce666295da87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_fb3cdc35-8ec6-41ea-a622-ce1b0d0fc8c3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_74256c2d-3642-4560-85dc-ce666295da87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4d23c83b-26a5-4349-8cd1-a4350e54e41d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_74256c2d-3642-4560-85dc-ce666295da87" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4d23c83b-26a5-4349-8cd1-a4350e54e41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d8f3dda-faeb-4d33-a992-3e4d44a73532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4d23c83b-26a5-4349-8cd1-a4350e54e41d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d8f3dda-faeb-4d33-a992-3e4d44a73532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_78bf5205-346c-4379-bacd-af6fc2854a29" xlink:href="halo-20230331.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d8f3dda-faeb-4d33-a992-3e4d44a73532" xlink:to="loc_halo_AntaresPharmaIncMember_78bf5205-346c-4379-bacd-af6fc2854a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f7803aeb-e651-49cb-bcdb-e731db59d7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_74256c2d-3642-4560-85dc-ce666295da87" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f7803aeb-e651-49cb-bcdb-e731db59d7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3d4a0c22-e11e-4ff9-a856-590ddce8a439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7803aeb-e651-49cb-bcdb-e731db59d7c5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3d4a0c22-e11e-4ff9-a856-590ddce8a439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_ad7c8692-e99f-42e7-9496-674254276379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7803aeb-e651-49cb-bcdb-e731db59d7c5" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_ad7c8692-e99f-42e7-9496-674254276379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7803aeb-e651-49cb-bcdb-e731db59d7c5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_a2417859-f6da-4796-a144-7616e9ffe192" xlink:href="halo-20230331.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_a2417859-f6da-4796-a144-7616e9ffe192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_ef497496-88e1-43b9-a411-e9b90f738b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_ef497496-88e1-43b9-a411-e9b90f738b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_f51e30f5-ece8-48d9-9d03-81d1026e5fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_f51e30f5-ece8-48d9-9d03-81d1026e5fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9b721406-6e14-4554-bf44-6ba81e69f86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9b721406-6e14-4554-bf44-6ba81e69f86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_eb3964d1-4eba-4e40-91fd-1735762b533b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_eb3964d1-4eba-4e40-91fd-1735762b533b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_52554f4b-34c7-48ec-a5cf-c25bc10b2daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_52554f4b-34c7-48ec-a5cf-c25bc10b2daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_6b620a25-15a1-4896-aa13-d76183817aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_6b620a25-15a1-4896-aa13-d76183817aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_c9ef993f-fe2c-47fa-8e03-ccd105facff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b4791c14-a7e7-4216-9480-f35d336d3bb1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_c9ef993f-fe2c-47fa-8e03-ccd105facff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7803aeb-e651-49cb-bcdb-e731db59d7c5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5aba814b-b9c3-4d56-a783-a60140bfb819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5aba814b-b9c3-4d56-a783-a60140bfb819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense_12d2c6fa-2759-4619-986c-ae9e619e27c9" xlink:href="halo-20230331.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense_12d2c6fa-2759-4619-986c-ae9e619e27c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_e90f3a3c-c225-47c2-b470-d1ce542314de" xlink:href="halo-20230331.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_e90f3a3c-c225-47c2-b470-d1ce542314de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_179e3517-bba8-462f-8a77-b8dd8c7a7070" xlink:href="halo-20230331.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_179e3517-bba8-462f-8a77-b8dd8c7a7070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_cd5b4eb6-70e9-4aa9-b3ba-96f7438d0bcc" xlink:href="halo-20230331.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_cd5b4eb6-70e9-4aa9-b3ba-96f7438d0bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet_db266ab8-87a0-4fb5-84a7-a22c11c59518" xlink:href="halo-20230331.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet_db266ab8-87a0-4fb5-84a7-a22c11c59518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_257464af-fe0e-433d-b63e-139c58623618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_257464af-fe0e-433d-b63e-139c58623618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities_72eda97a-4189-451f-ba8a-594cca061311" xlink:href="halo-20230331.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities_72eda97a-4189-451f-ba8a-594cca061311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_c4a5c083-29bb-4224-8c9b-1e9671a2f16d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_c4a5c083-29bb-4224-8c9b-1e9671a2f16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill_a94431ba-37eb-4340-a3fe-fbb2be9ea365" xlink:href="halo-20230331.xsd#halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_bb64b655-039e-4d8e-93a4-e1c10deb8384" xlink:to="loc_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill_a94431ba-37eb-4340-a3fe-fbb2be9ea365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ed4a16c2-4e32-4bce-aafc-477fdd9366ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7803aeb-e651-49cb-bcdb-e731db59d7c5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ed4a16c2-4e32-4bce-aafc-477fdd9366ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_a5926c97-0e88-4209-8a35-03d99767f0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7803aeb-e651-49cb-bcdb-e731db59d7c5" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_a5926c97-0e88-4209-8a35-03d99767f0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c7dbd2ee-9350-43e7-ad2c-d6ee5e9f51c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7803aeb-e651-49cb-bcdb-e731db59d7c5" xlink:to="loc_us-gaap_Goodwill_c7dbd2ee-9350-43e7-ad2c-d6ee5e9f51c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#BusinessCombinationIntangibleAssetsAcquiredDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_587f0612-9b1c-4f8e-87c1-64a5cb150742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1c4e27fd-c0bd-4668-9a92-09f8b1935c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_587f0612-9b1c-4f8e-87c1-64a5cb150742" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1c4e27fd-c0bd-4668-9a92-09f8b1935c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8488a70a-1434-4419-a669-f96052f2b6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1c4e27fd-c0bd-4668-9a92-09f8b1935c7d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8488a70a-1434-4419-a669-f96052f2b6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_465fc0ca-3210-4a34-bb3f-d1d39983cb59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8488a70a-1434-4419-a669-f96052f2b6b7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_465fc0ca-3210-4a34-bb3f-d1d39983cb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_953f4c9d-4e17-4f78-8c8d-8255f39badb3" xlink:href="halo-20230331.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_465fc0ca-3210-4a34-bb3f-d1d39983cb59" xlink:to="loc_halo_AntaresPharmaIncMember_953f4c9d-4e17-4f78-8c8d-8255f39badb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2123162a-3f42-4510-b6bd-4daf1ceda135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1c4e27fd-c0bd-4668-9a92-09f8b1935c7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2123162a-3f42-4510-b6bd-4daf1ceda135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c874cc60-5aa5-4920-b67c-a0e5e5f06615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2123162a-3f42-4510-b6bd-4daf1ceda135" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c874cc60-5aa5-4920-b67c-a0e5e5f06615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AutoInjectorTechnologyPlatformMember_1f24ffa2-efe2-4773-9011-0ea72f703679" xlink:href="halo-20230331.xsd#halo_AutoInjectorTechnologyPlatformMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c874cc60-5aa5-4920-b67c-a0e5e5f06615" xlink:to="loc_halo_AutoInjectorTechnologyPlatformMember_1f24ffa2-efe2-4773-9011-0ea72f703679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_XYOSTEDProprietaryProductMember_e6bedb4b-5018-49f1-a2eb-cbef717b466c" xlink:href="halo-20230331.xsd#halo_XYOSTEDProprietaryProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c874cc60-5aa5-4920-b67c-a0e5e5f06615" xlink:to="loc_halo_XYOSTEDProprietaryProductMember_e6bedb4b-5018-49f1-a2eb-cbef717b466c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TLANDOProductRightsMember_7a51e6aa-2369-40d7-80af-edd8e697bd27" xlink:href="halo-20230331.xsd#halo_TLANDOProductRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c874cc60-5aa5-4920-b67c-a0e5e5f06615" xlink:to="loc_halo_TLANDOProductRightsMember_7a51e6aa-2369-40d7-80af-edd8e697bd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_78498e82-d2dd-4acb-aeb2-c6dc70b74893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1c4e27fd-c0bd-4668-9a92-09f8b1935c7d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_78498e82-d2dd-4acb-aeb2-c6dc70b74893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7cd42138-4dcd-475c-ba99-16ace53b55c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_78498e82-d2dd-4acb-aeb2-c6dc70b74893" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7cd42138-4dcd-475c-ba99-16ace53b55c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_18c9a92f-61f5-4f67-813b-6593d2d6c8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7cd42138-4dcd-475c-ba99-16ace53b55c0" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_18c9a92f-61f5-4f67-813b-6593d2d6c8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_200bd14a-758a-41f6-ab2f-2ab26bdf9a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1c4e27fd-c0bd-4668-9a92-09f8b1935c7d" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_200bd14a-758a-41f6-ab2f-2ab26bdf9a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_55b64bcf-8aa6-4e45-911c-7a26719af3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_200bd14a-758a-41f6-ab2f-2ab26bdf9a34" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_55b64bcf-8aa6-4e45-911c-7a26719af3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c43444ac-5961-49ea-9777-c77326b9b830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_200bd14a-758a-41f6-ab2f-2ab26bdf9a34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c43444ac-5961-49ea-9777-c77326b9b830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_dc0c3a7d-64f2-477d-a534-348d190eb4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_200bd14a-758a-41f6-ab2f-2ab26bdf9a34" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_dc0c3a7d-64f2-477d-a534-348d190eb4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_fb8f68cc-74cb-4f40-b249-9d2b7dbe1cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_200bd14a-758a-41f6-ab2f-2ab26bdf9a34" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_fb8f68cc-74cb-4f40-b249-9d2b7dbe1cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ca52722f-2763-46c3-ba83-0e7bfbbc8c68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e368a2e8-9aa8-4baa-923c-d977aa1a05f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ca52722f-2763-46c3-ba83-0e7bfbbc8c68" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e368a2e8-9aa8-4baa-923c-d977aa1a05f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ce4891f3-a310-4b99-8720-a3ac32957d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e368a2e8-9aa8-4baa-923c-d977aa1a05f0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ce4891f3-a310-4b99-8720-a3ac32957d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeacd4c5-c5c2-4954-886a-e68f54ce4d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ce4891f3-a310-4b99-8720-a3ac32957d92" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeacd4c5-c5c2-4954-886a-e68f54ce4d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_8354240a-01dd-4424-b83e-2ec40da61a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeacd4c5-c5c2-4954-886a-e68f54ce4d4f" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_8354240a-01dd-4424-b83e-2ec40da61a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3f1b7cd6-ce47-4470-bbc0-ed4e3636aa48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeacd4c5-c5c2-4954-886a-e68f54ce4d4f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3f1b7cd6-ce47-4470-bbc0-ed4e3636aa48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_089302bb-d42b-4f1a-81ed-9d7e52829230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeacd4c5-c5c2-4954-886a-e68f54ce4d4f" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_089302bb-d42b-4f1a-81ed-9d7e52829230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_571524f2-fcf6-435a-8b4a-1008e8daa733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeacd4c5-c5c2-4954-886a-e68f54ce4d4f" xlink:to="loc_us-gaap_CommercialPaperMember_571524f2-fcf6-435a-8b4a-1008e8daa733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_e4587129-bfd4-47c1-9cfc-0b36687fcf04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeacd4c5-c5c2-4954-886a-e68f54ce4d4f" xlink:to="loc_us-gaap_AgencySecuritiesMember_e4587129-bfd4-47c1-9cfc-0b36687fcf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d75ccf-d6c5-4f1e-8035-df6deb401f03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e368a2e8-9aa8-4baa-923c-d977aa1a05f0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d75ccf-d6c5-4f1e-8035-df6deb401f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a931d007-5400-40a5-a3f5-f3b0ca42be23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d75ccf-d6c5-4f1e-8035-df6deb401f03" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a931d007-5400-40a5-a3f5-f3b0ca42be23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b88ebcb9-83a6-4a60-99fc-994805e52316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d75ccf-d6c5-4f1e-8035-df6deb401f03" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b88ebcb9-83a6-4a60-99fc-994805e52316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a602c9da-76eb-4afa-b24f-9286c714ac5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d75ccf-d6c5-4f1e-8035-df6deb401f03" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a602c9da-76eb-4afa-b24f-9286c714ac5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4be57881-7897-4bba-bbba-2355c1f7356f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d75ccf-d6c5-4f1e-8035-df6deb401f03" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4be57881-7897-4bba-bbba-2355c1f7356f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_200e1265-f29e-4f69-9e4c-f9784d84c6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e864dcbd-509d-4b4a-8817-e25d395eee16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_200e1265-f29e-4f69-9e4c-f9784d84c6f7" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e864dcbd-509d-4b4a-8817-e25d395eee16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4954b14b-effb-455d-9c9a-618775fb3f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e864dcbd-509d-4b4a-8817-e25d395eee16" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4954b14b-effb-455d-9c9a-618775fb3f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5681d818-1f56-4b4b-9bce-e7cd03227672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4954b14b-effb-455d-9c9a-618775fb3f27" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5681d818-1f56-4b4b-9bce-e7cd03227672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fc76e332-0daa-4ecf-8635-6c719b633c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5681d818-1f56-4b4b-9bce-e7cd03227672" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fc76e332-0daa-4ecf-8635-6c719b633c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1adabcc7-b6bd-4bd8-ad87-49d271b90d00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e864dcbd-509d-4b4a-8817-e25d395eee16" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1adabcc7-b6bd-4bd8-ad87-49d271b90d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68ac385f-08cf-460f-86bb-9c1a42cc0c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1adabcc7-b6bd-4bd8-ad87-49d271b90d00" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68ac385f-08cf-460f-86bb-9c1a42cc0c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_c7b11df1-5ca8-4255-9d4d-4dfbf6fd64bf" xlink:href="halo-20230331.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68ac385f-08cf-460f-86bb-9c1a42cc0c25" xlink:to="loc_halo_AntaresPharmaIncMember_c7b11df1-5ca8-4255-9d4d-4dfbf6fd64bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b82047aa-fe4b-4caf-8405-7964772bde9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e864dcbd-509d-4b4a-8817-e25d395eee16" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b82047aa-fe4b-4caf-8405-7964772bde9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_026046ac-6287-44b7-b503-fab945aebba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b82047aa-fe4b-4caf-8405-7964772bde9d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_026046ac-6287-44b7-b503-fab945aebba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_8862b3b6-1d11-4037-8374-5692dbf33ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b82047aa-fe4b-4caf-8405-7964772bde9d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_8862b3b6-1d11-4037-8374-5692dbf33ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9744c44-1711-4480-b5ff-728da5088a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b82047aa-fe4b-4caf-8405-7964772bde9d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9744c44-1711-4480-b5ff-728da5088a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_17aae73b-8db8-484e-ac01-0c478343047f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b82047aa-fe4b-4caf-8405-7964772bde9d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_17aae73b-8db8-484e-ac01-0c478343047f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6a0d6ac5-650d-4397-ba2b-f52c854ff1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b82047aa-fe4b-4caf-8405-7964772bde9d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6a0d6ac5-650d-4397-ba2b-f52c854ff1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a33048f2-ef2b-45ef-8f7a-cd4d4c736163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b82047aa-fe4b-4caf-8405-7964772bde9d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a33048f2-ef2b-45ef-8f7a-cd4d4c736163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d328fd89-384b-4077-bcb0-bbe967111a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_59ece3b6-0f13-4f39-ba1e-130d08db88ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d328fd89-384b-4077-bcb0-bbe967111a17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_59ece3b6-0f13-4f39-ba1e-130d08db88ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_cc4e93cf-332d-4d13-8b16-41337a940677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d328fd89-384b-4077-bcb0-bbe967111a17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_cc4e93cf-332d-4d13-8b16-41337a940677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_629a101b-26af-46e2-8b3e-49c9c0a81859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d328fd89-384b-4077-bcb0-bbe967111a17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_629a101b-26af-46e2-8b3e-49c9c0a81859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6a38c8ff-5580-4974-9e69-ec6335930f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ce33b509-3f40-4ac5-bfed-de5a1e1c1be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6a38c8ff-5580-4974-9e69-ec6335930f62" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ce33b509-3f40-4ac5-bfed-de5a1e1c1be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_202114ec-8f41-4059-94cb-cf6c43d88b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ce33b509-3f40-4ac5-bfed-de5a1e1c1be3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_202114ec-8f41-4059-94cb-cf6c43d88b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_981d1f2b-6396-4579-8406-e12df5c7a811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_202114ec-8f41-4059-94cb-cf6c43d88b08" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_981d1f2b-6396-4579-8406-e12df5c7a811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_cd9cbab4-d822-40df-8cd1-3f2191ec5d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_981d1f2b-6396-4579-8406-e12df5c7a811" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_cd9cbab4-d822-40df-8cd1-3f2191ec5d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b55639ea-f8f2-4a14-afe2-d5afa329ff9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_981d1f2b-6396-4579-8406-e12df5c7a811" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b55639ea-f8f2-4a14-afe2-d5afa329ff9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_757bfc78-25b3-4696-874a-21cd33188a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_981d1f2b-6396-4579-8406-e12df5c7a811" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_757bfc78-25b3-4696-874a-21cd33188a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_a12dec09-aa3c-4b29-a61a-123e9b327b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ce33b509-3f40-4ac5-bfed-de5a1e1c1be3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_a12dec09-aa3c-4b29-a61a-123e9b327b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9dffc669-c829-44b5-9454-fd713de39a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a12dec09-aa3c-4b29-a61a-123e9b327b9b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9dffc669-c829-44b5-9454-fd713de39a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_55ce983d-1c91-4463-af37-d11a48ff2ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9dffc669-c829-44b5-9454-fd713de39a12" xlink:to="loc_us-gaap_MoneyMarketFundsMember_55ce983d-1c91-4463-af37-d11a48ff2ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_f4fc1fae-aa60-45c1-be49-2cb34d62e390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9dffc669-c829-44b5-9454-fd713de39a12" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_f4fc1fae-aa60-45c1-be49-2cb34d62e390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a25a4bbb-772c-4076-8996-98aed026adce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ce33b509-3f40-4ac5-bfed-de5a1e1c1be3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a25a4bbb-772c-4076-8996-98aed026adce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_395f518c-fd5a-48ab-971b-e5673b1769b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a25a4bbb-772c-4076-8996-98aed026adce" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_395f518c-fd5a-48ab-971b-e5673b1769b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_e31514e4-454c-4516-b68b-de8d44cede27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_395f518c-fd5a-48ab-971b-e5673b1769b5" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_e31514e4-454c-4516-b68b-de8d44cede27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_083b6428-7b49-431b-b8be-c317cbe4fa31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_395f518c-fd5a-48ab-971b-e5673b1769b5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_083b6428-7b49-431b-b8be-c317cbe4fa31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_51fc4660-a2ff-4e67-a223-6fb0873c9a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_395f518c-fd5a-48ab-971b-e5673b1769b5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_51fc4660-a2ff-4e67-a223-6fb0873c9a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_c77c229b-e67a-4be3-a2ab-1bd640ac9903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_395f518c-fd5a-48ab-971b-e5673b1769b5" xlink:to="loc_us-gaap_AgencySecuritiesMember_c77c229b-e67a-4be3-a2ab-1bd640ac9903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_cc620b79-7cc3-4b6d-8398-cafa607ef398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_395f518c-fd5a-48ab-971b-e5673b1769b5" xlink:to="loc_us-gaap_CommercialPaperMember_cc620b79-7cc3-4b6d-8398-cafa607ef398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_045d776a-4089-4b44-a64d-c3907a7dc8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ce33b509-3f40-4ac5-bfed-de5a1e1c1be3" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_045d776a-4089-4b44-a64d-c3907a7dc8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9aabddef-037e-4a51-8b81-f41a6c0dafa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_045d776a-4089-4b44-a64d-c3907a7dc8f1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9aabddef-037e-4a51-8b81-f41a6c0dafa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_15a09eac-19ac-495d-a0af-c53d8ab7225b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_045d776a-4089-4b44-a64d-c3907a7dc8f1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_15a09eac-19ac-495d-a0af-c53d8ab7225b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a89dcf6a-9084-4c33-a756-18174a9d6978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_045d776a-4089-4b44-a64d-c3907a7dc8f1" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a89dcf6a-9084-4c33-a756-18174a9d6978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#RevenueDisaggregatedRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9d8b2d81-77ac-4c02-abb8-f3e0739a5bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_06be638e-c69a-4fe1-bbd3-b1919eb24574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9d8b2d81-77ac-4c02-abb8-f3e0739a5bcd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_06be638e-c69a-4fe1-bbd3-b1919eb24574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6a01e4d9-1838-4060-8811-717804e4cc4b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_06be638e-c69a-4fe1-bbd3-b1919eb24574" xlink:to="loc_srt_ProductOrServiceAxis_6a01e4d9-1838-4060-8811-717804e4cc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f80cd44b-871d-4322-863c-d464d196ea81" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6a01e4d9-1838-4060-8811-717804e4cc4b" xlink:to="loc_srt_ProductsAndServicesDomain_f80cd44b-871d-4322-863c-d464d196ea81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_be5c87dc-035d-4f74-92d2-380b8369c43c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f80cd44b-871d-4322-863c-d464d196ea81" xlink:to="loc_us-gaap_RoyaltyMember_be5c87dc-035d-4f74-92d2-380b8369c43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0f78d280-5b09-4e6f-93d9-aab1f7d761cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f80cd44b-871d-4322-863c-d464d196ea81" xlink:to="loc_us-gaap_ProductMember_0f78d280-5b09-4e6f-93d9-aab1f7d761cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BulkrHuPH20Member_82645d81-54b4-497d-92e5-7103a86aaa05" xlink:href="halo-20230331.xsd#halo_BulkrHuPH20Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_0f78d280-5b09-4e6f-93d9-aab1f7d761cc" xlink:to="loc_halo_BulkrHuPH20Member_82645d81-54b4-497d-92e5-7103a86aaa05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProprietaryProductsSalesMember_938b52aa-ec81-43b0-9407-c0d575b4bb4f" xlink:href="halo-20230331.xsd#halo_ProprietaryProductsSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_0f78d280-5b09-4e6f-93d9-aab1f7d761cc" xlink:to="loc_halo_ProprietaryProductsSalesMember_938b52aa-ec81-43b0-9407-c0d575b4bb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevicePartneredProductsMember_39251794-dc02-41e9-9264-73cb2840f2bd" xlink:href="halo-20230331.xsd#halo_DevicePartneredProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_0f78d280-5b09-4e6f-93d9-aab1f7d761cc" xlink:to="loc_halo_DevicePartneredProductsMember_39251794-dc02-41e9-9264-73cb2840f2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember_bb952b8c-6471-4786-b7da-5ba5bb3ca2ac" xlink:href="halo-20230331.xsd#halo_CollaborativeAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f80cd44b-871d-4322-863c-d464d196ea81" xlink:to="loc_halo_CollaborativeAgreementsMember_bb952b8c-6471-4786-b7da-5ba5bb3ca2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_UpfrontfeesMember_207c2fa5-8c52-4a36-95d1-d0a428ca0e8b" xlink:href="halo-20230331.xsd#halo_UpfrontfeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsMember_bb952b8c-6471-4786-b7da-5ba5bb3ca2ac" xlink:to="loc_halo_UpfrontfeesMember_207c2fa5-8c52-4a36-95d1-d0a428ca0e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevelopmentFeesMember_e0701b8d-736e-4d01-806b-8e9a7598e303" xlink:href="halo-20230331.xsd#halo_DevelopmentFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsMember_bb952b8c-6471-4786-b7da-5ba5bb3ca2ac" xlink:to="loc_halo_DevelopmentFeesMember_e0701b8d-736e-4d01-806b-8e9a7598e303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_SalesbasedmilestoneMember_a92350ea-8da7-4192-8bb4-51d2ed327410" xlink:href="halo-20230331.xsd#halo_SalesbasedmilestoneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsMember_bb952b8c-6471-4786-b7da-5ba5bb3ca2ac" xlink:to="loc_halo_SalesbasedmilestoneMember_a92350ea-8da7-4192-8bb4-51d2ed327410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeviceLicensingAndDevelopmentMember_20ff443e-e841-47ef-916f-4f80903e5350" xlink:href="halo-20230331.xsd#halo_DeviceLicensingAndDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsMember_bb952b8c-6471-4786-b7da-5ba5bb3ca2ac" xlink:to="loc_halo_DeviceLicensingAndDevelopmentMember_20ff443e-e841-47ef-916f-4f80903e5350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a1f598a6-9fa9-4388-811d-5dbd42a33eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_06be638e-c69a-4fe1-bbd3-b1919eb24574" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a1f598a6-9fa9-4388-811d-5dbd42a33eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6cea62d-8689-4af0-981a-b1fd68888d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a1f598a6-9fa9-4388-811d-5dbd42a33eb9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6cea62d-8689-4af0-981a-b1fd68888d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#RevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_575a9a1d-c0e4-4c98-b429-f1edc1e6b0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_590d2bb5-8144-4c68-889d-854802acd60d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_575a9a1d-c0e4-4c98-b429-f1edc1e6b0e9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_590d2bb5-8144-4c68-889d-854802acd60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d01298bf-b3c5-4862-af64-6fb189d89312" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_590d2bb5-8144-4c68-889d-854802acd60d" xlink:to="loc_srt_ProductOrServiceAxis_d01298bf-b3c5-4862-af64-6fb189d89312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_679f847d-33a9-41b9-9426-5efbd2789bdb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d01298bf-b3c5-4862-af64-6fb189d89312" xlink:to="loc_srt_ProductsAndServicesDomain_679f847d-33a9-41b9-9426-5efbd2789bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LicenseFeesAndEventBasedMember_fbcba8c2-154a-4c21-9376-a88a027fc76b" xlink:href="halo-20230331.xsd#halo_LicenseFeesAndEventBasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_679f847d-33a9-41b9-9426-5efbd2789bdb" xlink:to="loc_halo_LicenseFeesAndEventBasedMember_fbcba8c2-154a-4c21-9376-a88a027fc76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3a7bd753-677e-4d56-b39f-592fb5497c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_679f847d-33a9-41b9-9426-5efbd2789bdb" xlink:to="loc_us-gaap_ProductMember_3a7bd753-677e-4d56-b39f-592fb5497c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_401f592a-8caa-45e0-b696-dbc0067ebd73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_590d2bb5-8144-4c68-889d-854802acd60d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_401f592a-8caa-45e0-b696-dbc0067ebd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_323e77e8-4559-401a-9b68-81003cdc6cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_401f592a-8caa-45e0-b696-dbc0067ebd73" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_323e77e8-4559-401a-9b68-81003cdc6cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OthercollaboratorsMember_d36b6ced-f223-46e2-89a6-975a1b4012c2" xlink:href="halo-20230331.xsd#halo_OthercollaboratorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_323e77e8-4559-401a-9b68-81003cdc6cdb" xlink:to="loc_halo_OthercollaboratorsMember_d36b6ced-f223-46e2-89a6-975a1b4012c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b87a7558-00db-46e2-87c2-99194be6148f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_590d2bb5-8144-4c68-889d-854802acd60d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b87a7558-00db-46e2-87c2-99194be6148f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d554e089-9126-4678-b84b-d4f65488e21e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b87a7558-00db-46e2-87c2-99194be6148f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d554e089-9126-4678-b84b-d4f65488e21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6b660d65-7eca-42a4-9588-f0f5ca79a09c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b87a7558-00db-46e2-87c2-99194be6148f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6b660d65-7eca-42a4-9588-f0f5ca79a09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_199d1f97-5a12-46e3-b31a-a4ed51062c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b87a7558-00db-46e2-87c2-99194be6148f" xlink:to="loc_us-gaap_DeferredRevenue_199d1f97-5a12-46e3-b31a-a4ed51062c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_bdfcdca7-02ee-4be7-9173-4362b4533d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b87a7558-00db-46e2-87c2-99194be6148f" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_bdfcdca7-02ee-4be7-9173-4362b4533d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_a895ef2a-3dbb-4bfc-89b6-e3676552a68f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b87a7558-00db-46e2-87c2-99194be6148f" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_a895ef2a-3dbb-4bfc-89b6-e3676552a68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_c6acf4d3-8165-4fde-a312-ed57ee272e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b87a7558-00db-46e2-87c2-99194be6148f" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_c6acf4d3-8165-4fde-a312-ed57ee272e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f727c7ac-f130-4c8c-99d3-d62b8ec32685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets_885f3904-683d-44bd-b820-77407524f2f0" xlink:href="halo-20230331.xsd#halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f727c7ac-f130-4c8c-99d3-d62b8ec32685" xlink:to="loc_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets_885f3904-683d-44bd-b820-77407524f2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_79a8283f-24d1-4f31-8357-0e12fd6f74a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f727c7ac-f130-4c8c-99d3-d62b8ec32685" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_79a8283f-24d1-4f31-8357-0e12fd6f74a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_2b83b784-4e9a-4d79-99a1-af5e5acb095f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f727c7ac-f130-4c8c-99d3-d62b8ec32685" xlink:to="loc_us-gaap_DeferredRevenue_2b83b784-4e9a-4d79-99a1-af5e5acb095f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#RevenueAdditionalRevenueInformationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6c8d00bd-1601-4f1e-8562-1ce542ad7679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d1625c6e-d742-4332-ae85-9c0153dd61a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6c8d00bd-1601-4f1e-8562-1ce542ad7679" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d1625c6e-d742-4332-ae85-9c0153dd61a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_6c8e9cd0-7885-4442-bea7-b31c4006a8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d1625c6e-d742-4332-ae85-9c0153dd61a7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_6c8e9cd0-7885-4442-bea7-b31c4006a8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f37db388-3f71-421d-bc27-4105ab6cb346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_d1625c6e-d742-4332-ae85-9c0153dd61a7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f37db388-3f71-421d-bc27-4105ab6cb346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_889b274f-f142-480d-9938-b6d6a05123fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f37db388-3f71-421d-bc27-4105ab6cb346" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_889b274f-f142-480d-9938-b6d6a05123fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_106b2f84-57ee-4df3-a710-2fef16d976af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f37db388-3f71-421d-bc27-4105ab6cb346" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_106b2f84-57ee-4df3-a710-2fef16d976af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails_1" xlink:type="simple" xlink:href="halo-20230331.xsd#RevenueAdditionalRevenueInformationDetails_1"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#CertainBalanceSheetItemsAccountsReceivablenetDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cf6b400b-e0bc-4f89-842a-3332020cc602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromproductsalestocollaborators_598019ed-12df-4596-9130-3814ad1632f4" xlink:href="halo-20230331.xsd#halo_Accountsreceivablefromproductsalestocollaborators"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cf6b400b-e0bc-4f89-842a-3332020cc602" xlink:to="loc_halo_Accountsreceivablefromproductsalestocollaborators_598019ed-12df-4596-9130-3814ad1632f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromcollaborators_d1d304db-eb90-4c41-a1a1-0e84598b24d1" xlink:href="halo-20230331.xsd#halo_Accountsreceivablefromcollaborators"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cf6b400b-e0bc-4f89-842a-3332020cc602" xlink:to="loc_halo_Accountsreceivablefromcollaborators_d1d304db-eb90-4c41-a1a1-0e84598b24d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromroyalties_760f6a2e-c1e2-4816-92dd-412b79466589" xlink:href="halo-20230331.xsd#halo_Accountsreceivablefromroyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cf6b400b-e0bc-4f89-842a-3332020cc602" xlink:to="loc_halo_Accountsreceivablefromroyalties_760f6a2e-c1e2-4816-92dd-412b79466589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromproductsales_2ca08c35-1e2e-4741-aa1a-4c4737d59099" xlink:href="halo-20230331.xsd#halo_Accountsreceivablefromproductsales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cf6b400b-e0bc-4f89-842a-3332020cc602" xlink:to="loc_halo_Accountsreceivablefromproductsales_2ca08c35-1e2e-4741-aa1a-4c4737d59099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_e7870d4c-4d56-4801-977b-0fd0d60a7f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cf6b400b-e0bc-4f89-842a-3332020cc602" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_e7870d4c-4d56-4801-977b-0fd0d60a7f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_24786681-4504-4e3b-967c-492c0a657b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cf6b400b-e0bc-4f89-842a-3332020cc602" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_24786681-4504-4e3b-967c-492c0a657b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AllowanceforDistributionFeesandDiscounts_6b314e14-130d-4fc4-9e2d-b7684337d563" xlink:href="halo-20230331.xsd#halo_AllowanceforDistributionFeesandDiscounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cf6b400b-e0bc-4f89-842a-3332020cc602" xlink:to="loc_halo_AllowanceforDistributionFeesandDiscounts_6b314e14-130d-4fc4-9e2d-b7684337d563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_266de2cb-4dd2-4465-95bc-7de759d887e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cf6b400b-e0bc-4f89-842a-3332020cc602" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_266de2cb-4dd2-4465-95bc-7de759d887e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#CertainBalanceSheetItemsInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bdbb3a9f-2f46-4dc6-877c-6c5a9a259334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_580938ad-0a90-4a6f-a601-d8b2d57eb1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bdbb3a9f-2f46-4dc6-877c-6c5a9a259334" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_580938ad-0a90-4a6f-a601-d8b2d57eb1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_46b5799d-b306-4d98-9c45-dae952a1edc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bdbb3a9f-2f46-4dc6-877c-6c5a9a259334" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_46b5799d-b306-4d98-9c45-dae952a1edc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_8fc852a0-25c1-4cbc-93bf-b5b8beaceec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bdbb3a9f-2f46-4dc6-877c-6c5a9a259334" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_8fc852a0-25c1-4cbc-93bf-b5b8beaceec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_878bd40c-e74e-4db3-bc62-850971dd4a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bdbb3a9f-2f46-4dc6-877c-6c5a9a259334" xlink:to="loc_us-gaap_InventoryNet_878bd40c-e74e-4db3-bc62-850971dd4a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_847f78bd-5ba0-479e-8745-329e8f354624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6528bc71-f356-413d-a365-a9de24e4e93e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_847f78bd-5ba0-479e-8745-329e8f354624" xlink:to="loc_us-gaap_StatementTable_6528bc71-f356-413d-a365-a9de24e4e93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_428827cb-553c-44d0-bb9e-998918892b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6528bc71-f356-413d-a365-a9de24e4e93e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_428827cb-553c-44d0-bb9e-998918892b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7675f8c7-a1c1-4f4f-863d-0f0b497cc3db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_428827cb-553c-44d0-bb9e-998918892b11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7675f8c7-a1c1-4f4f-863d-0f0b497cc3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ComputerAndOfficeEquipmentMember_18cad97f-4876-4c62-850e-b6c873388f2f" xlink:href="halo-20230331.xsd#halo_ComputerAndOfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7675f8c7-a1c1-4f4f-863d-0f0b497cc3db" xlink:to="loc_halo_ComputerAndOfficeEquipmentMember_18cad97f-4876-4c62-850e-b6c873388f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0ca1f0c7-290a-4cf7-b5b4-531693cbd3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6528bc71-f356-413d-a365-a9de24e4e93e" xlink:to="loc_us-gaap_StatementLineItems_0ca1f0c7-290a-4cf7-b5b4-531693cbd3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_ca857109-b8de-4076-9619-238e285b1d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0ca1f0c7-290a-4cf7-b5b4-531693cbd3d7" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_ca857109-b8de-4076-9619-238e285b1d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_18c9ff00-445e-4d60-87ff-4afc69760c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0ca1f0c7-290a-4cf7-b5b4-531693cbd3d7" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_18c9ff00-445e-4d60-87ff-4afc69760c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_1a052bd2-2fa0-4e52-88d5-7186898a23af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0ca1f0c7-290a-4cf7-b5b4-531693cbd3d7" xlink:to="loc_us-gaap_OtherAssets_1a052bd2-2fa0-4e52-88d5-7186898a23af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_af0fb129-b172-4610-93d4-29a35ac1ba3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0ca1f0c7-290a-4cf7-b5b4-531693cbd3d7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_af0fb129-b172-4610-93d4-29a35ac1ba3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_04b94550-d482-4ddf-a4f3-7743d29070e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0ca1f0c7-290a-4cf7-b5b4-531693cbd3d7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_04b94550-d482-4ddf-a4f3-7743d29070e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bd142d80-6b2e-4d93-821f-5908903ca41d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0ca1f0c7-290a-4cf7-b5b4-531693cbd3d7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bd142d80-6b2e-4d93-821f-5908903ca41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1" xlink:type="simple" xlink:href="halo-20230331.xsd#CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#CertainBalanceSheetItemsPropertyandEquipmentnetDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f5974afd-1257-4a84-ac84-bb2487e63b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a26415f-7ec7-490c-b402-1650e415f50c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f5974afd-1257-4a84-ac84-bb2487e63b9e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a26415f-7ec7-490c-b402-1650e415f50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_be8d2a4a-86f9-4144-925b-f2492aa61a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a26415f-7ec7-490c-b402-1650e415f50c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_be8d2a4a-86f9-4144-925b-f2492aa61a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2e5f2061-dc0a-4b42-878e-916c7b111583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_be8d2a4a-86f9-4144-925b-f2492aa61a70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2e5f2061-dc0a-4b42-878e-916c7b111583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ResearchEquipmentMember_02337395-a03f-494f-9db8-e9110cf7c98f" xlink:href="halo-20230331.xsd#halo_ResearchEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2e5f2061-dc0a-4b42-878e-916c7b111583" xlink:to="loc_halo_ResearchEquipmentMember_02337395-a03f-494f-9db8-e9110cf7c98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ManufacturingEquipmentMember_ab8ca9f1-c65c-4b8b-97a7-fb2e3a5377dd" xlink:href="halo-20230331.xsd#halo_ManufacturingEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2e5f2061-dc0a-4b42-878e-916c7b111583" xlink:to="loc_halo_ManufacturingEquipmentMember_ab8ca9f1-c65c-4b8b-97a7-fb2e3a5377dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ComputerAndOfficeEquipmentMember_61449967-62c8-423c-8633-3f47191f0edd" xlink:href="halo-20230331.xsd#halo_ComputerAndOfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2e5f2061-dc0a-4b42-878e-916c7b111583" xlink:to="loc_halo_ComputerAndOfficeEquipmentMember_61449967-62c8-423c-8633-3f47191f0edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4303a64e-1309-4707-9657-2021ac049315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2e5f2061-dc0a-4b42-878e-916c7b111583" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4303a64e-1309-4707-9657-2021ac049315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79d7b825-5aee-4ca8-b7ec-4515306e6357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a26415f-7ec7-490c-b402-1650e415f50c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79d7b825-5aee-4ca8-b7ec-4515306e6357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_053e5a6a-2387-40e3-86b2-ae4e33083407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79d7b825-5aee-4ca8-b7ec-4515306e6357" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_053e5a6a-2387-40e3-86b2-ae4e33083407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ebbae123-a794-41b7-9229-27d7c119a605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79d7b825-5aee-4ca8-b7ec-4515306e6357" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ebbae123-a794-41b7-9229-27d7c119a605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b5de3cc4-f972-4491-9f1a-c1381d07e96b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79d7b825-5aee-4ca8-b7ec-4515306e6357" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b5de3cc4-f972-4491-9f1a-c1381d07e96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b9db2933-8789-4ba6-ad61-29851d038b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79d7b825-5aee-4ca8-b7ec-4515306e6357" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b9db2933-8789-4ba6-ad61-29851d038b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d5fd8fc3-6f31-46c7-b890-e0a1cd94d9c5" xlink:href="halo-20230331.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79d7b825-5aee-4ca8-b7ec-4515306e6357" xlink:to="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d5fd8fc3-6f31-46c7-b890-e0a1cd94d9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_59facd8d-5bd1-40b6-9266-f4f4682043dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79d7b825-5aee-4ca8-b7ec-4515306e6357" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_59facd8d-5bd1-40b6-9266-f4f4682043dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_7d678001-020c-4b6c-a5dd-a940da34e929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_79d7b825-5aee-4ca8-b7ec-4515306e6357" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_7d678001-020c-4b6c-a5dd-a940da34e929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#CertainBalanceSheetItemsAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2ca61e36-84ef-4af6-b2af-9d246c15a7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a5384be4-1477-4424-b65a-1934fb8ee1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2ca61e36-84ef-4af6-b2af-9d246c15a7a1" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a5384be4-1477-4424-b65a-1934fb8ee1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accruedmanufacturingexpenses_76757e2d-c77f-4f8f-a442-12b199f4c631" xlink:href="halo-20230331.xsd#halo_Accruedmanufacturingexpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2ca61e36-84ef-4af6-b2af-9d246c15a7a1" xlink:to="loc_halo_Accruedmanufacturingexpenses_76757e2d-c77f-4f8f-a442-12b199f4c631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_83263dbe-e936-49a0-a73b-02fa8453f672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2ca61e36-84ef-4af6-b2af-9d246c15a7a1" xlink:to="loc_us-gaap_TaxesPayableCurrent_83263dbe-e936-49a0-a73b-02fa8453f672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_8b2fa12b-6cee-4035-bec6-ab050dd84b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2ca61e36-84ef-4af6-b2af-9d246c15a7a1" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_8b2fa12b-6cee-4035-bec6-ab050dd84b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fd702e8e-1038-4462-ad7b-680e3d17313f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2ca61e36-84ef-4af6-b2af-9d246c15a7a1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fd702e8e-1038-4462-ad7b-680e3d17313f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4c1594c8-da01-4124-b302-9648ce4d6f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2ca61e36-84ef-4af6-b2af-9d246c15a7a1" xlink:to="loc_us-gaap_OperatingLeaseLiability_4c1594c8-da01-4124-b302-9648ce4d6f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_de900be4-d04e-4070-b518-6d1b95103225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2ca61e36-84ef-4af6-b2af-9d246c15a7a1" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_de900be4-d04e-4070-b518-6d1b95103225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccruedLiabilitiesNoncurrent_28cd3fa0-672b-4e76-90fe-7f1a42679bb1" xlink:href="halo-20230331.xsd#halo_AccruedLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2ca61e36-84ef-4af6-b2af-9d246c15a7a1" xlink:to="loc_halo_AccruedLiabilitiesNoncurrent_28cd3fa0-672b-4e76-90fe-7f1a42679bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ad63650d-3faa-45ea-9c2c-814c02b565a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2ca61e36-84ef-4af6-b2af-9d246c15a7a1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ad63650d-3faa-45ea-9c2c-814c02b565a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OperatingLeaseAccretionOfLiability_918ca4ee-a05e-440d-8f5b-4909a9290559" xlink:href="halo-20230331.xsd#halo_OperatingLeaseAccretionOfLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2ca61e36-84ef-4af6-b2af-9d246c15a7a1" xlink:to="loc_halo_OperatingLeaseAccretionOfLiability_918ca4ee-a05e-440d-8f5b-4909a9290559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_2546ccd0-9033-42e0-869d-878192d40965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2ca61e36-84ef-4af6-b2af-9d246c15a7a1" xlink:to="loc_us-gaap_OperatingLeaseCost_2546ccd0-9033-42e0-869d-878192d40965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_948c3b85-4a1a-498a-8a3f-adf4927ab99a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2ca61e36-84ef-4af6-b2af-9d246c15a7a1" xlink:to="loc_us-gaap_OperatingLeasePayments_948c3b85-4a1a-498a-8a3f-adf4927ab99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1" xlink:type="simple" xlink:href="halo-20230331.xsd#CertainBalanceSheetItemsAccruedExpensesDetails_1"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#GoodwillandIntangibleAssetsAdditionalDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8361b131-99d7-484e-92e1-b57b37d4b44a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_72f8d08e-af47-491d-847e-c95c6434001b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8361b131-99d7-484e-92e1-b57b37d4b44a" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_72f8d08e-af47-491d-847e-c95c6434001b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4f221024-03fa-4245-b002-3e2e764b7bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_72f8d08e-af47-491d-847e-c95c6434001b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4f221024-03fa-4245-b002-3e2e764b7bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dec2841f-d745-47bb-8a94-4ca24075f5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4f221024-03fa-4245-b002-3e2e764b7bbb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dec2841f-d745-47bb-8a94-4ca24075f5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_626fc621-fd47-4ac0-a668-f46400dca69b" xlink:href="halo-20230331.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dec2841f-d745-47bb-8a94-4ca24075f5fa" xlink:to="loc_halo_AntaresPharmaIncMember_626fc621-fd47-4ac0-a668-f46400dca69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6287d22f-4454-4dec-9327-e4a555377d14" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_72f8d08e-af47-491d-847e-c95c6434001b" xlink:to="loc_srt_RangeAxis_6287d22f-4454-4dec-9327-e4a555377d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6f5dd027-0bc6-4b24-b2b7-6e8036cfd9d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6287d22f-4454-4dec-9327-e4a555377d14" xlink:to="loc_srt_RangeMember_6f5dd027-0bc6-4b24-b2b7-6e8036cfd9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_65ec7bd4-7846-4664-8819-12bfa6913047" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6f5dd027-0bc6-4b24-b2b7-6e8036cfd9d1" xlink:to="loc_srt_MinimumMember_65ec7bd4-7846-4664-8819-12bfa6913047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a4d14237-a4ef-4678-8e80-3e11d8349941" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6f5dd027-0bc6-4b24-b2b7-6e8036cfd9d1" xlink:to="loc_srt_MaximumMember_a4d14237-a4ef-4678-8e80-3e11d8349941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_285569da-eb11-4e5d-922c-95af874633b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_72f8d08e-af47-491d-847e-c95c6434001b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_285569da-eb11-4e5d-922c-95af874633b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8290c5ab-3523-4071-a2f0-83a59b47690a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_285569da-eb11-4e5d-922c-95af874633b0" xlink:to="loc_us-gaap_Goodwill_8290c5ab-3523-4071-a2f0-83a59b47690a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4d1a39f5-6c39-4684-8bf7-70c50d858736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_285569da-eb11-4e5d-922c-95af874633b0" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4d1a39f5-6c39-4684-8bf7-70c50d858736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#GoodwillandIntangibleAssetsGoodwillRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6da32c72-4af8-4fdd-bb80-1946a65437ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_8056a73b-b0fa-4f06-991e-cfb9bc59a34f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6da32c72-4af8-4fdd-bb80-1946a65437ce" xlink:to="loc_us-gaap_GoodwillRollForward_8056a73b-b0fa-4f06-991e-cfb9bc59a34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_61a37bb6-45de-4b79-a8fb-a7d3a3e7826d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_8056a73b-b0fa-4f06-991e-cfb9bc59a34f" xlink:to="loc_us-gaap_Goodwill_61a37bb6-45de-4b79-a8fb-a7d3a3e7826d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_54ab904e-c74f-4817-80d1-3b1b39402e68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_8056a73b-b0fa-4f06-991e-cfb9bc59a34f" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_54ab904e-c74f-4817-80d1-3b1b39402e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c24ed741-bd54-4d30-a756-416f8ab97971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_8056a73b-b0fa-4f06-991e-cfb9bc59a34f" xlink:to="loc_us-gaap_Goodwill_c24ed741-bd54-4d30-a756-416f8ab97971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62fb46fe-19e8-448b-af14-f95bda813f18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_87346687-eb72-4f86-8335-d7058dfac932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62fb46fe-19e8-448b-af14-f95bda813f18" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_87346687-eb72-4f86-8335-d7058dfac932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_14992bc4-7967-43b2-8eab-53ae94ba368f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_87346687-eb72-4f86-8335-d7058dfac932" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_14992bc4-7967-43b2-8eab-53ae94ba368f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4387abb1-c096-4a44-b566-b89377ff9ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_14992bc4-7967-43b2-8eab-53ae94ba368f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4387abb1-c096-4a44-b566-b89377ff9ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AutoInjectorTechnologyPlatformMember_c537d319-cc8a-495c-bdc3-8b899cc96d1e" xlink:href="halo-20230331.xsd#halo_AutoInjectorTechnologyPlatformMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4387abb1-c096-4a44-b566-b89377ff9ec2" xlink:to="loc_halo_AutoInjectorTechnologyPlatformMember_c537d319-cc8a-495c-bdc3-8b899cc96d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_XYOSTEDProprietaryProductMember_404c67e1-8df6-4927-8972-32417cac035a" xlink:href="halo-20230331.xsd#halo_XYOSTEDProprietaryProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4387abb1-c096-4a44-b566-b89377ff9ec2" xlink:to="loc_halo_XYOSTEDProprietaryProductMember_404c67e1-8df6-4927-8972-32417cac035a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TLANDOProductRightsMember_b77d06fb-273f-4778-aceb-3489366682d6" xlink:href="halo-20230331.xsd#halo_TLANDOProductRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4387abb1-c096-4a44-b566-b89377ff9ec2" xlink:to="loc_halo_TLANDOProductRightsMember_b77d06fb-273f-4778-aceb-3489366682d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_56581cea-fb0c-4756-9fee-0f8ceff9f596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_87346687-eb72-4f86-8335-d7058dfac932" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_56581cea-fb0c-4756-9fee-0f8ceff9f596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_7376c668-7e9d-4d70-8ffe-8cc08b3023e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_56581cea-fb0c-4756-9fee-0f8ceff9f596" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_7376c668-7e9d-4d70-8ffe-8cc08b3023e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e4b44b7a-bb6a-4c67-9ce7-6b252cc66325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_56581cea-fb0c-4756-9fee-0f8ceff9f596" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e4b44b7a-bb6a-4c67-9ce7-6b252cc66325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3cf35f51-5a07-42db-8b34-7e3d2eb06843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_56581cea-fb0c-4756-9fee-0f8ceff9f596" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3cf35f51-5a07-42db-8b34-7e3d2eb06843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eec35d2d-7c23-47b0-90c3-653c21fca00c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_56581cea-fb0c-4756-9fee-0f8ceff9f596" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eec35d2d-7c23-47b0-90c3-653c21fca00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_01c6462f-3f98-41fd-a174-39583b41d169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_56581cea-fb0c-4756-9fee-0f8ceff9f596" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_01c6462f-3f98-41fd-a174-39583b41d169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0f886ce4-1f8c-4ca3-9986-79a35ee8ad46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_56581cea-fb0c-4756-9fee-0f8ceff9f596" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0f886ce4-1f8c-4ca3-9986-79a35ee8ad46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#GoodwillandIntangibleAssetsFutureAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_17ced5ec-50ab-41b5-b28d-7205433a42ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_612c6986-f6c0-42d6-8e84-c4bc3207232f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_17ced5ec-50ab-41b5-b28d-7205433a42ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_612c6986-f6c0-42d6-8e84-c4bc3207232f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9d9bab1b-9d3f-4cf7-9dc4-136b559d093b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_17ced5ec-50ab-41b5-b28d-7205433a42ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9d9bab1b-9d3f-4cf7-9dc4-136b559d093b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_59adef11-c6c7-4221-b96e-e11602d26207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_17ced5ec-50ab-41b5-b28d-7205433a42ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_59adef11-c6c7-4221-b96e-e11602d26207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_840b8f53-3775-4373-8e05-74c52b6baa65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_17ced5ec-50ab-41b5-b28d-7205433a42ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_840b8f53-3775-4373-8e05-74c52b6baa65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7a81f3a8-bd5d-4569-8ced-4e39b05da41b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_17ced5ec-50ab-41b5-b28d-7205433a42ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7a81f3a8-bd5d-4569-8ced-4e39b05da41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour_7714fc18-7b4a-4277-afee-f092c497dfa4" xlink:href="halo-20230331.xsd#halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_17ced5ec-50ab-41b5-b28d-7205433a42ef" xlink:to="loc_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour_7714fc18-7b4a-4277-afee-f092c497dfa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2eb11ea7-c3be-4b95-b57d-7969da48d995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_17ced5ec-50ab-41b5-b28d-7205433a42ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2eb11ea7-c3be-4b95-b57d-7969da48d995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#LongTermDebtNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_81e4dfdf-bd19-4456-849d-870809b9ce69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_81e4dfdf-bd19-4456-849d-870809b9ce69" xlink:to="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_db4b4e19-1b85-4271-93bb-acba9f11fccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:to="loc_us-gaap_DebtInstrumentAxis_db4b4e19-1b85-4271-93bb-acba9f11fccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_25b40c46-cfa2-410e-aa60-51a12019de00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_db4b4e19-1b85-4271-93bb-acba9f11fccf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_25b40c46-cfa2-410e-aa60-51a12019de00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member_34835781-4caf-49fe-ab18-ac3541c1000e" xlink:href="halo-20230331.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25b40c46-cfa2-410e-aa60-51a12019de00" xlink:to="loc_halo_A100ConvertibleSeniorNotesDue2028Member_34835781-4caf-49fe-ab18-ac3541c1000e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_a90663d3-e167-4552-a996-16bddb6ec717" xlink:href="halo-20230331.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25b40c46-cfa2-410e-aa60-51a12019de00" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_a90663d3-e167-4552-a996-16bddb6ec717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_44f42410-8eb1-49c7-bc6d-5ffa60823f9e" xlink:href="halo-20230331.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25b40c46-cfa2-410e-aa60-51a12019de00" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_44f42410-8eb1-49c7-bc6d-5ffa60823f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CreditAgreementMember_6356c93e-3965-44a1-bb8f-f28b54c78cd3" xlink:href="halo-20230331.xsd#halo_CreditAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25b40c46-cfa2-410e-aa60-51a12019de00" xlink:to="loc_halo_CreditAgreementMember_6356c93e-3965-44a1-bb8f-f28b54c78cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_183b6b71-21b7-4254-9920-193dec8ad658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_183b6b71-21b7-4254-9920-193dec8ad658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_58942cdc-c400-40f0-a393-163201884986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_183b6b71-21b7-4254-9920-193dec8ad658" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_58942cdc-c400-40f0-a393-163201884986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_3cbb72c5-5f0c-4278-ac61-cbee14601037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_58942cdc-c400-40f0-a393-163201884986" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_3cbb72c5-5f0c-4278-ac61-cbee14601037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_5e477687-aaeb-4489-87a2-dc70d7244589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_58942cdc-c400-40f0-a393-163201884986" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_5e477687-aaeb-4489-87a2-dc70d7244589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9140de34-282a-4da7-bc4a-11a198cca7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9140de34-282a-4da7-bc4a-11a198cca7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_57bc2de4-0fe6-4646-9d19-af97f6a932cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9140de34-282a-4da7-bc4a-11a198cca7e3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_57bc2de4-0fe6-4646-9d19-af97f6a932cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_52c63fd5-1d46-417e-a9c9-c7b455cf6345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_57bc2de4-0fe6-4646-9d19-af97f6a932cf" xlink:to="loc_us-gaap_ConvertibleDebtMember_52c63fd5-1d46-417e-a9c9-c7b455cf6345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_6cae7ce7-5721-4e93-a178-6ca4d1ba759c" xlink:href="halo-20230331.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_57bc2de4-0fe6-4646-9d19-af97f6a932cf" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_6cae7ce7-5721-4e93-a178-6ca4d1ba759c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TermLoanFacilityMember_7e5c5323-65ff-4bc9-b3a7-31b8c5edf2bc" xlink:href="halo-20230331.xsd#halo_TermLoanFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_57bc2de4-0fe6-4646-9d19-af97f6a932cf" xlink:to="loc_halo_TermLoanFacilityMember_7e5c5323-65ff-4bc9-b3a7-31b8c5edf2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_36bafc1c-1eac-4337-ae3d-b3c9ffa78840" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:to="loc_srt_RangeAxis_36bafc1c-1eac-4337-ae3d-b3c9ffa78840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1b136e43-13b0-4463-9dc9-564c68ba684c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_36bafc1c-1eac-4337-ae3d-b3c9ffa78840" xlink:to="loc_srt_RangeMember_1b136e43-13b0-4463-9dc9-564c68ba684c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_afe5dc67-e7c9-46ba-ab5a-1a5931b02383" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1b136e43-13b0-4463-9dc9-564c68ba684c" xlink:to="loc_srt_MinimumMember_afe5dc67-e7c9-46ba-ab5a-1a5931b02383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_38d5091d-e7e6-4c75-b0c9-2f61ac5a2205" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1b136e43-13b0-4463-9dc9-564c68ba684c" xlink:to="loc_srt_MaximumMember_38d5091d-e7e6-4c75-b0c9-2f61ac5a2205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_189cf13c-fc37-4e43-a470-d3c45a13edd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:to="loc_us-gaap_VariableRateAxis_189cf13c-fc37-4e43-a470-d3c45a13edd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7875bda9-4797-456a-9d0d-238da55f9881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_189cf13c-fc37-4e43-a470-d3c45a13edd7" xlink:to="loc_us-gaap_VariableRateDomain_7875bda9-4797-456a-9d0d-238da55f9881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_abca0c93-f289-4424-b34c-55d977b5b7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_7875bda9-4797-456a-9d0d-238da55f9881" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_abca0c93-f289-4424-b34c-55d977b5b7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_31fe183f-a706-4fa2-a200-fc44ec99f3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_7875bda9-4797-456a-9d0d-238da55f9881" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_31fe183f-a706-4fa2-a200-fc44ec99f3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_51e39d75-4564-4e2a-a55c-be165f187d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_7875bda9-4797-456a-9d0d-238da55f9881" xlink:to="loc_us-gaap_BaseRateMember_51e39d75-4564-4e2a-a55c-be165f187d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_1ff66883-5283-4420-99bc-6954777d399c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:to="loc_us-gaap_CreditFacilityAxis_1ff66883-5283-4420-99bc-6954777d399c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ac0254b9-6d61-4d69-b65c-c2c1b58c693f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1ff66883-5283-4420-99bc-6954777d399c" xlink:to="loc_us-gaap_CreditFacilityDomain_ac0254b9-6d61-4d69-b65c-c2c1b58c693f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_2c7aa166-fba7-4b30-8687-18c701f26e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_ac0254b9-6d61-4d69-b65c-c2c1b58c693f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_2c7aa166-fba7-4b30-8687-18c701f26e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodAxis_c6e890e5-da34-47ae-b383-25b6c403f9a2" xlink:href="halo-20230331.xsd#halo_AnnualInterestPaymentPeriodAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:to="loc_halo_AnnualInterestPaymentPeriodAxis_c6e890e5-da34-47ae-b383-25b6c403f9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodDomain_bb8a62b1-d970-44c8-8620-4bf37da30190" xlink:href="halo-20230331.xsd#halo_AnnualInterestPaymentPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodAxis_c6e890e5-da34-47ae-b383-25b6c403f9a2" xlink:to="loc_halo_AnnualInterestPaymentPeriodDomain_bb8a62b1-d970-44c8-8620-4bf37da30190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodOneMember_e1cbe51d-d200-40bc-92b0-14a83386a0e5" xlink:href="halo-20230331.xsd#halo_DebtInstrumentInterestPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_bb8a62b1-d970-44c8-8620-4bf37da30190" xlink:to="loc_halo_DebtInstrumentInterestPeriodOneMember_e1cbe51d-d200-40bc-92b0-14a83386a0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodTwoMember_8f12ea78-f7de-40f9-8380-18543cc2a678" xlink:href="halo-20230331.xsd#halo_DebtInstrumentInterestPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_bb8a62b1-d970-44c8-8620-4bf37da30190" xlink:to="loc_halo_DebtInstrumentInterestPeriodTwoMember_8f12ea78-f7de-40f9-8380-18543cc2a678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodThreeMember_110a6e19-3fd9-40df-8956-63620b9c0f85" xlink:href="halo-20230331.xsd#halo_DebtInstrumentInterestPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_bb8a62b1-d970-44c8-8620-4bf37da30190" xlink:to="loc_halo_DebtInstrumentInterestPeriodThreeMember_110a6e19-3fd9-40df-8956-63620b9c0f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodFourMember_0fa4131b-cb3b-4fbd-a7b5-0b2916d172c7" xlink:href="halo-20230331.xsd#halo_DebtInstrumentInterestPeriodFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_bb8a62b1-d970-44c8-8620-4bf37da30190" xlink:to="loc_halo_DebtInstrumentInterestPeriodFourMember_0fa4131b-cb3b-4fbd-a7b5-0b2916d172c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentAxis_bf544222-e65f-49c4-aa3d-7cb864f7bcdc" xlink:href="halo-20230331.xsd#halo_VariableRateComponentAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:to="loc_halo_VariableRateComponentAxis_bf544222-e65f-49c4-aa3d-7cb864f7bcdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentDomain_b2c99a77-b9e0-4052-bea2-8c794f26fa3f" xlink:href="halo-20230331.xsd#halo_VariableRateComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_VariableRateComponentAxis_bf544222-e65f-49c4-aa3d-7cb864f7bcdc" xlink:to="loc_halo_VariableRateComponentDomain_b2c99a77-b9e0-4052-bea2-8c794f26fa3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentOneMember_698e4984-287a-4680-a35f-f5418c132b33" xlink:href="halo-20230331.xsd#halo_VariableRateComponentOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_VariableRateComponentDomain_b2c99a77-b9e0-4052-bea2-8c794f26fa3f" xlink:to="loc_halo_VariableRateComponentOneMember_698e4984-287a-4680-a35f-f5418c132b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentTwoMember_603d72c8-56d9-4494-929d-6e89a9fe8434" xlink:href="halo-20230331.xsd#halo_VariableRateComponentTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_VariableRateComponentDomain_b2c99a77-b9e0-4052-bea2-8c794f26fa3f" xlink:to="loc_halo_VariableRateComponentTwoMember_603d72c8-56d9-4494-929d-6e89a9fe8434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_87242dfd-5c49-432c-94ba-196619e20c9d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36f435d2-67cd-415d-8317-9f000630a6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36f435d2-67cd-415d-8317-9f000630a6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fdb6cb6e-3aaa-4901-95f9-eed4910a5aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fdb6cb6e-3aaa-4901-95f9-eed4910a5aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_4576cf3e-ad52-4950-9a5c-019d93a741ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_4576cf3e-ad52-4950-9a5c-019d93a741ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_5b18901f-aa2b-4dab-b918-afefdaf91bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_5b18901f-aa2b-4dab-b918-afefdaf91bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3699909e-7127-48fd-8e9a-d50b4cb27323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3699909e-7127-48fd-8e9a-d50b4cb27323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_c0925f67-2807-4fad-8fc7-ea39b681e8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_c0925f67-2807-4fad-8fc7-ea39b681e8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_be24a0a4-b039-4ad9-a6bd-15342100105f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_be24a0a4-b039-4ad9-a6bd-15342100105f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2a851b97-033c-4c56-bc0a-2ee89e7ee85a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2a851b97-033c-4c56-bc0a-2ee89e7ee85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_daf6e700-b11f-4f84-84e0-a74de15e630b" xlink:href="halo-20230331.xsd#halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays_daf6e700-b11f-4f84-84e0-a74de15e630b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_0ad8468e-7b29-409c-8e62-4d375b701d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_0ad8468e-7b29-409c-8e62-4d375b701d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_329cf5e9-f2bd-44ab-94b1-050a40497c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_329cf5e9-f2bd-44ab-94b1-050a40497c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentCapCallTransactionCapPricePerShare_e7bae0cb-fe44-4a2a-afa3-0384f1c7d275" xlink:href="halo-20230331.xsd#halo_DebtInstrumentCapCallTransactionCapPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_halo_DebtInstrumentCapCallTransactionCapPricePerShare_e7bae0cb-fe44-4a2a-afa3-0384f1c7d275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_5405a6e2-8732-4843-833c-148b1623ed0e" xlink:href="halo-20230331.xsd#halo_SaleOfStockPremiumOverLastReportedSalePricePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage_5405a6e2-8732-4843-833c-148b1623ed0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b945437d-5fb9-4648-9d8f-4a74381c7437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b945437d-5fb9-4648-9d8f-4a74381c7437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PaymentForCappedCallTransactions_26bf8e23-136e-484d-a52e-e40865d4903f" xlink:href="halo-20230331.xsd#halo_PaymentForCappedCallTransactions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_halo_PaymentForCappedCallTransactions_26bf8e23-136e-484d-a52e-e40865d4903f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_00a25dd6-74b5-4992-954a-6bbfcb817f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_00a25dd6-74b5-4992-954a-6bbfcb817f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_fc6ea165-3647-4beb-85e7-84eb5578e8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_fc6ea165-3647-4beb-85e7-84eb5578e8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_cc1a0463-8414-4c89-bfeb-45293e95ff20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_cc1a0463-8414-4c89-bfeb-45293e95ff20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_5f2a50f6-b3d6-42ed-82d9-b6992c10fd86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_5f2a50f6-b3d6-42ed-82d9-b6992c10fd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f4aaae3f-37a7-4c66-88ed-beb1405bb379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f4aaae3f-37a7-4c66-88ed-beb1405bb379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_3acfd785-4320-4703-8811-7e98bfbd7f47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_3acfd785-4320-4703-8811-7e98bfbd7f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_16d28c83-c143-4d77-a176-2e6791f2a411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_16d28c83-c143-4d77-a176-2e6791f2a411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_b6e51940-eab0-4f23-9d8c-f1a3baec85ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_b6e51940-eab0-4f23-9d8c-f1a3baec85ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_deed3915-03ae-4574-a9bc-b5e90488dadb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_deed3915-03ae-4574-a9bc-b5e90488dadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_dc6dc408-b384-426e-9833-236024dae4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0babcf04-2b90-443c-9757-a730f085ff59" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_dc6dc408-b384-426e-9833-236024dae4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#LongTermDebtNetCarryingAmountofConvertibleNotesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c32de318-1a5a-4a7d-afbf-604bff2e08ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_55b1b0fb-de3a-4165-a943-5cafbe3f1ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c32de318-1a5a-4a7d-afbf-604bff2e08ad" xlink:to="loc_us-gaap_DebtInstrumentTable_55b1b0fb-de3a-4165-a943-5cafbe3f1ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_90699959-ef11-4e47-baca-d0a1e4ead923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_55b1b0fb-de3a-4165-a943-5cafbe3f1ba7" xlink:to="loc_us-gaap_DebtInstrumentAxis_90699959-ef11-4e47-baca-d0a1e4ead923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dbea2308-45cc-4dbd-a4e0-ee13094ef655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_90699959-ef11-4e47-baca-d0a1e4ead923" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dbea2308-45cc-4dbd-a4e0-ee13094ef655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_4971527b-cc70-44f5-a321-abeebf693cae" xlink:href="halo-20230331.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbea2308-45cc-4dbd-a4e0-ee13094ef655" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_4971527b-cc70-44f5-a321-abeebf693cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_19252e69-c483-4a31-8cb5-85f1688fb99b" xlink:href="halo-20230331.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbea2308-45cc-4dbd-a4e0-ee13094ef655" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_19252e69-c483-4a31-8cb5-85f1688fb99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member_7114d8fe-354d-4d36-a83a-243790ce061a" xlink:href="halo-20230331.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbea2308-45cc-4dbd-a4e0-ee13094ef655" xlink:to="loc_halo_A100ConvertibleSeniorNotesDue2028Member_7114d8fe-354d-4d36-a83a-243790ce061a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6519217f-b7fe-4354-a6ef-c40e0a3fd6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_55b1b0fb-de3a-4165-a943-5cafbe3f1ba7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6519217f-b7fe-4354-a6ef-c40e0a3fd6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fe76a1cb-9485-40e5-bad1-1fe9137f6519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6519217f-b7fe-4354-a6ef-c40e0a3fd6ab" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fe76a1cb-9485-40e5-bad1-1fe9137f6519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_266fe398-c91e-412e-874e-a2734931ff63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6519217f-b7fe-4354-a6ef-c40e0a3fd6ab" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_266fe398-c91e-412e-874e-a2734931ff63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_88e9fbe8-578b-41e6-89f1-cde56befb145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6519217f-b7fe-4354-a6ef-c40e0a3fd6ab" xlink:to="loc_us-gaap_LongTermDebtCurrent_88e9fbe8-578b-41e6-89f1-cde56befb145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_97040b99-fe0b-40a5-84f6-718d15bb9498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6519217f-b7fe-4354-a6ef-c40e0a3fd6ab" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_97040b99-fe0b-40a5-84f6-718d15bb9498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b0103be9-d661-4df7-946d-79862156011d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6519217f-b7fe-4354-a6ef-c40e0a3fd6ab" xlink:to="loc_us-gaap_LongTermDebt_b0103be9-d661-4df7-946d-79862156011d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_cf9b3288-eae9-4960-9bc7-665a02dd6c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6519217f-b7fe-4354-a6ef-c40e0a3fd6ab" xlink:to="loc_us-gaap_DebtInstrumentFairValue_cf9b3288-eae9-4960-9bc7-665a02dd6c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_34579582-549b-41c7-af5d-7ddc3a2b3128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6519217f-b7fe-4354-a6ef-c40e0a3fd6ab" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_34579582-549b-41c7-af5d-7ddc3a2b3128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#LongTermDebtNetComponentsofInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d9efa2f4-f030-4334-b089-380961825370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_adacaa54-0110-4b14-8852-821899cee7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d9efa2f4-f030-4334-b089-380961825370" xlink:to="loc_us-gaap_DebtInstrumentTable_adacaa54-0110-4b14-8852-821899cee7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6a2962df-3477-4dde-99a1-9fbc135de590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_adacaa54-0110-4b14-8852-821899cee7ff" xlink:to="loc_us-gaap_DebtInstrumentAxis_6a2962df-3477-4dde-99a1-9fbc135de590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b72347e9-2457-452c-be3a-0034a84bfabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6a2962df-3477-4dde-99a1-9fbc135de590" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b72347e9-2457-452c-be3a-0034a84bfabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_3092f159-a28d-4e2a-8060-59cca84d3b5a" xlink:href="halo-20230331.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b72347e9-2457-452c-be3a-0034a84bfabd" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_3092f159-a28d-4e2a-8060-59cca84d3b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_9729f3e2-f047-4998-9957-38c58585001b" xlink:href="halo-20230331.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b72347e9-2457-452c-be3a-0034a84bfabd" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_9729f3e2-f047-4998-9957-38c58585001b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A100ConvertibleSeniorNotesDue2028Member_744a4234-53e3-4c49-a2bb-5b35e541873c" xlink:href="halo-20230331.xsd#halo_A100ConvertibleSeniorNotesDue2028Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b72347e9-2457-452c-be3a-0034a84bfabd" xlink:to="loc_halo_A100ConvertibleSeniorNotesDue2028Member_744a4234-53e3-4c49-a2bb-5b35e541873c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cbd6f2e7-e67e-4ac5-aa0a-95624805121e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_adacaa54-0110-4b14-8852-821899cee7ff" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cbd6f2e7-e67e-4ac5-aa0a-95624805121e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d96cf275-b742-4c32-8d02-af864f0b6079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cbd6f2e7-e67e-4ac5-aa0a-95624805121e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d96cf275-b742-4c32-8d02-af864f0b6079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_081ce9c3-d2b4-42e2-bffa-629b53601015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d96cf275-b742-4c32-8d02-af864f0b6079" xlink:to="loc_us-gaap_ConvertibleDebtMember_081ce9c3-d2b4-42e2-bffa-629b53601015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7c4a723e-c4ae-4458-9a53-a25213d3b637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_adacaa54-0110-4b14-8852-821899cee7ff" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7c4a723e-c4ae-4458-9a53-a25213d3b637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_c8b5bdef-e8c1-43aa-b020-925bbe253a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7c4a723e-c4ae-4458-9a53-a25213d3b637" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_c8b5bdef-e8c1-43aa-b020-925bbe253a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_13a8f0d9-c6bd-4bae-a7b2-6d706640c536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7c4a723e-c4ae-4458-9a53-a25213d3b637" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_13a8f0d9-c6bd-4bae-a7b2-6d706640c536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_6118085f-176a-495b-8d07-44032460ecda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7c4a723e-c4ae-4458-9a53-a25213d3b637" xlink:to="loc_us-gaap_InterestExpenseDebt_6118085f-176a-495b-8d07-44032460ecda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_ef3dce4c-df79-4819-8ca9-061c83116ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7c4a723e-c4ae-4458-9a53-a25213d3b637" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_ef3dce4c-df79-4819-8ca9-061c83116ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#SharebasedCompensationSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_bc10ddd7-1996-4b59-8cc8-7cafeba44a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_546004c9-da90-4ee4-9532-0838e9ed42e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_bc10ddd7-1996-4b59-8cc8-7cafeba44a4b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_546004c9-da90-4ee4-9532-0838e9ed42e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f3419ee3-0331-49ac-8e60-dcbce9a5414b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_546004c9-da90-4ee4-9532-0838e9ed42e8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f3419ee3-0331-49ac-8e60-dcbce9a5414b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8f91af6d-c794-44f0-98ff-63b188da5566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f3419ee3-0331-49ac-8e60-dcbce9a5414b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8f91af6d-c794-44f0-98ff-63b188da5566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_516fdf55-da9e-4c0b-ab72-9fc8d200c3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8f91af6d-c794-44f0-98ff-63b188da5566" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_516fdf55-da9e-4c0b-ab72-9fc8d200c3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_36a9e418-94af-43d5-a992-0a37d918b0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8f91af6d-c794-44f0-98ff-63b188da5566" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_36a9e418-94af-43d5-a992-0a37d918b0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2047cfe3-6dd9-4102-a5d0-824e33737f31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_546004c9-da90-4ee4-9532-0838e9ed42e8" xlink:to="loc_us-gaap_AwardTypeAxis_2047cfe3-6dd9-4102-a5d0-824e33737f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f5d29ff-50cd-4ed3-adc8-77c5fc2c37ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2047cfe3-6dd9-4102-a5d0-824e33737f31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f5d29ff-50cd-4ed3-adc8-77c5fc2c37ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_159c7b7f-957f-448d-95e5-b5c58ad32b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f5d29ff-50cd-4ed3-adc8-77c5fc2c37ba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_159c7b7f-957f-448d-95e5-b5c58ad32b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember_fce3b7fc-1ae3-497c-883d-47a7d98e6e02" xlink:href="halo-20230331.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f5d29ff-50cd-4ed3-adc8-77c5fc2c37ba" xlink:to="loc_halo_RSURSAandPRSUawardsMember_fce3b7fc-1ae3-497c-883d-47a7d98e6e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_90921ba3-cf47-4e95-a2e9-3500e7dba21c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_546004c9-da90-4ee4-9532-0838e9ed42e8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_90921ba3-cf47-4e95-a2e9-3500e7dba21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_48a9c61f-0253-490a-8fc7-46b45144cb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_90921ba3-cf47-4e95-a2e9-3500e7dba21c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_48a9c61f-0253-490a-8fc7-46b45144cb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#SharebasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_c7496f49-5536-489b-a2fb-b324d4b97663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a3656a9-895a-452d-ba0c-3c3265d8cb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_c7496f49-5536-489b-a2fb-b324d4b97663" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a3656a9-895a-452d-ba0c-3c3265d8cb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_92a7b95c-c9d9-408a-a130-24dbcb51c19e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a3656a9-895a-452d-ba0c-3c3265d8cb1e" xlink:to="loc_us-gaap_AwardTypeAxis_92a7b95c-c9d9-408a-a130-24dbcb51c19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd0bf22c-de7d-401d-8038-99b139e60340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_92a7b95c-c9d9-408a-a130-24dbcb51c19e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd0bf22c-de7d-401d-8038-99b139e60340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_14c844a5-f5fb-42de-a3e9-c7442061d207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd0bf22c-de7d-401d-8038-99b139e60340" xlink:to="loc_us-gaap_EmployeeStockOptionMember_14c844a5-f5fb-42de-a3e9-c7442061d207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember_0b9494ff-284b-4ebc-8535-8020135a3fee" xlink:href="halo-20230331.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd0bf22c-de7d-401d-8038-99b139e60340" xlink:to="loc_halo_RSURSAandPRSUawardsMember_0b9494ff-284b-4ebc-8535-8020135a3fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a0c5ea01-9664-4b92-b4ae-0c66cb932f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd0bf22c-de7d-401d-8038-99b139e60340" xlink:to="loc_us-gaap_EmployeeStockMember_a0c5ea01-9664-4b92-b4ae-0c66cb932f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a2e02124-2325-4e13-abe9-a1140d086a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a3656a9-895a-452d-ba0c-3c3265d8cb1e" xlink:to="loc_us-gaap_PlanNameAxis_a2e02124-2325-4e13-abe9-a1140d086a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_186cb3e3-40de-4db1-8c18-d94567f532c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_a2e02124-2325-4e13-abe9-a1140d086a7e" xlink:to="loc_us-gaap_PlanNameDomain_186cb3e3-40de-4db1-8c18-d94567f532c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2021ESPPPlanMember_5cad7b96-bfe6-46f0-b372-a413ca418294" xlink:href="halo-20230331.xsd#halo_A2021ESPPPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_186cb3e3-40de-4db1-8c18-d94567f532c9" xlink:to="loc_halo_A2021ESPPPlanMember_5cad7b96-bfe6-46f0-b372-a413ca418294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa76e760-10da-4341-b860-f8fac7c6e812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a3656a9-895a-452d-ba0c-3c3265d8cb1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa76e760-10da-4341-b860-f8fac7c6e812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c05a0137-33c3-4777-a45d-76bef52bd87e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa76e760-10da-4341-b860-f8fac7c6e812" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c05a0137-33c3-4777-a45d-76bef52bd87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_40402d99-8a03-4586-b4c0-35dfb784824c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa76e760-10da-4341-b860-f8fac7c6e812" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_40402d99-8a03-4586-b4c0-35dfb784824c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_e123a824-d984-42da-a4e7-9da407c1e13b" xlink:href="halo-20230331.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa76e760-10da-4341-b860-f8fac7c6e812" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_e123a824-d984-42da-a4e7-9da407c1e13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_a10bf97a-1649-4baf-8bd1-e0270c0e7d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa76e760-10da-4341-b860-f8fac7c6e812" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_a10bf97a-1649-4baf-8bd1-e0270c0e7d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_5b30830c-2197-45a7-85ae-7aaf35bb0092" xlink:href="halo-20230331.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa76e760-10da-4341-b860-f8fac7c6e812" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_5b30830c-2197-45a7-85ae-7aaf35bb0092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8722d938-5cc0-45c2-98a3-dee8a316e3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa76e760-10da-4341-b860-f8fac7c6e812" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8722d938-5cc0-45c2-98a3-dee8a316e3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_368dcc7e-2d71-4c7c-931a-708b5f3b11f3" xlink:href="halo-20230331.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa76e760-10da-4341-b860-f8fac7c6e812" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_368dcc7e-2d71-4c7c-931a-708b5f3b11f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_518399b3-3ecd-4216-ba5b-ff04d8858878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_e2ed7581-b191-44a7-a0d8-15a1e0ebc095" xlink:href="halo-20230331.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_518399b3-3ecd-4216-ba5b-ff04d8858878" xlink:to="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_e2ed7581-b191-44a7-a0d8-15a1e0ebc095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bfc61a6a-18f3-42a8-ae19-dc42d8fb901f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_e2ed7581-b191-44a7-a0d8-15a1e0ebc095" xlink:to="loc_srt_RangeAxis_bfc61a6a-18f3-42a8-ae19-dc42d8fb901f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ad920f7c-782c-4311-ba53-47c53c02a9b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bfc61a6a-18f3-42a8-ae19-dc42d8fb901f" xlink:to="loc_srt_RangeMember_ad920f7c-782c-4311-ba53-47c53c02a9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3a134250-ae9b-4b9e-aed5-7ac9eaf3c239" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ad920f7c-782c-4311-ba53-47c53c02a9b0" xlink:to="loc_srt_MinimumMember_3a134250-ae9b-4b9e-aed5-7ac9eaf3c239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_34d68ae3-1e7c-4d9c-b115-6f43167b6cc0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ad920f7c-782c-4311-ba53-47c53c02a9b0" xlink:to="loc_srt_MaximumMember_34d68ae3-1e7c-4d9c-b115-6f43167b6cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_38ef9a57-f851-416c-be68-69e62e5ecdd6" xlink:href="halo-20230331.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_e2ed7581-b191-44a7-a0d8-15a1e0ebc095" xlink:to="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_38ef9a57-f851-416c-be68-69e62e5ecdd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_622d0e10-411d-4945-91b1-40001edebff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_38ef9a57-f851-416c-be68-69e62e5ecdd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_622d0e10-411d-4945-91b1-40001edebff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9219312f-66e1-4411-aed9-d6252e4c3e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_38ef9a57-f851-416c-be68-69e62e5ecdd6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9219312f-66e1-4411-aed9-d6252e4c3e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_298834ea-dfe0-4f1f-a8ea-bbba8920728a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_38ef9a57-f851-416c-be68-69e62e5ecdd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_298834ea-dfe0-4f1f-a8ea-bbba8920728a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a4f277c1-32a7-49cd-82fd-7df379b9a7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_38ef9a57-f851-416c-be68-69e62e5ecdd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a4f277c1-32a7-49cd-82fd-7df379b9a7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_485e29d5-4fc6-4cea-a2c1-53a443413b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_38ef9a57-f851-416c-be68-69e62e5ecdd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_485e29d5-4fc6-4cea-a2c1-53a443413b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_903ba106-a488-4d55-b4cb-b38f71fdc708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53a22764-ec24-41b1-8275-8ba910157f18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_903ba106-a488-4d55-b4cb-b38f71fdc708" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53a22764-ec24-41b1-8275-8ba910157f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6f6b135d-d3c7-44b7-b233-7c3216eec657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53a22764-ec24-41b1-8275-8ba910157f18" xlink:to="loc_us-gaap_AwardTypeAxis_6f6b135d-d3c7-44b7-b233-7c3216eec657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e7df95a-efa2-4873-8a7e-82e175b18902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6f6b135d-d3c7-44b7-b233-7c3216eec657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e7df95a-efa2-4873-8a7e-82e175b18902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_78a4eaf0-b289-4032-bac4-5c4f4b1b6692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e7df95a-efa2-4873-8a7e-82e175b18902" xlink:to="loc_us-gaap_EmployeeStockOptionMember_78a4eaf0-b289-4032-bac4-5c4f4b1b6692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9acc9a61-bfd0-4d3e-bd9e-ffb5b23c85b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e7df95a-efa2-4873-8a7e-82e175b18902" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9acc9a61-bfd0-4d3e-bd9e-ffb5b23c85b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_c8166f0d-6ab1-48c5-86b6-f570485df186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e7df95a-efa2-4873-8a7e-82e175b18902" xlink:to="loc_us-gaap_PerformanceSharesMember_c8166f0d-6ab1-48c5-86b6-f570485df186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_471d9018-dc46-480c-85fe-e96174f15c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e7df95a-efa2-4873-8a7e-82e175b18902" xlink:to="loc_us-gaap_EmployeeStockMember_471d9018-dc46-480c-85fe-e96174f15c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40dbca22-08d8-4c01-815e-65354cf4e4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53a22764-ec24-41b1-8275-8ba910157f18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40dbca22-08d8-4c01-815e-65354cf4e4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_84cc2945-c95c-4717-bfe4-36075e776d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40dbca22-08d8-4c01-815e-65354cf4e4c4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_84cc2945-c95c-4717-bfe4-36075e776d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b7469df6-530b-4cb2-bff4-cd83e61befa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40dbca22-08d8-4c01-815e-65354cf4e4c4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b7469df6-530b-4cb2-bff4-cd83e61befa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_31ce22df-3444-47da-adfd-a56cae19dcf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bd25fb0-1762-4e8f-95dc-2be68eb237c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_31ce22df-3444-47da-adfd-a56cae19dcf6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bd25fb0-1762-4e8f-95dc-2be68eb237c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_89c2f38f-7aef-413c-9553-bd0db045077e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bd25fb0-1762-4e8f-95dc-2be68eb237c1" xlink:to="loc_us-gaap_AwardTypeAxis_89c2f38f-7aef-413c-9553-bd0db045077e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_451be06c-60d8-4929-bcfb-e40c524182ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_89c2f38f-7aef-413c-9553-bd0db045077e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_451be06c-60d8-4929-bcfb-e40c524182ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_76adb3d3-b25d-4e0e-9f85-78a6b727e7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_451be06c-60d8-4929-bcfb-e40c524182ef" xlink:to="loc_us-gaap_EmployeeStockOptionMember_76adb3d3-b25d-4e0e-9f85-78a6b727e7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f5031624-990e-4a81-a4a0-a4e7e9c019e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_451be06c-60d8-4929-bcfb-e40c524182ef" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f5031624-990e-4a81-a4a0-a4e7e9c019e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_StockOptionsAndRestrictedStockUnitsMember_4e0ae5ac-712e-450e-a3bd-7e4e7eb9e06d" xlink:href="halo-20230331.xsd#halo_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_451be06c-60d8-4929-bcfb-e40c524182ef" xlink:to="loc_halo_StockOptionsAndRestrictedStockUnitsMember_4e0ae5ac-712e-450e-a3bd-7e4e7eb9e06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c996231-ddac-40e0-9c9d-28c8001b014d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bd25fb0-1762-4e8f-95dc-2be68eb237c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c996231-ddac-40e0-9c9d-28c8001b014d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c996231-ddac-40e0-9c9d-28c8001b014d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5ffd18a7-0a2f-421f-a0ad-06f25258bbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5ffd18a7-0a2f-421f-a0ad-06f25258bbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7932f2f3-48cc-4e48-bdc6-fed465a0e9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7932f2f3-48cc-4e48-bdc6-fed465a0e9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3d4c98a1-8b0c-4445-9b9e-1d292c137091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3d4c98a1-8b0c-4445-9b9e-1d292c137091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_aa714793-82e6-403a-8065-9507454ef3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_aa714793-82e6-403a-8065-9507454ef3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_499d3622-ada5-4b02-92b9-107cb9e210ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_499d3622-ada5-4b02-92b9-107cb9e210ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_21e729ac-9acb-432c-af53-a73fd1d54187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_21e729ac-9acb-432c-af53-a73fd1d54187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_659705a3-4a5f-4b2d-ab78-15eacf0056cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_659705a3-4a5f-4b2d-ab78-15eacf0056cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_92a90b54-e10c-4022-a70b-bb511f68bfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_92a90b54-e10c-4022-a70b-bb511f68bfaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_04cb291a-d47d-4d1a-9ebc-5e004666d648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_04cb291a-d47d-4d1a-9ebc-5e004666d648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2833ced7-7348-472d-b28c-09f3b75310a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2833ced7-7348-472d-b28c-09f3b75310a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_351178a4-1206-4fcb-a5e4-0a99d3a797c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_351178a4-1206-4fcb-a5e4-0a99d3a797c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_88b7db2f-37ac-4d61-9a2d-2c2cb4e0ad44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_88b7db2f-37ac-4d61-9a2d-2c2cb4e0ad44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4a1e7213-d71b-4b60-ae1a-44b8e16a4ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0467a22a-7a03-48a4-ac4a-39db90d6d64e" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4a1e7213-d71b-4b60-ae1a-44b8e16a4ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/StockholdersEquityShareRepurchaseActivityDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#StockholdersEquityShareRepurchaseActivityDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/StockholdersEquityShareRepurchaseActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ca3f0363-bb1e-4471-8915-7ed519ca9edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_e395c0b6-ed73-4f3b-b7ee-f95659e7bcef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ca3f0363-bb1e-4471-8915-7ed519ca9edf" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_e395c0b6-ed73-4f3b-b7ee-f95659e7bcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7a829f28-3526-4ad8-a380-af07774b8c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ca3f0363-bb1e-4471-8915-7ed519ca9edf" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_7a829f28-3526-4ad8-a380-af07774b8c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_4ff55729-359f-4b12-85bf-1990ad993786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ca3f0363-bb1e-4471-8915-7ed519ca9edf" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_4ff55729-359f-4b12-85bf-1990ad993786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TreasuryStockAcquiredFeeCostPerShare_6bc9e06e-3f9c-4c20-8381-71d62cbb3503" xlink:href="halo-20230331.xsd#halo_TreasuryStockAcquiredFeeCostPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ca3f0363-bb1e-4471-8915-7ed519ca9edf" xlink:to="loc_halo_TreasuryStockAcquiredFeeCostPerShare_6bc9e06e-3f9c-4c20-8381-71d62cbb3503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/EarningspershareComputationDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#EarningspershareComputationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/EarningspershareComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_aa8dc3bf-2f03-46c0-a019-eecbbd4b5dad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_785563b2-aab1-4d27-9b9c-808fbc776579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_aa8dc3bf-2f03-46c0-a019-eecbbd4b5dad" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_785563b2-aab1-4d27-9b9c-808fbc776579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_628c0e5b-06af-4cfb-8432-cce76cff9bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_785563b2-aab1-4d27-9b9c-808fbc776579" xlink:to="loc_us-gaap_AwardTypeAxis_628c0e5b-06af-4cfb-8432-cce76cff9bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9dbf249-7408-4f38-9896-d70b2a1f175f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_628c0e5b-06af-4cfb-8432-cce76cff9bac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9dbf249-7408-4f38-9896-d70b2a1f175f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_25c507ad-0100-4ee1-8d97-8b3c5d4e46f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9dbf249-7408-4f38-9896-d70b2a1f175f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_25c507ad-0100-4ee1-8d97-8b3c5d4e46f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RestrictStockUnitsPerformanceSharesAndESPPMember_bc87580b-2aa4-49b0-bb45-902a1f231f46" xlink:href="halo-20230331.xsd#halo_RestrictStockUnitsPerformanceSharesAndESPPMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9dbf249-7408-4f38-9896-d70b2a1f175f" xlink:to="loc_halo_RestrictStockUnitsPerformanceSharesAndESPPMember_bc87580b-2aa4-49b0-bb45-902a1f231f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f3fa9cfa-912d-4213-8d52-efa3a96d7275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_785563b2-aab1-4d27-9b9c-808fbc776579" xlink:to="loc_us-gaap_DebtInstrumentAxis_f3fa9cfa-912d-4213-8d52-efa3a96d7275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_654fc32d-cf11-4512-9e8e-0ae179a6b9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f3fa9cfa-912d-4213-8d52-efa3a96d7275" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_654fc32d-cf11-4512-9e8e-0ae179a6b9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_a64c0d41-3765-4c7e-bc32-7b4e52520c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_654fc32d-cf11-4512-9e8e-0ae179a6b9cd" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_a64c0d41-3765-4c7e-bc32-7b4e52520c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_8eccf9a7-822a-4b86-8b14-fb8ec4886f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_785563b2-aab1-4d27-9b9c-808fbc776579" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_8eccf9a7-822a-4b86-8b14-fb8ec4886f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ff96eff2-0de8-45d6-9343-1def19c17924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8eccf9a7-822a-4b86-8b14-fb8ec4886f78" xlink:to="loc_us-gaap_NetIncomeLoss_ff96eff2-0de8-45d6-9343-1def19c17924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1923d577-6a7b-4c81-bc52-64380f8c70de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8eccf9a7-822a-4b86-8b14-fb8ec4886f78" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1923d577-6a7b-4c81-bc52-64380f8c70de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ea3500a6-909b-4c3a-9373-8fe651ae8aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8eccf9a7-822a-4b86-8b14-fb8ec4886f78" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ea3500a6-909b-4c3a-9373-8fe651ae8aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ebe923fb-cbb1-4b62-a24b-c8b6bfc1d37c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8eccf9a7-822a-4b86-8b14-fb8ec4886f78" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ebe923fb-cbb1-4b62-a24b-c8b6bfc1d37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_b451b94a-b101-4628-9671-a57a8e09f3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8eccf9a7-822a-4b86-8b14-fb8ec4886f78" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_b451b94a-b101-4628-9671-a57a8e09f3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4820c525-676a-400d-94f2-b1b43a37496a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_b451b94a-b101-4628-9671-a57a8e09f3b3" xlink:to="loc_us-gaap_EarningsPerShareBasic_4820c525-676a-400d-94f2-b1b43a37496a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0ce8b3d3-28e9-4fc3-ac0c-0a65a6bb0e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_b451b94a-b101-4628-9671-a57a8e09f3b3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0ce8b3d3-28e9-4fc3-ac0c-0a65a6bb0e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/EarningspershareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="halo-20230331.xsd#EarningspershareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/EarningspershareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1b0da3b1-331c-43ba-9c97-af74a2055f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c28066c1-4713-4794-98d5-4a6ad2c89f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b0da3b1-331c-43ba-9c97-af74a2055f7e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c28066c1-4713-4794-98d5-4a6ad2c89f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>halo-20230331_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 halo-20230331_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#Z17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=E=&%S97<@
M665S96=A=   !9 #  (    4   0J) $  (    4   0O)*1  (    #,S8
M )*2  (    #,S8  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" "F 9D# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\[5]-D\;4Y2[O\O^'/D<^G>K"'9?G_PP %F 4$DG  [U]4Z;:_8=)M+3_GA
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MHD&EZU#=6B"..\5F9%& '4C./KD'ZYK*OAO9+G@SEQF 6'C[6D]CNO!GB?\
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M/J,UYM\3/$3W-Q'X<TTEW9E^T!.K,?NI_(_E78>*-=A\+>'6G7!EVB*VC/\
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MZ6V.3'("?Q7_ !KU.O+?C!_Q]Z5_N2?S6A :GQ$O'C^'MD@;FY>%7]P$+?S
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MEL<6#HO%8AU)[;O_ "-BBBBO8/J0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH XG7? MSX@\61ZE>WL1LT**+
M?:<[%Y*Y]SG\Z[8#' X%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %>,?%EYM8\<Z;HUH-\BQ*BC/\ '(W^ 6O9Z\Q\,V']O_%W6]<E&Z#3
MI##$3T+@>6,?158_B#7H8"2IRE6?V5^+T1Y>91=6$*"^TU]RU9Z%I6G0Z1I%
MKI]L/W=M$L8..N!R?J3S7G_Q4U7?<VFE1MQ&/.E ]3POZ9_.O2W8(A=SA5&2
M3V%>%W+7/BWQA(;<$O>3X3/\*#@$_11^E>)C*C<;=9$YE/DHJC#KI\CH_AIX
M>^U7K:Q=)^ZMSM@!'WG[G\!^I]J]2JKIFGP:5IL%E:KB*% H]_4GW)YJU6M&
MFJ<.4[,+AUAZ2AUZ^H4445L=04444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 07UTECI]Q=R_<MXFE;Z*"3_*L/P)HS:-X3MUN!
MB[NB;FY..=[\X/T&!^%=!-#'<0/#.BR1R JZ,,A@>Q%/K13M3<%U_0R=.]13
M?1?G_P ,<SX^U3^S/"<ZHV);K]PGT/WO_'<_G65\-/#WV2P;5[I,37(VP@C[
ML?K^)_0>]1>);9_%7CRUT9"WV6QC\RY8=LX)_$C:!]37?1QI%&L<2A$10JJ!
M@ #H*X8Q]I6<WLM$<<(>VQ+JO:.B]>HZBBBNH]$**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDL@BA>1@2$4L0/844
M4">Q@^#[$1Z6^J2X:ZU1OM,K#L&Y51[ '^==#116=/2",L.DJ4;=@HHHK0V"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>halo-20230331_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 halo-20230331_g2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#Z17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=E=&%S97<@
M665S96=A=   !9 #  (    4   0J) $  (    4   0O)*1  (    #,3(
M )*2  (    #,3(  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" 1A QL# 2(  A$! Q$!_\0
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M $%__):;_P"(H_X6AX/_ .@O_P"2TW_Q%'U7$?R/[F'US#?\_(_>CK**Y/\
MX6AX/_Z"_P#Y+3?_ !%'_"T/!_\ T%__ "6F_P#B*/JN(_D?W,/KF&_Y^1^]
M'645R?\ PM#P?_T%_P#R6F_^(H_X6AX/_P"@O_Y+3?\ Q%'U7$?R/[F'US#?
M\_(_>CK**Y/_ (6AX/\ ^@O_ .2TW_Q%'_"T/!__ $%__):;_P"(H^JXC^1_
M<P^N8;_GY'[T=917)_\ "T/!_P#T%_\ R6F_^(H_X6AX/_Z"_P#Y+3?_ !%'
MU7$?R/[F'US#?\_(_>CK**Y/_A:'@_\ Z"__ )+3?_$4?\+0\'_]!?\ \EIO
M_B*/JN(_D?W,/KF&_P"?D?O1UE%<G_PM#P?_ -!?_P EIO\ XBC_ (6AX/\
M^@O_ .2TW_Q%'U7$?R/[F'US#?\ /R/WHZRBN3_X6AX/_P"@O_Y+3?\ Q%'_
M  M#P?\ ]!?_ ,EIO_B*/JN(_D?W,/KF&_Y^1^]'645R?_"T/!__ $%__):;
M_P"(H_X6AX/_ .@O_P"2TW_Q%'U7$?R/[F'US#?\_(_>CK**Y/\ X6AX/_Z"
M_P#Y+3?_ !%'_"T/!_\ T%__ "6F_P#B*/JN(_D?W,/KF&_Y^1^]'645R?\
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MW_Q%'U7$?R/[F'US#?\ /R/WHZRBN3_X6AX/_P"@O_Y+3?\ Q%'_  M#P?\
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M'_"T/!__ $%__):;_P"(H^JXC^1_<P^N8;_GY'[T=917)_\ "T/!_P#T%_\
MR6F_^(H_X6AX/_Z"_P#Y+3?_ !%'U7$?R/[F'US#?\_(_>CK**Y/_A:'@_\
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ME)_WP:^KJ*/[:?\ )^/_   _U?7_ #\_#_@GRCY$W_/*3_O@T>1-_P \I/\
MO@U]744?VT_Y/Q_X ?ZOK_GY^'_!/E'R)O\ GE)_WP:/(F_YY2?]\&OJZBC^
MVG_)^/\ P _U?7_/S\/^"?*/D3?\\I/^^#1Y$W_/*3_O@U]744?VT_Y/Q_X
M?ZOK_GY^'_!/E'R)O^>4G_?!H\B;_GE)_P!\&OJZBC^VG_)^/_ #_5]?\_/P
M_P""?*/D3?\ /*3_ +X-'D3?\\I/^^#7U=11_;3_ )/Q_P" '^KZ_P"?GX?\
M$^4?(F_YY2?]\&CR)O\ GE)_WP:^KJ*/[:?\GX_\ /\ 5]?\_/P_X)\H^1-_
MSRD_[X-'D3?\\I/^^#7U=11_;3_D_'_@!_J^O^?GX?\ !/E'R)O^>4G_ 'P:
M/(F_YY2?]\&OJZBC^VG_ "?C_P  /]7U_P _/P_X)\H^1-_SRD_[X-'D3?\
M/*3_ +X-?5U%']M/^3\?^ '^KZ_Y^?A_P3Y1\B;_ )Y2?]\&CR)O^>4G_?!K
MZNHH_MI_R?C_ , /]7U_S\_#_@GRCY$W_/*3_O@T>1-_SRD_[X-?5U%']M/^
M3\?^ '^KZ_Y^?A_P3Y1\B;_GE)_WP:/(F_YY2?\ ?!KZNHH_MI_R?C_P _U?
M7_/S\/\ @GRCY$W_ #RD_P"^#1Y$W_/*3_O@U]744?VT_P"3\?\ @!_J^O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAW?X?Y!_;N)_EC^/^9]#_P#"S?"'_087_OQ+_P#$T?\ "S?"'_087_OQ+_\
M$U\\44?V/0[O\/\ (/[=Q/\ +'\?\SZ'_P"%F^$/^@PO_?B7_P")H_X6;X0_
MZ#"_]^)?_B:^>**/['H=W^'^0?V[B?Y8_C_F?0__  LWPA_T&%_[\2__ !-'
M_"S?"'_087_OQ+_\37SQ11_8]#N_P_R#^W<3_+'\?\SZ'_X6;X0_Z#"_]^)?
M_B:/^%F^$/\ H,+_ -^)?_B:^>**/['H=W^'^0?V[B?Y8_C_ )GT/_PLWPA_
MT&%_[\2__$T?\+-\(?\ 087_ +\2_P#Q-?/%%']CT.[_  _R#^W<3_+'\?\
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MRDF%PAAE\N2*0#&02""".""*Z+_A3WB?UL?^_P"?_B:/^%/>)_6Q_P"_Y_\
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M_G_XFCZ[AOYT']GXO_GVS@Z*[S_A3WB?UL?^_P"?_B:/^%/>)_6Q_P"_Y_\
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M44 0M9VKQ11/;Q-' 0T2% 1&1P"!VQ[57FT/2KBUBMKC3+.6"$YCB>!65#[
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MBTO3X(888;&VCB@??$B0J%C;U48X//45:HHI-M[C22V"BBBD,**** "BBB@
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M!R<>8H/IVS6IX3U*]U?PW;WFIPK#<.T@948,,!R!T]A5FVT'2[.S%K:V,,4
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MS;S6]Q:02PSG=+&\899#QRP(P>@Z^E1#2+**QDM;.WBLE>$PAK:-4**<\#C
MP23C&,F@!ND:F-7M9+J%%%J966WE5]WG(.-X]B0<=<C![U?J&TM8;&RAM+5!
M'!!&L<:#HJ@8 _*IJ "H[;_CUB_W!_*I*RH=#L'@1V2;+*"<7$@_]FIJW43O
MT-6BLW^P-/\ [DW_ ($R?_%4?V!I_P#<F_\  F3_ .*JK1[_ -?>3>?;\?\
M@&E43_\ 'Q%_P*J7]@:?_<F_\"9/_BJ8^A6 FC41RX;.?](D_P#BJ5H]_P"O
MO"\^WX_\ U:*S?[ T_\ N3?^!,G_ ,51_8&G_P!R;_P)D_\ BJ=H]_Z^\+S[
M?C_P#2HK-_L#3_[DW_@3)_\ %4?V!I_]R;_P)D_^*HM'O_7WA>?;\?\ @%ZW
M_P!5_P ";_T(U)65#H5@\>2DWWF'%Q)ZG_:I_P#8&G_W)O\ P)D_^*I6CW_K
M[PO/M^/_  #2HK-_L#3_ .Y-_P"!,G_Q5']@:?\ W)O_  )D_P#BJ=H]_P"O
MO"\^WX_\ NS??A_W_P"AJ6LJ30K!6CQ'+\S8/^D2>A_VJ?\ V!I_]R;_ ,"9
M/_BJ5H]_Z^\+S[?C_P  TJ*S?[ T_P#N3?\ @3)_\51_8&G_ -R;_P "9/\
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M8\5^*)]#N;6*QMY;AE_TB[6*UDFVP X(^0':QY(+<?(U=/3%@B2:25(D620
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7GV:UBM)KR-HY;B&,!]K?>P>V: -.UG^TV<,X&!+&KX],C-2TBJ$4*HPJC
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MV>T+]G:)3'M'0;<8Q44FB:5-;K!+IEF\*1>2L;6ZE5CR#L Q]W(!QTX%7J*
M((;*TMI6EM[:&*1D6,ND84E%SM7([#)P.V33H>LO^^?Z5+44/67_ 'S_ $H
MEHHHH *CG_U8_P!]?_0A4E1S_P"K'^^O_H0H DHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ,11_;=M_P \+_\ \ )O_B*T:,\X[T7CV"TN_P#7WF=_;=M_SPO_ /P F_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]LTKRY+J-)+%([I7\T,ZH YP ARZY^\,$X)QBMV/2-/AA6**R@2-9%E5%C
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M2&L-/AAL8VE$K!8$=6(X^8,.>.F""/THTWPA8Z:FG*I,@L)9;A,HH#329!?
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M^Q8_^?W4/_ I_P#&M*BCGEW#V<>QF_V-'G'VZ_SZ?:V_QH_L6/\ Y_=0_P#
MI_\ &N-U6Q\1V$.K^)?,2-[JSG22WB4K-;QB-C"=Y<J2A&3A1_K'.3CE;U-4
MMXK=$BUV*UFNX8Y()+\&XF8+(9-C[SA2 O *YQ\H6CGEW#V<>QUT.C(8\_;=
M0^\W_+T_J:?_ &+'_P _NH?^!3_XUREOI7B"5)KCSM4CABA<6MJ;P;RIF.0Y
MW'=((\@%B<9'.1D6DL_$*V)DTH7L0>9H8K?4+D2211.%!D9MS9*."P!8G&1W
M !SR[AR1['0_V+'_ ,_NH?\ @4_^-1G3;596B;4[P2*F]D-ZV0O][&>G'6N9
MBT_Q;#X@N1%=3M&!*(I9<M$8]A$0YE(W [23Y6<YR2#5K0-.OH_$%]=_8]4M
MXFTY(5;4;M9F:8.Y;;\[$#E>X'H!S1SR[A[./8V1IEO/';S0:C>RQ2$,CI>,
M0P*D@@@\BG?V?:>=Y/\ :MWYN[9L^VMNW;=V,9Z[03CT&:P]-TS7(+VTO+V:
M]DF:]1)(Y+K=&L'V;#83.W/F#.<%LY[4MWX6GNO%,MSNO8[>;4(YGDBO&4[!
M:R(=OS90;F ^7!_"CGEW#DCV.@_L6/\ Y_=0_P# I_\ &D.CQ#.;^_&.O^EM
MQ^M<BEEXQ.J6#RRW "+$H(^94PQ$GF8F56)'<H_M@UK>(;"^GU*\CMK&6>/4
M;>VA69&4+"8Y79B^2#C#C& <X-'/+N'LX]C7.D0JZHVH7P9L[0;MLGZ<TV+1
MD)D_TW4.'(_X^GK+OH+J\\46-W_8+[H93&MQ,8G41ASENNY#C#*5R3G:P';>
MTNXENK,S7%I)9R,[;H)64LG;DJ2.>O![T<\NX<D>Q#_8L?\ S^ZA_P"!3_XT
M?V+'_P _NH?^!3_XUI44<\NX>SCV,W^Q8_\ G]U#_P "G_QKE?&?PWC\1_9Y
MX=2GBN(?W>ZX8R@J3[GCFN\J.?\ U8_WU_\ 0A50K5(2YHO4BI0IU(\LEH9O
MAG0(O#/A^WTN"5IEAR3(W&YB<DX[<FM:BBHE)R;D]S2,5"*C'9!1114E!111
M0 4444 %-D4M$ZJ<,5(!]*=10!QVB6FKZ?I]C>Z78P3F;3H+:>UN96@>%X@0
M,':V1\S C';(ZFH-8\(ZOJ<EW*9+,27%LT9V%E4.;>2/@8.!N<?AD^U=Q10!
MC^'HF5M5F,;(EQJ$CIN4@L JH3@^I0_4<UL444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !45M_P >L7^X/Y5+45M_QZQ?[@_E0!+1110
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M1116!T!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ*#H_P#OM4M !1110!%/_P L_P#?%2U%/_RS_P!\5+0 4444 %11?ZR7_?\
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MYB?WUZ[>O?TJ,7EL;=IQ<1>2IPTF\;0?K3O'M_7W!:??\/\ @E/_ (2#3/\
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MPW(()&<$8IWCV_K[@M/O^'_!*\NO:<VS%P>&!/[I_P#"G_\ "0:9_P _#?\
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M% !1110 5%;?ZA?J?YU+45M_J%^I_G0!+1110 5%+_K8?]X_R-2U%+_K(?\
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MMU>RK#!$NYY'. HH FHK.TW7;'5)GAMC-',BAS#<V\D#E3_$%< D9XR.*T:
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MDSDQP*K1Q#=@(RA@Z2'&TC]X3D&NTHH XFX\(W\UT&^RZ=O98?*O?.?S=/V
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MQ)<[;>YU#57,3W"+.\]U;.B J_&$4%,D#[Q]!UKIO#&I?;]/S<7*2W$CR2J
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M[8H O6WCO0KS4HK:SO%FBD@>87*@^7\K*N-V,'EO7MBKU_XFTC3+@P7UX(Y
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MBR D8.XDH >@QT J]:^&7CU*.^OK[[7/YWGS-Y00.ZILCP > H+'N23G/&*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ J*V_U"_4_SJ6HK;_4+]3_.@"6BBB@ J*7_ %D/^\?Y&I:@N9HX9(#-
M(D8:3:"[ 9)!P!GO0!(\,<D+1,@V,""N/6J:Z+8+I\=DL 6&,Q,,<%C$RLF3
MWY4=>M7)98X(FDF=8T7JSG 'XT^@!D<,4*JL,:1JHPH50 *(X(H8_+AB2-,Y
MVJH _*DFN(;?9Y\J1^8VQ-[8W-@G ]\ _E38+RVNL?9KB*;*+(/+<-E6Y5N.
MQ['O0!FWNIV&ES+)=0R2W+E]@M[9II @/)PH)"C(Y]ZKV/BK0+F]V618-+M+
M3_971,O&)%#.5 R5(."<U8O]*CO3]J^W7.GRP>8IN+=U4^62"RG<I&. <XR,
M<$56MO#NBQ6=OI\<[RHSQW4:M,&:01QI&#[KM"Y]S[T .T_Q+9ZGKT>G6=M*
M(WM7NO-F@>+<%=%4KN W [LY'H/6F+XCE9H[R32672I)5C2\,J[^6VJYCQD(
M6/!SG!!QUQ9TWPW%INHI>?;[ZZ:*W-M#'<2*4BC)4X "C)^4?,<GU)ID?ABU
M\U-M]>/8I*)DL/,4P*X.X'[N\@-R%+%0>W H HWOB6 V-C<IIGG/+;O>QJQ4
M"/:Z*<G!Q_K,EAT"FN@M674+&VN+FW1695D"%ED"-ZAAP?8BL9O"5M"H$5_?
MH00EL5E4&T7>'PGR\C*K]_=P,=.*VM.L(M,T^*SMR[)$/O.<LQ)R2?J23Q@>
M@% $S01,P9HD)#;@2HX/3/UI%@A25I4B19&&&<* 2,DXS]23^)J2JYO[-3,#
M=0@P#,H\P?NQZMZ?C0 HL;0+(!:P@2?? C'S?7UI((8DN)Y$C178A"P4 E0.
M!GT&3^9J1[B%)XX7E19903&A/+XZX'?%)%_K)?\ ?_H* ):*** "HKG_ (]V
M_#^=2U%<_P#'NWX?SH EHHHH **** "BBB@ HHHH ***.E !17"/XWU%/!$F
MH-;0#5$<MY6T[/(!+[\9S_JAZ_>!K0U7QL+2PFGMM-O&B;SH[:\94,+R(CGD
M!]X7,9&<#/;K0!U=%<?JGBR^7P_=R6]K+IFH1:>]_!]M@61)T106 "29'+*"
M"01N'%3V_BF>SU"YL]8MY)8K>ZCM6U"*)8X0SHA7(+EN6;'R@@9&: .IHKBX
M?BAHUS"SVD%S<NP4P0V[PR23AG5!A5<[.77A]IP?8XN7GC)XK;S+31;^423&
MUAFQ&8S,"05(#[L!E(W8P2."<B@#J**XSPAK_B;5O#-_<ZK8Q)?QAOLP>V>U
M61L':I5V)Z[<MGOVQ4UCKFJZDMG86EU;+>2B:2>>>S9#"(R@,9AWYWYD7^+&
M.><B@#K:*R)KZ^TOPU?7FI?9Y[FSBDDS;@JLH525RI^Z3W&3CUK O_&E];^=
M#;6<CS62S1SR/"HCN9DMS)B,F0$ '!)(]LYYH [:BL&V\3H^CQW5Q:3K/YL%
MN\*[<^;(J$ '=C&7 SFLVY\>0)+%<6]O<R6:K(LD8MP99)5DBCV+EQ@J\F#D
M$$]#QR =A17,KXWM4>07VG7UE'#*T$\LHC*Q2K&9-AVN2<H,Y7(Y SGBH-0\
M:SVTD$(T34()YGB=$F1&\V-I%0[=KG#?,.&QCJ: .MHKG1XG>74+.V^R2VDI
MO!;75O<JI==T3NC!E8J0=O4$]QP:Z*@ HHHH **** "BBB@ HHHH **** "B
MBL_6]0ETW2S-;(CSO)'#$)20@=W"@L1V!.?TH T**Y>ZU[4/#<ZQZZR:FDT1
M>(V-N8Y P=$V["Y!!,@P<CO5A/%BRN;:'2;Z345D9)+%3%OCVJC%BV_9C$B?
MQ?Q#WP =!16#/XLA@D<OIU]Y$ 3[7/M0+:E@" P+;C@$$[0< U3LO&9:S:2Y
ML+B86[L+R>W5?+MQO(&0S;C\H#':#@'- '545S4_C6&$QNNDZC+:S2O%!=1K
M&4F9%9C@;]P'R, 2!GMU%;%AJMOJ4TZV>YXX=F9L#8Q9=V![@%2?J/>@"[11
M10 4444 %%%% !117-IXEG74]:MYH4V6SA+$J"#,VV,%3[[Y%''8B@#I**YO
M1O%:W?AR.]OHF%S$D"W*Q+\OF2!?NY.< MWK+M_&E^95:\MEBMTBMY7=(PWF
M!XY68*-^1_JQ@D=CZ@T =Q17,W'BUDA@+6%Q8O,\#)]K"X>)Y41R-C'! <<'
M!&1P:FT'QEIGB&[^SV1(=HC-'F2-MZ @9PC$KU'# 'GIUH Z"BN3_P"$PN(]
M%GN;C3YHV!N(X;DJODM(A?:,;MV#LZD $]^15V+Q7!M22>UN$M2_DM>[5\KS
M,<C&[=C.1G&,\9H WZ*Y\>+H%1&N-/OH#.BO:*ZH3<@LJ@+AC@Y=>&VXSSWP
M^R\0N\NKOJ5K)80:=&DC+* 65=A9CE2P(X[4 ;M%8I\1-'"&N=(U""25U2WB
M<1EIV;) &'(7@$G<1@"JP\8![IK2/1=2>\5G5[<+$"NQ48G<7VXPZX.>: .C
MHK%M/$T.HNC:=9W5U:'9ONT"!(RRAAD%@QP&4G .,^QK*7XDZ/)#))!'//@;
MH4A:)WF&X+PH?*\L.'V\4 =?169I.MIJL]U"+6>VDM7"2),4R#]%8X_'&1R,
MCFM.@ HHHH **** "BBB@ HHHH **** "HK;_4+]3_.I:RXM:LHX]C?:,J2#
MBUE(Z^H6FDWL)R2W9J45G?V]8_\ 3S_X!R__ !-']O6/_3S_ . <O_Q-5R2[
M$^TAW-&N:\865Q>"P^S:8M^\<K,NXH0C;<#<KX!0C()!W#@@&M3^WK'_ *>?
M_ .7_P")J.37;$R1<W/#?\^DOH?]FER2[![2'<Y[6++Q#?VMU816MUA&G=9A
M<H$G#?ZM%R201G^( #;WIUMHNIWUY&CC6+#2C,&>";4B9B1&^3O21F"%BGRA
MNJD\ UT?]O6/_3S_ . <O_Q-']O6/_3S_P" <O\ \33Y)=@]I#N<W9:)KJ6M
MC'=SWLAGMHSJ.^])/F[6#@8;Y1R/N8' /49K,B\)ZWIVC1_V;]JAN/L5C#.H
MNGD9Q&K"1%_?+@Y*\AEXS@UV_P#;UC_T\_\ @'+_ /$T?V]8_P#3S_X!R_\
MQ-')+L'M(=SC9-+U^70_)O8-3O6:WFCA2UO!;M#(6;;YN93O&TJ,EI,8.0<Y
MK9U'2M7N+/2+6UEN+>-+98KHV]QY9!\R#/(/78LHR.Q..M:L.N6(#\W/WS_R
MZ2__ !-2?V]8_P#3S_X!R_\ Q-+DEV#VD.Y6LO[0TG2[I6M+F^\FY86T7GAY
M7A)&#OD;DC)^\<\5S3:1KL5K!$MIJ7V@+";=K34%BBMAN!D61=X#'[W.ULC
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MI'B0[,*/G'(S@C%6F\2ZDUQ%MT^TD#SS6T,:71\QIHE?(*E>%)0X.<\J2.>
M"A;^%;VYO+,K:S:980W DDMC?M)YCK%(!(<'E=S1_+GG;DCCE]GX>UB."5X8
M6L[J&%6#27K2+>72L&$AY.U3AE.<$B3I\HI]UX_=Q#)I&G&[MY][138E8,J*
MN_A$8@AGV\\?*V2.,KJ/BV^GM5FT^*"VMA=6<,C37&V;,K1,0J%2"-LF.N3S
MCI0!4O/"_B$ZI93)=22G8C/(L@VV\Q<M*PRP.#D 8#<*!@=[=KH&HKXILKJ>
MQ8O;W,LMQJ#7A(G5E<(!'GMN P0 N.,BK6IZOJ5CXMGCB\E[=;6W2")YBB^;
M+*Z[G^4X'R=C[8YXETGQ)J&I>(3IC6%LB6\+/=7"7)8!@[( @V_,"5/)QC!'
M44 9L_AJX2>_G73S?07.HRSRVD5UY1ERBA&R2!P0W&1USV%7M!\-WUJFJ2:G
M=2M>7<:0QS?:'D$:"%%X!/!#AN< MC)ZU136-5L[$ZB^J)<"XN[B!;)X$&T*
M[@,A7!.T*&.[.0#TI^O^(-4L_P"SIK)Y/+^Q_:KGRXXV0 ,FXON(8* 6^YEO
M:@!9-*U.?0TTP>'[2!K.V>..X$RD,VS;B+'(W=]V/QZUIVDFJ'7TNY=&FBBN
M+=89"9XB82KL<G#<@@CIFJL6I7URTVHG6K:TA@O6MOL,L2[<!]@#M]_>PPPQ
M@?,O!'79T;4#>:/:SW4B>=-D=AN.3P!]!^E '.:OX:U"^U*]N9&=AB=K%?M+
M*JRLL(C8J#V*/UZ9/K5O6K#5WU;3[NS%X=ELT4QLY(%;<64\^:"".#]WFF7F
MHWUQ=:A.NLVVG1:;<K%]FEB5E(PIW2D_,-V>-N.,=35V'6+EX+-F=,RZE);O
MQ_ #)@?7Y1S0!!I&F:A#JEJEW:K%!IZSA)Q*&$_F."-JCD8 YSCGIGK63JGA
M[6+C4)VMK207+2S-_:(U JKQM&X1-F>,%D&,8&W<#FNEUC5KJSO+:TT^&VDF
MFCDF+74YB0(FW/(4Y/SC\ 36)IOC>\OH;>]DTV"*PD^RHSI<EY"\\2. JA<$
M R 9R,]1Z4 -N/#-Y:*8;6WDN]-#1/)9_;"'N&V.'.YCUW%&.2 =M.T[P_?1
M^$&LY;2+SH]0>Z^QS7!E21/.,@C9R.3@CDYY SD5/I/B#4=2\4Z?%<"TAM+K
M3)[N.*"Y\QF'F0!2X*@@@,PXR.3Z56T#6=6FN+:2^>X\J\OGCS/%"L941RM^
M[*$MU1>7P?UH DN=+U6^U(ZRNEI:20M"19F9#)<;&))9A\H(#87GUR126ND:
MO#J%G-_9\*F6X>>9S*K"%6F:0HX(^8@,-K)T;.3CK?UW6KK3=7MX+"W%S/<*
MD:))/Y<8+/C<?E)X S].,5'J&M:C-X46\L$@AO$ODMIE:0[ 5N!$^T[<D$@X
MX'!]: .FJ*Y_X]V_#^=<9%XRU'3=->74[);C>;DVIBD+._EW C 90O PZGC)
MP#QFMS1=:FUG3+AKJT:VG@F\MU*.H/0@@.JMT(Z@4 ;E%%% !1110 4444 %
M%%% !1110!YY8Z!J-\3=12SYM_W2HMRR)YHO7:4E <$[,#)[$BIK70-:T/3Y
M8--M))!<K?1[$N\>2\L[/%*=S=-I&<98>AKO:* .(?0M>6YW(TKPF5?)3[4?
M]'"L"['GYO,P3CG;T[FHXO!U_!:_)->-*-.0@OJ$AS>@G+GYNO/T]J[NB@#S
MV_\ #NNW%P%6UN7NS=2/-?\ ]H[8982'VIY6[L"@V[0/ESD]Y-/T;6K2Q\NU
ML;JPD:S%I/YM]YXEE8JOFK\QP$&\Y^4G(&VN^HH XQO",T%]?75D)4?[9:_9
M ETR*($CB23Y0<9(5QSUP*K0:?K&HZ>\KM-=6]K<?9%@BNC&UW;QLP+;B1\S
M-MZD9V=<&N\HH \[M/#WB"VOC?PVDZ)#,TD-K)?B23RO,A/E;B<#(5^,[0>,
MXYJ9O#?B"\N[W49);F"62$FVMOMQ 3=.S,AVD@,8L*&&0N[CI7?44 <1:^&;
MR[O8!<6][8Z0)V<V3Z@S./W>,LRN?E+8.T,1QGN14$6@Z^D$7]IPW%_;HP$M
MI#>['D 7:C;BPSMQR"PSG/)&#WU% 'FT?AG78=&EAGT^ZGDD2Y-I'#JI0V<C
MSRN&=\C=E7C^8;B-I&/5TOASQ0UO=QQ&95=X'DWW.]K@*,.B?O%&W.#R4/!&
M2.:]'HH Y"+0=5N/ ITR]DE\][J-U4R;7BB$R-MW!FP0H./F;'3-(NFZSHNH
MS2:=:3WM@))4@MA>#<JO'&0V9&Z!UDXSD;N!7844 <';>#=37R#>W5U-+]LB
M2>1;Z0![86RHX ST,BDGC)SFH[SP]KGV.:"2UNK[$,L-AY.I&$VI\V7RV8[@
M3^[,7S?,PVXQZ^@44 <3::#J&FQQ:E>2S-<QW9>Z:2[9U%KY9!4+G;C.#C&<
M\U8E@D@^%MI'<*S&*VMS*N#G:&0L,?0&NNHH Y)-,U5=3CA-@#;VVHSZ@MT)
MUVRAE?;&!]X-F3!R,8!.3TI88M>BUZ74(M*$ E@,L\ NU:.=_+ 1>>5D##:6
M VE0#SP!UE% &'H&Z35-<N"FQ9;M!C.?F6"-6Y]B,?\  :W*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HK;_ %"_4_SJ6HK;
M_4+]3_.@!PBC69I1&HD8!6<+R0.@)_$_G6?;>'=*M;]KV*QM_M)<NDIA7=%E
M0I"'&5! _4UIT4 9NG^'M*TR 1VMC;ABJ*\IA7?+LY4L0/F((S]:E;3K*/5%
MOH[.W2[D.U[A8E$C#'0MC)' J[44O^LA_P!X_P C0!!=:1IM[;+;WNGVMQ C
M^8L4L"NJMS\P!&,\GGW-$VD:;<WD=W<:?:RW,8 29X59T .0 Q&1S5RB@"">
MRM;I)4NK:&99D"2+)&&#J,_*<]1R>/>BVL;2S55L[6&W5$$:B*,*%4$D*,=L
MD\>]3YQUI%970.C!E89# Y!% &=9:)I5O=7%U;Z99Q7$SN)9DMT5Y 3D[B!D
MY[YIH\-Z!#''MT33D6!C+&%M$'EMQEEXX/ Y'H*NK+'!%))-(L:"0Y9VP!SC
MK3_,BE_=B16+!N PR0.#^1- &7 =#O\ 6+6[2SMY-0DMOM$-RUN/,$?W?OD9
M'WL8SWJ+0X="NY);O2M)2T>.9CYGV/R?,8@C>#@;L_,,]>OK45AX=U"RP_\
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M8^\-Y7?GMG_@-36UKKEM\/K2*TBNHM0#W+D2*GFKN\XH6 ^7=DH>.,FNXHH
MYA;+5X+'5+&.[N96*)]CN;EQN,C(=WS <8;';C/%9$NE6]QI]Q!HGAZ]TR\,
M.R>X:,)N;<O4DD3-D%MQW#@G///<S_\ +/\ WQ4M '$W=CX@2\-C:75_]E6<
M(MV2K2^6SVY;YB/3SN>W/H*9?+K<,+P3-K1BA:9+62RPTLC _NS(3U&.A/R]
M=W:NYHH J:5]H_L:R^W;OM7V>/SMW7?M&[..^<U-%_K)?]_^@J6HHO\ 62_[
M_P#04 2T444 %17/_'NWX?SJ6HKG_CW;\/YT 2T444 %%%% !1110 4444 %
M([;8V8=0":6D(#*0>A&#0!QEIXUOM4M]'CTZQ=+R^M6F?[5:2Q1%A&'VHS8!
MR<@')XYYJU;^)=1U:.T;3(K>W742[VSW:,?+A0#<[*&&YBQX4%>.2>U:%DFB
M-/:6UFX:328F2%0S?NU&8FZ]<;2.<\BB#1='U#0+"*S#_9(E$EG-#,Z.@(X*
MN#N&0?7D&@"C:^)+M+Q(;XV<L*3I#+=VX(C=9$W12+R=HR-I!)^\I!Q3(_&+
M0PWU[J2PQ6,-F+R$\JS(TCHFXDXRP53VQNQVJ_:^$-)M=%OM)$<DEE?,SS1R
M2$DLP&3N^]DD YSD'IBKDNAZ?/=Q7,EOEX514 8A<(6*#;T."Q(]\>@H XC4
M_B!K(T/3KG1;>PN9VNOLU[)"KW4*..H3RV&,J0P)/0@8)KMKS4)[;PS<:B81
M'<16C3^4_(5@A;:>G>GNEAIMT;M\02731P$C.';)"# XSSC/T]JDU2S.H:1>
M62N(S<P/$'(SMW*1G'XT <[%XRDM2UO?V4U[=#<0+"$ ;$BB=V.]\#F3@9)[
M<FIQXXLV6(1:?J,DEP8_LT2Q(&G20,4D&6 52$;[Y4C'(%.BM-(L+A8M1=!J
M+6ZK,4WA6\W9%D#G&XQJ!W&/>K=CI&CS_8[ZR3>+:-(8'#M@+'O4#D\XW..:
M *EMXUL+A8G-I>P1S<1/+&H$C!UC90 Q.59@#D 'G!-27OB^UM-4DT^*QO[R
MYB,@=+>-2 $2)V.68 #$Z=^3D"JL</A;4+G^Q(_,,L!FB5<2H Q8/(%D. 6#
M '@DC''2M6S\.Z=8MOB25Y2DB-++,SNXDV;MS$Y)_=H,GH% % &6OQ"T%]6C
ML4N,EVC0REXU"O(H95*%@YR&7D*0,\D<XMZCJ>H/JMQ8Z7):6JV=NMQ<7%U"
M\V0V_"JBLO\ <))S[8.>'P^$]*MKF&6V2>$1;,11W+K&Y0 *S*#AB !R?058
MU+0K/4[B.XF-Q#<1KL$]K.\+E?[I*D9&><'O0!AV'C;S[GR7A2\D:"+RXM/R
MS23%YE=07V@ "'/S8QR">E2KXS:74_)M-*OKI%MC)+%%$OFPNLA1U;<P7C'0
M$D]1D59_X1O09YI+:%)([BV2(%X9W22/!D96#@YR3))DYR=QSFHK?PSH.H*)
M[%[M6A\RV>:&[FC=SO)D#G(+$ODDG.?6@"P_BRQDTB>^L]\J1R)"C%,!G=%=
M>.N,.N>XYK)L/'N;>3[=93W,L://(;*#"0PKMR6+OR1GH.3V'%;)\):0;I9E
M@D15"_N$F=8B578K; =NX+@9QV'I3'T'0M*L[@R1&&&Y3[-*3(YW"0A<=>,D
M@9H ;K?B>/1+VT\V)Y[6>V>3]PA>1G\Z"- HSR"9^?H*S]0\;R6U]9HFG7$4
M0-P;]941G@$4:OCB3&2'!R-W';TV+K3]'N[Z"WN1NN+&!7C3>P*1^:C@\=?G
M@3_OGW--CT;1=4 U%(5N$NU>3>6;;(LL:HW'H4510 FH^*;+3+^.SEAN))9'
MB0>6JXS(&*\DC^X>!R3@ $G%4;'QDC6*27-M/<F-5:\N+2'$-N&/RY#-N/&"
M=N[ Y. 15H>#=)-JT$GVR57=6D:6\E9I HP$9BV2G7Y3QR:<?!^C[T*Q3(H5
M5>-+AU28*<J'4'#XSW^G2@ TWQ5:ZG?+;QVEY"DKRQPW$R*L<S1DAPN&+=B0
M2 " <$U7U+7[^QU35K:-+>18+6UDM058$/-))'ASGD JIX .,]:U8=%L8&M3
M%"0;2222'YS\K29W'KSG<:+K1;"]DNWN8=[7<"6\QWD912Q4#!X(+L<CG\A0
M!Q^L^+O$>F2SVRPV;-9SK%->+9R212%A&P&T2#RSMD_B8@D8XS75^'-2;5M!
MM[F:YM;F<C$S6BE8P_< ,21CCJ>>O>F1>&-+CA$3Q23KN=V\^9Y#(SKL+,2?
MF.W@$]!TJUI6DVNCVK060DP[[W>65I'=L 9+,23@*H'L * +M%%% !5+5=0_
MLVWBE\OS/,N(X2,XP'8+G\,U=JM?V$6HP)%.6"I*DHV''*G(_44 8L7CS0IT
M#Q2W3*4$H;[%, 8LX\P?+]P=VZ#BI#XUT7[2\"/=2R*[QJ(K*5A*Z'#JA"X<
MCOC/0^E3?\(O8_9Q#OGVBP.G_?&?+..>GWN.OZ5);^'K.V>U:-ILVLDTD>6'
M)DSNSQ[G% #X_$.F2VIN8[G=")8HMX1OO2;=@Z=]Z_3/-4K;QMH=U:&YBN)O
M*,:21E[613.K$*IC!7+Y) ^7/)'K38?!ME!)$(KN\%LAC=K7>ICD>, ([?+N
MR,*>" 2HR*DG\(V$\%G'YMS&UC;I!;R(X#1[65E?I@L"@ZC!Y!!!H C;QEIZ
MW,0.](6BE:4RQ.DL;HT2B/RRN[+>:,#&3QC.:F_X2W2O*5@;II6D,?V46DIG
M# !CF/;N P0<XQ@CUJ&3P;93-YMS=WLUW\S&[:11)O+1D/\ *H4%?)3   ZY
M!R:K7_AB^@*7>C7<LVI&1FFN[BX6*1P5"XXA=,84<>7VR"#G(!I6?BO1[^S-
MS:W+/$'1!F%U)+L44 $9.6!'M@^E;%<GHW@Y["ZTB6[F64Z?!+O82,3-,[E@
M3GJ%W/@GG+G@5UE !1110 4444 %<<WCK[/K%]%>00K8V4DRSR1F1I(4C4L9
M&&S;MXQ@,3R*[&LIM'L+W2=2T])F>"]DE$Y20%D9_O 'L1Z&@#,C\>::OFM>
M":-"S- L=M,\AB5$9G=-@*8WCKQ@@YYP+H\7Z0T)=99V.Y5CC%K)OFW E3&N
MW+@A6.0", ^E2/X;LGO+NY+S;[N.2.3## #JBG''H@_6HY_"MG-)#-%<75O<
MV\<:03Q.NZ/8&4$ J0<AV!R"#GI0!7B\>:!-="WCN+CS<G>ILY1Y6&VDOE?D
M ;CG'-;EM>P7<EPEN^\V\OE2'!P&P"0#WQD=.^1U%8EMX0M;"#4FAEGOKF_A
M=)3>RC$A;)Y*J,#+=AP.@XK3T33!HVBVMCYK3/$G[R9S\TKGEG/N22?QH OT
M4QIHTE2)I%620$HA;EL=<#OC-0WNHV6F0K-J-W!:1,VT//($!."<9/? )_ T
M 6:*C-S MJ;DS1B )YAE+#:%QG=GIC'.:=%+'/"DL+K)'(H9'0Y# \@@]Q0
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M<].P!/:LO3O&=_>QQ7CV-JM@6AC<Q3F1V>501LX (!(Y[Y[4 .\86FJSSO\
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M!&04C$8 7"[!C'^R ,>@J:?0=*N;22VGT^!H9)!*R;  7  #<=#@ 9]*T**
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M110 5%;?ZA?J?YU+45M_J%^I_G0!+1110 5%+_K(?]X_R-2U%+_K(?\ >/\
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M]JEJ*#H_^^U2T %%%% $4_\ RS_WQ4M13_\ +/\ WQ4M !1110 5%%_K)?\
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M]_E_QH_M73O^?^U_[_+_ (T<LNP<T>Y;J*+_ %DO^_\ T%0_VKIW_/\ VO\
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ME/[L*K;&P"=A #X)QQFEMM/UX75W?2IIL-U>>5"Z+(\J1QHK?,"57<Q9ONX
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M[7 60BY*@#+';D$@ ':0"!48\&6\8EC@U&]BMKDYNX%*;;CDGDE<C@[3M(R
M*Z2B@#BX/#&JG7+59F":397$EQ% +A70EE<!0OEAL?O#]YF [=JW?#&C-H>A
MQVLS^9<,3),Y8MECT&3U"J H/HHK7HH **** "BBB@ HHHH *R9=!TM[ZW>4
M'STNFO8P92"SX )QGE1\O'0$*>PK6KC=2TO7KOQ&VNV\=L%L9 EK;R(WG/$N
M?,"L&VCS,G&0?NH3Z  TK?PGH_FQ7%H\WDAE<Q1W!,4K(Q*EAT)!_P#00#TI
MEQX1TJ:QNK6T)6;R5B!,I;85C=$R,^DA^M.\,7$]OHC6MQIM[#+:!SB2-0)?
MF8@(<\_IUKGI=$\565O?7L#0_;-5A=9C9J1-%(<F-RS,5.P?N^ .,>F* .B@
M\&Z<L:?:WN;QT$:J;B=GV*C!@JY_A)49[G R34^D^'],T"YW6LD@>8>3$DLV
M0JCYMBCOP/<X'6L5M$UB"\N1!>ZH\,=[#';[[LM^X=4$S')RQ&7(+9*D#;CO
MGM'XDUFUM=0MBS7%I/+!"5==I\N":,SC/&7D; SD#Y<\9H ZA_#VBQ7%F)OE
MD6.:"%7F(,@DRSC&?F.-Q]0"WJ:K0^%-,_M#44NA'*MW;10+;[SE8D &X\YW
M$@98?W$]*Q?L?B"5_,TB*_CBCRUM_:SK)+'-Y4@9@6+$*28P,GKGC%518:N=
M4DN[&TU^.T%K'%,;JX5KAAYF9%B8L2#C'<#KMP: .F/@_18+.3[:99HUWO))
M<38P"A4\C   )Y&,=:LV'AW3X9H+Y9KB\G1Q+'<SSF1F&QE ST*XD; ]6S7*
MW5MXCDCC2"+5)('%RD$-Q(I*QM&-OG'=\S!@V P;Y6'(8$UN>%8=5M]2OH]0
M2Z$&R/RVF8! <8*HH)&!CJ-O7D9YH NMX3TIK.VM_+E"6L3Q0,LK!HPSI(2#
MUW!HU(/;%6-)T.VTB6YEAEN9YKME::6YF,C,5&T=>G'88K2HH **** "BBB@
M HHHH **** "BBB@ HHHH **** "JD%G;-""UM"22<DQCGFK=16W^H7ZG^=%
MQ63(GM["-T1X;=7D)"*54%CC.!Z\ G\*?]AM/^?6'_OV*YG7O#^L:OK8U*VN
MHK<Z=M-A$\0<R,,,QW9^0/\ ZL]3M!]:PA8ZJ^F:K?0VEU:SA]1>2[:^9_,3
M=,$B5,Y!!V8P,#9D$YIW861Z']AM/^?6'_OV*CDLK7S(L6T/WO\ GF/0UQUM
MX8OKN6V4VUSIVGK+&\]NVH-(9F57S)D-DJ24&"06QR!BG6_A_50S;(I;*Y1"
M6G>],JWEPK!DDQD[5^4YR!P^,8%%V%D=G]AM/^?6'_OV*CEBT^!XEFAMT:9_
M+C!0?,V"<#\ 3^%<5J/AGQ++=6DZ7+M+)&'D\N7*VMPSEF8$L/E *J,*W"?=
MYJXF@ZB?%5E<RV$C-!>R33Z@U[E)8RCA%$6>HW*,8 &TX)HNPLCIHAID]W/:
MQ10--;[?-41#Y-PR.<8Z<U/]AM/^?6'_ +]BN3OO#=PFHZA=I8/>6]U>^=+:
MPW1B:8>2BJV2P'RL&^7(ZYY( JUH&@ZCIS7UY?RR3WLEND4.^Y9U4!!P >,[
MN"V,G&:+L+(V+<:6\"R@69CFDVQ. NUR>@![U(!I;0I,HLS$[;$<;=K-G& >
MYSQCUKB=/\'ZE;V5E8B.+[)I4\%S:+Y@_P!;O4RC';;B3![^93K;P=JT.F6E
M@8XA;VDD&H1)Y@XNC(K2K_N@B1@>YD[8%%V%D=LL%B]Q)"MO%YD85F'E= <X
MYQ@]#23QZ=;!#<16\?F.$3<@Y;KC]#61JN@W&J^(8VN6D;3!L+QI<,@8A9."
M 1D99#[X'I45WH%WJ&AZ'#?QB:ZL;F.60M*>-JL,YS\QZ47861M?9[&>"":"
M"!XY"K*PC&&!Y!J5[6QC4&2"W0$@ LBC)/ %</=>$M5L]%BM-+DE56AMC<H;
M@N9I%+;U&Y@!D$=U! Q6S:Z3JL7@Z&WF!GNX;A9TAD< [%D#"/=D@' P.2.@
MSCFB["R-MUTR*"::5;1(H,^;(P4+'@9.X]L>].@AT^YMTGMH[::&10R21JK*
MP/0@C@BL#[%JO]DW:'24D:_GDN9(6N@&BY3:@(XWD D'. P')'-:6BC4([%+
M2_LUA982[2*R@%F=L*0HQNVX+$<9/&:+L+(DL[W0-1<II]SIMTRG:5@DC<@X
M)QQ]#^1J>VMK&82/%#;R(6^5E12#P.]<EHVF:[I]CISSV=[<R::4'V>>:U&\
M>4T9\HH!P"0?G.<>];WANWN]/T\:?/; &"%6,HDRK2-DL@XSQQS[BB["R--;
M6Q=F58+=F0X8!%RIQGGTXIWV&T_Y]8?^_8KD;C2]5O;B6^O]'D>&:8L^G1WJ
MH^1'&JR%P0" 5?C/1@<9X&5I6BZS]H^SW%M<R7]M#:1+>G469+5UC4OD$C?G
MGD [OXL47861Z']AM/\ GUA_[]BN5\9_#[3O%"P3^:UC/ -H>*,$,I/0CC\Z
MH7GAO6KBYE$%M<03LMRL]^NHD"?>C"/:@/!!(Z@;<<9ZUTVG:9)I7V^",%;(
MR(ULK2%R!M&[DDG[V:N%2<)<T7J14I0J1Y9JZ+'A_0[;PYHD&F61=HH0?F<\
ML2<DG\:TJ**B4G)W948J*45L@HHHI%!1110 4444 %-D)6)B.H4D4ZD8@*2W
M0#F@#B=)OKO3['P_?76MSW?]I0*]U!=%#M7R3(TB;5!4*<9ZC!]<5G7'B_59
M=#U4_P"FV]Q<*EQ8"2T-NT:F14,2LZ[6(4JV[GESV K<T&Y\*W#K%IVAQZ>-
M1BS&9--$"W:8W8!VX;CG![<XZUH7NMZ'+9WT]RJW::7,(ID\CS&20X "C')R
MP&1WR.QH P;"75+^QTN)]4O+>ZGO'81B6-Y(X(R/,64[,$@@KP!CS ,G&:2Y
MUFYCL7U9M;FCO?M4D$.GB-3!O5R! V%SO8=]P))R..*OW6H>&KDP7MYH+3S?
M:Q"6DTW=)!,Q0#=D94G*'/I@]JNW\/AFZUR>&^L[274XK87#R& >:L8/!$@&
M<C'0'(X/>@#'U#7[^/28F@O-MQ]OO8G VE@L<4[*",=BJ'\O6J6D:MK+:*@O
M]0FLA<W<-M)-<R1RRVV4+%LA0HW_ "!<@XW9[@5T=W>Z):W<-XFDM=7>IVY?
MS+:QWRR1 +G><9Q\RC!JRE]H]S+]C^S(9;EC;26[V_S81<X<8^Z 1C/'S#UH
M Y3Q)_PE2"[T?PKJ=U>R0I%,TRM"+B$LQ&S<R[""!NP1N ]017175SJMCX%\
MR[D\O4_*6,R?*Q1V8*&./E)&X$XXR*DLM4T+3&O+&QMUL+:Q#O,\5MY=NA !
M<;@-N0&&1_A5+6/$^BW.AWD6JKJ-G"T!<;[21))%'\48VY+#@XQD=2* *VJ^
M*M0BV26\5O%91ZK%8LYN0;AR)0''E[<<C.!G=@YQ5>]\?:E:0:?*NDV4_P#:
MB+)9QIJ/S8:2- '^3C_6C)&0,8K8M+SPUJFFGQ4EC"VR/S&N9K+;<*% (!#+
MN!Z8'TJS+9^'M/F$[Z?8Q3SRQY*VR>8SLXVDX&<[L<^HH RIO%^HQ-%(=/L3
M;OJ*:8V;TB03%PA(79RN<D#.XK@X J#1O%][%X5FN-6CAFO;;3VO?DFXF^>1
M0H^48^X!G'4UTKZ=HLVHM>R6=A)>H0&N&B0R*0<CYL9&"!^5$FGZ+/+;>=9V
M$DEO^\M]T2$Q9.=R<<<\Y% &$OBK69[N.&WTBSQ<RW,=LTEZP_U#E27PAQN
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %16W^H7ZG^=2U%;?ZA?J?YT
M2T444 %12_ZR'_>/\C4M12_ZR'_>/\C0!+1110 4T1HLC.J*'; 9@.3CIFG4
M4 10='_WVJ6HH.C_ .^U2T %%%% $4__ "S_ -\5+44__+/_ 'Q4M !1110
M5%%_K)?]_P#H*EJ*+_62_P"__04 2T444 %17/\ Q[M^'\ZEJ*Y_X]V_#^=
M$M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5%;?ZA?J?YU+45M_J!]2/U- $M%%% !44O\
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M)YS5Z]\)Q7_VYKF\F,E[:16LCA5'W&+;A[DFKOAU;_@]_P#(BV)=_P#@=O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSG_EG#_\;J7^S;O_ *#5[_W[@_\ C='*N_YAS/M^7^9H45G_ -FW?_0:O?\
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M,%QA=I8]>"/6NLK'T[PS8Z8U@T.]_L$,D4.\+P9""[\ <G'; Z\5L4 %%%%
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MBQ^5%C ) 7 SM!X'K5BP\1ZTVJ7MAY%I/<2:A-':^;<&-$BCCC8@D)DM\_0
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M/S' .>.]:VE^(VU+4EL!:JEQ$':[429\@ CR^W.\'(Z< ^E &[1110 4444
M%%%% !117+_\)-<6^O:U;W2HUM 4CLL+@O+L0M&3W),J8_'TH ZBBN%\.^+]
M4NH4M[J#^T-3D55,$2K"B,B#S6WDG(W'@8SSCU-6+/XA"^DECAT2[#1E(\/)
M&-TSNRK'U]4))Z >O2@#LJ*XNX\;W,&I2QSZ;<1269,4UDGER&9V\DH5DW
M8E[CUZ8YEO/'\-A(+2ZL&CU%9722W:9=J!51\[^ARLJ8&.I/I0!U]%86D^*(
MM7U);:&TFBCDMDN(Y)L(7# 'A#SQG!(SR"*W: "BBB@ HHHH **** "BBB@
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MU#+=22)'$@C$*1Q%0OHI9"R9'!V%<BM2STRWLKN[N8@3+=NK2,V.BJ%51@=
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ML[/*A9&9P_7&2PSC VD&M34+C53XHEM-+>*S20*TMPUL9&8"-C@<@=0!],T
M=-/]Q?\ ?7^8J6N,U^XO]1TKPQ>0R26S2W0DGC2,G.;:4X/H,\?4COBJ4VM^
M(=%T&"*21+AVM[:1[DPA!;*P8,/F.#@J.6/\7- 'H%%<M'K-Y+X1L-4OB8,7
M*&>2,'!A$F-YQ_"1@G'&#G..:K3:PK^'+H3WUS&;J>6:WG59!B 2@!BZ\HF"
M!N!!"G(Z9H [*HHO]=-_O#_T$5F>']4@N["UMPUQ]H%JDS+<!F;820"7( ;.
MT^Y&"1S6G%_KIO\ >'_H(H EHHHH *IZM8VNHZ;+;7]O'<0MC,<BY!YJY45S
M_P >[_A_.FFT[H32:LR/3]-L]*LUM=-MH[:!3D1QK@9]:LT44-MN[!))6044
M44AA1110 4444 %%%(QVJ3@G S@=30 M%9.F>(K34[.:Y,4]E%#*T+->H(LN
MI*D#GL015JZU2VLYH(I&9GGD$86-=VW@G<V/NK@=3QR/6@"Y14*7=M*LC1W$
M3B+(D*N#LQZ^E(E[:R*K1W,+!SA2L@.X^@H GHK/OM=TW3K&:[N;N+R86"R%
M7!VDD+@_B13DUBS:U:XD<P(LDD8$R["Y0D':#U!QP1U% %ZBJUMJ%K=) 8ID
MW7$0FCC8@.5(R#MZTS^U;,75U;O,L;VNSS3(=JC<,CD^U %RBJ:ZK:F:Y1V,
M2VVS?+*-D;;AD;6/#=>W>IWNK>)HQ)/&AE.(PS@;S[>O6@"6BLNU\1:?>W\M
MI;.\CPR2QRN$.R-H]NX,W0??&,]<'T-73?6@MQ<&ZA\D])/,&T\XZ]* )Z*J
MG4;9;\VA?]XL'VAC_"J9P"3VS@X^A]*>;ZT%OYYNH?)X_>>8-OYT 3T5$UU;
MK*D33QB1_N(7&6^@[T"[MR\B">+=%CS%WC*9]?2@"6BJ-OK%E<0O+YOE1K,T
M(>;Y!(P[J3]X'L1UJ[N&X+D;B,@9YH 6BHOM=N91%Y\7F%=X3>,E?7'I[U7N
MM7L[:W>7S//V8S';CS'Y8+G:.< GGTYH NT5$+JW:21%GC+Q?ZQ0XRGU':G0
MSQ7";X)4E7.-R,",^G% #Z*SM0U[3]-L#=S3K)&)5@ B8,3(Q "]>N36C0 4
M444 %%%5M0U"VTNR:ZO79(5*J2L;.26(4 *H)))(& * +-%5[*]AU"U%Q;B8
M(Q( F@>)N/\ 9< _I3KF[@M!&;F01B618DSW9C@"@":BBH+V\@T^QFN[Q_+@
MA0O(^TG:!U.!S0!/1144]U#;R01SR!&N)/*B!_B;:6Q^2L?PH EHHHH ****
M "BBB@ HHJC>:WI>G745M?ZE:VT\N/+BFF56;)P, GUH O45'-/%;1&6XE2*
M,$ N[ #).!R?4D"I* "BBB@ HHID\\5M;R3W,B10Q(7DD=@JHH&223T '>@!
M]%(CK)&KQL&1AE64Y!'K2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M. 3R<UVM%% !1110 5C^*=/GU306M[2,RR>=#)L$YA+!)%8@..5. <$5L44
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M/DY;<JJ&8!0-N" F1@%206;HZ** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ J*V_U/_ F_F:EJ*W/[G_@3?S- $M%&11D4 %12_ZV'_>/
M\C4N144I_>P_[Q_D: ):*,BC(H **,BC(H B@_Y:?]=#4M10'_6?]=#4N10
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M(V.PG=SM/( R*9 ^NQ2-<:A%>V27+1_;+JQL5>X;$>(\J%;.?XL!MIX&!D@
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M.U (BRC@CA7Z9!?%=]I<LT^D6DMTDL<SPJTB3 !U8CD-CC- %JBBB@ HHHH
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M+N')'L5/[!T?_H%6/_@,G^%']@Z/_P! JQ_\!D_PK0HHYY=PY(]C/_L'1_\
MH%6/_@,G^%<YXL^'&C:^D,J+_9\D'!:UC4!U)Z$?UKLZBN?^/=_P_G5QJU(/
MFBR9T:<X\LHZ$6FZ?;Z3IEO86:E8+>,1H"<G ]:M445FVV[LT225D%%%%(84
M444 %%%% !1110 4444 %%%% !1110 Q(8HGD>*-$:5MTC*H!<X R?4X 'T
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MOYFI:BMO]3_P)OYF@"6BBB@ J*7_ %L/^\?Y&I:BE_UL/^\?Y&@"6BBB@!
M,X &>OO2@   # '0"BB@"*#_ ):?]=#4M10?\M/^NAJ6@ HHHH BN/N+_OK_
M #%2U%<?<7_?7^8J6@ HHHH *BB_UTW^\/\ T$5+447^NF_WA_Z"* ):***
M"HKG_CW?\/YU+45S_P >[_A_.@"6BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BMO\ 4_\
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M\M/^NAJ6@ HHHH BN/N+_OK_ #%2U%<?<7_?7^8J6@ HHHH *BB_UTW^\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>halo-20230331_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 halo-20230331_g3.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#Z17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=E=&%S97<@
M665S96=A=   !9 #  (    4   0J) $  (    4   0O)*1  (    #,S<
M )*2  (    #,S<  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" 0M ]D# 2(  A$! Q$!_\0
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M JS_ .^GH_X79JW_ $"K/_OIZ/[+Q7;\0_MC!_S?@SV>BO&/^%V:M_T"K/\
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MK?\ 0*L_^^GH_LO%=OQ#^V,'_-^#/9Z*\8_X79JW_0*L_P#OIZ/^%V:M_P!
MJS_[Z>C^R\5V_$/[8P?\WX,]GHKQC_A=FK?] JS_ .^GH_X79JW_ $"K/_OI
MZ/[+Q7;\0_MC!_S?@SV>BO&/^%V:M_T"K/\ [Z>C_A=FK?\ 0*L_^^GH_LO%
M=OQ#^V,'_-^#/9Z*\8_X79JW_0*L_P#OIZ/^%V:M_P! JS_[Z>C^R\5V_$/[
M8P?\WX,]GHKQC_A=FK?] JS_ .^GH_X79JW_ $"K/_OIZ/[+Q7;\0_MC!_S?
M@SV>BO&/^%V:M_T"K/\ [Z>C_A=FK?\ 0*L_^^GH_LO%=OQ#^V,'_-^#/9Z*
M\8_X79JW_0*L_P#OIZ/^%V:M_P! JS_[Z>C^R\5V_$/[8P?\WX,]GHKQC_A=
MFK?] JS_ .^GH_X79JW_ $"K/_OIZ/[+Q7;\0_MC!_S?@SV>BO&/^%V:M_T"
MK/\ [Z>C_A=FK?\ 0*L_^^GH_LO%=OQ#^V,'_-^#/9Z*\8_X79JW_0*L_P#O
MIZ/^%V:M_P! JS_[Z>C^R\5V_$/[8P?\WX,]GHKQC_A=FK?] JS_ .^GH_X7
M9JW_ $"K/_OIZ/[+Q7;\0_MC!_S?@SV>BO&/^%V:M_T"K/\ [Z>C_A=FK?\
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M JS_ .^GH_X79JW_ $"K/_OIZ/[+Q7;\0_MC!_S?@SV>BO&/^%V:M_T"K/\
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MT";_ /\  5_\*/[!UC_H$W__ ("O_A7U'11_;,_Y/Q#^P(?SO[CY<_L'6/\
MH$W_ /X"O_A1_8.L?] F_P#_  %?_"OJ.BC^V9_R?B']@0_G?W'RY_8.L?\
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M3?\ _@*_^%']@ZQ_T";_ /\  5_\*^HZ*/[9G_)^(?V!#^=_<?+G]@ZQ_P!
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M#KGT(R*DJ/[9FOL?B:+(:;U]H_N/ES^P=8_Z!-__ . K_P"%']@ZQ_T";_\
M\!7_ ,*^HZ*/[9G_ "?B/^P(?SO[CY<_L'6/^@3?_P#@*_\ A1_8.L?] F__
M / 5_P#"OI^XN(;2!IKJ5(8D^])(P55^I-4/^$ET/_H,6'_@2G^-4LVJRVID
M2R.C'252WW'S?_8.L?\ 0)O_ /P%?_"C^P=8_P"@3?\ _@*_^%?42LKH&0AE
M89!!R"*6I_MF?\GXE_V!3_G?W'RY_8.L?] F_P#_  %?_"C^P=8_Z!-__P"
MK_X5]1T4?VS/^3\0_L"'\[^X^7/[!UC_ *!-_P#^ K_X4?V#K'_0)O\ _P !
M7_PKZCK'U7Q'%I#S?:-/U"2*%=[SPV^Z,#&3SGM51S>I-VC#\2)Y'2@KRJ/[
MCYT_L'6/^@3?_P#@*_\ A1_8.L?] F__ / 5_P#"OI#3=<BU*\EM?LEY:S1Q
MB0K<Q;,J21D<\\@UITI9O4B[.'XCCD=*:O&H_N/ES^P=8_Z!-_\ ^ K_ .%'
M]@ZQ_P! F_\ _ 5_\*^HZ*7]LS_D_$K^P(?SO[CY<_L'6/\ H$W_ /X"O_A1
M_8.L?] F_P#_  %?_"OJ.J=WJUG87$<5[(8!)]V1U(CSZ%^@/L336<5&[*!+
MR*E%7=3\#YH_L'6/^@3?_P#@*_\ A1_8.L?] F__ / 5_P#"OJ)6#J&4A@>A
M!ZTM+^V9_P GXE?V!3_G?W'RY_8.L?\ 0)O_ /P%?_"C^P=8_P"@3?\ _@*_
M^%?4=%']LS_D_$/[ A_._N"BBBO!/I HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q];GUJUCFN-.%@UO%"79;@/
MO. 2>G%;%<SXDMK$3M=:Q9WCV8C"O/;W<BA03C#1JPR.>H!K:BDYZ_U^1A7;
M4+K^OP8OA?3KFW*7KV>EV\5S"&_T57#C/('/ '/05TM8F@Z?HL7^DZ+-)(%7
M9AKN60)[%68X/X9K;HK2YIMAAX\M-+\M?\@HHHK$W(;J=K:UDF2"2X9!D11
M%F]AD@5R&HWW]I:E,(],UZVN/LR)<) L0\R(L^W.6/</@CGDUU>IM<)ID[69
M<3A?D*1AR#[*2 ?IFN9TZ*^OM1N)[3Q1$+UHDBF@DT\+(@0L1E"V1_K#SWKK
MH647)_K^AQ8F[DH*_P"'ZM?\,=7:HL5G"D<9C18U"HW50!TJ6FQAEC42-O8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8****0RGJMC_ &EISVN_9O9#NQG[K!OZ5'+I8EO;ZXW@?:[1+?&W[NTR'/\
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MI K*$MSK#/\ 9I3;6*L5\U/]9-CKM/\ ",\9ZGVJ5=!TP#]Y:K.?[TY,A_\
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MIMTT>'2]>T>'5K:V)-L3,T,D6>HW+R5]JT?#/@VUUCPS/=7D[17UT732XMX
ME:-2S9'<=JB\*Z5H.H:%JMQJMG>/<:;%YS&*X"!P3@+C'!&*IO#I-)/2RT_"
MVO=M$Q6*DXMR7O7>ORO=6[),2+Q]<1^(+>_&GP):VD$EO;64+;$B1QCK@Y/J
M>_M4%EXVO+7PC?>'YHA<6]R"(G9\&#)R0..1[<5NMX-T\>#[34[?2KN[DN+1
MYI)!?QQK$1G'RMRWKQZ5G:EX=T:U\$6VIVB7EW++"I:\AD4Q1RD_-&Z=4QV/
M>IC+#2LE'K;YJ_GZ^;*E'%Q3;ET;^32\O3R7D8>DZZ=+T?5[ 6XE&I1)&7+X
M\O:2<XQSU]J?X?\ $<OA^#44@AWO>P"%9!)M,1!R&'')_*L:BNYTH2O=;[_U
M\CSHUJD;-/;;Y_\ #G4'QO(/$$VJ)IUOB\@6+4+9SNCN3CYFQCY2<9[X/K3+
MWQ9;C1[G3?#^C0Z1#><73B=II)!V4,W1?:N:HJ/J]*ZTV]>FQ?UJLTU??R77
M?TOUL=L?B!:+<07\7AV'^U;>W6"&[DNF<)M7:&\O &:H:5XPBMK$6NLZ3'JJ
MQW9O(G:9HF24G))('(..E<Q12^JTDK6_%_YE/&5F[W_!?E;4Z>#QQ='4M2GU
M6SM]0M=48-=6C@JIQ]W:1RI X!Y_K5/4]<T^YCMHM*T"VTV."02%Q(TLKG)X
M+G^'IQCMU[5B452H4T[I?UZ;$/$U91LW?Y*_??<Z:7Q79WGB;4-5U+0H;N.]
MQB!IV5H2,8*N!P>/2L_Q+K\GB76Y-0E@2WW(J+&A)VJHXR3U/O6313C1A%J2
M6RL*>(J3BXR>C=]EN%%%%:F 5Z)'X@TH:]X*G-['Y6GVH2Z;!_=-CH>*\[K6
MM?#.I7?AJZUV&-396KA');YCZD#T&1GZUSUX0DESNW3[]#KPU2I!OV:OL_N=
MSJX_&@U'P[XBM=5O;</(T?V-$@6,N-Y)^ZHSQCK4OC?78M3MYFL/$&G363+"
M!9BW_?$C;GY]F>HSUZ#'M7,Z%X-OO$&G->VUU8V\2SBW'VJ8H6<@$ <'.<T^
MU\$7\\%U-=7NG:<EK=&TD-]<>7^\ S@'!!X_D:Y/98>%2ZE:SVT\O+R.WVV+
MG3Y7&Z:WU\_/S.L\:>*].U[1[[3['4XXS$871E!"W:XY0G'53SS3K7Q3X4TY
MK'1C/?36D%J;2:6$J+:0R#+N5/S$@]#VKA]&\+WVO:Y+I>F/;RRQ!F,OF?NR
M%.,A@.0>U9,L3P3/#,I22-BKJ>H(."*J.$HV]DI;:_?I<F6.KJ7MG%:Z7]'>
MQV=MXE_X1KP;/8Z'J,+7BZP[*PB#[H?* #KN''('/6K_ (?\0HO@<6J:_96&
MI->O-*U]#YN]2.O*MR3WKSJBMI82$EKO>_0YX8ZI%IK9*UKL] L]0TG4M+TN
MWO\ 6K>SGTK4I+B1GC;;<*7#;DP.^.G'6J\OB/3KVZ\9W(F\H:E#MM5D&&D.
MX?T&:X>BCZK&[=_ZO?\ ,'C9V2LOZ5OR/0K3Q9I>FQ^%'>4S+:VD\%VL0.^'
M> ,\]^_X5@7>@:!;6UQ.GBB&X &;:&*W=I'.,@/G 7W(S7.454<.H.\9-?=W
M;[>9,\4YJTXI]M^R7?R04445TG&%%%% !1110 4444 :D?AG696C6+3IG:6W
M^TH%P2T7]X<__7JM!I=[=6<MW!;L\$,BQR.,85F.%'XFO5]/OOL<VFW,$L8E
M@\,,R$D$!P 0"/J.E9\UUH^H>!;W5-*Q;S7M]:M=VA/^JE$@W%?]DYSZ=?H/
M,6,J7UCU2_$]AX"E;271O[E_F</J'@[Q#I5FUU?Z3<0P+]Y\!@ON<$X'O5"3
M2KZ**TD>UDVWHS;;1N,HSC@#GK7J]U9W6D^/-9U[4;F*WT.6!U<&=6^TY3"H
M$!)SGGD?SK,T;4K'35\'RW\\<(.G7$23O@B"1F(5CZ=QGWHCC)N-[)^GHW;U
M5ASP%-2:NUZ^J5^FCO\ @<3?^$/$&EV1O+_2;B&W7[TA (7ZX/'XU1M]+OKN
MPN;VVM9)+:UQY\JCA,],UTEUX7\3:3:ZC>W>HQ6L+ ^9(=1'^F9/08)+$]<-
MC-=9HDFC>']&T_0M1U>WMFO(VDU&U>!W,C2KA!O&57:,=?2KEBG&%XVD_*_S
M[F4,'&<[23@K=;;[+M_PR=CSS3O"6O:O8B\TW3);BW)($BE<9'7J:J3Z-J-N
MUJLMG*&NUWVZJ-QD'J ,FNNTBQ?1M#\<:?/(-\,,2*=WWAO;!'KQ6S;:E9V5
MQX=-Q=16LDNA2P073GY;>5C\K'T^M$L5-2=E==/NN..#IRBN9M/KM_-8X+4_
M"FNZ/:BYU/2Y[> G'F, 0#[X)Q^-4[G2KZSCM)+JUDC2]0/;LW253W'YC\Z[
MK2=*U+PI%K%WXHO(8[.YMI(O*:X64WDA!VD*"3P><G!YK0;5--FT?PUH&N&-
M;2YTV&2*Z&-UM."0#GT/0TOK4T]$I+NO3IZ#^I4VM6XOL_6VOD_ZT/,K^PNM
M,O9+2_A:"XC^_&V,C\JKUU'Q'97\?:B58,-R\@Y_A%<O7;2FYTXR?5'GUX*G
M5E!;)M!1116AB%%%% !1110 4444 %%%% !1110 4444 %?0_P ,?^2<:5])
M?_1KU\\5]#_#'_DG&E?27_T:]>-G'\!>OZ,][(O]YE_A_5'5T445\N?9!111
M0 4444 %5-3)^PM&IPTK+&"/<XJW5;4(GFL7$0S(N&0>X.:SJ7<'83V+"*$0
M*@PJC 'I6#XUA1_"MY*P/F0INC8$C:<CFMN"9+B!98SE6'Y>U5-;TYM6T6YL
M4D$33IM#D9 YSTJTTU=#+XJG> 1WEI..#O\ *8^H8=/SQ5RJ4Y\_48(4Y$)\
MV4^G!"CZYY_"LZOP_-"9=J&[N!:6,]R_W88VD/T S4U,FB6>"2*09212K#V(
MQ6RM?44K\KMN5M)MC::3;0MS((P9&_O.>6/XDFH;W2XKR^^TZA-YEI%%A;9N
M$#=W///''/2GZ+.TFFQPS\7-L!#.O<,!U^AZCV-4]<TG4=6FCC2YMUL%.9+=
MT;]\?1B#]W/;OWJZE^=W(HV]G'EVL-\*R-+9W3Q&1K W#?8C(228N.F>=N<X
M]JMZN/*DLKL<-#<*I(_NO\I'YE?RJS9)=QQ%;S[/Q@((%*@#TY-5=1;[3J%G
M91_,5D$\W^RBYQGZMC\J=+XB:_\ #MUTMZWT-.L[7G9=&F2-BLDY6%2.Q=@O
M]:T:I:Q;276D3QP#,VW='_O Y'ZBHCNCH6Y:BB2"%(HE"HBA54=@*R-7TZU'
MGWUY;7>HL5VI!&<^6 /X ,8)]>O2M.RNX[ZSCN(?NN.0>JGN#[@\51DL=3@O
M+B73[R-H[@[O*N@SB)L8^7!X'M2ZZB$\+W$EUX:LY)[@7$NTAW!R003P3ZCH
M?<4_50(;_3KT<%9_)<CNL@(Q_P!];#^%3:5IRZ99M$)&FDDD>:61@ 7=CDG
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M^^(%I)J-YJNF:"MIJ]TFQKN2[:78"H4E5V@ X'6N?_X1/Q%_T M1_P# 5_\
M"C_A$_$7_0"U'_P%?_"DZ6&;OI]_?Y^0U6QB5M>G3M>W3S8WPYK9T#7$U$P?
M:2L<B%"^W.Y2N<X/KFD\.:U_PC_B*WU06_G^06/E;]N[<I7K@^OI3_\ A$_$
M7_0"U'_P%?\ PH_X1/Q%_P! +4?_  %?_"M9.C*]VM59Z]/Z9C%8B/+9/1W6
MG73_ "-"7QO=-=Z7?PP+'J.GAD-P7W":,GA&7'8'&<]/2IU\9:=8O-=Z#X=B
MT_4ID*_:?M+2+'G[Q1" %/ISQ61_PB?B+_H!:C_X"O\ X4?\(GXB_P"@%J/_
M ("O_A6?)AGU7W_\$U57%KH_N_X&C\S4LO%NF)H>FV.K: =1DTYY7BE-XT8)
M=]QRH7GMW[4D/CB6:^U637+"/4+;5519[=9#%MV'*;6&<8K,_P"$3\1?] +4
M?_ 5_P#"C_A$_$7_ $ M1_\  5_\*/9X;77?S\[Z:Z:ZZ![7%Z:/3R\K:Z:Z
M::FI+X]NQKD%Y:6<,-G!:_8TL7)=6AQ@JS<$D^M5=1US0YM/F@TKPQ#9RSGY
MIY;IYFC'^QP-OZU5_P"$3\1?] +4?_ 5_P#"C_A$_$7_ $ M1_\  5_\*:CA
MTTT]O/\ /77YB=3%2333=_+\M-/D)KVN?VX-.'V?R/L-DEI]_=OVDG=T&.O3
MFM2/Q=87EG:Q>)="35)K-!'#.ERT#%!T5\ [L?A69_PB?B+_ * 6H_\ @*_^
M%'_")^(O^@%J/_@*_P#A3:H.*C?;S_6Y*EB5)RL]?*_X6L:-GXT_LLZE+I&D
MVMG<7Q505^:.*,=5",#G/&3G\*LK\099;K1[R_TZ.:[TN5F62)A$)(R/N;0N
M!@]_TK%_X1/Q%_T M1_\!7_PH_X1/Q%_T M1_P# 5_\ "I=/#-W=OO\ *WY%
MJKC$K*]O33>^UNYHZ;XYN[#0M6TF2'S[74(Y%C5GP;=GSD@XY'/3CGTJ[_PG
MFGM_9US+X<6;4--@6*WGDO&* J.&,84 \\]?QK!_X1/Q%_T M1_\!7_PH_X1
M/Q%_T M1_P# 5_\ "DZ>&;OI]_\ P1QK8R*2L]/*_GU1IV?CB:"SBBN;7[1,
MNJ?VC)-YNW>W=<8X^OZ5)J'C:U9-2DT311IUYJ>X75T]TTS%6.6"@@!<FLC_
M (1/Q%_T M1_\!7_ ,*/^$3\1?\ 0"U'_P !7_PI^SPU[W7W_P#!%[7%VM9_
M=^MKFPGQ%U"R33X-(M;>VM;&)42.2-96)_B;>1D9]JJ_\)9!'-X@:UTSR8]:
MC"^7Y^?(.<D_=^;)/3BJ/_")^(O^@%J/_@*_^%'_  B?B+_H!:C_ . K_P"%
M"IX9;6^_SO\ F#JXM[W^[RMV[&C<>*=*O_#]C8:EH+3W%C;M##<K>LFTGG=M
M"\\XXS2KXOL[;PW=:=IVAQVEQ>6ZV]Q.MPS*X'\7ED?>]\UF_P#")^(O^@%J
M/_@*_P#A1_PB?B+_ * 6H_\ @*_^%')A]K];[O\ S#VF*O>W2WPK;;L9%%:_
M_")^(O\ H!:C_P" K_X4?\(GXB_Z 6H_^ K_ .%='M:?\R^\Y?8U?Y7]QD45
MK_\ ")^(O^@%J/\ X"O_ (4?\(GXB_Z 6H_^ K_X4>UI_P R^\/8U?Y7]QD4
M5K_\(GXB_P"@%J/_ ("O_A1_PB?B+_H!:C_X"O\ X4>UI_S+[P]C5_E?W&11
M6O\ \(GXB_Z 6H_^ K_X4?\ ")^(O^@%J/\ X"O_ (4>UI_S+[P]C5_E?W&1
M16O_ ,(GXB_Z 6H_^ K_ .%'_")^(O\ H!:C_P" K_X4>UI_S+[P]C5_E?W&
M116O_P (GXB_Z 6H_P#@*_\ A1_PB?B+_H!:C_X"O_A1[6G_ #+[P]C5_E?W
M&17J=GXF\*:6MCHCW5]-;Q6S6UQ);[/LTC2CYW.?F.">#VQ7!_\ ")^(O^@%
MJ/\ X"O_ (4?\(GXB_Z 6H_^ K_X5SUHT:R2E+;S.K#SKX=MQAOW3.T\)^(=
M)\+Z+=64U[;W _M7 91N/E;0HF7(['G\*;I6J)!H6IV:>(M*%\^KF;[1?+YB
M3Q^7C<,J>2<<X[&N-_X1/Q%_T M1_P# 5_\ "C_A$_$7_0"U'_P%?_"L70HM
MM\^K]#>.)Q$4HJ#LMM^IU&D:SHVA:3>O?7\TM_J%WEI-)"!HTC;<I^; "LW.
M,5A^.)M,OM?_ +4T6=7AOXQ-)%QNAD_B5@.A[]^2:I_\(GXB_P"@%J/_ ("O
M_A1_PB?B+_H!:C_X"O\ X5K"%*%3VBGKZK^NAE4J5IT_9.&GH_ZZLR**U_\
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M4?\ P%?_  H]K3_F7WA[&K_*_N,BBM?_ (1/Q%_T M1_\!7_ ,*/^$3\1?\
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MU/;VZ6T95,L6.YG8Y+'U-2T4U"SNW=A8****L92N["1KC[58S>1<[0IW#*2
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MBUU-ELI[J.Y@66,R-"5(+ L6^;)'MCWK:#H6C?>]W_E_7F836(O*VUK+_/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "H?^7[_ +9_UJ:H?^7[_MG_ %H FHHHH **
M** "H5_X_7_W!_,U-4*_\?K_ .X/YF@":BBB@ HHHH *AC_X^YOHO]:FJ&/_
M (^YOHO]: )J*** "BBB@ J&+_CXG^H_E4U0Q?\ 'Q/]1_*@":BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ T :5%4;C6+6VBL9)=^V^E2*'"Y^9AD9].E7J "BD+*.K ?C06 QD@9Z9-
M"T5#=W=O8V<MW=RK#!"A>21CPH'>L2U\96EQ/;K/I^IV-O=.J6]U=VVR.5F.
M$7J64MGC>%].I (!T-%)N7=C(SZ9HW#.,C/IF@!:*3<N[&1GTS1N&[;D9],T
M +12 @G (S2T %%%% !1110 4444 %%%% !1110 5#_R_?\ ;/\ K4U0_P#+
M]_VS_K0!-1110 4444 %0K_Q^O\ [@_F:FJ%?^/U_P#<'\S0!-1110 4444
M%0Q_\?<WT7^M35#'_P ?<WT7^M $U%%% !1110 5#%_Q\3_4?RJ:H8O^/B?Z
MC^5 $U%%% !1110 5#'_ ,?<WT6IB0 23@#J:P['Q3H=]K<UC::I;RW/ $:M
M]XCJ >A_"J49/5(ERC%I-[FY1114E!1110 5#;]9O^NA_I4U0V_6;_KH?Z4
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MC:K-@':3GD=<C/24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% ')073^&-<U9M1TV^N(M0N/M$-[9VCW.X;%
M'ENL8+*5QP2,$'@YR*R5\/ZCJ.K6CW,6H:?8:CJ5Q=SVUO.T;)'Y"JJRLAX+
M,F[ /4]<YKH]*\76NHZ_?Z1+#):W%M.\4)D^[=! I8H?4;AD=1UZ5';^.-*&
ME65UJ<OV6:[1G6WC5YF50Q7<0JDA>.I % '/36>HVVZTU"'6)?#]KJ,R%;5Y
MGG:,HAB.5/FO&&9Q\I)X7/ -37<3G3]/\NT\1#P\L\OVF',OVH\+Y38!\_R@
M=V5X?.TD;<UVEOJEC=3>5;74<K^0EP-AR#&Q(5P>A!VG\JS8_&WAR6\-K'J]
MN9EA-PZ\XCC"[M['&%7'<X% ''MI^OR6Z/H$-_&B&[_LHZCN\V',.%WE\LH+
MYV[^?7C%3V\5VLWF>%8];L[A;.;[9)K1E$7F>6=F?-)4L),',>5QGMBNRTGQ
M+I.MS20Z;=^9+&H=HWC:-MIZ, P!*^XXJF_B2)_&\OAF>TS&;-9O/9@59F+#
MRRN/[J,<]^10!Q+1PO>^'[:Q/B6"\N;M8[^2YGF191Y;%N6;8_(SF+(XSTKI
M?"<NJ:GJ;MJ3RK%HBOIX(<[;N;(W2GGY@%" 9Y#%_:J>D7OA;2_&&N+%I5GI
MB:5;QR#42W$@=Y$D"C'R[7BV\=3QCIGH-+UWP['I-Q+87$-I:6A+SB2-H#'N
M.=S*X!&3GG')H W:*XZ_^(-J)3#HR17<H@,Q2ZD:U*XD1>0Z9 .\X.,9&*V+
MCQ;H=KJ1L;B_59U<1N0CF.-ST5I -JGD<$@\CU% &S17,Q>.--@AQK4\%I<O
M/<1Q6\#M<-(L4A0L JY)'&0!\O/IFKMSXMT.UM;6XDOU>.[0O (4:5I%'5@J
M M@9 )QP3@T ;-%0VEW!?6L=S9S)-!*-R2(<@BIJ "BBB@ KD/\ A$Y[G5=<
MO]QL;YM36ZTV\0AB%^R6\;!@#RC-&P*G&< ^AKKZP8/$ZR>.+OP]);&-8;>.
M6.Z+C$KMN)CQV(50W?(STQ0!R5IX6U*VCLW\2^&XO$,*VAB-C#)$Z6T_FNS2
M*DS*A#JRC=G>NS&,,:MZ3X$^T:O:2>)M,@O+6WTXQ10W#B>.)C,S!"&^\50@
M!B..0#6WIOC.UOO$&J:=,@MX[.:&&"9GS]I,FX @8X&Y& Y.<9JSJGBBUT[4
MK6S7$SO<^3<!2=T ,$DH; !W9$?0>OX4 9.E:)XDM/#<,1O(M\$,D0TNYC1X
MI5#L$5I!E@"FT=\>G45D_P#"*ZEJ6F#3YM*N+71UU.SFBTZ\NHY'B17+3897
M8>5]W:FXGAN "!6KI/Q%L]0L;;4KI;>QTU[>66>>>9D,)658Q\K*,J=PRW '
M2K\OCC29--OY],F^TSV<'GFWD1X6=<XW#<H)7/< CD>HH YR]^'ZI8^*O[-T
M:VCGSOT )L46S^0AW0C.(6,VXDC:2<$\8J/Q%X5NKNW\003>%!K.HWWG&RU4
MW$2^2K)A$+NPDBV],(I!]>3CL9?%VB6]ZMG<WRQW'RB0!&9(F8 A7<#:IY'#
M$=1ZTGBG7I/#^GP3PPPN9KA8#+=3&*"#()W2.%;:N0%SCJPH Y[1?#6JVGBB
MVO+BV"P1W3R,WF*<*;*&(' .?OHP_#/2MBZCU/1?$EWJ-CI<FK6FH)&)8[>6
M-)X9$!&0)&560C'\0(.>#GBW<>)+72[&U?7\65W.O-M$&G;(Z[0@)*CUQW&<
M5$?%VG"]'[^$:?\ 86O#>F3"J X3:1CKD_7/&* ,+Q5I'B#Q+HUE)/9"*.*[
M:6;2D,4S2Q;2$WB0B)V#88J6V]P25&<F#P;K8T*6&.TEC5S<^3:2&",0![9D
M "1$H@9ST5B._&379_\ ";>'5TV>_FU-+>VMV19FN$>(QEVVH2K@$ DX!QC\
MJ2?QOX=MC$)]1$?F(LF3#)B-6/#2';^[!_V\<<T 5]>LM072=#>ST^6^EL;J
M&66W@DC5]JJ0<%V53C/K56=]9BURZUBW\.7LRZEIL5H;;S[=9;:2*28@OF7:
M583=59B-O3FM/5O%EC8K?6]G-!<:C:P&46\LAC1CMW;3)M(!P0<<D YQBK>G
M>(=.U*]DLK>Y1KR%<RQ*#@$8W ,1AL$@''3OB@#DM/\ A]#(]TVOZ9;7SKI\
M$%N9L2(KJAW% ?NG<<;L X K'\N"S>/_ (333+;6]133;57>XO8 UA(L0\S)
MD<% 7RWF1;F/7J!GUBJUUIMC>RQRWEE;W$D7^K>6)6*=^"1Q0!Q_A[0;K4/@
MGI&DL1;W3:= 5$H)"N K@,#SC( />MFVU;Q#=S6]N_AQ[!MRFZN;BYB>$*#\
MPBV,78GMN5!W/3:>@HH \JU/P??3:'<V+^$UOM;>8O\ VZ;F%?,7S=P.\MYN
M=O&PKMXQG%:DG@=XM/N[^UTN$Z\VL"YANF93*D1N%+;7)^4&+=\H(ZGC)KT&
MB@#@K;0);?47^W^$EU+4C>-*NN&>)1L+DJ=^[SD*K@;%4KQ@'!S6--X(UT^(
M9Y7BGEO);TS)K$<5H"B%\C]ZQ\Y<+\NP(5_AY4YKU:B@#E_ WAB/P]IUU+-8
MQV^H7EU/+<29#.ZF5R@W9/ 4C"]!D^]=1110 4444 %%%% !1110 4444 %%
M%% !6?>V]U<7B"TO3:$(=Q$2ONY]ZT*A_P"7[_MG_6FG9W$U=6*']G:M_P!!
MQ_\ P%CH_L[5O^@X_P#X"QUJT57._P"DB/9KS^]F5_9VK?\ 0<?_ ,!8Z/[.
MU;_H./\ ^ L=:M%'._Z2#V:\_O9E?V=JW_0<?_P%CJ)=/U7[4X_MM\[!S]EC
MK:J%?^/U_P#<'\S1SO\ I(/9KS^]E#^SM6_Z#C_^ L=']G:M_P!!Q_\ P%CK
M5HHYW_20>S7G][,K^SM6_P"@X_\ X"QT?V=JW_0<?_P%CK5HHYW_ $D'LUY_
M>S*_L[5O^@X__@+'42:?JOVF4#7'R N3]EC]ZVJAC_X^YOHO]:.=_P!)![->
M?WLH?V=JW_0<?_P%CH_L[5O^@X__ ("QUJT4<[_I(/9KS^]F5_9VK?\ 0<?_
M ,!8Z/[.U;_H./\ ^ L=:M%'._Z2#V:\_O9E?V=JW_0<?_P%CJ*/3]5,\H&N
M/D$9/V6/TK7EE2"%Y9F"1QJ6=B>% Y)KBM&^)^A:KXB;3HA/$9W"PS2* DA]
M.N1GWK2*J33<5>WDC.<J5-I2E:_FSH_[.U;_ *#C_P#@+'1_9VK?]!Q__ 6.
MM6BL^=_TD:>S7G][,K^SM6_Z#C_^ L=']G:M_P!!Q_\ P%CK5HHYW_20>S7G
M][.<UG1M;N]#O;>VUMFEDA944P(N21TR.17AFA>&==G\3V]G;V5Q;W4,REG9
M"ODX/WB:^EJAC/\ I4WT6NJAC)48N*2U.3$8&%>49-M6)J***XCO"BBB@ J&
MWZS?]=#_ $J:H;?K-_UT/]* )J*** "BBB@ J"^LXM0T^>SN03%<1M&^TX."
M,<'UJ>J6M7LFFZ!J%]"JM):VTDR*_0E5) /MQ0!C3:+X@O;+^R[[4K,V#+Y<
ML\4#+<2)Z==H)Z$X^@H30]:TVZN(=$O+"/3[J8S,+F!GEB+?>"X(##TSTZ=!
M4^I>)&TR]@\^'?;'39[V;RU)<&-H@ O..?,/Y"D@\70&":34-/O-/:.!;A(I
M@C/,C':NT(QY)P-IP<D4 9E]X$DGTF&*WNE2[M[Z:\C99)85;S"V06B97!P>
MH/;IS447@&X^PHDE[&L[//)*=\TP)DB$8^:5V8X !Y-27_BK4%U,6]S97^CQ
M?8VF;<D,CD^8B@JP9E_B((/KGTK27QC:%[Y39W6ZTE\A5 5FFDW%0H4-E22,
MC<%R/FZ<T 9K>%=<O)-734[S3VCU"/RXYHHW\R!%'[M "<;0<L?4L?8"POA?
M4K^[-_KES9->&:T;;;0L(PD$AD ^8D[BS-SVXJQ>>(+Y;:$OIMSI<OVVVB<7
M/EN'CDD"MAD9ESC/?(X/<5+;>*TGN(/,TV]@L[IREM>N$\N5L$@8#%ES@XW
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MFSG-06_P^NY(;J6^OD2]9H&MI!/<W01H9!*N[SY&R-P&0,<=\FN]HH XJ_\
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MLYK6Y3S(9XVCD0G&Y2,$?D:EHH P8O"5N(YEO+^^O6DMS:H]Q(F88B02J[5
MY*KDMD_*.:LWGAVQOIFDN1(VZU^RD!]N%W!@01R&! ((/%:M% '-_P#"%P37
M#3ZCJVIZA,T/D!YY(QM3<K<*B*N<J.<9J5_"%G+<7<]Q=WLTEP,(S2@-;X;<
M"C  Y!Z%BV!QTXK?HH QD\-HT.V_U/4-0<3Q3![B1!CRVW*H5%5 ,]3MR<\G
M@89;>%;>WN8F-]?36T#,]O9R2KY4#'C*D*&.,G&YB!GCH,;E% '-KX*LQ X:
M^O7N3*)5NW,;2(0NW&"FPC'!W*2>I).#5@>%;=;&&*.]O4N893-'>JR"57(P
M<#;L (XV[=OMGFMRB@#+T708M%>]D2ZNKN:^F$\\UTX9F<(J<8  &%'   [8
M'%:E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %9][IMEJ-XBW]K#<A(R5$J!L<]LUH5
M#_R_?]L_ZTTVG=":35F4/^$8T+_H$6?_ 'Y6C_A&-"_Z!%G_ -^5K5HJO:3[
MD^SAV1E?\(QH7_0(L_\ ORM'_",:'_T";/\ [\K6K11[2?</9P[(RCX7T(@C
M^R;/G_IB*\ZG^"R2:\_V?5!'8%M_EF/,B@G[H/3\:]:J%?\ C]?_ '!_,UK3
MQ-6G?E9C5PM&K;FCL+:6T5E9PVMNNV*"-8T&<X51@?H*EHHKGW.E::!1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "H?^7[_MG_6IJA_Y?O\ MG_6@":BBB@ HHHH *A7_C]?
M_<'\S4U0K_Q^O_N#^9H FHHHH **** "H8_^/N;Z+_6IJAC_ ./N;Z+_ %H
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MZKM'[P,$&3Z?<_6L^/PC<V,L<^D:M]FN DD4C2VPD61&D+@8W#!!8X.>YXH
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M"Y1 ]G;/*%B:"*0.Y&1U=^G9:?-X4N0;V"PU=K6QU!BUU ;<.V2H5BCD_+D
M=0V#R,4U?"M_97E^^C:XUG;WSHSP/:K)Y6V&.(;&R"#B/J=PZ<<<@&O;:Y87
MGVC[+/YJV\23.Z@E2C*64@]^!7/Q>,WGU@>6]LNF<2;GCD\V2(VPF!&. >>^
M...M67\'R6H,>A:HUA!):I:SQO )BRKD!E)(VMAB,\CIQQ33X%M5F8P74D<?
ME^6D>P':HM_('/?@9H O:5XLTW6+B&*U%R@N(S+;R3V[1I.HZE"PYX.?I4MQ
MXDL+75)K"3SS)!%YLSI"S)&""0"P& 2%)Q2?\(^GVK1)OM#?\2F-D4;1^\W1
M[.?3UJMJ'A?^TO$4>HSW8$*(4,2P*)""I4IYHYV'.=I!Y[]J +&H>(K:UTJ*
MZA;<]U;O-:AD.'VQF3GTX%5=)\96.H1V"SI<6[WL:F*66W>.&5RNXJC$8/?'
MKBH(?!]P8HH+_5VN8+2VDM[15MPC('79N<Y.XA>!@*.3QZ/M?"=UY-C::MK#
M7]C8;3%#]F6-G95VJ9&!^;'H O.,YH N6?BJPO[J*.VCO&BF;;#=?9G\B4_[
M+XP0<'!Z&IX_$.GS:;I]_'([0:CM^S$1G+[E+#CMP.]4]+T#4=+^R6L>N.VF
M68"16_V9?,**,*CR$G( XR%!.!SU)AT_PE-92V$,NJ-/INFR%[2U\@*R\$*&
M?/S!0W' Z#.>X!!HOCF&]T&WO-0MKB.ZN9I8XK6*V<R2A&Y*IR2 ,9/058_X
M3S1<%3]L\X3BV^S_ &23S?-*[MFW&<XY]*2+PB]E;V3:;J307MD9Q'.\(=62
M5@SHR9&1E5((((*CMD%+#PC+;:O_ &G>ZK)>7+7/VAB851<^7Y>T '@8Y[GW
MH M?\)=IGV)9\7/FM,;<6@MV\_S -Q7R\9SM(;Z$'O3F\5Z8MB+AC.)&F\@6
MI@;SS)C=L\O&<[>?ISTK-U3P%9ZG=75U+)%)/+>_:XA<VRS1QDPI$5*$_,"$
MSG(()HM/ T=A:1-8W,%IJ$-T;F.XMK&.*,$IY94QC[R[21RQ.3D$<8 -2U\4
M:;=&% TT4TMS]E\B:%DD238S@,I'&54G/2DOO%6FV%R]O+]HDG241&*&!G;.
MW=D #D!>2:IOX2FFC:YFU1FU8W,=RMVL "(R*4"B//W=K,",Y^8\U!>>"Y[[
M3KB*XU5'N;N;S;B9K-2N=NU3&I.49>JL&)!)//  !U:,'167D,,BEID4?E0I
M'N9]BA=SG)..Y/K3Z "BBB@ HHHH X:Y^(DEOK5W:FUTUHK6_6R,(U/_ $V3
M<47>L'E\CY\_?Z GVK9B\9:;'8-<ZI*ME_I<]M''DR-)Y4C(6  SVSTXSUJQ
MHV@IIMUJ-Q,(99;N^>Y1Q'\R!@HVY_#]:QH?">J:5J/]J:1<V<MX6N4:*Z1A
M&8Y9S*,,O(8< ]0?:@#57QGX=>.%X]7MG6:4PH5;(WC&X''3&Y<DXQD TC>-
M?#B7SVC:O;K-&[1N"2%5U!+*6Q@,,'C.:YS_ (0;7 AD34+".\EOY;MKF".2
M)H!)LR% .''R8*/E6X)Y%:K^#7;1TLA-!D:VNJ,?+X8"X$I7'][ QF@#37Q9
MH;Z2^I#48A:I)Y3.P*D/_=VD;L^V,U-I/B+2=<DECTJ^CN9( K2QKD-&&SC<
MIY&<'K6+J'A.^DU^XUG3[JW6Y^TQ3V\4\9*';$8V5L<@G.0PY'XTRS\(7MYK
M>HZGXCNU5KV*!%BTJXGM3'Y>_K(C*SYW]_R[T 3_ /"0^(+BXU%M,T*SNK6Q
MN7@(_M%DGEV@$[4,6S)SP"X'N*LCQOH(TZRO)[T0K>Q^9%&R,9, X.54$C!X
M)Z9JC#H_B?39M0ATBXTM;:[N6FCFN/->6+< .1T8C'<\]ZS;KX=36MQ;SZ)=
MLSK:);2B2_NK7=M9FWY@<9R7/!''8T ;6N>.-*TN%XK.[L[S4F@\^WM#<A!*
MF,AM^"%7&?F/%:YUK3A827C7<8@BE,,CY^[(&V%?KNXKE+7X>-::;J=M%<0!
M[VQCM5?#L4(9F8Y=F8@EL\DUKR^%?-\61ZG]IQ996>6SV\27*C:DN?9>WJJ>
ME %R'Q3HD^JG3H=1B>Z#F/:,[2XZJ&QM+=L YR#6?K/CS1=*@NQ'=Q7%U;\>
M2&*JS9 V;\%=W/3K[5@Z;\-KG3I[.S%UYNF6DZRJTFHWA=@K;@/)$@B!SW Q
MWQVJU<^#M=/AZ3PW:7FFC2]Y:.>6!C,%W[]I4?+G/&[\<9H [JBBB@ HHHH
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MFQGV,!MC(897(.&^<\G(Z<4NL>&=.UV=9-26255@DMS&&PK*^,^^05!!!&*
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M3_4?RJ:H8O\ CXG^H_E0!-1110 4444 %0Q_\?<WT6IJAC_X^YOHM $U%%%
M!1110 5#;]9O^NA_I4U0V_6;_KH?Z4 34444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J+/^FX_Z9^GO
M4M0_\OW_ &S_ *T 34444 %%%% !4*_\?K_[@_F:FJ%?^/U_]P?S- $U%%%
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M2[I;FQTV&*9!M1\$E1[9Z?A3;GPCH%Y=27%UI-K++*<N63(8^I'3/OUK8HH
MHRZ+ILUC)92V4+6TKF1XRO!<G);ZYYS5>W\+:':PS10:7;HLZA9?DR9 #D!B
M>3@UK44 9E[X<T?4;Q+N^TZ":= %#LO4 Y /J!GO5B32K":"XAEM(FCN7\R9
M2O$C<<GU/ _*K=% %.ZTG3[[S_MEG#-]HC$4N]<[U!R ?H>:AM/#VDV,"16M
MA#&B3"=0%SB0# ;)[@5I44 4Y-)L)8;R*2TB:.^;?<J5XF.T+EO7Y54?@*JW
MOA;0]2NGN;[2[>>608<NF0_&.1T/XUK44 8UQX1T"ZG\Z?2;9I" "VS&X
M''48 &#6PJJBA4 55&  , "EHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH P=1U?P[H$DMG>21Q2WI::6"*)I&?(
MP794!(!QC)ZXIH\.>%M>M+.[CL;.\MXX5CMY(^5\M> O!P0,8P>G(JC;W?\
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M2&?3R\DLUP\Q$JRH#L:0D*Y1GPHP"0..*CTR:-/'>EP:3+KRVCVMP]Q'J+W
M1F&P [9_F)&>H^7GUH ZNW_L6TU>73[6.S@OYH?M$D,<:J\D>XC<<#D9R/QH
MM_[%%Y+I%M':":"+?):I&HV(^1R,8PV#]<5SVJ6%VGBW4-?M[6>273X+=852
M,DW$8\QI8T_O$B3H/XE7TJ@NBZPVL/JMO'/!?7VG_:&Y**LJ2AXX7/0#9\A'
M^\: .^M[>&T@6&UACAB3[L<:A57OP!3;B[@M6A%Q*L9FD$4>?XF/0?I7G]_=
M:]K>@PZ]IYNXK+4)T9K=#+OCM IVD+%\X+,=Q*?-M*CL:6Q@UN>TM_DN9HHM
M3C>U\^&?,8\MMQ)F_>%-V.7'!S@D8H ]%HK@-*%\;G3#!_;_ /;&_P#XFGVW
MSOLVW!\S&[]UUQL\KGIVW4S3]"U06_A]KB]UPRWA<:F7NYON[25!&<18( RN
MT^_- 'H5%<%+%J4"QV^HG66T:"]N(W:V:9K@ID&'+)^]9.6&5)/ R2,UI>"A
M="ZUSS/[6^Q?:T^P_P!J;]_E>2GW=_S;=V[[WS9SNYS0!U=%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5#_ ,OW_;/^M350O+"&_O$6=IU"H2/)
MN)(N_?8PS^--6ZB=[:%^BLO_ (1ZR_YZZA_X,KC_ .+H_P"$>LO^>NH?^#*X
M_P#BZJT._P"'_!)O/LOO_P" :E%9?_"/67_/74/_  97'_Q='_"/67_/74/_
M  97'_Q=%H=_P_X(7GV7W_\  -2H5_X_7_W!_,U1_P"$>LO^>NH?^#*X_P#B
MZB7P_9?:W'FZA]P?\Q*X_P#BZ+0[_A_P0O/LOO\ ^ ;-%9?_  CUE_SUU#_P
M97'_ ,71_P (]9?\]=0_\&5Q_P#%T6AW_#_@A>?9??\ \ U**R_^$>LO^>NH
M?^#*X_\ BZ/^$>LO^>NH?^#*X_\ BZ+0[_A_P0O/LOO_ . :E0Q_\?<WT7^M
M4?\ A'K+_GKJ'_@RN/\ XNHD\/V1NI1YNH<!?^8E<>_^W1:'?\/^"%Y]E]__
M  #9HK+_ .$>LO\ GKJ'_@RN/_BZ/^$>LO\ GKJ'_@RN/_BZ+0[_ (?\$+S[
M+[_^ :E%9?\ PCUE_P ]=0_\&5Q_\71_PCUE_P ]=0_\&5Q_\71:'?\ #_@A
M>?9??_P#2EE2&%Y96"1HI9F)P !U->?V/Q0\+3>(WB6&2(S.$6\:%0K'IR>H
M'N:ZF[\+:?=V<UM)+?[9HVC;.H3MP1CH7P?H:\NM/@QJ1UKR[J^M_L$;C=(A
M.]U]-N.#^-=>'AAVI>TE8XL3/%1<?913/:J*11M4 = ,4M<)Z 4444 %0Q_\
M?<WT6IJAC_X^YOHM $U%%% !1110 5#;]9O^NA_I4U0V_6;_ *Z'^E $U%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MV2-)HGBF19(W4JR,,A@>H([BG44 8^G^$]#TJ_%[8V"1W"J51R[-Y8/4(&)"
M^G&..*T;.RMM/M_(LX5BCW,VU>Y)R3]234]% !1110 4444 %%%% !1110 5
MBP^)(Y?&5UH#V[(8+>.5+@N-LC-N)3'8@#/?(STQ6U7,ZAX9O)Y-5N[*[A@O
M[BYCGLYF0D0[(E3#>N?GZ=F% $VG^+K2]UO4["11;I9310QS/)Q<-)D# QQ\
MRE1USBK6I^(;;3KRUMAMEDENE@E4/@PAHW<,1CGA#Q[UBW7@J=9C-IES%&\=
MM:+"LJDJTMO*[@MCG#;\''(J6/PUJ5SJL>J:C/:I<_;XKAXH-Q01QQ/&%!(!
M))?).* $TCQ[:ZK#!=".&&R8W7G3R7('E"&0J#M(!8,!NS_#G!K23Q;HUS#<
M'3[Z&ZEA@>81*V/,51GY21R/<9ZUS6J^$+VU\+3HLJW$D4-_\D<98N9Y6=<#
MO@-@CO6E)H&LZHMJFIRV$,5G#((3;(VZ1FB,8W _<4!B2H)[#/'(!HIXNTA+
M>S:_O(;6>Z@CF\EFR4#C(R<<#W..E6M?U?\ L3P[>:HD'VHV\1D2(/M\T]EW
M<XR2.:Y-_ -];M)]BN5D^U0Q)/OO[J *R1B,X6)@'!"YP<'MFNCO_#_VCPK;
MZ+;R*B1&W4LVX@I'(C,.23RJD#)/7J: *?B/Q+I\/@C^TY[$7\%RJ@6<A +9
M(W!NN"O)/H5JQI=OX;TBWGU&P\F)0WD33M(SLI#8V;F)(^;MZU2OO!\]Y)J\
M?VJ,6=U;S+9P[#^XEE7$CGU&>1_O-[4R'0[B3QDJLS_V?!%#=7*E"%ENU4HA
M4GJ H#''0HGJ10!N1^(]'EU0Z='J$+708IY8/\0ZKGIGVZUGGQ/H][X?WZV\
M=K%=O/;F!G+%U21HVZ#.#MS[9K&LO %S9S6UKYXDT^WN1.'?4+O<0'W@>2'$
M8.>_3OCM5VQ\,:MHMQ'>:9-8SW&V:*6.Y#*NUYWE4JP!((WX(Q@T :UQXH\/
MZ;;6QEU*UBBGA,EN%;(>-< E0.H&1]*FM?$>CWM]]CM-1@FG*[PB-G< ,G!Z
M'&><=*S-&\*/IFKVE]--#*T5O<JX6/;B2:993L'\*C!&.O2J]KX+DB\-Z%I4
MEQ&/[.:0S/$I&_?%+&2OOF3//H: -:+Q;H,UXMK'JMNTSR")%W??8G&%/1CG
MTK8KCO\ A&M<EAT:QN)M,6STFYAE22.-O,F6/@#!X0D>A/X"NQH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S[W4K33KQ&O9A$'0A<@
MG//M6A4/_+]_VS_K35KZB=[:&?\ \)/H_P#S^K_WPW^%'_"3Z/\ \_J_]\-_
MA6M157AV?W_\ BT^Z^[_ ()D_P#"3Z/_ ,_J_P#?#?X4?\)/H_\ S^K_ -\-
M_A6M11>'9_?_ , +3[K[O^"9/_"3Z/\ \_J_]\-_A42^)M(^UNWVU<;!_ W^
M%;=0J?\ 3'_W!_,T7AV_'_@!:?=?=_P3/_X2?1_^?U?^^&_PH_X2?1_^?U?^
M^&_PK6HHO#L_O_X 6GW7W?\ !,G_ (2?1_\ G]7_ +X;_"C_ (2?1_\ G]7_
M +X;_"M:BB\.S^__ ( 6GW7W?\$R?^$GT?\ Y_5_[X;_  J)/$VCBYE/VU<$
M+_ WO[5MU#&?]*F^B_UHO#L_O_X 6GW7W?\ !,__ (2?1_\ G]7_ +X;_"C_
M (2?1_\ G]7_ +X;_"M:BB\.S^__ ( 6GW7W?\$R?^$GT?\ Y_5_[X;_  H_
MX2?1_P#G]7_OAO\ "M:BB\.S^_\ X 6GW7W?\$P=0\6Z=;Z9<S6DXGN(X7>*
M((WSL 2%Z=SQ7DWA;XA>)KGQE:)-<M=QWDZQR6^P8"DX)&.F!S^%>[UF6>CZ
M;;:K<W=O86T5PQ&Z5(E#'(YYKHI5J4(R3A>YS5J%:I.,E.UOZ[FG1117(=H4
M444 %0Q_\?<WT6IJAC_X^YOHM $U%%% !1110 5#;]9O^NA_I4U0V_6;_KH?
MZ4 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7,P^(+L?$"\TN<1_V:L<4
M<+A?F6X*LY!/H5 _$8[UTU8M_P"%K/4+?4XI9KF-M1F29Y8W >)E14&PXXX3
M/.>6/X &1IGC*677]1BOD/V-IK5+ 1IR5F9D#,2>060GV%7]6\1O;ZS::?9(
MQD%]%#<!E'SH\,K@*<]<H.3BI+WPAI]XSN)+BWD^SP01O"P!B\EV>-UR#\P9
MCUR#T(H@\)V\=Q'=75]>7EVMVMTUQ,4#.RHR*I"J%"@.>@!]Z .?TKQM?/8P
M:CK"2V\,8OVFMQ;HS2K#*54JRR'!4#!&.2#VP3M2^+#]E;S-,O\ 3GGMY)+.
M6[C39*RH6QA78J<#.'"G@]ZKZGX*A_X1V>UTYYGG$5TL0DD !,[EVR0!T+''
MI[U;C\)))Y1U+5-0OEAB9((IWCVP%D*%@50%FVD@%RW7UH I0>/K..U@2:&:
MZGCMHI+QX&B5869 V,.ZEC@YP@8\COQ6CXBUI[?P3<ZMHLT;R/;J]I*R[E8O
M@(<=QEA5*?X?Z:[*;>XGMB8TCE*Q0.9=JA0Q,D;%3@ 97;Z]:V[S1K:]TF+3
MG,B6\;PN C<GRW5U!)SD$J ?49H YW7_ !9>VO@I;W3XT34R&$D;+N6)HC^^
MX[@8;'KP:UQXGM!9RRM%/YL5TMH8 J[WD;&W:,XPP8,#D<'G'2FW'A+3[F[U
M6XD>?.J6S6\J!QM0,NUF08X8@+D\_='O4$/AL#QDFIR*1;VMFD40+Y\Z4!E\
MP@="J,5![[SZ"@".W\?:3<W2(BS"UDF\B.]9XO+=RVT#;O\ , +<!B@'O4>E
M>+99[**-[*YU+47DN&:&S5%V1).\:L2[*H^Z!UR<'BI+;P'IMIJ$<]O-,D$4
MOFI:B*':#G.-^SS,9YQOQVZ<5*G@^"V,<FF:E?6%PGF SPF-C(KR-(5971E(
M#,<'&1ZT -;QM:O+:0Z?IFI7]Q=0RRB"")%:/RG"2*_F.H5@QQ@GG!QFEL_&
MVGWGV:;[->06-VK&WOID58I"JEF7&[>" K<E0#M."<C-S3O#5EIEY!=6[S&2
M&"6$F1]WF&202.['&2Q9<YZ<GBHH?"6GPZ3I>G%II+?3"QC#L"9,QO&0W'(Q
M(>F.U $"^,X2UBTFD:I%:ZA,D-K=/%'LD+_=) <L@/7YE%='7-IX,C#6*2ZS
MJ<MKI\R36MJ[Q[$*?=!(0,X'3YF-=)0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5GWNI6>G7B-?7,< ="%+G&>:T*A_Y?O^V?\ 6FK7
MU$[VT*'_  E&B?\ 03MO^^Z/^$HT3_H)VW_?=:M%5>'9_?\ \ FT^Z^[_@F5
M_P )1HG_ $$[;_ONC_A*-$_Z"=M_WW6K11>'9_?_ , +3[K[O^"97_"4:)_T
M$[;_ +[J%?$VB_:W/]IV^-@_CK;J%3_IC_[@_F:+P[?C_P  +3[K[O\ @E#_
M (2C1/\ H)VW_?='_"4:)_T$[;_ONM6BB\.S^_\ X 6GW7W?\$RO^$HT3_H)
MVW_?='_"4:)_T$[;_ONM6BB\.S^__@!:?=?=_P $QYO%FB0V\DO]HP/Y:%MJ
MOR<#.!7DZ_&76%UIK@VMM]B9@#!M.[;_ +WK7M[*&4JP!!&"".M</'\*O#7]
MO27?DS[%82"V\S]WD\],9Q[9KJP]3#QO[2-SBQ-/%3Y?92M^'^9VMO,MS:Q3
MID+*@<9]",U)2 !5 4  #  [4M<1Z 4444 %0Q?\?$_U'\JFJ&+_ (^)_J/Y
M4 34444 %%%% !4,?_'W-]%J:H8_^/N;Z+0!-1110 4444 %0V_6;_KH?Z5-
M4-OUF_ZZ'^E $U%%% !1110 4444 %%0)>VTE]+91SQM<PHLDD(;YD5LA21[
M[3^53T %%5I=0M(-0M[&:XC2ZN59H8B?F<+C<0/;(_.K- !114=Q<16MM)<7
M$BQPQ*7=V/"J!DDT 244V.1)HDDB8,CJ&5AT(/0TZ@ HHH)"J2> .30 45%:
MW,-[:175I(LL$R!XY%.0RD9!%2T %%%% !1110 4444 %%%% !1110 4444
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M;JZT]4#1O"KM;AAE>H^7(&15V^FM+>T,VH-&L",I+2CY0=PVGZYQCWH \_\
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M^T6MPJ*RW$6]7"CH0P[#J#F@#S=W)N] M[*^\51WES=K%J)NI+A$;*,6^_A
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M:L75R5&[KCFEHHKA/0"BBB@ J&/_ (^YOHM35#'_ ,?<WT6@":BBB@ HHHH
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MZ\3176JV=O<6<>I7=V%D(88D2-4.WN<JW';BF6O@V[C\26EQ):6HL[35+J>
M#:?)BDA4+M&./W@8X'UKO** /+=$\":WI]]IUO,]XWV2<22Z@);-5EP22V1!
MYQ+9Y#-SDY8]:VM%T*^T][2RNO#-C<2P3B236&G7+_-N\SH9-_L>,]\5W%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME+B>X1(YMZ[AL)//% &W10"" 0<@]"** "BBB@ HHHH **** "BBB@ HHHH
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M&@#=HJO%?6T][<6D4H:>V"F5 #\F[.WGIS@U8H **** "BBB@ HHHH ****
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MF_Z#>I_]]Q__ !%']B3?]!O4_P#ON/\ ^(J7^W]'_P"@M8_^!*?XT?V_H_\
MT%K'_P "4_QH_>=OP"U/O^)%_8DW_0;U/_ON/_XBH6T6;[;&/[:U+_5OSOC]
M5_V*M_V_H_\ T%K'_P "4_QJ%M>TC[;$?[5L<"-P3]I3U7WH_>=OP"U/O^(O
M]B3?]!O4_P#ON/\ ^(H_L2;_ *#>I_\ ?<?_ ,14O]OZ/_T%K'_P)3_&C^W]
M'_Z"UC_X$I_C1^\[?@%J??\ $B_L2;_H-ZG_ -]Q_P#Q%']B3?\ 0;U/_ON/
M_P"(J7^W]'_Z"UC_ .!*?XT?V_H__06L?_ E/\:/WG;\ M3[_B1?V)-_T&]3
M_P"^X_\ XBH1HTOVQA_;6I9V#G?'Z_[E6_[?T?\ Z"UC_P"!*?XU"->TC[8S
M?VK8XV 9^TIZ_6B]3M^ 6I]_Q%_L2;_H-ZG_ -]Q_P#Q%']B3?\ 0;U/_ON/
M_P"(J7^W]'_Z"UC_ .!*?XT?V_H__06L?_ E/\:/WG;\ M3[_B1?V)-_T&]3
M_P"^X_\ XBC^Q)O^@WJ?_?<?_P 14O\ ;^C_ /06L?\ P)3_ !H_M_1_^@M8
M_P#@2G^-'[SM^ 6I]_Q(O[%F_P"@WJ7_ 'W'_P#$5XAXB\ ^)4\3W,:6-SJ
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M6D5S$,2#.)W5G[>JC'I7144 9$GAJQEM)K=FFV37HO6PPSY@8-Z=,J.*2_\
M#%CJ%S<W,KSQW$YB998I-K0M%NV,G'!^8YSD'H1BMBB@#F)O EC>/<RZCJ&I
MWD]RD,<DTDX5@(I?,3;L50OS?W0,_7FI9?""3V]P+K5;^[N)H#;"YN60M%"Q
M&]4"*H!8#&[&[ISP*Z*B@"D=*MCJ-K>*&1[6)HHD7A0IQQC\!5.Q\+Z?87[W
M<7FN\GVG<LC J1/*)7&,?WAQ[>M;-% &%%X/TN#01I5OY\4:S&>.=93YT<N<
MAPQ[C. #D8X((XHC\)VOF>==W=Y>W7G1RFYG==Y\LY5,*H4*"3P ,YYK=HH
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MC ++_$5YP>V35!O >GQI'_9UW>:?(J&-I8/*8R)N9@I$B,."S8( //6NGHH
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M\(_^^!4M%%V%D1?9;?\ YX1_]\"C[+;_ //"/_O@5+11=A9$7V6W_P">$?\
MWP*\PUKX.QWWB*6>PU(6UM.QE>)HMQ3)Y"G/\Z]4J$_\?P_ZY_UK6E7J4G>#
M,:V'I5E::N0:1I<&BZ/;:=9Y\FW0(I8\GU/XGFKM%%9-MN[-DDE9!1112&%0
M#_C_ &_ZYC^=3U"/^/\ ;_KF/YT 34444 %%%% !4$/_ !^7'U7^53U!"?\
M3+CZK_*@">BBB@ HHHH ***/I0 45X/>67C#^V#]HM_%SZQ_;<;37$$[?V<U
MIYH("*IQC9C( ]<GK5F72_$UAX#2\O+OQ!YMSJS#4;=;QEN?LBO)M6 ,>"<J
M>#DCV% 'M]%?/UA<^)]4\/\ BN+PM<Z\\5O?VJ>3=7)EO$M@A\Q%(;A_NY ;
M=[YK2M=+\82^#IX[6Y\2PQS:K:B&.YC=+FW3=B5@QD=RF"#\W''<4 >WT5XQ
M<Z3XITW^V]&TE_$4\L.K6YT*[FFD=5#1*9&EE.0T0.00V?0#-=Y\.4O(/"BV
M^K1:DFIQ2N+UM19G,DN>61CP8S_#MX ]\T =71110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^+JK0[_A_P $F\^R^_\ X!J45E_\([8_\]-0_P#!E<?_ !='_".V/_/34/\
MP97'_P 71:'?\/\ @A>?9??_ , U*A;_ (_XO^N3_P UJC_PCMC_ ,]-0_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS#/M6U61HNFW%KJ.L7UX%62_N]Z*C;@L:(L:<^I"[B.Q;%:] !1110 4444
M%%%% !5#4;M;*XMY&AGF!W#$$1<CIV%7Z@E_X_8/]U_Z4UYB=[:%'^WX_P#H
M'ZG_ . 3_P"%']OQ_P#0/U/_ , G_P *U:*J\>Q%I]_P,K^WX_\ H'ZG_P"
M3_X4?V_'_P! _4__  "?_"M6BB\>P6GW_ RO[?C_ .@?J?\ X!/_ (5"VO1_
M;8S_ &?J7$;C_CS?U7VK;J%O^/Z+_KF_\UHO'L%I]_P*']OQ_P#0/U/_ , G
M_P */[?C_P"@?J?_ (!/_A6K11>/8+3[_@97]OQ_] _4_P#P"?\ PH_M^/\
MZ!^I_P#@$_\ A6K11>/8+3[_ (&5_;\?_0/U/_P"?_"H1KT?VQF_L_4ON ?\
M>;^OTK;J!?\ C^?_ *YC^=%X]@M/N4?[?C_Z!^I_^ 3_ .%']OQ_] _4_P#P
M"?\ PK5HHO'L%I]_P,K^WX_^@?J?_@$_^%']OQ_] _4__ )_\*U:*+Q[!:??
M\#*_M^/_ *!^I_\ @$_^%>*^(/B-XD?Q-<26UW+8QP2E([?8!@ ]&!ZGZU[_
M %SVH^#?#VJ:X+R_TJ&:?9N9CD;CGJ0#@_B*Z</6HTY-SC<Y,50KU8I4YV_
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M!/W05;(P<_-@9D?B/6M>>"YO(;:WTZWU6UAB%O-*DTLA*L2Q! "#<04.=W?
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M_P /\BC_ &M??]"_J'_?VW_^.T?VM??]"_J'_?VW_P#CM:E%',NWY_YARO\
MF?X?Y&7_ &M??]"_J'_?VW_^.T?VM??]"_J'_?VW_P#CM:E%',NWY_YARO\
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M5\FF:5=W\RL\=K"\S*G4A5)('OQ0!RVG:NMIH-MH,WA>^^V01);-8K9L;8X
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M=-LFO=:T_4!!!(6"I"T1DW':,N0C=!@ULOX_LX;1[NXTS48;5K5KNVE:-/\
M2HUP3M4-N!PP.&"D]J6Y\8RI:2"YT?4-*EGMY7LI;M8V69UC9]N$=BK;5+;6
M ) /H: *<W@J;^Q=8CMX+1=0O=66^CF/7"RQLI+8R" AQZ4:9I4D_CB]M59'
MT72[C[9%&!]V[E&YD],+DR>N9J@N/'D[>$GEEMK[2KJ727O;6]FMXW68I&&<
MK%OSD9!VOMS6IJ'C9-/COY8M'U+4;32U;[9>6J1[%95W,H5G#,0,9V@@9QG@
MX )=<B1O&&AFXSY%Q#=6G']YT5A]/EC>J]E#XLTFP31[6STZXC@410:C).4
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MFG9G2FFKH****0PJ$_\ '\/^N?\ 6IJA/_'\/^N?]: )J*** "BBB@ J$?\
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M(]Q0!=@U_3;JTO+FWG:2.R=H[C;$Y9& !(VXR>".@--TOQ'IFLW4UOI\[O-
MJM+&\$D94-G!PRCK@UGZ0)]-N/$UW/:W#*;TS1*L9+3*(4^X/XN01QWJ]X?T
M^>TLGN-0P=0O'\ZY.<[2>B ^BC _ ^M &K1110 4444 %%%% !1110 4444
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M 4444 ,EBCGCV31K(A(.UUR.#D?K3Z** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "H?L=O]N-[Y*_:3&(C+CYM@
M.=OTR2:FHH **** "H+:RMK-IFMH5C:XD,LI'5W/<_D*GHH @ELK:>[M[J:%
M7GMMWDR$<IN&&Q]14]%% !1110 C ,I4]",&HK2T@L+.*TLXEAMX4"1QH,!5
M'  J:B@ HHHH **** "H)?\ C^@_W7_I4]02_P#']!_NO_2@">BBB@ HHHH
M*IS6EO+JD$LMO$\BQOM=D!8<KT/XU<J%_P#C_B_ZY/\ S6C8+7)J*** "BBB
M@ J%?^/Y_P#<'\ZFJ%?^/Y_]P?SH FHHHH **** "H3_ ,?P_P"N?]:FJ$_\
M?P_ZY_UH FHHHH **** "H1_Q_'_ *YC^=35"/\ C^/_ %S'\Z )J*** "BB
MB@ J"'_C\N/JO\JGJ"$_Z7<?5?Y4 3T444 %%%% !1110!XO)\8+J/0KNW-P
M_P#;::VUI&?[/<PB$3[ -^W9G;[YS797'Q4T:VU*6 V6J2V-O<BTN-6CMLVD
M4V0"I;.>"0"0I'/6KG_"O](;PY/HGGW?V:>_-^S>8N_S#)YF =N-N>V.G>JE
MQ\+-#N-5EN3=:G'9SW/VN?2H[K%I+-D$NT>,\D D9QQTH SKWXEIJ,ENFCQZ
MC8QQZU%I\MS+91R1W!)8&-#Y@Q]T'<,X&.#FK5O\6](>;6%OM*U?38]&0->2
MW<"!4)("* KDEF)&!CZXK27X>Z2FGP6:3WBQP:K_ &LA#KD39)Q]W&W)Z8S[
MUFV7PCT:V75([K4]9U"VU8.;NVNKI3&\C,K>;A47#@J,'M0 Y_BQI5MI^I7&
MJ:1K.F3Z?;"Z:RO+94FFB+!=R#?M."1GD5J>&/'-CXGU*\T^*QU'3[NUC24P
MW\ C9XV^ZZ@$\'WP?:LW_A5.CS:?J-OJ.IZQJ4^H0"V>\O;L231Q!@VQ#MP!
MD G@UT%IX:LK/Q1<Z]$\QN[FUCM75F&P(AR"!C.>?6@#8HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH!!Z&B
M@ HHHH ***,XH ** 0>AS10 444 @]#F@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[YQS0!UE%<1!X[N;6\U9=4TF_=8M56PLHX$B9I2R9 XD]LY;  89Q@XN#Q[
M//\ .T35H19S+#?%TBQ:%MNTL1(=X(8',>_'?% '5T5R5Q\1]&M]0N("DS6U
MK.;>>]$D(CC<'##87$C '@E4(SGG@U(?'=KY]WMTK4FLK*Z-K=7_ )<8AB<,
M%SR^YEY!RJMC/.,$  ZFBN<\-:Y?ZKK6OVU]936\5C=B*!G\O#+M!_A<GWY
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M=IQ@#(]#574/!$%]'?6T>L:K96%^6:XLK:2,1L6^\0Q0NN3R0K =>.37344
M9]SHMO=?V9YCRC^S9A-#M(^9@C)\W'(PYZ8YQ3KG28+K6++4I'D$UD)!&JD;
M3O&#GCVJ]10!S%KX*-KI[:</$&JR:<T;Q_8W6VVA6SQN$(?C/'S?7-=)!"MO
M;QPH25C0(">N ,4^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@E_
MX_H/]U_Z5/5#41>&XM_[/:!9/FR9U)&./0BFM1-V1?HK*V^(?^>NF?\ ?J3_
M .*I-OB'_GIIG_?N3_XJJY?,CG\F:U%9.WQ#_P ]-,_[]R?XT8\0_P!_3/\
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M>+3[*">>>"T@CEN?]?(D0#2_[Q YZGK3;'2]/TN-TTVQMK-'.76WA6,,?4@
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M\?Q_ZYC^= $U%%% !1110 5!#_Q]W'U7^53U!#_Q]W'U7^5 $]%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"7_C^@_W7_I4]02_
M\?T'^Z_]* )Z*** "BBB@ J%O^/Z+_KF_P#-:FJ%O^/^+_KD_P#-: )J***
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2V^U-6!+,TF! !"TI)XYX7':K&G>*="U>[:VTS5;6ZF5"Y6*0'Y1U(]1R.E
M&M17,W7CO1Q<06VE75MJ-S-<BW\J.<+@D,<@X.?NXX]:M:+XKT_58K**6XMH
M-1NK2.Z-FEPLI167<,,.&&.XZCF@#<HKGY/&VAO;WQT_4+>]N+2WDG\B.3EP
MBDG![].HS3_^$RT.&.S&H:C;6=Q=0QRB"2490. 1D]NO4XH W:*H?V[I?]K2
M:9]O@%[''YCP%_F5<9R?PYJ+3?$VBZQ+)'IFIVUR\2[G$;YP/7W'O0!J45SD
MGCG1GO;2UTV\M[Z:XNEMV6*893.?F']X#':NCH **** "BBB@ HHHH ****
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MO#Y[]*ICP;JC6VGZ?+XA#:7IL\,MO"MD!,ZQ,I1))-V& "XRJJ>A.>0>OHH
MXQ/A\/M&FB;45DM;.W-NZK;;)9D*LK(9 W^K.[)4@G*@@BK]IX>UF&W6QN/$
M"RZ=%$T4:+8JLSKM*J))-Q#8!_A5"2.W(KI** .3@\(:AI@E70M;2U2ZBC2Z
M6>S\[<R1B/S(_G78Q55!SN'R@XZYC/P_A;4K=S>#[!#:-:-"( LTR-&4*/,"
M-R'.[;MSN (( Q7844 <)IGPOLK.X079T^>UBC>)%ATX13.K*4_>2;R"=I/*
M*G/H.*NOX0U>X_LZWO?$:RV&FW<5Q#$MBJRRB-LJLLF[!X'553D ],@]=10
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *@E_X_H/]U_Z5/4$O_']!_NO
M_2@">BBB@ HHHH *A;_C_B_ZY/\ S6IJA;_C_B_ZY/\ S6@":BBB@ HHHH *
MA7_C^?\ W!_.IJA7_C^?_<'\Z )J*** "BBB@ J$_P#'\/\ KG_6IJA/_'\/
M^N?]: )J*** "BBB@ J$?\?Q_P"N8_G4U0C_ (_C_P!<Q_.@":BBB@ HHHH
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M3A"P+]/ND8.>G-1&A"T6WOO^A<L1.\DEMM^IUTWC'P[;7"03ZS:1RR!61&D
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M-!)/NMI494)QO"E02N>K $#(SBHK_P"'5KJEQXI^WWLC6_B*.)'CC3:T&Q<
MALG/(!Z"J?AKX7KI4T[Z[J%OK&^U-I'BP6%DC888%MS$Y'T'M0!T%]XV\.Z:
M]ZM[J21?8+=+FY8QN5C1_N<@8+-V4?,>PI/#WCCP[XKNI[;0=0^U36\:R2H8
M)(RBL2 3O4>AXKFK7X1VEMX(N=#.JSR7DUTMVNI-&"Z/&?W0*DG<JJ N">>>
MF:U?"_@S4=&\4:AKVM:__:]Y?6T5NY%DMN%"$D$!6/K_ /7H Z^BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BD9@BEF(50,DD\ 52M-<TF_N/(L-3L[F;&?+AN$=L>N : +U%
M%,::-9DB:11(X)5"PRP&,D#OC(_.@!]%%% !148N(3<&W$J&95#F/<-P4\9Q
MUQ[U)0 44R2:.%0TTBQJ2%!9@ 2>@I] !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !4$O_']!_NO_ $J>H)?^/Z#_ '7_ *4 3T44
M4 %%%% !4+?\?\7_ %R?^:U-4+?\?\7_ %R?^:T 34444 %%%% !4*_\?S_[
M@_G4U0K_ ,?S_P"X/YT 34444 %%%% !4)_X_A_US_K4U0G_ (_A_P!<_P"M
M $U%%% !1110 5"/^/X_]<Q_.IJA'_'\?^N8_G0!-1110 4444 %00_\?=Q]
M5_E4]00_\?=Q]5_E0!/1110 4444 %%%% '%-JDV@ZYK]YK&N7\^FZ7##*L#
MI#C]YNXR$4]0 ,L/<U$/BC9)97<LEO!--!;FX2"QOXKDR $ J=I^5N1P>#SS
M74S:%I]Q-?R7$/F_VA&D=PK,<,$SMQZ'D\BJ3>$+*:UG@O;S4;Q)X_+(N+IF
MVKD'@# ZJ.>O% &.GBW4;74;D7.GW4T]Q<06\&F[X@+=FB9\[^,@[<MG..V:
MT7\7M9BXM]3TN:#48_*\JUBE63S_ #&*IM?@?>!!SC&#2ZYX2AU6^M[B)VC8
MWL=Q<,)F5L)$Z+L(Z$%@?3BIT\(:9]EN8[DW%W)=%#)<W$Q:7Y#E,-QMVGD8
MQS0!E:KX\N]#D,.J>';@3F(21K;W"2"7,BH%!X^;+#@X^M7QXEU*:>6WL] D
MGGM OVU?M2J(F90P13CYVVD'L.1SS2-X&TN:Z6ZO9KZ\N%"J);BZ9B KAP/3
M&Y0>E7+_ ,,V=]?/=K/=VDLRA9_LDYC$X' W@=<#C/7'&: .4N/&6J:C)%<V
M44MCI]SH,][DM&TL+@KAMI!!93QC..<]JVU\37TD$PTW2Y]0CLD"7-SYB1L9
M @9@B?Q$ CT&>!5N#P=I%M8Q6D,4JPPV+Z>@\TDB%B"1GUX'/6DN?!^GW$TC
MI->VR3*JW$5M<M&DX Q\P'<@8)&"10!SEI\2X;;3=.@NGM9[Q=.M[B\DN;Z&
MV+.\8;"*V-S'D\8'(&?3J[G6XG\(R:W8'?$UH;B$D=<KE<_I5;_A#=/CBACL
MKB^LEBMX[9A;7)3S41=J[O4@<9ZUHW^F)=:#<:;&2JR6[0J78G'RX&2>30!S
M6FQZQJNIS6UQXAOK8VUG;,?L\<&'=U)9CNC/<=L55B\4ZE9W<HU"62[DTV.Y
MBFBMHE6.Z*&/$I)R4(#\@' ^8^E;47A,2+%<W%_>VEZUO%#<&QN2J.47&>1]
M?2K"^$=+CMX8K=9[?R8FC22*=@XW,&+%LY+%E!R: *$?C"ZN[FSM=.T8W4]U
M:O<[DO(S"J*X7/F#.0<Y&!]<5(GB][@06MII4TFK2/*DEDTJJ(?**[RTG(V_
M.F" <[AP.<0+X$ABUJ"XM;JYMX8K:5#-%<,)VEDE$C,3C!!YSG\!6@?!^F"S
MMXH&N8)K=WD2[BG(G+/]\L_\6[OGT'H* *$_C@V\, ETMXKEKAK:>*6X1%BD
M4 A1(?E9F!RHXW<],5+?>+KF&'4;NPT2:]L=.WB:83JC,R#+!$/WL=,DCOC-
M3S^#-,N-,^PR2WGE/O\ M!%RVZY#_?$A_BSC\.V*+_P9IM^;M6EO(+>]!^TV
MUO<M'',2-I) Z$C&<8SB@#-T[Q1K-U?:LUII$NH6\,T31CSDB\M&MXGV+_?;
M+,><=0,^D$OQ!MK.6ZOI)?,LKB.T%A%*R0C?*LC'<[8"C"9)).,<>^N?!.FK
M<32VUSJ%J;@()U@NV590J*B@C_=4#C!Y-6)/"6DLKB*%X"5B$;0N5,/E A"G
MH0&/U[T 1^&?%=IXD-U%";<7%J1YBV]TEPA5NA#KQV/!P017.Z-?>)+_ %))
MH)M4EC&ISQS&X2V%IY"2NN%V@29 "@9[@YKL=,TF/2UEV7-U<R2D%Y+J8R,<
M< >@_ 5+I^GV^EVIM[12L9EDE()S\SN7;]6- ')V'Q/TK4+ZW6(VOV6YF\F%
MQ?Q&8DG 8P@[@"?QP02!5RQ\:378M+F?1IK73[JZ%JEQ).I;S"Q4'8/X2PP#
MGOG%7[;PK9VEU');W-\D$+[X[-;EA ASGA1VSSC./;%3CP[IXTVTL DGD6EP
MEQ$-YR'5]XR>XSVH S/$7B.;0=6DF=9)[.WTV2Y>WC W.P=0,$]\'IFJFJ^*
M+Y86M+JVGT6[)@FA:-XYV>-ID1@01@'Y@#UX)P:W]3\/V&KR.]ZCL9+<V[;7
M*_(6#'\<@<U0\3^''U>2WN+-(_M2M'&TDLS*$B$J2-A0IW-\@'./K0!EO\3M
M*34)8\VOV:&Y-LSM?1+,6#;"1!G<5W?B0,XK63Q'>7=Q*VEZ-)>6,,QA>X$Z
MHS%3ABB'[P!SR2,X.*F;PM9_;&FCN;Z&)I3,UK#<LD+.3DG:/4\D X--E\)V
M,EU++'<7UO%-)YLUM!<LD4CDY)('3)ZX(S0!D0>*M0M=7UZ/4+1IDANXK;3X
M(I%+2.Z9"]!@'[Q+$X&?2IM0\;W.E*8;_0;@:@TD:Q6L,Z.)E=MH97X'#<$'
M&,YYK7N?#.FW:WPFCDW7LB2NZR$,DB@!70C[I&!R*@C\(Z<&62XDNKN=9HY1
M/<3EWRA)5<_W023COWH -'U"^F\2:I9:@-@2WM;J.+(;R1('5DW #(W0L<GU
M],5NUF6&G30Z[JFHW31EKKRHH50D[8HP2,Y'7<\AX[$5IT %%%% !1110!5U
M3G2+SO\ N'_]!->;:9J[6G@</I'B;1I[^'3X_+M[:VC\Z%OE&6PY)QG!&!^%
M>IT4 <-J5]KV@75Q9P:A<:H[Z?\ :?,GMT9H")51V58U7< KEMIR?EZG-8]W
MK#KXAM9_#FNMXHN+?2KV6(%(Y-LF(L+NB51SC.S[WYBO4:* .!@U^\2?/A[7
M6\42&SFEFMVCC_<R*F4_U:J8R6^78^3^1J)_$!CT>YN--\82:CJ0L9)7LS;1
MMY#A<Y**@:'#<8D)_N]>:]#HH \SN)-:L+D>7J@DU2XM-+1M0DLHMP\Z\97&
M H^7!X4GCKG/-:.H:IK&C3:CI_\ :EQ/!#]G=]1G@1I+6)]PD?"*%.W:#DKA
M<Y.0#7=T4 ><W6H/>+);6NL-KVFI<VCK>E8V\N7SE!CWQJ$;CG@97OU%26_B
M&^DF@D.NL=;:Z$<OA[R4PBYP5V[?, "_-YA;:>O0XKT*B@#S#7_$U_::-JUY
M_P ).]EK=NS^5HRP1-L4' ^0J9&!7YO,SM[XVC%=$NJZJ_B,^'A/)]H2Z^U/
M<^6O_'GG(7IC);]WTS@$]>:T)O"5C<3DSW%]);-)YC6;W3&%FSGE3R1GG&<>
MV.*TX=.MX-1N;Y QN+D*KLS9PJ] /0<D_4T 6J*** "BBB@ HHHH *KZC<2V
MFEW5Q;PFXFAA>2.$=9&"DA?Q/%6** .%73@_@W_A)!XEU"2_:U^V"]6]<6Y;
M9G:+<'RMG&,;2??=S5V/Q3JAUC2[:XL8+>WO;:)_.E\P!YF!)12 54C ^5R"
MV>,XK1;P9X?:_-VVFQ^89/-*;V\HOUW>5G9G/.<9SSUJU-X>TNXUJ+5IK16O
M8<;)-S8R 0"5SM) )P2,B@#@M*\::SI7ANP@OXEOM3U"\NEBD2.XN%CCC?YM
MP1&<]0  ,8[C%;EMXTU"ZTZ&.+3-FISWGV2/[3'-;PM\N\O^\17QCC&,Y_.M
M^;PUI%QIHL9+)!;K(TJ!&9&1R22RL"&4G)Z'N1TJ/_A$]#_L=M+.GQFU:3S6
M!9BYD_O[\[MW^UG/;- &%>^,M6TR.YL[K3K.75;>XM(ML5P5@D2X=E5MQ&5(
M*ME2.P/<5-=^+M0\/K>IXDL[5Y8+![^(V$I*NB,JLK;P-IRPP>A&?0U;O_!&
MEW.CQZ;;01PV_P!MBNIQ*IE,^Q@<,S').  "2<8&.@J_I_AC1],CN5M+%?\
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M=?=_P3+_ .$BL?\ GGJ'_@MN/_B*/^$BL?\ GGJ'_@MN/_B*U**+P[?C_P
M+3[K[O\ @F7_ ,)%8_\ //4/_!;<?_$5"WB&R^VQGR[_  (W'_(.N/5?]BMJ
MH6_X_P"+_KD_\UHO#M^/_ "T^Z^[_@E'_A(K'_GGJ'_@MN/_ (BC_A(K'_GG
MJ'_@MN/_ (BM2BB\.WX_\ +3[K[O^"9?_"16/_//4/\ P6W'_P 11_PD5C_S
MSU#_ ,%MQ_\ $5J447AV_'_@!:?=?=_P3+_X2*Q_YYZA_P""VX_^(J$>(++[
M8Q\N_P#N#_F'7'K_ +E;50K_ ,?S_P"X/YT7AV_'_@!:?=?=_P $H_\ "16/
M_//4/_!;<?\ Q%'_  D5C_SSU#_P6W'_ ,16I11>';\?^ %I]U]W_!,O_A(K
M'_GGJ'_@MN/_ (BC_A(K'_GGJ'_@MN/_ (BM2BB\.WX_\ +3[K[O^"9?_"16
M/_//4/\ P6W'_P 14)\067VP'R[_ !Y>/^0=<>O^Y6U4!_X_Q_US/\Z+P[?C
M_P  +3[K[O\ @E+_ (2*Q_YYZA_X+;C_ .(H_P"$BL?^>>H?^"VX_P#B*U**
M+P[?C_P M/NON_X)E_\ "16/_//4/_!;<?\ Q%'_  D5C_SSU#_P6W'_ ,16
MI11>';\?^ %I]U]W_!,:Z\465M9S3K!?N8HV<+_9\Z[L#.,E,#ZFO&X_BUXD
M76A>220M;EL-:B(;=N>@/WL^^:]](!&",@UR47PZ\,1:_P#;4TT>8,2!"Y\L
M-GKMZ5UX>K0@G[2-SBQ-'$U''V<[6^1U4,GG01R@$!U#8/;(I]%%<)Z 4444
M %00_P#'W<?5?Y5/4$/_ !^7'U7^5 $]%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !4$O_']!_NO_ $J>H)?^/Z#_
M '7_ *4 3T444 %%%% !4+?\?\7_ %R?^:U-4+_\?\7_ %R?^:T 34444 %%
M%% !4*_\?S_[@_G4U0K_ ,?S_P"X/YT 34444 %%%% !4)_X_P ?]<_ZU-4!
M_P"/\?\ 7,_SH GHHHH **** "H1_P ?Q_ZYC^=35"/^/X_]<Q_.@":BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5!+_Q_0?[K_TJ>H)?^/Z#_=?^E $]
M%%% !1110 5"W_'_ !?]<G_FM35"_P#Q_P 7_7)_YK0!-1110 4444 %0K_Q
M_/\ [@_G4U0K_P ?S_[@_G0!-1110 4444 %0G_C_'_7,_SJ:H#_ ,?X_P"N
M?]: )Z*** "BBB@ J$?\?Q_ZYC^=35"/^/X_]<Q_.@":BBB@ HHHH *@A/\
MI=Q]5_E4]00G_2[CZK_*@">BBB@ HHHH *YKQWX<NO%&@06-C+#%)'>P7!,Q
M(4JCAB. >:Z6B@#R#7_A/KU])K=KI[Z!+9ZG>?;5N[V%S>1,6!,8< C:,$ ^
MG&*L:Y\*]8O]2UB"SFT5].UN=9Y[R\@=[ZT. "L+#C VC;DC&<=N>HBU:^T[
MQ)=_V_J4T$"K-/# ;=&MY8$7.4<#<'49+*Q.>PQ5>Q^)-AJ<JP0FWB:ZC<VI
MCOH9I,A25WQJ24) ]\'@T#,A_AA>Q^'-=M;==(N+[4-5^V12WD;L#$-N%9@
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M-ROE@[\R*QE.XE=J$$;>>2#69HFN^*=0T_4=2&HR7#65C \=F+- ))'CRSL
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M  77'_Q%5[.?8GVD.Z-6BLK_ (2.P_N7W_@NN/\ XBC_ (2.P_N7W_@NN/\
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M_"1V']R^_P#!=<?_ !%'_"1V']R^_P#!=<?_ !%'LY]@]I#NC5J _P#'^/\
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M*S.22HYP,X&3ZFDT[PKHVERR2VEEF22,PLT\KS$1GJ@+DX4X'RC .!Z5KT4
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M'_C[N/JO\J )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
-BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095677449744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-32335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HALOZYME THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">88-0488686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12390 El Camino Real<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">794-8889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HALO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,680,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001159036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095674029264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 96,383<span></span>
</td>
<td class="nump">$ 234,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">179,225<span></span>
</td>
<td class="nump">128,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net and contract assets</a></td>
<td class="nump">194,883<span></span>
</td>
<td class="nump">231,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">107,521<span></span>
</td>
<td class="nump">100,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">37,007<span></span>
</td>
<td class="nump">45,024<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">615,019<span></span>
</td>
<td class="nump">739,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">77,964<span></span>
</td>
<td class="nump">75,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">25,240<span></span>
</td>
<td class="nump">26,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">416,223<span></span>
</td>
<td class="nump">409,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">528,817<span></span>
</td>
<td class="nump">546,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">35,684<span></span>
</td>
<td class="nump">44,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,699,447<span></span>
</td>
<td class="nump">1,841,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,695<span></span>
</td>
<td class="nump">17,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">79,978<span></span>
</td>
<td class="nump">96,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">3,246<span></span>
</td>
<td class="nump">3,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,334<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">91,919<span></span>
</td>
<td class="nump">130,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">2,253<span></span>
</td>
<td class="nump">2,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">1,494,380<span></span>
</td>
<td class="nump">1,492,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">29,573<span></span>
</td>
<td class="nump">30,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent liability</a></td>
<td class="nump">15,472<span></span>
</td>
<td class="nump">15,472<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="nump">1,633,597<span></span>
</td>
<td class="nump">1,671,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">24<span></span>
</td>
<td class="num">(922)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">65,694<span></span>
</td>
<td class="nump">143,217<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">65,850<span></span>
</td>
<td class="nump">169,798<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,699,447<span></span>
</td>
<td class="nump">$ 1,841,511<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095674001696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">131,662,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">131,662,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095676202816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 162,143<span></span>
</td>
<td class="nump">$ 117,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">35,170<span></span>
</td>
<td class="nump">15,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">17,835<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">17,979<span></span>
</td>
<td class="nump">11,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">37,357<span></span>
</td>
<td class="nump">13,834<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">108,341<span></span>
</td>
<td class="nump">41,609<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">53,802<span></span>
</td>
<td class="nump">75,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Investment and other income, net</a></td>
<td class="nump">2,979<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4,543)<span></span>
</td>
<td class="num">(1,759)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income before income taxes</a></td>
<td class="nump">52,238<span></span>
</td>
<td class="nump">74,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">12,623<span></span>
</td>
<td class="nump">14,301<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 39,615<span></span>
</td>
<td class="nump">$ 60,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (USD per share)</a></td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (USD per share)</a></td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="nump">135,027<span></span>
</td>
<td class="nump">137,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="nump">137,900<span></span>
</td>
<td class="nump">141,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 99,640<span></span>
</td>
<td class="nump">$ 69,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">60,794<span></span>
</td>
<td class="nump">22,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember', window );">Revenues under collaborative agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,709<span></span>
</td>
<td class="nump">$ 25,534<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095676237968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 39,615<span></span>
</td>
<td class="nump">$ 60,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">924<span></span>
</td>
<td class="num">(2,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 40,561<span></span>
</td>
<td class="nump">$ 57,937<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095673672672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 39,615<span></span>
</td>
<td class="nump">$ 60,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">7,966<span></span>
</td>
<td class="nump">4,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,622<span></span>
</td>
<td class="nump">778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">17,835<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">1,835<span></span>
</td>
<td class="nump">971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of (premium) discounts on marketable securities, net</a></td>
<td class="num">(917)<span></span>
</td>
<td class="nump">541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Recognition of deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(499)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_DeferredRentPayments', window );">Lease payments recognized (deferred)</a></td>
<td class="nump">320<span></span>
</td>
<td class="num">(183)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="nump">3,874<span></span>
</td>
<td class="nump">12,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net and other contract assets</a></td>
<td class="nump">36,189<span></span>
</td>
<td class="num">(22,787)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(7,250)<span></span>
</td>
<td class="nump">6,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">8,881<span></span>
</td>
<td class="num">(9,168)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(24,006)<span></span>
</td>
<td class="num">(6,010)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">86,964<span></span>
</td>
<td class="nump">47,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(109,919)<span></span>
</td>
<td class="num">(184,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">61,134<span></span>
</td>
<td class="nump">136,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(11,377)<span></span>
</td>
<td class="num">(490)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(60,162)<span></span>
</td>
<td class="num">(49,305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayment of 2024 Convertible Notes</a></td>
<td class="num">(13,483)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(150,083)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised', window );">Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement</a></td>
<td class="num">(1,048)<span></span>
</td>
<td class="nump">624<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(164,614)<span></span>
</td>
<td class="nump">624<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(137,812)<span></span>
</td>
<td class="num">(884)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">234,695<span></span>
</td>
<td class="nump">119,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">96,883<span></span>
</td>
<td class="nump">118,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts accrued for purchases of property and equipment</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligation</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued for conversion of 2024 Convertible Notes</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DeferredRentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Rent Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DeferredRentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From (Payments) for Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095675149920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income/(Loss)</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 196,953<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 256,347<span></span>
</td>
<td class="num">$ (620)<span></span>
</td>
<td class="num">$ (58,912)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">4,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock and performance stock units, net</a></td>
<td class="nump">624<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(2,171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">60,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,108<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Mar. 31, 2022</a></td>
<td class="nump">260,256<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">261,713<span></span>
</td>
<td class="num">(2,791)<span></span>
</td>
<td class="nump">1,196<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Dec. 31, 2022</a></td>
<td class="nump">169,798<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">27,368<span></span>
</td>
<td class="num">(922)<span></span>
</td>
<td class="nump">143,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">7,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock for the induced conversion related to convertible notes</a></td>
<td class="num">(126)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock for the induced conversion related to convertible notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock and performance stock units, net</a></td>
<td class="num">(1,048)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">(151,301)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">(34,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117,138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">39,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,615<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 65,850<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 65,694<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33775-111570<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095675952912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Business</a></td>
<td class="text">Organization and Business <div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving the patient experience and potentially outcomes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary enzyme, rHuPH20, is used to facilitate the subcutaneous (&#8220;SC&#8221;) delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology (&#8220;ENHANZE&#8221;) with the partners&#8217; proprietary compounds. We also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first commercially approved product Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recombinant (&#8220;Hylenex&#8221;), and our ENHANZE partners&#8217; approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in Hylenex that works by breaking down hyaluronan (&#8220;HA&#8221;), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the SC space. This temporarily reduces the barrier to bulk fluid flow allowing for improved and more rapid SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as ENHANZE. We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (&#8220;IV&#8221;) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing typically required for IV administration, extend the dosing interval for drugs that are already administered subcutaneously and potentially allow for lower rates of infusion related reactions.&#160;ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient or caregiver. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of the proprietary IV drug.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&#8220;Roche&#8221;), Takeda Pharmaceuticals International AG and Baxalta US Inc. (&#8220;Takeda&#8221;), Pfizer Inc. (&#8220;Pfizer&#8221;), Janssen Biotech, Inc. (&#8220;Janssen&#8221;), AbbVie, Inc. (&#8220;AbbVie&#8221;), Eli Lilly and Company (&#8220;Lilly&#8221;), Bristol-Myers Squibb Company (&#8220;BMS&#8221;), Alexion Pharma International Operations Unlimited Company (an indirect wholly owned subsidiary of AstraZeneca PLC) (&#8220;Alexion&#8221;), argenx BVBA (&#8220;argenx&#8221;), Horizon Therapeutics plc. (&#8220;Horizon&#8221;), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (&#8220;ViiV&#8221;) and Chugai Pharmaceutical Co., Ltd (&#8220;Chugai&#8221;). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE. We currently receive royalties from three of these collaborations, including royalties from sales of one product from the Takeda collaboration, three products from the Roche collaboration and one product from the Janssen collaboration. Future potential revenues from ENHANZE collaborations and from the sales and/or royalties of our approved products will depend on the ability of our partners, in some areas supported by Halozyme to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our commercial portfolio of proprietary products also includes XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NOCDURNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have commercialized auto-injector products with several pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (&#8220;Teva&#8221;), Covis Group S.a.r.l. (&#8220;Covis&#8221;) and Otter Pharmaceuticals, LLC (&#8220;Otter&#8221;). We have development programs including auto-injectors with Idorsia Pharmaceuticals Ltd. (&#8220;Idorsia&#8221;) and Pfizer.</span></div>Except where specifically noted or the context otherwise requires, references to &#8220;Halozyme,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; in these notes to the condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and each of its directly and indirectly wholly owned subsidiaries<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095676544432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements have been prepared for purposes of and in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on February&#160;21, 2023. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., and Antares Pharma, Inc.&#8217;s wholly owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in our interim unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that we believe to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from our estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within 90 days or less from the date of purchase. As of March&#160;31, 2023, our cash and cash equivalents consisted of money market funds, bank certificate of deposits and demand deposits at commercial banks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are investments with original maturities of more than 90 days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#8217;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders&#8217; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the interim unaudited condensed consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in the interim unaudited condensed consolidated statements of income.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the lease terms of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. As of March&#160;31, 2023 and December&#160;31, 2022, restricted cash of $0.5 million was pledged as collateral for the letters of credit.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses, long-term debt and a contingent liability. Fair value estimates of these instruments are made at a specific point in time based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore, cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from 3 years to 12 years. We determine if an arrangement contains a lease at inception. Right of use (&#8220;ROU&#8221;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option. Short-term leases with an initial term of 12 months or less are not recorded on the condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs incurred to complete a business combination, such as legal and other professional fees, are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Asset</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and in-process research and development (&#8220;IPR&amp;D&#8221;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets with finite useful lives are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE and Device Royalties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. In general, when there are no valid claims of a specified patent developed under the collaboration covering the product in a given country, the royalty rate is reduced for those sales in that country upon the expiration of our patents covering rHuPH20. Janssen&#8217;s patents covering DARZALEX SC do not impact the timing for this royalty reduction. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted will become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also earn royalties in connection with several of our licenses granted under license and development arrangements with our device partners. These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#8217; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days after the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue under ENHANZE and Device Collaborative Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement generally require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner&#8217;s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally collect an upfront license payment from collaboration partners, and are also entitled to receive event-based payments subject to collaboration partners&#8217; achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for respective consideration. Under these collaborative agreements, our partners lead development of assets, and we do not share in significant financial risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to U.S. GAAP. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under all of our ENHANZE collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs. Each of the licenses grants the partners rights to use our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, we provide indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#8217; representations and are not obligations to provide goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our partners, which represent separate contracts. In addition to our licenses, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or (&#8220;SSP&#8221;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g., dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#8217;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of Investigational New Drug (&#8220;IND&#8221;) or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#8217;s commitment of resources to the program. We do not include any amounts subject to uncertainties in the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using an income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time, we have already transferred the related license to the partner. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Device License, Development and Supply Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several license, development and supply arrangements with pharmaceutical partners, under which we grant a license to our device technology and provide research and development services that often involve multiple performance obligations and highly-customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception of the contract and allocate consideration to each performance obligation based on relative SSP, which is generally determined based on the expected cost plus mark-up. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and we have a present right to payment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in the condensed consolidated balance sheets and recognized as revenue in the condensed consolidated statements of income when the associated performance obligations have been satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and milestones received in exchange for the grant of a license to our functional intellectual property, such as patented technology and know-how in connection with a partnered development arrangement, are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal of revenue will not occur when the associated uncertainty is resolved.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion on our collaborative arrangements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proprietary Product Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recombinant</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (&#8220;GPOs&#8221;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in accrued liabilities and net of accounts receivable in the condensed consolidated balance sheet. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Proprietary Product Sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial portfolio of proprietary products includes XYOSTED, TLANDO and NOCDURNA, which we sell primarily to wholesale and specialty distributors. Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued liabilities and net of accounts receivable in the condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnered Product Sales</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bulk rHuPH20</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Devices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the exclusive supplier of  OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to Otter. Because this product is custom manufactured with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in the condensed consolidated balance sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit-sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal of revenue based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our condensed consolidated statements of income, we report the upfront payments, event-based development and regulatory milestones and sales milestones as revenues under collaborative agreements. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from partners as a separate line in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of our proprietary and partnered products are included in product sales, net in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the footnotes to our condensed consolidated financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and device licensing, and development revenues), and additionally, by type of payment stream received under collaborative agreements (upfront license and target nomination fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include salaries and benefits, facilities and other overhead expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record compensation expense associated with stock options, restricted stock units (&#8220;RSUs&#8221;), performance stock units (&#8220;PSUs&#8221;) and shares issued under our employee stock purchase plan (&#8220;ESPP&#8221;) in accordance with the authoritative guidance for share-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#8220;DTA&#8221;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized. We recorded a provision for income taxes of $12.6&#160;million using an effective tax rate of 24.1% for the three months ended March&#160;31, 2023. The difference between our effective tax rate and the U.S. federal statutory rate of 21% is primarily due to tax benefits on Foreign Derived Intangible Income Deduction (&#8220;FDII&#8221;), tax detriments on 162(m) and other share-based compensation.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate our business in one operating segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties, and (ii)&#160;product sales of proprietary and partnered products. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption and Pending Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no relevant recently issued accounting pronouncements that would materially impact our condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095681869600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination</a></td>
<td class="text">Business Combination<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, we acquired all outstanding equity interests of Antares Pharma, Inc. according to the terms and conditions of the Agreement and Plan of Merger, dated as of April 12, 2022 (the &#8220;Merger Agreement&#8221;). Antares is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. We acquired Antares as a part of our strategy to expand as a drug delivery company and include specialty products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase consideration of Antares was $1,045.7&#160;million. Each share of Antares common stock issued and outstanding was converted into the right to receive $5.60 in cash without interest, less any applicable withholding taxes (&#8220;Merger Consideration&#8221;). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Antares has been accounted for using the acquisition method of accounting in accordance with ASC 805, Business Combinations, with Halozyme treated as the accounting acquirer, which requires, among other things, that the assets acquired and liabilities assumed be recognized at their fair value on the acquisition date. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our results of operations. We are still finalizing the liabilities assumed related to accrued expenses which are subject to change as additional information is received to complete our analysis. As a result, the preliminary estimates may be revised during the measurement period. These differences could have a material impact on our results of operations and financial position.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2023, we recorded measurement period adjustments which increased goodwill by $7.1&#160;million to adjust accrued expenses by $2.3&#160;million and deferred tax liabilities by $4.8&#160;million. The measurement period adjustments have been recorded to reflect facts and circumstances that existed as of the acquisition date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095761920096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:52.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,244&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,225&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:52.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,541&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(944)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,599&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, thirty-four available-for-sale marketable securities with a fair market value of $96.2 million were in a gross unrealized loss position of $0.1&#160;million. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of&#160;March&#160;31, 2023, because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our contractual maturities of available-for-sale debt securities were as follows (in thousands):</span></div><div style="margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:67.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.063%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,591&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year but within five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,599&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:29.421%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.337%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total estimated fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable <br/>&#160;&#160;&#160;securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,663&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,907&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,570&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,023&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,280&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,303&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no available for sale securities that were classified within Level 3 as of March&#160;31, 2023 and December&#160;31, 2022.</span></div>A contingent liability with a value of $15.7&#160;million was assumed as part of the Antares acquisition related to TLANDO. The acquisition date fair value was measured using the income approach, specifically the probability weighted expected return method for the development milestone payments and the option pricing methodology using the Monte Carlo simulation for commercial milestone payments and royalty payments. The fair value of the contingent liability will be remeasured on a quarterly basis. Estimates and assumptions used in the Monte Carlo simulation include forecasted revenues, cost of debt, risk free rate, weighted average cost of capital, revenue market price risk and revenue volatility. Estimates and assumptions used in the income approach include the probability of achieving certain milestones and a discount rate. These unobservable inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. Changes in the fair value subsequent to the acquisition date will be recognized in our condensed consolidated statements of income.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095681701408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disaggregated revenues were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"/><td style="width:78.555%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.292%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Sales of bulk rHuPH20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of proprietary products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of device partnered products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Upfront license and target nomination fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Device Licensing and development revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,534&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,143&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,279&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we recognized revenue related to licenses granted to partners in prior periods in the amount of $99.6 million. This amount represents royalties earned in the current period. We also recognized revenue of $0.4&#160;million during the three months ended March&#160;31, 2023 that had been included in deferred revenues in the condensed consolidated balance sheets as of December&#160;31, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands): </span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:76.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.176%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.065%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,545&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $123.6 million, of which $118.1 million relates to unfulfilled product purchase orders and $5.5 million has been collected and is reported as deferred revenues in the condensed consolidated balance sheets. The unfulfilled product purchase orders are estimated to be delivered by the end of 2024. Of the total deferred revenues of $5.5 million, $3.2 million is expected to be used by our customers within the next 12 months. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized contract assets of $32.3&#160;million as of March&#160;31, 2023, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods and for goods or services when control has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to the customer in accordance with the terms of the contract.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095682571088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Certain Balance Sheet Items</a></td>
<td class="text">Certain Balance Sheet Items<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net and contract assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from product sales to partners</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from royalty payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from other product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accounts receivable and contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,799&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for distribution fees and discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,916)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,914)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accounts receivable, net and contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,883&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,072&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,123&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,325&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,301)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,007&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,024&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract manufacturing organizations.&#160;Such amounts are reclassified to work-in-process inventory as materials are used or the contract manufacturing organization services are complete.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,964&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                            </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was approximately $2.6 million and $0.8 million, inclusive of ROU asset amortization of $1.4 million and $0.4 million for the three months ended March&#160;31, 2023 and 2022, respectively. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and payroll taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued outsourced manufacturing expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns and sales allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accrued expenses, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,978&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense associated with the accretion of the lease liabilities was approximately $0.7 million and $0.1 million for the three months ended March&#160;31, 2023 and 2022, respectively. Total lease expense for the three months ended March&#160;31, 2023 and 2022 was $2.1 million and $0.5 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts related to leases for the three months ended March&#160;31, 2023 and 2022 was $1.7 million and $0.7 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095762058880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, we acquired all outstanding equity interests of Antares. A goodwill balance of $409.0&#160;million was recognized for the excess of the consideration transferred over the net assets acquired and represents the expected revenue and cost synergies of the combined company and assembled workforce.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity impacting goodwill is presented below (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:84.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,223&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our acquired intangible assets are amortized using the straight-line method over their estimated useful lives of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RleHRyZWdpb246MTYzZDU4ODI5MmUwNGM4ZGEwZGI0YzJjNWY0NjIwZWJfNTU2_7b1e4645-8507-4bdd-a7da-977a1bcbb72c">seven</span> to ten years. The following table shows the cost, accumulated amortization and weighted average useful life in years for our acquired intangible assets as of March&#160;31, 2023 (in thousands).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"/><td style="width:47.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average useful life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,908&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLANDO product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,983&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480,117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,700&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528,817&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future annual amortization of finite-lived intangible assets is shown in the following table (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:82.561%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.010%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095682648624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt, Net</a></td>
<td class="text">Long-Term Debt, Net<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.00% Convertible Notes due 2028</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we completed the sale of $720.0&#160;million in aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the &#8220;2028 Convertible Notes&#8221; and collectively with the 2024 and the 2027 Convertible Notes the &#8220;Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2028 Convertible Notes, after deducting the initial purchasers&#8217; fee of $18.0&#160;million, was approximately $702.0&#160;million. We also incurred additional debt issuance costs totaling $1.0&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Convertible Notes pay interest semi-annually in arrears on February 15th and August 15th of each year at an annual rate of 1.00%. The 2028 Convertible Notes are general unsecured obligations and rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2028 Convertible Notes, rank equally in right of payment with all existing and future liabilities that are not so subordinated, are effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2028 Convertible Notes have a maturity date of August 15, 2028.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2028 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2022, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2028 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, February 15, 2028 until the close of business on the second scheduled trading day immediately before the maturity date. As of March&#160;31, 2023, the 2028 Convertible Notes are not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal, and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2028 Convertible Notes is 17.8517 shares of common stock per $1,000 in principal amount of 2028 Convertible Notes, equivalent to a conversion price of approximately $56.02 per share of our common stock. The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued or unpaid interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capped Call Transactions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the 2028 Convertible Notes, we entered into capped call transactions with certain counterparties (the &#8220;Capped Call Transactions&#8221;). The Capped Call Transactions are expected generally to reduce potential dilution to holders of our common stock upon conversion of the 2028 Convertible Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the principal amount of such converted 2028 Convertible Notes. The cap price of the Capped Call Transactions is initially $75.4075 per share of common stock, representing a premium of 75% above the last reported sale price of $43.09 per share of common stock on August 15, 2022, and is subject to certain adjustments under the terms of the Capped Call Transactions. As of March&#160;31, 2023, no capped calls have been exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to their terms, the capped calls qualify for classification within stockholders&#8217; equity in the condensed consolidated balance sheets, and their fair value is not remeasured and adjusted as long as they continue to qualify for stockholders&#8217; equity classification. We paid approximately $69.1&#160;million for the Capped Calls, including applicable transaction costs, which was recorded as a reduction to additional paid-in capital in the condensed consolidated balance sheets. The Capped Call Transactions are separate transactions entered into by us with the capped call Counterparties, are not part of the terms of the Convertible Notes, and do not affect any holder&#8217;s rights under the Convertible Notes. Holders of the Convertible Notes do not have any rights with respect to the Capped Call Transactions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">0.25% Convertible Notes due 2027</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed the sale of $805.0&#160;million in aggregate principal amount of 0.25% Convertible Senior Notes due 2027 (the &#8220;2027 Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2027 Convertible Notes, after deducting the initial purchasers&#8217; fee of $20.1&#160;million, was approximately $784.9&#160;million. We also incurred additional debt issuance costs totaling $0.4&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Convertible Notes pay interest semi-annually in arrears on March 1st and September 1st of each year at an annual rate of 0.25%. The 2027 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2027 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2027 Convertible Notes have a maturity date of March 1, 2027.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2027 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2027 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately before the maturity date. The 2027 Convertible Notes will be convertible, regardless of the foregoing circumstances, at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately preceding the maturity date. As of March&#160;31, 2023, the 2027 Convertible Notes are not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal, and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2027 Convertible Notes will be 12.9576 shares of common stock per $1,000 in principal amount of 2027 Convertible Notes, equivalent to a conversion price of approximately $77.17 per share of our common stock. The conversion rate is subject to adjustment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.25% Convertible Notes due 2024</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we completed the sale of $460.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due 2024 (&#8220;2024 Convertible Notes&#8221;). The net proceeds in connection with 2024 Convertible Notes, after deducting the initial purchases&#8217; fee of $12.7&#160;million, was approximately $447.3 million. We also incurred debt issuance cost totaling $0.3&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Convertible Notes pay interest semi-annually in arrears on June 1st and December 1st of each year, beginning on June 1, 2020, at an annual rate of 1.25%. The 2024 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2024 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2024 Convertible Notes have a maturity date of December 1, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2024 Convertible Notes at their option only in the following circumstances: (1)&#160;during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2020, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2)&#160;during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3)&#160;upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2024 Convertible Notes; (4)&#160;if we call such notes for redemption; and (5)&#160;at any time from, and including, June&#160;1, 2024 until the close of business on the scheduled trading day immediately before the maturity date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we notified the note holders of our irrevocable election to settle the principal of the 2024 Convertible Notes in cash and for the premium, if applicable, to deliver shares of common stock. The conversion rate for the 2024 Convertible Notes will be 41.9208 shares of common stock per $1,000 in principal amount of 2024 Convertible Notes, equivalent to a conversion price of approximately $23.85 per share of our common stock. The conversion rate was subject to adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed a privately negotiated induced conversion of $369.1&#160;million principal amount of the 2024 Convertible Notes (&#8220;2021 Note Repurchases&#8221; or the &#8220;2021 Induced Conversion&#8221;). In connection with the 2021 Induced Conversion, we paid approximately $370.2&#160;million in cash, which includes principal and accrued interest, and issued approximately 9.08&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the 2021 Induced Conversion, we recorded $0.0 million in induced conversion expense which was included in other income (expense) of the condensed consolidated statements of income in 2021. The induced conversion expense represented the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we completed a privately negotiated induced conversion of $77.4&#160;million principal amount of the 2024 Convertible Notes (&#8220;2022 Note Repurchases&#8221; or the &#8220;2022 Induced Conversion&#8221;). In connection with the 2022 Induced Conversion, we paid approximately $77.6&#160;million in cash, which includes principal and accrued interest, and issued approximately 1.51&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the 2022 Induced Conversion, we recorded $2.7&#160;million in induced conversion expense which was included in other income (expense) of the condensed consolidated statements of income in 2022. The induced conversion expense represented the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we issued a notice for the redemption of 2024 Convertible Notes. Holders of the notes may convert their notes at any time prior the close of business day prior to the redemption date. In March 2023, holders of the notes elected to convert the 2024 Convertible Notes in full. In connection with the conversion, we paid approximately $13.5 million in cash which includes principal and accrued interest, and issued 288,886 shares of our common stock representing the intrinsic value based on the contractual conversion rate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Carrying Amounts of our Convertible Notes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and fair value of our Convertible Notes were as follows (in thousands). </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"/><td style="width:69.570%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Principal Amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,509)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,620)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,383)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value based on trading levels (Level 2):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of outstanding notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363,525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,666,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization per period of debt discount (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes (in thousands).</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:71.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total coupon interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit and Term Loan Facilities (May 2022)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, in connection with the closing of the Antares acquisition, we entered into a credit agreement, which was subsequently amended, with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#8220;2022 Credit Agreement), evidencing a credit facility (the &#8220;2022 Facility&#8221;) that provides for (i) a $350&#160;million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and (ii) a $250&#160;million term loan facility (the &#8220;Term Facility&#8221;). Proceeds from a $120&#160;million draw on the Revolving Credit Facility and the $250&#160;million Term Facility were used to fund a portion of the Antares acquisition, repay Antares&#8217; existing debt and pay fees and expenses in connection with the Antares acquisition. The 2022 Credit Agreement contains an expansion feature, which allows us, subject to certain conditions, to increase the aggregate principal amount of the 2022 Facility, provided we remain in compliance with underlying financial covenants on a pro forma basis including the consolidated interest coverage ratio and the consolidated net leverage ratio covenants set forth in the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth years following the Closing in annual amounts equal to 2.50%, 5.00%, 7.50% and 10.00% of the initial principal amount of the term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales, subject to our right to reinvest the proceeds thereof.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the applicable Term Secured Overnight Financing Rate (SOFR) (which includes a SOFR adjustment of 0.10%), or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus 0.50%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus 1.10%, and (4) 1.00%. The margin for the 2022 Facility ranges, based on our consolidated total net leverage ratio, from 0.25% to 1.25% in the case of base rate loans and from 1.25% to 2.25% in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the Facility, we will pay (i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency fees. The commitment fees range from 0.15% to 0.35% per annum based on our consolidated net leverage ratio. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we entered into Amendment No. 1 to the Credit Agreement (the &#8220;Amendment&#8221;) among the Company, the Guarantors (as defined in the Credit Agreement), each L/C Issuer from time to time party thereto, Bank of America, N.A., as Administrative Agent (in such capacity, the &#8220;Administrative Agent&#8221;) and swing line lender (in such capacity, the &#8220;Swing Line Lender&#8221;), and each lender party thereto, which amends the Credit Agreement dated as of May 24, 2022 (the &#8220;Credit Agreement&#8221;) among the Company, the Guarantors, the Administrative Agent, the Swing Line Lender, each Lender and the L/C Issuers. The Amendment, among other things, increased the size of the revolving credit facility from $350&#160;million to $575&#160;million. The terms of the Revolving Credit Facility are otherwise unchanged. Concurrently with the entry into the Amendment, we repaid the entire outstanding Term Loan Facility and repaid all outstanding loans under the Revolving Credit Facility under the 2022 Credit Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Revolving Credit Facility was undrawn. We incurred a total of $3.6&#160;million in third-party costs related to the 2022 Credit Agreement which is recorded as debt issuance cost within prepaid expenses and other assets in the condensed consolidated balance sheets. As of March&#160;31, 2023, the unamortized debt issuance cost related to the revolving credit facility was $2.9 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095681862288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
<td class="text">Share-based Compensation<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total following table summarized share-based compensation expense included in our condensed consolidated statements of income related to share-based awards (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:78.491%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.319%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.322%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,865&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,742&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:78.491%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.319%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.322%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs, PSUs and ESPP</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,511&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,742&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We granted stock options to purchase approximately 1.2 million and 1.3 million shares of common stock during the three months ended March&#160;31, 2023 and 2022, respectively. The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (&#8220;Black-Scholes model&#8221;). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. The assumptions used in the Black-Scholes model were as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:65.407%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.008%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.851%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.68 - 39.98%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.14 - 41.23%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.48 - 4.27%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37 - 1.90%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, our Board of Directors approved our 2021 ESPP and our stockholders approved the plan in May 2021. The ESPP enables eligible employees to purchase shares of our common stock at the end of each offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Share purchases are funded through payroll deduction of at least 1% and up to 15% of an employee&#8217;s compensation for each payroll period, and no employee may purchase shares under the ESPP that exceeds $25,000 worth of our common stock for a calendar year. As of March&#160;31, 2023, 2,650,103 shares were available for future purchase. The offering period is generally for a six-month period and the first offering period commenced on June 16, 2021. Offering periods shall commence on or about the sixteenth day of June and December of each year and end on or about the fifteenth day of the next December and June, respectively, occurring thereafter. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized was as follows (in thousands, unless otherwise noted):</span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"><tr><td style="width:1.0%"/><td style="width:66.158%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.030%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining<br/>Weighted-Average<br/>Recognition Period<br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.94</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.12</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095762001056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity <div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, we issued an aggregate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143,931</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 172,607 shares of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of $16.87 and $17.21 per share, respectively, for net proceeds of approximately $2.4 million and $3.0 million, respectively. For the three months ended March&#160;31, 2023 and 2022, we issued 239,919 and 216,886 shares of common stock, respectively, upon vesting of certain RSUs and PSUs for which 70,733 and 68,425 RSUs were withheld from the RSU holders, respectively, to pay for minimum withholding taxes totaling approximately $6.5 million and $4.3 million, respectively. Stock options and unvested restricted units totaling approximately 7.8 million shares and 6.6 million shares of our common stock were outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, the Board of Directors authorized a capital return program to repurchase up to $750.0&#160;million of outstanding stock over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMTU2Nw_a30831a4-f6f2-4774-9f18-5ca5ed367463">three</span>-year period. During 2021, we repurchased 3.9&#160;million shares of common stock for $150.0&#160;million at an average price of $38.51. During 2022, we repurchased 4.5&#160;million shares of common stock for $200.0&#160;million at an average price of $44.44. All shares repurchased under our capital return programs have been retired and have resumed their status of authorized and unissued shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We had the following activity under the approved share repurchase programs (dollars in thousands, except share and per share data):</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"/><td style="width:50.368%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Price paid Per Share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,165,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,083&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,165,258&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,083&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)   Included in the total cost of shares purchased is a commission fee of $0.02 per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095681851712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income per share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per share</a></td>
<td class="text">per share<div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per common share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and the Convertible Notes are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares issuable upon vesting of stock options, RSUs and PSUs are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of our Convertible Notes are determined using the if-converted method. Since we have committed to settle the principal amount of the Convertible Notes in cash upon conversion only, the number of shares for the conversion spread will be included as a dilutive common stock equivalent. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerators and the denominators of the basic and diluted earning per common share computations is as follows (in thousands, except per share amounts):</span></div><div style="margin-top:11pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:77.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.237%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,615&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for basic earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common stock outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs, PSUs and ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:11pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from the calculation of diluted earnings per common share because their effect was anti-dilutive, include the following (shares in millions):</span></div><div style="margin-top:11pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:78.100%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.980%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>(1)    The anti-dilutive securities include outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and Convertible Notes<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095681862288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and ContingenciesFrom time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our condensed consolidated statements of income and balance sheets. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in our opinion, individually or in the aggregate, would have a material adverse effect on our condensed consolidated statements of income or balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095677344048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements have been prepared for purposes of and in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on February&#160;21, 2023. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text">The accompanying interim unaudited condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., and Antares Pharma, Inc.&#8217;s wholly owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in our interim unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that we believe to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from our estimates<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash Equivalents and Marketable Securities and Restricted Cash</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within 90 days or less from the date of purchase. As of March&#160;31, 2023, our cash and cash equivalents consisted of money market funds, bank certificate of deposits and demand deposits at commercial banks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are investments with original maturities of more than 90 days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#8217;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders&#8217; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the interim unaudited condensed consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in the interim unaudited condensed consolidated statements of income.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the lease terms of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. As of March&#160;31, 2023 and December&#160;31, 2022, restricted cash of $0.5 million was pledged as collateral for the letters of credit.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses, long-term debt and a contingent liability. Fair value estimates of these instruments are made at a specific point in time based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore, cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from 3 years to 12 years. We determine if an arrangement contains a lease at inception. Right of use (&#8220;ROU&#8221;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option. Short-term leases with an initial term of 12 months or less are not recorded on the condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs incurred to complete a business combination, such as legal and other professional fees, are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the condensed consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock', window );">Goodwill and Intangible Assets and Other Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Asset</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and in-process research and development (&#8220;IPR&amp;D&#8221;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets with finite useful lives are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue and Cost of Product Sales</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE and Device Royalties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. In general, when there are no valid claims of a specified patent developed under the collaboration covering the product in a given country, the royalty rate is reduced for those sales in that country upon the expiration of our patents covering rHuPH20. Janssen&#8217;s patents covering DARZALEX SC do not impact the timing for this royalty reduction. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted will become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also earn royalties in connection with several of our licenses granted under license and development arrangements with our device partners. These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#8217; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days after the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue under ENHANZE and Device Collaborative Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement generally require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner&#8217;s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally collect an upfront license payment from collaboration partners, and are also entitled to receive event-based payments subject to collaboration partners&#8217; achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for respective consideration. Under these collaborative agreements, our partners lead development of assets, and we do not share in significant financial risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to U.S. GAAP. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under all of our ENHANZE collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs. Each of the licenses grants the partners rights to use our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, we provide indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#8217; representations and are not obligations to provide goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our partners, which represent separate contracts. In addition to our licenses, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or (&#8220;SSP&#8221;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g., dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#8217;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of Investigational New Drug (&#8220;IND&#8221;) or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#8217;s commitment of resources to the program. We do not include any amounts subject to uncertainties in the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using an income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time, we have already transferred the related license to the partner. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Device License, Development and Supply Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several license, development and supply arrangements with pharmaceutical partners, under which we grant a license to our device technology and provide research and development services that often involve multiple performance obligations and highly-customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception of the contract and allocate consideration to each performance obligation based on relative SSP, which is generally determined based on the expected cost plus mark-up. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and we have a present right to payment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in the condensed consolidated balance sheets and recognized as revenue in the condensed consolidated statements of income when the associated performance obligations have been satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and milestones received in exchange for the grant of a license to our functional intellectual property, such as patented technology and know-how in connection with a partnered development arrangement, are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal of revenue will not occur when the associated uncertainty is resolved.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion on our collaborative arrangements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proprietary Product Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recombinant</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (&#8220;GPOs&#8221;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in accrued liabilities and net of accounts receivable in the condensed consolidated balance sheet. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Proprietary Product Sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial portfolio of proprietary products includes XYOSTED, TLANDO and NOCDURNA, which we sell primarily to wholesale and specialty distributors. Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued liabilities and net of accounts receivable in the condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnered Product Sales</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bulk rHuPH20</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Devices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the exclusive supplier of  OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to Otter. Because this product is custom manufactured with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in the condensed consolidated balance sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit-sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal of revenue based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our condensed consolidated statements of income, we report the upfront payments, event-based development and regulatory milestones and sales milestones as revenues under collaborative agreements. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from partners as a separate line in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of our proprietary and partnered products are included in product sales, net in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the footnotes to our condensed consolidated financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and device licensing, and development revenues), and additionally, by type of payment stream received under collaborative agreements (upfront license and target nomination fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include salaries and benefits, facilities and other overhead expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record compensation expense associated with stock options, restricted stock units (&#8220;RSUs&#8221;), performance stock units (&#8220;PSUs&#8221;) and shares issued under our employee stock purchase plan (&#8220;ESPP&#8221;) in accordance with the authoritative guidance for share-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#8220;DTA&#8221;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized. We recorded a provision for income taxes of $12.6&#160;million using an effective tax rate of 24.1% for the three months ended March&#160;31, 2023. The difference between our effective tax rate and the U.S. federal statutory rate of 21% is primarily due to tax benefits on Foreign Derived Intangible Income Deduction (&#8220;FDII&#8221;), tax detriments on 162(m) and other share-based compensation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate our business in one operating segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties, and (ii)&#160;product sales of proprietary and partnered products. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption and Pending Adoption of Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption and Pending Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no relevant recently issued accounting pronouncements that would materially impact our condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill and Intangible Assets and Other Long-Lived Assets Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095675830080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text">As a result, the preliminary estimates may be revised during the measurement period. These differences could have a material impact on our results of operations and financial position.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095673972176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of available-for-sale marketable securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:52.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,244&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,225&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:52.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,541&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(944)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,599&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of contractual maturities of available-for-sale debt securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our contractual maturities of available-for-sale debt securities were as follows (in thousands):</span></div><div style="margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:67.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.063%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,591&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year but within five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,599&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of assets measured at fair value on a recurring basis</a></td>
<td class="text">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:29.421%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.337%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total estimated fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable <br/>&#160;&#160;&#160;securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,663&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,907&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,570&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,023&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,280&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,303&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095676090240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of disaggregation of revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disaggregated revenues were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"/><td style="width:78.555%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.292%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Sales of bulk rHuPH20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of proprietary products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of device partnered products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Upfront license and target nomination fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Device Licensing and development revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,534&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,143&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,279&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of accounts receivable, deferred revenues from contracts with customers, and amounts under collaborative agreements included in transaction price</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands): </span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:76.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.176%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.065%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,545&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095676531040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of accounts receivable</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net and contract assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from product sales to partners</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from royalty payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from other product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accounts receivable and contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,799&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for distribution fees and discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,916)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,914)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accounts receivable, net and contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,883&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,072&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,123&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Schedule of prepaid expenses and other assets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,325&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,301)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,007&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,024&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text">Property and equipment, net consisted of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,964&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and payroll taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued outsourced manufacturing expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns and sales allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accrued expenses, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,978&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095677731696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text">The following table shows the cost, accumulated amortization and weighted average useful life in years for our acquired intangible assets as of March&#160;31, 2023 (in thousands).<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"/><td style="width:47.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average useful life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,908&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLANDO product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,983&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480,117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,700&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528,817&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity impacting goodwill is presented below (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:84.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,223&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future annual amortization of finite-lived intangible assets is shown in the following table (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:82.561%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.010%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095681688896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Carrying Amounts of our Convertible Notes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and fair value of our Convertible Notes were as follows (in thousands). </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"/><td style="width:69.570%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Principal Amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,509)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,620)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,383)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value based on trading levels (Level 2):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of outstanding notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363,525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,666,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization per period of debt discount (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Interest Income and Interest Expense Disclosure</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes (in thousands).</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:71.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total coupon interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095673503920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expense</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total following table summarized share-based compensation expense included in our condensed consolidated statements of income related to share-based awards (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:78.491%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.319%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.322%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,865&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,742&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of share-based compensation expense by type</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:78.491%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.319%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.322%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,620&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs, PSUs and ESPP</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,511&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,742&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in Black-Scholes model</a></td>
<td class="text">The assumptions used in the Black-Scholes model were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:65.407%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.008%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.851%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.68 - 39.98%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.14 - 41.23%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.48 - 4.27%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37 - 1.90%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule of unrecognized estimated compensation cost by type</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized was as follows (in thousands, unless otherwise noted):</span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"><tr><td style="width:1.0%"/><td style="width:66.158%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.030%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining<br/>Weighted-Average<br/>Recognition Period<br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.94</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.12</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095681825632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock', window );">Schedule of share repurchases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We had the following activity under the approved share repurchase programs (dollars in thousands, except share and per share data):</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"/><td style="width:50.368%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Price paid Per Share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,165,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,083&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,165,258&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,083&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)   Included in the total cost of shares purchased is a commission fee of $0.02 per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23309-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTreasuryStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095675884560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of reconciliation of numerators and denominators of basic and diluted computations</a></td>
<td class="text">A reconciliation of the numerators and the denominators of the basic and diluted earning per common share computations is as follows (in thousands, except per share amounts):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:77.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.237%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,615&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for basic earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common stock outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs, PSUs and ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:11pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from the calculation of diluted earnings per common share because their effect was anti-dilutive, include the following (shares in millions):</span></div><div style="margin-top:11pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:78.100%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.980%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>(1)    The anti-dilutive securities include outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and Convertible Notes<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095676440512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>collaborator </div>
<div>product</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_RoyaltiesReceivedNumberOfCollaborators', window );">Royalties received, number of collaborators | collaborator</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=halo_BaxaltaMember', window );">Baxalta</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_RoyaltiesReceivedNumberOfProductsSold', window );">royalties received, number of products sold</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=halo_RocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_RoyaltiesReceivedNumberOfProductsSold', window );">royalties received, number of products sold</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=halo_JanssenMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_RoyaltiesReceivedNumberOfProductsSold', window );">royalties received, number of products sold</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_RoyaltiesReceivedNumberOfCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties Received, Number of Collaborators</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_RoyaltiesReceivedNumberOfCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_RoyaltiesReceivedNumberOfProductsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties Received, Number of Products Sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_RoyaltiesReceivedNumberOfProductsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=halo_BaxaltaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=halo_BaxaltaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=halo_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=halo_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=halo_JanssenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=halo_JanssenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095677447248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095677378768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Leases (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of leases</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of leases</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095675880192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue and Cost of Product Sales (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice', window );">Period of contract termination by written notice</a></td>
<td class="text">90 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Period Of Termination By Written Notice</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095676142496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 12,623<span></span>
</td>
<td class="nump">$ 14,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate, percent</a></td>
<td class="nump">24.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095677335856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095676553600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Narrative (Details) - Antares Pharma, Inc - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 24, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 1,045,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare', window );">Consideration transferred, cash paid per acquiree share (in usd per share)</a></td>
<td class="nump">$ 5.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense', window );">Business combination, provisional information, initial accounting incomplete, adjustment, accrued expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet', window );">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill, Purchase Accounting Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, provisional information, initial accounting incomplete, adjustment, accrued expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred tax liabilities, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095675884560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination -Purchase Consideration (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>May 24, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Antares Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 1,045.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095673392800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 24, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 416,223<span></span>
</td>
<td class="nump">$ 409,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Antares Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense', window );">Business combination, provisional information, initial accounting incomplete, adjustment, accrued expense</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet', window );">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred tax liabilities, net</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill, Purchase Accounting Adjustments</a></td>
<td class="nump">$ 7,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 409,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, provisional information, initial accounting incomplete, adjustment, accrued expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred tax liabilities, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095672627968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 179,244<span></span>
</td>
<td class="nump">$ 129,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(944)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">179,225<span></span>
</td>
<td class="nump">128,599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">6,079<span></span>
</td>
<td class="nump">1,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">6,070<span></span>
</td>
<td class="nump">1,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">10,206<span></span>
</td>
<td class="nump">7,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">10,202<span></span>
</td>
<td class="nump">7,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">120,555<span></span>
</td>
<td class="nump">111,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(98)<span></span>
</td>
<td class="num">(934)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">120,500<span></span>
</td>
<td class="nump">110,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">23,639<span></span>
</td>
<td class="nump">7,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">23,635<span></span>
</td>
<td class="nump">7,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember', window );">Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">18,765<span></span>
</td>
<td class="nump">2,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">$ 18,818<span></span>
</td>
<td class="nump">$ 2,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095676230192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of loss positions | security</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair market value of gross unrealized loss position</a></td>
<td class="nump">$ 96,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized loss position of debt securities</a></td>
<td class="nump">126,000<span></span>
</td>
<td class="nump">$ 944,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Credit losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">179,225,000<span></span>
</td>
<td class="nump">128,599,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Antares Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, liability</a></td>
<td class="nump">15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095673470000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Contractual Maturities of Available for Sale Debt Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">$ 154,591<span></span>
</td>
<td class="nump">$ 114,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year but within five years</a></td>
<td class="nump">24,634<span></span>
</td>
<td class="nump">14,246<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 179,225<span></span>
</td>
<td class="nump">$ 128,599<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095674236800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">$ 179,225,000<span></span>
</td>
<td class="nump">$ 128,599,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets measured on a recurring basis</a></td>
<td class="nump">249,570,000<span></span>
</td>
<td class="nump">320,303,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">6,070,000<span></span>
</td>
<td class="nump">1,146,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">10,202,000<span></span>
</td>
<td class="nump">7,130,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">120,500,000<span></span>
</td>
<td class="nump">110,535,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember', window );">Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">18,818,000<span></span>
</td>
<td class="nump">2,784,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">23,635,000<span></span>
</td>
<td class="nump">7,004,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">70,345,000<span></span>
</td>
<td class="nump">191,704,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets measured on a recurring basis</a></td>
<td class="nump">209,663,000<span></span>
</td>
<td class="nump">305,023,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">120,500,000<span></span>
</td>
<td class="nump">110,535,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">18,818,000<span></span>
</td>
<td class="nump">2,784,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">70,345,000<span></span>
</td>
<td class="nump">191,704,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets measured on a recurring basis</a></td>
<td class="nump">39,907,000<span></span>
</td>
<td class="nump">15,280,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">6,070,000<span></span>
</td>
<td class="nump">1,146,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">10,202,000<span></span>
</td>
<td class="nump">7,130,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">23,635,000<span></span>
</td>
<td class="nump">7,004,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095674204848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Disaggregated Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 162,143<span></span>
</td>
<td class="nump">$ 117,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">99,640<span></span>
</td>
<td class="nump">69,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">60,794<span></span>
</td>
<td class="nump">22,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_BulkrHuPH20Member', window );">bulk rHuPH20</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">22,069<span></span>
</td>
<td class="nump">16,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_ProprietaryProductsSalesMember', window );">Proprietary Products Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">27,961<span></span>
</td>
<td class="nump">5,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_DevicePartneredProductsMember', window );">Device Partnered Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10,764<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember', window );">Collaborative Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,709<span></span>
</td>
<td class="nump">25,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_UpfrontfeesMember', window );">Upfront License Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_DeviceLicensingAndDevelopmentMember', window );">Device Licensing and development revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,709<span></span>
</td>
<td class="nump">$ 534<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_BulkrHuPH20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_BulkrHuPH20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_ProprietaryProductsSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_ProprietaryProductsSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_DevicePartneredProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_DevicePartneredProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_UpfrontfeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_UpfrontfeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_DeviceLicensingAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_DeviceLicensingAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095673721232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 162,143<span></span>
</td>
<td class="nump">$ 117,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenues</a></td>
<td class="nump">5,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilities', window );">Deferred revenues</a></td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">32,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember', window );">Other collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenues</a></td>
<td class="nump">123,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_LicenseFeesAndEventBasedMember', window );">License Fees And Event-Based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">99,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">60,794<span></span>
</td>
<td class="nump">$ 22,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">$ 118,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_LicenseFeesAndEventBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_LicenseFeesAndEventBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095676583152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue - Accounts Receivable, net and Deferred Revenues from Contracts (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets', window );">Accounts receivable, net</a></td>
<td class="nump">$ 162,545<span></span>
</td>
<td class="nump">$ 186,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">32,338<span></span>
</td>
<td class="nump">44,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenues</a></td>
<td class="nump">$ 5,499<span></span>
</td>
<td class="nump">$ 5,499<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, after Allowance for Credit Loss, Current, excluding Other Contract Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095681768240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue - Additional Revenue Information (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Deferred revenue, remaining performance obligation, expected timing</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue, remaining performance obligation</a></td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095675966768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Accounts Receivable, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_Accountsreceivablefromproductsalestocollaborators', window );">Accounts receivable from product sales to partners</a></td>
<td class="nump">$ 58,502<span></span>
</td>
<td class="nump">$ 62,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_Accountsreceivablefromcollaborators', window );">Accounts receivable from revenues under collaborative agreements</a></td>
<td class="nump">2,356<span></span>
</td>
<td class="nump">18,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_Accountsreceivablefromroyalties', window );">Accounts receivable from royalty payments</a></td>
<td class="nump">100,829<span></span>
</td>
<td class="nump">100,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_Accountsreceivablefromproductsales', window );">Accounts receivable from other product sales</a></td>
<td class="nump">6,774<span></span>
</td>
<td class="nump">6,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">32,338<span></span>
</td>
<td class="nump">44,102<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Total accounts receivable and contract assets</a></td>
<td class="nump">200,799<span></span>
</td>
<td class="nump">232,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_AllowanceforDistributionFeesandDiscounts', window );">Allowance for distribution fees and discounts</a></td>
<td class="num">(5,916)<span></span>
</td>
<td class="num">(1,914)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable, net and contract assets</a></td>
<td class="nump">$ 194,883<span></span>
</td>
<td class="nump">$ 231,072<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accountsreceivablefromcollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due from collaborators, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accountsreceivablefromcollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accountsreceivablefromproductsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable from product sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accountsreceivablefromproductsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accountsreceivablefromproductsalestocollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable from product sales to collaborators</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accountsreceivablefromproductsalestocollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accountsreceivablefromroyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due from royalties, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accountsreceivablefromroyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AllowanceforDistributionFeesandDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for Discount and Distribution Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AllowanceforDistributionFeesandDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095677372304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 22,453<span></span>
</td>
<td class="nump">$ 13,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">27,402<span></span>
</td>
<td class="nump">40,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">57,666<span></span>
</td>
<td class="nump">45,970<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories, net</a></td>
<td class="nump">$ 107,521<span></span>
</td>
<td class="nump">$ 100,123<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095675956976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid manufacturing expenses</a></td>
<td class="nump">$ 50,084<span></span>
</td>
<td class="nump">$ 51,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">4,739<span></span>
</td>
<td class="nump">4,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">7,424<span></span>
</td>
<td class="nump">14,984<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Total prepaid expenses and other assets</a></td>
<td class="nump">62,247<span></span>
</td>
<td class="nump">71,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Less: Long-term portion</a></td>
<td class="num">(25,240)<span></span>
</td>
<td class="num">(26,301)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other assets, current</a></td>
<td class="nump">$ 37,007<span></span>
</td>
<td class="nump">$ 45,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095676174832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Property and Equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 54,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(16,171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,756)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Subtotal</a></td>
<td class="nump">38,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use of assets</a></td>
<td class="nump">39,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,469<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">77,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,622<span></span>
</td>
<td class="nump">$ 778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Right-of-use asset amortization</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ResearchEquipmentMember', window );">Research equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">8,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ManufacturingEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">31,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ComputerAndOfficeEquipmentMember', window );">Computer and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">8,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 6,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,729<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095673775680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and payroll taxes</a></td>
<td class="nump">$ 10,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_Accruedmanufacturingexpenses', window );">Accrued outsourced manufacturing expenses</a></td>
<td class="nump">12,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">2,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Product returns and sales allowance</a></td>
<td class="nump">29,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">19,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">34,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,788<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses</a></td>
<td class="nump">109,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_AccruedLiabilitiesNoncurrent', window );">Less long-term portion</a></td>
<td class="num">(29,573)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,433)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses, current</a></td>
<td class="nump">79,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_OperatingLeaseAccretionOfLiability', window );">Expense associated with accretion of lease liabilities</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts related to leases</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accruedmanufacturingexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued manufacturing expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accruedmanufacturingexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_OperatingLeaseAccretionOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Accretion Of Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_OperatingLeaseAccretionOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=123410239&amp;loc=SL49130611-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095673359888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 24, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 416,223<span></span>
</td>
<td class="nump">$ 409,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Antares Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 409,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095674003392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Goodwill Rollforward (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">$ 409,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Measurement period adjustment</a></td>
<td class="nump">7,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending Balance</a></td>
<td class="nump">$ 416,223<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095675226048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 541,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">60,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">480,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">ATRS-1902 (IPR&amp;D)</a></td>
<td class="nump">48,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangibles, net</a></td>
<td class="nump">$ 528,817<span></span>
</td>
<td class="nump">$ 546,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_AutoInjectorTechnologyPlatformMember', window );">Auto Injector Technology Platform [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">49,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 352,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_XYOSTEDProprietaryProductMember', window );">XYOSTED Proprietary Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 136,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">11,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 124,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_TLANDOProductRightsMember', window );">TLANDO, Product Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 2,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_AutoInjectorTechnologyPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_AutoInjectorTechnologyPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_XYOSTEDProprietaryProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_XYOSTEDProprietaryProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_TLANDOProductRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_TLANDOProductRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095672625040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets -Future Amortization (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 53,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">71,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">71,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">71,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">71,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour', window );">Thereafter</a></td>
<td class="nump">141,257<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 480,117<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, Yea, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095665150656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Net - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 24, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($) </div>
<div>trading_day </div>
<div>businessDay </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>trading_day </div>
<div>businessDay </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($) </div>
<div>trading_day</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 15, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,525,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,538,483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,400,000<span></span>
</td>
<td class="nump">$ 369,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount paid for conversion of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="nump">$ 77,600,000<span></span>
</td>
<td class="nump">$ 370,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Stock issued for conversion of debt instrument (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,886<span></span>
</td>
<td class="nump">1,510,000<span></span>
</td>
<td class="nump">9,080,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Induced conversion expense related to convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member', window );">1.00% Convertible Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 720,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_DebtInstrumentCapCallTransactionCapPricePerShare', window );">Cap call transaction, cap price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.4075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage', window );">Sale of stock premium over last reported sale price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_PaymentForCappedCallTransactions', window );">Payment for capped calls</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member', window );">1.00% Convertible Senior Notes due 2028 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 720,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Lenders fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">702,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.8517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt, convertible, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member', window );">1.00% Convertible Senior Notes due 2028 | Period One | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Convertible, threshold trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Convertible, threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member', window );">1.00% Convertible Senior Notes due 2028 | Period Two | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Convertible, threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays', window );">Convertible, threshold consecutive business days | businessDay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">0.25% Convertible Senior Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 784,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">0.25% Convertible Senior Notes due 2027 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 805,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Lenders fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.9576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt, convertible, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">0.25% Convertible Senior Notes due 2027 | Period One | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Convertible, threshold trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Convertible, threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">0.25% Convertible Senior Notes due 2027 | Period Two | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Convertible, threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays', window );">Convertible, threshold consecutive business days | businessDay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">1.25% Convertible Senior Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 447,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">1.25% Convertible Senior Notes due 2024 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 460,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Lenders fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.9208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt, convertible, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">1.25% Convertible Senior Notes due 2024 | Period One | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Convertible, threshold trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Convertible, threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">1.25% Convertible Senior Notes due 2024 | Period Two | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Convertible, threshold trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Convertible, threshold consecutive trading days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from revolving credit facilities</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | SOFR | Revolving Credit Facility | Variable Rate Component One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Fed Funds Rate | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Minimum | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Minimum | SOFR | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Minimum | SOFR | Revolving Credit Facility | Variable Rate Component Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Minimum | Base Rate | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Maximum | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Maximum | SOFR | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Maximum | SOFR | Revolving Credit Facility | Variable Rate Component Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Maximum | Base Rate | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from revolving credit facilities</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Term Loan Facility | Year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Term Loan Facility | Year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Term Loan Facility | Year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Term Loan Facility | Year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DebtInstrumentCapCallTransactionCapPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Cap Call Transaction, Cap Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DebtInstrumentCapCallTransactionCapPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Threshold Consecutive Business Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PaymentForCappedCallTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for Capped Call Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_PaymentForCappedCallTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_SaleOfStockPremiumOverLastReportedSalePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock Premium Over Last Reported Sale Price, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_SaleOfStockPremiumOverLastReportedSalePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 40<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123467568&amp;loc=d3e6835-112609<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InducedConversionOfConvertibleDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_VariableRateComponentAxis=halo_VariableRateComponentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_VariableRateComponentAxis=halo_VariableRateComponentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_VariableRateComponentAxis=halo_VariableRateComponentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_VariableRateComponentAxis=halo_VariableRateComponentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=halo_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=halo_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095673871104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Net - Carrying Amount of Convertible Notes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total Principal Amount</a></td>
<td class="nump">$ 1,525,000<span></span>
</td>
<td class="nump">$ 1,538,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total unamortized debt discount</a></td>
<td class="num">(30,620)<span></span>
</td>
<td class="num">(32,383)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, excluding current maturities</a></td>
<td class="nump">1,494,380<span></span>
</td>
<td class="nump">1,492,766<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total carrying amount</a></td>
<td class="nump">1,494,380<span></span>
</td>
<td class="nump">1,506,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of outstanding notes</a></td>
<td class="nump">1,363,525<span></span>
</td>
<td class="nump">1,666,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">1.25% Convertible Senior Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total Principal Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total unamortized debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of outstanding notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 32,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization per period of debt discount (in years):</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">0.25% Convertible Senior Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total Principal Amount</a></td>
<td class="nump">805,000<span></span>
</td>
<td class="nump">$ 805,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total unamortized debt discount</a></td>
<td class="num">(13,509)<span></span>
</td>
<td class="num">(14,359)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, excluding current maturities</a></td>
<td class="nump">791,491<span></span>
</td>
<td class="nump">790,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of outstanding notes</a></td>
<td class="nump">$ 682,938<span></span>
</td>
<td class="nump">$ 784,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization per period of debt discount (in years):</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member', window );">1.00% Convertible Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total Principal Amount</a></td>
<td class="nump">$ 720,000<span></span>
</td>
<td class="nump">$ 720,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Total unamortized debt discount</a></td>
<td class="num">(17,111)<span></span>
</td>
<td class="num">(17,875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, excluding current maturities</a></td>
<td class="nump">702,889<span></span>
</td>
<td class="nump">702,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of outstanding notes</a></td>
<td class="nump">$ 680,587<span></span>
</td>
<td class="nump">$ 849,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization per period of debt discount (in years):</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095674199424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Net - Components of Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Total amortization of debt discount</a></td>
<td class="nump">$ 1,835<span></span>
</td>
<td class="nump">$ 971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Total coupon interest</a></td>
<td class="nump">2,339<span></span>
</td>
<td class="nump">787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Total amortization of debt discount</a></td>
<td class="nump">1,638<span></span>
</td>
<td class="nump">971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">3,977<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">1.25% Convertible Senior Notes due 2024 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Total coupon interest</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Total amortization of debt discount</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rates</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">0.25% Convertible Senior Notes due 2027 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Total coupon interest</a></td>
<td class="nump">$ 503<span></span>
</td>
<td class="nump">$ 503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Total amortization of debt discount</a></td>
<td class="nump">850<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">$ 1,353<span></span>
</td>
<td class="nump">$ 1,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rates</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member', window );">1.00% Convertible Senior Notes due 2028 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Total coupon interest</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Total amortization of debt discount</a></td>
<td class="nump">764<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">$ 2,564<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rates</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A100ConvertibleSeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095677495296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 7,966<span></span>
</td>
<td class="nump">$ 4,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3,455<span></span>
</td>
<td class="nump">2,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember', window );">RSUs, PSUs and ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">4,511<span></span>
</td>
<td class="nump">2,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3,101<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 4,865<span></span>
</td>
<td class="nump">$ 2,725<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095675981632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=halo_A2021ESPPPlanMember', window );">2021 ESPP Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,650,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | 2021 ESPP Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">ESPP purchase price of common stock, percent of market price</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate', window );">Minimum employee subscription rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee subscription rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount', window );">Maximum contribution amount</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Purchase period (in months)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=halo_A2021ESPPPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=halo_A2021ESPPPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095677792240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Assumptions Used in the Black-Scholes Model (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems', window );"><strong>Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected term (in years)</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.48%<span></span>
</td>
<td class="nump">1.37%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.27%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems', window );"><strong>Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">39.68%<span></span>
</td>
<td class="nump">41.14%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems', window );"><strong>Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">39.98%<span></span>
</td>
<td class="nump">41.23%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095676497136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Unrecognized Estimated Compensation Cost (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 45,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 44,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (years)</a></td>
<td class="text">2 years 11 months 8 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 9,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (years)</a></td>
<td class="text">2 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (years)</a></td>
<td class="text">2 months 15 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095673692800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount (shares)</a></td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramPeriodInForce1', window );">Stock Repurchase Program, period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Stock repurchased</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 150,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Weighted-average price paid per share (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44.44<span></span>
</td>
<td class="nump">$ 38.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchased (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,083<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares of common stock issued as a result of stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,931<span></span>
</td>
<td class="nump">172,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock options weighted average exercise price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.87<span></span>
</td>
<td class="nump">$ 17.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock issued during period, shares, restricted stock award, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,919<span></span>
</td>
<td class="nump">216,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Number of RSUs withheld to pay for minimum withholding taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,733<span></span>
</td>
<td class="nump">68,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments for tax withholding for restricted stock units vested, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=halo_StockOptionsAndRestrictedStockUnitsMember', window );">Stock options and restricted units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding stock options and restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramPeriodInForce1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramPeriodInForce1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=halo_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=halo_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095677333280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Share Repurchase Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Total Number of Shares Purchased (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,165,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Weighted-average price paid per share (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.01<span></span>
</td>
<td class="nump">$ 44.44<span></span>
</td>
<td class="nump">$ 38.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Total Cost</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 150,083<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_halo_TreasuryStockAcquiredFeeCostPerShare', window );">Fee per share (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_TreasuryStockAcquiredFeeCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock Acquired, Fee Cost Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_TreasuryStockAcquiredFeeCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095672506320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share - Computation (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 39,615<span></span>
</td>
<td class="nump">$ 60,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding for basic net income (loss) per share (shares)</a></td>
<td class="nump">135,027<span></span>
</td>
<td class="nump">137,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding for diluted net income (loss) per share (shares)</a></td>
<td class="nump">137,900<span></span>
</td>
<td class="nump">141,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (USD per share)</a></td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (USD per share)</a></td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common stock outstanding (shares)</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">1,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common stock outstanding (shares)</a></td>
<td class="nump">2,173<span></span>
</td>
<td class="nump">2,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=halo_RestrictStockUnitsPerformanceSharesAndESPPMember', window );">RSUs, PSUs and ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common stock outstanding (shares)</a></td>
<td class="nump">468<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=halo_RestrictStockUnitsPerformanceSharesAndESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=halo_RestrictStockUnitsPerformanceSharesAndESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140095673727264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share - Antidilutive Securities (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from per share calculation (in shares)</a></td>
<td class="nump">26.2<span></span>
</td>
<td class="nump">15.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>halo-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:halo="http://www.halozyme.com/20230331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="halo-20230331.xsd" xlink:type="simple"/>
    <context id="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic69506cb60d54b0a81669b48b2a0720f_I20230428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="i135c9d6e5363476397deb7376556416f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i18f57f446331441d9650bc51a98fef4b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iff52cfa922bd4a86a7aed2b93a6ae7b7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i02fe07952df9422992b4f26248091821_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1aebf4236d314680b3e3c0a72977aef1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iff57a29a29d64188b30a100687f1c479_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic4ce36d68328465ea06f53e7683604f0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i33911352c8cf4d3a8a5655b090781af3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0705f79cf1bd46bcaee4afc74fd6c446_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6b2c4a20e00545ee9fa2fa2f54922dfc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5fa2dc7b7b064cb99cda5c7d5980ae6b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1b299dba797b49119fe3c2869cbaf39c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9905a464af014a85bc6f52a18e89e039_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if0766222d7af490eb043ec6ffb786970_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2f658ce1d6a2456c8372b0a418d493e9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2a6aa3f2f5da44ffbb88bbeeb79b6e56_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i84c942c19de040e2bca58d2705871d43_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i72b6265ecd0a45ccb0aab3916e41a95c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5998c0ad8cb74ba3b06cbd6c2a277c24_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0432ad1ce41f4fc3bbc7778eedfc105d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i021aeb69fccf46cb9a81f74872450bc2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i32b531446d00413c935a571e48773de0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i38e034be49cf4c1387b7a092a63f997c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia9f57fa1e6ff47c8a4b0c2f4270f8890_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f33835107a94cc08d1aa2cd3aad8d31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8890ea7491a742b486450ebcf13b21de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if89afe2a91d940bfadc08e4c9ffc41c6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if6708ca65ef9487b8ff8abff52cfb4b9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if5a21714774e40ffb9b1684869c5a218_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i02a2a1340b5245dea5832883a6cd93ae_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2ac0a4f26d31423b9dc549a8198fd81b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i61fd7db612a2481293d23ce396675ed6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i14262341c01e414e9cd5feb0ef8cd2dd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i986a9c4e8321407fabcf25854ef0b832_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0e6992830095415c90ee103cb5429d20_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:BaxaltaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7137d05d5f4045da8aacbc2092346351_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia457f78bd8504520987402033058bd04_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:JanssenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i26d023fcab96411da642d788b3f4972f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2c07e926241e4fcea8142ef7b8204548_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i278958ca21434e13ac5e9b20db531704_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="icab3fab76ada402db8fe4009786133b9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i74ddf974e26d4522a765f4b90853db19_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9508cd66d39746d1ab48f1c43c197c90_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i094f2eeb06f242e3ac6bed7262ca9174_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i785729d9e19d43c9874a0e5eb4644380_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibfbf3f7b961745d186224a612c84b694_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i00ffb999a0c746d5bbbfb9ce0f56de51_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if283cea3fe1d4a6a91ac40d41123cd0b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a820e39ab6e40f887d12c0d67623ad2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if9cf1d8f181a422daa99c4f7cb0bae61_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic5537e8e933a456da81116ac3891b12a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if8ff50c7e57541459bb9e2d11625d308_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0ac12a8fcf7d4256b1c58e9d42cb1c4e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib4c6ea833f4e4d4d8e62e3e2a8a60dd7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ica79dc0bdab840cba3dd0e9299d602b2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia6ee6e33f59c4afbba6c572de982c78a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7ac74b74a58e4c778cbccec9b7a58c03_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5f15c4e1aaa429cbc707bcf75d4d317_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i33428793de6741fe9231fd34e586de77_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0971204a009d4734a0ecb98a017e3a11_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6d798995adad4c12bb8d4fa1faf537eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibceadab060e443d8beb30c8b6c154f6b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6952ec39a8ea49e9acc3bd6d2f0d8165_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i739a42f476d6422e927a07b0a6b5e866_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic958d8a4445145abae1f919a5908815c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i60e05f4ffbae45dfb1945eb2ab5d061a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i40dd3bd58ac142339fe5aa795ac93db9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i24130c3f089b46b6857ad5fc1d6bf622_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i455b329b075a48c29ca83f974487d0d2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia88d5d7bf4c148048b1766fdfc7b91e8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7ec8a06ba4b34aafb950e3a31d87cc34_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3b9d9e738fde4ed2857f748c87e3787d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9f8f8b13262e4f419f206a41f9565cc3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b874a74f5924476b565a9f6bcfca413_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1ace94c58553416888e3d388acdf4e1f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i562e413729c347808d2b496afa73e048_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b8ac74092c34340beea79e2b5c3eaef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d3aaf097a2b46f7a4fde671aaa22952_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie0a569c32a674df0839180908bd55f41_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i51cd82ac5a0347999d0942cb559d69f1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4e036a3c236442fcbc74bb9450bb41b6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2ded6c148b24f77bf4d9c161e49d9de_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4f6244ff2fcd468a96760b50de6410df_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie15ed974b99c4d81aa1e6764b03ef509_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4f2e433d91b04a038142f3674a77dbab_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6b20fa8736c942e5a6d16eb5dd856c4d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8349bd4411084a29b491605b9e981c86_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5040df1f6b0340d2b9bdc087ac6bc75a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0e44c7bdff0d4afab55d0f20c2a08e26_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i79f57590019f4701b5d3b0b88015539e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4051c56e33f74f188cc8eccd23a7f58f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:UpfrontfeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4d4b107661c44956a8eb7be6f8c14f9d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:UpfrontfeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if58b9fca0ec74a9995562d09ff0ab3ac_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DeviceLicensingAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i39a11b871a3346cd9599297d2004c0c3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DeviceLicensingAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic22dc841bc6041cba127ce0958181fb1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:LicenseFeesAndEventBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iafdfb78b51284e9cb1aba46fd7125d17_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:OthercollaboratorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iff33634f84774f3e98705b7f0fa793f5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icd9786c1eb264d80a62f434a14aac146_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9f4f1582f5974e0fa962b63fed33147c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i68980f1c77a7473ab18bec2713ab9e05_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib377635631014ff39344d0ec6e220cf8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifed31096856d45c5a8a866ba7b9fccce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1795cd05c98547769da8f152dffa740b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i47f684ec05774a41841a55c9d11bc8ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i429394b48f8f49c9bd5c34d8ea70ef6f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i463667de7a9840d9887b692b9090956f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i04990caa9f1d4feeb66916e444f5b67f_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i859ed6ba27774ade9888f1c580577c1a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i81c6c189dc1c414db846950051a68f58_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i48becb7672924502ac96083bb5cd5d79_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ieeb34905ee5a413ba8c2930d948203a1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia90c2ed74ead443583b931534d578bb2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaa015d0540a840c79bc449df56401a5f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i25336e1752ef44b4b8ba6f295a047c8d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:TLANDOProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6e130d5a6e9b4d66b803cb5e487a55ef_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:TLANDOProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if3d4edc7f65c461d9431d7d9efcc56e9_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="ifd6f3969e6c8426fa1c64cce894e6e50_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i5418d7fce8df4268a313fe8e25d35226_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="ia9437143ea354b0fb66fc8e352a8fad9_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i4b687461f70242228d9fa67322314ce3_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="ic03a55962ac146dfb9a17293e7c10f01_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i875da9e8bc6f447e83c35dccc1bce549_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="i297284b6b3114aa4a934c8c77af6a7ef_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i49ac4e10c151449aa37064756bff906c_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib53c28890ced4a5e81b120e58423d483_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i62e04ec34e84456a9a1c1c9fce36d738_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0a51169caaa348e8906636fb88af0a07_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i98820adb7b114fab89f1dcfab8fb0f09_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i2bd17b29b4a74fd99bf9cb4435a081cf_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i295b45eca4f04978ad6b88c2a0a40c9b_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="icf91861e2376494b8f674c6a659fb5c1_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="ibc695c8e9d5e48179ccc383f1676101c_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i09030ba483314a21b46d9dd361c0aa83_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i8cf5bff84e7842eab1e94ae576059f7e_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i0b9f1075f25446e3857aa8ab0613536f_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifbcb0ae49876436997c9d2b2422116d1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3eda99a3ab274f3189aed8a7cd000ecc_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i7511bded3501417cb4e2415a6bcbd39b_D20230301-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6e312be945a2402db2f373983b98f7d7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i82c04eddabc54f759c9fb4de56fb03f4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3aafe649a1244a06b7cb31af4030dfbd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6816f5120aee4e1790a693cbeb24b81b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i256de7cb03ee49139431754c4ae916aa_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i166af7e00a904a83b5854157af961f65_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i03816f914d7a447986a953007197bb96_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4fb3535e833444bdbbab874679ac6563_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9afd86f45c5e469cbf3764deb77b2e92_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib5ffcb548d7140e1ac76a8652c62766b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7a88cde3434f468b8176c193c6db698f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i818a916aac4f44ffa2bd008ffe38a30a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i96d86a86d4dc47ecb2dfffda2f52ab0f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i388d4ea90c0548c39bda4283394ecd6c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i62ec2ac8d55a4479a3ff4cc2ff76befb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i46a442da67054fd9b76638faf6b88d76_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icd4da77d8421473cb59e66faa8374380_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic86e248bcecd4584b1f877e96f7336cd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i66a48adbd00143d6b8660e90fb91cae0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5e21cdfacc224f85abe16a6d40aec853_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0d608edf583c4031bb38b269eb42b8ea_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0d5d7ddddf33471496c67ca9c24baf70_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib68465c427954f66928ec69ce2d8bcfe_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i96dbb0d9515a4b9983f224b01c185b89_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A100ConvertibleSeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0426add4fd0d41e9ac294788c419aadb_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i064840ce987b44589b1984f31ec23ee9_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i52bc8208b75542fe834c04c4a32935e2_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i80af1fed659d4797a60c80b15182657c_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i92b9cedcf3f2470db29567877e9ab56b_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i6c4153c5687046e5b97fe69b5b5dd0a7_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i849dc496423d470899ceba933ef3cddb_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="ic433e02b2e524802bd9b3db31defcb80_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="ic21b915c10f948c5be0345f6cca32742_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i921873efde3f4390ba5cf90029a46dfe_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="iaccbd76f32744459bd6ce7634d990a3e_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="idbbefd52056444bfada4f4742cd5491a_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i9b315f13ef0b4d7da409254361bf6681_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i1c4765296dd7441193e31a2d3b55cc50_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="iab25dbdafb934ddaa1edddfd20909764_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i77ffcd92787e44a4b19b0c3b9575a7ab_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="if5ac304dab2f4cac876a9781e63af963_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="ie4bb445d76ad4d60806edb24823f807a_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="ice8cda3f37824ceaadbd1c40fb40a92e_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="i04c8df8cf25c44f5aab2fcfc36944999_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifb2e8da7a634478895e75cec60c5c338_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i26ffd244af4f411f8cd2468455cda38a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4e27c05190e1407887ac69c8d7d33adf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i84f9ba0217ca4943af62f30063a6142b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id845f28873224a6287ebf2f2b47ef3d0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4a6aae30a5394516b3ad5c031cec59c6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia721a5e3252544d3821885e9d7a30919_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i457c8fcb2ad444429cbae63ee2c523ba_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i16324593b4c9487687f61647a729634f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5c3a0c9ac8ff414aa0504ce40bfa1e50_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i92a039cdfbbf4fa8af99885fb9696846_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ic595728a50dc437dbd456b98049dd40d_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i5ed2833f90c64a0b9b7117a1df7588fe_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i98636a07909a4eb082fd10e5a0c20ab2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic6ab22e429fd4490ace65357489d0522_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if0e2d808937f41cb849c6d6eec760399_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9c07ee50572b4618820f8dd73892a316_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9c8cad373a064499b7994b46613c260c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0aabdf6a6ae54c86b1cc74c5d60a1f07_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1b6b375c49834699b6901ea74bf476d4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idf2b9ab6a89d4df59dd4955dcef17ae1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia1343ec306ed4444b65da6a899a7f2c3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ida5a69f1405a496f802d78313d35c0c3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i335649d465744f89957988f0508a596e_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6f605f48fb46486b8c32365ccf871ecf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9f8d6a392c1d4fe8b9e5be6142532df5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RestrictStockUnitsPerformanceSharesAndESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i752be5578b5b423d8fc0ff6e421f4f83_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RestrictStockUnitsPerformanceSharesAndESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4b70d8e746f94570afba56b0ac99fe35_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i71746ecec304430aa330b98c5496d867_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="collaborator">
        <measure>halo:collaborator</measure>
    </unit>
    <unit id="product">
        <measure>halo:product</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>halo:segment</measure>
    </unit>
    <unit id="security">
        <measure>halo:security</measure>
    </unit>
    <unit id="trading_day">
        <measure>halo:trading_day</measure>
    </unit>
    <unit id="businessday">
        <measure>halo:businessDay</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80L2ZyYWc6M2M0ZWMyZDcyNjZlNGU0M2E3MTM2YjhjMTY3NzcxMzMvdGFibGU6YTAxMzMyYWExZWVmNDcyYWJkNmI2MTNlNjYxYjc1MmYvdGFibGVyYW5nZTphMDEzMzJhYTFlZWY0NzJhYmQ2YjYxM2U2NjFiNzUyZl8xLTEtMS0xLTk3ODM5_f0d519b2-fec7-41c1-9d1b-80942cc5203c">0001159036</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80L2ZyYWc6M2M0ZWMyZDcyNjZlNGU0M2E3MTM2YjhjMTY3NzcxMzMvdGFibGU6YTAxMzMyYWExZWVmNDcyYWJkNmI2MTNlNjYxYjc1MmYvdGFibGVyYW5nZTphMDEzMzJhYTFlZWY0NzJhYmQ2YjYxM2U2NjFiNzUyZl8yLTEtMS0xLTk3ODM5_42fbd222-cf60-4337-9da8-e8f94526ba1f">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80L2ZyYWc6M2M0ZWMyZDcyNjZlNGU0M2E3MTM2YjhjMTY3NzcxMzMvdGFibGU6YTAxMzMyYWExZWVmNDcyYWJkNmI2MTNlNjYxYjc1MmYvdGFibGVyYW5nZTphMDEzMzJhYTFlZWY0NzJhYmQ2YjYxM2U2NjFiNzUyZl8zLTEtMS0xLTk3ODM5_97c37082-4627-4f4d-b7de-91d5c9994530">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80L2ZyYWc6M2M0ZWMyZDcyNjZlNGU0M2E3MTM2YjhjMTY3NzcxMzMvdGFibGU6YTAxMzMyYWExZWVmNDcyYWJkNmI2MTNlNjYxYjc1MmYvdGFibGVyYW5nZTphMDEzMzJhYTFlZWY0NzJhYmQ2YjYxM2U2NjFiNzUyZl80LTEtMS0xLTk3ODM5_0de42ceb-3d55-441d-aeb0-0b0da5212324">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80L2ZyYWc6M2M0ZWMyZDcyNjZlNGU0M2E3MTM2YjhjMTY3NzcxMzMvdGFibGU6YTAxMzMyYWExZWVmNDcyYWJkNmI2MTNlNjYxYjc1MmYvdGFibGVyYW5nZTphMDEzMzJhYTFlZWY0NzJhYmQ2YjYxM2U2NjFiNzUyZl81LTEtMS0xLTk3ODM5_9e762000-a1d8-48dd-98d8-f66a96f92f6c">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="icd9786c1eb264d80a62f434a14aac146_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82MS9mcmFnOjcxYzdlNDczNTdhMDRiMTI4YTM3MzA4NzUzNDUxNWE1L3RhYmxlOjVkNGQ1YmI3MjRiMzRmNjE5MTdlYjA2MzE5OWQ3YTBmL3RhYmxlcmFuZ2U6NWQ0ZDViYjcyNGIzNGY2MTkxN2ViMDYzMTk5ZDdhMGZfMS0xLTEtMS05NzgzOQ_0df02f8f-ea62-4d5b-a88c-bede3498527f">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i859ed6ba27774ade9888f1c580577c1a_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RleHRyZWdpb246MTYzZDU4ODI5MmUwNGM4ZGEwZGI0YzJjNWY0NjIwZWJfNTU2_7b1e4645-8507-4bdd-a7da-977a1bcbb72c">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:StockRepurchaseProgramPeriodInForce1
      contextRef="i335649d465744f89957988f0508a596e_D20211201-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMTU2Nw_a30831a4-f6f2-4774-9f18-5ca5ed367463">P3Y</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <dei:DocumentType
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xODAx_d96bd9be-cd6d-4fe1-953b-61fc3cd9f0b8">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6ZTM4MWRiMjEwODQ5NGUwZWI1YjUwNzliNTI1NzRmNTkvdGFibGVyYW5nZTplMzgxZGIyMTA4NDk0ZTBlYjViNTA3OWI1MjU3NGY1OV8wLTAtMS0xLTk3ODM5_66645477-e82e-42fb-ba4b-6394133d9cc8">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xMzQ_e2d2fbdb-9e7c-45d3-a2f1-ce14770415ab">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6YWZmN2Q1OWU3MTU2NGM4ZWI4MjBmMzc0NTczZmE0ZjIvdGFibGVyYW5nZTphZmY3ZDU5ZTcxNTY0YzhlYjgyMGYzNzQ1NzNmYTRmMl8wLTAtMS0xLTk3ODM5_c05487bb-ca46-42f0-932c-dea53064bfe8">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xODAy_a94785c1-1e00-47ca-a8b6-33be488ad6b8">001-32335</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xODAz_7ae1884a-b12b-4afa-adec-d9d9d5be549c">HALOZYME THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6YWRjOGQxN2VjNzc0NDZlMTk1NTgyMjRlMWQ5MDE2NWEvdGFibGVyYW5nZTphZGM4ZDE3ZWM3NzQ0NmUxOTU1ODIyNGUxZDkwMTY1YV8wLTAtMS0xLTk3ODM5_a8e5d858-0863-4858-8244-beb7915ed547">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6YWRjOGQxN2VjNzc0NDZlMTk1NTgyMjRlMWQ5MDE2NWEvdGFibGVyYW5nZTphZGM4ZDE3ZWM3NzQ0NmUxOTU1ODIyNGUxZDkwMTY1YV8wLTItMS0xLTk3ODM5_917caed3-6d8f-4054-8e80-6d281b5ad9dd">88-0488686</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6YWRjOGQxN2VjNzc0NDZlMTk1NTgyMjRlMWQ5MDE2NWEvdGFibGVyYW5nZTphZGM4ZDE3ZWM3NzQ0NmUxOTU1ODIyNGUxZDkwMTY1YV8zLTAtMS0xLTk3ODM5_8b5f80d2-b1d8-4c86-80c2-c1363d6c86c3">12390 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6YWRjOGQxN2VjNzc0NDZlMTk1NTgyMjRlMWQ5MDE2NWEvdGFibGVyYW5nZTphZGM4ZDE3ZWM3NzQ0NmUxOTU1ODIyNGUxZDkwMTY1YV8zLTItMS0xLTk3ODM5_fc905586-af08-40f6-a617-d3f51a2c5816">92130</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6YWRjOGQxN2VjNzc0NDZlMTk1NTgyMjRlMWQ5MDE2NWEvdGFibGVyYW5nZTphZGM4ZDE3ZWM3NzQ0NmUxOTU1ODIyNGUxZDkwMTY1YV80LTAtMS0xLTk3ODM5_c894ed68-f5fe-4cca-999f-d4995427581c">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6YWRjOGQxN2VjNzc0NDZlMTk1NTgyMjRlMWQ5MDE2NWEvdGFibGVyYW5nZTphZGM4ZDE3ZWM3NzQ0NmUxOTU1ODIyNGUxZDkwMTY1YV81LTAtMS0xLTk3ODM5_7d95e45b-a1b0-4fe8-ab30-76e7e64c3719">CA</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xODA0_1c9be45b-4965-4574-9872-766c370dae6c">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xODA1_a534bbd0-1714-4a70-b332-83b41fd3dae9">794-8889</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6NDRlZGMzYjUzNzk0NDQ3YmFkMzcxMTE1NGU3ZTcwZTQvdGFibGVyYW5nZTo0NGVkYzNiNTM3OTQ0NDdiYWQzNzExMTU0ZTdlNzBlNF8xLTAtMS0xLTk3ODM5_c6c8e19f-224e-4e5e-8ebb-e438699e45f6">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6NDRlZGMzYjUzNzk0NDQ3YmFkMzcxMTE1NGU3ZTcwZTQvdGFibGVyYW5nZTo0NGVkYzNiNTM3OTQ0NDdiYWQzNzExMTU0ZTdlNzBlNF8xLTEtMS0xLTk3ODM5_88b293d1-4b77-4761-abe5-ceb6ced8e42d">HALO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6NDRlZGMzYjUzNzk0NDQ3YmFkMzcxMTE1NGU3ZTcwZTQvdGFibGVyYW5nZTo0NGVkYzNiNTM3OTQ0NDdiYWQzNzExMTU0ZTdlNzBlNF8xLTItMS0xLTk3ODM5_8968fe28-cd66-4831-bcbf-5ae8d2759ce4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xNzk4_95f43754-8fd1-488f-bfdb-86612507acc8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xNzk5_9379dae8-6117-46aa-a2a4-86e7979f3c0d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6OGRiYmQ1NzBjMzNhNGIzNWJmODk0ZjU0OWI4N2ExYTUvdGFibGVyYW5nZTo4ZGJiZDU3MGMzM2E0YjM1YmY4OTRmNTQ5Yjg3YTFhNV8wLTAtMS0xLTk3ODM5_8357dfec-5ace-4c84-8e36-2ad366292f18">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6OGRiYmQ1NzBjMzNhNGIzNWJmODk0ZjU0OWI4N2ExYTUvdGFibGVyYW5nZTo4ZGJiZDU3MGMzM2E0YjM1YmY4OTRmNTQ5Yjg3YTFhNV8xLTMtMS0xLTk3ODM5_b947aea3-505a-4cd1-a51b-e3d79b5eb00a">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGFibGU6OGRiYmQ1NzBjMzNhNGIzNWJmODk0ZjU0OWI4N2ExYTUvdGFibGVyYW5nZTo4ZGJiZDU3MGMzM2E0YjM1YmY4OTRmNTQ5Yjg3YTFhNV8yLTMtMS0xLTk3ODM5_49520257-6c99-41fd-b3f1-325ab83d8c9d">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xODAw_3881ad8e-8e2e-4be0-9132-7c87b0985bf7">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic69506cb60d54b0a81669b48b2a0720f_I20230428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xL2ZyYWc6YWIzNjk4MWQyMzM1NGNhMGE3Njg0YmQ0MDU2MThmODEvdGV4dHJlZ2lvbjphYjM2OTgxZDIzMzU0Y2EwYTc2ODRiZDQwNTYxOGY4MV8xNzgz_736438b5-6382-40d8-abf4-8c8730b927be"
      unitRef="shares">131680440</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMy0yLTEtMS05NzgzOQ_0875a742-a983-4f5a-a37d-8015c5ad74c8"
      unitRef="usd">96383000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMy00LTEtMS05NzgzOQ_8f7f5ac5-2908-4eff-985e-039c393458d5"
      unitRef="usd">234195000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfNC0yLTEtMS05NzgzOQ_fc881290-e620-4284-b3e2-d33a30d9cf87"
      unitRef="usd">179225000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfNC00LTEtMS05NzgzOQ_6ab6437a-81bb-42ea-ad14-810935def97a"
      unitRef="usd">128599000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfNS0yLTEtMS05NzgzOQ_1b4d77d6-64c9-4f3c-bbb5-f2d55283b4e0"
      unitRef="usd">194883000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfNS00LTEtMS05NzgzOQ_f493e8c8-0c07-4377-ad05-a0eed50580e0"
      unitRef="usd">231072000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfNi0yLTEtMS05NzgzOQ_a0c423f6-ea1e-450d-b738-233961f8cc7a"
      unitRef="usd">107521000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfNi00LTEtMS05NzgzOQ_84c82732-b6dd-4049-8956-b6d623c935a2"
      unitRef="usd">100123000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfNy0yLTEtMS05NzgzOQ_548c8159-ae59-4ccc-a361-9f920aade76b"
      unitRef="usd">37007000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfNy00LTEtMS05NzgzOQ_a545694e-297c-42a2-84df-403fd41f1534"
      unitRef="usd">45024000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfOC0yLTEtMS05NzgzOQ_602a2729-3b32-4534-8ea1-e70378968a00"
      unitRef="usd">615019000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfOC00LTEtMS05NzgzOQ_63810561-cc02-4ad5-9284-2cd7c6581c5d"
      unitRef="usd">739013000</us-gaap:AssetsCurrent>
    <halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfOS0yLTEtMS05NzgzOQ_78c2a10d-915f-4b4c-93b7-977d8f20e47c"
      unitRef="usd">77964000</halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfOS00LTEtMS05NzgzOQ_761e4fe7-dee6-42e0-a593-b3660036ed6f"
      unitRef="usd">75570000</halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTAtMi0xLTEtOTc4Mzk_efc2f052-06e9-4d85-93fe-b6337d662bdd"
      unitRef="usd">25240000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTAtNC0xLTEtOTc4Mzk_857b3e3f-58f9-41a0-8522-c15a4aa2d792"
      unitRef="usd">26301000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:Goodwill
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTEtMi0xLTEtOTc4Mzk_914c34f5-3071-4609-ba64-7b7a8332b50f"
      unitRef="usd">416223000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTEtNC0xLTEtOTc4Mzk_00abfe9f-961f-4a19-8f44-1b00379d11f8"
      unitRef="usd">409049000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTItMi0xLTEtOTc4Mzk_49c7c425-5da4-4647-a614-6d6e2423b822"
      unitRef="usd">528817000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTItNC0xLTEtOTc4Mzk_a379c9ac-14f8-4736-bd7a-a9a13fa14454"
      unitRef="usd">546652000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTMtMi0xLTEtOTc4Mzk_c8f23cdc-dce0-477d-9b21-fa2681db8537"
      unitRef="usd">35684000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTMtNC0xLTEtOTc4Mzk_799695de-a1e7-4168-975f-02af04cc9f7c"
      unitRef="usd">44426000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTQtMi0xLTEtOTc4Mzk_53d0495d-fdfe-4976-9049-0ff1b075b824"
      unitRef="usd">500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTQtMi0xLTEtOTc4Mzk_f75cf02e-0bcc-40de-a4e9-b69b6ce4f1d9"
      unitRef="usd">500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTQtNC0xLTEtOTc4Mzk_a4c0eb52-64be-457d-8034-62a0de985814"
      unitRef="usd">500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:Assets
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTUtMi0xLTEtOTc4Mzk_3f95ee2f-8571-48ff-b0f1-4c68bf221bb4"
      unitRef="usd">1699447000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTUtNC0xLTEtOTc4Mzk_d5be142e-80fb-4947-9dc9-33ccecfbc6fc"
      unitRef="usd">1841511000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTktMi0xLTEtOTc4Mzk_6facecaa-1e0c-4576-a1a3-450d33074cd9"
      unitRef="usd">8695000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMTktNC0xLTEtOTc4Mzk_85b874bb-73a4-4e6d-9a40-c2467253a596"
      unitRef="usd">17693000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjAtMi0xLTEtOTc4Mzk_4aba9fea-283d-4024-8b2d-fff1bee3a58b"
      unitRef="usd">79978000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjAtNC0xLTEtOTc4Mzk_daea1b25-dda8-4fb2-8e1b-e57a8c2ce208"
      unitRef="usd">96516000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjEtMi0xLTEtOTc4Mzk_2120e3ca-15a5-47a8-afa8-924f3af4ff64"
      unitRef="usd">3246000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjEtNC0xLTEtOTc4Mzk_006c64a8-9e4b-4037-828b-791137cd7e5d"
      unitRef="usd">3246000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjItMi0xLTEtOTc4Mzk_69825864-2a9b-42d1-9407-03c23c03f810"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjItNC0xLTEtOTc4Mzk_c85420fc-5eb0-46dd-90cf-5a84b4a8b95c"
      unitRef="usd">13334000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjMtMi0xLTEtOTc4Mzk_2930cf5a-600e-46b4-bc46-55efb770eaad"
      unitRef="usd">91919000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjMtNC0xLTEtOTc4Mzk_e3ef670a-7b30-4139-a400-6326d576f9ad"
      unitRef="usd">130789000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjQtMi0xLTEtOTc4Mzk_17f7b04b-e6b7-4fda-97b6-8ef669d96021"
      unitRef="usd">2253000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjQtNC0xLTEtOTc4Mzk_f14bb70b-5e0b-4d39-9061-92654e5d0b13"
      unitRef="usd">2253000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjUtMi0xLTEtOTc4Mzk_21646df0-abe0-4871-b042-2bac6b950061"
      unitRef="usd">1494380000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjUtNC0xLTEtOTc4Mzk_c96e87e5-4aad-4937-843e-791600b317f6"
      unitRef="usd">1492766000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjYtMi0xLTEtOTc4Mzk_4385028e-8a0f-4273-81b3-73753729ebc9"
      unitRef="usd">29573000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjYtNC0xLTEtOTc4Mzk_3fbb4482-f2bc-4371-8ad4-5c99cc81498f"
      unitRef="usd">30433000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjgtMi0xLTEtOTc4Mzk_d55b40ea-eee7-4257-b4ae-ba3e83c1abfc"
      unitRef="usd">15472000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjgtNC0xLTEtOTc4Mzk_fc4da0d1-f0c5-430f-8a89-a4750022c55e"
      unitRef="usd">15472000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjktMi0xLTEtMTEyOTQ2_144b413f-22d0-44db-a578-6551bdf8b49e"
      unitRef="usd">1633597000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjktNC0xLTEtMTEzMzY1_d466a083-d837-4490-9e6d-7495ad15b697"
      unitRef="usd">1671713000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjktMi0xLTEtOTc4Mzk_875b0dc7-8d88-4c7c-9664-645427026476"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMjktNC0xLTEtOTc4Mzk_7bd08627-dccf-41c1-99d3-b9f0e1759944"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjowN2EwYTI5MDRhNzQ0YmNhYjY3MzgyNDllYWNlYmQ4OV8yMg_b0145f05-311a-4a9e-a3e6-1ee979caaf3f"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjowN2EwYTI5MDRhNzQ0YmNhYjY3MzgyNDllYWNlYmQ4OV8yMg_dee80915-7e8a-49cd-8583-441ada17dcc4"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjowN2EwYTI5MDRhNzQ0YmNhYjY3MzgyNDllYWNlYmQ4OV8zNg_454a56fd-0d8a-4f37-8a25-63f3f3564151"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjowN2EwYTI5MDRhNzQ0YmNhYjY3MzgyNDllYWNlYmQ4OV8zNg_d71271b7-2ec3-44bf-9e0d-630e431fca89"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjowN2EwYTI5MDRhNzQ0YmNhYjY3MzgyNDllYWNlYmQ4OV81OA_11dee7d2-4023-4221-95a6-1ed00c312010"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjowN2EwYTI5MDRhNzQ0YmNhYjY3MzgyNDllYWNlYmQ4OV81OA_6ed8ec3d-eff4-4ab0-8cfe-25989b6eb112"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjowN2EwYTI5MDRhNzQ0YmNhYjY3MzgyNDllYWNlYmQ4OV81OA_b3f4587e-84c1-4418-9398-ab33dc71c17c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjowN2EwYTI5MDRhNzQ0YmNhYjY3MzgyNDllYWNlYmQ4OV81OA_fa19de7c-efa4-4bf9-9c14-f77fdbf666e3"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtMi0xLTEtOTc4Mzk_2131d2dc-0cf9-416f-94cd-d0f2111d027d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzEtNC0xLTEtOTc4Mzk_0a71dff4-f9da-46ee-a49a-6295f604d068"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzItMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjo5MDA2MTQxZDg0NjM0MGZjODgyNDE1ODFiNGU0Y2NjNV8xOQ_3927048e-057d-48be-aaf3-70d8bae641fc"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzItMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjo5MDA2MTQxZDg0NjM0MGZjODgyNDE1ODFiNGU0Y2NjNV8xOQ_aa1d73c7-f085-4b1a-9379-97b6ef9ff783"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzItMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjo5MDA2MTQxZDg0NjM0MGZjODgyNDE1ODFiNGU0Y2NjNV8zMw_96907a6c-a19b-4493-be21-26bdad455a77"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzItMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjo5MDA2MTQxZDg0NjM0MGZjODgyNDE1ODFiNGU0Y2NjNV8zMw_d78e7f6e-a88b-416c-97aa-c008b1203d1f"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzItMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjo5MDA2MTQxZDg0NjM0MGZjODgyNDE1ODFiNGU0Y2NjNV81NQ_9d23cd6d-4da7-4884-9af7-9409edbaf244"
      unitRef="shares">131662000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzItMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjo5MDA2MTQxZDg0NjM0MGZjODgyNDE1ODFiNGU0Y2NjNV81NQ_c31fcaf3-9ea9-49ec-9f51-735bb0dd55cb"
      unitRef="shares">131662000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="iff52cfa922bd4a86a7aed2b93a6ae7b7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzItMC0xLTEtOTc4MzkvdGV4dHJlZ2lvbjo5MDA2MTQxZDg0NjM0MGZjODgyNDE1ODFiNGU0Y2NjNV82Mg_28033cec-e60d-47b4-9bab-d559ecbf62c6"
      unitRef="shares">135154000</us-gaap:SharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzItMi0xLTEtOTc4Mzk_435b39c0-1e21-4445-854c-584bc53b9e88"
      unitRef="usd">132000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzItNC0xLTEtOTc4Mzk_b04ee4cb-8690-4027-96ee-9a5d799adaae"
      unitRef="usd">135000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzMtMi0xLTEtOTc4Mzk_056149a7-87f7-4d4e-b3ff-f833beb59979"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzMtNC0xLTEtOTc4Mzk_5903b02c-c76e-419c-8041-4dc254b5dedf"
      unitRef="usd">27368000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzQtMi0xLTEtOTc4Mzk_77250e63-2ad6-4d29-9e19-8035f61bdf34"
      unitRef="usd">24000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzQtNC0xLTEtOTc4Mzk_7561ebc8-882e-4d2d-9762-31be4ce559ce"
      unitRef="usd">-922000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzUtMi0xLTEtOTc4Mzk_17a2f79d-01c0-48ce-9c50-509e2e895b97"
      unitRef="usd">65694000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzUtNC0xLTEtOTc4Mzk_58baa6a3-a4fd-4a42-951d-f513e9c3761f"
      unitRef="usd">143217000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzYtMi0xLTEtOTc4Mzk_63c0b4ff-e40f-4efe-8529-2a9f3185346e"
      unitRef="usd">65850000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzYtNC0xLTEtOTc4Mzk_27ddceba-d845-4a1c-9a3d-d2cfce69c146"
      unitRef="usd">169798000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzctMi0xLTEtOTc4Mzk_40102e95-1b75-4f23-b98f-79d958248348"
      unitRef="usd">1699447000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8xOS9mcmFnOmU5ZGRiNmVmNmIwYzQ3MTI4MDVjMThjMzk5NDNkYWM3L3RhYmxlOjA1OGEwZjMyOTc5MTQ3NWZhYzY4MGQxNmE2OTRiYzA4L3RhYmxlcmFuZ2U6MDU4YTBmMzI5NzkxNDc1ZmFjNjgwZDE2YTY5NGJjMDhfMzctNC0xLTEtOTc4Mzk_49516b24-b5b2-42cb-8219-0327f75b00ab"
      unitRef="usd">1841511000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02fe07952df9422992b4f26248091821_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMy0yLTEtMS05NzgzOQ_5c1f8fc9-dbbb-4eae-8239-00687adb17ac"
      unitRef="usd">99640000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1aebf4236d314680b3e3c0a72977aef1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMy00LTEtMS05NzgzOQ_73ed1339-a647-4fcc-a2b5-ff6939b64cdd"
      unitRef="usd">69605000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff57a29a29d64188b30a100687f1c479_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfNC0yLTEtMS05NzgzOQ_91abc59b-21e6-4586-9184-5c364e3552ee"
      unitRef="usd">60794000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4ce36d68328465ea06f53e7683604f0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfNC00LTEtMS05NzgzOQ_a676622e-dac7-48cd-851f-7685f903a430"
      unitRef="usd">22140000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33911352c8cf4d3a8a5655b090781af3_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfNS0yLTEtMS05NzgzOQ_6a450291-f693-4010-b5cb-dfc938d46c2f"
      unitRef="usd">1709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0705f79cf1bd46bcaee4afc74fd6c446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfNS00LTEtMS05NzgzOQ_3ce52400-7450-4a58-b0ba-9d08869648a0"
      unitRef="usd">25534000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfNi0yLTEtMS05NzgzOQ_aa48af5d-9116-48c9-ba93-b880329acf3c"
      unitRef="usd">162143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfNi00LTEtMS05NzgzOQ_72e9a009-e518-4787-bf5f-1a9a5713ccd9"
      unitRef="usd">117279000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfOC0yLTEtMS05NzgzOQ_f8a0a52e-f317-4737-afa2-2c99ea9a28d4"
      unitRef="usd">35170000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfOC00LTEtMS05NzgzOQ_c587b972-55a4-487c-938b-c44b5d83bfc7"
      unitRef="usd">15922000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfOS0yLTEtMS05NzgzOQ_a87b6df8-93f3-418b-8d0d-37d5173e31d9"
      unitRef="usd">17835000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfOS00LTEtMS05NzgzOQ_79bcd59a-c745-4177-b597-717c9f9c30d1"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTAtMi0xLTEtOTc4Mzk_1b1b9b40-4e3b-46d7-9b3e-a1ad0d2f22e8"
      unitRef="usd">17979000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTAtNC0xLTEtOTc4Mzk_ea98ae8e-baa4-4622-aea5-5f14f9a6cd73"
      unitRef="usd">11853000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTEtMi0xLTEtOTc4Mzk_e804189b-0542-408a-aa4e-4710f12e6d00"
      unitRef="usd">37357000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTEtNC0xLTEtOTc4Mzk_75678afa-7390-48bd-a625-4ac7d3784146"
      unitRef="usd">13834000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTItMi0xLTEtOTc4Mzk_38c018e1-23cf-47f1-b8aa-713f0e3dcc5f"
      unitRef="usd">108341000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTItNC0xLTEtOTc4Mzk_04b1858f-1c33-4e32-a64b-53665f0f6d4c"
      unitRef="usd">41609000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTMtMi0xLTEtOTc4Mzk_a6e0fd2c-7ff5-446e-8b91-0af44c2ff497"
      unitRef="usd">53802000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTMtNC0xLTEtOTc4Mzk_39c60277-024b-481e-837c-b56f92d3ac1b"
      unitRef="usd">75670000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTUtMi0xLTEtOTc4Mzk_a943b249-71e8-464c-8ad5-aff471e42d68"
      unitRef="usd">2979000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTUtNC0xLTEtOTc4Mzk_670c43d7-9d84-4303-ad70-a9066ca57d5e"
      unitRef="usd">498000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTctMi0xLTEtOTc4Mzk_33dec92f-21f7-4160-87c2-2e2ad85412ab"
      unitRef="usd">4543000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTctNC0xLTEtOTc4Mzk_10bfb479-4285-4c97-9813-19b231d3f124"
      unitRef="usd">1759000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTgtMi0xLTEtOTc4Mzk_fd65778b-7847-434a-85a4-bcab0db827f4"
      unitRef="usd">52238000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTgtNC0xLTEtOTc4Mzk_e2601ccb-dda4-4100-ad0a-c811dc212ce1"
      unitRef="usd">74409000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTktMi0xLTEtOTc4Mzk_e25a52ac-6d0f-4432-993d-ff82c1385986"
      unitRef="usd">12623000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMTktNC0xLTEtOTc4Mzk_d561eee6-8870-47eb-af50-3e27e2d6b67a"
      unitRef="usd">14301000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjAtMi0xLTEtOTc4Mzk_a05dc2af-f6f2-4211-8a21-4e617c2266e5"
      unitRef="usd">39615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjAtNC0xLTEtOTc4Mzk_bf9b4e8e-c062-41f4-afaf-c7a1bffe2e71"
      unitRef="usd">60108000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjMtMi0xLTEtOTc4Mzk_4e97d3e5-ed1b-4d18-93a5-21f3e27e9685"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjMtNC0xLTEtOTc4Mzk_cf0076d6-441a-42e6-b71e-4b31214efe85"
      unitRef="usdPerShare">0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjQtMi0xLTEtOTc4Mzk_c9d1d16d-0b01-4663-bf3a-6ee44ae1db14"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjQtNC0xLTEtOTc4Mzk_d3e970b5-b3de-41e1-995f-c961b08ab46d"
      unitRef="usdPerShare">0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjctMi0xLTEtOTc4Mzk_17513582-fc31-4a13-b423-149043fe44d8"
      unitRef="shares">135027000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjctNC0xLTEtOTc4Mzk_8ceb9378-f96a-49e2-9016-6616c9cc1011"
      unitRef="shares">137658000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjgtMi0xLTEtOTc4Mzk_19ac4b41-4f8e-4052-8dfe-f1b30fb63010"
      unitRef="shares">137900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yNS9mcmFnOjQyN2FlZDQ1ZWExMTQ1MzFhM2Q2YmNiM2Q5ZjZiZTNjL3RhYmxlOjdmNGE5NzY2MjI2NzQ3OWU4YzAzODNiZjY4NDVlMTViL3RhYmxlcmFuZ2U6N2Y0YTk3NjYyMjY3NDc5ZThjMDM4M2JmNjg0NWUxNWJfMjgtNC0xLTEtOTc4Mzk_b2901024-1e68-4f96-9800-eba073ed0029"
      unitRef="shares">141277000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yOC9mcmFnOjNmNWE0ZGZmYTQwMzRjMWRiN2RlOTdhNTliMDQ2ODE4L3RhYmxlOmU2ZTBkYTYwOGRhYTRlMzdhMzlkYWNiMWUzZDFiMmFjL3RhYmxlcmFuZ2U6ZTZlMGRhNjA4ZGFhNGUzN2EzOWRhY2IxZTNkMWIyYWNfMi0yLTEtMS05NzgzOQ_e3aef642-ff83-4de9-9fe7-ff6f76710f3a"
      unitRef="usd">39615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yOC9mcmFnOjNmNWE0ZGZmYTQwMzRjMWRiN2RlOTdhNTliMDQ2ODE4L3RhYmxlOmU2ZTBkYTYwOGRhYTRlMzdhMzlkYWNiMWUzZDFiMmFjL3RhYmxlcmFuZ2U6ZTZlMGRhNjA4ZGFhNGUzN2EzOWRhY2IxZTNkMWIyYWNfMi00LTEtMS05NzgzOQ_5661f12f-3bca-47b6-bf65-8c8f864f219b"
      unitRef="usd">60108000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yOC9mcmFnOjNmNWE0ZGZmYTQwMzRjMWRiN2RlOTdhNTliMDQ2ODE4L3RhYmxlOmU2ZTBkYTYwOGRhYTRlMzdhMzlkYWNiMWUzZDFiMmFjL3RhYmxlcmFuZ2U6ZTZlMGRhNjA4ZGFhNGUzN2EzOWRhY2IxZTNkMWIyYWNfNC0yLTEtMS05NzgzOQ_434dff0e-c28e-49ec-9c75-0b0cec97c371"
      unitRef="usd">924000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yOC9mcmFnOjNmNWE0ZGZmYTQwMzRjMWRiN2RlOTdhNTliMDQ2ODE4L3RhYmxlOmU2ZTBkYTYwOGRhYTRlMzdhMzlkYWNiMWUzZDFiMmFjL3RhYmxlcmFuZ2U6ZTZlMGRhNjA4ZGFhNGUzN2EzOWRhY2IxZTNkMWIyYWNfNC00LTEtMS05NzgzOQ_e178ecaa-45d4-406f-9180-c0500cbf37ce"
      unitRef="usd">-2171000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yOC9mcmFnOjNmNWE0ZGZmYTQwMzRjMWRiN2RlOTdhNTliMDQ2ODE4L3RhYmxlOmU2ZTBkYTYwOGRhYTRlMzdhMzlkYWNiMWUzZDFiMmFjL3RhYmxlcmFuZ2U6ZTZlMGRhNjA4ZGFhNGUzN2EzOWRhY2IxZTNkMWIyYWNfNS0yLTEtMS05NzgzOQ_a852e564-132c-4cb9-b149-2a6c8c2243f6"
      unitRef="usd">-22000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yOC9mcmFnOjNmNWE0ZGZmYTQwMzRjMWRiN2RlOTdhNTliMDQ2ODE4L3RhYmxlOmU2ZTBkYTYwOGRhYTRlMzdhMzlkYWNiMWUzZDFiMmFjL3RhYmxlcmFuZ2U6ZTZlMGRhNjA4ZGFhNGUzN2EzOWRhY2IxZTNkMWIyYWNfNS00LTEtMS05NzgzOQ_266fb7db-38e6-44bd-916c-48f976f48246"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yOC9mcmFnOjNmNWE0ZGZmYTQwMzRjMWRiN2RlOTdhNTliMDQ2ODE4L3RhYmxlOmU2ZTBkYTYwOGRhYTRlMzdhMzlkYWNiMWUzZDFiMmFjL3RhYmxlcmFuZ2U6ZTZlMGRhNjA4ZGFhNGUzN2EzOWRhY2IxZTNkMWIyYWNfNy0yLTEtMS05NzgzOQ_23ababfd-a8d6-4249-ab29-ae7942af5e40"
      unitRef="usd">40561000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8yOC9mcmFnOjNmNWE0ZGZmYTQwMzRjMWRiN2RlOTdhNTliMDQ2ODE4L3RhYmxlOmU2ZTBkYTYwOGRhYTRlMzdhMzlkYWNiMWUzZDFiMmFjL3RhYmxlcmFuZ2U6ZTZlMGRhNjA4ZGFhNGUzN2EzOWRhY2IxZTNkMWIyYWNfNy00LTEtMS05NzgzOQ_db088e26-87db-41f7-88f1-1fbb75b8962f"
      unitRef="usd">57937000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNC0yLTEtMS05NzgzOQ_c8721cb6-1ba9-4832-8a51-077773ca09fb"
      unitRef="usd">39615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNC00LTEtMS05NzgzOQ_6a2a34c4-3988-435e-845f-bd655584d211"
      unitRef="usd">60108000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNi0yLTEtMS05NzgzOQ_a0d7a229-178f-4357-a787-b8ea1eb03800"
      unitRef="usd">7966000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNi00LTEtMS05NzgzOQ_47fa9571-6d3d-40d3-bc3c-2f87d7cc0eb3"
      unitRef="usd">4742000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNy0yLTEtMS05NzgzOQ_379e6773-df6c-4df6-8f8c-5fb4bd141b07"
      unitRef="usd">2622000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNy00LTEtMS05NzgzOQ_d6705206-4c48-48ec-aafe-b9964b199277"
      unitRef="usd">778000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfOC0yLTEtMS05NzgzOQ_09489f4e-f2dd-4ab4-89c3-0e2397f759fc"
      unitRef="usd">17835000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfOC00LTEtMS05NzgzOQ_b76da42e-f9b5-49ec-a138-e794350ada50"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfOS0yLTEtMS05NzgzOQ_ef22c717-d3f4-474c-b78c-97a4d4d09067"
      unitRef="usd">1835000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfOS00LTEtMS05NzgzOQ_b3e96c50-06e8-4582-b193-d2e56913c380"
      unitRef="usd">971000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMTEtMi0xLTEtOTc4Mzk_e2612630-efc3-4f53-82b4-0b485fabae28"
      unitRef="usd">917000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMTEtNC0xLTEtOTc4Mzk_466765f5-f5f4-43cf-a7d2-01fdb897f4b3"
      unitRef="usd">-541000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMTMtMi0xLTEtOTc4Mzk_fbb8d738-1d60-4134-9063-c25057281688"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMTMtNC0xLTEtOTc4Mzk_4bd95f78-58f3-4fc4-bfac-c3de734965d3"
      unitRef="usd">-80000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMTUtMi0xLTEtOTc4Mzk_02408076-8396-40c4-89cf-100c0b0163e5"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMTUtNC0xLTEtOTc4Mzk_fc4f5ba4-21ed-4bb4-9967-f811c0c50d17"
      unitRef="usd">-499000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <halo:DeferredRentPayments
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMTYtMi0xLTEtOTc4Mzk_6ac22dd6-30c0-4efa-abd3-dd80f88658f4"
      unitRef="usd">-320000</halo:DeferredRentPayments>
    <halo:DeferredRentPayments
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMTYtNC0xLTEtOTc4Mzk_3eac5228-89a0-406e-a4c2-568d671a6b29"
      unitRef="usd">183000</halo:DeferredRentPayments>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjAtMi0xLTEtOTc4Mzk_9d25a356-46d5-4ff8-b152-9d1510514487"
      unitRef="usd">-3874000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjAtNC0xLTEtOTc4Mzk_fb5e3cd6-a016-4bde-bcf7-cad8d47e8e92"
      unitRef="usd">-12926000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjMtMi0xLTEtOTc4Mzk_b669099d-a95e-4cac-86ac-8c186b5930f8"
      unitRef="usd">-36189000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjMtNC0xLTEtOTc4Mzk_ac02a855-447c-41cd-92d6-ce5430581d38"
      unitRef="usd">22787000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjQtMi0xLTEtOTc4Mzk_a4de22dd-fba9-4807-8d82-6e813a701337"
      unitRef="usd">7250000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjQtNC0xLTEtOTc4Mzk_10d5d3d5-4630-454f-b196-c41bca3f9001"
      unitRef="usd">-6298000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjUtMi0xLTEtOTc4Mzk_f10fb532-0a41-4165-9c59-60bbb32fb33e"
      unitRef="usd">-8881000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjUtNC0xLTEtOTc4Mzk_f173f171-2516-438a-b93a-264df7aeb3a8"
      unitRef="usd">9168000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjYtMi0xLTEtOTc4Mzk_7a734486-1bdf-4f57-9eab-e6078c2608ef"
      unitRef="usd">-24006000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjYtNC0xLTEtOTc4Mzk_f23e9817-0a0b-4891-a83b-7354208afced"
      unitRef="usd">-6010000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjctMi0xLTEtOTc4Mzk_b638fcf3-a24f-4eaa-8d5a-382d172a940c"
      unitRef="usd">86964000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjctNC0xLTEtOTc4Mzk_4fc447dc-8c53-4dfb-b526-751a25603c43"
      unitRef="usd">47797000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjktMi0xLTEtOTc4Mzk_671f37df-238b-466e-8b94-61e3d279cf54"
      unitRef="usd">109919000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMjktNC0xLTEtOTc4Mzk_3528d7ae-f3ef-47a2-a0b2-9e1d1f800a4c"
      unitRef="usd">184815000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMzAtMi0xLTEtOTc4Mzk_7fcb8226-a550-4279-92f8-94af5fb1c928"
      unitRef="usd">61134000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMzAtNC0xLTEtOTc4Mzk_fcd8ea81-3bc1-4f16-9fbf-50d37cc4463d"
      unitRef="usd">136000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMzItMi0xLTEtOTc4Mzk_2491f04a-3dd2-4292-bc83-f93fb4f92e94"
      unitRef="usd">11377000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMzItNC0xLTEtOTc4Mzk_d61ef9c6-f7ca-4760-b873-b690ed6aeb79"
      unitRef="usd">490000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMzQtMi0xLTEtOTc4Mzk_fa45a0a5-0c72-4e06-9a5a-3a1ccb8ed082"
      unitRef="usd">-60162000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfMzQtNC0xLTEtOTc4Mzk_79b524ee-7b87-4fcd-8810-c2fd2e3894d0"
      unitRef="usd">-49305000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDItMi0xLTEtOTc4Mzk_646d9097-ad5a-4514-8f3d-929600068872"
      unitRef="usd">13483000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDItNC0xLTEtOTc4Mzk_3aa5d605-da9f-4d46-9739-1e1df75a30a6"
      unitRef="usd">0</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDYtMi0xLTEtOTc4Mzk_4b3361a9-d3a1-4322-bd5a-c86ff2ed833d"
      unitRef="usd">150083000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDYtNC0xLTEtOTc4Mzk_e52731d4-8c8b-4ffa-af1f-a774c9bbaa46"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <halo:ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDctMi0xLTEtOTc4Mzk_3b531ee8-4660-4cac-b3de-0179b945ffaf"
      unitRef="usd">-1048000</halo:ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised>
    <halo:ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDctNC0xLTEtOTc4Mzk_3abd0211-788c-4f7d-a157-93556dbbadb7"
      unitRef="usd">624000</halo:ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDgtMi0xLTEtOTc4Mzk_541a2118-811f-451c-bce3-43d7456e981f"
      unitRef="usd">-164614000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDgtNC0xLTEtOTc4Mzk_22be2780-9c53-4e24-aa93-f79bd337db02"
      unitRef="usd">624000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDktMi0xLTEtOTc4Mzk_e036c677-dd5a-47cb-a8d4-ff032a9706b0"
      unitRef="usd">-137812000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNDktNC0xLTEtOTc4Mzk_429d6185-1b29-4ad2-95a9-0dfb7707df71"
      unitRef="usd">-884000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTAtMi0xLTEtOTc4Mzk_51e1b28a-4ca0-433b-8156-e2ffa42f1c3f"
      unitRef="usd">234695000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6b2c4a20e00545ee9fa2fa2f54922dfc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTAtNC0xLTEtOTc4Mzk_84b38600-24d3-4331-a753-227877954e92"
      unitRef="usd">119219000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTEtMi0xLTEtOTc4Mzk_6fac3701-358c-487a-b8a3-a856046c4ff4"
      unitRef="usd">96883000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5fa2dc7b7b064cb99cda5c7d5980ae6b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTEtNC0xLTEtOTc4Mzk_441b6964-cd33-4824-ad58-986f60bf2f3d"
      unitRef="usd">118335000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTQtMi0xLTEtOTc4Mzk_edf87ca4-02d1-4f67-a5b4-bf72394d1405"
      unitRef="usd">390000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTQtNC0xLTEtOTc4Mzk_b630f69b-11c0-45ca-a269-14908701d997"
      unitRef="usd">309000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTUtMi0xLTEtOTc4Mzk_9d1643fe-05e5-4e1d-b526-613965bc1887"
      unitRef="usd">406000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTUtNC0xLTEtOTc4Mzk_d53f293d-c4e8-4313-a3e7-37210824aa09"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssued1
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTgtMi0xLTEtOTc4Mzk_5c5aa0e5-9df6-4cf3-8530-1063ad2c0eb1"
      unitRef="usd">125000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zMS9mcmFnOmEzZjljNjA3NDBhNjQxMjJiYTk5MjVjZDAwZjQ0ZDc1L3RhYmxlOjQ3YmRlMmRlYzJiYTQyYzE4ZWM2YzJjZDZjMTJkMDRjL3RhYmxlcmFuZ2U6NDdiZGUyZGVjMmJhNDJjMThlYzZjMmNkNmMxMmQwNGNfNTgtNC0xLTEtOTc4Mzk_41feedd4-9089-4df2-95c4-0dbf5642e17a"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:SharesOutstanding
      contextRef="iff52cfa922bd4a86a7aed2b93a6ae7b7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMy0yLTEtMS05NzgzOQ_c41ce06e-e034-4bf3-9bd9-ad5fc8e16ed2"
      unitRef="shares">135154000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iff52cfa922bd4a86a7aed2b93a6ae7b7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMy00LTEtMS05NzgzOQ_276af887-b45e-4bdd-88e2-b0c90326e570"
      unitRef="usd">135000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1b299dba797b49119fe3c2869cbaf39c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMy02LTEtMS05NzgzOQ_343e8416-9a37-4ee1-9f4e-31c85a7af780"
      unitRef="usd">27368000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9905a464af014a85bc6f52a18e89e039_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMy04LTEtMS05NzgzOQ_8f1ff4e7-45ad-4412-b977-46a9c78428da"
      unitRef="usd">-922000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if0766222d7af490eb043ec6ffb786970_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMy0xMC0xLTEtOTc4Mzk_e04e9c51-fdf5-4a9e-a7f3-61b74ec44de7"
      unitRef="usd">143217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMy0xMi0xLTEtOTc4Mzk_df0d1275-b538-4bbe-8008-d303ee4ea6be"
      unitRef="usd">169798000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2f658ce1d6a2456c8372b0a418d493e9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNS02LTEtMS05NzgzOQ_b04247d7-7176-49ce-b83f-ce25764b493a"
      unitRef="usd">7966000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNS0xMi0xLTEtOTc4Mzk_808c0e4d-acda-446a-b3ce-f86aa4b5261a"
      unitRef="usd">7966000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i2a6aa3f2f5da44ffbb88bbeeb79b6e56_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNi0yLTEtMS05NzgzOQ_2f09ee45-6c97-45d6-849d-9d73d8995b43"
      unitRef="shares">289000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i2a6aa3f2f5da44ffbb88bbeeb79b6e56_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNi00LTEtMS05NzgzOQ_082c2663-8b66-41a9-b878-0aeee1545d5b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i2f658ce1d6a2456c8372b0a418d493e9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNi02LTEtMS05NzgzOQ_bb56360f-f3e2-4d7e-b82c-178d4e8066df"
      unitRef="usd">-126000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNi0xMi0xLTEtOTc4Mzk_153d07df-b7bb-4f70-87be-ee0bd97416f4"
      unitRef="usd">-126000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2a6aa3f2f5da44ffbb88bbeeb79b6e56_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNy0yLTEtMS05NzgzOQ_0fca664d-5da4-44db-a893-ef80922367dd"
      unitRef="shares">384000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2a6aa3f2f5da44ffbb88bbeeb79b6e56_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNy00LTEtMS05NzgzOQ_cd1bc484-bac8-434c-ad37-23bc3de53b0c"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2f658ce1d6a2456c8372b0a418d493e9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNy02LTEtMS05NzgzOQ_f609d7af-c3ef-455e-a478-d46d9beff896"
      unitRef="usd">-1049000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNy0xMi0xLTEtOTc4Mzk_a00f820a-7b3e-4a4a-9b3f-de330608c514"
      unitRef="usd">-1048000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i2a6aa3f2f5da44ffbb88bbeeb79b6e56_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTAtMi0xLTEtOTc4Mzk_71c25089-346b-4016-9c32-0f690231415a"
      unitRef="shares">4165000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i2a6aa3f2f5da44ffbb88bbeeb79b6e56_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTAtNC0xLTEtOTc4Mzk_d7f32c65-5031-4f51-b491-1780178fa7bf"
      unitRef="usd">4000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i2f658ce1d6a2456c8372b0a418d493e9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTAtNi0xLTEtOTc4Mzk_520d9753-ba05-413f-bcc8-b4d730a22847"
      unitRef="usd">34159000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i84c942c19de040e2bca58d2705871d43_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTAtMTAtMS0xLTExMDcxNw_75c58b92-a3bb-44bb-9fac-010dae983f42"
      unitRef="usd">117138000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTAtMTItMS0xLTk3ODM5_1dc00844-35b6-417c-bd35-aa49d83c5ccf"
      unitRef="usd">151301000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i72b6265ecd0a45ccb0aab3916e41a95c_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTEtOC0xLTEtOTc4Mzk_b35cedbd-1bed-4639-9218-f25be1354021"
      unitRef="usd">946000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTEtMTItMS0xLTk3ODM5_5ab80d27-bdd1-4a10-abe2-9c0ee74bca72"
      unitRef="usd">946000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:NetIncomeLoss
      contextRef="i84c942c19de040e2bca58d2705871d43_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTItMTAtMS0xLTk3ODM5_11ca4ab1-0ccd-4abb-80d0-c21e99904df2"
      unitRef="usd">39615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTItMTItMS0xLTk3ODM5_93a732b3-a49e-4049-9527-6775eafa3288"
      unitRef="usd">39615000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i5998c0ad8cb74ba3b06cbd6c2a277c24_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTMtMi0xLTEtOTc4Mzk_277fb509-deda-43f4-a18e-a0b8c24a44a9"
      unitRef="shares">131662000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5998c0ad8cb74ba3b06cbd6c2a277c24_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTMtNC0xLTEtOTc4Mzk_c320e5cc-a3b9-435d-808e-a9ac5288c3ef"
      unitRef="usd">132000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0432ad1ce41f4fc3bbc7778eedfc105d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTMtNi0xLTEtOTc4Mzk_0a781828-b620-4229-bd6b-69ce030ff9e6"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i021aeb69fccf46cb9a81f74872450bc2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTMtOC0xLTEtOTc4Mzk_2054b948-1e94-4f4a-b31f-5b8cec02b858"
      unitRef="usd">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i32b531446d00413c935a571e48773de0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTMtMTAtMS0xLTk3ODM5_b175bdc8-98fa-4ad7-aa1f-b68a5b7ac649"
      unitRef="usd">65694000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMTMtMTItMS0xLTk3ODM5_2bd0c0c4-8530-45c1-868b-6f8503c22ff6"
      unitRef="usd">65850000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i38e034be49cf4c1387b7a092a63f997c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzQtMi0xLTEtOTc4Mzk_42776422-e6e9-48be-aad2-9a5afdb9d960"
      unitRef="shares">137498000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i38e034be49cf4c1387b7a092a63f997c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzQtNC0xLTEtOTc4Mzk_09fc1c82-43bf-492c-aefa-36748d956da8"
      unitRef="usd">138000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia9f57fa1e6ff47c8a4b0c2f4270f8890_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzQtNi0xLTEtOTc4Mzk_208e2fd2-7302-4feb-b743-09faba495b7b"
      unitRef="usd">256347000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1f33835107a94cc08d1aa2cd3aad8d31_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzQtOC0xLTEtOTc4Mzk_9b3bd26f-72fb-4ec8-a8d4-05fafd69040c"
      unitRef="usd">-620000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8890ea7491a742b486450ebcf13b21de_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzQtMTAtMS0xLTk3ODM5_88cad2a0-9dcb-4389-81b4-14509f5d7a6a"
      unitRef="usd">-58912000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6b2c4a20e00545ee9fa2fa2f54922dfc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzQtMTItMS0xLTk3ODM5_82606457-bba3-4472-91cf-aede5639cea7"
      unitRef="usd">196953000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if89afe2a91d940bfadc08e4c9ffc41c6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzYtNi0xLTEtOTc4Mzk_d5efefc6-f078-45f8-bdb3-d845cc239acc"
      unitRef="usd">4742000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzYtMTItMS0xLTk3ODM5_b52336d4-b5f5-4f81-9e3b-49cc335d6e2d"
      unitRef="usd">4742000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if6708ca65ef9487b8ff8abff52cfb4b9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzgtMi0xLTEtOTc4Mzk_e1ddcb4e-6c91-4170-a685-c524e5c4945b"
      unitRef="shares">390000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if6708ca65ef9487b8ff8abff52cfb4b9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzgtNC0xLTEtOTc4Mzk_8d5da50e-6814-4c84-b454-871cefcaaa20"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if89afe2a91d940bfadc08e4c9ffc41c6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzgtNi0xLTEtOTc4Mzk_3f809e1b-738a-4298-a322-66065adc27e3"
      unitRef="usd">624000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfMzgtMTItMS0xLTk3ODM5_9fdfeca3-9e2c-4704-8f76-410bcc117de4"
      unitRef="usd">624000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="if5a21714774e40ffb9b1684869c5a218_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDItOC0xLTEtOTc4Mzk_48907bff-2287-4eec-acbe-66a68eef167b"
      unitRef="usd">-2171000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDItMTItMS0xLTk3ODM5_8fc65890-fb88-4ce6-a8af-8352f8b8f230"
      unitRef="usd">-2171000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:NetIncomeLoss
      contextRef="i02a2a1340b5245dea5832883a6cd93ae_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDMtMTAtMS0xLTk3ODM5_4418e13e-a35a-49ed-9fa3-95d8a642be0a"
      unitRef="usd">60108000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDMtMTItMS0xLTk3ODM5_0c173f22-971f-4ee2-81b0-28df0201fcd7"
      unitRef="usd">60108000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i2ac0a4f26d31423b9dc549a8198fd81b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDQtMi0xLTEtOTc4Mzk_4211be5a-3c1f-486e-8bcd-33b17a0ab6ed"
      unitRef="shares">137888000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2ac0a4f26d31423b9dc549a8198fd81b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDQtNC0xLTEtOTc4Mzk_6a204307-cbab-453f-a016-decf07d39239"
      unitRef="usd">138000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i61fd7db612a2481293d23ce396675ed6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDQtNi0xLTEtOTc4Mzk_1e90fb34-5df5-4310-9b12-d7f2d3d56e3a"
      unitRef="usd">261713000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i14262341c01e414e9cd5feb0ef8cd2dd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDQtOC0xLTEtOTc4Mzk_09357979-54f1-4bf0-adde-cb3e0d341646"
      unitRef="usd">-2791000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i986a9c4e8321407fabcf25854ef0b832_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDQtMTAtMS0xLTk3ODM5_4fc13640-58c7-46a7-8d88-3f4553b0d6ea"
      unitRef="usd">1196000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5fa2dc7b7b064cb99cda5c7d5980ae6b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl8zNC9mcmFnOjBkNjI0Mzc2MWMwYTRmNzdiZGM2OWZiNzNhMzU3NTM5L3RhYmxlOmRlYmU2OWMzODg2ZDQ5Mjk5NmIzOTkwNTFkNThlNzU1L3RhYmxlcmFuZ2U6ZGViZTY5YzM4ODZkNDkyOTk2YjM5OTA1MWQ1OGU3NTVfNDQtMTItMS0xLTk3ODM5_b790b32c-c165-4878-bd06-44b9b2e42038"
      unitRef="usd">260256000</us-gaap:StockholdersEquity>
    <us-gaap:NatureOfOperations
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80MC9mcmFnOjU2ZDNkMGZkMjJlYTRhMWNhMDI0N2I1NTRjMmVhYjcyL3RleHRyZWdpb246NTZkM2QwZmQyMmVhNGExY2EwMjQ3YjU1NGMyZWFiNzJfNTAyOQ_4bc0d48b-57ee-454f-9595-62def5cc38e4">Organization and Business &lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving the patient experience and potentially outcomes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our proprietary enzyme, rHuPH20, is used to facilitate the subcutaneous (&#x201c;SC&#x201d;) delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; drug delivery&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;technology (&#x201c;ENHANZE&#x201d;) with the partners&#x2019; proprietary compounds. We also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our first commercially approved product Hylenex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; recombinant (&#x201c;Hylenex&#x201d;), and our ENHANZE partners&#x2019; approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in Hylenex that works by breaking down hyaluronan (&#x201c;HA&#x201d;), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the SC space. This temporarily reduces the barrier to bulk fluid flow allowing for improved and more rapid SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as ENHANZE. We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (&#x201c;IV&#x201d;) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing typically required for IV administration, extend the dosing interval for drugs that are already administered subcutaneously and potentially allow for lower rates of infusion related reactions.&#160;ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient or caregiver. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of the proprietary IV drug.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&#x201c;Roche&#x201d;), Takeda Pharmaceuticals International AG and Baxalta US Inc. (&#x201c;Takeda&#x201d;), Pfizer Inc. (&#x201c;Pfizer&#x201d;), Janssen Biotech, Inc. (&#x201c;Janssen&#x201d;), AbbVie, Inc. (&#x201c;AbbVie&#x201d;), Eli Lilly and Company (&#x201c;Lilly&#x201d;), Bristol-Myers Squibb Company (&#x201c;BMS&#x201d;), Alexion Pharma International Operations Unlimited Company (an indirect wholly owned subsidiary of AstraZeneca PLC) (&#x201c;Alexion&#x201d;), argenx BVBA (&#x201c;argenx&#x201d;), Horizon Therapeutics plc. (&#x201c;Horizon&#x201d;), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (&#x201c;ViiV&#x201d;) and Chugai Pharmaceutical Co., Ltd (&#x201c;Chugai&#x201d;). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE. We currently receive royalties from three of these collaborations, including royalties from sales of one product from the Takeda collaboration, three products from the Roche collaboration and one product from the Janssen collaboration. Future potential revenues from ENHANZE collaborations and from the sales and/or royalties of our approved products will depend on the ability of our partners, in some areas supported by Halozyme to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our commercial portfolio of proprietary products also includes XYOSTED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, TLANDO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and NOCDURNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also have commercialized auto-injector products with several pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (&#x201c;Teva&#x201d;), Covis Group S.a.r.l. (&#x201c;Covis&#x201d;) and Otter Pharmaceuticals, LLC (&#x201c;Otter&#x201d;). We have development programs including auto-injectors with Idorsia Pharmaceuticals Ltd. (&#x201c;Idorsia&#x201d;) and Pfizer.&lt;/span&gt;&lt;/div&gt;Except where specifically noted or the context otherwise requires, references to &#x201c;Halozyme,&#x201d; &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; and &#x201c;us&#x201d; in these notes to the condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and each of its directly and indirectly wholly owned subsidiaries</us-gaap:NatureOfOperations>
    <halo:RoyaltiesReceivedNumberOfCollaborators
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80MC9mcmFnOjU2ZDNkMGZkMjJlYTRhMWNhMDI0N2I1NTRjMmVhYjcyL3RleHRyZWdpb246NTZkM2QwZmQyMmVhNGExY2EwMjQ3YjU1NGMyZWFiNzJfMzM2OQ_060827fa-a2b9-4b79-8a74-b2fe52b14930"
      unitRef="collaborator">3</halo:RoyaltiesReceivedNumberOfCollaborators>
    <halo:RoyaltiesReceivedNumberOfProductsSold
      contextRef="i0e6992830095415c90ee103cb5429d20_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80MC9mcmFnOjU2ZDNkMGZkMjJlYTRhMWNhMDI0N2I1NTRjMmVhYjcyL3RleHRyZWdpb246NTZkM2QwZmQyMmVhNGExY2EwMjQ3YjU1NGMyZWFiNzJfMzQzMQ_257b9a8a-6c72-4d16-80c6-11fd98cd7864"
      unitRef="product">1</halo:RoyaltiesReceivedNumberOfProductsSold>
    <halo:RoyaltiesReceivedNumberOfProductsSold
      contextRef="i7137d05d5f4045da8aacbc2092346351_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80MC9mcmFnOjU2ZDNkMGZkMjJlYTRhMWNhMDI0N2I1NTRjMmVhYjcyL3RleHRyZWdpb246NTZkM2QwZmQyMmVhNGExY2EwMjQ3YjU1NGMyZWFiNzJfMzQ3Mw_f79227fe-2a5b-4fa8-a297-fadc5c03e48a"
      unitRef="product">3</halo:RoyaltiesReceivedNumberOfProductsSold>
    <halo:RoyaltiesReceivedNumberOfProductsSold
      contextRef="ia457f78bd8504520987402033058bd04_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80MC9mcmFnOjU2ZDNkMGZkMjJlYTRhMWNhMDI0N2I1NTRjMmVhYjcyL3RleHRyZWdpb246NTZkM2QwZmQyMmVhNGExY2EwMjQ3YjU1NGMyZWFiNzJfMzUxOA_fc5f38ef-393b-45c1-8113-2ede1b0f8064"
      unitRef="product">1</halo:RoyaltiesReceivedNumberOfProductsSold>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU4MTA_d77363f4-90a5-455e-ae01-cb518c816dca">Summary of Significant Accounting Policies&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited condensed consolidated financial statements have been prepared for purposes of and in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on February&#160;21, 2023. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., and Antares Pharma, Inc.&#x2019;s wholly owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in our interim unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that we believe to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents and Marketable Securities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within 90 days or less from the date of purchase. As of March&#160;31, 2023, our cash and cash equivalents consisted of money market funds, bank certificate of deposits and demand deposits at commercial banks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities are investments with original maturities of more than 90 days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#x2019;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders&#x2019; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the interim unaudited condensed consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in the interim unaudited condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the lease terms of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. As of March&#160;31, 2023 and December&#160;31, 2022, restricted cash of $0.5 million was pledged as collateral for the letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses, long-term debt and a contingent liability. Fair value estimates of these instruments are made at a specific point in time based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore, cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from 3 years to 12 years. We determine if an arrangement contains a lease at inception. Right of use (&#x201c;ROU&#x201d;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option. Short-term leases with an initial term of 12 months or less are not recorded on the condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs incurred to complete a business combination, such as legal and other professional fees, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired, including intangible assets and in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;amp;D &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;amp;D asset is expensed in the period of abandonment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and IPR&amp;amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;amp;D asset exceeds its respective fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our identifiable intangible assets with finite useful lives are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ENHANZE and Device Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. In general, when there are no valid claims of a specified patent developed under the collaboration covering the product in a given country, the royalty rate is reduced for those sales in that country upon the expiration of our patents covering rHuPH20. Janssen&#x2019;s patents covering DARZALEX SC do not impact the timing for this royalty reduction. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted will become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also earn royalties in connection with several of our licenses granted under license and development arrangements with our device partners. These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#x2019; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days after the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue under ENHANZE and Device Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ENHANZE Collaboration and License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement generally require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner&#x2019;s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally collect an upfront license payment from collaboration partners, and are also entitled to receive event-based payments subject to collaboration partners&#x2019; achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for respective consideration. Under these collaborative agreements, our partners lead development of assets, and we do not share in significant financial risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to U.S. GAAP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under all of our ENHANZE collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs. Each of the licenses grants the partners rights to use our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, we provide indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#x2019; representations and are not obligations to provide goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our partners, which represent separate contracts. In addition to our licenses, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or (&#x201c;SSP&#x201d;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g., dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#x2019;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of Investigational New Drug (&#x201c;IND&#x201d;) or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#x2019;s commitment of resources to the program. We do not include any amounts subject to uncertainties in the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using an income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time, we have already transferred the related license to the partner. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Device License, Development and Supply Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have several license, development and supply arrangements with pharmaceutical partners, under which we grant a license to our device technology and provide research and development services that often involve multiple performance obligations and highly-customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception of the contract and allocate consideration to each performance obligation based on relative SSP, which is generally determined based on the expected cost plus mark-up. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and we have a present right to payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in the condensed consolidated balance sheets and recognized as revenue in the condensed consolidated statements of income when the associated performance obligations have been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License fees and milestones received in exchange for the grant of a license to our functional intellectual property, such as patented technology and know-how in connection with a partnered development arrangement, are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal of revenue will not occur when the associated uncertainty is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 5,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion on our collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Proprietary Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Hylenex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recombinant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (&#x201c;GPOs&#x201d;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in accrued liabilities and net of accounts receivable in the condensed consolidated balance sheet. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Proprietary Product Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our commercial portfolio of proprietary products includes XYOSTED, TLANDO and NOCDURNA, which we sell primarily to wholesale and specialty distributors. Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued liabilities and net of accounts receivable in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Partnered Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bulk rHuPH20&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Devices&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the exclusive supplier of  OTREXUP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to Otter. Because this product is custom manufactured with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in the condensed consolidated balance sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit-sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal of revenue based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our condensed consolidated statements of income, we report the upfront payments, event-based development and regulatory milestones and sales milestones as revenues under collaborative agreements. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from partners as a separate line in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from sales of our proprietary and partnered products are included in product sales, net in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the footnotes to our condensed consolidated financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and device licensing, and development revenues), and additionally, by type of payment stream received under collaborative agreements (upfront license and target nomination fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include salaries and benefits, facilities and other overhead expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record compensation expense associated with stock options, restricted stock units (&#x201c;RSUs&#x201d;), performance stock units (&#x201c;PSUs&#x201d;) and shares issued under our employee stock purchase plan (&#x201c;ESPP&#x201d;) in accordance with the authoritative guidance for share-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#x201c;DTA&#x201d;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized. We recorded a provision for income taxes of $12.6&#160;million using an effective tax rate of 24.1% for the three months ended March&#160;31, 2023. The difference between our effective tax rate and the U.S. federal statutory rate of 21% is primarily due to tax benefits on Foreign Derived Intangible Income Deduction (&#x201c;FDII&#x201d;), tax detriments on 162(m) and other share-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate our business in one operating segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties, and (ii)&#160;product sales of proprietary and partnered products. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adoption and Pending Adoption of Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no relevant recently issued accounting pronouncements that would materially impact our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU3NzA_e5333fc2-9447-4032-ae7a-ae9208b9d18d">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited condensed consolidated financial statements have been prepared for purposes of and in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on February&#160;21, 2023. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU3NTI_325b5c42-6db3-4baa-b8da-e6199907fe12">The accompanying interim unaudited condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., and Antares Pharma, Inc.&#x2019;s wholly owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU3NDk_180153c3-cf88-45b2-abfe-29e704d04f14">Use of EstimatesThe preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in our interim unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that we believe to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from our estimates</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU4NzA_ca379771-3aae-4f5c-a965-89c65bfee251">&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents and Marketable Securities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within 90 days or less from the date of purchase. As of March&#160;31, 2023, our cash and cash equivalents consisted of money market funds, bank certificate of deposits and demand deposits at commercial banks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities are investments with original maturities of more than 90 days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#x2019;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders&#x2019; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the interim unaudited condensed consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in the interim unaudited condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the lease terms of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. As of March&#160;31, 2023 and December&#160;31, 2022, restricted cash of $0.5 million was pledged as collateral for the letters of credit.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDIxMQ_53d0495d-fdfe-4976-9049-0ff1b075b824"
      unitRef="usd">500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDIxMQ_f75cf02e-0bcc-40de-a4e9-b69b6ce4f1d9"
      unitRef="usd">500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU4NzU_25c47da6-c574-4c15-b9ee-0f909c0d62dd">&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses, long-term debt and a contingent liability. Fair value estimates of these instruments are made at a specific point in time based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore, cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU4MTU_c2a1c061-acd7-4de2-a20b-d64e073e2851">&lt;div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU4MDI_62cca281-2bf7-4c7e-9f72-182966dfd08f">&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from 3 years to 12 years. We determine if an arrangement contains a lease at inception. Right of use (&#x201c;ROU&#x201d;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option. Short-term leases with an initial term of 12 months or less are not recorded on the condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i26d023fcab96411da642d788b3f4972f_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNzMwOA_9d171877-952c-4721-b408-cc5b8ca8f96a">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i2c07e926241e4fcea8142ef7b8204548_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNzMxNA_7042dd3c-b33b-4a5c-9cff-ec6d7583c712">P12Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU4MzQ_a533e6c1-c3ba-47a6-859e-9dc3b663e982">&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs incurred to complete a business combination, such as legal and other professional fees, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <halo:GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU3NTA_a5574ab0-c15f-4ad0-9160-4a896a005f87">&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired, including intangible assets and in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;amp;D &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;amp;D asset is expensed in the period of abandonment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and IPR&amp;amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;amp;D asset exceeds its respective fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair value of the reporting unit with the carrying value, including goodwill. If the carrying amount of the reporting unit exceeds the fair value, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our identifiable intangible assets with finite useful lives are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.&lt;/span&gt;&lt;/div&gt;</halo:GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU3Mjk_75e8ade7-13ed-4e25-8818-decce92eb8a8">&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ENHANZE and Device Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. In general, when there are no valid claims of a specified patent developed under the collaboration covering the product in a given country, the royalty rate is reduced for those sales in that country upon the expiration of our patents covering rHuPH20. Janssen&#x2019;s patents covering DARZALEX SC do not impact the timing for this royalty reduction. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted will become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also earn royalties in connection with several of our licenses granted under license and development arrangements with our device partners. These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#x2019; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days after the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue under ENHANZE and Device Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ENHANZE Collaboration and License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement generally require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner&#x2019;s purchase orders, and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally collect an upfront license payment from collaboration partners, and are also entitled to receive event-based payments subject to collaboration partners&#x2019; achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for respective consideration. Under these collaborative agreements, our partners lead development of assets, and we do not share in significant financial risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to U.S. GAAP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under all of our ENHANZE collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs. Each of the licenses grants the partners rights to use our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, we provide indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#x2019; representations and are not obligations to provide goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our partners, which represent separate contracts. In addition to our licenses, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or (&#x201c;SSP&#x201d;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g., dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#x2019;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of Investigational New Drug (&#x201c;IND&#x201d;) or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#x2019;s commitment of resources to the program. We do not include any amounts subject to uncertainties in the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using an income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time, we have already transferred the related license to the partner. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Device License, Development and Supply Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have several license, development and supply arrangements with pharmaceutical partners, under which we grant a license to our device technology and provide research and development services that often involve multiple performance obligations and highly-customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception of the contract and allocate consideration to each performance obligation based on relative SSP, which is generally determined based on the expected cost plus mark-up. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and we have a present right to payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in the condensed consolidated balance sheets and recognized as revenue in the condensed consolidated statements of income when the associated performance obligations have been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License fees and milestones received in exchange for the grant of a license to our functional intellectual property, such as patented technology and know-how in connection with a partnered development arrangement, are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal of revenue will not occur when the associated uncertainty is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 5,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion on our collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Proprietary Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Hylenex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recombinant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (&#x201c;GPOs&#x201d;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in accrued liabilities and net of accounts receivable in the condensed consolidated balance sheet. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Proprietary Product Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our commercial portfolio of proprietary products includes XYOSTED, TLANDO and NOCDURNA, which we sell primarily to wholesale and specialty distributors. Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued liabilities and net of accounts receivable in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Partnered Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bulk rHuPH20&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Devices&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the exclusive supplier of  OTREXUP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to Otter. Because this product is custom manufactured with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in the condensed consolidated balance sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit-sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal of revenue based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our condensed consolidated statements of income, we report the upfront payments, event-based development and regulatory milestones and sales milestones as revenues under collaborative agreements. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from partners as a separate line in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from sales of our proprietary and partnered products are included in product sales, net in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the footnotes to our condensed consolidated financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and device licensing, and development revenues), and additionally, by type of payment stream received under collaborative agreements (upfront license and target nomination fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <halo:RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfMTYzMzA_00ca7c3a-0eca-4abe-9c40-3bc1b5674db2">P90D</halo:RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU4NjE_c505a0c1-d6c4-469c-adb4-d2bd89e39f6a">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include salaries and benefits, facilities and other overhead expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU4Nzg_69aface7-dc7c-469a-9f5a-0da4fc31f00f">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record compensation expense associated with stock options, restricted stock units (&#x201c;RSUs&#x201d;), performance stock units (&#x201c;PSUs&#x201d;) and shares issued under our employee stock purchase plan (&#x201c;ESPP&#x201d;) in accordance with the authoritative guidance for share-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU3NDA_f6f37319-2f9e-4d6c-9a29-64b8bf2bfa2b">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#x201c;DTA&#x201d;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized. We recorded a provision for income taxes of $12.6&#160;million using an effective tax rate of 24.1% for the three months ended March&#160;31, 2023. The difference between our effective tax rate and the U.S. federal statutory rate of 21% is primarily due to tax benefits on Foreign Derived Intangible Income Deduction (&#x201c;FDII&#x201d;), tax detriments on 162(m) and other share-based compensation.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNTQ5NzU1ODY4OTk1_40725f8a-565c-4b5e-948c-6c8f0154de42"
      unitRef="usd">12600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDQ0MzI_6bbbf637-7319-4869-ae5a-c4231402752d"
      unitRef="number">0.241</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU4MDQ_7cb5c240-9153-4129-a7fb-a404cec0716b">&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate our business in one operating segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties, and (ii)&#160;product sales of proprietary and partnered products. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDQ5NjA_786a9d62-e81d-49f1-a8d4-bae1443cbf7b"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80My9mcmFnOjQ2ZWIzNzcyY2RhZDRlZDM4NTJhNTkzODY5OTg4NmYxL3RleHRyZWdpb246NDZlYjM3NzJjZGFkNGVkMzg1MmE1OTM4Njk5ODg2ZjFfNDU3Nzk_8a7d562b-e078-4b97-8741-0b2bf5162625">&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adoption and Pending Adoption of Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no relevant recently issued accounting pronouncements that would materially impact our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80OS9mcmFnOmEyY2RjNTI3ZGVjZDRiNWZiNGY0NTA3MjhhNGMyY2M2L3RleHRyZWdpb246YTJjZGM1MjdkZWNkNGI1ZmI0ZjQ1MDcyOGE0YzJjYzZfODA5Mw_12bdd894-1a57-40c4-8326-b697164d9858">Business Combination&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 24, 2022, we acquired all outstanding equity interests of Antares Pharma, Inc. according to the terms and conditions of the Agreement and Plan of Merger, dated as of April 12, 2022 (the &#x201c;Merger Agreement&#x201d;). Antares is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. We acquired Antares as a part of our strategy to expand as a drug delivery company and include specialty products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total purchase consideration of Antares was $1,045.7&#160;million. Each share of Antares common stock issued and outstanding was converted into the right to receive $5.60 in cash without interest, less any applicable withholding taxes (&#x201c;Merger Consideration&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of Antares has been accounted for using the acquisition method of accounting in accordance with ASC 805, Business Combinations, with Halozyme treated as the accounting acquirer, which requires, among other things, that the assets acquired and liabilities assumed be recognized at their fair value on the acquisition date. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our results of operations. We are still finalizing the liabilities assumed related to accrued expenses which are subject to change as additional information is received to complete our analysis. As a result, the preliminary estimates may be revised during the measurement period. These differences could have a material impact on our results of operations and financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2023, we recorded measurement period adjustments which increased goodwill by $7.1&#160;million to adjust accrued expenses by $2.3&#160;million and deferred tax liabilities by $4.8&#160;million. The measurement period adjustments have been recorded to reflect facts and circumstances that existed as of the acquisition date.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i278958ca21434e13ac5e9b20db531704_D20220524-20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80OS9mcmFnOmEyY2RjNTI3ZGVjZDRiNWZiNGY0NTA3MjhhNGMyY2M2L3RleHRyZWdpb246YTJjZGM1MjdkZWNkNGI1ZmI0ZjQ1MDcyOGE0YzJjYzZfNjEz_e46cbb6e-58b5-4646-b661-0fbe142d77bb"
      unitRef="usd">1045700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare
      contextRef="i278958ca21434e13ac5e9b20db531704_D20220524-20220524"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80OS9mcmFnOmEyY2RjNTI3ZGVjZDRiNWZiNGY0NTA3MjhhNGMyY2M2L3RleHRyZWdpb246YTJjZGM1MjdkZWNkNGI1ZmI0ZjQ1MDcyOGE0YzJjYzZfNzE1_8ca8206f-a13b-4ef7-853a-e2117088f68d"
      unitRef="usdPerShare">5.60</halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80OS9mcmFnOmEyY2RjNTI3ZGVjZDRiNWZiNGY0NTA3MjhhNGMyY2M2L3RleHRyZWdpb246YTJjZGM1MjdkZWNkNGI1ZmI0ZjQ1MDcyOGE0YzJjYzZfODA5MA_2a2060ed-a93f-4559-87c8-baf15e135fc3">As a result, the preliminary estimates may be revised during the measurement period. These differences could have a material impact on our results of operations and financial position.</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="icab3fab76ada402db8fe4009786133b9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80OS9mcmFnOmEyY2RjNTI3ZGVjZDRiNWZiNGY0NTA3MjhhNGMyY2M2L3RleHRyZWdpb246YTJjZGM1MjdkZWNkNGI1ZmI0ZjQ1MDcyOGE0YzJjYzZfNTQ5NzU1ODQ2NDY5_7b595070-781d-4a6d-831f-0269b2d8411f"
      unitRef="usd">7100000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <halo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense
      contextRef="icab3fab76ada402db8fe4009786133b9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80OS9mcmFnOmEyY2RjNTI3ZGVjZDRiNWZiNGY0NTA3MjhhNGMyY2M2L3RleHRyZWdpb246YTJjZGM1MjdkZWNkNGI1ZmI0ZjQ1MDcyOGE0YzJjYzZfNTQ5NzU1ODQ2MzU0_34a25537-0b1f-472f-b5c4-ede4c602bc05"
      unitRef="usd">2300000</halo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense>
    <halo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet
      contextRef="icab3fab76ada402db8fe4009786133b9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl80OS9mcmFnOmEyY2RjNTI3ZGVjZDRiNWZiNGY0NTA3MjhhNGMyY2M2L3RleHRyZWdpb246YTJjZGM1MjdkZWNkNGI1ZmI0ZjQ1MDcyOGE0YzJjYzZfNTQ5NzU1ODQ2MzY4_9282060c-e027-4158-ad1d-0a915df33127"
      unitRef="usd">4800000</halo:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfMjEzNA_346c7db0-01cc-4a7b-813b-52f23cd32c4a">Fair Value Measurement&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(944)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, thirty-four available-for-sale marketable securities with a fair market value of $96.2 million were in a gross unrealized loss position of $0.1&#160;million. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of&#160;March&#160;31, 2023, because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our contractual maturities of available-for-sale debt securities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year but within five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.967%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale marketable &lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had no available for sale securities that were classified within Level 3 as of March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;A contingent liability with a value of $15.7&#160;million was assumed as part of the Antares acquisition related to TLANDO. The acquisition date fair value was measured using the income approach, specifically the probability weighted expected return method for the development milestone payments and the option pricing methodology using the Monte Carlo simulation for commercial milestone payments and royalty payments. The fair value of the contingent liability will be remeasured on a quarterly basis. Estimates and assumptions used in the Monte Carlo simulation include forecasted revenues, cost of debt, risk free rate, weighted average cost of capital, revenue market price risk and revenue volatility. Estimates and assumptions used in the income approach include the probability of achieving certain milestones and a discount rate. These unobservable inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. Changes in the fair value subsequent to the acquisition date will be recognized in our condensed consolidated statements of income.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfMjE0Ng_3086169e-ff48-4ae1-afb0-2fff306c0299">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(944)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i74ddf974e26d4522a765f4b90853db19_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfMi0yLTEtMS05NzgzOQ_89f69f16-b35e-42d1-8440-a82cc189155f"
      unitRef="usd">6079000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i74ddf974e26d4522a765f4b90853db19_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfMi00LTEtMS05NzgzOQ_26903bd7-7d85-4bc4-a680-9a40448bbf04"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i74ddf974e26d4522a765f4b90853db19_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfMi02LTEtMS05NzgzOQ_2d773898-9ad3-42ae-af6d-4ee8d769a6ef"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74ddf974e26d4522a765f4b90853db19_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfMi04LTEtMS05NzgzOQ_07984dff-f5b1-4fc5-82d6-fb105e3ee468"
      unitRef="usd">6070000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9508cd66d39746d1ab48f1c43c197c90_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfMy0yLTEtMS05NzgzOQ_1137dd32-97b8-4e0f-a658-a68a7a12f594"
      unitRef="usd">10206000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9508cd66d39746d1ab48f1c43c197c90_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfMy00LTEtMS05NzgzOQ_28438864-85ed-426f-9746-0af9a4991f4b"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9508cd66d39746d1ab48f1c43c197c90_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfMy02LTEtMS05NzgzOQ_b3f07a41-a4d4-4f9a-8155-557caffce162"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9508cd66d39746d1ab48f1c43c197c90_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfMy04LTEtMS05NzgzOQ_ff69365e-466b-46f3-8442-473fbb5af5fa"
      unitRef="usd">10202000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i094f2eeb06f242e3ac6bed7262ca9174_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNC0yLTEtMS05NzgzOQ_36b8fadd-84ab-407f-b0f0-2527a9e3cf88"
      unitRef="usd">120555000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i094f2eeb06f242e3ac6bed7262ca9174_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNC00LTEtMS05NzgzOQ_24bc664e-0fb8-4082-baea-600ccbeb4e7d"
      unitRef="usd">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i094f2eeb06f242e3ac6bed7262ca9174_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNC02LTEtMS05NzgzOQ_59a19720-94c1-4bae-9ea5-ab19b599d35c"
      unitRef="usd">98000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i094f2eeb06f242e3ac6bed7262ca9174_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNC04LTEtMS05NzgzOQ_92c3e5fb-bd67-4231-89e1-7d1be306ab07"
      unitRef="usd">120500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i785729d9e19d43c9874a0e5eb4644380_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNi0yLTEtMS0xMDAzOTc_21deb1a3-7b13-49d7-a8f1-a9b6816dc751"
      unitRef="usd">18765000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i785729d9e19d43c9874a0e5eb4644380_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNi00LTEtMS0xMDA0MDE_a4411341-6e0c-4b01-954e-7c5e3cf3c5d7"
      unitRef="usd">54000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i785729d9e19d43c9874a0e5eb4644380_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNi02LTEtMS0xMDA0MDU_eccce0d1-42ea-4d88-b719-9bc788928159"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i785729d9e19d43c9874a0e5eb4644380_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNi04LTEtMS0xMDYyNDU_e12c7718-36a5-4d8b-ad86-0d29b7a2473a"
      unitRef="usd">18818000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibfbf3f7b961745d186224a612c84b694_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNi0yLTEtMS05NzgzOQ_cba1c33e-4f51-49b0-80c3-2db406ec41b1"
      unitRef="usd">23639000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibfbf3f7b961745d186224a612c84b694_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNi00LTEtMS05NzgzOQ_2507b89b-f0fb-415e-8c8b-8d8259a8329a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibfbf3f7b961745d186224a612c84b694_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNi02LTEtMS05NzgzOQ_b0f849f0-7852-4c40-b9f3-bf63f0e46671"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibfbf3f7b961745d186224a612c84b694_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNi04LTEtMS05NzgzOQ_2ef835c6-8e8b-48b8-9f0f-8d101401abbf"
      unitRef="usd">23635000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNy0yLTEtMS05NzgzOQ_7a392e41-704d-4fbd-9a17-a84447304cd0"
      unitRef="usd">179244000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNy00LTEtMS05NzgzOQ_8eb4e037-c30f-4858-93f7-b5c5d9cf9a6b"
      unitRef="usd">107000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNy02LTEtMS05NzgzOQ_54a3dddd-707e-4fbf-9854-4c046e61770f"
      unitRef="usd">126000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjRhYWJkMWY5Nzk5NTQ1ZTc4ZjQ4OTA2ZmRmYTdlMjdkL3RhYmxlcmFuZ2U6NGFhYmQxZjk3OTk1NDVlNzhmNDg5MDZmZGZhN2UyN2RfNy04LTEtMS05NzgzOQ_960fdfb5-acc1-4711-903e-a44a16605f93"
      unitRef="usd">179225000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i00ffb999a0c746d5bbbfb9ce0f56de51_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfMi0yLTEtMS05NzgzOQ_6c45ea28-302f-4e40-bb92-b92a512ad22b"
      unitRef="usd">1146000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i00ffb999a0c746d5bbbfb9ce0f56de51_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfMi00LTEtMS05NzgzOQ_5d49b3ce-e479-4b9f-b186-b475920f8ad1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i00ffb999a0c746d5bbbfb9ce0f56de51_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfMi02LTEtMS05NzgzOQ_11bc47c7-3eab-4644-b5e2-61f6556d0ede"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00ffb999a0c746d5bbbfb9ce0f56de51_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfMi04LTEtMS05NzgzOQ_d08a02b5-0d37-4d9c-b856-07e08b775f24"
      unitRef="usd">1146000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if283cea3fe1d4a6a91ac40d41123cd0b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfMy0yLTEtMS05NzgzOQ_476e38db-e340-4eea-b248-ab65e194a0ac"
      unitRef="usd">7139000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if283cea3fe1d4a6a91ac40d41123cd0b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfMy00LTEtMS05NzgzOQ_831b538f-e19e-432c-b361-383cf73c0919"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if283cea3fe1d4a6a91ac40d41123cd0b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfMy02LTEtMS05NzgzOQ_2f06e77b-3e70-460d-b406-f9ee2ebd09a0"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if283cea3fe1d4a6a91ac40d41123cd0b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfMy04LTEtMS05NzgzOQ_6e9c3473-0e10-4156-8096-528026f92386"
      unitRef="usd">7130000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8a820e39ab6e40f887d12c0d67623ad2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNC0yLTEtMS05NzgzOQ_c39540bd-f967-4155-ac40-686b4ba56fe1"
      unitRef="usd">111469000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8a820e39ab6e40f887d12c0d67623ad2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNC00LTEtMS05NzgzOQ_4a9969c3-fa3d-4bda-99ae-a25e8cf06e62"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8a820e39ab6e40f887d12c0d67623ad2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNC02LTEtMS05NzgzOQ_fc40ef6d-8eb2-4b2c-9700-67a609cac865"
      unitRef="usd">934000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8a820e39ab6e40f887d12c0d67623ad2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNC04LTEtMS05NzgzOQ_7472d948-e2b8-44af-90d1-ea0479833b48"
      unitRef="usd">110535000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if9cf1d8f181a422daa99c4f7cb0bae61_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNS0yLTEtMS0xMDA0Mjk_a6d8d404-d10f-4b29-b8ce-96b735729eeb"
      unitRef="usd">2783000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if9cf1d8f181a422daa99c4f7cb0bae61_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNS00LTEtMS0xMDA0MTY_606fe906-9828-493b-a2ba-bda288a4cf0d"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if9cf1d8f181a422daa99c4f7cb0bae61_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNS02LTEtMS0xMDA0NDM_651d5272-abd6-4741-98ea-f6a5bc3869fd"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if9cf1d8f181a422daa99c4f7cb0bae61_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNS04LTEtMS0xMDYyNDc_9457e7ef-99ca-4f4b-b12f-f83cca6b19ae"
      unitRef="usd">2784000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic5537e8e933a456da81116ac3891b12a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNi0yLTEtMS05NzgzOQ_24f0b536-a613-4b0f-b7f3-301b9e4f5e88"
      unitRef="usd">7004000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic5537e8e933a456da81116ac3891b12a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNi00LTEtMS05NzgzOQ_4e6a0fb2-b6e9-4820-b059-9b2e2840d8f3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic5537e8e933a456da81116ac3891b12a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNi02LTEtMS05NzgzOQ_8033e6be-71b7-46a5-b4ae-8e6fb454756a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic5537e8e933a456da81116ac3891b12a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNi04LTEtMS05NzgzOQ_f27cb643-b16d-4190-8207-953e1792ba6e"
      unitRef="usd">7004000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNy0yLTEtMS05NzgzOQ_038dd454-a123-4ea7-9066-c0ffb3209181"
      unitRef="usd">129541000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNy00LTEtMS05NzgzOQ_9fbe69ed-690d-4af8-976c-428029c56868"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNy02LTEtMS05NzgzOQ_0f837b75-9cfd-45ef-aa8e-1a4c310dc156"
      unitRef="usd">944000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjE2NGNiZjkwZTQ1OTQyMzQ4MjYwNjcyYmI4ZTcyMTVkL3RhYmxlcmFuZ2U6MTY0Y2JmOTBlNDU5NDIzNDgyNjA2NzJiYjhlNzIxNWRfNy04LTEtMS05NzgzOQ_be765c6d-6d48-4f03-97cb-8e968c013ca0"
      unitRef="usd">128599000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfMTI5_20ccd232-b262-4145-84c8-34793bef58e3"
      unitRef="security">34</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfMjAx_36416b88-6308-430a-989a-64e5f07b1dcd"
      unitRef="usd">96200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfMjQ4_210cd5bc-645f-41d2-a932-f1435db07086"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfMzE1_eb25609e-9d8d-4e57-b198-5f9147055a98"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfMjEzMQ_0fcb9931-4635-492e-a929-4b12d1a3e631">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our contractual maturities of available-for-sale debt securities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year but within five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjc5ZjI2OTg3NDgwZjQyZTU5YmI4MmIyYzdjYWJkYmE2L3RhYmxlcmFuZ2U6NzlmMjY5ODc0ODBmNDJlNTliYjgyYjJjN2NhYmRiYTZfMi0yLTEtMS05NzgzOQ_39e86570-9067-4cf2-b326-314f77055fc1"
      unitRef="usd">154591000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjc5ZjI2OTg3NDgwZjQyZTU5YmI4MmIyYzdjYWJkYmE2L3RhYmxlcmFuZ2U6NzlmMjY5ODc0ODBmNDJlNTliYjgyYjJjN2NhYmRiYTZfMi00LTEtMS05NzgzOQ_000287ff-dc08-4edf-b401-b4216906639e"
      unitRef="usd">114353000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjc5ZjI2OTg3NDgwZjQyZTU5YmI4MmIyYzdjYWJkYmE2L3RhYmxlcmFuZ2U6NzlmMjY5ODc0ODBmNDJlNTliYjgyYjJjN2NhYmRiYTZfMy0yLTEtMS05NzgzOQ_2102fc40-76e4-42e9-82ff-b5104ac9f7b2"
      unitRef="usd">24634000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjc5ZjI2OTg3NDgwZjQyZTU5YmI4MmIyYzdjYWJkYmE2L3RhYmxlcmFuZ2U6NzlmMjY5ODc0ODBmNDJlNTliYjgyYjJjN2NhYmRiYTZfMy00LTEtMS05NzgzOQ_64ce472f-bc7e-48d4-91e6-d9ae2f9be39b"
      unitRef="usd">14246000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjc5ZjI2OTg3NDgwZjQyZTU5YmI4MmIyYzdjYWJkYmE2L3RhYmxlcmFuZ2U6NzlmMjY5ODc0ODBmNDJlNTliYjgyYjJjN2NhYmRiYTZfNC0yLTEtMS05NzgzOQ_90b6ea49-ebb9-43e6-a68c-c5c9f6542ffa"
      unitRef="usd">179225000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjc5ZjI2OTg3NDgwZjQyZTU5YmI4MmIyYzdjYWJkYmE2L3RhYmxlcmFuZ2U6NzlmMjY5ODc0ODBmNDJlNTliYjgyYjJjN2NhYmRiYTZfNC00LTEtMS05NzgzOQ_8434fc74-1966-4f6d-9ba0-8bf3d898b6d3"
      unitRef="usd">128599000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfMjEzOQ_45ff0e0a-56a8-4035-9f65-3be530d515f4">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.967%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale marketable &lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if8ff50c7e57541459bb9e2d11625d308_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMy0yLTEtMS05NzgzOQ_c55aa793-90df-4c76-8f43-29559e9fb08d"
      unitRef="usd">70345000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0ac12a8fcf7d4256b1c58e9d42cb1c4e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMy00LTEtMS05NzgzOQ_b9b1dfb0-2cdd-4d46-8e0e-67f0afd3410d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib4c6ea833f4e4d4d8e62e3e2a8a60dd7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMy02LTEtMS05NzgzOQ_d17b7492-a334-4149-886c-4db035f41fd3"
      unitRef="usd">70345000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ica79dc0bdab840cba3dd0e9299d602b2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMy04LTEtMS05NzgzOQ_a6656851-a7b8-4068-92a4-0fdf1106ba8b"
      unitRef="usd">191704000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia6ee6e33f59c4afbba6c572de982c78a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMy0xMC0xLTEtOTc4Mzk_13083cb4-6e40-47b9-83a3-fa793178ce30"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7ac74b74a58e4c778cbccec9b7a58c03_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMy0xMi0xLTEtOTc4Mzk_b25e8251-0f36-4464-9e56-a069ddf213b2"
      unitRef="usd">191704000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib5f15c4e1aaa429cbc707bcf75d4d317_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfNy0yLTEtMS05NzgzOQ_d621c880-853c-4b1a-a279-b69ff952c892"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i33428793de6741fe9231fd34e586de77_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfNy00LTEtMS05NzgzOQ_a93b4418-e355-4b80-933c-4608a9c1b209"
      unitRef="usd">6070000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74ddf974e26d4522a765f4b90853db19_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfNy02LTEtMS05NzgzOQ_947c4487-de24-4572-bbf0-5a4165c5ea7c"
      unitRef="usd">6070000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0971204a009d4734a0ecb98a017e3a11_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfNy04LTEtMS05NzgzOQ_ed6c293f-4701-4910-9991-5eacd6b885e7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6d798995adad4c12bb8d4fa1faf537eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfNy0xMC0xLTEtOTc4Mzk_d77fd8af-ae30-44a3-9a7f-a49de2ab75b2"
      unitRef="usd">1146000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00ffb999a0c746d5bbbfb9ce0f56de51_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfNy0xMi0xLTEtOTc4Mzk_b20fa466-e230-4457-ae66-0ad77997761e"
      unitRef="usd">1146000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibceadab060e443d8beb30c8b6c154f6b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOC0yLTEtMS05NzgzOQ_60f0c7b9-bd90-438b-a5e3-6e2c1f8c9481"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6952ec39a8ea49e9acc3bd6d2f0d8165_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOC00LTEtMS05NzgzOQ_07fe72af-488c-4395-b469-0a2e2a522fab"
      unitRef="usd">10202000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9508cd66d39746d1ab48f1c43c197c90_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOC02LTEtMS05NzgzOQ_c5c478d2-1ebf-4d7c-b5e9-610c9ab6d844"
      unitRef="usd">10202000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i739a42f476d6422e927a07b0a6b5e866_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOC04LTEtMS05NzgzOQ_c2cd3a24-573f-43c5-b873-6987e926b328"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic958d8a4445145abae1f919a5908815c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOC0xMC0xLTEtOTc4Mzk_66cce6a0-0ab2-4700-98be-2fd1164d7ad5"
      unitRef="usd">7130000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if283cea3fe1d4a6a91ac40d41123cd0b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOC0xMi0xLTEtOTc4Mzk_37a30529-eb1c-4252-86da-155d00182703"
      unitRef="usd">7130000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i60e05f4ffbae45dfb1945eb2ab5d061a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOS0yLTEtMS05NzgzOQ_336dc3b6-1bfd-4c99-877e-10e40117896c"
      unitRef="usd">120500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i40dd3bd58ac142339fe5aa795ac93db9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOS00LTEtMS05NzgzOQ_4da8eace-eed1-44f5-a0ab-a0575c05a99f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i094f2eeb06f242e3ac6bed7262ca9174_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOS02LTEtMS05NzgzOQ_f818087c-7763-457e-80b5-8254d75f57ad"
      unitRef="usd">120500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i24130c3f089b46b6857ad5fc1d6bf622_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOS04LTEtMS05NzgzOQ_f40b4df8-5528-42e3-bf02-bc8cf04340ca"
      unitRef="usd">110535000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i455b329b075a48c29ca83f974487d0d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOS0xMC0xLTEtOTc4Mzk_784b8e22-9a71-4f37-8394-3627f9a87989"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8a820e39ab6e40f887d12c0d67623ad2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfOS0xMi0xLTEtOTc4Mzk_9160c44b-b420-4a69-9adf-7b74f6a7de81"
      unitRef="usd">110535000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia88d5d7bf4c148048b1766fdfc7b91e8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTAtMi0xLTEtMTAwNDY2_3d8db391-0c7b-4ec5-a7e2-f8a45a853d3d"
      unitRef="usd">18818000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7ec8a06ba4b34aafb950e3a31d87cc34_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTAtNC0xLTEtMTAwNDcx_71fbf03f-00c4-4807-b755-c42d1184c476"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i785729d9e19d43c9874a0e5eb4644380_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTAtNi0xLTEtMTA2MjU3_f0d1c0c0-fdac-4070-8805-92e3087b745c"
      unitRef="usd">18818000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3b9d9e738fde4ed2857f748c87e3787d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTAtOC0xLTEtMTAwNDc4_1beb87bf-068b-4e25-84f3-6bd5582b15c2"
      unitRef="usd">2784000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9f8f8b13262e4f419f206a41f9565cc3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTAtMTAtMS0xLTEwMDQ4OA_ef55fda6-2c9a-4caf-bdf8-2eae803b6da3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if9cf1d8f181a422daa99c4f7cb0bae61_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTAtMTItMS0xLTEwNjI1OQ_fed73bb3-cdcc-46da-84e4-bfa5b60041d3"
      unitRef="usd">2784000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9b874a74f5924476b565a9f6bcfca413_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTEtMi0xLTEtOTc4Mzk_d6a68dc2-9858-4b8b-876a-472d7e1ef7cf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1ace94c58553416888e3d388acdf4e1f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTEtNC0xLTEtOTc4Mzk_fffff83c-6007-4663-8bb5-2fc53427c1b2"
      unitRef="usd">23635000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibfbf3f7b961745d186224a612c84b694_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTEtNi0xLTEtOTc4Mzk_52712408-a287-4a94-bfae-4c4ea304f69f"
      unitRef="usd">23635000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i562e413729c347808d2b496afa73e048_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTEtOC0xLTEtOTc4Mzk_fcadb062-92b2-458f-9e2c-3f4ad8794595"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0b8ac74092c34340beea79e2b5c3eaef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTEtMTAtMS0xLTk3ODM5_b45b277d-3405-474a-9c48-bb1433d58dec"
      unitRef="usd">7004000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic5537e8e933a456da81116ac3891b12a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTEtMTItMS0xLTk3ODM5_e62460b5-ddf6-4b47-a21c-88df01a2c674"
      unitRef="usd">7004000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3d3aaf097a2b46f7a4fde671aaa22952_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTItMi0xLTEtOTc4Mzk_9d6cc9e0-28b8-44cf-9081-33567c487620"
      unitRef="usd">209663000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie0a569c32a674df0839180908bd55f41_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTItNC0xLTEtOTc4Mzk_b444bc28-756e-413b-b63f-ebb12f303c7a"
      unitRef="usd">39907000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTItNi0xLTEtOTc4Mzk_206e8987-da3f-46b8-a490-f359a0713d0b"
      unitRef="usd">249570000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i51cd82ac5a0347999d0942cb559d69f1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTItOC0xLTEtOTc4Mzk_db1a2a13-5dfd-4713-a94c-9cdba65ca44d"
      unitRef="usd">305023000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4e036a3c236442fcbc74bb9450bb41b6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTItMTAtMS0xLTk3ODM5_8951dce7-8ce4-4cb1-b275-74508fcd7a9f"
      unitRef="usd">15280000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RhYmxlOjFkMjk1MjBkMDBmYTQ2OGJiMGM2YTdkNDQxYTcwMjU2L3RhYmxlcmFuZ2U6MWQyOTUyMGQwMGZhNDY4YmIwYzZhN2Q0NDFhNzAyNTZfMTItMTItMS0xLTk3ODM5_e4189d18-5577-4f9b-a55d-6d27b8d53cde"
      unitRef="usd">320303000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if2ded6c148b24f77bf4d9c161e49d9de_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfOTQx_0ec6a141-6786-4c5b-b6f2-be51c015c874"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4f6244ff2fcd468a96760b50de6410df_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfOTQx_2ad87e83-6a6c-40d9-98ae-27dc674140e9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie15ed974b99c4d81aa1e6764b03ef509_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81Mi9mcmFnOjYxOTQzMGE0NDkxNjQ5MDJhMDFmYWM2YzcxOTY3ZjZhL3RleHRyZWdpb246NjE5NDMwYTQ0OTE2NDkwMmEwMWZhYzZjNzE5NjdmNmFfMTA3OA_ec4aebbe-323c-43e2-a9d7-01d729f2fea7"
      unitRef="usd">15700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMjM3MA_72864c8f-c9e4-4b15-a72f-7bf278b6133c">Revenue&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our disaggregated revenues were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Sales of bulk rHuPH20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale of proprietary products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale of device partnered products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Upfront license and target nomination fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Device Licensing and development revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, we recognized revenue related to licenses granted to partners in prior periods in the amount of $99.6 million. This amount represents royalties earned in the current period. We also recognized revenue of $0.4&#160;million during the three months ended March&#160;31, 2023 that had been included in deferred revenues in the condensed consolidated balance sheets as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.176%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $123.6 million, of which $118.1 million relates to unfulfilled product purchase orders and $5.5 million has been collected and is reported as deferred revenues in the condensed consolidated balance sheets. The unfulfilled product purchase orders are estimated to be delivered by the end of 2024. Of the total deferred revenues of $5.5 million, $3.2 million is expected to be used by our customers within the next 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized contract assets of $32.3&#160;million as of March&#160;31, 2023, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods and for goods or services when control has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to the customer in accordance with the terms of the contract.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMjM3OA_88a28a3d-ee36-4f1e-b2da-40ca9a0855bd">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our disaggregated revenues were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Sales of bulk rHuPH20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale of proprietary products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale of device partnered products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Upfront license and target nomination fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Device Licensing and development revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02fe07952df9422992b4f26248091821_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMi0yLTEtMS05NzgzOQ_2b8cef10-5e1c-4d8f-bdbd-b4908ab959df"
      unitRef="usd">99640000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1aebf4236d314680b3e3c0a72977aef1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMi00LTEtMS05NzgzOQ_69a8ed10-4294-4240-858b-fb23d5edaf2a"
      unitRef="usd">69605000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f2e433d91b04a038142f3674a77dbab_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfNS0yLTEtMS05NzgzOQ_fb43bc53-d98b-42ca-992f-e6243cd66d23"
      unitRef="usd">22069000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b20fa8736c942e5a6d16eb5dd856c4d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfNS00LTEtMS05NzgzOQ_b1e84c31-b7ac-4938-8724-704bfd755278"
      unitRef="usd">16448000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8349bd4411084a29b491605b9e981c86_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfNi0yLTEtMS05NzgzOQ_9ab82552-06ba-45b8-8c29-528ee71a1092"
      unitRef="usd">27961000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5040df1f6b0340d2b9bdc087ac6bc75a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfNi00LTEtMS05NzgzOQ_b103f2c0-8bce-461c-8112-7af5e649bc7c"
      unitRef="usd">5692000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e44c7bdff0d4afab55d0f20c2a08e26_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfNy0yLTEtMS05NzgzOQ_2844c4bc-1679-4b5a-8fdb-3d17d176f614"
      unitRef="usd">10764000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79f57590019f4701b5d3b0b88015539e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfNy00LTEtMS05NzgzOQ_38dcbcda-76dd-40e4-8005-0c467b404199"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff57a29a29d64188b30a100687f1c479_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfOC0yLTEtMS05NzgzOQ_c21d5757-b24f-4612-85c7-07967753e539"
      unitRef="usd">60794000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4ce36d68328465ea06f53e7683604f0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfOC00LTEtMS05NzgzOQ_a10ac197-3199-40a1-bd44-64e4666fcc06"
      unitRef="usd">22140000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4051c56e33f74f188cc8eccd23a7f58f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMTEtMi0xLTEtOTc4Mzk_ba5e1819-9e42-46e2-8fc9-a57f33ec01dc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d4b107661c44956a8eb7be6f8c14f9d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMTEtNC0xLTEtOTc4Mzk_dc638c4d-8254-40eb-8670-e7dd709e55a5"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if58b9fca0ec74a9995562d09ff0ab3ac_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMTQtMi0xLTEtOTc4Mzk_cdf08752-8b65-433b-b835-eaef4a6d7064"
      unitRef="usd">1709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39a11b871a3346cd9599297d2004c0c3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMTQtNC0xLTEtOTc4Mzk_53414200-2ff9-4a7d-814c-1885203f6e26"
      unitRef="usd">534000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33911352c8cf4d3a8a5655b090781af3_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMTUtMi0xLTEtOTc4Mzk_e4586a7b-134e-48e1-bbf7-f9914fad9c16"
      unitRef="usd">1709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0705f79cf1bd46bcaee4afc74fd6c446_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMTUtNC0xLTEtOTc4Mzk_f601584a-08d3-40a1-96ab-fb3ee31c9aee"
      unitRef="usd">25534000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMTctMi0xLTEtOTc4Mzk_6bb21707-b43b-4483-ad0f-4ea26078f152"
      unitRef="usd">162143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjgxYzE5M2MxYzBkNDRiYjQ4MzJmMmEzNDE2NTM4NDYwL3RhYmxlcmFuZ2U6ODFjMTkzYzFjMGQ0NGJiNDgzMmYyYTM0MTY1Mzg0NjBfMTctNC0xLTEtOTc4Mzk_d92565cf-b280-4410-a29d-368e070f5bd4"
      unitRef="usd">117279000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic22dc841bc6041cba127ce0958181fb1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMjAz_4aa3aaa1-2a7e-4c20-b885-14fc7e9c3665"
      unitRef="usd">99600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfNDc2_32d212bd-b232-40f5-bd99-fe1b1c2762fe"
      unitRef="usd">-400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMjM3Mg_b6e9310f-8bac-4344-bc98-5096fb0f5797">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.176%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <halo:AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjcxMTZlYTc0OTQ1MTRkNDI5NjQ3MzdmZWQ2ZjJlZDg3L3RhYmxlcmFuZ2U6NzExNmVhNzQ5NDUxNGQ0Mjk2NDczN2ZlZDZmMmVkODdfMS0yLTEtMS05NzgzOQ_29604a05-8724-46cc-b0a4-e478b1e00c8d"
      unitRef="usd">162545000</halo:AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets>
    <halo:AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjcxMTZlYTc0OTQ1MTRkNDI5NjQ3MzdmZWQ2ZjJlZDg3L3RhYmxlcmFuZ2U6NzExNmVhNzQ5NDUxNGQ0Mjk2NDczN2ZlZDZmMmVkODdfMS00LTEtMS05NzgzOQ_3c98827b-410c-45ca-8bfb-71529ada15b2"
      unitRef="usd">186970000</halo:AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjcxMTZlYTc0OTQ1MTRkNDI5NjQ3MzdmZWQ2ZjJlZDg3L3RhYmxlcmFuZ2U6NzExNmVhNzQ5NDUxNGQ0Mjk2NDczN2ZlZDZmMmVkODdfMi0yLTEtMS05NzgzOQ_7cae7cb1-bf55-4f21-864c-091adc8dff41"
      unitRef="usd">32338000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjcxMTZlYTc0OTQ1MTRkNDI5NjQ3MzdmZWQ2ZjJlZDg3L3RhYmxlcmFuZ2U6NzExNmVhNzQ5NDUxNGQ0Mjk2NDczN2ZlZDZmMmVkODdfMi00LTEtMS05NzgzOQ_fccba1ad-563f-4fed-9322-2ee3fbd7a91c"
      unitRef="usd">44102000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:DeferredRevenue
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjcxMTZlYTc0OTQ1MTRkNDI5NjQ3MzdmZWQ2ZjJlZDg3L3RhYmxlcmFuZ2U6NzExNmVhNzQ5NDUxNGQ0Mjk2NDczN2ZlZDZmMmVkODdfMy0yLTEtMS05NzgzOQ_7647f70f-3c6a-480a-bee2-6c66730a561b"
      unitRef="usd">5499000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RhYmxlOjcxMTZlYTc0OTQ1MTRkNDI5NjQ3MzdmZWQ2ZjJlZDg3L3RhYmxlcmFuZ2U6NzExNmVhNzQ5NDUxNGQ0Mjk2NDczN2ZlZDZmMmVkODdfMy00LTEtMS05NzgzOQ_19fd8799-e5d3-4f9d-abc1-4b5fdda08d64"
      unitRef="usd">5499000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="iafdfb78b51284e9cb1aba46fd7125d17_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMTU5NQ_15a79e3e-3a57-48d9-8c82-406a65409d7f"
      unitRef="usd">123600000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent
      contextRef="iff33634f84774f3e98705b7f0fa793f5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMTYwOA_7f7faa8d-e771-4e27-ae7b-ef49010b722f"
      unitRef="usd">118100000</us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMTY1OQ_f6895d07-20a4-4c1b-8bba-a05051c68eda"
      unitRef="usd">5500000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMTg4NQ_f6895d07-20a4-4c1b-8bba-a05051c68eda"
      unitRef="usd">5500000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="icd9786c1eb264d80a62f434a14aac146_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMTg4OQ_f0b8e14a-0436-47cf-b51d-10d1b6a9b456"
      unitRef="usd">3200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl81OC9mcmFnOmE2OGFhMzQ5MzA0ZDQ0ZDU5ZmU4MTY1NWU3MTc5YzJlL3RleHRyZWdpb246YTY4YWEzNDkzMDRkNDRkNTlmZTgxNjU1ZTcxNzljMmVfMjUyODg3Njc0NDQyNjQ_3fea4cc2-e0b5-462e-ad97-e186498f825b"
      unitRef="usd">32300000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTU1NA_b3561bce-3d89-4add-9dc7-785dcaf0b04e">Certain Balance Sheet Items&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net and contract assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from product sales to partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from royalty payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from other product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accounts receivable and contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for distribution fees and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accounts receivable, net and contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract manufacturing organizations.&#160;Such amounts are reclassified to work-in-process inventory as materials are used or the contract manufacturing organization services are complete.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;                            &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense was approximately $2.6 million and $0.8 million, inclusive of ROU asset amortization of $1.4 million and $0.4 million for the three months ended March&#160;31, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and payroll taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued outsourced manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns and sales allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accrued expenses, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense associated with the accretion of the lease liabilities was approximately $0.7 million and $0.1 million for the three months ended March&#160;31, 2023 and 2022, respectively. Total lease expense for the three months ended March&#160;31, 2023 and 2022 was $2.1 million and $0.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts related to leases for the three months ended March&#160;31, 2023 and 2022 was $1.7 million and $0.7 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTU3OA_0887bbea-df4e-4315-a41a-32825b975e5a">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net and contract assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from product sales to partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from royalty payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from other product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accounts receivable and contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for distribution fees and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accounts receivable, net and contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <halo:Accountsreceivablefromproductsalestocollaborators
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfMS0yLTEtMS05NzgzOQ_eee67c55-7dba-4a77-a8bf-86e6cf43d7a5"
      unitRef="usd">58502000</halo:Accountsreceivablefromproductsalestocollaborators>
    <halo:Accountsreceivablefromproductsalestocollaborators
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfMS00LTEtMS05NzgzOQ_f566b19c-74e3-4001-9546-3a6ca0f6fb2b"
      unitRef="usd">62979000</halo:Accountsreceivablefromproductsalestocollaborators>
    <halo:Accountsreceivablefromcollaborators
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfMi0yLTEtMS05NzgzOQ_c035c340-2add-43c3-8462-36bcafe26147"
      unitRef="usd">2356000</halo:Accountsreceivablefromcollaborators>
    <halo:Accountsreceivablefromcollaborators
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfMi00LTEtMS05NzgzOQ_ae6a5f10-315d-4f9a-972c-60274961e9de"
      unitRef="usd">18776000</halo:Accountsreceivablefromcollaborators>
    <halo:Accountsreceivablefromroyalties
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfMy0yLTEtMS05NzgzOQ_d69f3183-b442-4f7c-a919-acd3aa5d587f"
      unitRef="usd">100829000</halo:Accountsreceivablefromroyalties>
    <halo:Accountsreceivablefromroyalties
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfMy00LTEtMS05NzgzOQ_5aa710e1-4147-49ed-a599-16a5800fc62d"
      unitRef="usd">100900000</halo:Accountsreceivablefromroyalties>
    <halo:Accountsreceivablefromproductsales
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfNC0yLTEtMS05NzgzOQ_702d2708-25ff-4717-937e-539bf31337f8"
      unitRef="usd">6774000</halo:Accountsreceivablefromproductsales>
    <halo:Accountsreceivablefromproductsales
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfNC00LTEtMS05NzgzOQ_ea52d587-a656-4b8c-a897-3bcf430c6e4f"
      unitRef="usd">6229000</halo:Accountsreceivablefromproductsales>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfNi0yLTEtMS05NzgzOQ_7cae7cb1-bf55-4f21-864c-091adc8dff41"
      unitRef="usd">32338000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfNi00LTEtMS05NzgzOQ_fccba1ad-563f-4fed-9322-2ee3fbd7a91c"
      unitRef="usd">44102000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfNy0yLTEtMS05NzgzOQ_00e91ba5-771d-400c-8b5e-1942ffe27f17"
      unitRef="usd">200799000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfNy00LTEtMS05NzgzOQ_bd5e4f79-b274-477c-b782-bbbf83512c19"
      unitRef="usd">232986000</us-gaap:AccountsReceivableGrossCurrent>
    <halo:AllowanceforDistributionFeesandDiscounts
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfOC0yLTEtMS05NzgzOQ_d61fde90-8e0d-49e7-a5fb-4ae117e355f2"
      unitRef="usd">5916000</halo:AllowanceforDistributionFeesandDiscounts>
    <halo:AllowanceforDistributionFeesandDiscounts
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfOC00LTEtMS05NzgzOQ_3ad5f8f6-0eb5-4bae-8470-6478f7b0e7ae"
      unitRef="usd">1914000</halo:AllowanceforDistributionFeesandDiscounts>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfOS0yLTEtMS05NzgzOQ_49112911-d7b6-4a1d-a5f6-4633b8880f6d"
      unitRef="usd">194883000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjQ0NmE5Y2M3Nzg4MzRjYWZiODAyOWQwMTY3Nzk4OGZjL3RhYmxlcmFuZ2U6NDQ2YTljYzc3ODgzNGNhZmI4MDI5ZDAxNjc3OTg4ZmNfOS00LTEtMS05NzgzOQ_18121d21-adc9-4f27-b493-027e10fcc359"
      unitRef="usd">231072000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTU2OQ_1518d764-680f-471d-8f2a-f0f89ec39e5e">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOmVjYmEyMjM1MDc0NzQzNWU5NzM2OTUyM2M0MmNhMDY1L3RhYmxlcmFuZ2U6ZWNiYTIyMzUwNzQ3NDM1ZTk3MzY5NTIzYzQyY2EwNjVfMS0yLTEtMS05NzgzOQ_458a8cb1-6b1e-436d-bb04-84378434c5bc"
      unitRef="usd">22453000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOmVjYmEyMjM1MDc0NzQzNWU5NzM2OTUyM2M0MmNhMDY1L3RhYmxlcmFuZ2U6ZWNiYTIyMzUwNzQ3NDM1ZTk3MzY5NTIzYzQyY2EwNjVfMS00LTEtMS05NzgzOQ_fd7c6bd8-8b2d-4b43-a438-8c674393bf4e"
      unitRef="usd">13792000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOmVjYmEyMjM1MDc0NzQzNWU5NzM2OTUyM2M0MmNhMDY1L3RhYmxlcmFuZ2U6ZWNiYTIyMzUwNzQ3NDM1ZTk3MzY5NTIzYzQyY2EwNjVfMi0yLTEtMS05NzgzOQ_38461262-a04c-4ce8-8087-64ebb932400d"
      unitRef="usd">27402000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOmVjYmEyMjM1MDc0NzQzNWU5NzM2OTUyM2M0MmNhMDY1L3RhYmxlcmFuZ2U6ZWNiYTIyMzUwNzQ3NDM1ZTk3MzY5NTIzYzQyY2EwNjVfMi00LTEtMS05NzgzOQ_dc83d6ae-1402-45af-81ff-eb2aceb06adb"
      unitRef="usd">40361000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOmVjYmEyMjM1MDc0NzQzNWU5NzM2OTUyM2M0MmNhMDY1L3RhYmxlcmFuZ2U6ZWNiYTIyMzUwNzQ3NDM1ZTk3MzY5NTIzYzQyY2EwNjVfMy0yLTEtMS05NzgzOQ_406e2c2f-3816-490d-9c10-7ef9fd28efcf"
      unitRef="usd">57666000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOmVjYmEyMjM1MDc0NzQzNWU5NzM2OTUyM2M0MmNhMDY1L3RhYmxlcmFuZ2U6ZWNiYTIyMzUwNzQ3NDM1ZTk3MzY5NTIzYzQyY2EwNjVfMy00LTEtMS05NzgzOQ_7125f20e-95c2-4a9d-ab6f-4b0db360b23a"
      unitRef="usd">45970000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOmVjYmEyMjM1MDc0NzQzNWU5NzM2OTUyM2M0MmNhMDY1L3RhYmxlcmFuZ2U6ZWNiYTIyMzUwNzQ3NDM1ZTk3MzY5NTIzYzQyY2EwNjVfNC0yLTEtMS05NzgzOQ_26166d8c-8f8b-4cd2-8eb1-01122aaad727"
      unitRef="usd">107521000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOmVjYmEyMjM1MDc0NzQzNWU5NzM2OTUyM2M0MmNhMDY1L3RhYmxlcmFuZ2U6ZWNiYTIyMzUwNzQ3NDM1ZTk3MzY5NTIzYzQyY2EwNjVfNC00LTEtMS05NzgzOQ_c7e653e5-3ab0-4c49-aebb-cfedba6141cc"
      unitRef="usd">100123000</us-gaap:InventoryNet>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTU4NA_6b8bdd0d-c048-4895-8af1-7a6609f63a98">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfMS0yLTEtMS05NzgzOQ_b1210f5a-7a77-41d2-a594-5adadd9636f8"
      unitRef="usd">50084000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfMS00LTEtMS05NzgzOQ_e4c7781d-1622-4908-9d31-a4dd6f4f6351"
      unitRef="usd">51694000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfMy0yLTEtMS05NzgzOQ_6425d082-8c77-4b44-a07e-c3633a486c33"
      unitRef="usd">4739000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfMy00LTEtMS05NzgzOQ_238fa135-d13a-4069-b767-f7f4ef894d2e"
      unitRef="usd">4647000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssets
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfNC0yLTEtMS05NzgzOQ_8be55ce2-b26e-4a04-9b8f-62869b82bdb9"
      unitRef="usd">7424000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfNC00LTEtMS05NzgzOQ_b6222df6-eb8b-401f-9643-a98bd3bba9a4"
      unitRef="usd">14984000</us-gaap:OtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfNS0yLTEtMS05NzgzOQ_36d3daed-e8d7-453b-966a-90a8fce24f03"
      unitRef="usd">62247000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfNS00LTEtMS05NzgzOQ_767f5d7c-32ef-474c-9468-ceba4028530e"
      unitRef="usd">71325000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfNi0yLTEtMS05NzgzOQ_50017a16-b06f-4906-bc43-8eb41ed163fd"
      unitRef="usd">25240000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfNi00LTEtMS05NzgzOQ_d5c0338f-f0e7-4906-9e78-2e162904b782"
      unitRef="usd">26301000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfNy0yLTEtMS05NzgzOQ_851625e6-0a0e-4170-827d-722110bcb753"
      unitRef="usd">37007000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjE2ZGUwMzJhNTI3YTRkOTY5ZDU5YjY0NmIwYTQ3NTZkL3RhYmxlcmFuZ2U6MTZkZTAzMmE1MjdhNGQ5NjlkNTliNjQ2YjBhNDc1NmRfNy00LTEtMS05NzgzOQ_0ae89138-d163-4e46-a58c-e92aa90bba66"
      unitRef="usd">45024000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTU5MQ_75da8702-ddcb-425a-b26d-abc6e8b045b1">Property and equipment, net consisted of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9f4f1582f5974e0fa962b63fed33147c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfMS0yLTEtMS05NzgzOQ_95d2a6d6-e9eb-4455-862f-cc490ba9f744"
      unitRef="usd">8836000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i68980f1c77a7473ab18bec2713ab9e05_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfMS00LTEtMS05NzgzOQ_18187332-fcf3-4d3d-8839-c9bd4eaad687"
      unitRef="usd">7380000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib377635631014ff39344d0ec6e220cf8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfMi0yLTEtMS05NzgzOQ_4733e8d8-948c-4e4e-945f-9a807c5a4e0d"
      unitRef="usd">31007000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifed31096856d45c5a8a866ba7b9fccce_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfMi00LTEtMS05NzgzOQ_6a3e1fed-f557-44f9-9643-3de159b2411e"
      unitRef="usd">27893000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1795cd05c98547769da8f152dffa740b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfMy0yLTEtMS05NzgzOQ_60ccf84f-185f-4831-8b38-90d53763f2ea"
      unitRef="usd">8173000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i47f684ec05774a41841a55c9d11bc8ab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfMy00LTEtMS05NzgzOQ_86dd82a5-dbfb-4361-99ae-ae138b0fc67a"
      unitRef="usd">7855000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i429394b48f8f49c9bd5c34d8ea70ef6f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfNC0yLTEtMS05NzgzOQ_52d21daa-9164-4a7a-8467-ab9d73966643"
      unitRef="usd">6699000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i463667de7a9840d9887b692b9090956f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfNC00LTEtMS05NzgzOQ_8fc52b52-c8a8-4497-87db-b8e49398a510"
      unitRef="usd">6729000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfNS0yLTEtMS05NzgzOQ_c063bcc7-28bf-453a-9037-701a4d145096"
      unitRef="usd">54715000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfNS00LTEtMS05NzgzOQ_9cfb9d7b-a2ee-4616-9899-1e405f629982"
      unitRef="usd">49857000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfNi0yLTEtMS05NzgzOQ_3225f686-a984-4552-ba5f-3bef565fe7a1"
      unitRef="usd">16171000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfNi00LTEtMS05NzgzOQ_c66f5eba-1837-4115-8d52-7ef615279a1b"
      unitRef="usd">14756000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfNy0yLTEtMS05NzgzOQ_db650520-a02c-42cb-8ff7-0b3c892f496c"
      unitRef="usd">38544000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfNy00LTEtMS05NzgzOQ_f54a662c-d98c-446b-8b60-48e09d4058d9"
      unitRef="usd">35101000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfOC0yLTEtMS05NzgzOQ_3425b502-7f65-45ba-82c5-0b8f2c5dab92"
      unitRef="usd">39420000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfOC00LTEtMS05NzgzOQ_46f43087-dfd3-4c86-8fab-4da92a98ee90"
      unitRef="usd">40469000</us-gaap:OperatingLeaseRightOfUseAsset>
    <halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfOS0yLTEtMS05NzgzOQ_abbc1d78-2dab-4b57-8e94-427c39fc04d9"
      unitRef="usd">77964000</halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjFmYzFhZGQ5MzRjODQxYjNhM2YwNDJiOWMyNjk1NDkyL3RhYmxlcmFuZ2U6MWZjMWFkZDkzNGM4NDFiM2EzZjA0MmI5YzI2OTU0OTJfOS00LTEtMS05NzgzOQ_60f52cb2-b06e-4136-95ee-c43eedabf686"
      unitRef="usd">75570000</halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfNjg2_76d0e78d-f4a5-4f37-aaeb-d9fad8170bc0"
      unitRef="usd">2600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfNjkz_f39f84a2-7995-4679-bb3e-b981e60d9eeb"
      unitRef="usd">800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfNTQ5NzU1ODE2MjE1_9d995671-6d12-4312-bbbb-9931a1dc8787"
      unitRef="usd">1400000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfNzQz_77905fc3-8ccf-449e-b5cf-e2d0dcd60a98"
      unitRef="usd">400000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTU5Mg_99a48d41-5d1a-4a65-bf50-d4c00062c5df">&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and payroll taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued outsourced manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns and sales allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accrued expenses, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfMi0yLTEtMS05NzgzOQ_24505cd4-fe29-4ef8-9028-4e6fca954132"
      unitRef="usd">10837000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfMi00LTEtMS05NzgzOQ_6f46a6f3-1cb2-4663-863c-c1d8696b6328"
      unitRef="usd">19939000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <halo:Accruedmanufacturingexpenses
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfMy0yLTEtMS05NzgzOQ_b6d8ee9b-2daf-49cf-a367-27d41b85fef8"
      unitRef="usd">12456000</halo:Accruedmanufacturingexpenses>
    <halo:Accruedmanufacturingexpenses
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfMy00LTEtMS05NzgzOQ_498880f0-76df-4df0-b019-96b5ddf28e7b"
      unitRef="usd">12190000</halo:Accruedmanufacturingexpenses>
    <us-gaap:TaxesPayableCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfNC0yLTEtMS05NzgzOQ_ded44106-fd4c-4b22-bdab-9a97629e2fdf"
      unitRef="usd">2638000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfNC00LTEtMS05NzgzOQ_53bf67b7-c6fe-4de6-a988-d8c92aba502a"
      unitRef="usd">0</us-gaap:TaxesPayableCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfNS0yLTEtMS05NzgzOQ_91987079-a850-4272-9320-a92696d3aff7"
      unitRef="usd">29610000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfNS00LTEtMS05NzgzOQ_a71048dd-5f69-44ff-b4f9-cbed3f48a085"
      unitRef="usd">30261000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfNi0yLTEtMS05NzgzOQ_2a978923-7b4a-4125-85a1-54a13b7ebe6b"
      unitRef="usd">19947000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfNi00LTEtMS05NzgzOQ_4a9ab397-9795-45e2-a4d1-929a9af5a267"
      unitRef="usd">29771000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfNy0yLTEtMS05NzgzOQ_339f0d64-753e-4e47-b2da-ac4a6d4828af"
      unitRef="usd">34063000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfNy00LTEtMS05NzgzOQ_b78565a8-cfa1-40cd-9f10-555bcaa2635a"
      unitRef="usd">34788000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfOC0yLTEtMS05NzgzOQ_23ed6aa6-5867-47d7-8409-b8b452383fd4"
      unitRef="usd">109551000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfOC00LTEtMS05NzgzOQ_3d967cc5-a7fd-42e1-a067-1ca2072853f6"
      unitRef="usd">126949000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <halo:AccruedLiabilitiesNoncurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfOS0yLTEtMS05NzgzOQ_d789e655-1de2-43bc-9808-304dbcdd2cb5"
      unitRef="usd">29573000</halo:AccruedLiabilitiesNoncurrent>
    <halo:AccruedLiabilitiesNoncurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfOS00LTEtMS05NzgzOQ_235b1fc9-883e-4f95-8ccd-7e9bfb27847c"
      unitRef="usd">30433000</halo:AccruedLiabilitiesNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfMTAtMi0xLTEtOTc4Mzk_f5644a30-4749-41a7-8455-9f667251d386"
      unitRef="usd">79978000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RhYmxlOjNjY2QxN2ExYmIwMjQwNDg4N2JkNmVhODJmZjQ2NjhhL3RhYmxlcmFuZ2U6M2NjZDE3YTFiYjAyNDA0ODg3YmQ2ZWE4MmZmNDY2OGFfMTAtNC0xLTEtOTc4Mzk_519166b9-69ab-47fa-b77b-a563167d7a75"
      unitRef="usd">96516000</us-gaap:AccruedLiabilitiesCurrent>
    <halo:OperatingLeaseAccretionOfLiability
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTEwNQ_29da5d2a-3b81-4271-ad8b-71381b5d1a9b"
      unitRef="usd">700000</halo:OperatingLeaseAccretionOfLiability>
    <halo:OperatingLeaseAccretionOfLiability
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTExMg_6952adb2-20f3-4b25-8eb7-54d2d47bbd34"
      unitRef="usd">100000</halo:OperatingLeaseAccretionOfLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTI4NA_fb1ee0ce-eebb-4456-ace6-ecd6abb2ebed"
      unitRef="usd">2100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTI5MQ_bae0a391-21f2-49b3-9fa2-0c4c162a58c5"
      unitRef="usd">500000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTQ1Mg_22f1db9b-7f49-4b3c-b992-bdf23c8407d0"
      unitRef="usd">1700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82NC9mcmFnOmEzZGQxYjBhNWUzMDRmYTBhNDhlYTU0ODA5MDJmMjUzL3RleHRyZWdpb246YTNkZDFiMGE1ZTMwNGZhMGE0OGVhNTQ4MDkwMmYyNTNfMTQ1OQ_3d59a287-252d-4367-9301-066077a2fc9f"
      unitRef="usd">700000</us-gaap:OperatingLeasePayments>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RleHRyZWdpb246MTYzZDU4ODI5MmUwNGM4ZGEwZGI0YzJjNWY0NjIwZWJfMTAyOA_c28fdaa5-e774-4147-95c5-bb21557c42ab">Goodwill and Intangible Assets&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 24, 2022, we acquired all outstanding equity interests of Antares. A goodwill balance of $409.0&#160;million was recognized for the excess of the consideration transferred over the net assets acquired and represents the expected revenue and cost synergies of the combined company and assembled workforce.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the activity impacting goodwill is presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement period adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our acquired intangible assets are amortized using the straight-line method over their estimated useful lives of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RleHRyZWdpb246MTYzZDU4ODI5MmUwNGM4ZGEwZGI0YzJjNWY0NjIwZWJfNTU2_7b1e4645-8507-4bdd-a7da-977a1bcbb72c"&gt;seven&lt;/span&gt; to ten years. The following table shows the cost, accumulated amortization and weighted average useful life in years for our acquired intangible assets as of March&#160;31, 2023 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average useful life &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auto injector technology platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XYOSTED proprietary product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TLANDO product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ATRS-1902 (IPR&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future annual amortization of finite-lived intangible assets is shown in the following table (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="i04990caa9f1d4feeb66916e444f5b67f_I20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RleHRyZWdpb246MTYzZDU4ODI5MmUwNGM4ZGEwZGI0YzJjNWY0NjIwZWJfMTQ0_289bc0ed-2e84-4fa6-8050-709eaa5e2211"
      unitRef="usd">409000000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RleHRyZWdpb246MTYzZDU4ODI5MmUwNGM4ZGEwZGI0YzJjNWY0NjIwZWJfMTAyOQ_2467bea4-2153-4a5c-aceb-6b9d68adc7f3">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the activity impacting goodwill is presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement period adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjk0N2VlYTAxM2FjMjQ4MDJiMmVjNTVjYzI5ZmU3MDM0L3RhYmxlcmFuZ2U6OTQ3ZWVhMDEzYWMyNDgwMmIyZWM1NWNjMjlmZTcwMzRfMC0yLTEtMS05NzgzOQ_b4b653aa-eeb4-4664-9125-93ac2a9aa05d"
      unitRef="usd">409049000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjk0N2VlYTAxM2FjMjQ4MDJiMmVjNTVjYzI5ZmU3MDM0L3RhYmxlcmFuZ2U6OTQ3ZWVhMDEzYWMyNDgwMmIyZWM1NWNjMjlmZTcwMzRfMS0yLTEtMS05NzgzOQ_6cd17fec-b06b-431f-ac78-a59409492426"
      unitRef="usd">7174000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjk0N2VlYTAxM2FjMjQ4MDJiMmVjNTVjYzI5ZmU3MDM0L3RhYmxlcmFuZ2U6OTQ3ZWVhMDEzYWMyNDgwMmIyZWM1NWNjMjlmZTcwMzRfMi0yLTEtMS05NzgzOQ_737bb8fa-fc05-4bdc-bd9f-fe34414ade20"
      unitRef="usd">416223000</us-gaap:Goodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i81c6c189dc1c414db846950051a68f58_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RleHRyZWdpb246MTYzZDU4ODI5MmUwNGM4ZGEwZGI0YzJjNWY0NjIwZWJfNTYy_8a3a8d49-68b6-478d-a697-143e9afb83e4">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RleHRyZWdpb246MTYzZDU4ODI5MmUwNGM4ZGEwZGI0YzJjNWY0NjIwZWJfMTAyNg_1eedb7fa-46c8-45e7-bd6d-7dcebb5c3025">The following table shows the cost, accumulated amortization and weighted average useful life in years for our acquired intangible assets as of March&#160;31, 2023 (in thousands).&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average useful life &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auto injector technology platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XYOSTED proprietary product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TLANDO product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ATRS-1902 (IPR&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i48becb7672924502ac96083bb5cd5d79_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMS0yLTEtMS05NzgzOQ_9fef4a34-dc88-4e4a-87d6-c4edcf486551">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ieeb34905ee5a413ba8c2930d948203a1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMS00LTEtMS05NzgzOQ_a83add82-8a8d-4a65-a38a-5554c8b7f9ac"
      unitRef="usd">402000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ieeb34905ee5a413ba8c2930d948203a1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMS02LTEtMS05NzgzOQ_432c7631-36af-482d-84d7-c2d4af666fd8"
      unitRef="usd">49092000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ieeb34905ee5a413ba8c2930d948203a1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMS04LTEtMS05NzgzOQ_f9972e24-f338-4240-84d6-355e80ce81f4"
      unitRef="usd">352908000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ia90c2ed74ead443583b931534d578bb2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMi0yLTEtMS05NzgzOQ_8833b42d-a083-4b93-8298-b38ba290e8ef">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iaa015d0540a840c79bc449df56401a5f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMi00LTEtMS05NzgzOQ_a355c7c4-af34-41ac-aa87-39d9ff7680c5"
      unitRef="usd">136200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iaa015d0540a840c79bc449df56401a5f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMi02LTEtMS05NzgzOQ_e1cb9677-dea5-436a-9fdf-48f614734974"
      unitRef="usd">11643000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iaa015d0540a840c79bc449df56401a5f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMi04LTEtMS05NzgzOQ_b43e3eb7-77ed-44d1-b34f-4e192d7d11bd"
      unitRef="usd">124557000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i25336e1752ef44b4b8ba6f295a047c8d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMy0yLTEtMS05NzgzOQ_41968bcc-f5e2-464d-aef3-708c5d4ea1fd">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6e130d5a6e9b4d66b803cb5e487a55ef_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMy00LTEtMS05NzgzOQ_ecb8fc3a-cdf0-42c9-bb78-b93c4a7c917b"
      unitRef="usd">2900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6e130d5a6e9b4d66b803cb5e487a55ef_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMy02LTEtMS05NzgzOQ_acf6675b-0cf7-414e-944b-b783b11d3406"
      unitRef="usd">248000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6e130d5a6e9b4d66b803cb5e487a55ef_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfMy04LTEtMS05NzgzOQ_0fcc30cb-e17e-4ef8-8a61-620a1da805e4"
      unitRef="usd">2652000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfNC00LTEtMS05NzgzOQ_b0d75b35-a520-44ef-a286-a3beb80b3e78"
      unitRef="usd">541100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfNC02LTEtMS05NzgzOQ_827f7593-9a27-4c85-93b4-d3b3206ef7d3"
      unitRef="usd">60983000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfNC04LTEtMS05NzgzOQ_8486e8d8-156a-4459-8a13-7899dd5d248e"
      unitRef="usd">480117000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfNS04LTEtMS05NzgzOQ_ef2fedf4-afae-44b5-8876-9c35878f7173"
      unitRef="usd">48700000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOmQ1MmVmODZiNzQzYzRjMjM5MDI5NWZhOTM1OTQ3ZmEyL3RhYmxlcmFuZ2U6ZDUyZWY4NmI3NDNjNGMyMzkwMjk1ZmE5MzU5NDdmYTJfNi04LTEtMS05NzgzOQ_28120e1d-e943-432a-b6cb-c9a66aaa8404"
      unitRef="usd">528817000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RleHRyZWdpb246MTYzZDU4ODI5MmUwNGM4ZGEwZGI0YzJjNWY0NjIwZWJfMTAyNw_f3b8e324-d458-4902-b09d-55b186cffb85">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future annual amortization of finite-lived intangible assets is shown in the following table (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjczZjIwODU3NjIyNDQyODc4NTY5YjdjM2RmZDViM2RlL3RhYmxlcmFuZ2U6NzNmMjA4NTc2MjI0NDI4Nzg1NjliN2MzZGZkNWIzZGVfMS0yLTEtMS05NzgzOQ_6e177a1f-b4c1-45da-86c8-e56b61dea278"
      unitRef="usd">53504000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjczZjIwODU3NjIyNDQyODc4NTY5YjdjM2RmZDViM2RlL3RhYmxlcmFuZ2U6NzNmMjA4NTc2MjI0NDI4Nzg1NjliN2MzZGZkNWIzZGVfMi0yLTEtMS05NzgzOQ_b1b5aa02-43e2-4d77-887c-0f7d04cdc2d8"
      unitRef="usd">71339000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjczZjIwODU3NjIyNDQyODc4NTY5YjdjM2RmZDViM2RlL3RhYmxlcmFuZ2U6NzNmMjA4NTc2MjI0NDI4Nzg1NjliN2MzZGZkNWIzZGVfMy0yLTEtMS05NzgzOQ_914c84d4-3350-40ba-941a-831642db48e9"
      unitRef="usd">71339000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjczZjIwODU3NjIyNDQyODc4NTY5YjdjM2RmZDViM2RlL3RhYmxlcmFuZ2U6NzNmMjA4NTc2MjI0NDI4Nzg1NjliN2MzZGZkNWIzZGVfNC0yLTEtMS05NzgzOQ_d27c21ed-1396-4959-b59b-60342bd87dbc"
      unitRef="usd">71339000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjczZjIwODU3NjIyNDQyODc4NTY5YjdjM2RmZDViM2RlL3RhYmxlcmFuZ2U6NzNmMjA4NTc2MjI0NDI4Nzg1NjliN2MzZGZkNWIzZGVfNS0yLTEtMS05NzgzOQ_98107109-e18a-4838-857a-78844df81dbb"
      unitRef="usd">71339000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <halo:FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjczZjIwODU3NjIyNDQyODc4NTY5YjdjM2RmZDViM2RlL3RhYmxlcmFuZ2U6NzNmMjA4NTc2MjI0NDI4Nzg1NjliN2MzZGZkNWIzZGVfNi0yLTEtMS05NzgzOQ_ad3cdc01-f9b3-4cdc-b0da-f46cbf178411"
      unitRef="usd">141257000</halo:FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl82Ny9mcmFnOjE2M2Q1ODgyOTJlMDRjOGRhMGRiNGMyYzVmNDYyMGViL3RhYmxlOjczZjIwODU3NjIyNDQyODc4NTY5YjdjM2RmZDViM2RlL3RhYmxlcmFuZ2U6NzNmMjA4NTc2MjI0NDI4Nzg1NjliN2MzZGZkNWIzZGVfNy0yLTEtMS05NzgzOQ_7bc5ed5f-cb4f-434c-9b25-7150dcb1dd6f"
      unitRef="usd">480117000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:LongTermDebtTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTc5Mjg_45c9a0fc-4405-4666-b43a-61b41a04ac64">Long-Term Debt, Net&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;1.00% Convertible Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, we completed the sale of $720.0&#160;million in aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the &#x201c;2028 Convertible Notes&#x201d; and collectively with the 2024 and the 2027 Convertible Notes the &#x201c;Convertible Notes&#x201d;). The net proceeds in connection with the issuance of the 2028 Convertible Notes, after deducting the initial purchasers&#x2019; fee of $18.0&#160;million, was approximately $702.0&#160;million. We also incurred additional debt issuance costs totaling $1.0&#160;million. Debt issuance costs and the initial purchasers&#x2019; fee are presented as a debt discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2028 Convertible Notes pay interest semi-annually in arrears on February 15th and August 15th of each year at an annual rate of 1.00%. The 2028 Convertible Notes are general unsecured obligations and rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2028 Convertible Notes, rank equally in right of payment with all existing and future liabilities that are not so subordinated, are effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2028 Convertible Notes have a maturity date of August 15, 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their 2028 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2022, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#x201c;measurement period&#x201d;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2028 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, February 15, 2028 until the close of business on the second scheduled trading day immediately before the maturity date. As of March&#160;31, 2023, the 2028 Convertible Notes are not convertible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, we will pay cash for the settlement of principal, and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2028 Convertible Notes is 17.8517 shares of common stock per $1,000 in principal amount of 2028 Convertible Notes, equivalent to a conversion price of approximately $56.02 per share of our common stock. The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued or unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Capped Call Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the offering of the 2028 Convertible Notes, we entered into capped call transactions with certain counterparties (the &#x201c;Capped Call Transactions&#x201d;). The Capped Call Transactions are expected generally to reduce potential dilution to holders of our common stock upon conversion of the 2028 Convertible Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the principal amount of such converted 2028 Convertible Notes. The cap price of the Capped Call Transactions is initially $75.4075 per share of common stock, representing a premium of 75% above the last reported sale price of $43.09 per share of common stock on August 15, 2022, and is subject to certain adjustments under the terms of the Capped Call Transactions. As of March&#160;31, 2023, no capped calls have been exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to their terms, the capped calls qualify for classification within stockholders&#x2019; equity in the condensed consolidated balance sheets, and their fair value is not remeasured and adjusted as long as they continue to qualify for stockholders&#x2019; equity classification. We paid approximately $69.1&#160;million for the Capped Calls, including applicable transaction costs, which was recorded as a reduction to additional paid-in capital in the condensed consolidated balance sheets. The Capped Call Transactions are separate transactions entered into by us with the capped call Counterparties, are not part of the terms of the Convertible Notes, and do not affect any holder&#x2019;s rights under the Convertible Notes. Holders of the Convertible Notes do not have any rights with respect to the Capped Call Transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;0.25% Convertible Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, we completed the sale of $805.0&#160;million in aggregate principal amount of 0.25% Convertible Senior Notes due 2027 (the &#x201c;2027 Convertible Notes&#x201d;). The net proceeds in connection with the issuance of the 2027 Convertible Notes, after deducting the initial purchasers&#x2019; fee of $20.1&#160;million, was approximately $784.9&#160;million. We also incurred additional debt issuance costs totaling $0.4&#160;million. Debt issuance costs and the initial purchasers&#x2019; fee are presented as a debt discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2027 Convertible Notes pay interest semi-annually in arrears on March 1st and September 1st of each year at an annual rate of 0.25%. The 2027 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2027 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2027 Convertible Notes have a maturity date of March 1, 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their 2027 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#x201c;measurement period&#x201d;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2027 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately before the maturity date. The 2027 Convertible Notes will be convertible, regardless of the foregoing circumstances, at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately preceding the maturity date. As of March&#160;31, 2023, the 2027 Convertible Notes are not convertible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, we will pay cash for the settlement of principal, and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2027 Convertible Notes will be 12.9576 shares of common stock per $1,000 in principal amount of 2027 Convertible Notes, equivalent to a conversion price of approximately $77.17 per share of our common stock. The conversion rate is subject to adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;1.25% Convertible Notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, we completed the sale of $460.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due 2024 (&#x201c;2024 Convertible Notes&#x201d;). The net proceeds in connection with 2024 Convertible Notes, after deducting the initial purchases&#x2019; fee of $12.7&#160;million, was approximately $447.3 million. We also incurred debt issuance cost totaling $0.3&#160;million. Debt issuance costs and the initial purchasers&#x2019; fee are presented as a debt discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Convertible Notes pay interest semi-annually in arrears on June 1st and December 1st of each year, beginning on June 1, 2020, at an annual rate of 1.25%. The 2024 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2024 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2024 Convertible Notes have a maturity date of December 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their 2024 Convertible Notes at their option only in the following circumstances: (1)&#160;during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2020, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2)&#160;during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#x201c;measurement period&#x201d;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3)&#160;upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2024 Convertible Notes; (4)&#160;if we call such notes for redemption; and (5)&#160;at any time from, and including, June&#160;1, 2024 until the close of business on the scheduled trading day immediately before the maturity date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we notified the note holders of our irrevocable election to settle the principal of the 2024 Convertible Notes in cash and for the premium, if applicable, to deliver shares of common stock. The conversion rate for the 2024 Convertible Notes will be 41.9208 shares of common stock per $1,000 in principal amount of 2024 Convertible Notes, equivalent to a conversion price of approximately $23.85 per share of our common stock. The conversion rate was subject to adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, we completed a privately negotiated induced conversion of $369.1&#160;million principal amount of the 2024 Convertible Notes (&#x201c;2021 Note Repurchases&#x201d; or the &#x201c;2021 Induced Conversion&#x201d;). In connection with the 2021 Induced Conversion, we paid approximately $370.2&#160;million in cash, which includes principal and accrued interest, and issued approximately 9.08&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the 2021 Induced Conversion, we recorded $0.0 million in induced conversion expense which was included in other income (expense) of the condensed consolidated statements of income in 2021. The induced conversion expense represented the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, we completed a privately negotiated induced conversion of $77.4&#160;million principal amount of the 2024 Convertible Notes (&#x201c;2022 Note Repurchases&#x201d; or the &#x201c;2022 Induced Conversion&#x201d;). In connection with the 2022 Induced Conversion, we paid approximately $77.6&#160;million in cash, which includes principal and accrued interest, and issued approximately 1.51&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the 2022 Induced Conversion, we recorded $2.7&#160;million in induced conversion expense which was included in other income (expense) of the condensed consolidated statements of income in 2022. The induced conversion expense represented the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, we issued a notice for the redemption of 2024 Convertible Notes. Holders of the notes may convert their notes at any time prior the close of business day prior to the redemption date. In March 2023, holders of the notes elected to convert the 2024 Convertible Notes in full. In connection with the conversion, we paid approximately $13.5 million in cash which includes principal and accrued interest, and issued 288,886 shares of our common stock representing the intrinsic value based on the contractual conversion rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Carrying Amounts of our Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount and fair value of our Convertible Notes were as follows (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,506,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value based on trading levels (Level 2):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of outstanding notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,666,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization per period of debt discount (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revolving Credit and Term Loan Facilities (May 2022)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, in connection with the closing of the Antares acquisition, we entered into a credit agreement, which was subsequently amended, with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#x201c;2022 Credit Agreement), evidencing a credit facility (the &#x201c;2022 Facility&#x201d;) that provides for (i) a $350&#160;million revolving credit facility (the &#x201c;Revolving Credit Facility&#x201d;) and (ii) a $250&#160;million term loan facility (the &#x201c;Term Facility&#x201d;). Proceeds from a $120&#160;million draw on the Revolving Credit Facility and the $250&#160;million Term Facility were used to fund a portion of the Antares acquisition, repay Antares&#x2019; existing debt and pay fees and expenses in connection with the Antares acquisition. The 2022 Credit Agreement contains an expansion feature, which allows us, subject to certain conditions, to increase the aggregate principal amount of the 2022 Facility, provided we remain in compliance with underlying financial covenants on a pro forma basis including the consolidated interest coverage ratio and the consolidated net leverage ratio covenants set forth in the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth years following the Closing in annual amounts equal to 2.50%, 5.00%, 7.50% and 10.00% of the initial principal amount of the term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales, subject to our right to reinvest the proceeds thereof.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the applicable Term Secured Overnight Financing Rate (SOFR) (which includes a SOFR adjustment of 0.10%), or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus 0.50%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus 1.10%, and (4) 1.00%. The margin for the 2022 Facility ranges, based on our consolidated total net leverage ratio, from 0.25% to 1.25% in the case of base rate loans and from 1.25% to 2.25% in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the Facility, we will pay (i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency fees. The commitment fees range from 0.15% to 0.35% per annum based on our consolidated net leverage ratio. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, we entered into Amendment No. 1 to the Credit Agreement (the &#x201c;Amendment&#x201d;) among the Company, the Guarantors (as defined in the Credit Agreement), each L/C Issuer from time to time party thereto, Bank of America, N.A., as Administrative Agent (in such capacity, the &#x201c;Administrative Agent&#x201d;) and swing line lender (in such capacity, the &#x201c;Swing Line Lender&#x201d;), and each lender party thereto, which amends the Credit Agreement dated as of May 24, 2022 (the &#x201c;Credit Agreement&#x201d;) among the Company, the Guarantors, the Administrative Agent, the Swing Line Lender, each Lender and the L/C Issuers. The Amendment, among other things, increased the size of the revolving credit facility from $350&#160;million to $575&#160;million. The terms of the Revolving Credit Facility are otherwise unchanged. Concurrently with the entry into the Amendment, we repaid the entire outstanding Term Loan Facility and repaid all outstanding loans under the Revolving Credit Facility under the 2022 Credit Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the Revolving Credit Facility was undrawn. We incurred a total of $3.6&#160;million in third-party costs related to the 2022 Credit Agreement which is recorded as debt issuance cost within prepaid expenses and other assets in the condensed consolidated balance sheets. As of March&#160;31, 2023, the unamortized debt issuance cost related to the revolving credit facility was $2.9 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if3d4edc7f65c461d9431d7d9efcc56e9_I20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMjk_fcfca158-4410-4b60-959c-8ce1c7665e1f"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if3d4edc7f65c461d9431d7d9efcc56e9_I20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTAw_e4e98dea-51c7-49bc-a7d0-d3c0a588431f"
      unitRef="usd">720000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if3d4edc7f65c461d9431d7d9efcc56e9_I20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTM2_47868e88-502e-4360-b2f9-18cce3107dc6"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="if3d4edc7f65c461d9431d7d9efcc56e9_I20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNDE4_547292b0-3112-428f-9200-743b794564bc"
      unitRef="usd">18000000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ifd6f3969e6c8426fa1c64cce894e6e50_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNDQw_5b55822e-ffc2-4b96-81bb-c704dd86d567"
      unitRef="usd">702000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ifd6f3969e6c8426fa1c64cce894e6e50_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTAx_058fd478-28e3-4a0e-87f1-c6b2da28179e"
      unitRef="usd">1000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if3d4edc7f65c461d9431d7d9efcc56e9_I20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNzI0_56f4126d-c814-4245-9526-1dbef82d25b0"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i5418d7fce8df4268a313fe8e25d35226_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTYyOQ_d5b0a876-6983-481c-b29e-96ea504ee93d"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i5418d7fce8df4268a313fe8e25d35226_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTY3Nw_b154625b-f4c5-4fed-8970-562c74280ef9"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i5418d7fce8df4268a313fe8e25d35226_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTcwNA_b319c04f-d319-4e80-b3dd-f324ded7ae9c"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <halo:DebtInstrumentConvertibleThresholdConsecutiveBusinessDays
      contextRef="ia9437143ea354b0fb66fc8e352a8fad9_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTg0MQ_f9e768c3-4581-4e0f-a105-9ca97d329eb3"
      unitRef="businessday">5</halo:DebtInstrumentConvertibleThresholdConsecutiveBusinessDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ia9437143ea354b0fb66fc8e352a8fad9_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTg5Mg_b4b0410d-ccd3-473a-a1db-b413088a305b"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ia9437143ea354b0fb66fc8e352a8fad9_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTkzMg_88bae73b-fdcc-46e2-99b8-52a1090f4204"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ia9437143ea354b0fb66fc8e352a8fad9_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMjExOA_bdbf4cff-ac55-41fe-8d87-ced9c56a6277"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ifd6f3969e6c8426fa1c64cce894e6e50_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMjk2OQ_92b4d427-453a-4162-b3bf-1784d546cd35"
      unitRef="number">17.8517</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="if3d4edc7f65c461d9431d7d9efcc56e9_I20220831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMzA5OQ_a68517f1-e365-4f89-974e-576ee870b0c7"
      unitRef="usdPerShare">56.02</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <halo:DebtInstrumentCapCallTransactionCapPricePerShare
      contextRef="i4b687461f70242228d9fa67322314ce3_I20220831"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMzk3Mg_3c793a2d-4881-460a-ab3b-0b6a37168ebc"
      unitRef="usdPerShare">75.4075</halo:DebtInstrumentCapCallTransactionCapPricePerShare>
    <halo:SaleOfStockPremiumOverLastReportedSalePricePercentage
      contextRef="ic03a55962ac146dfb9a17293e7c10f01_D20220801-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNDAyOA_ed55bce7-e453-406c-ae54-99c2c6c6a416"
      unitRef="number">0.75</halo:SaleOfStockPremiumOverLastReportedSalePricePercentage>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i875da9e8bc6f447e83c35dccc1bce549_I20220815"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNDA3MA_9c5273f6-5d2d-482a-8612-ddcdc4b817cd"
      unitRef="usdPerShare">43.09</us-gaap:SaleOfStockPricePerShare>
    <halo:PaymentForCappedCallTransactions
      contextRef="ic03a55962ac146dfb9a17293e7c10f01_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNDU0Nw_59213aaa-ae2a-4c51-9263-c9652dcde8af"
      unitRef="usd">69100000</halo:PaymentForCappedCallTransactions>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i297284b6b3114aa4a934c8c77af6a7ef_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTA1Nw_bdad9cb9-8172-4e9d-97f0-503ef5d52475"
      unitRef="number">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i297284b6b3114aa4a934c8c77af6a7ef_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTEyNw_31f90907-ae57-4791-9d2b-d6e368666eaa"
      unitRef="usd">805000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i297284b6b3114aa4a934c8c77af6a7ef_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTE2Mw_5abda9d4-c34f-414f-991c-eb60301a2cc8"
      unitRef="number">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i297284b6b3114aa4a934c8c77af6a7ef_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTM1OQ_87e519c0-59ba-4039-90f0-bf48b039720a"
      unitRef="usd">20100000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i49ac4e10c151449aa37064756bff906c_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTM4MQ_ededc773-d749-4909-abee-a82d1d382039"
      unitRef="usd">784900000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ib53c28890ced4a5e81b120e58423d483_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTQ0Mg_982498c9-3fe9-4054-ae7e-29ebb00452fe"
      unitRef="usd">400000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i297284b6b3114aa4a934c8c77af6a7ef_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTY2Mg_21fc5e68-b760-4d95-a852-f2a76847546e"
      unitRef="number">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i62e04ec34e84456a9a1c1c9fce36d738_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNjU3OA_b9809cf8-31d7-4510-a2d1-99cfe8343970"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i62e04ec34e84456a9a1c1c9fce36d738_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNjYyNg_20383e8e-580b-4f85-92d4-5b8c4c7867e6"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i62e04ec34e84456a9a1c1c9fce36d738_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNjY1Mw_bc9cc1e0-5c6a-4662-9d40-371677bbb15b"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <halo:DebtInstrumentConvertibleThresholdConsecutiveBusinessDays
      contextRef="i0a51169caaa348e8906636fb88af0a07_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNjc5MA_c47ce75d-4f31-48dc-8a98-c8485d3e8714"
      unitRef="businessday">5</halo:DebtInstrumentConvertibleThresholdConsecutiveBusinessDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i0a51169caaa348e8906636fb88af0a07_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNjg0MQ_c6272799-d1bf-4ea1-9ba7-05470ebb42d0"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i0a51169caaa348e8906636fb88af0a07_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNjg4MQ_d978ef21-76ea-460d-b030-2be6d5c1dc1d"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i0a51169caaa348e8906636fb88af0a07_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNzA2Nw_ce819a59-6993-46d1-832a-08e88e268678"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ib53c28890ced4a5e81b120e58423d483_D20210301-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfODE1Ng_d2e495a9-2f85-4483-8bb9-4cda721f212f"
      unitRef="number">12.9576</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i297284b6b3114aa4a934c8c77af6a7ef_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfODI5MA_a66b7393-3f97-4aae-ba3c-160532ae288d"
      unitRef="usdPerShare">77.17</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i98820adb7b114fab89f1dcfab8fb0f09_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfODUwNA_c4c79ef2-31a1-4436-90ca-3afe65bf31ee"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i98820adb7b114fab89f1dcfab8fb0f09_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfODU3Nw_640a8746-24cf-4c71-bc29-3028371e212e"
      unitRef="usd">460000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i98820adb7b114fab89f1dcfab8fb0f09_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfODYxMw_67288958-0884-456a-ac66-4b32079a9b36"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i98820adb7b114fab89f1dcfab8fb0f09_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfODc5MA_6428512b-b020-43e3-8c7c-1a1660ccbabf"
      unitRef="usd">12700000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i2bd17b29b4a74fd99bf9cb4435a081cf_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfODgxMg_3cd90b24-ad16-406e-89ed-0ef3ed8bf525"
      unitRef="usd">447300000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i295b45eca4f04978ad6b88c2a0a40c9b_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfODg2MQ_bbff20f3-bc6b-4988-b69a-cad26c1266ea"
      unitRef="usd">300000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i98820adb7b114fab89f1dcfab8fb0f09_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfOTEwNw_b0dad8f2-a3f8-487d-ae0c-74c063d705be"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="icf91861e2376494b8f674c6a659fb5c1_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTAwMjY_bd7c5675-c4b5-4031-af19-a2470da5be29"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="icf91861e2376494b8f674c6a659fb5c1_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTAwNzQ_40a38738-cc10-4e33-a178-4c124a688348"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="icf91861e2376494b8f674c6a659fb5c1_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTAxMDE_3dfeddf8-bb92-428c-8770-eda137ad2a7e"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ibc695c8e9d5e48179ccc383f1676101c_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTAyMzg_ae66e4fa-9f30-4dfa-93dd-bbde3ade61f6"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ibc695c8e9d5e48179ccc383f1676101c_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTAyODk_8fec02ed-18eb-40af-8e32-a73ad38fe88d"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ibc695c8e9d5e48179ccc383f1676101c_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTAzMjk_d6bbecc0-3530-4c4e-8993-eec19174fb60"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ibc695c8e9d5e48179ccc383f1676101c_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTA1MTU_68e48dcc-1c3c-4bd2-8e85-82361fff416d"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i09030ba483314a21b46d9dd361c0aa83_D20210101-20210131"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTE0MTQ_437a3f1a-86ad-413f-b30f-ed648a6ef95f"
      unitRef="number">41.9208</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i8cf5bff84e7842eab1e94ae576059f7e_I20210131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTE1NDg_c13f9b7a-a696-464a-9898-671e4b2706a2"
      unitRef="usdPerShare">23.85</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i0b9f1075f25446e3857aa8ab0613536f_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTE3MDE_65462db2-ff69-4bfd-bff7-6c7c6a3b71d0"
      unitRef="usd">369100000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i0b9f1075f25446e3857aa8ab0613536f_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTE4ODE_2d2321c1-510c-4f00-b8bd-35a90657a8bc"
      unitRef="usd">370200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i0b9f1075f25446e3857aa8ab0613536f_D20210301-20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTE5NjU_94c354bd-33f6-4c1e-8a78-abaf7272768f"
      unitRef="shares">9080000.00</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="ifbcb0ae49876436997c9d2b2422116d1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTIxODE_57c6168e-bfaf-470c-bdc8-7a36bf409ff3"
      unitRef="usd">0</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i3eda99a3ab274f3189aed8a7cd000ecc_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTI1ODc_2eb1fe05-5d9a-4dc8-b11f-a77fd9ecc1a5"
      unitRef="usd">77400000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i3eda99a3ab274f3189aed8a7cd000ecc_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTI3Njc_0a1a61c8-b843-454b-8ed0-b0e9f50c730b"
      unitRef="usd">77600000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i3eda99a3ab274f3189aed8a7cd000ecc_D20220801-20220831"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTI4NTE_f8f8f669-f4a1-47d7-8b37-ee3a10733d83"
      unitRef="shares">1510000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="i3eda99a3ab274f3189aed8a7cd000ecc_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTMwNjc_7f617ab1-6c3c-48c6-91e3-4fe2be79484e"
      unitRef="usd">2700000</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i7511bded3501417cb4e2415a6bcbd39b_D20230301-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTQ5NzU1ODMyODgx_eae86732-3be1-4803-b3f6-9528c5c349b5"
      unitRef="usd">13500000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i7511bded3501417cb4e2415a6bcbd39b_D20230301-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfNTQ5NzU1ODMzMTcz_8ba37d8c-d701-4827-8540-7e09c8b3d6c5"
      unitRef="shares">288886</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTc5MjI_3e9d95ae-a21d-44dd-b415-ef2e1febc6df">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Carrying Amounts of our Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount and fair value of our Convertible Notes were as follows (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,506,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value based on trading levels (Level 2):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of outstanding notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,666,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization per period of debt discount (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i6e312be945a2402db2f373983b98f7d7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMi0yLTEtMS05NzgzOQ_d6661092-716c-4c4b-bd43-6fabeabe2b0e"
      unitRef="usd">0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i82c04eddabc54f759c9fb4de56fb03f4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMi00LTEtMS05NzgzOQ_c31434f4-ecba-4a59-a1bb-812b89567b8c"
      unitRef="usd">13483000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3aafe649a1244a06b7cb31af4030dfbd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMy0yLTEtMS05NzgzOQ_0d1199da-f48e-4af5-9c07-f27f9c1da4c1"
      unitRef="usd">805000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i6816f5120aee4e1790a693cbeb24b81b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMy00LTEtMS05NzgzOQ_049111be-dcc4-4c50-a9d7-f75a2abc48da"
      unitRef="usd">805000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i256de7cb03ee49139431754c4ae916aa_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfNC0yLTEtMS05NzgzOQ_2202e26d-1144-4621-8f27-ac5d9157f99f"
      unitRef="usd">720000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i166af7e00a904a83b5854157af961f65_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfNC00LTEtMS05NzgzOQ_8f964dbc-c1b2-4c38-8625-93fcdc303ba1"
      unitRef="usd">720000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfNS0yLTEtMS05NzgzOQ_010ceb4a-4d82-4949-a067-94033f41728a"
      unitRef="usd">1525000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfNS00LTEtMS05NzgzOQ_7259345b-8e8e-419a-8322-7d62c59f6a6d"
      unitRef="usd">1538483000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i6e312be945a2402db2f373983b98f7d7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfOC0yLTEtMS05NzgzOQ_8a1c9d6b-f2ce-4d38-a8db-4f3edd083004"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i82c04eddabc54f759c9fb4de56fb03f4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfOC00LTEtMS05NzgzOQ_2a99291e-2a7e-4c01-81c8-c9c0dbbe25d0"
      unitRef="usd">149000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i3aafe649a1244a06b7cb31af4030dfbd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfOS0yLTEtMS05NzgzOQ_6e47b544-cea2-4058-8f9e-7e03815815ba"
      unitRef="usd">13509000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i6816f5120aee4e1790a693cbeb24b81b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfOS00LTEtMS05NzgzOQ_d9968260-a5cf-440e-bebc-995dc85e741d"
      unitRef="usd">14359000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i256de7cb03ee49139431754c4ae916aa_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTAtMi0xLTEtOTc4Mzk_19500276-bc4d-46bd-9785-0f8f0c0ee784"
      unitRef="usd">17111000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i166af7e00a904a83b5854157af961f65_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTAtNC0xLTEtOTc4Mzk_7b0c3964-d021-4b6d-8b0d-9f4adf5c36cc"
      unitRef="usd">17875000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTEtMi0xLTEtOTc4Mzk_79e4d2de-d8d4-4b2f-b72a-56a71871e51b"
      unitRef="usd">30620000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTEtNC0xLTEtOTc4Mzk_ab864574-c4b9-40e7-a1c3-a89cfab460bb"
      unitRef="usd">32383000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebtCurrent
      contextRef="i6e312be945a2402db2f373983b98f7d7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTQtMi0xLTEtOTc4Mzk_dcc0cfa7-3ef4-4e80-8db9-c74710be44f0"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i82c04eddabc54f759c9fb4de56fb03f4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTQtNC0xLTEtOTc4Mzk_a943227a-20d4-4d0b-9c16-67185fe74de8"
      unitRef="usd">13334000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3aafe649a1244a06b7cb31af4030dfbd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTUtMi0xLTEtOTc4Mzk_5b79fdff-73a9-46ff-804a-b884ff4ceea7"
      unitRef="usd">791491000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6816f5120aee4e1790a693cbeb24b81b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTUtNC0xLTEtOTc4Mzk_fea7e419-9eca-4103-86b8-c4ff016be99b"
      unitRef="usd">790641000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i256de7cb03ee49139431754c4ae916aa_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTYtMi0xLTEtOTc4Mzk_3eac5eaf-9170-4765-aa75-2c0df8149be4"
      unitRef="usd">702889000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i166af7e00a904a83b5854157af961f65_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTYtNC0xLTEtOTc4Mzk_018b210d-baae-49af-82c0-a58901406bb0"
      unitRef="usd">702125000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTctMi0xLTEtOTc4Mzk_53d4a18b-c0be-4e24-886a-59c17454940e"
      unitRef="usd">1494380000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMTctNC0xLTEtOTc4Mzk_edb2605a-9d85-42c8-90cf-a20f24063bfc"
      unitRef="usd">1506100000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i6e312be945a2402db2f373983b98f7d7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjAtMi0xLTEtOTc4Mzk_e580f19b-1ccd-4e6e-bed2-816cee40fb65"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i82c04eddabc54f759c9fb4de56fb03f4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjAtNC0xLTEtOTc4Mzk_aa6d3da3-f3fe-4415-bb0a-ff38bf5c0444"
      unitRef="usd">32176000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i3aafe649a1244a06b7cb31af4030dfbd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjEtMi0xLTEtOTc4Mzk_e73db72b-ad9a-4399-837a-9f9d1ece2634"
      unitRef="usd">682938000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i6816f5120aee4e1790a693cbeb24b81b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjEtNC0xLTEtOTc4Mzk_738965d0-782b-42bc-a44a-981d559fbf01"
      unitRef="usd">784770000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i256de7cb03ee49139431754c4ae916aa_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjItMi0xLTEtOTc4Mzk_763bda3f-e07e-4726-87bb-6fa69c5ff6cd"
      unitRef="usd">680587000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i166af7e00a904a83b5854157af961f65_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjItNC0xLTEtOTc4Mzk_e5d11e3b-ea58-45b0-abbb-8c87ec725bcc"
      unitRef="usd">849823000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i135c9d6e5363476397deb7376556416f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjMtMi0xLTEtOTc4Mzk_cf3fc32d-2bda-4493-b953-45767b874352"
      unitRef="usd">1363525000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i18f57f446331441d9650bc51a98fef4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjMtNC0xLTEtOTc4Mzk_0841f982-e70e-495a-8cd6-73d20a2cc365"
      unitRef="usd">1666769000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i03816f914d7a447986a953007197bb96_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjYtNC0xLTEtOTc4Mzk_31fc0e90-d005-44fd-b0e8-5f21863de70c">P1Y10M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i4fb3535e833444bdbbab874679ac6563_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjctMi0xLTEtOTc4Mzk_942f60f0-319c-4328-9b37-b1b1498849c6">P3Y10M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i9afd86f45c5e469cbf3764deb77b2e92_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjctNC0xLTEtOTc4Mzk_aba8d88b-c006-4737-a21f-a9581b20e472">P4Y2M12D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="ib5ffcb548d7140e1ac76a8652c62766b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjgtMi0xLTEtOTc4Mzk_c720884d-f1c0-40e0-8d7f-5eec0a97d27e">P5Y4M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i7a88cde3434f468b8176c193c6db698f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjhkMmYwNjUwMzA0NTRmZGU5MTdkMWE4ZWI5MjE0ZjBjL3RhYmxlcmFuZ2U6OGQyZjA2NTAzMDQ1NGZkZTkxN2QxYThlYjkyMTRmMGNfMjgtNC0xLTEtMTA2Mjgw_29873911-6e83-4bd2-b1f9-bfc7d03e55f5">P5Y7M6D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTc5MzE_fb0d4e70-fa0a-463d-8574-90783929796b">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i818a916aac4f44ffa2bd008ffe38a30a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMy0yLTEtMS05NzgzOQ_17717c9f-59ff-4b32-a5b5-8027f92a6aac"
      unitRef="usd">36000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i96d86a86d4dc47ecb2dfffda2f52ab0f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMy00LTEtMS05NzgzOQ_5f917379-5f2e-4dad-9b27-14e69daa7d4f"
      unitRef="usd">284000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i388d4ea90c0548c39bda4283394ecd6c_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfNC0yLTEtMS05NzgzOQ_340c78f0-f333-4dc3-99b7-047e5b9f3d37"
      unitRef="usd">503000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i62ec2ac8d55a4479a3ff4cc2ff76befb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfNC00LTEtMS05NzgzOQ_645b06ba-db49-4db5-af5b-213c4c78073a"
      unitRef="usd">503000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i46a442da67054fd9b76638faf6b88d76_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfNS0yLTEtMS05NzgzOQ_1638edb8-7304-48e9-96d2-1763cef8c663"
      unitRef="usd">1800000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="icd4da77d8421473cb59e66faa8374380_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfNS00LTEtMS05NzgzOQ_da3914b4-f13d-4a4d-9849-3992e766b99a"
      unitRef="usd">0</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="ic86e248bcecd4584b1f877e96f7336cd_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfNi0yLTEtMS05NzgzOQ_f765ede6-a4a2-4a57-b8cc-64624564564a"
      unitRef="usd">2339000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i66a48adbd00143d6b8660e90fb91cae0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfNi00LTEtMS05NzgzOQ_442b987b-7818-44ca-adb7-60b73bc42f73"
      unitRef="usd">787000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i818a916aac4f44ffa2bd008ffe38a30a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfOS0yLTEtMS05NzgzOQ_17f8f3d7-ecbd-43fc-a43f-f0a802c537c1"
      unitRef="usd">24000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i96d86a86d4dc47ecb2dfffda2f52ab0f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfOS00LTEtMS05NzgzOQ_25937cac-f39a-4f1e-b230-a35181bcdb4b"
      unitRef="usd">127000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i388d4ea90c0548c39bda4283394ecd6c_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTAtMi0xLTEtOTc4Mzk_e509d405-0708-49c7-b93b-0720c8430d46"
      unitRef="usd">850000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i62ec2ac8d55a4479a3ff4cc2ff76befb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTAtNC0xLTEtOTc4Mzk_8a33de40-dc8c-402e-b191-3144de91540f"
      unitRef="usd">844000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i46a442da67054fd9b76638faf6b88d76_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTEtMi0xLTEtOTc4Mzk_a523074d-38a4-438b-9db1-3201c50ce46f"
      unitRef="usd">764000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="icd4da77d8421473cb59e66faa8374380_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTEtNC0xLTEtOTc4Mzk_13bf92db-f059-42b2-a9d0-d1111ad8b5a2"
      unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ic86e248bcecd4584b1f877e96f7336cd_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTItMi0xLTEtOTc4Mzk_aaa1e944-a31f-4794-a1ed-a1557c1eed72"
      unitRef="usd">1638000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i66a48adbd00143d6b8660e90fb91cae0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTItNC0xLTEtOTc4Mzk_0cb28d0d-5f00-4a6a-b332-c30e5c6fde25"
      unitRef="usd">971000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="i818a916aac4f44ffa2bd008ffe38a30a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTUtMi0xLTEtOTc4Mzk_1a518d50-ad01-4582-8ec5-d33153f71af2"
      unitRef="usd">60000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i96d86a86d4dc47ecb2dfffda2f52ab0f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTUtNC0xLTEtOTc4Mzk_544097d2-33b8-4a15-ada2-6066f3837b52"
      unitRef="usd">411000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i388d4ea90c0548c39bda4283394ecd6c_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTYtMi0xLTEtOTc4Mzk_999550e3-8c19-46e1-b0d3-7a7ec4922ecc"
      unitRef="usd">1353000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i62ec2ac8d55a4479a3ff4cc2ff76befb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTYtNC0xLTEtOTc4Mzk_1c940053-805f-447c-8835-4cb023ca751b"
      unitRef="usd">1347000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i46a442da67054fd9b76638faf6b88d76_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTctMi0xLTEtOTc4Mzk_5e344a8d-bfba-400c-9498-b6c0301ea16d"
      unitRef="usd">2564000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="icd4da77d8421473cb59e66faa8374380_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTctNC0xLTEtOTc4Mzk_295a6e87-0bc8-494f-9746-25dc7ef00406"
      unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ic86e248bcecd4584b1f877e96f7336cd_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTgtMi0xLTEtOTc4Mzk_6b40a6f3-d2cd-4d89-8cab-44fe12784065"
      unitRef="usd">3977000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i66a48adbd00143d6b8660e90fb91cae0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMTgtNC0xLTEtOTc4Mzk_7a4ff7d2-488f-48fd-ab61-b9be0dbcf0ad"
      unitRef="usd">1758000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i5e21cdfacc224f85abe16a6d40aec853_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMjEtMi0xLTEtOTc4Mzk_8ea3cb33-c4e1-41b2-811b-7330f02bbd91"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i0d608edf583c4031bb38b269eb42b8ea_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMjEtNC0xLTEtOTc4Mzk_b4e91584-7f9d-44bf-be43-c25bfe543283"
      unitRef="number">0.018</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i0d5d7ddddf33471496c67ca9c24baf70_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMjItMi0xLTEtOTc4Mzk_71c0b3c0-8531-46c0-b062-b4614cd941f7"
      unitRef="number">0.007</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib68465c427954f66928ec69ce2d8bcfe_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMjItNC0xLTEtOTc4Mzk_6229a131-fde1-4ce9-b672-6f4caa09214d"
      unitRef="number">0.007</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i96dbb0d9515a4b9983f224b01c185b89_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RhYmxlOjgwZjIxMGFiYTlmNjQ5YjE5OWVjNzBiZjU5ZGRlODc3L3RhYmxlcmFuZ2U6ODBmMjEwYWJhOWY2NDliMTk5ZWM3MGJmNTlkZGU4NzdfMjMtMi0xLTEtOTc4Mzk_233f326a-a170-4f17-8fc2-19d81bf8d552"
      unitRef="number">0.015</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0426add4fd0d41e9ac294788c419aadb_I20220524"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTQyNzE_92936ffa-d7b1-42bd-8c29-62649f84b14e"
      unitRef="usd">350000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i064840ce987b44589b1984f31ec23ee9_I20220524"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTQzNDU_aba66ffb-b9e4-4e38-afb2-64a1ea0a6052"
      unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i52bc8208b75542fe834c04c4a32935e2_D20220524-20220524"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTQ0MDY_cccdd739-ae16-4aeb-8b3f-63f6fabbc6a1"
      unitRef="usd">120000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i80af1fed659d4797a60c80b15182657c_D20220524-20220524"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTQ0NTU_58fb721b-6cbe-4021-a46e-4ec0cc90bacf"
      unitRef="usd">250000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i92b9cedcf3f2470db29567877e9ab56b_I20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTUzOTE_47c21c24-23d3-4173-8e17-1d76f0f271fe"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6c4153c5687046e5b97fe69b5b5dd0a7_I20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTUzOTU_491e05b9-c099-4ea1-a511-1c025d434f16"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i849dc496423d470899ceba933ef3cddb_I20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTUzOTk_abe166bf-9547-4b8b-96df-5107e8c1567a"
      unitRef="number">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic433e02b2e524802bd9b3db31defcb80_I20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTU0MDY_113a815c-51a5-40bd-bb83-bb3cba04cc6d"
      unitRef="number">0.1000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic21b915c10f948c5be0345f6cca32742_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTU4NDA_de4cfaa0-c9a9-4060-8a28-0a8ab23d64ec"
      unitRef="number">0.0010</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i921873efde3f4390ba5cf90029a46dfe_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTU5NDg_8f6974f1-5364-4d79-930a-5d144181a8b8"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iaccbd76f32744459bd6ce7634d990a3e_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTYwNTI_f90683eb-7ec5-4be4-8780-6148b202718e"
      unitRef="number">0.0110</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="idbbefd52056444bfada4f4742cd5491a_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTYwNjQ_8588f10b-2d37-4e2a-853f-bf974444180f"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9b315f13ef0b4d7da409254361bf6681_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTYxNjY_6357648b-3aeb-4c1a-979e-74d720769a86"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i1c4765296dd7441193e31a2d3b55cc50_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTYxNzI_0a4fae26-5c41-42bd-923d-24e33b0e7cc5"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iab25dbdafb934ddaa1edddfd20909764_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTYyMTU_e570db9b-8f1d-45f9-b7ab-1d1b0a3467c0"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i77ffcd92787e44a4b19b0c3b9575a7ab_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTYyMjE_0a7b6044-d022-48fb-8486-6e34d65ce2bf"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="if5ac304dab2f4cac876a9781e63af963_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTY1MTU_ef7503bd-d99e-4d42-ae6b-b21cd64b5a01"
      unitRef="number">0.0015</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ie4bb445d76ad4d60806edb24823f807a_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTY1MjE_de94cea7-0605-4abb-bfad-59ddbe8cb2ad"
      unitRef="number">0.0035</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0426add4fd0d41e9ac294788c419aadb_I20220524"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTcyNzg_ee296d26-29b5-4c82-8fd6-4b15603aba49"
      unitRef="usd">350000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ice8cda3f37824ceaadbd1c40fb40a92e_I20220831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTcyODQ_b1db399f-7812-4009-a773-a3984799c1d0"
      unitRef="usd">575000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i0426add4fd0d41e9ac294788c419aadb_I20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTc2MzU_6605c917-c345-440c-ad40-d9dd85b6fc1b"
      unitRef="usd">3600000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i04c8df8cf25c44f5aab2fcfc36944999_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83MC9mcmFnOjk0YjMwMWI0ZjlhNDQ0NDA4YTFiYWY5NzE0MTNjNmUyL3RleHRyZWdpb246OTRiMzAxYjRmOWE0NDQ0MDhhMWJhZjk3MTQxM2M2ZTJfMTc5MTM_e8d78b3e-b9c4-44a6-96fd-a4770086db23"
      unitRef="usd">2900000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMjU0NA_865ed7d3-96cf-4793-aed0-0a62c6e5f5c5">Share-based Compensation&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total following table summarized share-based compensation expense included in our condensed consolidated statements of income related to share-based awards (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense by type of share-based award (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs, PSUs and ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We granted stock options to purchase approximately 1.2 million and 1.3 million shares of common stock during the three months ended March&#160;31, 2023 and 2022, respectively. The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (&#x201c;Black-Scholes model&#x201d;). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. The assumptions used in the Black-Scholes model were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.68 - 39.98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.14 - 41.23%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.48 - 4.27%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.37 - 1.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, our Board of Directors approved our 2021 ESPP and our stockholders approved the plan in May 2021. The ESPP enables eligible employees to purchase shares of our common stock at the end of each offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Share purchases are funded through payroll deduction of at least 1% and up to 15% of an employee&#x2019;s compensation for each payroll period, and no employee may purchase shares under the ESPP that exceeds $25,000 worth of our common stock for a calendar year. As of March&#160;31, 2023, 2,650,103 shares were available for future purchase. The offering period is generally for a six-month period and the first offering period commenced on June 16, 2021. Offering periods shall commence on or about the sixteenth day of June and December of each year and end on or about the fifteenth day of the next December and June, respectively, occurring thereafter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized was as follows (in thousands, unless otherwise noted):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.030%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;br/&gt;Weighted-Average&lt;br/&gt;Recognition Period&lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMjU2MQ_fbeda742-1add-4886-b355-5b5bd0bf1865">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total following table summarized share-based compensation expense included in our condensed consolidated statements of income related to share-based awards (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifb2e8da7a634478895e75cec60c5c338_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmE0MDg1MTRlNWRlNTQ3NjRhZDE4NWVjMGFjNDk5MzUxL3RhYmxlcmFuZ2U6YTQwODUxNGU1ZGU1NDc2NGFkMTg1ZWMwYWM0OTkzNTFfMi0yLTEtMS05NzgzOQ_7cbe0a1a-38ee-4345-aa59-a0b0dd1a534b"
      unitRef="usd">3101000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i26ffd244af4f411f8cd2468455cda38a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmE0MDg1MTRlNWRlNTQ3NjRhZDE4NWVjMGFjNDk5MzUxL3RhYmxlcmFuZ2U6YTQwODUxNGU1ZGU1NDc2NGFkMTg1ZWMwYWM0OTkzNTFfMi00LTEtMS05NzgzOQ_2c80e801-b55d-4725-80b8-82a8354082a5"
      unitRef="usd">2017000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4e27c05190e1407887ac69c8d7d33adf_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmE0MDg1MTRlNWRlNTQ3NjRhZDE4NWVjMGFjNDk5MzUxL3RhYmxlcmFuZ2U6YTQwODUxNGU1ZGU1NDc2NGFkMTg1ZWMwYWM0OTkzNTFfMy0yLTEtMS05NzgzOQ_c8039d70-12a5-4b39-8154-2b7ac7df83b0"
      unitRef="usd">4865000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i84f9ba0217ca4943af62f30063a6142b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmE0MDg1MTRlNWRlNTQ3NjRhZDE4NWVjMGFjNDk5MzUxL3RhYmxlcmFuZ2U6YTQwODUxNGU1ZGU1NDc2NGFkMTg1ZWMwYWM0OTkzNTFfMy00LTEtMS05NzgzOQ_5def9469-e3f6-4783-b7c5-99a94fb2dd73"
      unitRef="usd">2725000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmE0MDg1MTRlNWRlNTQ3NjRhZDE4NWVjMGFjNDk5MzUxL3RhYmxlcmFuZ2U6YTQwODUxNGU1ZGU1NDc2NGFkMTg1ZWMwYWM0OTkzNTFfNC0yLTEtMS05NzgzOQ_2c32eda8-806f-4592-b131-4c71edb28c5a"
      unitRef="usd">7966000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmE0MDg1MTRlNWRlNTQ3NjRhZDE4NWVjMGFjNDk5MzUxL3RhYmxlcmFuZ2U6YTQwODUxNGU1ZGU1NDc2NGFkMTg1ZWMwYWM0OTkzNTFfNC00LTEtMS05NzgzOQ_6e756b25-0ac8-411a-b23f-5c153ea8fd05"
      unitRef="usd">4742000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMjU2Mg_ebad31d8-6c42-47ec-ba34-fb2bf94ed710">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense by type of share-based award (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs, PSUs and ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id845f28873224a6287ebf2f2b47ef3d0_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmViMmFjZjcyNzdhZjQ2MDk5ZmM5NjhjZjI1NDQ4MzQxL3RhYmxlcmFuZ2U6ZWIyYWNmNzI3N2FmNDYwOTlmYzk2OGNmMjU0NDgzNDFfMi0yLTEtMS05NzgzOQ_d0a6d64c-2864-4b58-a32b-e8fabb0bfed9"
      unitRef="usd">3455000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4a6aae30a5394516b3ad5c031cec59c6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmViMmFjZjcyNzdhZjQ2MDk5ZmM5NjhjZjI1NDQ4MzQxL3RhYmxlcmFuZ2U6ZWIyYWNmNzI3N2FmNDYwOTlmYzk2OGNmMjU0NDgzNDFfMi00LTEtMS05NzgzOQ_9eeea65e-0418-480f-a4dd-b431cbbe942f"
      unitRef="usd">2620000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia721a5e3252544d3821885e9d7a30919_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmViMmFjZjcyNzdhZjQ2MDk5ZmM5NjhjZjI1NDQ4MzQxL3RhYmxlcmFuZ2U6ZWIyYWNmNzI3N2FmNDYwOTlmYzk2OGNmMjU0NDgzNDFfMy0yLTEtMS05NzgzOQ_41f02de5-4bd6-4fd9-b852-4c346018b926"
      unitRef="usd">4511000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i457c8fcb2ad444429cbae63ee2c523ba_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmViMmFjZjcyNzdhZjQ2MDk5ZmM5NjhjZjI1NDQ4MzQxL3RhYmxlcmFuZ2U6ZWIyYWNmNzI3N2FmNDYwOTlmYzk2OGNmMjU0NDgzNDFfMy00LTEtMS05NzgzOQ_5735c0e0-d77d-4bbf-a5ee-f3149b2aab87"
      unitRef="usd">2122000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmViMmFjZjcyNzdhZjQ2MDk5ZmM5NjhjZjI1NDQ4MzQxL3RhYmxlcmFuZ2U6ZWIyYWNmNzI3N2FmNDYwOTlmYzk2OGNmMjU0NDgzNDFfNC0yLTEtMS05NzgzOQ_e21524aa-d4ce-45f6-a5d6-51b1f6078a26"
      unitRef="usd">7966000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmViMmFjZjcyNzdhZjQ2MDk5ZmM5NjhjZjI1NDQ4MzQxL3RhYmxlcmFuZ2U6ZWIyYWNmNzI3N2FmNDYwOTlmYzk2OGNmMjU0NDgzNDFfNC00LTEtMS05NzgzOQ_292c0418-4bdf-4a3d-950f-b8206cff2f02"
      unitRef="usd">4742000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMzQ0_e958b6cd-1d76-4349-9910-08667c83e7a1"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMzUx_3d50737a-4038-4f60-a394-efe8c55fc3be"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMjU0Nw_f918b76f-780e-4708-85ec-4e4840bfd48b">The assumptions used in the Black-Scholes model were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.68 - 39.98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.14 - 41.23%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.48 - 4.27%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.37 - 1.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i859ed6ba27774ade9888f1c580577c1a_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfMi0yLTEtMS05NzgzOS90ZXh0cmVnaW9uOjRmZjU3ZTEzOTAxYTQzMjlhMDkxOTkyYzA1YTU1NzYzXzQ_8204905f-c412-4e9f-b2ad-8b8dd4900ab1"
      unitRef="number">0.3968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i81c6c189dc1c414db846950051a68f58_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfMi0yLTEtMS05NzgzOS90ZXh0cmVnaW9uOjRmZjU3ZTEzOTAxYTQzMjlhMDkxOTkyYzA1YTU1NzYzXzc_895505d1-01b7-4111-827a-69ece6c5fd17"
      unitRef="number">0.3998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i16324593b4c9487687f61647a729634f_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfMi00LTEtMS05NzgzOS90ZXh0cmVnaW9uOjQ5ZjllZWNkNGY1NDQwMjc4MDhiMDExZTI5ODI3ZmY2XzQ_ffc76af4-44a8-4e66-8d2d-13a9942ca82b"
      unitRef="number">0.4114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i5c3a0c9ac8ff414aa0504ce40bfa1e50_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfMi00LTEtMS05NzgzOS90ZXh0cmVnaW9uOjQ5ZjllZWNkNGY1NDQwMjc4MDhiMDExZTI5ODI3ZmY2Xzc_9b2447f4-0794-4900-9962-5f92e476e7cc"
      unitRef="number">0.4123</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfMy0yLTEtMS05NzgzOQ_b7165deb-f401-46fa-be2d-935ed33a2aaf">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfMy00LTEtMS05NzgzOQ_edb54079-38dc-480d-ac37-de39c51d1c99">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfNC0yLTEtMS05NzgzOS90ZXh0cmVnaW9uOjk5ZTliMGFhYzQ2OTQ3YTBhYTk5NGNmMDZiMTY1ZDYxXzQ_237d8a3e-924a-419f-a793-58737bc95d3e"
      unitRef="number">0.0348</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfNC0yLTEtMS05NzgzOS90ZXh0cmVnaW9uOjk5ZTliMGFhYzQ2OTQ3YTBhYTk5NGNmMDZiMTY1ZDYxXzc_441414eb-ab48-4142-b764-5682da76187b"
      unitRef="number">0.0427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfNC00LTEtMS05NzgzOS90ZXh0cmVnaW9uOjk2YTlkMDYzMTFiYjRjYWViNDIzODc3M2ZmMjZmNDg3XzQ_4a7429f9-74a2-40fb-9227-2ece99a276b9"
      unitRef="number">0.0137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfNC00LTEtMS05NzgzOS90ZXh0cmVnaW9uOjk2YTlkMDYzMTFiYjRjYWViNDIzODc3M2ZmMjZmNDg3Xzc_1a1b4327-4b2b-4ebe-9e28-be99539c49c9"
      unitRef="number">0.0190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfNS0yLTEtMS05NzgzOQ_c0a9ac73-475c-4cb9-8a0d-835369110693"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMwNDg3ZjU1YTdhNTQ0Mzc5MjgxNjQzZjI3YzFmZWFlL3RhYmxlcmFuZ2U6YzA0ODdmNTVhN2E1NDQzNzkyODE2NDNmMjdjMWZlYWVfNS00LTEtMS05NzgzOQ_0050166e-43d1-4a82-b522-df19ee1bf926"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i92a039cdfbbf4fa8af99885fb9696846_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMTU0MA_b377cf3e-a805-457b-be6d-ce134fe764aa"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate
      contextRef="ic595728a50dc437dbd456b98049dd40d_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMTc0Mg_fa5104b4-bb19-4608-ac7e-f05b55ca97f5"
      unitRef="number">0.01</halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="ic595728a50dc437dbd456b98049dd40d_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMTc1NQ_37088511-7d0c-46f8-8378-a141cd6bdd16"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount
      contextRef="i92a039cdfbbf4fa8af99885fb9696846_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMTg3Nw_f61e0b0c-adae-4d08-8a11-29a2dafac6a8"
      unitRef="usd">25000</halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i5ed2833f90c64a0b9b7117a1df7588fe_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMTkzNw_4a63e288-da99-48cf-bf86-b406e4025d57"
      unitRef="shares">2650103</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="i92a039cdfbbf4fa8af99885fb9696846_D20210201-20210228"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMjU0Mw_da510416-07a7-4d7d-aa20-71120fe38d80">P6M</halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RleHRyZWdpb246OGIyNmJlNzEwNjg3NDYzOGE0MmExNjNjNTNhNTI0OWJfMjU1OQ_6154242f-d77d-4221-8b0f-7c326e807d97">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized was as follows (in thousands, unless otherwise noted):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.030%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;br/&gt;Weighted-Average&lt;br/&gt;Recognition Period&lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i98636a07909a4eb082fd10e5a0c20ab2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMyMDcyNTA2NjJjNzQ4ZTU4ZTJiYzVhMWY4YzJiNWQ0L3RhYmxlcmFuZ2U6YzIwNzI1MDY2MmM3NDhlNThlMmJjNWExZjhjMmI1ZDRfMi0yLTEtMS05NzgzOQ_45e9e64e-f393-492a-b959-6c20f2793aa1"
      unitRef="usd">45810000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="id845f28873224a6287ebf2f2b47ef3d0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMyMDcyNTA2NjJjNzQ4ZTU4ZTJiYzVhMWY4YzJiNWQ0L3RhYmxlcmFuZ2U6YzIwNzI1MDY2MmM3NDhlNThlMmJjNWExZjhjMmI1ZDRfMi00LTEtMS05NzgzOQ_af5ae3b7-4bd7-4a93-a054-6475c3ed5086">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ic6ab22e429fd4490ace65357489d0522_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMyMDcyNTA2NjJjNzQ4ZTU4ZTJiYzVhMWY4YzJiNWQ0L3RhYmxlcmFuZ2U6YzIwNzI1MDY2MmM3NDhlNThlMmJjNWExZjhjMmI1ZDRfNC0yLTEtMS05NzgzOQ_8462b5fa-bd91-4d5f-aa5b-9043d4d7ee85"
      unitRef="usd">44291000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="if0e2d808937f41cb849c6d6eec760399_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMyMDcyNTA2NjJjNzQ4ZTU4ZTJiYzVhMWY4YzJiNWQ0L3RhYmxlcmFuZ2U6YzIwNzI1MDY2MmM3NDhlNThlMmJjNWExZjhjMmI1ZDRfNC00LTEtMS05NzgzOQ_0aa91662-f35a-4b9c-a3fb-9f27f01a1a7d">P2Y11M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i9c07ee50572b4618820f8dd73892a316_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMyMDcyNTA2NjJjNzQ4ZTU4ZTJiYzVhMWY4YzJiNWQ0L3RhYmxlcmFuZ2U6YzIwNzI1MDY2MmM3NDhlNThlMmJjNWExZjhjMmI1ZDRfNS0yLTEtMS05NzgzOQ_b6c599ac-9186-43d8-bd64-7723e1f34468"
      unitRef="usd">9351000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i9c8cad373a064499b7994b46613c260c_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMyMDcyNTA2NjJjNzQ4ZTU4ZTJiYzVhMWY4YzJiNWQ0L3RhYmxlcmFuZ2U6YzIwNzI1MDY2MmM3NDhlNThlMmJjNWExZjhjMmI1ZDRfNS00LTEtMS05NzgzOQ_a2aef425-c318-4216-9b83-2fb760237cf4">P2Y1M13D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i0aabdf6a6ae54c86b1cc74c5d60a1f07_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMyMDcyNTA2NjJjNzQ4ZTU4ZTJiYzVhMWY4YzJiNWQ0L3RhYmxlcmFuZ2U6YzIwNzI1MDY2MmM3NDhlNThlMmJjNWExZjhjMmI1ZDRfNi0yLTEtMS05NzgzOQ_783c3dae-dcbb-4b74-99de-0960bbd9dedc"
      unitRef="usd">111000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1b6b375c49834699b6901ea74bf476d4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83My9mcmFnOjhiMjZiZTcxMDY4NzQ2MzhhNDJhMTYzYzUzYTUyNDliL3RhYmxlOmMyMDcyNTA2NjJjNzQ4ZTU4ZTJiYzVhMWY4YzJiNWQ0L3RhYmxlcmFuZ2U6YzIwNzI1MDY2MmM3NDhlNThlMmJjNWExZjhjMmI1ZDRfNi00LTEtMS05NzgzOQ_796cea2a-7fb9-4775-9ae2-3898e6057172">P0Y2M15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMjcyMw_fcd23c89-c32b-4911-b7d5-1397617717e7">Stockholders&#x2019; Equity &lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and 2022, we issued an aggregate of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143,931&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 172,607 shares of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of $16.87 and $17.21 per share, respectively, for net proceeds of approximately $2.4 million and $3.0 million, respectively. For the three months ended March&#160;31, 2023 and 2022, we issued 239,919 and 216,886 shares of common stock, respectively, upon vesting of certain RSUs and PSUs for which 70,733 and 68,425 RSUs were withheld from the RSU holders, respectively, to pay for minimum withholding taxes totaling approximately $6.5 million and $4.3 million, respectively. Stock options and unvested restricted units totaling approximately 7.8 million shares and 6.6 million shares of our common stock were outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2021, the Board of Directors authorized a capital return program to repurchase up to $750.0&#160;million of outstanding stock over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMTU2Nw_a30831a4-f6f2-4774-9f18-5ca5ed367463"&gt;three&lt;/span&gt;-year period. During 2021, we repurchased 3.9&#160;million shares of common stock for $150.0&#160;million at an average price of $38.51. During 2022, we repurchased 4.5&#160;million shares of common stock for $200.0&#160;million at an average price of $44.44. All shares repurchased under our capital return programs have been retired and have resumed their status of authorized and unissued shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We had the following activity under the approved share repurchase programs (dollars in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Shares Purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Price paid Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;First quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,165,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,165,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)   Included in the total cost of shares purchased is a commission fee of $0.02 per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id845f28873224a6287ebf2f2b47ef3d0_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfOTU_02538ec0-a379-4ce9-a18f-d29303bb67bc"
      unitRef="shares">143931</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4a6aae30a5394516b3ad5c031cec59c6_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMTAy_44049df0-2a60-4949-affb-40d5c6c9f7b0"
      unitRef="shares">172607</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="id845f28873224a6287ebf2f2b47ef3d0_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMjMz_9e574452-067f-4efc-a28b-994ed1410795"
      unitRef="usdPerShare">16.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i4a6aae30a5394516b3ad5c031cec59c6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMjQw_7b285d3d-0fc9-4542-b2ad-df56bf2ab187"
      unitRef="usdPerShare">17.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id845f28873224a6287ebf2f2b47ef3d0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMzAy_f151d1d2-ab93-4619-9d7c-874c831bae45"
      unitRef="usd">2400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i4a6aae30a5394516b3ad5c031cec59c6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMzA5_ebc4d628-5a50-4fea-b004-d59a3f6a9c6b"
      unitRef="usd">3000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="if0e2d808937f41cb849c6d6eec760399_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMzcy_a102cfc4-5307-4ea9-a841-b3bd65ffe397"
      unitRef="shares">239919</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="idf2b9ab6a89d4df59dd4955dcef17ae1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMzc5_2914aabd-09f6-49b0-916e-6fa2f07adb22"
      unitRef="shares">216886</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="if0e2d808937f41cb849c6d6eec760399_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNDY4_080a8e99-8fd3-4817-84d5-9f44f0cd4182"
      unitRef="shares">70733</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="idf2b9ab6a89d4df59dd4955dcef17ae1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNDc1_578e8169-e3f9-48c7-b949-9496207e35fc"
      unitRef="shares">68425</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if0e2d808937f41cb849c6d6eec760399_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNTkz_022a003f-0736-4fa2-9385-f7c7620ed8a5"
      unitRef="usd">6500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="idf2b9ab6a89d4df59dd4955dcef17ae1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNjAw_d517bf0c-17e7-479f-8127-a82f1e88872d"
      unitRef="usd">4300000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia1343ec306ed4444b65da6a899a7f2c3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNjg1_f95d084d-85f2-418e-981d-73b857e3db0b"
      unitRef="shares">7800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ida5a69f1405a496f802d78313d35c0c3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNjk5_8e29b016-cae4-41f4-9493-de4672c8ad1b"
      unitRef="shares">6600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i6b2c4a20e00545ee9fa2fa2f54922dfc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMTUzNg_55149783-759f-4a3e-a520-d8a192d08c34"
      unitRef="usd">750000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ifbcb0ae49876436997c9d2b2422116d1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNTQ5NzU1ODE4NDE1_d8b49568-7ac1-4519-ae1d-c328b995497a"
      unitRef="shares">3900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i335649d465744f89957988f0508a596e_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMTY5OQ_7efe87e5-64ca-432a-859d-884129ce7840"
      unitRef="usd">150000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ifbcb0ae49876436997c9d2b2422116d1_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNTQ5NzU1ODE4NDI4_610fc134-c123-4edc-924b-d4280551cdef"
      unitRef="usdPerShare">38.51</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i6f605f48fb46486b8c32365ccf871ecf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNTQ5NzU1ODE4NDM2_3b993e1a-b6f8-4a66-8728-9a2ef8a2eaf3"
      unitRef="shares">4500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6f605f48fb46486b8c32365ccf871ecf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNTQ5NzU1ODE4NDQ5_0318b22d-5dee-49d8-8f18-f3a1194b1964"
      unitRef="usd">200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i6f605f48fb46486b8c32365ccf871ecf_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfNTQ5NzU1ODE4NDY1_eb5400ce-d8be-4555-9d51-9c24d13fdee0"
      unitRef="usdPerShare">44.44</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:ScheduleOfTreasuryStockByClassTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMjcyNw_c4837e7b-0024-4bbb-aaf9-50ce01a6189c">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We had the following activity under the approved share repurchase programs (dollars in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Shares Purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Price paid Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;First quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,165,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,165,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)   Included in the total cost of shares purchased is a commission fee of $0.02 per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfTreasuryStockByClassTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RhYmxlOmYxNWY1NDI3NDAwZjRhN2Q5ZTcwNDkzMDk2Y2Y2YzNkL3RhYmxlcmFuZ2U6ZjE1ZjU0Mjc0MDBmNGE3ZDllNzA0OTMwOTZjZjZjM2RfMi0yLTEtMS05NzgzOQ_cb7a2000-de1d-47b7-81d4-33d4aa37ebc5"
      unitRef="shares">4165258</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RhYmxlOmYxNWY1NDI3NDAwZjRhN2Q5ZTcwNDkzMDk2Y2Y2YzNkL3RhYmxlcmFuZ2U6ZjE1ZjU0Mjc0MDBmNGE3ZDllNzA0OTMwOTZjZjZjM2RfMi00LTEtMS05NzgzOQ_706de026-92c6-4eb8-98d1-6370300a949e"
      unitRef="usdPerShare">36.01</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RhYmxlOmYxNWY1NDI3NDAwZjRhN2Q5ZTcwNDkzMDk2Y2Y2YzNkL3RhYmxlcmFuZ2U6ZjE1ZjU0Mjc0MDBmNGE3ZDllNzA0OTMwOTZjZjZjM2RfMi02LTEtMS05NzgzOQ_b80ff3ef-2c99-4f32-8301-4096db06d604"
      unitRef="usd">150083000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RhYmxlOmYxNWY1NDI3NDAwZjRhN2Q5ZTcwNDkzMDk2Y2Y2YzNkL3RhYmxlcmFuZ2U6ZjE1ZjU0Mjc0MDBmNGE3ZDllNzA0OTMwOTZjZjZjM2RfNi0yLTEtMS05NzgzOQ_2c69a68e-28d7-4361-bea8-6e431ae136b6"
      unitRef="shares">4165258</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RhYmxlOmYxNWY1NDI3NDAwZjRhN2Q5ZTcwNDkzMDk2Y2Y2YzNkL3RhYmxlcmFuZ2U6ZjE1ZjU0Mjc0MDBmNGE3ZDllNzA0OTMwOTZjZjZjM2RfNi00LTEtMS05NzgzOQ_a9798caa-eec3-46fd-ac33-57546593b5ef"
      unitRef="usdPerShare">36.01</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RhYmxlOmYxNWY1NDI3NDAwZjRhN2Q5ZTcwNDkzMDk2Y2Y2YzNkL3RhYmxlcmFuZ2U6ZjE1ZjU0Mjc0MDBmNGE3ZDllNzA0OTMwOTZjZjZjM2RfNi02LTEtMS05NzgzOQ_29b0231e-c597-48ac-8201-546223cae975"
      unitRef="usd">150083000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <halo:TreasuryStockAcquiredFeeCostPerShare
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl83OS9mcmFnOmZhYmM3MDg1ZTQzYjQxY2RhZjc3MmYzOGIwYWUwNzJkL3RleHRyZWdpb246ZmFiYzcwODVlNDNiNDFjZGFmNzcyZjM4YjBhZTA3MmRfMjYyMg_ead554ff-ee8c-4af4-8609-51c782d8523f"
      unitRef="usdPerShare">0.02</halo:TreasuryStockAcquiredFeeCostPerShare>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RleHRyZWdpb246MDQzYWYyZmNkOThiNDA4OWJkNWEyZDllNzVkNTEzNWJfMTY1MA_f887dbc0-098c-436b-9f3e-8e7238810a69">per share&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per common share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and the Convertible Notes are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive common shares issuable upon vesting of stock options, RSUs and PSUs are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of our Convertible Notes are determined using the if-converted method. Since we have committed to settle the principal amount of the Convertible Notes in cash upon conversion only, the number of shares for the conversion spread will be included as a dilutive common stock equivalent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerators and the denominators of the basic and diluted earning per common share computations is as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding for basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive potential common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs, PSUs and ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding for diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from the calculation of diluted earnings per common share because their effect was anti-dilutive, include the following (shares in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)    The anti-dilutive securities include outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and Convertible Notes</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RleHRyZWdpb246MDQzYWYyZmNkOThiNDA4OWJkNWEyZDllNzVkNTEzNWJfMTY1MQ_14f553ae-05dc-47b0-a753-c2bca2a4ff7e">A reconciliation of the numerators and the denominators of the basic and diluted earning per common share computations is as follows (in thousands, except per share amounts):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding for basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive potential common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs, PSUs and ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding for diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfMy0yLTEtMS05NzgzOQ_e3aef642-ff83-4de9-9fe7-ff6f76710f3a"
      unitRef="usd">39615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfMy00LTEtMS05NzgzOQ_5661f12f-3bca-47b6-bf65-8c8f864f219b"
      unitRef="usd">60108000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfNS0yLTEtMS05NzgzOQ_11edaa67-6878-4231-864f-d2f537206da7"
      unitRef="shares">135027000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfNS00LTEtMS05NzgzOQ_ea021a79-a6d8-471a-9b7a-7b7e17afa9d8"
      unitRef="shares">137658000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="id845f28873224a6287ebf2f2b47ef3d0_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfNy0yLTEtMS05NzgzOQ_31c0e694-8363-470c-86c6-e19179ebfcfe"
      unitRef="shares">2173000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i4a6aae30a5394516b3ad5c031cec59c6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfNy00LTEtMS05NzgzOQ_05741a63-2235-40c0-a3fc-c598a848f9ed"
      unitRef="shares">2043000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i9f8d6a392c1d4fe8b9e5be6142532df5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfOC0yLTEtMS05NzgzOQ_b76e3990-54f1-48f6-9eac-5df1c4426ca5"
      unitRef="shares">468000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i752be5578b5b423d8fc0ff6e421f4f83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfOC00LTEtMS05NzgzOQ_b5f21748-288c-4e46-b0e0-579638d96972"
      unitRef="shares">317000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i4b70d8e746f94570afba56b0ac99fe35_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfOS0yLTEtMS05NzgzOQ_0afb597f-b63d-4945-96c3-8702241833f9"
      unitRef="shares">232000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i71746ecec304430aa330b98c5496d867_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfOS00LTEtMS05NzgzOQ_68418482-e713-41d0-bd5e-5529faa8f086"
      unitRef="shares">1259000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfMTAtMi0xLTEtOTc4Mzk_d9d0273a-dd22-4e07-b4ec-d092b39bae07"
      unitRef="shares">137900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfMTAtNC0xLTEtOTc4Mzk_4a7e5f45-4abd-4fa5-a73e-9a321d23cc4e"
      unitRef="shares">141277000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfMTItMi0xLTEtOTc4Mzk_4e97d3e5-ed1b-4d18-93a5-21f3e27e9685"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfMTItNC0xLTEtOTc4Mzk_cf0076d6-441a-42e6-b71e-4b31214efe85"
      unitRef="usdPerShare">0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfMTMtMi0xLTEtOTc4Mzk_c9d1d16d-0b01-4663-bf3a-6ee44ae1db14"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmRmNWI5Y2UwMGU4MDQzOWQ5OGRhZDkwZWRjYmQ1NDExL3RhYmxlcmFuZ2U6ZGY1YjljZTAwZTgwNDM5ZDk4ZGFkOTBlZGNiZDU0MTFfMTMtNC0xLTEtOTc4Mzk_d3e970b5-b3de-41e1-995f-c961b08ab46d"
      unitRef="usdPerShare">0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RleHRyZWdpb246MDQzYWYyZmNkOThiNDA4OWJkNWEyZDllNzVkNTEzNWJfMTY1Mg_e3db26e4-1ebf-4c2a-9aea-0c3c74b9cd24">&lt;div style="margin-top:11pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from the calculation of diluted earnings per common share because their effect was anti-dilutive, include the following (shares in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)    The anti-dilutive securities include outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and Convertible Notes</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmY3ZDM1Mjg5NGYyZTQ2M2Q5YzBjZGJlZmYzYjcwOGMwL3RhYmxlcmFuZ2U6ZjdkMzUyODk0ZjJlNDYzZDljMGNkYmVmZjNiNzA4YzBfMi0yLTEtMS05NzgzOQ_9df5382e-78b7-402a-9d79-040a7ebb1701"
      unitRef="shares">26200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i96b8d98b57a84de784b2bd683ed77b9b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84Mi9mcmFnOjA0M2FmMmZjZDk4YjQwODliZDVhMmQ5ZTc1ZDUxMzViL3RhYmxlOmY3ZDM1Mjg5NGYyZTQ2M2Q5YzBjZGJlZmYzYjcwOGMwL3RhYmxlcmFuZ2U6ZjdkMzUyODk0ZjJlNDYzZDljMGNkYmVmZjNiNzA4YzBfMi0zLTEtMS05NzgzOQ_a9f68aea-5c7a-40ff-be21-d7e30e4a8cce"
      unitRef="shares">15400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4MDdjNDY1YzQ3NDQ5ZjU4MzIzMjE3ZDg5MjhmZGIyL3NlYzoyODA3YzQ2NWM0NzQ0OWY1ODMyMzIxN2Q4OTI4ZmRiMl84NS9mcmFnOmI3YjJmNjM3OTk3ZDQxNTRiOTlhY2NmNzcxYzJjMTM1L3RleHRyZWdpb246YjdiMmY2Mzc5OTdkNDE1NGI5OWFjY2Y3NzFjMmMxMzVfMTAwNQ_acb8cfeb-c0cc-4cb4-975e-f161f6ea3411">Commitments and ContingenciesFrom time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our condensed consolidated statements of income and balance sheets. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in our opinion, individually or in the aggregate, would have a material adverse effect on our condensed consolidated statements of income or balance sheets.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>81
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M!;!'J(:ZW(9=U%I"!?/D6F2CRL+4"KLM1B@.$N(&'W?@8R_XS_4:LD'(-M@
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M!HFL3U7J&RUVU<'$@]!:%-7EEE%(]]( WC\*H8\WY0?:LZWE_U!+ P04
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MPQ3_>8 T!K@_%T)O)N: YK],]!=02P,$%     @ '8*I5L22B(=^!P  F1\
M !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6RM66UOVS@2_BN$;[%(@+H6
M*5DOV<1 ZEYQ"VQ[07.]_4Q+M,VM)'I)VDGWU]]0DBU;I+C)(4#16/)P_,QP
M9IX9\O9)R.]JRYA&SU59J[O)5NO=S6RF\BVKJ'HO=JR&;]9"5E3#H]S,U$XR
M6C2+JG)&@B">5937D\5M\^Y!+F[%7I>\9@\2J7U54?GC RO%T]T$3XXOOO+-
M5IL7L\7MCF[8(]/?=@\2GF8G+06O6*VXJ)%DZ[O)/;Y9AHE9T$C\E[,G=?89
M&5-60GPW#[\6=Y/ (&(ER[510>'/@2U961I-@.//3NGD])MFX?GGH_9/C?%@
MS(HJMA3E[[S0V[M).D$%6]-]J;^*IW^QSJ"YT9>+4C7_HZ=.-IB@?*^TJ+K%
M@*#B=?N7/G>..%L >MP+2+> #!=$(PO";D'8&-HB:\SZ2#5=W$KQA*21!FWF
M0^.;9C58PVNSC8]:PK<<UNG%4M0%; HK$'Q2HN0%U?#PJ.$/[)962*S1DJHM
M^@0[KM#5MYKN"PXRUVB*OCU^1%<_7:.?$*_1?[9BKVA=J-N9!F1&_RSO4'QH
M49 1%"'Z+&J]5>B?@*:X7#\#BTYFD:-9'XA7X6<JWZ,0OT,D(*$#S_+ERXD'
M3GCR<MCH"T?T_7O')-6\WK1ARS5G3B^U6B*W%I/1-VI'<W8W@9153![89/'S
M/W <_.(R\8V471@<G0R.?-H77Z  \3H7%7.9V:Z-F[6FSAP681;C^>WL<([?
MEHH#'*0GJ0M@\Q.PN7<G[HL_(*G:R-8""E$NZIR7#-4GQ.:]><I-U.^D.'"(
M2;3Z86)<.#;RQF7B_"UW\HV473@L/CDL]N[DXY9*-C65LD#@': /14T!=AG=
M:IJ?[5B2Q?%@6VVA*(F(>U>3$\C$"_(C \MS3EMFJ M$*R$U_VL4:6*!(#$A
M Z2V4)*,A%]Z IIZ@=Z?X3*5E=>:UAN^*MWU(+40X"0-AXEB2P5NE-D)9?8J
ME 5;:51PE8M]K5TX,QNG#=,6RA+L!HJ#GKZ"5T&]@D"H^+ZZ/N$%!JN!,>5W
MIBGX&2F6[V63N.],FCO)*K"@3C.<#.QQ2,VC,8/.^!A[#?I-J 8QP-\)14MC
M%/MSSW>F9CG!8L_V=TAMD70D1##I@1(OT*]0.C<U[V-DS:2$(B'9@=5[9]WO
M-'JAVB+3*,M&P/;\B[ULM_B-00%#._JCK?RRQ?X7P+TZ K]V(@XM."&Q,-M"
M4XC_$<P]A6(_AWX\>O1(2_39724Z/1<@TR0:HK2E,,E(/ *S)U3L9]3E%BH8
M4P-V5(J!GTTI+CE=\7*<*?&;4N5;:;MT1D^6V,^6]WE7<R#"&#^8@M-4F<83
M0F^9!!*MM83NH?.1TR4V1X8Q3K/ACMIB4T*2-!G9TIY-L9].?ZTAA;60(UTJ
MMHEQFI"YE1:V6$RR$0+%/8-B/X4^2+:CO$#LV?0B3)VYUN-1FR/3-,5#Q+84
MU/UX#')/I_AO^/08%5" &@YJ6I0\EWO6V^&$;7/FE$0PH0^!.^1,L^P&3GIV
M)7YV_>)J@UT]L L\L?DQC;-X6)<<8E&29"-!3'HB)=A;ETP0JY? ]/+Q:^O/
M6VF[-+HG9>(GY8>]S+?49 50LK/I<;K 0;HXR#(\K#A.P31*SV:W2^ ]01,_
M03](D3-6*+26HD+0]W2)75'= 7^=138EQQB'5NS98CB,@V L<7KN)G[NOM@'
M2!Y(&?VC,<C;RQ&;HZ< .QFVGBZY*!M#W5,Y\;)CG^Y[U;0=\.^%.31WUI]X
M.%&YY*(L#,;"I^==$GN3_1.O*<SQ?P_42]^O3O8WTG9I=$_3Q$_37UG7T)H@
M(P&)S!G> 2+-S)/HB] C/G#0-Z3&6</:66?+C4583][$3]X N<L,@QG:V@JF
M!Z5%_MV)U,''>!X$-M07C\"D)VWB)^W+BL25VD.$6;#1OBZ@\S!9K<T)40[;
MP0\P:I2T;@=,LZ)IW5'3MDA6-B>LW2&3,L<K4,RT+MEH57"P.PZB=.@$6RPF
MD=L-8=\"A"]L :ZZHG!]T0RL7YAXH6.DQG$4XV%)=@B.6]$W Z%_JC96%"R7
MS1@(A<U8]*ZURVS= ?BF[N85R%0M>6[VR'SO-,:>IR&#DA0/ZYU+,$W'K.E9
M/O2S_/+%Z!'5:,4VO*[-%ADN8I*+PFF4S>TDC.)L>(SCD,,X(WAD1@_/SLC]
M+<#KK&*FZ_?:8W-[%J=6Z7"(81C>PQ%*"OL6((R\E/2XW^W:G*9E<QA5"K67
M30&I13UM[#CC5S#'E4O.D3GT-A^OOB=X(VV7?NJ;CM#?=-Q7[6QTG(?60J+=
M_]<^A79[$6;#L=0E%(P%;]^ A/[!O[G_G(KU%*KD\?1#K#0%L::38L]Y<T[2
MF%<V94BL2KX9/:$.'>?DUMSG$!KAO;#O*D)_5[$\9S=#>]V>Y$UOH;KCOI>W
M&]W/G=_C8&(5%5MH:,CL[)*S8G+3W/TJU$S6[<7@Z>WI?OF^N54=O/^ ;Y;M
M+7&OIKVT_DPEE$H%^[,&E<'[!!PKVWO@]D&+77.5NA):BZKYN&44&@ C -^O
M!7BA>S _<+J-7_P/4$L#!!0    ( !V"J5;.D*RCP 8    M   8    >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&ULS5I=;]LV%/TKA%=L"5#7(O5AJTL"M(Z$
M!=A'D;3;P[ '16)BH9+HBG32_OM=2JYMD31C!^S6ET2R[CV7O(>\)(]T]LC:
MCWQ!J4"?ZZKAYZ.%$,O7DPG/%[3.^"NVI T\N6-MG0FX;>\G?-G2K.B<ZFI"
M/"^:U%G9C"[.NM_>M1=G;"6JLJ'O6L17=9VU7][2BCV>C_#HZP_7Y?U"R!\F
M%V?+[)[>4/%A^:Z%N\D&I2AKVO"2-:BE=^>C-_AU2D+IT%G\6=)'OG.-9%=N
M&?LH;ZZ*\Y$G6T0KF@L)D<&_!SJG5261H!V?UJ"C34SIN'O]%3WM.@^=N<TX
MG;/JK[(0B_/1;(0*>I>M*G'-'G^AZPYU#<Q9Q;N_Z'%MZXU0ON*"U6MG:$%=
M-OW_[/,Z$3L.V-_C0-8.Y% '?^W@*PYDNL<A6#L$BD,0[7$(UPZAVJ39'H=H
M[1!UN>^3U67Z,A/9Q5G+'E$KK0%-7G1T==Z0X+*1(^M&M/"T!#]Q,6=- >.$
M%@BN.*O*(A-P<R/@'PP@P1&[@SN6?URPJJ M_PDEGU:E^()./C39JBC!^A2-
MT8>;2W3RXA3Q1=92CLH&O5^P%<^:@K]$+P;W9Q,!#9?A)_FZD6_[1I(]C7S/
M1%89W.9VMSFK:QB\7>L-WI=V[S<%= X&?U:A=UE9C*\:-,^6I;DER1-8>;ZJ
M5U67VC_$@K:0[1HJP4).T0>*KIJ<U71R\BOC_-0 G]KAKZF &@+82=8V97.O
MI'@"8V(S,,AF8) .,]B#V;/\$MW2^[*1H#"!JZS)*3H!,GN:3U$FT"7-7R$?
MOT3$(]C$K36.K)RO^3++Z?D($L)I^T!'%S_^@"/O9Q/C/5C8@<FJ^7"!_6D0
MS\XF#[O4NHR9N 1+'8$-./4WG/K/Y/00'GOL:#?U<12'_C#U<X.9K]*CVY P
M\H/IT"S1S<81\89&J<$HG,68;,P&J0HVJ0HZ/W]/JF!&PD+-8;1#7KJK4UG$
MC)7P[VM650@6NL>L+?XQI2YP.05<@EVZ!$M<@J6.P ;LAQOV0^M$N9'E;2QW
M+ 6"R@S;.)YU&R'Z65Y3$\>A5IF":4"4R6$->RQWAT1,7$9,'8$-.(DVG$16
M3JXX7W6U"C8D>;^R<SD;T7+5RB<""0;\T#8O>6?4/V5+21Q'L/- #Y0+6?7@
M(;1/M&4N%^3>;M64 K8J#6SF=Q8X$]'69AX[F2.-0S]6*MRERX")2[#4$=A@
M/$PWXV'Z?XX'^7Q)V^[L)J.HH\0T,J8:F1$)E HPU98KE>X#4!)K:HYET1'8
M@,79AL69E<5^-YP/=L-EMQM&)]6>W?#;F9:A,<%3K&3:&OC86NL2+#FH_:FC
MD -:X@TML966WZ$,]C28\A_K(]3#GK+)FULC')M_EV")2[#TJ60,\H^][;G<
M.VBO3IO"<OCZ+6LWFW9B/%A;HQR[6JW1E./7;*;N[YU&39RBI:[0AKSNZ"WX
M.;P>Q"76LD\B#TY.RL1;V]F/8$8P*$+*<2XQV(W)-%:+E<$,P_%PSRS8BA#X
M&Z@0YN0YE2&P28<(<1BH678J1#A%2UVA#:G=:A'8D1AAIM/7"8CBJ2H$S;%)
MC@A5EG0P,O6CF3H5=+-Q3(@Z$PPM"WQ8W_?,A:TB@?]+20([U22<HETZ14N<
MHJ6NT(:#8"M,8/?*!-:%@FD<::N&4VWBH)B)TYBI*[0A-5M] C]3H( S)()C
M#DS68I5WO#4/,%G[=W/]2P$XJO:_BO*VHJAA@IK?D^AZP1@3C<KHR4/F04")
MO<='\_,MY *\U0OP,P6#9_+SE$YD;\[1%5:7!<@L5EEU&3)QBI:Z0ANRO]49
ML%UH^&[D0WL[CQX6NI;@S[1=J%/UPBE:Z@IM."RV.@>V"QW?H8J(=45AC+U
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MVOYSV_Y&L&7W>>@M$X+5W>6"9@5MI0$\OV-PV%W?R"].-Q\]7_P+4$L#!!0
M   ( !V"J5;-B$G$B D  ,D7   8    >&PO=V]R:W-H965T<R]S:&5E=#@N
M>&ULG5AI;QM'$OTK#08($H B=3AQ8$L"*/F0LK(EF+:RF\5^Z)EI<CKJF9YT
M]_#PK]]7U7.1D@7O?B'GJ/MX53VG:^L>?*Y4$)O"E/YLE(=0O9I.?9JK0OJ)
MK52)-POK"AEPZY937SDE,V8JS/3X\/#7:2%U.3H_Y6=W[OS4UL'H4MTYX>NB
MD&Y[H8Q=GXV.1NV#3WJ9!WHP/3^MY%+-5?A2W3G<33LIF2Y4Z;4MA5.+L]'L
MZ-7%"Z)G@GNMUGYP+<B3Q-H'NKG.SD:'9) R*@TD0>)OI2Z5,20(9OS=R!QU
M*HEQ>-U*?\>^PY=$>G5IS1\Z"_G9Z+>1R-1"UB9\LNLKU?CS"\E+K?'\*]8-
M[>%(I+4/MFB884&AR_@O-TT<OH?AN&$X9KNC(K;RC0SR_-39M7!$#6ETP:XR
M-XS3)25E'AS>:O"%\UNWE*7^*F.(RDQ<U!XDWI]. \03T31M1%U$4<??$'4B
M/M@RY%Z\+3.5[?)/859GVW%KV\7QLP(_2#<1)T=C<7QX?/*,O)/.UQ.6=_(=
MOH[%I2V]-3KK7;]SRJLRQ =V(=[I4I:IED;,\5"A%(,7_YXE/C@4TW^>BE T
MX,73!E"#O?*53-79J")=;J5&YS_^</3KX>MGW'O1N??B.>G_6RK_3U'B2AK[
M=5LH\3E73E:J#CKU8W%=IA.AO9 BT;;*)?I%!)7FI35VN165D8$ 1*2VJ&2Y
M%2&7053.KG2FO-!E:5>2VI.59=J[NN);9*@F(SS:(N1@4V)ID1!D1Q?,7R[Y
M:05VY$>H3:4<KM(HJK(!3Y%"LQ6 )*A7?B)N:T?**Q &()%0);DT%NZJOKLZ
M/AR3)[57F0A6+&2JC:;\LQY?)VD=9*EL[<5//_[PV_'QX>OY)5\<O?X9@&!@
M-V22A>5?P!Z(R5R]]&S/PM0Z@P5_*&%T"FQ3,,L-0P6570A3#B_<C6'3"!5>
MH^6-3*SC@,&O3.'/5N115J<H40XN6!*DC,6__7@U^_CG6X%2>_GB-9O3&SK0
MW?K3T'=.=;&OI NE<I[>'+U\O1-$LM'69>.=--ZVEHT!6&6-0(;:Q;2 ME".
M6DM_1=Q1&F0GL'H%%W'#"LGR5N&8C3Z 0$2M\2U69^<U5>B2F62V0M\B[K(.
M]B!FP0Z"K-L:6&CGP\ 8!%-65%7@;>2*JZU1I=JTL7.J48Y::\/5D+3A&K.+
MP[COAVU?2:R-5F.*&X(EA$(B7C1S(*[LJS,&A@H;+X8&Y34"+?*M-+6S)62@
MO&)M3UIN*FW*9)R&*-&E4QEWCBX[7[F >"\0R58D&/8/%-O,KGOI4-3Y/QNX
M+I"7VL6&2]/:.>),I4MLOLU<;"-(9ZPHY%_("Q=.22:@9\@VM2& Q:"NC70@
M"DYOVG?S2\$(.@$ D2L*O$XZ#75PI$Y5="^14*P<=U-M'F+?X1>("M/LFHRB
MJHL@0J6"!!06X0:H@1)JAIV<8[;#?8]:Y<L58*E038/+Q"CJ6:HLPD)?I[F0
M'N)*FQI$RD!ZT(G-J(&Y-F"B$W!NR:#2XB@XL*S41D$(^->( /W[ B;W[_9Q
M!%M,=)336E7 E6Z"M4E_C&-#[Z(Y$:00DRB;-#?UNP-7Q-S6]2YL-0#?@5.'
MVL_B&15#BV"6LNT>L(I&8YSZN]9<0'B3H#07.G#FG"V:X).C*RW;VG  >44^
MR0S+DJ9)3203#*C&;=94--4VQ"]=@GBERB&P7]_WP,X6-:B:]0CU.!; *FQB
M(H<P&*U*L83E5/D92J-"N89N:+73B6NQDV2;4NZ&6D '!K8YJ5VF2BX/"2J/
MW9/\\#FD4@YKU^4>T=@-0K2YU<(I<''&7=\_BE=+5D@:CUSB"[U1V0%U ;>'
M9;P=BEGS"GP0 :MY'[8599S;DY*)-^3K(XUCZGJ%RN8L15YD!"M2$YT8?RX7
M0D5IZ BR[:0HQ^'MAS-A^=X"P)W/PO"/:#G&6![4B[HY91@9055R:?DG \$X
ML3!JH^FN3XZM8M&W )!CV]C/ ? 4I:&D"7E*?J "%]BK-,,$+!O:.]QK""=!
MOZ2FG8@;Z8-!H:7*!1R\=NJX+=0#ZL<Z^K.3^4%A.LDS1&:9#M$$M4D-8K'2
M8=NF9+!BD25&+U2+QNW(2M36-KEKJ+"'Z8@N#5UG'U)/)C*HT'P -7QEH_K:
MW $1RF.$'S)%8F(UNSB[]6XBKNQB@<E7'MQ(\<GBW#H6-R&;,.,3[WA9;5N<
MG_7SZ[-\4)D4=SMXY<&""HL;!X(T>Q^78KE!'J7X,M\5&67T,N\6V'+<+DU\
MUM/\+DN/PX>XT):09,_(YFU//DL2'%#WJ.+#GNBMT>)&FZ83+IO5NZ7F-SWQ
MA4.16G/P88M%1<S1JTGRB.?BPWQ@ W4 2CK&:B]$MY5JT_<%QXM"4YUUXK \
M:!06=A?L&;GE96%=Q@[V.M,RELZ,VN9/H&>*C-Q<_MQ[&E4/U@Z,TG(C+NXO
M9AU1?-;37%FGO\+>X<D%)Y-! !N*GN5>ZWMQU7?K3WP ,3:!A[Y2O,!B@[Q"
M3;>^\4Z#[FD<0K^_-W)CYXA _@\Z9_5>D/1NOG"*\GHI]5[Q0?*$Z[GCBV0M
M)\^VMH/C\$B5YH-176%2<LNVS;-00#P>G\/9M=MO8P Y8RP!43 1VZ-0/%M1
M=Y.Q7F(9:<"^T+@.6.+0_EON31RFB+1NU?'9"1R45M[(VM6$1#F+I3+HEK9?
MR*,2GN?=RAQWZ7YU_C;2[4%,Z\*>MI #3QJ@\NI1+'0)0&0,W./K3&.W&R#L
M?&UP9$?:N-'5F=Y1,PCM$L=%\2G1+53LD$_$NYJ/5_U.L9N 9[!U)T'\:(IQ
MT[M+/M*QZM&I90T(P4I5*38U+J );9G;EJ<_OV%*>9Z'&)>^781B@W3?%,+3
M1T:LU%A]FZ,C?6CDF8=A2#FWKCVT$4[3</_^T]7^2?0)HGA0'%0DF;VP1MO]
M_;'71D??6#90\L]_W<X_OWW3GA\Q86YF']_<MO=DP\?;RS=?/GV<M<_Z S1/
MQ1T3]P^U@UR@\#VBY\C(;ZW;?35_5JO],0<@R6I KJ8#" _0;J*!N$?%2[O"
MT>L]=NU*S"=RXB:F)^67.ZAV&V@UW9NH4'!SV3$Q20]H<)\]'V[K<!3K2C%T
M82<2302N,USJQP-\QYV&:,?*.) G3WV'FPX^KR(32_Z(3,!3ER%^:>V>=M^I
M9_'S;$\>/W)_P%#2:#NC%F ]G+S\921<_' <;X*M^&-M8D.P!5]B6\R4(P*\
M7UCT=W-#"KJO]^?_!5!+ P04    "  =@JE6V/\(G,,I  !QA0  &    'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;-5=:Y/;5G+]*ZA):DNJXHQ>]F9CR:H:
M2=ZU$Z]7D=9Q*JE\ (%+$BL0H'&!H>A?G^[3W?<!@B,YWDI5/EB>&0+WT;<?
MIU^7+X[]\,'OG!N+C_NV\U]?[<;Q\-6C1[[:N7WI;_J#Z^B333_LRY%^';:/
M_&%P98V7]NVCIX\?__[1OFRZJY<O\+>WP\L7_32V3>?>#H6?]OMR.+UR;7_\
M^NK)E?WA7;/=C?R'1R]?',JM>^_&'P]O!_KM41BE;O:N\TW?%8/;?'UU^^2K
M5U_P\WC@WQMW],G/!>]DW?<?^)?OZJ^O'O."7.NJD4<HZ7]W[K5K6QZ(EO&S
MCGD5IN07TY]M]#]B[[27=>G=Z[[]J:G'W==7?[@J:K<IIW9\UQ^_=;J?+WF\
MJF\]_BV.\NP7SZZ*:O)CO]>7:07[II/_EQ^5#LD+?WA\X86G^L)3K%LFPBK?
ME&/Y\L70'XN!GZ;1^ =L%6_3XIJ.#^7].-"G#;TWOGPOAU'TF^)]L^V:35.5
MW5C<5E4_=6/3;8NW?=M4C?,O'HTT'[_UJ-*Q7\G83R^,_:SX<]^-.U]\T]6N
MSM]_1.L,BWUJBWWU]-X!_UP.-\6S)ZOBZ>.GS^X9[UG8_#.,]^S"> N[+/[K
M=NW'@9CEOY<V+.-]L3P>"]!7_E!6[NLKDA#OACMW]?)W__#D]X^?W[/:+\)J
MO[AO]-]X5'^OL8M7I6\\/_B6M]B-):3KKSM'$E;U^T/9G?CYIAO=T.R+J2NG
MNAE=750]L4'GY2=/P]4E_WG3=&57-65;>!K+D<"/OMB5=ZY8.]<51,A#.?!S
M_5 <IN'0>X?IRZZF23#I4-,(CB1GW!4_=ICL/8_EBZWKW%"V[8F?<P?^I(Q[
M.@P-S7QHZ<$'O_N'/SQ]^OCYCS?O;XH_W=Z^Q>]/GC_$/!AYI"T.$S_,?QK<
M=FJQ=ZR&/\2[[UTU#<W8Z&/??*QV9;=UQ>M^OV\\=)G-]?Z;UV&6P;6@QM@7
M9?'S5 Y$/5HU;;X?QH)>8AU4/'E\_6\W.)6AI@VTIQ5/?"KJONCZD<A1M5--
M!]&VMJ:F$\4-#4CKJ1M?M;V?Z.QH\)^GADF[/A5AWZ!S6?!)MFYTA2?#0&,M
MG=(-G[IWO_&H>56T>%H/K7=P1 "_ZZ>65D7D)C/#ATRC_&WJ1(^'LT@F^]53
M**4P>#\-Q6W73?3.NS-R_ROHP=.=7#D4CC59\<95;K]V@^FBIRN:MW4)G]#1
M8A2W'B:6JZ>JM$"RA%!QN>E!V91&V /]V]>^.(C$T7N\C096D<V;QXF7]=_(
M7LB.C[NFVJUX=SQ.?V@Z'I?.<5]V9&OYH55!8E5TM!7O>8ER[INR&6P>68PR
M4EPI'VX3&(H>)0,(&2"D,*A$V [.5KX2&OFIVF4+YD-L/*2R[UHHHH[IT=($
M)% #?Y \?U/\12:C/]L*>,XYQ;!%D@S;9D-#-[3\JF0P8'OK%\<J.SKND02$
M]NXK6@ESP,W?6].9S(XZ[-0),;\MV_Z7T][Q?$-Y<-/85'Y5?-=5-Z [<^UQ
MU[-JZX\=C>ZGM6_JAO;HZ#E[/7GCEDZ4Q?[MKB3"R@>KBY^P9GKR3\]]/LG[
M(^FPV53YV\5W;[\O;O^T,"[]E717VPK!E(!QS_P"&=[.EY7P4+0!KFT(^C -
M;XH?/8[M&^*5/50\GX<8B<"OO_5$^"&6QF8\J5$)VE%UIB\FS[IZ7WYPA0MK
MX3V4G@#N0;8P[LJQ*#<;DE$YX+WL5=1Z5#^_78-F' E=1R+"$DKBM.WYCVNV
MVR1^M-Z[LIWH;4R=+_YO4[W%H"M1(1 @1KTUJ[,=26@_-"P+F).D@\PG%F:"
M(Z=(:E)^I)?NB$UZHE;/NO><.D<^X[9Q=-9$3]'YON_*=<MZLG:B1ZIFJ*8]
M[9GL/.WLU8G_2IJ*F(),V2K=!2V8^/-O('G/!&@ZUI:$9FJW'1RXAVR)&T9R
M6>B :9DD!1XJ:<5>P@2E(]O9EV1<&SK H=@,_3ZGV$WQNO2[XAOB"*)H. I"
MJ1_<B TD8 "/NN11U7B\G!VY#B1B;4,?,T_<.55S*UA 5EKT]!TMN>%1:5L5
MC;82 NY! O I<=,_/R[J\D34'@I"*EY6S12L<> ;AE"$2+PC482>H=72,1NH
M7F&'/#JV4EU8-+,#V9*^(^RQQW:+#1T6K7===A\*)BX@I$Q9$[?[1JE3DU.)
M_]G?1L8:>U((S-7\.M$U(:%/\-3@4N*(:!(_;DDH6J&#/(BU#:Q3RTB1BY10
M*66^.;@*ZV:%U]2L_3>-@#+>7L&&B!DI&KK[E@I:$0,SYKPKFY:?N2:U<NV)
MF!$[Q?W@I98D1&8EGK0)Z6^.N8&DA"UZ/VT%9D )U+;UDVR->9;DB Y', NQ
M JBQ=J>>I9/%2<==ERV0L_C_>%O$/@"+B!>"06!EU4'5$ETF+Z;K,/25<W5"
M9MZE&MC9/HV<S&J1E!#" $<(2 ,BG!'NG&(EH0,FURC@A96;^@)31^+3-K_0
MIUL2=F% 0K\>X)=!M*I@J"96H(/;<<#ACJ>AWUWQ@!]_J,Z&8D9:9TF'#8OC
M\!K1NH,DDWZL/I#!I&/W2C#(SW@2X%#U(O'[1:XAOTHPCKH[9"Y(D'X)=HV6
MMV](#?*1DL(G)*L?,*H7RP*;)-P@MEV05C90^G+C,RP<B2OJ&X014JSH<$9#
ME)]ML!(S!</,(]T4/[G ."9S0=XJ6>7>$9\+&4@>*_A: &B7#I3?6:0J+89P
MPP\L#XKW+@\BJJEB]QA 0)A)#14Q&]M'40@D8> #L10\,I&42(&1+BZ&(#E[
MKJ>5*K/_<\J_HTG(@O,#L$@_!A/;.NA"-^P%S)-P;LJJ:77=9*=YR<%G!*/1
M8N@_>G6D]WQ"!+:GLNE35/7U!!C/DX5IP)Z8VB];)%!CP>$:XD9@I>C%?WQ\
M\V6Q;]H6;B(M@3Q8'!=K4@*Q1(^!#(7Y)F>KOBG^R KDWW'F]-<_!K#U74>3
M34),X/^)F),V)U[$EJPVU"B/G.B@/6V+3+.\1LLE7FA(TS+7C#M&(D39[(4=
M_<Z;/QGZ.A!T8L;Y15Q7.L7#-#+V%)Z1"9BF<1 S+#QVD.VOBN_)=+0%4:]V
MA"&%)OV:0U3@4!U8E(4O?IYZ)BQ-7XD<2/!4>=H_U^&>9L/I&,*Y,+V?&"8:
M7M?@I9HXJQK9V1C@I=EO89W/P0TR^;-L\JD[WPU-*&0D'A[9&!%>[ VOD)"4
MA?M(8,:O)"RPZ0-_P]L4]X\8F%B]YBG[0\%L3)Y0"F,)9[.H)(Y\Y!5S[N8X
M:K5DV"XHC. @$35<@PVNQ.$AK.@^'ECT?:(S#"N$]P[E25YBK3^Y^-**=%6W
MO699I VN1?%PZ ?1,=9$;5.N60.<5#2$32/83LQ[W#0?Z+[D,-3(=M+T^X&\
M$-%BS3[Q*0;7DC_2C78N21S$6#G.I]!&\;V8:?4!U$3?]>V=2_"]Q>'H?1-V
MGP0XS=\1O\6X8$4'UG'8@.:J'=,'; 9,092O&F^K _J SR6N'93)^6'_G8[0
M/+WL%$'O&.=,4*?Y4S&<$T(>=);TQX,2,6H/3V]4Y>2#J?2DYT9A$:4S/NCS
M,R?5_9G\G+H]V.;UNJP^L+E*6)Z0&?G'#*[ ENE'\,3_.D#QG3+$S?@\.A*'
MDH"E("#PHZCB.4J</!^=ZL9$MSQ5%7(3?E^6;QX:(]4ZE#*Q:KR^$R=LIO9X
M'L++]!"1AW;!3_/+XI8#_/2U:\W!F>NUE:J5$'LB^2B86O3)J7$M_)0[_BWS
M"_@]TEK.?B':DU($\^M?0E1B'$A\V9D;^@]NN*X)+A%70IN'430'2 ^YKMKQ
MUM+3(%4KK*P$L? V:UW OWX-Y(#(8CP/8HIX !'F!]<[ 4GBF QL*7L=S:LR
M2MD9K[*];8;ZFA#[&,GM:<1*P"@]#-0T6X]/%[3, 72.=TTM,?3E%?(GB,T8
M^)FM$!'_^];W'0W9<=R%'DY_AL<J#F#)L), *M0/7(P!F%& +GA'P<%K_I1
M?Z+6.)!+NQO\>-UT*_VIGT:)&!%R7AB(AV!:F6IF^27<)3F5RH7 ,Z<IF,5)
MCPVB5-8L*"04*Q&-$.WA?1,(JT1A\"8$F4D>@H1BQ5X.(<FR7<58(3.LVHHY
M:09WU[@CPP_$@M6K1Q:IAP-+)^D^5EB*(&9FVC4!:*0]:-C)@SE"N&Q,]7U@
MV":9%Z24S-!@ ;>Q_*"2VIM"%YQ%Z)I>\XQ>[@FL;29H7=:H7OE(5/O/$S\V
MZK0[A+'$$^<#X##?QX,&P538L/>AKZ=*P-&9'3 %%::! DH6!]Y24TDOL@,
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MG4M;4D3LTZGLM-@*=J-U.V@&.SE$'OKN81YU/ALX!(\^;\M2"_?@[N$ESGS
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MMT @NZ3BT]&,) /I0A68=*I;\#0<CD2/?++\F$856,:E""';R1=.^ONUT"K
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M>1; ^ZUSL7M@!_V?E=6_4$L#!!0    ( !V"J5;M"&LBL04  +<.   9
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MB2WJ>9HZU.-9D.4Y +'9?YC? 7)?*+-# 36*V,_6TU:8-3%:6K0]!]TZT''
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M@<6W^G,",2*)!R27\;,&WPL]@R0*( [CY!E[R1A9XNPEST<&6ZUJN"*LFCJ
MLFM+N')Y10U_763&[?]]+ '>?GK</D_+B6E%CF<3&@>#^@XGYZ]^B9;AVV?0
MIR/Z]#GKS]7E18KPH=-05$;L=AIWPF)!(^1.#.Q1(P@#6R5I)@V\KAJPI>J,
M: KSY@0^E1KQF_*ZFO!7#+?J04A;D9DI;#;!,@UIL:1%N( ;K8J.DFR$1!-
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M<#5(PSC9^:0\.(.O$G+NYDX8A]216ZYX5POR$)CPT8G67LT<%/AELWH$NQW
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MV@GBP&)U;VIQLIDP/UIR?V%5A%D&56*$A9(PC6.:8VA__549L_@;G_(P[8T
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M1HIR&QQN-?3"V1MKRZ6N*E*FI+<F*#/3DXII[#T'?](-L"&2W6*-=][BY3_
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M9$JLRV*SIP ==VHL%%Q>E6:&:PB9F?Q&@BUS('L%P%":F-09&>$.S[L"OE)
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M;\#Z6B,P[0LKZ/\;X_HO4$L#!!0    ( !V"J59J*81L> 0  $H*   9
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M>=CBWP.Q&&"_#B&=)Q)@^C^R_1M02P,$%     @ '8*I5GV^-?#8-@  B[T
M !D   !X;"]W;W)K<VAE971S+W-H965T,C N>&ULU7UID]M&EN!?0:AG.J0(
M5$DJV;+;AR)*A]N:5=LUDC7NG8W] !))$BT0H)% E>A?O^_,?(F#59)[.F(_
M6"Z20!XOWWWE=S=M]\'OG.NSC_NZ\=_?V_7]X9N'#_UZY_:%/V\/KH%?-FVW
M+WKXV&T?^D/GBI)>VM</+QX]>OIP7U3-O6??T7=7W;/OVJ&OJ\9==9D?]ONB
M.SYW=7OS_;W']_2+M]5VU^,7#Y]]=RBV[IWKWQ^N.OCT,(Q25GO7^*IMLLYM
MOK]W^?B;YX^_QA?HB?^JW(TW?V>XE57;?L /K\OO[SW"%;G:K7L<HH#_7;L7
MKJYQ)%C';S+HO3 GOFC_UM%_H,W#9E:%=R_:^M>J['??W_OZ7E:Z33'4_=OV
MYD<G&_H2QUNWM:=_LQM^]NG3>]EZ\'V[EY=A!?NJX?\7'P40YH6O'RV\<"$O
M7-"Z>2):Y<NB+YY]U[4W68=/PVCX!VV5WH;%50V>RKN^@U\K>*]_]HY/(VLW
MV;MJVU2;:ETT?7:Y7K=#TU?--KMJZVI=.9_=U[\>?/>PAZEQ@(=KF>8Y3W.Q
M,,V3[&]MT^]\]JHI79F^_Q"6'-9]H>M^?G%RP+\5W7GVY'&>73RZ>')BO"<!
M#D]HO"<+X\UM^/]<KGS? =[\W[D-\WA?S(^'Q/2-/Q1K]_T]H!;ONFMW[]F?
M__3XZ:-O3ZSVB[#:+TZ-_NQYX2N/9W:%8S=]@1@^M\C/&";[9>> 6-;M_E T
M1P1(U?2NJ_;9T!1#6?6NS-8M'&/C^2\/\"H+_'I3-46SKHHZ\S"6 ^+M?;8K
MKEVV<J[) !"'HL/GVBX[#-VA]8ZF+YH2)J%)NQ)&<$ $_2Y[W]!D[W LGVU=
MX[JBKH_XG#O@+T4\M$-7P<R'&O'TSW_Z^N+BT;?OS]^=9W^]O+RBSX^_?4#S
MT,@];+$;\&'\JG/;H::]TVKP1WKWG5L/7=57\MBKC^M=T6Q=]J+=[RM/?$GG
M>O?J19BE<S5!HV^S(OMM*#J 'JP:-M]V?08O(3O)'C\Z^\]SHK.NA W4QQPG
M/F9EFS5M#^!8UT,)!U'7NJ:J829,S S64U9^7;=^@+.#P7\;*@3MZIB%?1.<
MBPQ/LG:]RSPP>1AK[I3.\=2]^X-'C:N"Q<-Z8+V= P#X73O4L"H -X@,/&08
MY1]#PRPYG(69[).G$$C1X.W099=-,\ [;R?@_E\$#YSNZ(HN<\B)LI=N[?8K
MURDON<AAWMH9/(&CI5'<JAN04UX(TR&0&4#%Y=J#TBD5L ?XMRU]=F"*@_=P
M&Q5).)14GDZ\*/\!K)]W?+.KUKL<=X?CM(>JP7'A'/=% W(3'\HS(*NL@:UX
MCTOD<]\45:?S\&($D>)*\7"K@%#P*,@RH@&0^IU0A.Y@LO*<8>2']2Y9,!YB
MY8DJVZ8FT=(@/&J8  BJPQ_,\^?9SSP9?*TKP#G'$*,M F7H-BL8NH+EKPN4
MZ[JW=G:LHH'C[H% 8.]^#2M!##@_P8B_#(SXRY,<]$5 V 4&?/KU?S*K5:;1
MR[!#PZ?Y8U&WOQ_W#C&V*PYNZ*NUS[/7S?J<#A[)YF;7(F]M;QH8W0\K7Y45
M -G!<_JZ>>,24 KYSM6N@)/E'_+%7Y U/O[J6Y].\NX&F.AHJO3M[/75F^SR
MKS/CPK? /.N: 28 C'O&%T!R-[Y8,Q)'(>3J"M0HA.&I\W\:SO_IR0-\[PGS
M7@&Z[U%*S:' IXV *,&",M#L'T4*? @Y4M4?1; &"2%RPV>#1WFU+SZXS.E2
M"(R%!X7]P%#L=T6?%9L-\"G&L3V#FT5;9,%_7(HD1$'\'M@$<BE@*=L6OURA
M[@(L"-9[7=0#O$U3IXO_QU!N:="<V2@Q$53B2V3I.^!2;5<A/Z Y@4. "D$+
M4^;!B 2B@O^$EZX!4UN 5HOR9PJ=&T2SNG* ;@!/EGN^;8I5C;*B=,Q+UU6W
M'O:P9]!U8&?/C_@M<&O 2Q#GN=T%+!A(Y!\$\A8!4#4H,4!'+]VV<X0\($]=
MUX,)!@<,RP1"],26<S1Z!F*\O)U] 0I&!0?899NNW:<0.T$.7P5R^.HT.RS\
M+GL%* 5'$LX25/4/KB<(C#2JMS WP!\!CF_.$<\_;3YZU)E'14PA_'9@N@%;
MJBOX&9'XVHELRDEM04D#3U\#C"L<%<YA#:/E?.)[.C,B+$#_OSS*RN((Z-%E
MH%YZ!C,>>4D8ND&]%]1([X!]$6^&U0)>JB63TY'@Z+25]<*B$7]! 6@;4!CW
MM-UL ]@%ZUT5S8<,L8$L.9ZR!/+TE4"G!*N>_J??]:@@[H&)(AGBZX"0!H3>
M'%GG+'"8EP !;8&*:X8#/TAKZU .%1$BBY 0MH*(?G!K6C<*B:I$D;VI6)/&
M[66H/2#F1^WDU%()5D!Q:"A<%U6-SYP!'SSS ,RH\,;]T$LUD#3/"D2D$\)W
M#K$!R!K5L';8LFY(7*O4K1]Y:TAD0/AP.*QH BH0-%;NV"([0?J7<5=%3>8.
M.V#H;>9301N,2EX0HLA=&Y(- )?!L[@_=.W:N=* &7<I6M%HGPI.1+4(2N(:
M08<$ZX?TN@G@IA K0*5#</6L<2(W%@-N:(!\ZNIW^'4+W(D1$$P63Q8+6CXB
M,XB7(L?OW X]/M<X#7QVV7U\_(%8B*+HPSH+.&P2D8Y> U@W1,G T-<?0,F
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M+*OYTW(;6 EROO<'B@44ZYTR0&'%;.I+C&!Q'$ +RIRZ7YV[\SP;<+3H#9:
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MT+P[=1A)!M0;#0F]'/D@WK'G\-+F/&IK,TT)"/&DL0-#W([3A,D#7:&UIFO
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M4>AX='J<,-<-A,[PMHDB+*PG2<=E33,47'"@\\I:OS-"@F$JY[\!4$L#!!0
M   ( !V"J58-2(G[^@0   4.   9    >&PO=V]R:W-H965T<R]S:&5E=#(R
M+GAM;+U7;6_;-A#^*P>W*&) B27JQ5::&'"2MAO0 $&3=!^&?:#ELZU%$EV2
MBNO]^AU)27$:QTDP8!]LDJ>[X[T^)$_60MZI):*&GV51J=/>4NO5\6"@LB66
M7!V)%5;T92YDR34MY6*@5A+YS J5Q8#Y?C(H>5[UQB>6=B7')Z+615[AE015
MER67FS,LQ/JT%_1:PK=\L=2&,!B?K/@"KU'?KJXDK0:=EEE>8J5R48'$^6EO
M$AR?)8;?,GS/<:VVYF \F0IQ9Q:_STY[OC$("\RTT<!IN,=S+ JCB,SXT>CL
M=5L:P>UYJ_VS]9U\F7*%YZ+X(Y_IY6EOU(,9SGE=Z&]B_1LV_L1&7R8*9?]A
M[7B'80^R6FE1-L)D09E7;N0_FSAL"8S\9P18(\"LW6XC:^4%UWQ\(L4:I.$F
M;69B7;729%Q>F:1<:TE?<Y+3X\\\E_"=%S7")7)52Z2(:SBXX=,"5?]DH&D3
MPSK(&H5G3B%[1F$(EZ+22P6?JAG.'LL/R+C.0M9:>,;V*KSD\@C"P /FLW"/
MOK#S.+3ZPI<]OLA55@CCM((_)U.E)17)7[M\=BJCW2I-XQRK%<_PM$>=H5#>
M8V_\X5V0^!_W&!QU!D?[M(^OJ1%G=8$@YL#O>5Z8U!Q2/QXJ3E3JI3O4A@8*
MLUKF.D>URX>]N^SV8?+*[2 3U*9*X\P8J9<(<U%0O^?5 @[RBBBB5KR:J?XQ
M4#ZS99=0F)1"ZOP?DCP72L,7*92"VXH IK#4+P0LZBGY*ZUIWT]*Y]2:1-A*
MZX0^Z<,IS^Z(OF7D>T@\?YC2&-#O(/#[#<FGO>5*2%)$'3W5VT*![S$_@93X
MP[Y;,;@]NCX"+6W#;!YQ,]^+XQBB$ [24=^M?1\F"ZRR#4P%Q0""D3=,8H@C
MTMDWJU$P(@O*$F66\P)6?(426.@E80H?WHU8P#["0=1WI-C8/TP]%D5FY@^M
M+RSIMW06PP5F6$Y)21-F]O^&.?""**&QM7U[YKX]'^^A%VQ[G?8MQ=\3\B#P
MHF1;)*10!92IF&+U*/#,&XY"8#;L9AX]C?K0\_VHT]6.CDK&L]2+(U,]S$0]
MC2(;=3;RXC2%/;T>=[T>O[K7J:<L(-5D' 6_]7<W"OP2QEW]OW?GW?U_0YV,
M7>[G)O?W-O=DA*CE?S(1UB@1N&J@0KT$%$]K^H(,6>=Z27*B0M@@ER8;<439
M,#D*@L@+X]#R\;DFT8YM6NM6=$ZW DND^HBHOR(@,6;KMVVG5Z4XZ5*<O![.
M30LI*-W).P.N'P69+BUT\:& 20.D=/G(=R9V[W[/)_8!HALXM_<R:GOEP71#
M^?Q;R#9?&]";%7HNZ5PM 7_4.5E)=P4%E*]7'TQO\=4IIB+)J/P60EI$JI6U
MV-C_(+W,49IJV;R]B+[B/19T(+B1P8W05,P[B_X-K.>_QH@N1;AI0@+SVJ#1
M>QCZ7AC%C^"Q(P5IX TMZ&QA9T/;?RP_A\NM'G?BN?^6YE#Y)6SNN-TIV P/
M(&EP^B6T;@[$3E6S;O&ZH^_"[^:H['C<TB%Y2WP&U[O/[@AMAL?XWJ(\\U,O
M24*:A:F7V@.6103\%"\B^;%G*LD C<=&ED0^A'ZX$QP&6U=SLFAA'R#FOE17
MVMW2.VKWQIFXJ_T#NWL@42DOS"%=X)Q$_:,A ;ITCPZWT&)E+_I3H>G98*=+
M>J>A- ST?2Z$;A=F@^[E-_X74$L#!!0    ( !V"J59>*1(RY@,  %D)   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;(U6VV[;.!#]E8$:% D@1%?+
M46H;2-)=I, 6#9*T^[#8!UH:6T0D4DM2<?OW.Z1DU0U4)R_2B)PY/(><&6JQ
MD^I)5X@&OC>UT$NO,J:]# )=5-@P?2Y;%#2SD:IAAC[5-M"M0E:ZH*8.XC#,
M@H9QX:T6;NQ.K1:R,S47>*= =TW#U(]KK.5NZ47>?N">;RMC!X+5HF5;?$#S
MM;U3]!6,*"5O4&@N!2C<++VKZ/)Z9OV=PS>..WU@@U6REO+)?GPJEUYH"6&-
MA;$(C%[/>(-U;8&(QG\#IC<N:0,/[3WZGTX[:5DSC3>R_IN7IEIZ%QZ4N&%=
M;>[E[A8'/8Y@(6OMGK ;?$,/BDX;V0S!Q*#AHG^S[\,^O"4@'@)BQ[M?R+'\
MR Q;+93<@;+>A&8-)]5%$SDN[*$\&$6SG.+,ZAZ?470(IX]L7:,^6P2&4.U<
M4 P(USU"_!N$!#Y+82H-?X@2RU_C V(S4HKWE*[CHX"?F3J')/(A#N/D"%XR
M2DP<7O**Q(V2#=P05T6I0-ML*KAQ&XP*_KE::S?^[]0&]/CI-+XMFTO=L@*7
M'M6%1O6,WNK]NR@+/QQAGX[LTV/HJP<JP[*K$>0&2J[9=JMPRUQ&TXCJM>DI
MUD=QIUE_Z=3A(EB."\ .%0+3L)$U%;*&4R[ 5++33)3Z[!(>*X7X2RJX\[./
M&.[E#U8;3C GD.=^EH9D9&2$,[A3LNSH0#2C_/-!4"-ZL*:5M^[J)U"WW=UM
M'$(<^V&60Y3Y:7KA?*Q+JV2K.!KJ*-:V4!KBN9]G$<S\+(]'SQ*?>8'0,F4$
MB2E_ND>A/\]2>/_N(H[B#_ H#:OWLX>\B#-YYBD91"8B%??[[>E(L0*JQIJM
MI6*VU0"C741J8+3"UY:R3QBHB8'0-"5*(,I; A62RKH_T T2TIY%///#,(2/
M/>N_7" 76Q=*4JB=MA9[?T(0^?,PAUF2#OS5&ZF=#)$G=L6)<)K/K-C$6M'<
MC^<Y',GKV9C7LS?G-2L*V5DN"@ODS[83^;:UHE*'*>@*N!@*6/<57 P53"=D
M-X8U/= KFKDHZLZFJ$UBQ81F_1U!F53@5"T=U3)=2U=3HJ2I'*^A"3&MD3SZ
M(WTI]W1TJSE;\YK; CI[;1=Z:391AD2G,?+67-MRILTF!D,16Z>794S-MZC&
M[DO95V"S)LK#2 R3LOKBL'DR2V?6NLC\?!["ETFY2>PGR06DJ1^%,2WQ4OC,
M3_-\>$YE6G!PW9'HK;O4-3A>_<TWCH[_#5?]=?G3O?_I(+E;+C34N*'0\'Q.
M!ZWZB[S_,+)UE^=:&MIA9U;T[X/*.M#\1DJS_[ +C']3J_\!4$L#!!0    (
M !V"J5:B<),8S@4  ,@/   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM
M;*U776_;-A3]*X07% G UM2WE"8&DG3% K18D'3KP[ '6J)MHI+HDE2<[-?O
MD%*4C]ENB_7%HF3><R_O.;R\/-DH_<6LA+#DKJE;<SI96;L^GDY-N1(--V_4
M6K3X9Z%TPRU>]7)JUEKPRALU]31D+)TV7+:3V8G_=J5G)ZJSM6S%E2:F:QJN
M[\]%K3:GDV#R\.%:+E?6?9C.3M9\*6Z$_6-]I?$V'5$JV8C62-42+1:GD[/@
M^#QW\_V$/Z78F"=CXE8R5^J+>[FL3B?,!21J45J'P/&X%1>BKAT0PO@Z8$Y&
ME\[PZ?@!_;U?.]8RYT9<J/JSK.SJ=))/2"46O*OMM=K\)H;U) ZO5+7QOV33
MSXW3"2D[8U4S&"."1K;]D]\->7ABD+,=!N%@$/JX>T<^RG?<\MF)5ANBW6R@
MN8%?JK=&<+)UI-Q8C7\E[.SL0F@+ZL@YKWE;"G+CE7!I16/(X2<^KX4Y.IE:
M>'+SI^6 >MZCACM0(_)1M79ER*]M):KG]E-$.(89/H1Y'NX%_,CU&Q(%E(0L
MC/;@1>.R(X\7[<![OMQK47,K*O).FK)6IM/"D+_.YL9JB.;O;<OOT>/MZ&XC
M'9LU+\7I!#O%"'TK)K-7OP0I>[LG]GB,/=Z'/KO!QJRZ6A"U@*A+U;768'^4
M0MXZOK:%NQ=P>[AG_T6FI$6R>%N1$NRZW!!NC, <O!MI7 H1DUT)LE UMKML
ME^00XK(KU1G8F:-C B;+E:?R'8";N=#^98L[LM"J(6NMJ@Z>#(<4B55DS;5M
MA3;D@"0Y35B(01K2(BMV@VAQ*]H.]AWTJ!%N7?.YTMQ5!,*76@C4&=B%-$I2
M$N0TR](]:.J>U_8>D=SW9@%C- \+_RP8VVVID!O]8DDIG,7X#0%P\2*O$0**
M<A+'-, Z/RG+ZVV4;^7D 'N%T:PHW A 18XE.5:\\%'.207*M)QWOCPN!&)Q
M./@Z.#A,:!&D1^0PP#,^VNU_MS .2%#$-,\C'T1 61:2/5L@&;= \MU;0+;@
MUBHMA=DF_;U VZ5_^8C8K^S_R_N:;U"UK="2UYZ:D,:)2TH0@:*0?,;1]5JV
MKR&-4A@(,:,Q&(\9C=* O)>M1(FOR%*IRI DHVF:DACT9&Q@1;Z,&= LHTD8
M^!&C01CMRWPZ9C[][LPC8VLN*R+NT"*803Z]Q'OZM_&Q%WX['U??\O,3"'KP
MT?"V6T# G7;&HT?4&D99'KM!0-,B)K\/6_E%:#'-H@*_:9P-4X8006@8DR#&
M/HP'SKZ9O[ZRA8 Z(%E HS A'Z".8_)!M<O74!/*H])^^QZ&"28R;-8PI1$+
MCK[7!T67H36T Q]11AESSB MAFCWZ"4;]9+]@%[02VH43A>#^-K)M2N?7J[;
ME+(7>)=2=GKX&9L8;OP_(S)2E=,\2AT_-,H9+)_)9YSG2A\RBVV=%Q'*?+/N
MK*/ D;%82!3DQ[DY#;((>'GBZ$;'N5)U162#]-T.YU0*"1;NY,"9<=/-K:<:
MTH3Z@L3Q5\ Z<^=0UW1];U,)I*F4O.^%X9<W3CK_]!\.@Q1> U?K@9&@Z#^!
MC7#,QD[Z48)S*""^<W=9[$S?A R'50&),U>SXK0@^ZA MC):I XR2VB"(K9'
M:?FHM/Q'VB+=B4?5;Y/77K2=/=$SV)_3]WC($I( YB,]:"XTP(CE=[[^!&@Q
MHLP?J+2(BM$0%RVC.EV*G;4K<&=-ZAY!P<AE"U=B@(43WS^$-$6;\>J7/ S"
MMXXZWY]H :BV+QE]K\+'_B$L:!HP$C$:XH :*MW+]+A04;PP-\N"7LNDEGPN
M:PEA1#%E:>0>69X_-A?/(=S""YHD_AA#:2OBPM= 4F\I@9B81= PHHJCZ&@'
MYM.*ER'"+,>@2&D2I%MU.'URNVJ$7OH[I.,>75!_T1J_CM?4L_YV]CB]O^-"
M!$N)C-9B 5/V)D-WHOM[8_]BU=K?U>;*XN;GARM<M85V$_#_0BG[\.(<C)?W
MV;]02P,$%     @ '8*I5HJ1:_"D!   %PL  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&ULK59M;]LX#/XKA&\86L!K_):W+@F0-NM68-V*-K?=<+@/
MBBW'VF3)D^2FO5]_E!R[:9<&A\-]22B)?$A*#VE.-E+]T 6E!NY++O34*XRI
M3GL]G1:T)/I$5E3@22Y520PNU;JG*T5)YHQ*WHN"8- K"1/>;.+VKM5L(FO#
MF:#7"G1=ED0]G%$N-U,O]-J-&[8NC-WHS2856=-;:GZOKA6N>AU*QDHJ-),"
M%,VGWCP\/1M8?:?PA=&-WI'!9K*2\H==7&93+[ !44Y38Q$(_MW1<\JY!<(P
M?FXQO<ZE-=R56_0+ESOFLB*:GDO^E66FF'HC#S*:DYJ;&[GY0+?Y]"U>*KEV
MO[!I=(>1!VFMC2RWQAA!R43S3^ZW][!C, I>,(BV!I&+NW'DHEP00V83)3>@
MK#:B6<&EZJPQ.";LH]P:A:<,[<SLO939AG$.1&1P*0P1:[;B%.9:4Z/A:$EP
MI8\G/8/.K$DOW0*?-<#1"\ Q7$EA"@WO1$:SI_8]#+*+-&HC/8L. EX1=0)Q
MZ$,41/$!O+C+/'9X\7_+?,%TRJ6N%84_YRMM%/+GKWW7T'A)]GNQ-76J*Y+2
MJ8=%HZFZH][L]6_A('A[((>DRR$YA#Z[Q1K-:@Q:YG#!!#/TS4<D^9Y\]D5^
M$'M_Y,N"0BXYEC(3:S"6'* +N=%@\"25VOA8:&E=UIP8C(.44AGV-VDJ$"]Z
MX\K$GMQ1A54/M:9YS8&SG (3\$")TNA"@:P50OVLF4)M]I@/:=Z':)LTDB(M
M.E; $2*80M8:7>GC$_AZR-M1Z^X8WBNI-9P3I1YL7E\(K_'B=O*8[^;Q"7OE
M<]W:2 SR._8:#-W0M!"2R_4#5&AO6R<,X14D0>0'06"EL1^,(Q3B?N2/@Q'\
M\>WS[?+= BHE*\6HP09IY:Q.#80!A/' QSX+8>@/DAC"*/'[_2$L/\X_+3YW
MBLIFJZV^!<7?9(32H!_!4AK"(6\HPAU%'J]4^R PI5?03T(_=/$- G\\BFV@
MH\ /PR',ES>W;\)Q$,'1Y?7-:U)6;Q?'2#-L@ X4%?TAFC:.]F%'(W^$0 =8
MW^]8W__7K&^K>!^_#Z+LY_>\_3I9;$MI]]5@Y@%865D97WS=-@ZFP5D*RY"5
M_;X](^ IG!%.1$JW;%W0E)8KJEK"1HX32(5D#%>4V&:#WSL#%55,(FFS[_@!
M<#M#/QPFS]"><1^A0B0)2@>N>-!=\>!_:BP^7-3&=LDG)?+N'J<&3?>]RD''
M+W<=J@TK72WFC3\B1(U4>])A,-H7.-ZV#7PSVZ\$N(?ZM9D][R#SU/SBA3;)
M 9;\BN)D4N&9<]:&UKR?QGY8\PPREN?XYKF2I76I'W-Q78P@@L89P@;O^IUF
MU@M>;(8YH*:%Q)7MGBX)1T6F+"_L=BDQ>(G Z(+8]J-/X!NVM;T/ C?43FH9
M*J.[+6_ZL=\/$KM*8!CZ<3RV<G]''NS(PU;&5\$Q,#>(%6+CB&P_<M7_V#7V
M,;&W,ZR45*W=2.;N2IAF;NEVNZEOW@P[C^K-R(@5L&9" Z<YF@8G0ZQXU8QA
MS<+(RHT^*VEPD')B@9,K558!SW,I3;NP#KI9>/8/4$L#!!0    ( !V"J5;&
M^K+OP00  /$,   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;)5766_;
M.!#^*X3:+6) :]U7:AO(B09H@R!)NP^+?:"EL2U4$KTD%2?[ZW=(R;*3F-[N
M@T12G.,;SL'19,/X3[$"D.2YKAHQM592KD\=1^0KJ*D8LS4TN+-@O*82EWSI
MB#4'6FBFNG)\UXV=FI:--9OH;W=\-F&MK,H&[C@1;5U3_G(.%=M,+<_:?K@O
MERNI/CBSR9HNX0'D]_4=QY4S2"G*&AI1LH9P6$RM,^_T/%+TFN!'"1NQ-R?*
MDCEC/]7BIIA:K@($%>122: X/,$%5)42A##^[F5:@TK%N#_?2K_6MJ,M<RK@
M@E5_E(5<3:W4(@4L:%O)>[;Y KT]&F#.*J'?9-/1)J%%\E9(5O?,B* NFVZD
MS_TY[#&DKH'![QE\C;M3I%%>4DEG$\XVA"MJE*8FVE3-C>#*1CGE07+<+9%/
MSKZR9OG[(_":7,)<VN06X^#DD<XK$*.)(U&#HG/R7MIY)\TW2 O(-];(E2!7
M30'%:WX'D0WP_"V\<_^HP&^4CTG@V<1W_>"(O& P-]#R H,\922Y+$5>,=%R
M('^>S87D&!I_'3*VDQ4>EJ72Y52L:0Y3"_-! '\":_;I@Q>[GX\@#0>DX3'I
MLP=,OZ*M@+ %N:"<OY3-DOR@50N"T*8@5T*6&)10D&M:\NT.$FL3;QHTJ\7D
MD>*08<=5JQ@85)[5K$4I2C)K.;E@S1-P66* D%LF4>7C"DB^I:::6@-<*%A/
M"I:9=P/H RK(@E58'00Y*1LB5ZP5*$",Q@3=GZ^T_R\AAWH.7"_N>-GDY9I6
M6WT8'>$!\1_)IP^I[_F?<>8%=I@&BC(Y0)FZD>VZ[C B67J +/%=O;T='YE$
M$#LXW6$I;7;D=Y+T/$BU\N\-XD6!_Z#7"N6F B/Q5PTX\<)L9,)_@N9%+NXC
ME1U$'>$A"TZ\Q/8\;Z0G:1*->AM:(S34'+AV[+LC/?7M( U&N_CX7QX(@M!D
M09)Y=IAY.**RT#-ZP/7M-,WTZ/E1C_YM_*E##S,\B;1W@!O;'CKC>A>3JI07
M!.\%3/]"L5;P!!4>T%<U$G]T^BLVX7%X26RR*4Y].PM2DJ2AG23&J(I3UX[2
MA*1A9J=^T-OT-G^DD)@5"FG3P_#L( Y4H.EY',=V$F?D'M1=W!^&\BC5U]\:
M<P>?DA5*W&L7J[1[ <J%V>BMR=XX,UD;X%8X]DU61N,0G_A(:8R&TA@=K4\W
MC<2Z(525RUD-NMH,WZZ>L5\1L%?D#Q7 XPI42>M*DCI&J6[#OFO!_!!8H;#B
ML7K-&N@K8[G5#KUV!4F1P6(!NN_8D7"J3@/;*0(4BYNQ-KZMA8\K#O#J?M67
MHGKYR-XBG)T28^@&,;[\U)B&D1OHQ^!$STXQC;;!T"??&]TH'Q,]PS'!H#[;
M#\)WD6?$B9\QJ!&BJ6!'6*S#T%@FXO -2GH4ATX@S-2/)$N\73!MW6F$&:OZ
M$GJ>"2:F:!2H=YB8H/IV] [LNWA"Q]E9DFB<2922*U-<_6?ZIN0W$UAWG.!F
M]S;Y?QSAYJUS=BB-G;TVM :^U,VV(/J$NXYT^#KT\V==&[LC[WX&\.)?EHW
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MNWM@<L&:)D@T^YB9SA)_E%QQJJ_!#8\1=BBY2$"0*%0II_FG2OIIA[,Z:J&
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MT/\\\D U<Z@QC*Q<[V^DH4GBMCF-;E0V@/R9E.9@V 3=GT'\%U!+ P04
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M]%.#VDV@\8TB7^P;;H'N-VGV+U!+ P04    "  =@JE6P3M6=-\"   <"P
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M9KJ<>!\\R# G:Z8?Q/8+MGZ<P%0PY9ZP;7,##]*UTJ)JP49!17GS)KNV#@<
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MLB2_W%*RICPS4+]O&)-O-]G7Q?)K\NQ_4$L#!!0    ( !V"J5:D7YI7BP,
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M.*-+QD\<"35JZ\\Z''7MEO;YS]5W4"%Y5GT?8 N<!)T:K)$_FL9+H;5UOM1
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M)DZ+,MXJJ3^-]3HU_<ACB;[S9"W0C>#Y6@I=(X5.T66>"Y6_'EP@KE#-MB@
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MTK0D."#ZW[Y Z"X0"M>A</WTCL^?M-]PVD&@MMSS!&;%S'8QLWZO4N8S4Y[
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MI&1I?K@"$@'/ M3]!6-R?Y(]H-J &O\$4$L#!!0    ( !V"J5:G@_DQ)P0
M ,$6   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;+5876_;-A3]*X16
M#"V01J(DRW9F&XBM%BO0;$'2;@_#'ACIVA8JB1Y)V=U^_4A)EBU+)N*&>;%%
MBO=<GL.O(TYVE'WC:P"!OF=ISJ?66HC-C6WS: T9X==T [E\LZ0L(T(6V<KF
M&P8D+H.RU'8=)[ SDN36;%+6W;/9A!8B37*X9X@764;8OW-(Z6YJ86M?\9"L
MUD)5V+/)AJS@$<37S3V3);M!B9,,<I[0'#%83JU;?!/BD0HH6_R1P(X?/2-%
MY8G2;ZKP*9Y:CNH1I! )!4'DWQ86D*8*2?;CGQK4:G*JP./G/?K'DKPD\T0X
M+&CZ9Q*+]=0:62B&)2E2\4!WOT)-:*#P(IKR\A?MJK:#@86B@@N:U<&R!UF2
M5__D>RW$40 ^%^#6 >YI@'\FP*L#O.<&^'6 7RI342EU"(D@LPFC.\14:XFF
M'DHQRVA)/\G5N#\*)M\F,D[,'F +>0'H/?J-,$;4(*"W(0B2I/R=K/WZ&**W
M;]ZA-RC)T9<U+3C)8SZQA<RM$.RHSC.O\KAG\GCHCN9BS=&'/(:X'6_+/C<=
M=_<=G[M:P#O"KI&'KY#KN%Y/?Q;/#W=[PD-]> C1N? 6&Z\9!J_$\\[A)9RL
M5@Q6I%P-=(GV _/79]D4?1*0\;_[9*]P_7Y<M6O<\ V)8&K);8$#VX(U^_DG
M'#B_]&EF$BPT!-;2TV_T]'7HLR]4D%3N2Z6&O=.UB@_*>+4Y;F<X<+$OI]+V
M6)&>9GCH#L?M9J&V-S_(==!P'6BY[F<*@XBN\N2_T^55\:TP!D=$?,<Y(:O-
M<^GP&P)K21(TD@1:24)8 F,0:V= T%%DX(]/!G:AS7.I)$%G,K4RMJ@.&ZK#
MEU,==JD..J.OS7,I54-@+4E&C20CK20+>=(P:2@0X1Q$KR"CCB">ZWFC$T6T
M:2Y59-09?-_'CML_^N.&ZEA+]7>Q!H:D"4C)$Y7'-V6]=+4@EQX2)L%"0V M
M\;!S,#_.*QV[-; A28VBA:;0VJ(>.4K\\AVIQCA>@=CU@LZFI,]UL3*&T-K*
MN =E7*TRGY-(?C$!^@C T6T>HP]2(/%^+K];>L]L/=S%D\PD6F@*K2WEP2_C
MUS+,V*AC-HH6FD)KBWHPS?BEKKD&.%ZVXW'/JC7DAVM57L-=XX.]QGI_?<]H
M7$@WP4D*_ KE('J5,6F>%T;10E-H;0$/9AP'K[563=KOA5&TT!1:6]2#[<=Z
MW_^,M=IU_8$S'/NG:W78,::N_! ^6=*AOCL_2O=@Z;'>TY^:BBL4%;*<"[2A
M3$VK7@6ZGAOC$>YN5T:-OBFT2BG[Z&XO [8J[TBYM/Q%+JK;LJ:VN8>]+6\?
M3^KG^&91W:8>8*K+W3O"5DG.40I+">E<#^648=5]:540=%/>(#Y1(6A6/JZ!
MQ,!4 _E^2:G8%U2"YM9Z]C]02P,$%     @ '8*I5E)LTK&" @  AP8  !D
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M8<'%I681?=GK.XJWMG*LN=+'VS9K_5* , %ZON)</75,,7)O3_X74$L#!!0
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M8D\(TAC@][40^F5BNHZARTQ_ E!+ P04    "  =@JE6C=Z-P*D"    !P
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M<>JVW[:&5773LF;*8@-LADM\HD [!UR?*V7?#-<%NT<O_PM02P,$%     @
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M:X%ZOV9,[B:Z-_='<?(;4$L#!!0    ( !V"J5;SI(BUQ 0  " ;   9
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M050#\/V*<_5R4SGH3FMF_P-02P,$%     @ '8*I5M%C*W-V P  ZQ$  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULM9AO;]LJ%,:_"O*=IE9:Z[]-
MFMXD4EK?[59:I6I=MQ?3?4'MDQ@-0P8X:;_]!=MUX\IARD3?) ;S_. \/MC
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M>K\5/^MM #0]1K6XTL)QLP/FYXMI.&]W !H@HYI"-8UJ!M4LI;D=4 ?(D3]
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MLB)>$WX,,/P,D(NPB9 ]_8+.ZW1DH8/KWPL7>+@7[T&"RUQ(OE&+28*_KE0
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M0.$KQ+9\8]\=[W VQGG8[Q%ZU/0-R&K-/]Q@5_#;Q,*Q,B"X6X IS@T\V%-
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M5-_:(DYAK%*&$=.<U=*P:>2X3GL:NCE!]_\X-6Z#";9-MT:W:=1Y:F8YW=D
MNB\;B2 M%&T,9XW%S9GCU!@VC;!CN>T4L5&4.J.7))X0ZV=4/N"/$/F,HX],
M@D#>$6*QGZ*O:(@(]"]VZ6$8"ZVZ-:4N (\J!!G<6,&/A%8-GA3!DW'$(,.I
M)*]=2]T6&^)..U*W:!YP;XG^43G(4"MDIG7"31M,.M0+%T4?#ZGZ0P0!-XNX
M;=0Y-FVFN$.R<%'I<7^IO]UN(7F+*'ARJI2@E64*A4F)0H-E:C,KFTP,W*5;
M19'&O:50@0S1+6>H;HU:Q,="JVY-4<:Q,ZYN];8%%P<_$EHU^*)%P$-ZA"&Z
MY3:.CV68]>SM-ZIR+/H"/*0QN%RXFAV :S7.6XO1M$-J2=$ED/XN8;AR94"5
M=Q33JN]KJ]6T0V!)4;%);U&\2+PRJ)HP&?6NZ[MF5:I%?27]]14KD._KESM0
MO_H7N_0(CX56W9JBKI-QIP)DU+' 6&C5X(L>@0SI$0;H%VD;!AAU.6BQ,CI2
MMV@12'^+\(/RE:%6W@CM>N/58M3%MV@52'^K<(%XV8W=(E:38].JBV-1LTG_
MN_=%RN6TME3U.5#_BI<FLEX:IX; =\F46:#DWT[GC_G3?)+]/IG?UIY?XZM5
M.H\N8-+Q^#WE.S\2*("M@C0FCLH"GDZ<TQO)#LG0=LVD9&%RN0?J 8\-U.];
MIK0SNXD7R.?^RV]02P,$%     @ '8*I5I;;%26H P  4Q$  !D   !X;"]W
M;W)K<VAE971S+W-H965T-3DN>&ULQ5A1;YM($/XK*RXZM9(;8#$XR=F6$B?5
M56HD*VYZ#U4?-C VJP#+[:[M]'Y]=Q>,P<9<4R'EQ=Z%F6^_^69 ,XRWC#^+
M&$"BES3)Q,2*I<RO;%N$,:1$G+,<,G5GR7A*I-KRE2UR#B0R3FEB8\<)[)30
MS)J.S;4YGX[96B8T@SE'8IVFA/^X@81M)Y9K[2X\T%4L]05[.L[)"A8@'_,Y
M5SN[0HEH"IF@+$,<EA/KVKV:N8%V,!9?*6Q%;8UT*$^,/>O-IVAB.9H1)!!*
M#4'4WP9FD"0:2?'XMP2UJC.U8WV]0_]H@E?!/!$!,Y;\0R,93ZP+"T6P).M$
M/K#MWU &Y&N\D"7"_*)M:>M8*%P+R=+263%(:5;\DY=2B)J#PFEWP*4#/G08
MGG#P2@?/!%HP,V'=$DFF8\ZVB&MKA:871AOCK:*AF4[C0G)UERH_.5W$A,,'
M+42$9BQ5U2&(T?<#.GGK[D6O ;V[!4EH(MXKX\?%+7IW]AZ=(9JA+S%;"Y)%
M8FQ+Q5&?9(<EGYN"#S[!QT/W+).Q0'=9!%'3WU:Q50'B78 WN!/PGO!SY+D#
MA!WLM?"9_;H[[J#C57I[!L_[!;WGY(=Z("2ZYIQD*]#KP4[<""G]T(SD5)*$
M_@?1 %VG;*VLOWU6D.B3A%1\;].W.'_8?KY^*UR)G(0PL=1C+X!OP)K^^8<;
M.'^UB=,36$.J8275L N](558KS\H)&H+OD ,#*)^@VVFH\L@&-N;>E#'1L/1
M$%=&#;)^1=;O)BM9^(Q8K@FVEGVG^VO3TA-8(]*@BC1XXPH.^I2J)["&5*-*
MJE'O%5P@^K7B](:^?U#!QT8XP$Y[!5]49"\ZR3XL'L4 S=6O2=S=8CYOX]<)
M\MKD] 36B/>RBO?RC>OXLD^I>@)K2.4Z^R[!Z;V22\AZE0Y]USTHY18K[.(3
M;V.WUM:XW=6L1" \C$WR(MBH?C77:6TEV@GUVD3UA=8,'.\#QV]<UB6!ON3J
M":TIU[X=<SM;F-\K;._X'>TZ1X5];(4==W2BL/=-D?L_79&:>&BV&J 59,!)
M8M)((C4:4"$YT4-1*^=.U%<GK2>TI@;[7LOUW[K&>VW7^D)KRK5OV-S.)N?W
M:CPX;I(O@L,^I,4*C[!_4.-V;3Q-@:_,U"X4%96)8I"KKE9?!J[-/'QP_49_
M,3!C[QZF^-R@QK05S01*8*D@G?.14IP7$WRQD2PW0_ 3DVJD-LL82 1<&ZC[
M2\;D;J,/J+ZC3'\"4$L#!!0    ( !V"J5;U%YW>#00  ,$3   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8P+GAM;,6876_;-A2&_PJA%4,"M-:7OY+9!A*K
MQ0HLA5&WW<6P"UJB+2&BJ)&4G0#[\3ND%-E*5*8>"#07L43Q?4D^Y)%X.#LP
M?B]20B1ZH'DAYDXJ97GMNB)."<5BP$I2P),MXQ1+N.4[5Y2<X$2+:.X&GC=V
M*<X*9S'392N^F+%*YEE!5AR)BE+,'V])S@YSQW>>"CYGNU2J G<Q*_&.K(G\
M6JXXW+FM2Y)14HB,%8B3[=RY\:\C?Z@$NL:WC!S$R3520]DP=J]N/B9SQU,]
M(CF)I;+ \+,G2Y+GR@GZ\4]CZK1M*N'I]9/[!SUX&,P&"[)D^9]9(M.Y,W50
M0K:XRN5G=OB=- ,:*;^8Y4+_1X>Z[N3*07$E)*.-&'I LZ+^Q0\-B!,!^/0+
M@D80_*@@; 3A<\'P.X)A(]"HW7HHFD.$)5[,.#L@KFJ#F[K0,+4:AI\5:M[7
MDL/3#'1RL4XQ)^\4N00M&87E)+">D'?H$^8<JUE!%Q&1.,O%)91^74?HXLTE
M>H.R GU)625PD8B9*Z$SRM*-FX9OZX:#[S3LHSM6R%2@]T5"DA[]TJP/#7H7
M(+0D@B<2MX'1\ /9#% P?8L"+_#[^F.6WV$^0*&OY6&///IQ>6 83=C.:ZC]
MPG/G]08FM=@1"%V)-H_HM-X*/^KBFP/F"?KK#[!$'R6AXN^^Z:W;'_:WKUY7
MUZ+$,9D[\#X2A.^)L_CU%W_L_=;'UJ999,FLPWW8<A^:W!=KR>)[Q$K%6J =
ML)9 ]@)B12C2XK(/I='R7)2UV4B;J;?^?N'#1P#^9N[^E%)/O;!;KP-@U (8
M&0&HZ$'OUZL56N6XZ!NM47_N:&V:19;,.MS&+;?Q3P[8L4WN-LTB2V8=[I.6
M^\2X7C]5=$,X8MLF0!'>PZ<.;W*"8%=51W ?3:/KN30G+V(Q&(\\WPN?Q:RE
M1CN@IBVHJ1&4CNE_T>OQ;;0YEXQ-L\B260??58OOZB?']Y5-[C;-(DMF'>Z^
M=]SA>J\OW++B<0I04<FSF*APCQFE@%^H#_9;5!(>*]3P /*?>TBX=,7>?6W=
MG!^<A*LWF(ZZL;HT]^I<A+;<N@Q/L@3?R/ N*S):441HF;-'0B!/W(B89WJ?
M@R!-Z"?E]Y'R_.>DC&V?3<J26Y=4<"05F$GAA_]#*N@CY;]84\:VSR9ER:U+
MZIBA^,:->$LJACR.9YNJ/@>@K.K_X#9NX]./Y L^5O,(6VY=/L=,PC>G$JOV
ME45XQNHD@NJ<MS>)>,5MW&A[,VV;"4ADRZW&YIZ<;5#"=_J,2,"B@652)_=M
M:7L.=:-/7YZ5+]7YE#XS.=K4AUN0>^\RR-9RL@5+;S"!C1BOSXOJ&\E*?8*R
M85(RJB]3@A/"505XOF5,/MVH!MI3N\5_4$L#!!0    ( !V"J58E'^K5@ ,
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MOCLK#_25-X+NBP-HCU0(FA27.X)ELL@;R.^WE(JWF]Q!?:QR_3]02P,$%
M  @ '8*I5@=^^(M. P  3PP  !D   !X;"]W;W)K<VAE971S+W-H965T-C0N
M>&ULK5==3]LP%/TK5H8VD*#Y;BO61H(V:'M@0A3&P[0'-[EM+)(XLYT6_OUL
M)X2VA/"A]B&QG7O.O?=<)[X=K2F[YPF 0 ]9FO.QD0A1G)HFCQ+(,._1 G+Y
M9$%9AH6<LJ7)"P8XUJ L-1W+ZIL9)KD1C/3:%0M&M!0IR>&*(5YF&6:/YY#2
M]=BPC:>%:[),A%HP@U&!ES #<5M<,3DS&Y:89)!S0G/$8#$VSNS3<*#LM<%O
M FN^,48JDSFE]VKR,QX;E@H(4HB$8L#RMH()I*DBDF'\JSF-QJ4";HZ?V"]T
M[C*7.>8PH>D=B44R-H8&BF&!RU1<T_4/J//Q%5]$4ZZO:%W;6@:*2BYH5H-E
M!!G)JSM^J'78 $B>=H!3 YSW MP:X.X"^J\ O!K@[0*\5P!^#="IFU7N6K@I
M%C@8,;I&3%E+-C70ZFNTU(OD:I_,!)-/B<2)8"9H=)_0- ;&OZ'P7TG$(SI!
MLP0S0-=0E"Q*9!W0F2JH>G8X!8%)RH^DU>ULB@X/CM !,A%7"(Y(CFYS(OBQ
M7)3CFX26'.<Q'YE"1JM\FE$=V7D5F?-*9#:ZI+E(. KS&.(6_*0;[[Z%G[[A
MW^D@,*7,C=;.D];G3B?C%*(><NUCY%B.W990-_P2LP;NMN7S?N]."SS\=/!;
M8KC-QG,UG_L*7[W5_IS-N6#R<_&W;8=4%%X[A?J$GO("1S VY#>2 UN!$7S]
M8O>M[VWJ[I-LND^R<$]D6W7PFCIX7>S!#14X1;_*; X,T47UYG-T5;_X,3JL
MWNRCMOIT4G^T/A69K\G4\;8*/+OO._YP9*XVI=^GTW!/9%O2^XWT?J?T=_H4
M@_@$KX#)0QD5C$3RBDF,"ED-+3PZ+/G&M+4,G6X^6H:*;+A1!K??L^R=(KRT
M\KR>YVU;A2U<PY[_S+4E6[^1K?^.'3NA7+1I46'[&RYMWY*_[<@F[69#=R?-
MEV:.]9(M[ SXD[MHT,@QZ)3C N!CNZ63[J.[9?"BPE;/<G94W*?'<$]DE=;F
M1N>4 5OJEI6CB):YJ [V9K7IBL]T,[BS/I7=<M7</M-4K;8\MI<DYRB%A:2T
M>@/Y4K"J?:TF@A:Z/YM3(;L]/4QDQP],&<CG"TK%TT0Y:/Y#!/\!4$L#!!0
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M$:0TWQ1')P)8;9DL_S[7J_7QS,?B4.)H_58=VQ1G#P>8\LP'_AQO8B900M<
M:5V/@%%>'J.4-Y)GQ4G$BDO)T^(RHB2DN3* W]<<HE7=J ?4AUG^OU!+ P04
M    "  =@JE6!"9CHG,"  #P!0  &0   'AL+W=O<FMS:&5E=',O<VAE970V
M-BYX;6RM5%%OVC 0_BM6)DVMM)*0I&QB$ EHI^T!"15M>YCV8)*#6'7LS':
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M'8*I5B/N$P3O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ '8*I5IE<G",0!@  G"<  !,
M ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  =@JE6X%W*
MI]8%  #-'@  &               @($."   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ '8*I5N 5:1.>!@  RQL  !@
M ("!&@X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( !V"
MJ5:R+TR3_0(  *D*   8              " @>X4  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    "  =@JE6 :*8CK %  #G&@  &
M        @($A&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ '8*I5DR$SJ00 P  UP@  !@              ("!!QX  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( !V"J5;$DHB'?@<  )D?   8
M              " @4TA  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    "  =@JE6SI"LH\ &    +0  &               @($!*0  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ '8*I5LV(2<2("0
MR1<  !@              ("!]R\  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( !V"J5;8_PB<PRD  '&%   8              " @;4Y
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  =@JE6"(OS
MEZ(%  "X#   &0              @(&N8P  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( !V"J5;M"&LBL04  +<.   9
M  " @8=I  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
M'8*I5OYA] 2[!0  N@T  !D              ("!;V\  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    "  =@JE6;*"107<&  #$$   &0
M            @(%A=0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( !V"J59KOX1\] 0  ,@*   9              " @0]\  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ '8*I5O4]V+2!%
M-U4  !D              ("!.H$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    "  =@JE638 *_@P'  #2$   &0              @('R
ME0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( !V"J59J
M*81L> 0  $H*   9              " @36=  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ '8*I5@VCQ';4!   *0P  !D
M     ("!Y*$  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !V"J59>*1(RY@,  %D)   9              "
M@0GJ  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ '8*I
M5J)PDQC.!0  R \  !D              ("!)NX  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    "  =@JE6BI%K\*0$   7"P  &0
M        @($K]   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( !V"J5;&^K+OP00  /$,   9              " @0;Y  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ '8*I5KW4*=MT!   C@L
M !D              ("!_OT  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    "  =@JE6F%<&D]4"   8!@  &0              @(&I @$
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( !V"J58W5D,(
MP@,  #()   9              " @;4% 0!X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ '8*I5L$[5G3? @  ' L  !D
M ("!K@D! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  =
M@JE6/0+4IB\"   A!0  &0              @('$# $ >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( !V"J5;N67'T/P(  *L&   9
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M970S-BYX;6Q02P$"% ,4    "  =@JE6V#29MRX"  #@!   &0
M    @('O' $ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M !V"J58^718OM@,   </   9              " @50? 0!X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ '8*I5JB>#PDK!0  61X  !D
M             ("!02,! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    "  =@JE6I%^:5XL#  !2#@  &0              @(&C* $ >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( !V"J59R#JC?H (
M *,&   9              " @64L 0!X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ '8*I5GY]I*U>!P  H4(  !D              ("!
M/"\! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  =@JE6
M\P,@M9<$  ",&@  &0              @('1-@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    ( !V"J5:G@_DQ)P0  ,$6   9
M      " @9\[ 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%
M  @ '8*I5E)LTK&" @  AP8  !D              ("!_3\! 'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  =@JE6(7]0;6D"  "S!0
M&0              @(&V0@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M 0(4 Q0    ( !V"J59O%"A6:0,  '$*   9              " @59% 0!X
M;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ '8*I5HW>C<"I
M @    <  !D              ("!]D@! 'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q02P$"% ,4    "  =@JE60VQ'0[("  "6!P  &0
M@('62P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( !V"
MJ5;SI(BUQ 0  " ;   9              " @;]. 0!X;"]W;W)K<VAE971S
M+W-H965T-3 N>&UL4$L! A0#%     @ '8*I5O)R8KE[!   N1$  !D
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M=#4U+GAM;%!+ 0(4 Q0    ( !V"J5;Y(V/-[A<  !63 0 9
M  " @71F 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @
M'8*I5I?([-=L!0  1AL  !D              ("!F7X! 'AL+W=O<FMS:&5E
M=',O<VAE970U-RYX;6Q02P$"% ,4    "  =@JE6DQ8V(*0$   #&   &0
M            @($\A $ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4
M Q0    ( !V"J5:6VQ4EJ ,  %,1   9              " @1>) 0!X;"]W
M;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ '8*I5O47G=X-!
MP1,  !D              ("!]HP! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX
M;6Q02P$"% ,4    "  =@JE6)1_JU8 #  "^#0  &0              @($Z
MD0$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( !V"J5:M
MM;6;9@,  'D.   9              " @?&4 0!X;"]W;W)K<VAE971S+W-H
M965T-C(N>&UL4$L! A0#%     @ '8*I5D[&+Q4Y!@  8BD  !D
M     ("!CI@! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4
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M   .%@  #0              @ &3J0$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( !V"J5:7BKL<P    !,"   +              "  1>M 0!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( !V"J5;XR!T=$04    L   /              "
M 0"N 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  =@JE6'M^97AP"   ]
M)P  &@              @ $^LP$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    "  =@JE6I7\.<>X!  "0)@  $P              @ &2
LM0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     2@!* #T4  "QMP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>214</ContextCount>
  <ElementCount>307</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>66</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/OrganizationandBusiness</Role>
      <ShortName>Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombination</Role>
      <ShortName>Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Certain Balance Sheet Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItems</Role>
      <ShortName>Certain Balance Sheet Items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Long-Term Debt, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/LongTermDebtNet</Role>
      <ShortName>Long-Term Debt, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensation</Role>
      <ShortName>Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Net Income per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/NetIncomepershare</Role>
      <ShortName>Net Income per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Business Combination (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombinationTables</Role>
      <ShortName>Business Combination (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/BusinessCombination</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/FairValueMeasurement</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/Revenue</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Certain Balance Sheet Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsTables</Role>
      <ShortName>Certain Balance Sheet Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/CertainBalanceSheetItems</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Long-Term Debt, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/LongTermDebtNetTables</Role>
      <ShortName>Long-Term Debt, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/LongTermDebtNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/SharebasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/StockholdersEquity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/EarningspershareTables</Role>
      <ShortName>Earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Organization and Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/OrganizationandBusinessDetails</Role>
      <ShortName>Organization and Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/OrganizationandBusiness</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Summary of Significant Accounting Policies - Revenue and Cost of Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue and Cost of Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Business Combination - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombinationNarrativeDetails</Role>
      <ShortName>Business Combination - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Business Combination -Purchase Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails</Role>
      <ShortName>Business Combination -Purchase Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Fair Value Measurement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails</Role>
      <ShortName>Fair Value Measurement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Fair Value Measurement - Contractual Maturities of Available for Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails</Role>
      <ShortName>Fair Value Measurement - Contractual Maturities of Available for Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Fair Value Measurement - Assets Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Assets Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Revenue - Disaggregated Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails</Role>
      <ShortName>Revenue - Disaggregated Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueNarrativeDetails</Role>
      <ShortName>Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Revenue - Accounts Receivable, net and Deferred Revenues from Contracts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails</Role>
      <ShortName>Revenue - Accounts Receivable, net and Deferred Revenues from Contracts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Revenue - Additional Revenue Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails</Role>
      <ShortName>Revenue - Additional Revenue Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Certain Balance Sheet Items - Accounts Receivable, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails</Role>
      <ShortName>Certain Balance Sheet Items - Accounts Receivable, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Certain Balance Sheet Items - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails</Role>
      <ShortName>Certain Balance Sheet Items - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails</Role>
      <ShortName>Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Certain Balance Sheet Items - Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails</Role>
      <ShortName>Certain Balance Sheet Items - Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails</Role>
      <ShortName>Certain Balance Sheet Items - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Goodwill and Intangible Assets - Additional (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Additional (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Goodwill and Intangible Assets - Goodwill Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Goodwill Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Goodwill and Intangible Assets -Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails</Role>
      <ShortName>Goodwill and Intangible Assets -Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Long-Term Debt, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails</Role>
      <ShortName>Long-Term Debt, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Long-Term Debt, Net - Carrying Amount of Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails</Role>
      <ShortName>Long-Term Debt, Net - Carrying Amount of Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Long-Term Debt, Net - Components of Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails</Role>
      <ShortName>Long-Term Debt, Net - Components of Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Share-based Compensation - Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails</Role>
      <ShortName>Share-based Compensation - Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Share-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails</Role>
      <ShortName>Share-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Share-based Compensation - Assumptions Used in the Black-Scholes Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails</Role>
      <ShortName>Share-based Compensation - Assumptions Used in the Black-Scholes Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Share-based Compensation - Unrecognized Estimated Compensation Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails</Role>
      <ShortName>Share-based Compensation - Unrecognized Estimated Compensation Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Stockholders' Equity - Share Repurchase Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/StockholdersEquityShareRepurchaseActivityDetails</Role>
      <ShortName>Stockholders' Equity - Share Repurchase Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Earnings per share - Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/EarningspershareComputationDetails</Role>
      <ShortName>Earnings per share - Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="halo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Earnings per share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/EarningspershareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Earnings per share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife, us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1, us-gaap:StockRepurchaseProgramPeriodInForce1 -  halo-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="halo-20230331.htm">halo-20230331.htm</File>
    <File>ex101-amendmentno2tocredit.htm</File>
    <File>ex31110qq12023.htm</File>
    <File>ex31210qq12023.htm</File>
    <File>ex3210qq12023.htm</File>
    <File>halo-20230331.xsd</File>
    <File>halo-20230331_cal.xml</File>
    <File>halo-20230331_def.xml</File>
    <File>halo-20230331_lab.xml</File>
    <File>halo-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>halo-20230331_g1.jpg</File>
    <File>halo-20230331_g2.jpg</File>
    <File>halo-20230331_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="742">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>87
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "halo-20230331.htm": {
   "axisCustom": 2,
   "axisStandard": 20,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2021-01-31": 742,
    "http://xbrl.sec.gov/dei/2021": 29
   },
   "contextCount": 214,
   "dts": {
    "calculationLink": {
     "local": [
      "halo-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "halo-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "halo-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "halo-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "halo-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "halo-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 526,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 3,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 8
   },
   "keyCustom": 28,
   "keyStandard": 279,
   "memberCustom": 33,
   "memberStandard": 33,
   "nsprefix": "halo",
   "nsuri": "http://www.halozyme.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.halozyme.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Business Combination",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.halozyme.com/role/BusinessCombination",
     "shortName": "Business Combination",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Fair Value Measurement",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.halozyme.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Revenue",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.halozyme.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Certain Balance Sheet Items",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItems",
     "shortName": "Certain Balance Sheet Items",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Goodwill and Intangible Assets",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Long-Term Debt, Net",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.halozyme.com/role/LongTermDebtNet",
     "shortName": "Long-Term Debt, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Share-based Compensation",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.halozyme.com/role/SharebasedCompensation",
     "shortName": "Share-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.halozyme.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Net Income per share",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.halozyme.com/role/NetIncomepershare",
     "shortName": "Net Income per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.halozyme.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "20",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Business Combination (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.halozyme.com/role/BusinessCombinationTables",
     "shortName": "Business Combination (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Fair Value Measurement (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.halozyme.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Revenue (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.halozyme.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Certain Balance Sheet Items (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsTables",
     "shortName": "Certain Balance Sheet Items (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Long-Term Debt, Net (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.halozyme.com/role/LongTermDebtNetTables",
     "shortName": "Long-Term Debt, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Share-based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.halozyme.com/role/SharebasedCompensationTables",
     "shortName": "Share-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.halozyme.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Earnings per share (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.halozyme.com/role/EarningspershareTables",
     "shortName": "Earnings per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "halo:RoyaltiesReceivedNumberOfCollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "collaborator",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Organization and Business (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.halozyme.com/role/OrganizationandBusinessDetails",
     "shortName": "Organization and Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "halo:RoyaltiesReceivedNumberOfCollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "collaborator",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i26d023fcab96411da642d788b3f4972f_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails",
     "shortName": "Summary of Significant Accounting Policies - Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i26d023fcab96411da642d788b3f4972f_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "halo:RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Summary of Significant Accounting Policies - Revenue and Cost of Product Sales (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue and Cost of Product Sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "halo:RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails",
     "shortName": "Summary of Significant Accounting Policies - Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i278958ca21434e13ac5e9b20db531704_D20220524-20220524",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Business Combination - Narrative (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
     "shortName": "Business Combination - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i278958ca21434e13ac5e9b20db531704_D20220524-20220524",
      "decimals": "2",
      "lang": "en-US",
      "name": "halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i278958ca21434e13ac5e9b20db531704_D20220524-20220524",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Business Combination -Purchase Consideration (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails",
     "shortName": "Business Combination -Purchase Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Income (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Fair Value Measurement - Narrative (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails",
     "shortName": "Fair Value Measurement - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Fair Value Measurement - Contractual Maturities of Available for Sale Debt Securities (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails",
     "shortName": "Fair Value Measurement - Contractual Maturities of Available for Sale Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Fair Value Measurement - Assets Measured at Fair Value on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Assets Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Revenue - Disaggregated Revenues (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
     "shortName": "Revenue - Disaggregated Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i4f2e433d91b04a038142f3674a77dbab_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Revenue - Narrative (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.halozyme.com/role/RevenueNarrativeDetails",
     "shortName": "Revenue - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "halo:AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Revenue - Accounts Receivable, net and Deferred Revenues from Contracts (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.halozyme.com/role/RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails",
     "shortName": "Revenue - Accounts Receivable, net and Deferred Revenues from Contracts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "halo:AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "icd9786c1eb264d80a62f434a14aac146_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Revenue - Additional Revenue Information (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails",
     "shortName": "Revenue - Additional Revenue Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "icd9786c1eb264d80a62f434a14aac146_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "halo:Accountsreceivablefromproductsalestocollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Certain Balance Sheet Items - Accounts Receivable, net (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails",
     "shortName": "Certain Balance Sheet Items - Accounts Receivable, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "halo:Accountsreceivablefromproductsalestocollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Certain Balance Sheet Items - Inventories (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails",
     "shortName": "Certain Balance Sheet Items - Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
     "shortName": "Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Certain Balance Sheet Items - Property and Equipment, net (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails",
     "shortName": "Certain Balance Sheet Items - Property and Equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails",
     "shortName": "Certain Balance Sheet Items - Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Goodwill and Intangible Assets - Additional (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
     "shortName": "Goodwill and Intangible Assets - Additional (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i81c6c189dc1c414db846950051a68f58_D20230101-20230331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i18f57f446331441d9650bc51a98fef4b_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Goodwill and Intangible Assets - Goodwill Rollforward (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails",
     "shortName": "Goodwill and Intangible Assets - Goodwill Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Goodwill and Intangible Assets -Future Amortization (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails",
     "shortName": "Goodwill and Intangible Assets -Future Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Long-Term Debt, Net - Narrative (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
     "shortName": "Long-Term Debt, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i3eda99a3ab274f3189aed8a7cd000ecc_D20220801-20220831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Long-Term Debt, Net - Carrying Amount of Convertible Notes (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
     "shortName": "Long-Term Debt, Net - Carrying Amount of Convertible Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i135c9d6e5363476397deb7376556416f_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Long-Term Debt, Net - Components of Interest Expense (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
     "shortName": "Long-Term Debt, Net - Components of Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ic86e248bcecd4584b1f877e96f7336cd_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentPeriodicPaymentInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Share-based Compensation - Share-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails",
     "shortName": "Share-based Compensation - Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Share-based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
     "shortName": "Share-based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Share-based Compensation - Assumptions Used in the Black-Scholes Model (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails",
     "shortName": "Share-based Compensation - Assumptions Used in the Black-Scholes Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i98636a07909a4eb082fd10e5a0c20ab2_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Share-based Compensation - Unrecognized Estimated Compensation Cost (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
     "shortName": "Share-based Compensation - Unrecognized Estimated Compensation Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i98636a07909a4eb082fd10e5a0c20ab2_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i6b2c4a20e00545ee9fa2fa2f54922dfc_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i6f605f48fb46486b8c32365ccf871ecf_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Stockholders' Equity - Share Repurchase Activity (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.halozyme.com/role/StockholdersEquityShareRepurchaseActivityDetails",
     "shortName": "Stockholders' Equity - Share Repurchase Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Earnings per share - Computation (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.halozyme.com/role/EarningspershareComputationDetails",
     "shortName": "Earnings per share - Computation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i4b70d8e746f94570afba56b0ac99fe35_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Earnings per share - Antidilutive Securities (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.halozyme.com/role/EarningspershareAntidilutiveSecuritiesDetails",
     "shortName": "Earnings per share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i38e034be49cf4c1387b7a092a63f997c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "i38e034be49cf4c1387b7a092a63f997c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization and Business",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.halozyme.com/role/OrganizationandBusiness",
     "shortName": "Organization and Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20230331.htm",
      "contextRef": "ibe54a469d5f04835a9d8d192ee5f6635_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 66,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "halo_A025ConvertibleSeniorNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.25% Convertible Senior Notes due 2027",
        "label": "0.25% Convertible Senior Notes due 2027 [Member]",
        "terseLabel": "0.25% Convertible Senior Notes due 2027"
       }
      }
     },
     "localname": "A025ConvertibleSeniorNotesDue2027Member",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_A1.25ConvertibleSeniorNotesdue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.25% Convertible Senior Notes due 2024 [Member]",
        "label": "1.25% Convertible Senior Notes due 2024 [Member]",
        "terseLabel": "1.25% Convertible Senior Notes due 2024"
       }
      }
     },
     "localname": "A1.25ConvertibleSeniorNotesdue2024Member",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_A100ConvertibleSeniorNotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.00% Convertible Senior Notes due 2028",
        "label": "1.00% Convertible Senior Notes due 2028 [Member]",
        "terseLabel": "1.00% Convertible Senior Notes due 2028"
       }
      }
     },
     "localname": "A100ConvertibleSeniorNotesDue2028Member",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_A2021ESPPPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 ESPP Plan",
        "label": "2021 ESPP Plan [Member]",
        "terseLabel": "2021 ESPP Plan"
       }
      }
     },
     "localname": "A2021ESPPPlanMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, after Allowance for Credit Loss, Current, excluding Other Contract Assets",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current, excluding Other Contract Assets",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_Accountsreceivablefromcollaborators": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableGrossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from collaborators, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.",
        "label": "Accounts receivable from collaborators",
        "terseLabel": "Accounts receivable from revenues under collaborative agreements"
       }
      }
     },
     "localname": "Accountsreceivablefromcollaborators",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_Accountsreceivablefromproductsales": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsReceivableGrossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable from product sales",
        "label": "Accounts receivable from product sales",
        "terseLabel": "Accounts receivable from other product sales"
       }
      }
     },
     "localname": "Accountsreceivablefromproductsales",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_Accountsreceivablefromproductsalestocollaborators": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableGrossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable from product sales to collaborators",
        "label": "Accounts receivable from product sales to collaborators",
        "terseLabel": "Accounts receivable from product sales to partners"
       }
      }
     },
     "localname": "Accountsreceivablefromproductsalestocollaborators",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_Accountsreceivablefromroyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsReceivableGrossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from royalties, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.",
        "label": "Accounts receivable from royalties",
        "terseLabel": "Accounts receivable from royalty payments"
       }
      }
     },
     "localname": "Accountsreceivablefromroyalties",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_AccruedLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities, Noncurrent",
        "label": "Accrued Liabilities, Noncurrent",
        "negatedTerseLabel": "Less long-term portion"
       }
      }
     },
     "localname": "AccruedLiabilitiesNoncurrent",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_Accruedmanufacturingexpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued manufacturing expenses",
        "label": "Accrued manufacturing expenses",
        "terseLabel": "Accrued outsourced manufacturing expenses"
       }
      }
     },
     "localname": "Accruedmanufacturingexpenses",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_AllowanceforDistributionFeesandDiscounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for Discount and Distribution Fees",
        "label": "Allowance for Distribution Fees and Discounts",
        "negatedTerseLabel": "Allowance for distribution fees and discounts"
       }
      }
     },
     "localname": "AllowanceforDistributionFeesandDiscounts",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_AnnualInterestPaymentPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Interest Payment Period",
        "label": "Annual Interest Payment Period [Axis]",
        "terseLabel": "Annual Interest Payment Period [Axis]"
       }
      }
     },
     "localname": "AnnualInterestPaymentPeriodAxis",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "halo_AnnualInterestPaymentPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Interest Payment Period [Domain]",
        "label": "Annual Interest Payment Period [Domain]",
        "terseLabel": "Annual Interest Payment Period [Domain]"
       }
      }
     },
     "localname": "AnnualInterestPaymentPeriodDomain",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_AntaresPharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antares Pharma, Inc",
        "label": "Antares Pharma, Inc [Member]",
        "terseLabel": "Antares Pharma, Inc"
       }
      }
     },
     "localname": "AntaresPharmaIncMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_AutoInjectorTechnologyPlatformMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auto Injector Technology Platform",
        "label": "Auto Injector Technology Platform [Member]",
        "terseLabel": "Auto Injector Technology Platform [Member]"
       }
      }
     },
     "localname": "AutoInjectorTechnologyPlatformMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_BaxaltaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baxalta [Member]",
        "label": "Baxalta [Member]",
        "terseLabel": "Baxalta"
       }
      }
     },
     "localname": "BaxaltaMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_BulkrHuPH20Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "bulk rHuPH20 for use in collaboration products",
        "label": "bulk rHuPH20 [Member]",
        "terseLabel": "bulk rHuPH20"
       }
      }
     },
     "localname": "BulkrHuPH20Member",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_BusinessCombinationConsiderationTransferredBonusAwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Bonus Awards",
        "label": "Business Combination, Consideration Transferred, Bonus Awards",
        "terseLabel": "Business Combination, Consideration Transferred, Bonus Awards"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredBonusAwards",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Equity Interests Issuable, Equity Compensation Awards",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issuable, Equity Compensation Awards",
        "terseLabel": "Consideration for Antares equity compensation awards"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share",
        "terseLabel": "Consideration transferred, cash paid per acquiree share (in usd per share)"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination, provisional information, initial accounting incomplete, adjustment, accrued expense",
        "label": "Business combination, provisional information, initial accounting incomplete, adjustment, accrued expense",
        "terseLabel": "Business combination, provisional information, initial accounting incomplete, adjustment, accrued expense"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedExpense",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred tax liabilities, net",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred tax liabilities, net",
        "terseLabel": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred tax liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNet",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net assets Acquired, Excluding Goodwill",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net assets Acquired, Excluding Goodwill",
        "terseLabel": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Net assets Acquired, Excluding Goodwill"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentNetAssetsAcquiredExcludingGoodwill",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other long-term liabilities",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other long-term liabilities",
        "terseLabel": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other long-term liabilities"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherLongTermLiabilities",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Short-Term Investments",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Short-Term Investments",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Short-Term Investments"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Contract with Customer Liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Contract with Customer Liability",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Contract with Customer Liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Accrued Expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Accrued Expenses",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Accrued Expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Contract with Customer Liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Contract with Customer Liability",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Contract with Customer Liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_CollaborativeAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreements [Member]",
        "label": "Collaborative Agreements [Member]",
        "terseLabel": "Revenues under collaborative agreements",
        "verboseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeAgreementsMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_ComputerAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer and office equipment.",
        "label": "Computer and Office Equipment [Member]",
        "terseLabel": "Computer and office equipment"
       }
      }
     },
     "localname": "ComputerAndOfficeEquipmentMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DebtInstrumentCapCallTransactionCapPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Cap Call Transaction, Cap Price Per Share",
        "label": "Debt Instrument, Cap Call Transaction, Cap Price Per Share",
        "terseLabel": "Cap call transaction, cap price per share (in usd per share)"
       }
      }
     },
     "localname": "DebtInstrumentCapCallTransactionCapPricePerShare",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "halo_DebtInstrumentConvertibleThresholdConsecutiveBusinessDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Threshold Consecutive Business Days",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Business Days",
        "terseLabel": "Convertible, threshold consecutive business days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveBusinessDays",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "halo_DebtInstrumentInterestPeriodFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest, Period Four",
        "label": "Debt Instrument, Interest, Period Four [Member]",
        "terseLabel": "Year four"
       }
      }
     },
     "localname": "DebtInstrumentInterestPeriodFourMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DebtInstrumentInterestPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest, Period One",
        "label": "Debt Instrument, Interest, Period One [Member]",
        "terseLabel": "Year one"
       }
      }
     },
     "localname": "DebtInstrumentInterestPeriodOneMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DebtInstrumentInterestPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest, Period Three",
        "label": "Debt Instrument, Interest, Period Three [Member]",
        "terseLabel": "Year three"
       }
      }
     },
     "localname": "DebtInstrumentInterestPeriodThreeMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DebtInstrumentInterestPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest, Period two",
        "label": "Debt Instrument, Interest, Period two [Member]",
        "terseLabel": "Year two"
       }
      }
     },
     "localname": "DebtInstrumentInterestPeriodTwoMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DeferredRentPayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Rent Payments",
        "label": "Deferred Rent Payments",
        "negatedTerseLabel": "Lease payments recognized (deferred)"
       }
      }
     },
     "localname": "DeferredRentPayments",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_DevelopmentFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Fees [Member]",
        "label": "Development Fees [Member]",
        "terseLabel": "Event-Based Development Fees"
       }
      }
     },
     "localname": "DevelopmentFeesMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DeviceLicensingAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Device Licensing and Development",
        "label": "Device Licensing and Development [Member]",
        "terseLabel": "Device Licensing and development revenue"
       }
      }
     },
     "localname": "DeviceLicensingAndDevelopmentMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DevicePartneredProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Device Partnered Products",
        "label": "Device Partnered Products [Member]",
        "terseLabel": "Device Partnered Products"
       }
      }
     },
     "localname": "DevicePartneredProductsMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, Yea, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Yea, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and Intangible Assets and Other Long-Lived Assets Policy",
        "label": "Goodwill and Intangible Assets and Other Long-Lived Assets Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets and Other Long-Lived Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "halo_JanssenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Collaboration [Member]",
        "label": "Janssen [Member]",
        "terseLabel": "Janssen"
       }
      }
     },
     "localname": "JanssenMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_LicenseFeesAndEventBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Fees And Event-Based [Member]",
        "label": "License Fees And Event-Based [Member]",
        "terseLabel": "License Fees And Event-Based"
       }
      }
     },
     "localname": "LicenseFeesAndEventBasedMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_ManufacturingEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing Equipment [Member]",
        "label": "Manufacturing Equipment [Member]",
        "terseLabel": "Manufacturing equipment"
       }
      }
     },
     "localname": "ManufacturingEquipmentMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_OperatingLeaseAccretionOfLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Accretion Of Liability",
        "label": "Operating Lease, Accretion Of Liability",
        "terseLabel": "Expense associated with accretion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseAccretionOfLiability",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_OthercollaboratorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other collaborators [Member]",
        "label": "Other collaborators [Member]",
        "terseLabel": "Other collaborators"
       }
      }
     },
     "localname": "OthercollaboratorsMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_PaymentForCappedCallTransactions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for Capped Call Transactions",
        "label": "Payment for Capped Call Transactions",
        "terseLabel": "Payment for capped calls"
       }
      }
     },
     "localname": "PaymentForCappedCallTransactions",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From (Payments) for Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "label": "Proceeds From (Payments) for Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "label": "Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_ProprietaryProductsSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proprietary Products Sales",
        "label": "Proprietary Products Sales [Member]",
        "terseLabel": "Proprietary Products Sales"
       }
      }
     },
     "localname": "ProprietaryProductsSalesMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_RSURSAandPRSUawardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Unit, Restricted Stock Awards, and Performance Restricted Stock Unit awards [Member]",
        "label": "RSU, RSA, and PRSU awards [Member]",
        "verboseLabel": "RSUs, PSUs and ESPP"
       }
      }
     },
     "localname": "RSURSAandPRSUawardsMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_ResearchEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research equipment.",
        "label": "Research Equipment [Member]",
        "terseLabel": "Research equipment"
       }
      }
     },
     "localname": "ResearchEquipmentMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_RestrictStockUnitsPerformanceSharesAndESPPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restrict Stock Units, Performance Shares and ESPP",
        "label": "Restrict Stock Units, Performance Shares and ESPP [Member]",
        "terseLabel": "RSUs, PSUs and ESPP"
       }
      }
     },
     "localname": "RestrictStockUnitsPerformanceSharesAndESPPMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Period Of Termination By Written Notice",
        "label": "Revenue, Remaining Performance Obligation, Period Of Termination By Written Notice",
        "terseLabel": "Period of contract termination by written notice"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "halo_RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche",
        "label": "Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "RocheMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_RoyaltiesReceivedNumberOfCollaborators": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties Received, Number of Collaborators",
        "label": "Royalties Received, Number of Collaborators",
        "terseLabel": "Royalties received, number of collaborators"
       }
      }
     },
     "localname": "RoyaltiesReceivedNumberOfCollaborators",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "halo_RoyaltiesReceivedNumberOfProductsSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties Received, Number of Products Sold",
        "label": "Royalties Received, Number of Products Sold",
        "terseLabel": "royalties received, number of products sold"
       }
      }
     },
     "localname": "RoyaltiesReceivedNumberOfProductsSold",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "halo_SaleOfStockPremiumOverLastReportedSalePricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock Premium Over Last Reported Sale Price, Percentage",
        "label": "Sale of Stock Premium Over Last Reported Sale Price, Percentage",
        "terseLabel": "Sale of stock premium over last reported sale price, percentage"
       }
      }
     },
     "localname": "SaleOfStockPremiumOverLastReportedSalePricePercentage",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "halo_SalesbasedmilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-based milestone [Member]",
        "label": "Sales-based milestone [Member]",
        "terseLabel": "Sales-based milestone"
       }
      }
     },
     "localname": "SalesbasedmilestoneMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]",
        "label": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]"
       }
      }
     },
     "localname": "ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]",
        "label": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]"
       }
      }
     },
     "localname": "ScheduleofSharebasedCompensationArrangementsValuationInputsTable",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "terseLabel": "Maximum contribution amount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate",
        "terseLabel": "Minimum employee subscription rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "terseLabel": "Purchase period (in months)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "halo_ShareBasedCompensationAwardUnvestedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Award, Unvested",
        "label": "Share-based Compensation Award, Unvested [Member]",
        "terseLabel": "Equity Compensation Award, Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardUnvestedMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_ShareBasedCompensationAwardsVestedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Awards, Vested",
        "label": "Share-based Compensation Awards, Vested [Member]",
        "terseLabel": "Equity Compensation Awards, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardsVestedMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_StockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options And Restricted Stock Units [Member]",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "terseLabel": "Stock options and restricted units"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_TLANDOProductRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TLANDO, Product Rights",
        "label": "TLANDO, Product Rights [Member]",
        "terseLabel": "TLANDO, Product Rights [Member]"
       }
      }
     },
     "localname": "TLANDOProductRightsMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_TermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Facility",
        "label": "Term Loan Facility [Member]",
        "terseLabel": "Term Loan Facility"
       }
      }
     },
     "localname": "TermLoanFacilityMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_TreasuryStockAcquiredFeeCostPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury Stock Acquired, Fee Cost Per Share",
        "label": "Treasury Stock Acquired, Fee Cost Per Share",
        "terseLabel": "Fee per share (usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredFeeCostPerShare",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityShareRepurchaseActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "halo_UpfrontfeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fees [Member]",
        "label": "Upfront fees [Member]",
        "terseLabel": "Upfront License Fees"
       }
      }
     },
     "localname": "UpfrontfeesMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_VariableRateComponentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Rate Component",
        "label": "Variable Rate Component [Axis]",
        "terseLabel": "Variable Rate Component [Axis]"
       }
      }
     },
     "localname": "VariableRateComponentAxis",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "halo_VariableRateComponentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Rate Component [Domain]",
        "label": "Variable Rate Component [Domain]",
        "terseLabel": "Variable Rate Component [Domain]"
       }
      }
     },
     "localname": "VariableRateComponentDomain",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_VariableRateComponentOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Rate Component One",
        "label": "Variable Rate Component One [Member]",
        "terseLabel": "Variable Rate Component One"
       }
      }
     },
     "localname": "VariableRateComponentOneMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_VariableRateComponentTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Rate Component Two",
        "label": "Variable Rate Component Two [Member]",
        "terseLabel": "Variable Rate Component Two"
       }
      }
     },
     "localname": "VariableRateComponentTwoMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_XYOSTEDProprietaryProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XYOSTED Proprietary Product",
        "label": "XYOSTED Proprietary Product [Member]",
        "terseLabel": "XYOSTED Proprietary Product [Member]"
       }
      }
     },
     "localname": "XYOSTEDProprietaryProductMember",
     "nsuri": "http://www.halozyme.com/20230331",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r263",
      "r264",
      "r380",
      "r400",
      "r565",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r447",
      "r532",
      "r552",
      "r561",
      "r562",
      "r581",
      "r594",
      "r598",
      "r625",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r447",
      "r532",
      "r552",
      "r561",
      "r562",
      "r581",
      "r594",
      "r598",
      "r625",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r323",
      "r535",
      "r582",
      "r597",
      "r628",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r323",
      "r535",
      "r582",
      "r597",
      "r628",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r440",
      "r447",
      "r508",
      "r532",
      "r552",
      "r561",
      "r562",
      "r581",
      "r594",
      "r598",
      "r625",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r440",
      "r447",
      "r508",
      "r532",
      "r552",
      "r561",
      "r562",
      "r581",
      "r594",
      "r598",
      "r625",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r263",
      "r264",
      "r380",
      "r400",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r596"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r326",
      "r327"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "totalLabel": "Total accounts receivable and contract assets"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r239",
      "r326",
      "r327",
      "r564"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Total accounts receivable, net and contract assets",
        "verboseLabel": "Accounts receivable, net and contract assets"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of (premium) discounts on marketable securities, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Total accrued expenses, current",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r35",
      "r132"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r57",
      "r59",
      "r60",
      "r240",
      "r547",
      "r557",
      "r558"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r56",
      "r60",
      "r199",
      "r553",
      "r554",
      "r563",
      "r605",
      "r606",
      "r607",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income/(Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average useful life (in years)"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r448",
      "r449",
      "r450",
      "r611",
      "r612",
      "r613",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r156",
      "r158",
      "r175",
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash provided by in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AgencySecuritiesMember": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities issued by government sponsored entities.",
        "label": "Agency Securities [Member]",
        "terseLabel": "Agency Securities"
       }
      }
     },
     "localname": "AgencySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r158",
      "r169",
      "r174"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r67",
      "r82",
      "r207",
      "r392"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Total amortization of debt discount",
        "verboseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r82",
      "r120",
      "r127"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangibles"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive shares excluded from per share calculation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r589",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r214",
      "r228",
      "r261",
      "r308",
      "r317",
      "r321",
      "r337",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r469",
      "r471",
      "r480",
      "r596",
      "r623",
      "r624",
      "r638"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r53",
      "r261",
      "r337",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r469",
      "r471",
      "r480",
      "r596",
      "r623",
      "r624",
      "r638"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Fair value of assets measured on a recurring basis"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses",
        "terseLabel": "Unrealized loss position of debt securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r329",
      "r344"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r103",
      "r332",
      "r545"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year but within five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r103",
      "r331",
      "r544"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r100",
      "r328",
      "r344",
      "r539"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale marketable securities",
        "totalLabel": "Estimated Fair Value",
        "verboseLabel": "Debt securities, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r99",
      "r344"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r159",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails",
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r182",
      "r183",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r190",
      "r191",
      "r194"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred",
        "totalLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r190",
      "r191"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r188",
      "r190",
      "r191",
      "r466"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Business Combination, Consideration Transferred, Liabilities Incurred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredOther1": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.",
        "label": "Business Combination, Consideration Transferred, Other",
        "terseLabel": "Business Combination, Consideration Transferred, Other"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredOther1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r468",
      "r608"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "negatedLabel": "Change in amount of contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r189",
      "r192",
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration, liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r189",
      "r193"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combination"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombination"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles",
        "terseLabel": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory",
        "terseLabel": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "verboseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r184",
      "r185"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r184",
      "r185"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Total"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r184",
      "r185"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Amounts accrued for purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash acquired"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r33",
      "r84"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r11",
      "r85",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents and Marketable Securities and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r79",
      "r84",
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r79",
      "r206"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r47",
      "r135",
      "r218",
      "r233"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r134",
      "r136",
      "r366",
      "r367",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r611",
      "r612",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19",
      "r596"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock, Value, Issued"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r61",
      "r245",
      "r247",
      "r254",
      "r541",
      "r549"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r198",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of accounts receivable, deferred revenues from contracts with customers, and amounts under collaborative agreements included in transaction price"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r414",
      "r415",
      "r436"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsReceivableGrossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Contract assets",
        "verboseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails",
      "http://www.halozyme.com/role/RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerRefundLiabilityCurrent": {
     "auth_ref": [
      "r629"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.",
        "label": "Contract with Customer, Refund Liability, Current",
        "terseLabel": "Product returns and sales allowance"
       }
      }
     },
     "localname": "ContractWithCustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r139",
      "r377",
      "r378",
      "r383",
      "r384",
      "r385",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r589",
      "r591",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r65",
      "r535"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "verboseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Operating expenses"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r86",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "verboseLabel": "Amount paid for conversion of debt instrument"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r86",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Stock issued for conversion of debt instrument (shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r215",
      "r216",
      "r226",
      "r265",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r491",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/EarningspershareComputationDetails",
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r142",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt, convertible, conversion price (in usd per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r43",
      "r145",
      "r146",
      "r148",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt, convertible, conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "terseLabel": "Remaining amortization per period of debt discount (in years):"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Convertible, threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Convertible, threshold percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Convertible, threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r208",
      "r210",
      "r377",
      "r491",
      "r577",
      "r578"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Total Principal Amount",
        "verboseLabel": "Aggregate principal"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r385",
      "r479",
      "r577",
      "r578"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Total fair value of outstanding notes"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Lenders fee"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r42",
      "r208",
      "r396",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rates"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r42",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r45",
      "r265",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r491",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/EarningspershareComputationDetails",
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to interest.",
        "label": "Debt Instrument, Periodic Payment, Interest",
        "terseLabel": "Total coupon interest"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r45",
      "r145",
      "r147",
      "r148",
      "r149",
      "r207",
      "r208",
      "r210",
      "r225",
      "r265",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r491",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r207",
      "r210",
      "r626"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Total unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r209",
      "r383",
      "r394",
      "r577",
      "r578"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Unamortized debt issuance cost"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r330",
      "r344",
      "r349",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of available-for-sale marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r335",
      "r345",
      "r575"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair market value of gross unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r336",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of loss positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).",
        "label": "Deferred Credits and Other Liabilities",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).",
        "label": "Deferred Credits and Other Liabilities, Current",
        "verboseLabel": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r454",
      "r455"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r82",
      "r306"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r435",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of disaggregation of revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r255",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r279",
      "r281",
      "r287",
      "r288",
      "r289",
      "r293",
      "r475",
      "r476",
      "r542",
      "r550",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r255",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r281",
      "r287",
      "r288",
      "r289",
      "r293",
      "r475",
      "r476",
      "r542",
      "r550",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareDilutedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Earnings per share:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomepershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and payroll taxes"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized Expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Remaining Weighted-Average Recognition Period (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails",
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r144",
      "r237",
      "r249",
      "r250",
      "r251",
      "r266",
      "r267",
      "r268",
      "r270",
      "r276",
      "r278",
      "r296",
      "r338",
      "r413",
      "r448",
      "r449",
      "r450",
      "r462",
      "r463",
      "r474",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r489",
      "r553",
      "r554",
      "r555",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination.",
        "label": "Equity Interest Type [Axis]",
        "terseLabel": "Equity Interest Type [Axis]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.",
        "label": "Equity Interest Issued or Issuable, Type [Domain]",
        "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r200",
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r385",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r477",
      "r505",
      "r506",
      "r507",
      "r577",
      "r578",
      "r589",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r385",
      "r441",
      "r446",
      "r477",
      "r505",
      "r589",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r385",
      "r441",
      "r446",
      "r477",
      "r506",
      "r577",
      "r578",
      "r589",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r385",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r477",
      "r507",
      "r577",
      "r578",
      "r589",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r385",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r505",
      "r506",
      "r507",
      "r577",
      "r578",
      "r589",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "verboseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Fed Funds Rate"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r494",
      "r498",
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Right-of-use asset amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r333",
      "r334",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r347",
      "r348",
      "r351",
      "r393",
      "r411",
      "r473",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r575",
      "r618",
      "r619",
      "r620",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-Lived Intangible Asset, Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r357",
      "r360",
      "r361",
      "r363",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r126",
      "r537"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r121",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r126",
      "r536"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Net Carrying Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Finite-lived intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r113",
      "r114",
      "r538",
      "r596"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Measurement period adjustment"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r116",
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Goodwill, Purchase Accounting Adjustments"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsGoodwillRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r62",
      "r211",
      "r219",
      "r235",
      "r308",
      "r316",
      "r320",
      "r322",
      "r543",
      "r574"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r262",
      "r277",
      "r278",
      "r307",
      "r456",
      "r464",
      "r465",
      "r551"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "verboseLabel": "Income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r248",
      "r452",
      "r453",
      "r458",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net and other contract assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r533",
      "r608"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Recognition of deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Dilutive potential common stock outstanding (shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r359",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "ATRS-1902 (IPR&amp;D)"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r123",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IndefinitelivedIntangibleAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.",
        "label": "Indefinite-lived Intangible Assets Acquired",
        "terseLabel": "Indefinite-lived intangible assets acquired"
       }
      }
     },
     "localname": "IndefinitelivedIntangibleAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InducedConversionOfConvertibleDebtExpense": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.",
        "label": "Induced Conversion of Convertible Debt Expense",
        "terseLabel": "Induced conversion expense related to convertible notes"
       }
      }
     },
     "localname": "InducedConversionOfConvertibleDebtExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r119",
      "r124"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Total intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r209",
      "r221",
      "r252",
      "r305",
      "r490"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r67",
      "r390",
      "r397",
      "r579",
      "r580"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Total interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Interest Income and Interest Expense Disclosure"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r25",
      "r112"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r1",
      "r51",
      "r596"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories, net",
        "verboseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r52",
      "r295",
      "r352",
      "r353",
      "r354",
      "r534",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r27",
      "r112"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r26",
      "r112"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of contractual maturities of available-for-sale debt securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r39",
      "r261",
      "r337",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r470",
      "r471",
      "r472",
      "r480",
      "r573",
      "r623",
      "r638",
      "r639"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r217",
      "r231",
      "r596",
      "r610",
      "r621",
      "r636"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r261",
      "r337",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r470",
      "r471",
      "r472",
      "r480",
      "r596",
      "r623",
      "r638",
      "r639"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r17",
      "r216",
      "r229",
      "r384",
      "r395",
      "r577",
      "r578"
     ],
     "calculation": {
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Long-term debt, excluding current maturities"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Long-Term Debt, Net"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r45",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r297",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "verboseLabel": "Organization and Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r79",
      "r80",
      "r83"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r63",
      "r83",
      "r220",
      "r234",
      "r238",
      "r244",
      "r246",
      "r251",
      "r261",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r277",
      "r278",
      "r286",
      "r308",
      "r316",
      "r320",
      "r322",
      "r337",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r476",
      "r480",
      "r574",
      "r623"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Adoption and Pending Adoption of Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r308",
      "r316",
      "r320",
      "r322",
      "r574"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r499",
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Total operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r495",
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts related to leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails": {
       "order": 2.0,
       "parentTag": "halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right of use of assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r40"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r14",
      "r213",
      "r227"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r111",
      "r253",
      "r482",
      "r487",
      "r489",
      "r540",
      "r548",
      "r605",
      "r606"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Tax",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r55",
      "r58",
      "r481",
      "r488"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "negatedTerseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r242",
      "r243"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Investment and other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r2",
      "r4",
      "r622"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Payment of debt issuance cost"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "terseLabel": "Payments for tax withholding for restricted stock units vested, net"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r71",
      "r98",
      "r256"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r159",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18",
      "r596"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "totalLabel": "Total prepaid expenses and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r31",
      "r32"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Total prepaid expenses and other assets, current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "auth_ref": [
      "r14",
      "r213",
      "r227"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "negatedTerseLabel": "Less: Long-term portion",
        "verboseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r2",
      "r4",
      "r355",
      "r356"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid manufacturing expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from convertible debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Proceeds from revolving credit facilities"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r69",
      "r98",
      "r256"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r74",
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Net proceeds from stock options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r35",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r34",
      "r131"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r133",
      "r232",
      "r546",
      "r596"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails": {
       "order": 1.0,
       "parentTag": "halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "terseLabel": "Repayments of convertible debt"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments of Secured Debt",
        "negatedLabel": "Repayment of 2024 Convertible Notes"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r178",
      "r236",
      "r646"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r6",
      "r14",
      "r84",
      "r89",
      "r559"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units",
        "verboseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r150",
      "r230",
      "r451",
      "r556",
      "r558",
      "r596"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r237",
      "r266",
      "r267",
      "r268",
      "r270",
      "r276",
      "r278",
      "r338",
      "r448",
      "r449",
      "r450",
      "r462",
      "r463",
      "r474",
      "r553",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r303",
      "r304",
      "r315",
      "r318",
      "r319",
      "r323",
      "r324",
      "r325",
      "r434",
      "r435",
      "r535"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r439",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "verboseLabel": "Revenue and Cost of Product Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r424",
      "r425",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Deferred revenue, remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Deferred revenue, remaining performance obligation, expected timing"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r501",
      "r595"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of accounts receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of acquired indefinite-lived intangible assets. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. Indefinite-lived assets are assets that are not subject to amortization. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total.",
        "label": "Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table Text Block]",
        "terseLabel": "Schedule of Acquired Indefinite-lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r222",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r182",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r182",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expense by type"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of numerators and denominators of basic and diluted computations"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "auth_ref": [
      "r91",
      "r93",
      "r281",
      "r285",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r158",
      "r168",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r158",
      "r168",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r121",
      "r125",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r121",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r10",
      "r28",
      "r29",
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Schedule of Other Assets [Table Text Block]",
        "terseLabel": "Schedule of prepaid expenses and other assets"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r35",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r159",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used in Black-Scholes model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table Text Block]",
        "terseLabel": "Schedule of share repurchases"
       }
      }
     },
     "localname": "ScheduleOfTreasuryStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "terseLabel": "Schedule of unrecognized estimated compensation cost by type"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "SOFR"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Share-based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee subscription rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r162",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "verboseLabel": "Outstanding stock options and restricted stock units (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r157",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/EarningspershareComputationDetails",
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Stock options weighted average exercise price (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r159",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r165",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Average expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "ESPP purchase price of common stock, percent of market price"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Equity, ending balance (in shares)",
        "periodStartLabel": "Equity, beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "verboseLabel": "Number of RSUs withheld to pay for minimum withholding taxes (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r90",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r49",
      "r144",
      "r237",
      "r249",
      "r250",
      "r251",
      "r266",
      "r267",
      "r268",
      "r270",
      "r276",
      "r278",
      "r296",
      "r338",
      "r413",
      "r448",
      "r449",
      "r450",
      "r462",
      "r463",
      "r474",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r489",
      "r553",
      "r554",
      "r555",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r296",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Common stock issued for conversion of 2024 Convertible Notes"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r48",
      "r144",
      "r145",
      "r150",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for the induced conversion related to convertible notes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r18",
      "r19",
      "r144",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Stock issued during period, shares, restricted stock award, net of forfeitures (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r144",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r144",
      "r150",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Number of shares of common stock issued as a result of stock option exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r49",
      "r144",
      "r150"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for the induced conversion related to convertible notes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r49",
      "r144",
      "r150"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock and performance stock units, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount (shares)"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramPeriodInForce1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Stock Repurchase Program, Period in Force",
        "terseLabel": "Stock Repurchase Program, period"
       }
      }
     },
     "localname": "StockRepurchaseProgramPeriodInForce1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r18",
      "r19",
      "r144",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Repurchase of common stock (shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r18",
      "r19",
      "r144",
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r18",
      "r19",
      "r144",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Total Number of Shares Purchased (shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityShareRepurchaseActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r22",
      "r23",
      "r97",
      "r596",
      "r610",
      "r621",
      "r636"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Equity, ending balance",
        "periodStartLabel": "Equity, beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit) (textual)",
        "verboseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r155",
      "r260",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Certain Balance Sheet Items"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItems"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r333",
      "r334",
      "r393",
      "r411",
      "r473",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r618",
      "r619",
      "r620",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Weighted-average price paid per share (usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails",
      "http://www.halozyme.com/role/StockholdersEquityShareRepurchaseActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r19",
      "r144",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Stock repurchased (shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r144",
      "r150",
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "terseLabel": "Stock repurchased",
        "verboseLabel": "Total Cost"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails",
      "http://www.halozyme.com/role/StockholdersEquityShareRepurchaseActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r571",
      "r589",
      "r591",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r298",
      "r299",
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r280",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (shares)",
        "verboseLabel": "Weighted average common shares outstanding for diluted net income (loss) per share (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r279",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (shares)",
        "verboseLabel": "Weighted average common shares outstanding for basic net income (loss) per share (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.halozyme.com/role/EarningspershareComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467568&loc=d3e6835-112609",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=SL65897772-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r601": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r602": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r603": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r604": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130611-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0001159036-23-000039-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001159036-23-000039-xbrl.zip
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M\5I;<D+_,9! G5FQ;WH=GKUP3ST^,B _? A _EYPBI@_68T5L1H18*?)II1
M&0; EX 9JN11417XBX);AH86G2=L/"Y([XXF\/X7!? GO7_QCN222S)S*9_=
ML_DE@P!1E0 /:'(&3,_>^'1K:BV;Y![KW/X=M<&070]&P_[5%:-W;YR_+;VO
M3_E-#J<+Q2NL8YV,LA0G&:7G)O0FN]A,P0CX$[';\Z2#EUBX3G6@RRV'+02
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MZ>7]U9\#+'9$[C1IC3E4B=UN09X,P9?20 5T^/"6APT7I;E;@]E,H#T.;S3
M<\!<L$N8RU@S#><F+&CGG15OKN5>[#V"*RFE*]]/- 5_+7_>HW6BC,6N=.:)
MNHR/BOY(#W38ZRU=0D0QLM@=Z<QPW#&!.S2@\X0H6=KU)K5JS,VRV"#^<ZB'
MP"4&-Q\9:<^9%-<@LQ.$._+%OSQ%?PWI.[85:SZ+K9@[65RND.**I(@SUU&Z
MXBO"V2-JCXTR=FD:QU+6*FV6Z=[=0)63B; 6X!L98:BPH*#V0*!]3LEKQ#(2
ML"&"Q[]44"\6(/R1"#3?+;8D\MU!PYN7'=??E^;I)(A*1H%0HUTN[9=] 8B-
M+%4O=SXSX->4>].2S65?5VRZX\[%J="C$)=M4M(SAGMXC0?8T<"2UK:B,RM1
ML0M"#"O)8EH &,S^)ID@0'"6G#-9.KGW_.Q9)?<=W!)1#@\U$D<1XPZ.ZQ Y
M[G@Z@U@Q38$BFBHY!<J#$1]EI^PZHT>8Q%+- 5MG8Y5R(K\%8 3<DQ0)W@8,
MGG@NV[D"^6JO^K:2B_Q2L%FWH<M:A[@60)?05,EC YW%EP-,(['D\XZ(W(BN
MTT&F:ZBL51-2=S"E7(0U3/:[KX-WVIS]F-]N>_O-.OV>;S7^#Q8#9S_U>^ZG
M_K(--MM:7J7=WMI:\:I;V[ZEM;;OM=[N/[G:NM?<;SZYUFK=:^]O;_[N.5B$
MY-%:O]56\ZJ-VM-/;,-KM?(96W8(TPN!Q2+)4$];.6EB'KTKU L+F8R'.A56
M=5*+,7YRT6PF'^I3BV^HU_H3+$3H&Z2@XG\^Q[EGB$[I=.)V;?CP3.3T*F6Y
M'^381SYG[:)[;NL1GCT"#C]T$O9SS<&=O/?B_B[[E!/7K_8:6(*YSWP/.]WR
M/R=M_>0X>''_9W0_*_1I&X N,?=;(UN8][T.[] CDFXV\E#&G0>)7WCC9>&\
MN+_C/N5<_I<:C*"C-7>2M^4IZ,V*H>P.-S:.<>YY[6"-[^Z\N1"K]-6-3OK$
MQQ0VWF58$;$[/*FLNO ALG%BMW?9]F#]UA<CLL_T-0WWPLC1_P!02P,$%
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MA,\5D0$YIZ'\8Q%Q,IIR11.>&N'K,AG&OD= Q(A@0<R4FC=[[8/#HEA-*&/
M))60!Z;7W,_1*V(& >]5 /;M;S8_=2_WXI\?_>[$-%HX"4,RI3-.%)\)/@<.
M-E.AR<\I5; RP@6YYHE4ALB8G$D5D7JM\O,C88-(=0M%:G_'(]78L4A]H!KB
M Y&(%N0VEO.0LPDL+ALPY<+$)!@02\BHH)^*F-!X0=+8J)2#_9!C;;J%^%$2
MP97"Q1A0'V[!8HR$(48ZN0V!F/M<:ZH6*!+16P[CKNG4<(^!,3!D:',UC($"
MOE"0FT$LANY@"8-5/Y\*?TITBA^K_G.N>*8$'8B$#B&)8STP%V8*#NJ$^]9
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M(YQW/-S9_ZL%C'"Z\VX7"+&;-=^!3KA*^N!PV'CW=P9$;84_=X='G_R9)4R
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MJZD1)D@KYT?WT=N&XQ0S*+]Z>-CE62MS6;\1VA8>X3,X6JY!7<,24,GIFBV
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M9\'U@]_/VG#*3MR#7WO1N'1L;ZR&2B+^_C0W7O?==)\1Z5BA!I_V21/&FYK
MY>$Z'<$%Y8I$GGJ2@=1K0:R@,7A@-";=HKGNZVHY!?5"WA]^:,$4)#/ZGT%6
M8*(_ADEC3_?/#;V0UB<G9U1$,PBE%8K826DDD]18K&QP1&+XJ /BR[]:O*PT
MFF$]*RJEH%Q0@*,,C*JFC'GP+T4 9\/%"NRU?#R-&J8S2!IOD(,&K)HP)<V&
MD1:*I_Z+CAMEE!#6R!01<"X\)V%: *%F)U%8:NX\XDXK#N!4:&\4F"KB(T!3
MABI0(>[QA'K3;9\-^B&'DW9B!"!;-:EB,@IPZQSBX$88AL%M-QQ(YS&X[\I4
MH/3CTA-KAIF=1%/-4F-3%9EVVGKN:&K@8"0*451@5]6CB#4^^7TPO7#2;?GM
M]EG>/2]<]ZJXYTQ0(:0/TFC%D-=*22LTL1K!_[BH0*+@DI-JAON+F-;(&:,C
M]BR&8(706 3&6.16R!&I5IW6'TF6&\W3?Z0](-?! [XC,EFFU-9"I8;.7"53
MY;"I2!1Y-P4=2VJDKXVLD[4'[><8*%;8"8>5]@X[AIFWB@G-$>+8"!6YJBC!
MS.5S)1A+T0@KA22:,(Z(<5H@1:T%^,Z]U!4@V-0.RZP?WF?GP6^#NNL<9[85
MBC+;O3^&#7/:S=^T3*\WK14'_>YVYS2X?C??#^ZDTVUUCY.QZZ?0X7,D-U@V
MRC3B(?!4J,&:5(2, C9ABB!JJK#G;NFI_"18T@ \(<%+%HQGC'(044TQ!^3/
MI;*6/&LY_9_#G;W]K<V[&:#/442-09A[Q!DRJ?N;U#8E*OG(!4/@EU? P5MJ
M C]-"5!.J0A8<A(B ^?<*FM$))H;Q*13_EE+Y_[[C>;FSHA@N]GQR?-,XP7Z
M@J'D1@1MF1?"*D2=Y8$I:3@/SU(NYT+:IUDIH)X%[V04W#&! >!0[*77(;J4
MOJM'#KU:7FJ][W:.^R%OI[+O=X,M;[J=\Y#W$P73";.J%I+N=;M 20FB,$)3
MS]P+G:R;-[O]T-L<!)A*]=01!34COO B4BUT$$XQ(J(!AY4Y%Y1F002.1JF&
M:IQJN&*0Y660VUF.ZO%9CFI&NZX85EY&8!\?@9N4H9C&H$)JS,[):)_.BIOF
MSTW?.8+=X$/[+,5./Q1,<',2OGSN3B<\$Q8? $PH^+N?&Y]UCO_Q9CAAVW91
M3SN49)HZ87RO\?'Q]W2S!SQ:1B5F-!C*F471"A&="B W1D7C]4IVYL6Y^Q?=
MI1?HRLF.':W'/"@[XQ,VOT-VF!5* JR-$A%&"%%>1R,D)81BY@)=?G2[3(SR
M)$#3(0INH1:DR/_UT6J#)=$T2(=11+A"ZFV9:+5XS*<D]T8'99V(C,F@J*/<
M.^>P=8&SB6>)^8J>WRY[F,\B'*<E4: C+<4I 9\939E3*04W"B-'H1J\S*&:
M)4 4TWR!"/\27\@GY0L\NX0<;1P+&#G,,8,OADHDF.3"QJB1*+>. E^4.GFI
M&629:'5#)Q?4>IQ.QC.+S5I.'5%*(Q<\,SPH;#%!@2M&J&>*5HBP/[WD+YZ;
M! F(!4=94(QQ80"Y.>QT!& MO*1JQ4T+XJ8%^,9/']59"(LCPS$6VAFP@4P%
MT)Q"4!&M4B8B@^2*Q7\>%O]Z^*>2+*Z5(LAX*RTX =%8E7)[7?H0+3C@A9^&
M-<84K3C[<<[A^D.L[0O69D_I!6!=Q[A.T2R\0^NQM*G@86IAY+6V43N;DJH,
M>.VN*.&4&*/0?<O-(4M%K&F1+\GU*)&_3=D?$'FBN64\.,,B8EHJXP58M%0T
MSS#DM*T095>ROWAV<E%C)7 @5 JF&1@.(9D31G =+7=XQ4Z+8J?GZ @LAL>M
M$YH[%;1/F6Q8:N<<531B(04PMEOQ^$_$XT_N"2R&QQ%P&K*&J505Q1!LF?#:
M>RJP0\9,HH-X[.SBE;-;#5B0O,7')@(7I\YF =!%;F-4+$C%2# 6!\U,X%(@
M  8RC%:75ERTQ%QT<WD)SV@3L=41(\DCX8R)0!67H%Z,10)33D5<0%"M$I&:
M:)U%)C"M &=3H;5TVA.;,ELP%A[?TL_SV##_I(KHQJ;U'RF;&KS1VE!C22K_
MAY4VP2LCG8>7"\XM(,7D6^=M(1D<DF-L??"4(\RP=)8%PC W OC04SWN/4/G
MN%OG6^>-/EY.9[D#AF)BP=AQ0Q@BWI)()=5I*Z**TE>@"NBRVJ#9[7M1Q"$6
MO#?6<18EUTY'RWS@(EI$(UO^FB/+2J,9MJDU)@;!M,&$,8.$!15$L8D,5(Z/
MUE=9CA::*33+JHU81(X)P)+  I8:&:&ILP%0B56X B6QEI1$LY,BPH4/(#F(
M HDTIFF'G^3,@2NFL3"FRE*TT#S,V4D1%L* 0XR0T8@9P E<<0!:TD0M<!05
MJ'VZI"2:8>$KFC2=QLQ+PYC42AC-*4(2:VFM%K=:+U245@L.4WU3!X99>8<L
M6LHI#XI2QICUUAJ;-HU(;9S@@E:H)L$RV;+%%R+0)GHE8JI_&YC0SL:T/NF#
ME=*2H,FS$-D%$W8A$FMYC,YRIKS$# 5LG!1&"4Z<(%*(*O3$74:[N7B)E48I
MYP-EE$4F%#@04C@,_H3P5NA1T[BJ2^SB]X+-7V(55J9P-AP0EL5HB/4(J1@#
M58:B*M2G7*T)+8^>T (,.VA\S[QC,CB;ZJ5';TCDQ%AT6T^LV*DR[+20'FQ4
M*<]"JAR( %0XJJTWC( _H%EP7E2A4^*2LM//Z'8($APQ3GG.BTB!H3$RYTB,
M4M@0[4HY592;%M-'60 3$6^$!-T4O;;@X% 534P9VUY6H</YDG+3S^A@.4!,
M1DJO&,%,IK*,.@@14W*?9%2AE6ZJ*#<MIG>M$H$P91V@),85LS@J*8,645(J
M7)6JN<Z2FRJI&038&65\<LLQHVD_D! H:!2MQLZ$GU4S5%(N>2#8^6@ =!(6
M%3<V8&' 6T8F.,7I\J_X+IMR?R9)3\@+I(*/7%''$,764F6)T,$R8E4PHY),
M*\:H!F.0&3(&]]+#GT@IDYAIX81T1CO"K(D2K33&TKNJ3Z(PK% L%08G4H/W
M*80F*CBA72 >8%\,*X51);Z8G;[0PEN+O.:8&V:U5C0"U+ (.ZRX57JE+Y;>
M?7P:@,&(,-ZSZ)%G.&CCB&92*<>P-N!=+'][P#=Y\%G_K7%9"X9UDRMVPWFW
M=9YUCF^>].3<43YNXS@/1:_(I]81,^I)B 1+?7F"5M(RQI6V6*NT_28X0L.D
ML\02\\+].J)L^ $_O^^:SHH'ONR)$NL40<I*SAF)05'F4$H]ID13<%-'407@
M@?JR,\-/J1ANQS*FV>(KL8SI4W\D<P29B&/P@FO/I)9&(*>0Q1PK(KAT%>*@
MGTJ=+)YS4@-I%[R+@$V91-X2S84L M3&<E$!+%)=AOGJ\T;-ECL#T]H&FN6A
MU_]@ANG.T]4XBK-N#FER]M,5FWD22R@  G/JN% 2,1&XU3(&H2VWW'MDY(H;
MJ\^-3U(6YFGZA3/M'=.B*/LLD=*@*:W1E(9(G:^"G[;BQJ]RXPF,IR+\Z!BP
M'B*6!& Y!1^\MM1;BGV(SBJTXL?J\^/;[B"O"CL2;#7FJ0&-9LIQ&Q!E/ KG
MP'&5K$INZ]\FSXQMA5U T3>=UKW@!L H.^<A[Z2.I6^SCNDX<&+3J7O=F$^.
M;'=\N-R[,&?IR*RXM_K^].,$9YH ;[KMLV[GYC/O/3Z7'GF+<,FPDH Q?*"1
M48VLX2YJA(@VJ?53J)!<_03L^W45\C;XD)O6VT''][9B#*Z?G8='*HI*,K!Q
MSGHI8K("C'%MO7!!"LJ\ULC0*C'PRC L3K)Z>?_5KND<CR8^?6V8RZP]:#]'
MH?'6@LKG( TB;;"/QAL6&< HYSG3V%1 :.XC6-9Y!,%6XKAX<:RDT(#_BWG$
M ):095Z"R"!-.*,"VRB$PBNA>1:\.0/]\(?IA>>*M[!C4G"BA?< N##6-%!L
MB*>6<^<XJH 4_$2\^MVP9B4%7_8Z+.'>>A.M!D_#&X-#2M7U!&FDI6 5D((5
M@'K.@O_]@:ZG[ZFV$(F5,D;G-9%*!L8,LUA;Y*C57'(CC:V Q*[D:O%R]70&
M=26QMVOK<^,H8AYL;63.."6%T5+A(&BJPDDK(+$K?^N9Q@("LRF#V@-+>I:V
M\"$1O"5,$1H5DE4(H#T?#GHZI5U)WG1!.6]HI%(1YD+:Y.'!:T?1,F0T&>\0
MFT-+C9^7)7\X;4+-:O>/4SXJ%PEWC(%%3<;414>%9DSKRNX*JT(6SX_QP.QV
M@$5+@O+@XPC*TLXOS8/D+CB!''>4J@K5!-GNN&X[[/5!,Z8KWW>=22T ;VN(
M7C"Y.]D %1K.0ZM[EL[=NCR#NSUU,&HAA4*(B-&G?AR1188QB#M\$XIQGNR
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M^-1Q(VKD!#/(:BLQE@;[*+E2HTJ#2PV"%TJ(V07PM1)4&"0UTH8%BQ2)'J/
MP=P29"Q9?D(LTJU\$I(X ?-. C@7$9P,C8P+@E,NF=(><5)=DNR&7C_/7#_X
M@B@'G:S? S^C(F2)*)5!14I3"1C46<6T$UZ$X*0 K%-A!W[N]%F\'Z\=D@$<
M!T >E@FL%$%1>2^I N1*L:BLC'T(>>SF;=-Q8>_$Y$\1W7X:.^24,YY*\/-$
MRAZP4FL&I!&8.B)0E9IR+8XRBY<K9(SU41AA F=."8N=D\QQ+Y#!$<G*RM6W
M@/EED2ELA:62.Z8590)D2FB$@Y$,?'(I/*N^3#TQ518O3SX2JXT5!K ?\Y$G
MEUAS[EV(X"X%7(' UU*"CL4L 6'*:' TY?.FU0,KN#>)M-K(2%P%&K7<MV8P
MY6#U-CK^/GI61%]ZPXW0$3/$#=,B*D2\5!133[E#(_HL=1OJ9:3/K;;2/T ?
M2KE@H <%^,(L@MAPJ96*B"-EN!9E.1:,QT'E>1#JVR.L^/$1UEFUXQ91(!Z9
MBH"G&6 RY2BA@CL7E<3!+:+/^I/JZUG-FP:74!BJB<.>Q:"L#MR&E"K%*0%C
M7%W\5"[VCC3!M1ZXXZ* ODCQS.>(K"0G-G NE>4VU455T:$816 $1U NM+K(
M:KF(NYBD5BN15T$R$37C$IEH#1<6&:=U#+1*DGO?AH$'^M84.W2S?O8\0PL2
M SF#2_B9,8J,H119K1P'J.:5D!42V&6DZ=/+Z<OL\A6HG>X@=Z%7?CT)QA>#
M]]GYZ]_AK]&F X6D*SJ1 =#3J7\AH01+KS11T5OR3Z+L]36]_K %-&QGG?I)
M2!O07Q%YUO_M(O/]DU<8H?^U5ISW^O?>F>F\_MWF+^'J\G-YD[NW,ODQW*W?
M/7O%X4YI_'73RHX[KUQ(56[AAOVT57I\ONWF\!YUUVVUS%DOO!I_^,UGO;.6
M&0+J;66=4"\N^FUT=]OM][OMX@$%Q9UIC1Y2/*\\?/T6ZZA\DS[,5]^/GSPZ
MO%X<>MGW=X]IM:[1PX?1.IX<>UG<.Q^?,)I,>M9?*ZZ#MTJS]N\UNG;KQ4>O
M@L_ZM5ZWE?G:OU#QY[?1\321Y,[!,^-]UCE^A6JX>,3U&%X6$_5EPM '").&
M.#X=1MS-7XV?%X$3Z]&TL];PU?_>!['LU9KAHK;;!:/XOU_T3*=7[P'OQO+$
M7G857F$86?GUHIP,"?<I2#F:'/ V8/H.FMO[6YNUO?V-_:V]F[PU-?AE&>W>
MUIN#W>W][:V]VD9SL[;U/V_^W&B^VZJ]V6DTMO?VMG>:2_\*GTSO!%BGW^V\
MJ&VNOUFO$01VX,%A3[&-F O;L$>]Q=N=W4;M=]"#G6ZG";8  %MMI"YW0TP-
M&0-GA@GM>41,46ZT5QYK$@*/0MR/8VH=DRR:#]FKS:XK+$S"AFNC& ?]>V@W
MN^?OR>[Y(6T,_.G6^=$[?;ISNLT:F_ZTN7F(#Z\^TN;F1WYT>L :5]M7C=,M
M>K1YS!NG)^VC=]O#][39.KSJ#G<V-RB<2YJ?&JAY]1'M?#K$.YN-(5QSV20?
MV<[^-CMJ[V:-EKI\3XZ&AY^<./RT?=4\_<P:GS[">0W<?-<\:;S;HLW38W38
M_H@:FP>DL7_2WMG<.O?O_F;^S[]:1Z1U;D_/3@Y/&V1G__CR:!/&='6 #LG6
MQ>&^(SN;N]G1YL>+YO[AY<Z[0];X6UW"V"[_\5JDTO*A[KSP=7#A<%US:NL"
M1T>=UQ%9M?8:H_K'PAI=4V%B'V;+%>)17%&[P\8S'H>Z-0QV[S!^:9C\<VVG
M$WY]C%CQTDC,U2AJMJX$_AZ;R-8E%X\RB=]D:>DZ0--OL;0/F=6Q921GE\DV
M3BNL5HAWIZ9[MG8?8:[-\MC6UM/EK\@ZX5._Y25F*G^<>M3IH =(=_AXY;B1
M9Z95 V_3=7VH-?8>D@/R-08L\<K3*\:/ T"Y(6\-=\-9-^^OU0H/N0\/@$D
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M?-SZW2]/J#,3ZMG(@ZDL7/^A5 /T#W;:%BJ,:<'KC$M6UTH24&'@^TKD31"
M6Q17MW77KT^9X)6:3+4^G'0[/VV"%_['<,JL]:B.)69U9B2J6TI)75'+</04
M2 /&16I65TKIQ^=WS2]K\!L3'WZY3OSY[W\I@N5OO5H_M,)9XH-:IV"$%RDP
MW1HDQ58S(+8U=P,I+GHS\E>7R,I-X9-"$Z/TCI '7SL;Y+U!RO/H=VMP1A&4
MQ>07^VNR;REI=</U7WWM34<Y!NEE'_'N\\UID'R=2/D].0V4KO-'I@E\RVVQ
M7@<--/ND!K:.T>.V9-QON<<3#N(<OOW,KR"^$9F+/1E?+")Q]^ W@\5%KD/O
M9_U6D4$5C#NIN9;I]1X!FGZ:V<E-H4/WAFW;;?WR*)#\J+DI]_4\YZEKCC+S
M"KX*E^XD=1JJ@;*^.,G@EVN-_H@IG8>DWULPYK>?A=&?$*2.S/@0$ULHFTJ"
MU#*"TMS<;1V]:UP=GAY<-:\^(Q@;/6R__=RX<I>-_2VXQP$]VG<71_L?;T50
MNJCY[N_/AU?-K+G?H#O['^%:GQU^^@CWV8)K#]#1OF\UK_YH-=_"&.^$3853
M >M8)X2%.@L\U%6PMAX854)K\$RB*'>8@( 5!?9>U/[_5)\)U\Y,7CLWK<'W
MY%.M1.-I16-D7DKKLI*+1\C%UJV5:66)IA[7F96RSJ3 =0,TJ;M@A0M>!49\
MN0-@(=S__*W\'.S&U@@[E+M<;H?G$[*H?&1^?O)S:Q59::%B("J5HQ)U(!*N
M6V=CG9N@/)%<N\  !8-7W30];_Y3VI9:JL,4^K7W[]]\AU@]*9C[L9LO]LS5
MJRW/@%>OMGJUI1KPZM5^@E=[S(KCK2#U-Q>"F66$?KOC4UYTJ-EAS9T$0 ;M
M5*'QXB04R?(I&C^U,?,7_&NY*GMB>K68M8*OF58+SDCE75*,_S^#+$7X^]V:
M#:,3X,:C(']Y*:8IR;ZLOC&*]T\M$XRA8EH#2(=3]8V:AZ.=X^+4LSR 5Y"^
M85(KJF?U:K_ _0!4UGH#=U+KG733/M%QM8O^B>G??HL+<W.H:9SEQ:,7^?5%
MS71\[1<R];86\"F<9$_A7=)%Q?EP91K*Z&:IYDVO&$DQ4M/KUS2J>3/LK3]8
M ..I<V3>#/(<AE46X$F.:M_T![U* NWO7V4$0,[^T3PR*M,NF9B\3:5BW49O
MZTH(3#B2IB@:>!AZMP'QS3R$1\KH)YCKQ*:]'Y+.RZ?=K_W%9S_$LLWN?15<
MYCHMZ='J4<5CJJMJD\X!==/.^GW04J$%:B?O=E+,H#6LA?.0#VO;*91@7)$"
MM&GZIBQ*<TL)7]]C>MEU=P!G,L23BMT-QX-6N35FK[Y?^R7-KOR-4+(^.J%_
MDA7[[\_@<;\^M3(NQSM1KZ'WZ^*4Y]0$I_D=Z=*?3WGR?S25VIN@Z@)C66?"
MF+HA!G2I"%)+':E#_@O*<Z5"5RIT_BH4M):IM>!-0@V,.ZC0/%5G*K1*GA#>
MO;_6@'GK]Q[HM4'WPE/R,98"C=.&.1B^2( 6;@< ,,W:<>TX[U[T3\:'UP'?
MAF)L/L2L4Q1C*U(Y4^X/@==\8(3%8?S;^+2OGO#P^,8G)E [.OF!L8[/S#JE
MB4A5><@8ID]C\_6O)N@L&^],\L0JDPN$US7AL\\%8NL$?U_9E"^.5JXKHF<_
M6KPN'EGD9;957Y_IDLQU0<'\#:B2XVX^O&=%ICBI4#)N=%*E%V=VWNUF< PW
MK_XX;5PU3YKOX!Z?_H)S/B,8(SQWFS7)UN7A_L'MQ1EV].XO@$0'M/$.GD:V
M$$ G?-@^A+&EPO8?^>'I,3W<?WO2O*]<"M!'^AA<G1N7]DJI5*.!BCHQG@I!
M-(D8?,[W]QN .>Z\K4QQX\=69AE5_I^V4,]RVF:I=3;N,N"SG[_9LQV[C^V>
MR#0]:OZ6DM>:]X'LARL#KWCO^WGON4W;+-EP[R&7Z2>8QYFRWY,CUH)2?PQZ
M\.1>[_DV$I@34@6$VKB)5*UFT@1#ZQQQ TC5X[KAV-8#]5);'BQ"YEL:"3S2
MXGWO9M_G)HRS5&I;]X=V5BIMR53:F$[O"C*]*:FT4FT_J-J&=U0;TQR(P&5=
M.*WK:4=IW=*8N@5P8Q7URFG_S:KM3I[' A<8%A/8U&J=2?(]@4TLUSF63Q'8
M%/K[]DY^Y9'B">*:<EUP-?/;$KS.Q.SWC\)ME?Z!WEM8S<*Z+,2:;L<O+.VD
M3=KWKDAE\;[U_&(5'[S=3K=8A!_TRF4AF(&R(>$]S7JZ>?&LUC ]_"*#1\-C
M:QUXM6YR6\ZS7N$]=TS')=L'/G6J@)U.[O5-QYO<]VJI]$WF']IX37\QO]Z[
MPE.;]\(D>FAA\H<*>E1MP;)W$EJM,8/5?@&V*98-RTX(7UZ4>SA5XC#T?F#)
M^;&=YQ[71N'I?<4T@\\83_U0N8V+?ZA2V'B5]A^F[KDVH+K&E-2E4](BK;B-
M\JMX:)5-<6^2257T4MH/5-8927JD.^@7UJ(P&R<F#[VQ=LGO%BIQY1;57KE%
M=;(W=;)9%6Y9W.-%D=JUR'XM(T7SMDCA@B$/.EFI9LIW7+NI>IS0' EG!?*<
M6604%D);IBPQ2!(4_]DN- XC@&5\<%G;M'K_7MMNOKTGZ;:8HF*CU5[QJ)WK
M";[9!!AH4/?=?GUT0T!) 'W@7N@G4TS-J^.K?R05C"K+ZX(J4F?(IR)SD=45
M*":*K";2AK77F.(70J$7C$W*HHXIO$CME)H6@=!LG.59J]1$1(U;%"].!-8?
MU?WN5MQE055S /^!!D'?XU&"+ZK1X^K;?'NQ]R]M(D8WMP*3![<"?T-MNM&0
M"%DO@F3=TB-XE8>4I'L>KF?K?]T,NHT&B*XO,18&,^C?O:1DQM>_V_SE[0C'
MU-_IWH46(@I)QP1W#""!CEQ10L$8>*6)BMZ2?^3:^)J3_-K1.PYUFP?SN6XB
M\-,KT[HPPU[J93C-A< DHQ=FZ76_=:1+V(3KB]WJ'A#&91G[_L8?[[=2U]LW
M.\W]K>;^WIT1+Q#Z+2B#3XMU0;\K@T^O(SK[8(QDZYR1)XAS83'[OF=\':/O
M&^N7[\KYXV)R54@*G%^K@LJ_TU.4!)_/!-Q7([L<&V#_4?>A5X,.J+)TUMKK
M#V ^?ZCV[4P77[^I\_N7K$2,3X-VOS*;OYNE&4OM)$_^YK^^CJHP6GN]-VB#
MR1H6^[2RWN?:6_!TNGGO]Y?FOJ6IA='['AQ3K.H^+%4K1O@V1J _3O+[71],
M?J31U;*?>O]R%'D*AO\:<)\1EWVK(7E*CO_&L7P#QU.P@!N[^R5 V"YV+6'R
M6^WM=G.C^69[XSVX4V]W=AL;^]L[S9E)QDRUXIS#/>5B93^T1U46UF>/%%?6
M?:8L+M9>OYTLW!9-3(H"$D]MVI^XO\8*5"XYVZ4^+5VXL),R!^!3$:\LDO#_
M,"W@QE#;.PFAWZO]<M Q Y_!D5]K]50PSIW4*"YCVL56TLW@0K&$-/J5+ DJ
MO2\C<05,GXJ9Q-S,[TJU+#<W$/Z@:KDV;\F3W>ZX;CO<4C#[\)Q0:W2+*B);
M13[4/3IGI69^4L:2*S6SXH:2&]0CU4Q* <O#"9R7*B2ME,Z*S;Z5S=1*Z:RX
MH> &BA^K=$SOI/:VU;VX[4"M5,V*N;[ 7'JE:E;<4'(#>Z2J*1),3[HM>$1O
ME)Y;V_K/(.L/5ZIGQ6R/9S:,5KIGQ0XE.\A4FZ4/8^IW:P\HH?L6+:85SDJ'
M_&1,PQ#H$+Q:A;V["DM6J[!+SKL*O/R&Z9CC0H]--CEM9CTWZ/72KJ$$C38Z
MIC7L907JNE9_23^6NW73.;NA-VB5P&SG+)1#6I8\K94NG"<_T?GY<A72A72E
M"Y><=S$2:Z\_I@(!6;_8:E3H-?BA-?Z>U&*KVQND':(;MCOHC_O(I=S4E:[[
M&?E%\I6RNZOLV$K9+3WSEHE0_1P(4RBZ#WG7!9]TVTJ3_8S,,$--=CO%GM])
ML;\G!7V5XOYSI;@#B:9SW*^3W'?2QN%5@OLJP;WB2A7SM=?OP[%IE::UZ!2V
MLJT_)1O(^64)5TF';:R4V-)SKUI[O80[;U?Z:ZX<L-)?J^6M2C(OP6NO#SIE
M&;^06JSNF599WF^4*335>SL%00YZ(1T< ;:5MOLI&6:E[58+6-5D7K;V>C-$
M4RS$'YRECM:ADW7S*2VWTF@_(U.L--IJE:J:S"O77C?@&L!M,0!<FUJ!7VFR
MGY$95IKL/DW&5YILV9F7HK77.T77B^U.60(=;K7283\C&ZQTV'TZ3*QTV-(S
M+UU[O75YDMGLZ>MTK537,E)?SJX.R>TD(?;3U>%<[0]<CK%\BPR(M==[V^^:
M&_L'NUM[*QWX,])?SJHLRM=:H+ G:X#R';F-3]JGA\RB"TLJ$[WX-BQ3?87$
M3=%]HHYGCVQM\F E]>FW^9;W*'_*TA[I<;>>!7'/SB"OV4$/?N_U4A/)WL">
M!E>T^313;=YR>.URE7?0<:!!3=9)*R*IB:EK#8KN;_V3;B_4?.BY/+-ER\G4
M!JXW:A;:,C:TX.>4J4K0;]/S6/R$?TM7C(Y^,'F_MOVBECR<&GE1>\)MEN.'
M%UWKX/J/ W@V*+<AG'[6S?OKM?V3 "]6SD#YNF7OU=AMM;H723T]IC?/5RE_
MGX1\\58+$H;=8B)VDT8%<NYW:XF%_ABQT&-%XD9/=_H((:ECM3 9*5A$?&M[
MR!D.X>9T859RS7;JOIBG-HK]3I&?T<U3O]ZS/ O]I*W@LQ^ *+O4/3#57^C5
M?+=H()P'%\9[]-I)E.&_U*]Q #3MPI7F+/7]-2V0;[AG%J]_J)D\%+?HVG11
M*>:FUH=W!8F!UX21O  EXDYJT62M 9P-=_# +,/:17?0\DG!I'Z&?1!/N")K
MGYDL+][#V*R5LDI \QR'3A+/U$/R/'0&H?=P]ZL57\V<KT9Y/(_AK=(DW,-H
MKJ"U!1;K];J@BI.J*%M0>P#@\(!$V*2*\\G5P)3 $BM2+T"%I&:FJ0]F$N!!
MA \@MWE!'*"2!PM=B/V@4_1.@U\'G8NLU4I&/S493[VF 23VP,J"[$[=HF".
MWN#LK#4L>Y8#TFA]KN5_#C[\25"Z4;<(ZN?F BX#HYL5*@?N=9R8XT71R;K;
M&3.*#^>9"[TQL/A/N=MX6#SE/\5.XS2._PRRQ*]VF)[7S:?9N%<,-[5.']UB
MQ'H)'P##_PGDZ(3+ZW%-,WQW6AB^POTO2GT&QZ8?/BZS-3X?7B>TNF<)U-3*
M5NWMD"?4DET5R*06(@RW/R5+A1HM9;$WZ)V5C=_'CYF N/P:Y70G*&=RFDLM
M[FQW_//DWB<F;P>_$KXY"M^G9-] -)+<G&2Y+S@E*^LG >'20E>M Y:ZUTL,
M" \NV3^.F7K,A-<0?')./D)G<*?$YSXU8L[L(-$\0?;S;N;@_"1JME#7B3LF
M2L!X<.F*ULWE^:Y;/S.%RC_.3?O.X9YIG[5N/J.XWYWS %J 8!?'4EOH7D+7
M9BQ\TV^T7@.]!%H%9J7H*EWP*""%4 +O[ 96:(?0'_V:1"CKET6E"BSOQE>F
MU[HA)*/Y33T+5CP_7X-S49B09#02OP]+3_-S&-Y4335SG(?"XRN Y+1,C$T%
M8%"8^I$B*R)2)?"<7#E!KU^Z_8OD]<(-@5D+D;EIT5[<9!LW@K QAGS%-W/D
MF[%M?LBH;C7_W&@>;3W)L$713/GKX[X3;$P,4*?K]W2*M:87RE#N?_\+2[;
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M8+@RW'H:(AV))C4L!PS5R+[.8%Y31IH5>6&*7/*-40N]81AP:E+=K:++#*&
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M[]*Y8KD\6?.?ENIDS5^HYD\S'4]\X )J( R)3 <1!71<#( 3S!T3/*BD^8C
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MB0VW+D<G_4%$9)>=&C5=BM?M3Q^C(:,9#PY EY9B2!'#&C/ 2<0RDM"'H5]
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MFSIV6@^491 PJ#SV4C&3:IERUN1J;F:2/2DUUN>*/"E9GY]6GTN>%&FTYIH
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M)\Y:EM)]H6P2.G>;G)Q3LHX(L)#PKHP BT* :7(&J4&2R0"0)21YO'$JEF<
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MT3YPBE.A70*H\PJHX$7\DP?!!8*!Z*J*I\VJ(#5/CLY ]^R +A=/6QF@@U-
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MC(_/?)'4UW-;=T2:P:XRL"O'Y1.A/!>" !=21E_\"620%K!@J'&((@-%JKG
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M8*0@P' %O>/:&Z%2PX5YXN">SA]5/Y+UY*79ZLO"OH?X70Z+,KKQWQ,?4S_
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MH#80(!F! $%.M,,6>H,V-A%>P_CZC#AKBCB5VP4_(DXF^I4@42FD"07OG:-
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M$'0_U;0?=D?^P ^^=*T?-Y_>][;_J5=\RC_Z[-)G"EL5A6T?E(Y7#*28"B>
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M0OT9)N:_[X&A!*\>#2YZ)<E1@[(Y66TZ=$KU#66C#&*/_XBQ9< -0J9=$6Y
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M6$QKXIB$5M3B2SUEV-H'*C';%7CMI $=,>IT#Y#/72XP%J(?B[&YZ]9O3H9
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M?3;TU@<8A1NZ4W,JIHG(62Q@0&9RD.O5CZ*&4ML>)\?0":=V,40C;^/7]PY
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MK ASR^<\SJ,P82$'@\]9+T;X;2?R=B+O/HN\.R#Q6FG7E7T[%_<;2CR_)_'
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MK["Y'X81Z/#U^.$.0')G>?D.L/(NVO #HPU:0_,B]H(LM&(.>MF/T]@"QBY
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MIL XP6%IK>$*0!6 >B* <MS+:#5CB4>0ZJ"CI)%%P"PK<0BJL*@ZH]1\]?I
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M"C1:6TUQ9#E,(W*<-.@QH1X'J21E]K$UNJS3#U3KN=T  WKI.7?(<8H1M]*
M@H>$<@.!)*T*,0?-UF^A?F6I 9L'\=B?-5S_D=KCE<W.B_+=6@<1E$O<$ZXQ
MUXXH*5-(.;2<Q%OWDROP]N2U<7<V1S-X@\^G<"S=9T$'QPQ!.34 \>@%LBI2
ME+3EPN8J$BR[%W13$UVC[<ZBULN.-(Q>V]Q4@CO&K4W."" QEI&@E??LD7V&
MQ0ZYMT:WWUS6:/]]7Y'D$F8)82 N""!:(:>$0)[GKI^:>ZYDB35\#2JMA:(F
MF$A,X,P;K7(I$1$=EYPS73("ZJW7/U9J"M=C^PD'XK''* 7K$<<*(ZVQ0(9&
MAG6V1X0O*_7+5VOFLDXKIE.(/ 8*6IX4UUZKR)16H?@7ZJS6VU>7:[Y/7'2@
MO;!<2YT).!5(\\20=$$(31T1GJYMT*;2=>I-4;1ZV>E[22<PI1F5-/+$B4D4
M2\M),D(*(.!E'Z"F"EW]^4^EU*>M+7B'S?V8A(!%6B+JC47<VX1<WNNCT4:-
MF9/!LL+ 7X%2)^,3&-"):&(YI<%:8SQ/RCOL;)2E1E#--?O#A6:WCSZ0O&T?
M@V+.,>2#S[5V@X7%.G+DDA5.8LQ);AQ<M\6Z-)(J1][RR%>61O*FW^O%@>_8
M;N/$GL1!21]Y5([KL@M*\20,Y5Q)!]36FB2=3QZH+BL^YEJNA&]'\YOB05JI
M@Z?(:*%S\7F'M)) =14-*I((#*=$FK\&C2;61\.]T$(P3J36.K+ M+8^)!Y)
M*B[F.JMU>RZ$K6*<FGD$3%8!NY4,:><$HLG#]%*5NTH NV5-6:M0EZ+5RR[X
MF%QB23DCB>(B$"TIY582ZC5WTI3\D7IK]=QB+:@BE&.-+-6@U=94YFI$W/-H
M&>9)YK2PHM4O7:M%]BP3IJCQC"N-=:".&VF352QBKHN'N:8*O3V_3'L;');
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M*X6WG <@J%@T85DL@%H M0#J8Y<PC)A)RSQEDG.:O/.*.V>XP,YQXF[?I*P
MZI.X4.?WG;41)/BHD/:1(^X=08XJ@13,H$X^*)L#Q(AH4ET8:@'4 JB/;O+K
M)%3B7()1SSD)1@*4>D&LT2DF?OM^4@50GP90Y[?\.=$FD%S<62G$D\F-UD5
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M*@<3X1 E)SC<$.)9YO81YI;FX.JH&9)6YOI;P2"C;414A1S#13B.9FWCN+\
MZ N_:-C99.3!;@QA3"^UL&N,#NVH<1H'L>&[=CCLI$X,C=/.Z+!SW/@K?HO=
M!FO88:.?&BT[\(>3]8*19B.K><,>A\96]+'GXN#*5W3]*A8N0O0E=)Q"$E6
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M4B5DM=A=GKT/QW]/YJX@W>,@W6+>*M-<$BHILIA[Q'T$D,-:(<FC<X91$)0
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M$BV>YV*4Z60!B5$@S"*.I4%.2842S&E,VO! 8]9BR56-M/@U.!.W+VT:E>R
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M<1VQ"1P+'0S G6B2:ZHFUQ3N7KRK[U/^G.LSC8<Q__5X_<U>N)G_'$U8 >?
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MHY=^5<!_6>!_37\!RF*0UDHDM%2(JZ"0YM@@IQT7E&F6 L^Y8*8IQ,KT4BG
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M!5?44(<1(X0B#O04&8HQ4IPY9;B0/&<&$'T50H*QS/6%1R!R/ZMZ0Y#L&TE
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ME2OK6/*F3_W18>1UV44[3Z$WVOM.XU^V4QV\?-9F&1:CE5K#W+V\,I.'O;5
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MP9M4SWT;KY-;OL<)O=4W+QLLH>N4LL<T6''=R\YP$D;" 1@=5^.35X1;;N
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MZ<2"0M&[@#A+^8A%EE#"5F/J!5.> #2L?IID :$"0DM*V"X@M& 0FG3:J3"
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MI.T?C<_VC[Z>X'_'1F\CI#!PF0$4!ONI1ZKE!J[JZ9&EFF9D,09.<A B\/Y
M=^R!8:\FBSWO7DB;OG&;OG%KPL*WE(2_;5CX5PN\%80^S8FX9CBJ;X2.:O'
M4WTX.-4Q7<W4-.9;/AA;IC/4[@KN>R/L-L+N,2W\&I>EMQ1RJT#%=W=9^M"
MQ$]$_!G=;@>>%L<FCU4C]'W5BDU#]>  54OSG2@ V>AH%N7O##1OM2+ED0K
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MLH8$QX\NDM&'R ZMD>,4XU+353M*QM1P.!ZB"0*K B9#!0<,A=M0E#0@>&Y
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M8LD3Y]-@\&_8K9R$+%FR\1)#MRKI(Y*JHG2AZ-T(DA/@NOZ@S.SZ<&0V>"4
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MBIRVGHP<$)#[)%]3Y8 7\PPUR0&&/9 =Q^Q' JRO'.79\AC3[V>4G2%BPW5
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MJFYX4.T:@\&[S$M3M$T2U&P=@QK"9N]!+RL16JLFBDT(R\I[>"9>6K-6N3<
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MDU7:TZ0,1H(.$K5!I;HB%/I)_W44/V:T3-LD7&__@4TC<E4X8,[V-$*]W+-
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MH>LX0[??^2EA@*XQPY3.>]0)3B=*:I*BM+A(+E)F+'>1^)IU&J9+,J.FF37
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M]^E32U^^Q(^@(+]MEZ3-R5F-P)=(!^F@%)5#F*WA'.EH3I)&D*2*@<.>L=*
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M9OA)A7%I !:W$UI<SD4SNP-FY<"1*#%EJ< FFX>J3A1&2%:N?W"\!5RP7KM
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M'LTI7UK[RH8HB29)!;J >;$*K$!"K>.)7VU,)R_+3[*)VR;3)AJP-X/-6PN
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M8P]K^"G(A$NTQ/"$(^@([ON]!>F=&59JA/,R@ %DHL+J-HG2[,3673-QB%A
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MP"X=([P"OGK2R0Y&MA )N+!<.&7!0,& LW-N2!ZMYA8^R%&T'E*T;LH%=),
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M@H9<9=/4-["P$21X$![956HYHIRXQ-+OYW-,Y[50N:5(YFPJG/!CY%CA\LI
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MQE EPMCG=;9/_6K1!I/8>&4('^I(X 'U/;'VC,&U<\67Q&Z$0%)6*IAZ+,R
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MPLX%L2\QRF@0KF(%9<38PLFW./+?PY*,K7K18(HE8<"JP&VNU:N&I7LFP7S
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MYQN@>!YB]&<I]+$=Q<&;;%1AJ&,'=T0BGT?R>929IZ;4_!':VR8I_[",0>/
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M :]V]KN$Z"/Y'>:[-2C@([S5>M?Q\N_#9IIG!7H*K_(8/-W+F/<0:1%]%>_
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M7,.D_R]@.357:=NRK6GP;8(0>\\71!UQ;$+\973B< #*,ZC#Y-@-%;]E_]6
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ME Y=+@F(G1X43S0L'@0P;15&##KF/M;R!C!#,IH;TV#?J6^G)E9&V8A+;75
MLL&\4U5%17!*%C"".^W)WO.\SP9P^OPVHSB?2$:#(>/20 Z6T<X:(P1;! 2%
M4EC#?1+RT&'6(808'R3E&XILYRG>FZLUK$\^Q>P3SI???I^$Z9)<BAK@_%3/
MHJI[03^A:9A^?(-A@>_JA+XM?Y#G43$_*TOR/5(Z.:[SC_DE?IIC&I^*8IJ?
M'<_FR_&_5R]'5C/E BT\Z;T$%52!R&JT0@C413,C7;GOB.-@:(=D->U!L&%*
M]R 1BM]FTW2VH%RV*4G2'BRX>!J97_D(R6=O$RTJ'Z\SKW^0XA+?D"RR!IM9
M!Z$T(\P_9[/\93R9C'@Q6<<D@!L?0*%"HBN-ESOKF*/Q9=-')Y\C&)+]U4#H
M.TULPYCT,DP_CN,$SVB&RU=?T^2DYEI<( M9JRQE!*\D#4\0ZVBP9!$Z36,U
MGES#/J[Y-NB&%ZO<BP[-!=*,*N]PL9R/$VFSS0>Z:SM4$,&E0'YC"3K5H#L'
MGZ0 HX/.:)GVHH_:V![C-K0QWP]M.@FG>83GEVF:'>.'\/6"W2,RRHMSG$P?
MM+$ZK EB= 98]C)[1OXL]O&+;L>T#3GL]T..1I/?C SOE[/TY]%L0O.XJ!Q=
M?AM9J9/1WD-6T8)B-H!W9 YK'1WC,C&G^Y#@)I8&IO7I=*^^^C2Y):D<M:&G
M6Q?JL1(C.29>0+)<_XM*&M[+CKX.9D@1@#V9L,& WFOJFS'\Q>SX>#9=0Y&=
MY@YEHF?K3(O-U8 <@<HF<&99HM7;A]_7D0S)/6\L_;TFO5WH,N=Q'7N8_$Z^
MW"_3%^'3>!DF:^!&#(57FGN02M!>GIV (*R!S'B0+'*?B^L3";P7VY \ZL;T
M:"R8ED>BYV&BE;]/@#[-\0BGB_%G/%79;V:+JJW?%M+=HR1T2,%;(&H;L@2(
MU;%: MK(R*,+.;%N.60/ 3HD/[TUE3J*K*&_M@SC*>9783XEYW%Q)1Q9QFF\
M'#&?M58.@?1CJ'XD Z=S@>)+,,E'<3.PW,I/NP_;D-SZQNQI+)@>:4@C40):
M:PMPI0E + A1HR91&F]KD+'8/O;*&HC&605K+G A><D8.;ALR 4V(8,K@; H
M&;U#[GRZ?F>D2V+!P\(1CY!^]" >W)-4L./\=\DK6,/"0G92U 3@+,@-EM5(
M="J"YSIHEIW-K']JP<.(\ A)1WL1H<',]\RUY"%[Q4E&J),C-B8$S[@%KHL(
MALDB<GR47,O!I!CM)_W]9KR9Y%>6VAJ8-2;R'+032A,)@R!U6]-EM%00 @$Q
M+)C"5!<&W(YI2-9S*R8TDD S1CP_69 =MEB0^1['T]5,O)A-ZYD^0:I7,\=Y
M=<9?KW>>@OZV!EF@#8+S!*9X!.7(;72R7BF)M*E9+Q5V\L/V@CTDN[H5KPXG
MQQYJZ-DT;W PHK79<<- EU@(%:G)F)DF$RG'[!ES)?6)&-^'K*67P9W)V9 #
M%:1DH+Q@$!F-V1D;>=*!,=8GE^!6+V,PEO?^K+A##S]HXGL>^Z"(LJC(P/JZ
M[0<9P 6EJMO+1"R.(^^SA]['Z\$8WNUYL*<8FIZ1C)?'J[O@TWRQ8:?*3^^<
M]\)QB*&>=HJ4P6=>P&I69-$<8PS=CDMN 350V[P]05H)YAI3_O;T^L2]H==-
M*X*\7]*?*^"S<AJ&;5\6Y*YG=*L-LO7 &A4(N4ANO0QFCZQ+23!?P&"]+Z97
MHL\9+*;$<K$^8Y]@\08P^^\]BQ6YSU(M%R,9-/F=VH$0ELS/+&B]D"L*3)NB
M36)<R=QIP[F*Y('F"'3=9O:EP<V=98]I;W@PLHI'OJ;AULUM'M+R7^/ET8N3
MQ9(&.;](MZM9,O1_KB<X2@AG&%I@69&&C/46C"^I7K*AK51K;E2?&-$.8(=D
MR;1F4&_9-2/9;[A<&[)TRCEF'1A1 ]XE, C1%7 ^*RU#"5GWV5ZNP-@_6?C\
MF\[G?SP]H<D^$S+IJ^=89G.\R#/#Q:NO)"/B'+GE\V^_$%5609\JN=EDLJ+%
M$N>X6(Y8<5E854!+;T#9>N*5M04ADV7UHIE,?2R^CH,:DFNY.Q]O9B@/@P4-
M<^#/@)ZII><XQ3)>CDIRG#N9@3-)-G0T 4+F",QJ'9QV2!M91TK> /3 ?;VO
M:=":3_M-?V,N]"%WO3R_&D&JAU[D96>(V@M22YAST8G[3HG.!]OBVC@:,<D<
M%3=0=$&:IVPAA*Q BQ"B06T,ZZ,L[W4T'G<+'PHW;QSK["G#MB=\-,#954!G
M^\K(J:!YL @QQEKP! -$7@*0UV&4SC*09=COE.]67$,RUP=+L7:2;7EU;C6P
M<Q"B%*FU]F!\/=36TH$3T4-!\C.<T%9@GT/D:T >&*?L:R8,E5#["*]A!/Q:
M."09%,XK!E:958FZ"%X$#4ESS(A<!-,G,?SN*-1N(WM;ZGW%57P:YY_'"1?O
M9Y,\2EHQBS* ]BS6DWX/CAD#SNI$TM,VQCX'F[=C&I*2WXL3F^)M#<30\@HI
MTM?4^XDO\3-.9JMB"N=K$'E!GKT#%@1!2EY!('1@, >,3&<6^U2$NQ/6D-1S
M4W*T$T:[$V)<[?#_) ]P'B:U4$8^'D_'BV75%9\OU+T)HB@:(2B;:OHH9[4X
M40)Z945(UC#L4SIS.WQ#.BALRI@.XFEWBV:MI,K;<OT6_0A1"G3>0%""]'NT
M')PF&6MO"Z'-T=L^QMG=N(:4Y=>4*@W%\;C'R!NN]O0]4[[S@0<Y8-Y^R(U.
MFS<\\.+J5/8B2Z41LI?V[.I42IHV$T%F/\<4<Z>&#;>#:GLV1)XJX\%$R#Q5
M-\9*B%YJ, JCS=X4W<EOO.-LZ+%MX#9\N+XI[3[O;4-4&Q?8',-D_&_,_X>L
M\ZIDPWA:8;Z=7O8U>#8?+^A'+^GE]./O.!_/\L6\1)?KCDI"MB:#XMY#C-I!
MDM)%VGU0=BJGW&M$P[*[^Q!R$&SHSNU5]&<V)T%-3R^ I&\?YF&Z.!-G_G\G
MBU6V604NO O,&P'*>7([-$_U.I"&@HD,CJR-ZA0=: !^4(&W0U.VEY ?V?H+
MBZ/7D]F7#NW%[GG,82R]>X;7R+ZKC5?H2;_/9Y_']&W/O_VQJ,6(:I^.10WF
M/TOD/IXEILLB6,!Z!0C)=\2L:A&\!$;*++,63G4J.+D]QKWK X5OJ^G_,'N6
M_N=D/,>[VQJ-:+'PDID'[C*CU5K3ET(,P(M/:%46OE,5] <"'53F8B?*W2@X
MU%&6#6N]SA)B7IW 5$QORSTH$YD)4KD":55&648.P9/U4"1G3*3DL?0Y@'\H
MTB'9B(=B7$]AMJ/<]75Q:R7ED2M9QDS&"-.%C %/]FH,C@&WTA-.PW2G2A/;
M8QR48?=8.UL;";8[.Z4YN%;C\D8-S*MOK'WRU%LBPW5>:W>_Q-._Z?5I\O"K
MK^DH3#_B.[*47A6R2FF,UD7O!-FHD=$JBE@@<B_!1ZFMR#QYUZE^VT''V2"R
MM8F<%QE":^24G-Q071Q8:24Q5 =R0H0!:[E2DB4M.W6=W1[CH&)BP^7[AC!;
M#Q*T3,W?=@>MFI-QF@8T5H'B48.SH=!.AS+QXFBOZY.5OJL[\LAQLN^>I/N2
MH#=)7X^G89JNXK-&N%@;2/!,6E<)ZV@1Y036%,,S5Z%T,M>WQSBH(_'OGJ3[
MDN Q2*IB4$X4 X4+PE=$!.]J_?&"V;C@E>!]<C9V)>DNV4V?SHSFMV7EA-5Z
M?M4#,Z3)G/7D@14:, \!0JT#B1:=L,'(I/I4F[L%T/<0J-F70C>3G?:737/O
MF!QVPG4RISUC08[\>B7:D".-1B)X4SPHXS($9PNY;DXJ+HW.I<^A\/W8AG8-
MZ1#T:2RQ9KW'+D)!:P!_62Q.:/ $[_U1F.-B]>=SPIO//O1L/J\ZJO[S0G&]
M_50G^]57G*<Q?7)D,Q<F(;GS5I-A;K,$9U*"X*4PQ@2I;]@4M[8<ZP5R2$9%
M9QX.2MZ]S8=-CF(.Q63/-:C$:G,D%$ +KK8C93%@$IS,GD%%"_;-"N)!%R:Y
M(Y;4V)WB%GQ!!<$XEVJ--"^Z#7B864&=V')WDM!#Q- N#?IB!=>#=IPN5M,S
M*C[%8@H)#4ELBN65)V%JV$2D5&KOL#X1L\UXAA1X.! W&@BF84>ERY:2].\)
M;NHM6;N>)JT")%.S^%4LX )Q6&<7A?5*.>Q#F6W0?0?ZNS6!F@NM4_Y\]8U>
MCA=I=C)=_C['X_')\<@DV@-M8.!2(FYG[\&A2, S:J.M,RSTR<2]%]J0LN@/
M1*2VXFK9RV1^RNFK^,ZPU>L%9_@6IY'6E1$[LM%)BYH!F9FT@0KA:YNS1%R(
MZ)/04MD^63^[X7U@#=U'\8";$ZZ_9-OUJKW,EEUE2%PYNKX\MY:FH'$60:@:
MF;58;3N9H#!O:U8.;;9]8BS;X7M@A\H?@F4=)->R-,RUH/^F"F07%:9'-C&K
M:?,%F111O\BJQI,#%H4RY/"+HOJ4FW@@T"$UNSP0S7J*LDUL[[)W"FGTLUC/
M"%-MCY(3B%)JI7PKB?:V@/#6T8]*3OSZ:?3FH-RF;]^&!NX'V6[:3'''G86T
M[4JKOL.$X\\UN6_$@\!B3,V2$+54)OD'P2&'5(3FPBEE3)]3WFW0;4,>_X.0
MIYO4.O*IFF13^J555B#ZJ+CU@,$4&GBFS2SY"-Q)E:37.>4^5VSNA+55I)']
M\!3:55 =N4-F_:<PSN?;Y=GU<++W5U>!SBYT1TPV^2(@%EZS'$J"F(T#+$E$
MD\A,"WW.N'?#NQ7;'OL,O#_;FHOV "J15'7=66O0C%S2$\SK?2V\-T)*4<TS
M4[O(2 [D;7) &[10+O+<*15J-[Q;T? 'BZ$?0+(=67B^5-;JE8V0\RB#X^!J
M"PVE?>UFB 9T48(Y'K/KE*NQ%;RM./;8MQ?ZDVQ?P1VJ4(U*)7)G&&04IE:]
MQ1HP4^ 8ZNA4D$9V"H7N7:B&_] Q]KTDU?46\X;V9[^?I2A=:7[VLO8=GBRN
M8MKN!O-#']'B]O)>PVIT<WES9[G+9Z^NN)]N+'P4LT\BJ]IN)T4B!%E+47H&
MWF2GG:$?6M9EZ3X$99^>B1N?==J*Z+S2YJ+F*6$F[;Y*6*K.L?9)EL(5"+$J
M%)9H_]4Q0"Z>N\A4I'E\[ F[;Q!#RI#IQM;M&B[V)T&;V.I^Z"OHT[?7<T">
M?0GS3+X2@8VIY'K<)4'E6D:6>P'%QBR$#)[?B/EOCM#VPSBDM)WNA!V2O#NW
MK=TXGC4/ZI?3AJ=Y)%)QB:D S 4.RI8(,5H/.CEI2PC9=RHRO!_N(64+#7&C
MW5?4CT'/59B)CQ0JQ4W2P+1 4@$6P:552WCF/(M9VD[=D1X,=4B91D,DX0X"
M/;A.?SZ;GBS.]V_!M$LZU#SWVJ:B]IA1*D'DEI$3EY1,UVOK[*VOUYX_I&;<
M@]/%N\KIT+[V^W2$^62"LW(:&#BKEY'#='U/II^='-=+9RU]\)T>W<DWWW\:
M^OGL[S#-/DYK/<5?,DZ7XS(.%W&<<YS/-N'\#9<C%W,2*3,@'9)JCTIR4$+M
M%*&2YRPRE]7!M-,^ ^F@UW>&<UHB<'GZR;-3J,VG3]FIX%,6H&@A@-+9@F-!
M@C62Z\B5*?)@097^PQUX-.%@ZV@+$V1@W.MI/K<9ZF56RF+$2E V!0>B!-+?
M6!)XJP4D;I!,M&Q#IU9TAQC=P",</]XBVI59@UPSM]<YB\K*2%,.FMP:4#XH
M<)+\&\&%R-J1;],IH?<@PQMX?.6'6#5MN#7(97.>N/9MY .WP18!MK:!5;6X
MOO<\UOZ/W(1:_33U.<'N,IR!1WQ^B&6Q&W>Z!8[:*,7W1[/Y\@/.C]>O0Z%0
MU@HR(05SI!VY".!IMFG&+5=<8L[^^GW<K>--_6 //$QU\#4P<.(,5#]<39]9
M^5D?CL*T=B?\,IY,1HXA*EYJ$T]M21(I03V\@!R85ZS(Q-7P?9)[A_G 6WT_
M_%H:/M<&JV?6?G#W]36C<D9'TE"2%5!:&7!1,.#<.$TJUQ=S?64=3.ML.X@'
MWE+LF\4ZA(7SV )Y$*L&J9)N#OA:)OI(.Z\]-[7UJ?*D=;D Y[D#GGA) IDI
M[+L)/M\^S$'=_!S"TAH^V0:YGFJ;]ANC7.G>$2J,DML,3.< B@ERZ3(QWQ:I
M9)0*?:?+JX<9WZ"NO_ZH*Z@1O89GSFT<V-VZES$1?+(26(JJYAUJB*4$,-DS
M'[!(IW?.6SG@.(9UZ7<("V< 0GD0N0:IB,[O>GT(7]>O$-HD?6#6@1:ZUE5+
M'KSF!4*Q06@7351]2I#W']NP[C,/82$-E%?#TSY7+=)Z[?:B 7P(WB=16.V0
M7+/;4R#;-)%N-<(X3\,3WAQ<R]R.]Z&WJ7_\13!4LG1-T7P=QO/_"I,3_!7#
MXF2^JGM=KV[,IKAJ>GK1+Z_,YHLPP5_#_$]<UC?6.^?MG*;9\O$M4C6[34>C
M=,WK[0MK+<NU)M>G=W!KP=W%\GE8C&F[15P9]4!V"A$M14T[+5>0;$(?N&/(
M.]V0?B#2O6^*W_V\E$Z.*R,P_W,^6RPN>X;7(GK/JSCK-?<1L[)$:1R$D+!>
M<F?@O$V 1GO%@Z]);H\Q7=O!'U2ODJY4O7'[_.#2;U?B8$?HM?+C)72CI9<R
M&1"8:U5M4< 733,H+,'FF4O7)V;4!/Z0DA"_"][N+OQNO+W:2??RU2@X;86*
M$E(*I5Y_B1"-RH A*)&1L6C[E%7?%N&0DOD>E7U-1/@(YNII?.8D3'X-RS/(
M5TVUFS/9W&;= T,_P[75Q'2R7F_E&UJI=+(92B%MK(0O$%A4P+W PKDLO=K=
M[K9EM)Z)2VG5F.-X^G:*_Q?#_$+&HQRBM*+V.TBU?58AS]'5_H4Z(;?""LEE
MG^#<?KB'=&&G"Q<?ML$V%?.!]/HEYF=EB7."_.%H/COY>/1Z_'F%?G$)WR64
MM146Z!@#F=,F@U=D4^MHDO$J!BFO1\0.R])[AS!DN_11"=M6^ <W&4Z#=V=O
MY+"\^,QL&M[5(<_'TX\K^ZJQG?#P!_<R#O:<@E86P0K%Q;-K@XS)K"(:D<\=
M-$,#)9*AJ901$!-:R$KR0&9N)MNSS^9Q&Z1]-]:S;LG7>B1O&GNPA1M+Z&0(
MEE9P"$ &>(3$8W$ZDGF?^A2=WAKBH#1Y$PY=WPG[2.OPWK=V,J:($:3TB= A
M:0./"I")57B W,0^]_!:>M\'T[%=J-1%5EUUY@N<+VMD-$QJK]3W1XC+7VCB
M%C=K]D]QN8>*W.DY+33B_@-LI0!O/' 5Z3M+@!RAMQYY4A!CK&F.$B'8>ECH
MC2GT+^-RGYS:NW'M=1Y__M7SBZ^N"_'3?)9/TK(>JBV6LS2;T*_-YO5[R*(-
M*L=(%JWUKM87B!&\H4GQBCD;2\"BMVOE\N!'#TK/M:/*E2/OOO)HD\.Q&>-5
M5$P6JSP70,X.>1R%_!Z'-!7%>*O(Y\DL;)> L<7#!J6T#LJ+W>>\)Q/FLV]A
MLM*A2K'@9#:0+9+W6S/S/+F_E:J2##2=2]R'!1</&M2AP4$9L-M<]Y3^^EXU
M4HEI41L*T\!H<XHL0V1DDRNCL[>&2[+'&RF+(5UW?SSM\* 9;^8 ;<K*79GO
MM=[]V:"3T_7<*@!:)D%Y9: .EVP=JQ@K6@3=I\_.%N"&=$V\ W=ZB:EE\]UK
M8UY#Q'/*+B4&ID1=$=&(72A@I6.)"V53ZE/U]RY4[4=\1<K%&H%15E5NL'9C
M]Q"RC[5-@P@L8;:].E8_P-48F@6^(V<V] MN)9I&>G8RF7VIKG&9S5^.%\OY
M.)[4"7J-N C3?-'(>!2#\%:;!(;5FMXETRYA90#F2XJH<L[^>JCR%FV[Y1,?
M:'EWSG%K38A^D_\H\:*U!GT=HD0;OKUG;.B^P32*"%W4]ZEY["&G)!(JD%8I
MLK!K^R4M)'$H))V<9\KT:C]YB6+_QF!GW_4N?/DU+'$^#I,%?>_;\@X7./]<
M;X6@Y9*93#!D)":70)Y$(I^"JR@"36KD?<J9W(]M2 IH9V[<;/G55"0->\B=
MX?K7;/YG;;DX2[BX!DSJ4E 4 6AJM5&G-#@?.01N,1KKF>O6MO!><$.*"[4G
M2R.AM&?+Z_%TO#C"7$O67 .FK"[1I *)E0PJ2 6.BPB%N^@P\WKBTI<MMX,;
M4@RI/5L:">51#)>KE8ZKU;56ZKB#*;/5\WH:-P\?<"-SY\Z:TJ)P;;$XP%2O
M\=4RAR$*"UB$Q<RXYMAG\6Y?=GS?$9]["U$&6RPKM(%&VD"%BQ #SQ"=+H$+
MPZ3N$W+8"&=(1D\SAES?J?871#--MAK29CQ9,(=!"$C.L7K8YL$CN7L:BS:1
M&5]X'W/G=DQ#LG*ZL:.12-I2Y'Q<TC'M&(+$PD%I+<"[S$!+%0IRDXWHDQ__
MP.X+AS)>^I)@ATD?K-$RXH<V6T;\T0V7ZX,^A.G"G39<D.%<+(9:H(R#5\J3
M+K%,%L4%VC[A],.9+E>_^[)VSJCPR'UQ$J(6#A0J).U)8^>>91V-R%STB>9L
MA^^[,6X>PJ&[C9LFHFJFRN["=JYC3?;*AA" 257KQ!A;VYF1+88RLL0P9J<.
MSJ'OS?[I1:!=A/1(*O&TAT18:Q_1)V7UGB?U58';#W)/U;<ZG[JU,4<ER:=5
M;\+IQS<8%OBN+H"WY8_%:;F<U:VAM4OM+_'3'-/X=.E,\]GMYM7+D4R>>0P&
M>."VYA;I6B<*@5NRV*)U@>GMBO\? NW^&^(M&&LP#E/6P=7[4UAO4B&Y'$%F
M =)QJ[3UAO,^U^CN0C4$'3I,,M[<1QO)MITG>=>TD,[(TN6:S9E3KBU+ WC)
MZ0_KR*VU(3/1AVYWPAJ"ROT^^-9.N@WMO3N6@/<YJ$1T4$[K6G2G-NLP""FI
MQ*T,T9=>,=YMM[>=<JTVR9G^/<$- K^]U97-2>2B!>B@#:@8(SC:(4 JJ[A/
MT93<QY5J-8)!U:1J1L0-"5R'EW?_];G*0ALE=$Y+Z2$7R4#YS,$9&4";XES2
MCL5X/:.Z\PI=X1J"2NA.K(:B>:P;@^N%+_O<%=STA,ZW!.\=5+O[@?51ZZ5$
MSSSQ]:*Z.115B$N ?M5'U"L@ \)!]"RH8"1FUR?1?2MX/5+]B9DGES57OYT'
M)*0IW"A-2\&0S:08UFNZ)M5>*YBL";G75K4]QB%X3OW8M4W^?P/9=?*%+LNZ
M"U:L1*/!D<%,8Y8*@A,*DO3),,:LT'WJIMX":$C*KC]K6DBEV86S.M;C,#TI
MM91:K8J"YU6<BQ'*U=K-RF1RIM (\$DB:-+W62E;;+CNNMQZU>S6IPSIG+6?
MY-M.=K/MX4/XBN<]A\[W*>%984*17ZYL(C0>P7$KH&2;3. Q)]/G9&(#F('=
M0.R\+>PKC6:T>$4&Z^P;DGV\<OG6FX6<PW(ZY, 3()GA9/C7VSHAU5:]D4O'
MLC"A3]F5>Z$-[.)A9\JTE53C9)X;H[^X<4E85!$%G&!$ZI 21",2<)F8)BN)
M1=LGZG,WKB&U8SV $=).1@-RO=LF -WZC,.[WYV2?+;CF2_1:9\B^&AKG(?5
M$$]"0&8PT/^88[<+P_T<\'6C;.WKUM)'HHY&11/) E<"E'097"X:K)8%DY,Z
ME'NY=>]3OC^/^2%TV&0![S_9+>_)W[(!TA8JI=0>4HGU]BGYZ\$%"UDFPVV6
M"EVG(LW[Z*=A.<F[$*6M9+JJIO,6XF%ZH\WX]==[1(9W>$H+];3OX)K=%[[Z
MK-]P^>IKFIQD<IXO6KC[K*573H!01 L5E*R7&C2@*2PXYABYT%W6ZC;H]MVB
MZD6S);X9?[[9S+X>OW!OBBLL IF"I5YF"^ DK\'%;'4VR:G<)Q/W;EQ#TFK-
M.71]KVHHHH:W1S.6VW'=G("02V1,D0O!+8)2FD/(SH'1P?)BI;3=+AX_#.F0
M]&!W:G45XV-IQ]<GRY,YKJ<,]-&/MS^GLX;<<H"-=.0]VT\T*6,J%C03HKKR
M!H+.$;2IG4I-*3KUJ;+Z$ W1=-3K$W_F1]?Z_1]H=#@2AA61,@>#L=2+3@@^
M<0?2NZ2\D4:9/L[LCH"'I$D;,NT!.K29.)LIUX>!_8W6^8<O./F,O\ZFRZ/%
MB":":RDSL%6%6>2T6UM"KZ.(JL;U>>Y3_7\_W$-2O(-AXE["?21"KOKPS$[F
M(T,F2,XV@L.:N\6%!YH?6D%9)($*M1=]'*?=\ [IL'@P!-Q)F(]$O'=X',9D
M\<S?EM?C!0FP@A^A#CS7KGXL)@Y*U.HZ11@P/DH,A26?^YPF-@ _I"/JP5!R
M?S&W26^Y'74%FI9X)6V90*YN,5PL*&N#(=><O"CKR&^SNN;C2 _6HQ#.VB+*
M]2RIS>'__7 ,Z4B[ \4.+:E'U+D?OLQ& 9-7M>TRYX&1O:H<T%<G0$))N(/U
MG<X5=H([I#/QP6QONXBR:ZCES6SZ\0/.CVO#G5JB-<SGW\;3CP3]9+J<E1>S
MZ6>D0=0"KK/E7FGJ.SZI1;BEQ2 ;!5S6H8RR*=XQRXD%WM0: PF\C!(B\DST
M<$:R/D5,UU'LNY==F=S+,UDME+"U'[))M02O8JQ6R430&+*1.B<=^VQ6F_$,
M*12R,P>N[ST-IKZ92EO'<I$)Q'@6=3!*"@6*90:AU(N5C&G2MH9AZG/I8 .8
M(44@NA!@ETG?4K6<O5__B&&!__C+_P=02P,$%     @ '8*I5K#M_VZ&9@
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MXYV'G]>M=WC-E7,,^7SZW=[E&,X0/_>N/YEDDE_1E^->+"5GH6EW195 F<0
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MC?H*0"?"H=T$W<#3>9,GMTQPYJ4D9RL";:FTG2I&8*22$!+34B(74;8Q<N_
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MFOQ\JP6DE"+7V0KCMTY-7N/Y)\"=?4E_/\5MJQLL2+(<7;$61'"<G/44:]#
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M+KJ//:5-P]R-UK;0&Y>%%#DF0Z:"5=J6X%EPW*F0=?%%+.V-^]CS&K;!%8P
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M[^!E4K1DE!HC#]@LS7@UJB>O_<Y$WJ"V^2%L;X:#>+4A,16\TII!4HY0IE0
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M-L3OACI;:&3)!>!N\>D%F/CY!9Z?TTDZ&&.L0J?O3&&2?_#A$XYR+]N F<4
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M?NLWZU[W6E?^UYKKNF<8V"1L$;@M*RDC"2 @( !1\#\ MG3[4L+#RAP %!0
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M VXKHDSL5$9V])R@&!W#6*N9>N(.+XOIR)U4X2M%."3ITXP3#OX!R3]OT?\
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M9H>KH0\YHZ0I P0H0[\V+REZI(]W0F% ^O?G82KS]"=E,*!Y P:$%)Z>R_F
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M]@B3WBD0I\1!N\&V%/$C'4:Z[Q.2,QD2*(5=CK9RA!A=J^8Q\)0+59^97?&
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MG.A6_-EK7F9P1N:&;(2*C^W3%![[C8[G4;3FV*VI*%=O/N/(+![[X8_33(B
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M9I.*O Y0 &9P+646[C1:EE5&JO2@?R4=\"I\:IP'<)Y.N<KS*-2M[<FEK>$
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MG,C.32;2D%_U6?:'5&\L;P<:'2/V;& ,3TPO 1S[^9*^C9-JJ0Z1;O,I4N5
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MWDK6<%71).W&+&K#>^RW-[??3MBMZW)<HNO@?A:NJ68)*OB*E!&:ZE!F(^#
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M[7GVT[6&0(:Z!(:P'@WY6>Z*2R2W[-,#HB3__6,>B^G2")E/+^K]KT]2QQX
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MONH VBH>)@C@-0!G'6Z[/O'D6^]J)!;K3%.T0@TQ=I-KAMKH<,RRTL;V3 O
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MJ&1:V;T3T%2*-^!1&GT1%_[S3+?BJ:,JFV1OF]XQ;![M$(84Q!?*^406!]G
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M$^-5AB7#&U,YY^C#8+TEZHK63(WFJ/D>W?5)\.%7W=C/; Q"AE]:Y04[(2;
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MJT6IBK%4S51I=T+DU<>"#DP( [5[/ K[V2$*'SQAU#=VNBJ^LW$Q/WYUQ^Z
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M_/+PP3:I<7XABNV;1:LEA "Y=!6KO1537/U010'B^,;68WGTVK$Z=5E?7R:
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M9=+%RA;N^LT$NX8/9Z1'.Q[MCMK0$I:B%$"43#SR!<OU$[F9$H&_W=NHHJ5
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M.+_D_%]#]6I<JU_=!OO8^8=T%B'9N$QP&=!+8%1CL$E1'] R%(5]?6MZ3<.
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M0CN*UQF!5T5.R<&A/;=<:M!5W1'=%/%UU>=31>0O"G%KU<E31QL=K F8'KV
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M>V)I7W-.Q.YZ[[M,PY0L\1T.KVSTKU>:M[-L0#8<BYOY+C4/%O&Y\1?_@U2
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MG!6@30J.\DMYY;E>%<&.^ZGY,X@X4,P1_4!#&DO[M)#OK%!--D_MI=27C^,
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M(73<P%#.@^X=_6VLS\<9 U0W3CK;43_S+S]OQ#9UTJ^N-0U(/-#=;]8:$EC
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MV-+K"J<*U&3;((B4U$4VGPCY*4>[KR"#E,8YH<.]X*C3_-)8;/2-@Z^'4!K
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MRM/:GCP?@?;Q(W(T3-:A( [E!BAC&,<ZJ1&?1L_M1@6413F'[+<-,7D@GIV
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M\)_EZT]<AL]N8G;'=DM0RKY#(+WN!S&R=]"M@)>H,#]'V-)S9SV>NW/NSOK
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M<)-LL0T#4R*BWG>%A"'NQ8819KYLMIE0P.J;<7[9&!FG0ETK+D;3SR9U?D\
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M]S;]T<=.D.@UI\ WH.'",N9]&K"RN[C2I[ =E@!)PL(;WL<H4B2K$!;.OQ7
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MZRSGT%435IW/"\U[^XMGZ3P?Z?>VE\^PGZ^P?3@@73$FVDF(*3@QIKZ4_;H
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MW&(%O!B#!\*ORV0)A,E:F.+&<T5JE"RV)[;W][AU;[?4=^NYP7,:&@:[9W_
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MPFKQGP?1I2\(AKX8905+Z7S1:!D) U7ZN6Z#-YQ%?NAK',(3[,OM5D^+5NS
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M$IJ0G6?K%T%/JUP[UO;05XT23/51KPV=>9" I7/5S0&V>"?O.K%+FA=]?X4
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M=C>BLH@([1;5U8QL_\)S6$R54V2@X):M2H/.#YZB/_^PX)^9*9Z58:\?RA1
M$LJ,\RI#2^X)!Z/.<+%<NI\7V".OS"@?PUI*%_T$Z, ^7!^";93,-U5$?J.O
MFX_VSM\BK)'0HN1T$^'A9A[>9K39(MAF7^%_E4QQZNA)-U*W=DN"QXD9'E2T
MD#9KJ 0+=G2^A[&CFK?BURZM=87Z4NS 41O"W+55?H47"?@]E0Y4S@'UYNK!
M[LLF*3!YY<0\PYR*5/BPJF9</2&8+"[?L5@-@1D2#<H.7:=W[I3>H7*:M!G)
M#&5_^(=C4>EYJT0S??BMAJH@-X!!=);1$2OO9L"U64<9&W45/B>/ASWLBI\^
ME0UJC^]O5GNXS$P_W?M8L4E-<HA3 %!^V$P3&TLE>?PZ)?6++#O[]U.'L2]_
M?;%@YK]ZIO.I>2?D) SQ3#_JQT'/YKA^WN4E]XE#*6NIE]"-4ZWC2UQODW#6
M05_)R]1<_?NQW=+)3A)=Y2%W*;3&>Y]A&5\LP; ^7CE[-U(B,.K3.9S4XZ%W
M'UMAY02W!3W<3TR;]8+!GP$)O"/+^O6P<BOK-YXS-%OI'Z=AC2N@07'@\>U/
MNXPZY"2QC8F)%^BR]#1&I0$3;7 UOPSTC" 7%BI!;?QJ"E$:IP%2__-OF-E)
M$4N%N38<H,(IEH[ZV,V<+SB!S#HVP*Q;"01!)$T$^8RK_MNAZ[D;N^270"7]
M]Q.MV:NFR4WI$$AZ].A3,VTX5 5>K2HDW);T];/@QY%']" .FE=J39-;&K7]
MA"4@"=%B2*OT-PX_-8-3Q#WS18>)>N?X]1?KJZJHW8#J1Y.#*R.07XZ\GSR\
MD$$"=[GD?CFCJR?&US@^JK<^?&;%J_MJ[ZLD[5BJ*Q)@O&]"/24XG0C!PZ7+
M@@8]<#1Q3.+SE#5TQZ(<4%5,];6$ZC; O0F#S88/;T>7COL/#7%ZG;=??T9R
MYM)N\4?,Y/Z(*&DZ"^6A">3BAI8.69UT/>)JU*>1\EW[-TETR>:%-ECJ<2I>
MQK>5YV6Q/2:=,[PV9RJ9I$02[#:UE9U;)>]/:&GJ;8X]()L*OET9Y!3ZZ:^-
M8SOR!+O-#/2?V>76K=#!R7.C5'DX4'50?CY/E'U'+>9B3LJ=KRUV1P)ESD;Z
M-$\*A3'BUK7<:%T>)*LFX7.T7?_:*WH*35A=LND\I\%O+M;Z:W&W\^:&E24;
MD("DVVG(2+N"P+#'W@5L>(&EL01BCR_BE]YUCA^K[W<Y<13KX4JQ/IPT$M4^
M1I[@7N:9>%]9PTZ J$W,$(:GYJKS0;SL1-OZ+P-1N8" 77ABX+"673>>E4/2
MM_1$OR,B/4*ZO#^'.R9[_.ND":F:SE(D6Z?6M0_+$A;+.X4<NU?U[&$^O9=B
MHB4'M7H)\F\>,H5'U<*XKQ)"ALH@OX^\K#^%9:(JWM14$Q+@\)<IJ/E85.J@
M+-PTMF6SVB1:__YS)9A%WO?<Z+XHF:!U2[5UO[S(@LMPI!_[]@5KD@_$VK!W
MKCU9;?B);O%R[&[HE:P@WD!@?\"DX_U?2E1)HZQ?/48"+31VY@RQ%<,]"#]U
MJ/5\R+N*4(YD$]BC.NA1>)Q7O4>U6X?(&2*>)6/>3EM94?F&#)7;$K3&R$AR
M^%&[[F)  &"8U/4/G'8N(;CM]ET4>67[^!C$8]TN&7N77*U<60J?86QZ?*R#
M^6&D_)@VZTFR%R7E44'S3L(]FNF;=D;\W5'ZX3R)R\M=HMW2'DO=DB(%TK]?
MF5"F7$M_U;R"F??KP7:<-$JP0W,_$G@C5E/=B-CF<-^PF?2$*C;O7$8$Y;R#
M'9,);>()<WAWP](\P+@#(O,"A=_.Q1WPIT#C[L&T.>V+=1.3*M5X/;,0\@2Y
MZ>,^*Y0Q?S'/2)Q-CYH-MI# )\E<]N-J)5\.<#TEB7;S7X:5$=U8^CY/P^*1
M("3^LD.&M/3/1M#_P<1-$!+@.V_[,HK0.?Z'8\M50B]ZMPG-=4Y-)BW4];^_
MZ_D+M'Y11#+"9!'B%"-C]P]L]=&'?&K:^?=H3;KF[L^RDYM0)<8X9:+L0%IA
M8*C@4+$Q))"U[)+^9C:-\*D.UE\.IR-I,U@4^[IJ7^S]?FDPN(/Z^-&F!.LW
M6M;6,Z[1U_"J8_1S';37]E+:GS,MNS:\+F[7:>=%V^BG)GF&*9(/%+YM&O1M
M,E.E3XQH8_=BI9DO*Q'^JX="D1$.5_5 X8%P)"L12>:[C:J9_!$057]$!DBX
MU \B4'T6.*VOS'339DAH$KKT :>OGU?77R3Y41,<"50*Z(W.-8<K,QG:!ZE^
MTT;/V)Z)M4W_2Y?IMY)D/!Z_O;[67!*DQ:Z=*FTQ!\U"U%4PA,+_P6,%.CZ,
ML#Q.\>\HW6NNZ<JL1 WV%]-=LEAZR<33AZJY!S'_#\=F.X(A@;=^<QNHO2S'
M>7@HA\E? 9;U0Y'@LL*+TBT^MF+(G\;ZLR@[U=/$:;K_^UK[$BKJ_Q?LH3'V
MS\]A\UF"@(2?COVOJ753\(DY$F":5SQ30@)9Q@W2?V(^-@EV3R230AL&;S^)
MG78EMH_49.]]2Q'^8L.NJP]*J:8@OG[&/]FUVB\2(LK2.#-**TBB;L+GY_F[
M?2F:^F9.D&Q2]S-.YYWF*9?UM(ZHJI[F]:?0QXA^"O^@XD&]/8,Y=])0*X-N
MA.Z[<[ZT<OE[C"M99R-'1ZM@2LU>,O&W7Q;*#@6Y2$8XMZ:^Z*(R_;+7)1M,
M=E&5NGT+AILX'GC9S]Q-+^48LA"#=:\@.:!$X-A&L8MP&$LZQV90__8JB.--
MG?<T]PS\L"P%[AW8]=7. GP,Z;5+H##Q>[=P*5)(YJYD5=(^KI<CGAU_5HMX
M\5DKZ;;HJD61R'#%4EP]#EOFNY'^I%8?GQ!N6#ZI_H,Z R_IT1X_EU'5FH&:
M;*J<CT_\H(KULD@@U\<":Q?K]!LLKZ#9:?*37:K*]K'[6+J9]KID&P?IV4U6
MUC6Y>>VB(O.RD'A<\7J'6!U1$/4($DAC[R-)7B'__N6?@/^47S#[OU'8L:G,
M'1D#!Z].?2RW'Y!6OWMC4.UI'<K87<@,:M%H5R]?1_BT(P'_*"1 JM):OZ$J
M<^_WEV1[2T^WR2_/I"^TR'";/AYH4G,W+S>8'*\@@5W-#_:?-NE3R7$(?'\,
M]:1^0S_SW5<W5$[]#0DTHV9):)8E_.(X#'%)CV /PYPQ\V;'3S39G^8Y/X"<
M% @9008\F[<'D<"WO/=&1ZQ_ZIK+,SYNK2K&\QH]G6T__804);Z]X%_H_U>B
MS:BK$F3V,ZE1^VC.*.F3P__0L9.KW@[WARUV2JEO(X$KF2T>7RK_!4S_X)PG
M_YL_5*H]+)UN:_0L.F=17MI<T?_^3;7_]"#[=Y0,))"X?6Y]:6L;C#!IWDP_
M?(>=]^L7*-E1BVD4:AUWA/ _UD1E</2EB%F$U3.6S% VX'O)0ZV54;5-8:B^
M0=(GY\DKS6._NVF&NAF"R#K5',4SV=V5'H&P TE_$QJ%D%HZXU)6ZT2-ZN)'
M]KMNX+,^)&!$>)!?0.U? 8$_N&2[8OO]"T:HPBMA7CBY8DS4-%+TT,J35-$K
M5'%OUAF--L*9<+Y80QIW:F;<ELH]WX7D<T=,FS7G/8^4ZQYI"AMRBIN^RIGI
MUT_LMQ5O7*9,LD<)Y&[6/)GBXQ\>*^=NN%UDF\2A:WNV(4R11&GF6DZT<<U9
M%MTEW7CTJZSF:W*IXPN!O4OU-F/!E!F6L0NW_8.5GN[YBCQC&_-'U_(]]^4\
M\ I\NXQ(:!L]E_=)PV=(NG>R^>2<[-VJ:J[M>!&^Y[[PXZ^>KE,:N#(^,,\!
MN:X_< 32I)>Z^58OV?[SE*?$/ESPQ@EI^H>=$Y_SN^@DWQRDN]>#9R+JFPDJ
MLRV#AE5F2F<^]ZNWKY="AJ9<UUC#)4P\,FRUJ\XLZR9?)6Z*/>.(HVV:K:4Y
M7$!HSI![]L^WC4=&CD5S344,-<1M:)CT K2] T]<'AMZ7AW6&*W$O30^6M/C
MN:96M2_!7H;VG!*MR11>6DQ&AYLT9D14XG;+N4ZQERHH^*JF/0G]FP,:GQ&9
MN2&=L8G3581EMYE!/*RQ>+%T[=7<+A>BLM162)]T-/HY9T9-94T"W_H^G8=I
MD"S_:FA'7(<40]6.Y72%Q!@!YM[$A&+5)Z)H7FUG88OP@S.?L6QZPJMOI6!G
M+#E' B,9>UD/B!PJ+!:K+MH8XYY/2*Y2?QA/:2*E8NZH18LD#RG6X[S_*H#8
M$?4\29;0RE=3S8&MEJ8_$*91TH?ZN7M[N2%@#&$?S[(1J+#8%/3!_5ILJ?[F
MJ87,S6BAZ T"KWX9EHQOJ1"548<-#0K["YC\YI(NSO/;R@LU4\>.U+OM;MZ2
M)?EV&&%%:^IKQ&0]$NZMU[.&*46+J=I' ^*.'R,28\5(V6-#CY,@.XBG.9E3
MO9",KT:3F,0#5^3G9*_*=W^K::;R'-;\W" [)O3X:QO5U].5"@.)8H&W'\+!
M$C?6/$OO%;E]?K4;9]=L,U>$Z%UXB@1LA#:_'JV&ACX.2'Z=D!I6C!,;$$[7
M^&F&R#-18_B"WYPY,)IJ+*O,%!:C! ;7IQ"US**OJMG1\:9)!Q-Y!C\BDN-,
MTV6PY"R+G3"\?HT52SK>>,R7GJRYM!V29SS)*;2S$4!M;?.6(OUM6'YWUX=.
MTG14XG+>\WD;%F:DG-#CD[?U1,^<3X!9GA.7[+1<KDIRW4:,+.*X<>848FQU
M0S>L9T*_]P()E#(R2UA_XXC"6O.N+$H@YD[GUE[?*.?T4(B\G__D'E;XR#%"
M>$P -X+\7%O<IX:[N*]]WN!^C_FC<+X U2D,:_AXY4R+,FH+B*C(NN?/6#%"
M45E'47%D-OF>7OAFVMUYFL-"Z]:6PT;N,Z5 U_<5=MHOVV/8&"G[/<^>C/HH
MDD\H0[BDB273&";J5T_73R ZHIOFG1Z?Y4K[<B6+WNO).# 7!>)>)39GFMT_
MT^3SG%</:Z4*RKE:F#NCZB!PC4K\MKG\BRJ"V4ZN3F@.:L\<:()'YMV7FYY'
M<7-$D2(F<^;(L;@>?8F2\LP,MBW!5;A61U+G7E;RP%G?QB+RX?<EH.7536'1
M#V=:+J:CQ5-^XU[>A^?=B^WB,Q7GA_L'J\<$.]*O>"[N67IP[83:9"1;D$<_
M'.QT;.S27G[1[@)'2(R!&ZS=<L<O$]R"#F]&=H.S^15?7M$5$9?EG]0Q?V>C
M_"[YBVGM/F?NFSX,S#M/!J8-EV/2Y-!IAE:IB(8J_8P/)KV:QQ\7M0B9][8&
M=K@,J-IVIL6FI);404S@,?50O5:BQM1#".3P-,6];+[8K+<#[JWU%O;F@1.>
MXU>_U'&[0$O,5XZ.O+%>I-4LU25V^H='Z7/-9>-M4+Y.R?9O H$+C.):FI%8
M^0*)TU?M4JW.M5ZH73?J<\'O:TA3\8T-@[W8]VT)-HXWVV^%#Z[?6#.F'44"
M%2SUZ)OJC35)HKJN3[+#Z3N*>\(4QQJ;::5GW^:9W?"%5YX?P!%88"DKKN.(
M0Q\_@CU&?)A87\2&=@5QSISC<K!ZM!=MO=;!+D%UCFW<*LHK7Y:2E$2YB[G!
M,3&Z[Q8I%5@ESX;M_>E/QS&."O/+1NQ+8K>^(71?D+M)X+][!FSPZSSU916W
MC;4U9D0EB97<$?4&,N5H.#+4?AMLK''K231Y!DH0[8F>8TP:.;Y&Q*78]K*=
M;\\=SPKU1/F=G-YK$GW&"S).+T70\?R-/5<D;2K&&E2_:=4T[B"!([?4EQHP
MM;":J6GG[ "5:^/\G=[N;V<-DL4;!1T$<^N&#]Y2*8D[5+RT9!69/CU]C[W!
MKCY[J:J2L"@A6)HJUK_X*<*!.2^YUWPDHVM<LC:C3O@8#)$#(X$NXE++/A_O
MPHV&\\G\$CMCSK(1 0//B4=5?@H7"1%97@_MKRI,Q7==<$ ^)JU[NK0M[<Z=
M*[=8A(J,;!(RTA#XX(W:E>+V>G ',HVGQ$G%\<9G)]TQ]N?MID#?*^;RD*G<
MO1K'G>[3J-YEZ=E/)81UZ_DA:5R\T+Q?W03\(N*U;8ZXI+?)\,6GPEOS(J5<
M,VI@EJ7Q!^<K&3H1<UB#(;?*AM_U:< ;K%UR3NIP.7S<XE2J]SIR1!^_>00E
MVI^ SPBZ]][;)?%(Z,OSS-GB*NZ2TM2VHU:*O+,9%[/^C$-*-2A!I\Q$H<!D
M6MG+C[&;,_K3H%RLO\G4BQ<P\Q)O[1C7VE*A)@74UHD_MKC;%@1=@E_0MN^2
M1T!WML,W-[9N$H.4;9EKXJ\GON"I]D("%C3HG=[YA:C5-$C28G739L9RA*NX
M.-N",X=9ABE%6"(ML^KI!<-JP3VO F,YOVHEQ$ 2_]5!MDF"^7VZ-HI+NUM2
M%&%&+(C6-DU>YKX-#S58]/:=ERO0I=.F!JU[<Z.EB_LC(9W$V^#42^U V"Y!
M;8ZM"\C[I"()]'2QKJ*V2E;++"RV*#LMK79;TW17^E6E@J\D.+?7U$$J)_>R
MQ#KIJAM^Y%VT($P[ \_[6P:KVX=3)N?W#XN-QZX:.!'?+;HCKZ:B<#9J<G+O
MD/IQ9F^.G=.$(<A=VGR?;N 3,<$R=9"T/DG>J<FP<OH%6@U\O[J@L:3A4FF<
M)S1-F5\+[,=053<X%;O=(RJ+YG'5\"QRNE*GU9]Y]/"<^MQNQ;1LU%PK >A2
M?)-B21&^<$9G T'SJJ,Y\SU+B56 N%93Q;=$X3NBT3/,7KQXAF5H!AV^(+P:
M]8W#[[%24ZU:&>QQNPO'P!+T":YP[XO#?/O '/ 9Q-B2^=52Q!$JK]@;WA4=
MV4T,,=OQSR^:[(/>L',[TAT%3P(M(_STR3$OAHH(*=8VYPR*[_<<=3Z.I9S7
MLPSHT330[3I-C8DTH9O"DBQ4:+BVW.HQSF=[SWCM9*H((>ONVU*U.34PM9Y4
MYZI*+)5D&O>QBUM;QG,QLD7+/;*@MV8+:XU]<J6QN'D.&I,4=,O!KYG6]_M#
M1ZX-[J%S1MO8MS&62"R/?4,OUCS&I85RM=-^%*H[3;9SLC,=^;2OI396(0U$
MP](^V<EJ&U4G66A54^"\WV04>>8[&9;LF!G*CO\S:?XE:?YO5WY%-+^ _M0?
M"51!?@^/#D+:Y++EHD]9K?3"O_G\Q6G2G^'A076D0 +S6PZ92$#_=W?#$%*L
M9U&+CS5Y(9T?D8#Z1=[?(?K%$96"#^@O_/H.?M^K>EWXTE5Z*/=O"/_=T6R9
M 8Y\GB2 NK*">:*40>%\R7#*XSP@,^8->X(90*L@>?O>@.)_^H_@_#.%_3>D
M<_,@B^>(KW\$SN3D$G*,M2\H>+]Y]PP);!$NV?P9N694S]_"^O<W>4Y.TM>D
MXY754)MF^AN7<GN_FR:_.FED% ^R>RP\^/MN,T4SAY^1@&+2;_#_/0**MHD@
M7:4%$'C*S!E:,=4UO.P[71+7?3YC]37C;Y5*\$+7DBKC(V#".RM$RG;F3TMD
M,\._GBOM[Y.T8+ -L.ZN"R"!$..;H9*/S\4URG>3VG($M],MK<P,1)^C]SAF
M;\W&A0?-ORLU#M=+#@J]A9:$B1;C5"<HB49[5T2@3\B .EE5^A'1&Z-74U1@
MO'LMFVMLE//D",[ZL0;<;P8&4>2K_HRO5I8\R!*4<0VD9H6(L36DLH4K#9([
MIGEV*IL*S3D3DAJJSIB;,NP6QM^TYWE\N4<=XJ;>K\(?.0E_7YQ3SIAI\+$
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MX.8!+A?5BR3R3M#X.N]IHI)]!>WSH$*MASFCU-LLQWX^_M4D0/^V,/<&2HB
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M<(IC 6E:,= \=B55IP_TKJ]("BO]C?^)L'O/L"[S0!F9P?*Z@O7/)ZXR:%W
M#>^ .DU6:O: \O3U%!D[$U .<C3><)L<888RBT8?ZOV..O]UT;JLOM3 "61D
MEO^!Y(*.T7S@M2OVN]G),M?<GM/)Z-N%<_$C(/H$FELUMQZ&?[9L\3P"5\A$
M5F-JPX] 5N"%]<BAF<:_VTB*_R$*S:SQX<+4Q]QJ\8S0Y^X9.$-/6.WV??A^
MS7#;R(QQ<<$?<'WL-XI?9DJ%FV*$*R&@&U3A!]@>J;_0WE4/YET\B_#@W+RL
MI+_E5W\$TI_VQ1+#IS^)0RPR4QX!&<1*?1\/MI8_J"A3IQ7<YRAQ]O0B1U]H
MWN]:_6[)^;/UFS^)A._MZSQ\"7\$?,NGBC$=6[9)_W>F&:[X\]W)YQ(A43QA
MT_!QR'HLJ?]Z@I\4?IPSC3]<E'7P6#/-EG9I8))"H")Z2GL'1S"LM!??FOE"
M57 ^QYS:_EKH)ITJ5"6V=&,X_-^;:]'UXEED[K^:Z[^W8LE3GVQL#\6;:JJG
M9K*CL%7?PS+)$+'Q8BTGX@0XS=PI@LQ!IO8@)Y1^K9D7USS"KHDWVC]"'X%L
M^3/MG1^AL;BU61!>5EQ<C1B3677JC&#ZP,/_T)22QURT,LEQO7<@RJHK.=8\
M\<6/M>T\?R<.XD&=E&Z%,UI0%5<]_B[X_KD:)=Q^%V LGW'E=S%PRW2K4LF%
MTJQ;V07'V!FT/6U!\X/GYL5K\:FJV<+ 3W(#2&>W^:&#3!_,X\@779F04 39
M)W)%W^_H4]JP7: )$5WTR*=>@!AE[(PM?)&'>4_1UFA)CS\A/,^:Y+@=$LS\
M;(M!Z\<^&.I<,AKJ1@-GV=:'"9/@M21#,VX8O+"M<K!P8]T[8Q*'!6*I%K5(
MT"4D3K_8'I+ \;45:@^BVK/F%SB1=1EBH9;^:KP1.P,&$*-5#*X*E?3>Z<S-
M&&P=>X7EV/2A@!6_![\H,S-8(?VRFR8[;H +Q6E^;^Y4/VY IOK,+%&^2\S_
M92QE:%B;@Y!M\BB"M:N&;F.TAKS"J:+%.=)=[48P]RFI!$F#R//N48>>R?(+
MV/8K Y66!NZ;]:%H?;QB ILJ!HKG\ $B0D8**X-S%RM%^JY^US8_F'/FMAWN
MJZ$T.$(ZW\ RL-5X>/$\(YY@-'N56==BFMHO@Q.@#Y7U#G'3):\'8LND<5&T
M'+^$M9H_82QT75>UC?#W:K5AVK?*-4TC\9=O%0ELA+*N3<P7\@RN%'52N_7(
M)Y3*P^4\6B (4?.)]@F-4^\V0;IA\^ZJFRNHR?7O7"ITY D4N6/AV>0P$E#9
MO(UN<>#RC) $T%/I!HDY*AK+P#K(;B4'62G%7<EH!#Q.>IVV\Y4PTKSS8 LX
MWCNJ8CESG\R^/,U'P,1@?D0@M'J0YFW4>S+1X7&W[A5A5/JJ(K27N]SNS3^*
MJ=8;IS*&M\G!SR/%)5%8R^'SR9K-*%])=X%&_\US[C\HB'S-& '6@@H+-^K&
M+MZ79?*(?525$; 5W&:XNZ-^HO 8:'S>!/I0KT1KHG<#SM4AUOQ-0T,5O>@I
ML;Y^$IN;O(A"OTK?9OCR; E0%5@,?%P@;JK4T$$WYWD"4NH=[(CO:ZM%79:B
MD\&N.=J>0G(V]!KEMQ9==^K;A!ED=2C*><\^+P>L#R]\YRD9#P8V/]T3J"?I
MUSS))$>S<:@H)8N4*0%=RKH<.S;E(P"T[@])Y;NJK^SLJC=7-@8O/.SV6LLD
M,K8C?N4:E_0&-2]^+DD,!E:<#+XI[["(8^@+&!%(&\W7=0B4OZ.2,E-_Z>=B
M#D^2Q#LD"CJZ.9"VS6YN?MMD]KDXZ_7</+R%"4;)H9!D[QR"2 _1B773TXP*
MGP#&+G1]N_[GX=E5;PV+%%%QPY+96Z^NA KO#58-1@XB%YDH:WFZFU;+ROF!
M3]HK\XD6=T^[/Q.>WG/03I%'\%A/'A-F<*OYM1>SGIZD7. Z74T!$ [OE;$F
M/RWHVW9>).--J-=YI*=EA=<(IOE<Z>AH&\!.W\]B&*D@ZL#B()1R_R0N!XX6
MPNZ__! WTN7/-X^,3?EL9M3S;"8I_T"F6/:?%N0Z+ZGV&A?&PB<6E++)T].3
MLC>W7S??NR67/I+T_KBBJ(#[8N=-.BK78>MX2%K5MD9D&X/ZE"40QS:PH3-
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ML5*/O]ZRC!YQ57FKM1F4B5]I!<OV->)EL [,^5Q#Y98%['E-:*.PFY,-R*9
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M 1$"54]M"]N9FDFOTG?']1\!BQ'X$#(2,T3T/,2#F"TOWHUZ"T,:[0OG\H'
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M",FM.9(?+LX8(NB]V+F(JCA09_;]1M2MJ4;[0+)=TF]S0%--S0%6*1?9T"O
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MOY,\;CH(%XYXXZ!:PR*@.9TXSI7ZW9,@=F WF?-4C$KF,A$SR81J&SD<ID<
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M! 9HG_P<7O\.5?\X!_*S]QY&_0& P[]C4@OE2[(;O>M,>.S]G4C?P.V'J@=
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M-/M%ST>9(?MN7&)<Z?_\2V2X*+Z]=_H7_0] RM0TW*,!^Z,P]A<%TN-@;3\
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M8_I/'>[P[7$@H#NHE;JDLZG$FI\OO9DX@8S,)RZ[1/?X$,#UOIKQ8QW7O/Q
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M$FI[9_.@CE#-G_8MQKJ1Q/I8^KQLYVG$#_$6( W*S^1:CB7<J35CP#GECYY
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MHGWDO%SP /@\5NU2:5WX*7(/7^I[3"/2$P6Y)X<&S(A<8V5N2#V^"(RESP.
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MQ:JD#SD *!6M31%I(Q)CR$I8 1X<;&A<M*?E_4ZRR FW= !OQ_(C?'5NB0V
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M63Y; ?>;^"4VR,3W9+G0?(L4F.4J=M>ZE-/:@XXPR2CJBCGAII6JTM('R1_
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MLG@>1Q&L* IW&%E/ )P30YQD)I\)YQ5K:C$ @0[V,0'H]AY"QP[G7$3[]@^
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M./N^@7%,78B9'OA]W9\2.8<Z,=7SO/,99OJ*-J.;=-L&I/UUM:^9J[](Y?
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M8MC]U^OD>QB!2X5?;O^30<WUZ?]O:3!7&DDN'U_7$5M[S)3M=!=<)GG5-#R
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ME:,BGXSM\XM24]4R(1N'IZ7E:N@1<=K*[';!@-FP&Q(P8&.OW$)Q=%P[P"&
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M=4XVG4$W__/P_1!3.NI_)[5:^LS0#U<))[$*X<5'T8]]9^N^49'\ 'C&'_8
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M*=1'$-OR&6'\B80&5[4?(:>/_C(=#UVW%=[._LXQ3VQMY(JC]ECWB(N&;AX
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MZ$4;ZAJ-^(4:ZMNS(HQ]/I$]K/B7'>Z'D8]X$X@_&3SGEI ->=G/]0!06+>
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MKULV\DVA;+MNC!+>)0LZC:F$]9%"!)0,Z0Z.J*$&Z#]XGA2=*R+;<L-NY6>
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MO5@7B8@DGAY?+H)T1)T9*;/5YT>NG\@WY>)*B]H&\!JY>6*NYH X0I^L7F[
M\\*80GG76>Z=F8^.UTLL7W/2Q9V=,FWM0*)VY$XHB:TZ1\%Q%,QX\JM_U!']
M)PH"":IF.0*R:?!R'@CDJH.!;$LJPX6.JH4%\ LXT!R7PF. XAV>K$9Y,,O!
M BSEI<](Q;1T1'2R"N5V"N<6]/,RFA>ZJD,EKBBF2YD1/S\V6N\%FX"(6P'T
M-992[-?B&J>8%(11JCJV)('X?J SK&N'!7U#)Q)W5^0YY=?!]>6BW "6WD(]
MZ:*Z2"*!\?DOM!43A'BQWD'9YIGGQ!=4"1<(YK^2+2^D;GL[YB>_8^\UD(RV
MF>0&T+140SL:!"XOOBQV*3 *Y^$440J):;G#=+(L;2]FW(GJCQ0\Q#1D2LO]
M%)#0LLM<U5$\H;?,3)F>[#31H*SS$Z 47\=/7.%=[\G'14)2.6I2M;J^5E[8
MK2'$',M/ 6!5H2%% #D39YP05#;B^(;L&ZIW,/["PG0+*2/ZN8G<)'!RIDM5
M9+Q\;!.2AL)=->X4J&N3_20J?V>H_ML,40$$!](9XH1Q_DK".+@ ]+<Y];PR
M@@U"$5X9B6[Y)E9Z7U8D'!!UL!:G8?&1U)PFVQ+Y.27Z6=[^T34K<0)U4B,L
M70Y5F(1JFH$ H*5HYT!.&XT^U8<N4XRZ>-Y?:&O C)B[(^*\*Z\.PM3P7K)_
MR?J#BONR.C-#4S%O)WZY;J/9+6])"#8)?6(4RATT-ZK4) N0O0#Y+;1^N'0X
MY?UB[<[=LA=]1JY'HD"&/O#IAY2Z[];4S1DA.P&"IA'3J\P;T?FS6WV.];[O
M82$J'Z-3S'A8S.WLQ\54D:V$26ISI$.9XA4.'UN!4$+@5 MU*JW-:-+N6]_U
M T_]N;QK?Y/X_"7O6O;_+N^:[ / <.6WO&L-_[N\:W_B0./XGWF@@;!%E$52
MSG'FC[_H%YC7/F9L. ]=.3XFDUC:7?"VKD*CT&HP(=09Y[?R8]J<M-^'I*27
MH]TJO&XY/&[P:'>"U?([!#N47@G\5(/("/&;^[FX0'QP39%=)-:?7;+(:^RR
MV#T 0G23C^P<OWO9'-LFI_G>4I($)*V]*,.YK<_P\\JV-BJZ:EYY?5SQ(] F
M[EM2/=CMHK@(A]R%<"% B)X*:O>.E4SLLK0>WZ@@$D^5\],J-X_B%[K@3J&M
M>%&<:P+H4X3Y*X=^8EA[%,32_(V;)07BQ P>%:5>? ]"M#1U(EE2C$NQ7=IT
M&A+9<K<=GTL-?E:+?ZK+WLG9)0'ZE 03-(V2QP[+L+O8\%>6.[R0#NE9(KTP
MBJ/6:GB)TSJKDUVYD9X\X2*9,5ZJ/8!',8-G%2E Q%Y<@9["*EG[*'S9KKXY
M,6IR/C%]J/FCQ'Z_.;/3KUGR]DNGV3HSR8!S4M?UMR:J#78^1+5!RC;S[\;C
M&\&>J[X!J_8;6V+."!-[-_NPETE<,%BWV&P-R7BEO=B'3R%,*!<-0]X(T5X;
M6O4W0S$5+XJ,]/FA"?H1<<U2/5QO>2B<XN(&F(3+EUZ\.J8J,C-K4:7-<[,I
MJ(F%QGY[C\5M%AC\G%(8F:H?-4%UTA[2*EO8R9=@B,VIPJWHNBV5N/3)G*D$
M@7?J?&,,3>,_(4U%UGW]*VT$?'%XDF>]D&&-)#1L6A0-)=D_ $[5D?NP1D1X
M5I+-;WQ_6<,AY[10Q804OM3Z?G%N%#&V@NUM0.8\2:6UZI%KDDYSN"+;4_8?
MB0ZF%+2K_>0E3+_B382R,2;[DM36,0^(_6I>O+%*UB7F>:45-2^$V0!6S\9?
M"-/HW#,0\?@(-3)8]CK[I821VV T47_00DRZZ!*)Y;%CN+&,D'FJ./6VLNH3
M9@NYJ*OG)6(5ZGJ\-!H8Z$JSSF_ &3:;7.)^D[^#?")5_;+K?O<*L88M2S#C
MBO43H%*8=,,J0.#PSB='?NV7FE9->^@^^&+8<9R5D TP0!&YFH&U>I[;W9?D
MH>CBXCXSD^8K4'_)ZCQ+DW3JX?@:4/ED]=EE4[\2I"\9SFZM.%7AYI*_4#?\
MOK[ZUR=%VL5=.?@0*H'U88#+GE9E*^F[V0Z'NN:Z6Q7N>2\,GF?D8HCJ'NO5
M^$?R-)%C:-+6<".R^VE["#\)P\<BD&-G]4>2-?7@ 29ZI.5D]6/&F/SK+)C(
M>UR25.UN018]_#RJU6=7NI(N:ZHFZH+-GX<NN&Q/VO(Z"6AA*+=\D;L4L:01
M1*8@)"0;P,%@Z&V7]X\<PLW]K5=DGX>VCS]LI?'78Y#*VFP:"OFG;$7B*IUE
MXP2;S#).[+\MF(3DM"?=[(IZZB@'$UA[ KD=*_K03.UX3GMA2?$)W>4V7[K]
M-L0N<EF/9BX1! Y-^..4N)8R"/I0I<4"[4#C_*QMQ$KAWWS 5="]#]:<CH5\
M*;FQGE+N6\)?20A?:!Z--,"%K/SLX7T8^&CA$YA&A^&C 1;6IAA" T\ 2,"-
M#5,DYY6>9K$3HQY^\C?L\8?-KVEZZ-O55'!^1$GVDC&6.(A=B'QNC5NHW$EI
M7V'W>^44^'.BR6<4L&)K KN87%J Z1LS<Q>4?0_[I%3C%9D?PQ;?^(8<>^$C
M$\UK\RL_+Q_*M:E#_&4PG<*:I$-S!Z"\C)E]J_W)H=23];BL%*L $59_<D_;
MG533&8@R"U^(,D24P#(=+1[P4W,0OH3*SD,IHZJY:##2:^:WXAN=C=-$>07_
MPGG'"V=WT:YOG^ZHQC584'OR-0(8])HN\%08)K6>O3,K9E;Z?95=1V^?$]AV
MZH;)G\GPP5:0J[27O@SE=.PC2;$LZ=NM#G,I2L/,YV-KX2.*_,INRNL15BL]
M&0%.9T <;ZNZLL 'P'MBK3"UFNAO=@KV,V!@VMX!\5.@L7D9EXZ[.4MLWG-&
MP@]H2 4>4W]9W[55#6YO.67;.D[N5FH6!@63,QQ@!=69\[V@4H/AB%UO[%_O
M7^$=5N2'Z#<_MZ1Y=CV&RC ;?=:X.HG]N??S_NQI/UXH>0\[U28PD^<5]S;+
MS$>XPP$8'NZC5N-UH;'\M<^HZZ68T+;PBP:)D:)V%*,7G6.+^CO/K0D_MUX(
MXBD#R]!1NDJ0$5&]AN5]5F_+8I[L>/O5W<!6YI@C#A2:AMZV,!CZE B-(@1E
M3B$TY.X6Z7VQ6Z$?#"QP"TA>M) 5>AKIE$$EO$X8U(%;/K$N&WU"6$_6;4B2
M6L#T5F/++BOY*@"-LG9J]C5*N4X2-\P@.YK$'$\N.+>8!.FDDE/Q:'/I,O1.
M(*1]Z$:U_,(Y?^#;T+)^&/T":XMX)[);-O;XN@.V0-;%W'FZ/GMD(4,<M:,U
M$I!#XD)TO4"_\5@@PJ[P1;%:":BB? M/L47BS1G V>\7:TK;$?+*FS%RM42B
M+?EJ 3-@2^:$(-8S%[3WH6C/)Y%Q7_G9*C]%M340KIERW6';F%HE1E2PMTQ3
M2'DU,/S1L#84E?O4''OT&^]7E"5Y.%6P-5460]T^<=RR"7NJS<8#0$LI";A*
M)4]!X5;6W]=.3NQL\-EV3/69B,AUEEML[#<UU:_!_09]T*-W)1=Y'GYN%HP)
M>C&:;O51B3+EED]<!L5^K<\4/8X0]@= #02"E72;.TNM%;N_UIFZ@?1KE53.
MKQC)R%<W1R 6EC+-?M]7XR5GM$1]V[C7$M?'.TQ_U2 5HQRCD:!3KZQHP0TL
MO\):4R8X7PHQCV[5P6E953Q7U5S7#-U@@U\[L*^#/IJB$74ADJ[3?CI2H!=O
MS%,^XCLRTC-:$6-G$ZE:^/'"17Q$JBZ) .&'F3+B[GS7.B4/CQ3G[CN)\7)V
MON\I'&9-P>KM1+:[/6^%@ F=&TZ=_0;3$_S^!XIN)&G4C$82QQ461K>U(;HZ
M(VC:;D(' S^J*\68W#@J&":67E;75Q!>J5 1TC/K[BH.&QT-\:2W.=\HY'_D
MY"?B*O^@'0X$$^U3>5F8B<NA[TF13_UY-4-.\9S!+C'1L0FH7\S<!27.&6$]
MS7;IY4\(YF^.?+H;ZE^(%?X_Y_+N\?R>W@>ZKUSN:_\U,Q+0V"]YY0$ F,ZM
M\5\C'GL ;!,[/ !\-1X Z.T?'P!2W_UO?T3\-9N4Q]]R"94-N_E'DD'"/D2U
M$CTSDK8W>,ZDC[BQ85'<3V,^9=6BL19%X#J9<U<V<NX03+?>@P(]D&7?_\%.
M&Y7'D$=*"KC<6V[^LH?M<6!R?B)TK$:0VQ9^WVY=O'-Y<9/Y&>4@_6>0*T[4
M+K9>J?>K5-2H?!!X)O4$DH?>));A49;8SVJT8%XON&FX$$*@H9#]=XO%KNV_
MV"[^$"'E;PX+6]O?;1=_N"I_YT_]6]YHU7\!H[\+TO^GY"?Z9Y0_;"?\?;PP
M_QXG)J1C_8;SYL<#8-C6]O'SWQTMB/^7_2R/E[__@[(__'F"*F$K)W_/1P*-
MJ)'#KRPQFFI* #_"T1T)\:/*%B<^,KD.<R\V=(LXND_XI2(9[PBKBW:)TBJS
ML"\^BQ@:C+3D)O$F.NTR(_;^1BH(":>GB 1<C(R^?>E$) 7&C2 RDP+O"198
M%R!*79@+I/$^=A]F]"Q?)+J^B96O1OT]$_3_U/+ON9;^D,&MI/0/E3_T_^]&
MC;2_NS?^</6_%)OH_Y ]FS7^*C779&\9,WY2.?C /AEWF#W5+^B0SW&82(TB
M<&6B&993;ANL6!=JCI<\W!RT@% =(R"K<D]>&V,+@+.?ESW%':0@>H<PS6[5
M /W$L/0CY0LFCSD-"U'GVU\K"9*)SO?D8ZV@O/DK=TSR-A>RZ"@/RFGH;1*Y
ML#9:/($I>KKX*/">?[=!@@%:/6-??HX:/8-IY_G#KL3R28<H(>;H*WG#RY(#
M7_F\9?U%(Y"MSD^4AINM94#,7N8GA$T=LIAH-SOW9.6&F?)*UQ4<_M9@3;DH
MQO9%KF\4<+FO#EE%*N?E;4]UCI_>,6CHV1B$?=QHA3SYH0&!H]'PCP%861JT
ML1PQUI?;.'6.DQ)]8]Y8.H K7O#7BE4/.A:_QZ"3J6@TC^.0\S[H]S;!!E,A
M'TWWY3"%9D^6%S08-<20GY(%C\5[DE)_1A*;5?$GX%]JA/J3#^ D>UP<E_;!
MN=TV*',E1.Q'1*U)?K0%=W8=^#[-Q590X41Y3^69@4?C%^R^?YJQ)5QL?1R:
M\I9L7263]21!]EE?/(3UAY"ZM\_645G64;S-"FQE/@NF\P" K&Q>B_8=S(VL
M5#48((/']:NO(N0_&7V:JOA0\SAP$GY@R2XDG!/4M]-.<+[=:JZ;@BQC.J5F
M>2)R[[I,!/#9E).;$(.;0QOLBG82>CVV\J-'XEVH%MT,/48-EO\3/J>WD9J,
M;P;555V([EF:DZ6/*FZET?WL!GF+1^A7B$X;CL^S?U-=0#LHMKU[9O;,^3NC
MMP7G#X'0)"%+EH)4'3GU_(!RIZPUB42E2SA*Z'?)_6JV#MNVH.7GA76)M*G&
M4OG]M AZ@?%<CVO,7G&EN<QQ8MV^CD!S9'5]@1@F6P48N7!)T)Y%L":JZ8D"
M=G!GR>N^-,B4IM][(V%NT85A]OP2Y$VMK'B9'#T*"],3$74T65D7/,^M5]%=
M2S];+YL$QA<-"Q++:RN^6 YPJ%,&1,9E=O-[2Q+9G-IFF89O9JJQ6_"4J[Q!
M2/#^H0)!+AI"]7:1(N?3H0R+./LLYT3!Z83?G!QN%Z%/&VY)$1^]2]@GO)HI
MO*.?O(++]@*\4Y@_X5=_CVE3D#FA!T\U.C(01G_R .#0,\T(?!RVL_]*#?J7
M(NWG<B$N =^S>@#0,2;8.[4 ,JR/'J=H.6FK!@7>MJ:R0QV_J3*O8B  %YJ?
M*;SF!"L'+S\?J_.IKY_D!X%*$C$3PZ7>:4S%: SL2)%-Z?*ZK;=1&$I#"AZG
MC""O880_BW#7:FP_S>K6X7J,05WN597:M%E-."C"AI^\3.$P*LV0K8 PV;$;
MA\2\<5<X&_L;:U9"'XQ\88524KVAK1':$.]/)RSL&*[8^7.R>%CR_AD[#LE^
M7T[QPN.D?$&1B\% *K6*E[!0]3H<L)1;[&^_XP^; &<Y!!CW4Z<<$5\G.F5D
M=:=%J#Z"XG)EH+=5$<3YF&,+K]U1W*^_#6"K8;B1*3R>>3$QJ]K:T)X&WX',
MFZ58\F:E^'MBN5=&_Y-=<W^WRJ4U1<GW&U-,NFW4MDZM*\;I4Z!8H?=4(0<&
MCDW+X:=#M0<RUE"\1"G%">8V%'/UZ4RW5WEJ,H*>>KLIOOFS&V[_/ 6QCO4'
MOB8W"+#3CN6%$\78HLS)<\NG!!%TH8!H#$-J<P-7=31:MS6C%WIV99_?E.OX
M?&0/"&4?)>LE"!S1#V!3O  XS93;O2/,TIZN=*!K#!4?6_!Z3D?T&LA3&[7>
M_'GNO#(S' "ONN.LW/,N6CAGFF1/A;P;JEYP<+EO?BY(3//LOB*4N[]DL&MP
M]4 .;G<P2Y0TUEHBWLK],UX@D>%4D$=P$0U ^#K(><D.FAL@7%;!:CB]:CG5
M4<L^D$0<"?H9>Q>/)NR,AHR%LC";,?WRJ+Z8#374LOI^$!0C9!BP E[H>">P
M;G]WW"%Q-4HXIR%%P3\;^/,GO"/4)X4].UZA,(@<S#!GH>@[W&/-C?H517U=
M4M#@V=?99&YC11\^Q\4!VA,/8T/C2O-8!<'K<IZ" !0I--*MR:;?F@*A-V@Z
M-BJL*L,6(*@+4GBI4["TX"[,\=6I7^4=_\3XGQ<O(R.BT].<$WX#M^,TUXBX
MU?557WSF5=2L%W@ 6&+2='U2XU'M?S<M1*+-!,@XS:P,!VQ)KCU]O^W-F,HP
M: ,MPE*(H7(\6>81N6N5\#DK->]LS@.!;WS;:;$+=FJ[V5M9+9!'JGD^*0*7
M0@$</*5%.<(;5.WA@/5G:T>W<FF,4SK*(%$7^]WZ!8;4)S4UI$C^9:(U6D'.
MV4$LOXK"ZE(@,WWK/9@<GPE4"6SJ66I%#EAR%05QY]"NM#'H&^B:E9B1$H*[
MR$)3&(PP0<I:S>%\S?K[=P=#<1_N!N[=YGJUI4?63H*CFR+O)$/J6#T$@_=Q
M8?QY,C28? /CGYA/$05I1PY:7!H1T9'^\I@84X_:OXVLH<Q/;M6%"WXDHA22
MY2U[KK:LV!KDGO"-Q65;J*QJ#=MX_59D^;+'CCTTW8.PAYL]O+SFPP)+S6 +
M6N"TMC#@;$#<[1]71@* EJ[.GH<U?VLJ!A^$W+P2O5=9%N#T?$W5?9><]9%0
MJN&"W2>Z[=@;_4YK7XZSBL2][ZI70&GZJ7/H2S%+]B[0DF)\H;NP%_@:/=#H
MV\5/XL&=[TBC!6Z/\P1?C!>.&;.OK-R=UV^=-Q(/_$)_G<"21],5BVR(^PK3
M&E:J=X7T.G1B]E72(0R3.Y\CRXV_/-XK <^>;C1IA5%Z$-]Q[FL?ZYA--H[R
M+7F/K@%H1S=/-GJ<;:,^V@;O>Q/W)TV" #J*C0"3:/%=J 31K.L>Z#NV^%E3
MA1M)G'72CLG0Q]8<\C=2/64A \B5(JX_6FR9D8*;KOP]G&?)'%NBL5G\A,L+
MDH2!O&JW.62U.==(" FMN&HJ"!H@7XFVIGB%<_![1TS%"HWUJ<-#T.7'+['Q
M]3WK]=23RVVHC^/$?XWZF'!S)((JV]6SPC7B?:+Q/$5KIZ[#$SFZ]0S$Y=2?
M1HE_.K R)E];8T.T/I.4($4G;X^/AR;V'RTC G4R8'ZK1ZKZWGOV_ET=YQW)
MZ-]2])XWW/W:-;GB3O]+:&V6MOR6A/VUN=\"P7FOW/OS2]Z1J#Y^\S>2^ZOC
M[G[7_XJ:\Z\1M@\8%L4S1$E-CF*^2FY>:C[2W1W_OM8LW2OI\H8/0".)'Q@0
M:_<XRS094CFO@7ZFM O8[P3*SE:O%)KN9"W^EH%E\#E[>#-.$I\JXJ@J/NF[
M85S5K:LH&PU9E_J-PY'B7EE@4#AS/M?_IZ__!/KZ-\KZWT)?#W^GK_]H3"_=
M%?F<E&!C7R>:<F"*_#Q>YROR69GV-U^Y(+L8C)#Z^K3-I%UB[FY2=Q9RID"#
MU^&?IDQ>B]0X%FXTDPN\HQ\_QR3]R5;'"CXXZ.09I AX#[!FFBB37N?$,>QE
MJ[\9SOB(L\*=)"5CL6I]+%0I!U_VL]:<J5/EE&^IAD+HE#WT*X;4W)[?-KXJ
MHFH_:W\V6<GOC[-D \M("^W_HM=:5L$&8E,-0)WG3NX\OYE5SE&5'6Q?F5G9
M<"J7E6<@:+E[)'>GH@N?=;HF/'.:6L*?6\G%\UEM)LKIQ9@*%UL=X\1!"GI+
M#&T%QN=5$*+=8U'\<WX:RH?Q_3)7#].:.M]3S&N&3CX :B&)8Z&^'$93'HM.
M0>*]NE^^M$SD'/65E=C,ZLXD-3L%*>#CGRPH@43OVHNBQ66I=8/<VSN..+/O
M:P6JON<] /CJ1*''$A\9DVX^>1>4Z<LM&#O1L!2-I64ISYP-VS\'3G#FM"J,
MS-J8.+[>,93\<%Q^):F;K'BTM!D9__WIR$RZ95,GQ3ZUX/=#UNPCE5E>\"6U
M7=J%E3X ]505Q".TGXW=O9SK:E;2Y-9Q[6^$&>*EE!L,6]GZY<8'\=7(6=Z5
M5ZN;9K=L10Y&'!"T<",I4RN=DR^5+VQ;5/:A(U; ]-W/:V<-.2IZ;YVEF: Y
MS=@8RJJJ!,Z&VCF^K_?TNUJ4/MO1)[Z@8FB=X?#5M\NKO[*?48:<\(S0Q+"8
MXT$&L3#$78)US[WM7[&8'/WPUR_-+F ^OWNJT'8L\+%P%]/<OQ0$6A(0Z 8&
M<(\JO3G6>=^<,_FJS);SQ;754R[[I9T8@],5XAV#I#)XV<)W.^7N0E5+R$6!
MLJ9%$MVUI4IDF#$&4MI.X>12.WU$\=L-@:T7L)J45X+784A"MW,',V$R:>&0
MLP< ;;FL+F/\Q,6UK:NY\42ZHDC:+BXY(:1P56@.YZ!Q="I0?1A>\61!F^SM
M346Y1\$,-Y("TN%;4_.I#=TD:FR[9O_ A'VB!A[I$A',/:*HB&ZZ;R1*99$G
M!$A7U(6'PS*3<./LO5\%#BB]&\@DKCEBK[&8A6-C8MV!KGNPLMVI<VA5QYH9
M$4MA<E3]G</.A@>>9_K++!T(![OF?%5B.+D3S3*)&\EY29VJ@\HXG2*_S_;;
MB1=U9%8PDAO=M'D;6+CG]>$Y)JBVX+,M&%<>\FWP#I^H[R?;1F1P^,Z=1^'R
MKL<]=8P:S\OOWLJ&0$0-=-@[,_0^B58MI2A^H;X;/C"%K/PKS?J2]&0)YK']
M?9JVYFEVL[JFT01>!8&.L:D)NS1# Z5=YY6%B@CL[XX6Y.@WLRAP-0P3<+-_
M&/3G4[Y:->RA"?+D]SQE7T9^D-!*BWD_"5]1BA^5.QK)^17GXV5=E(J]&1E[
M?R&L=TH30RV XPC8T=Y_+E18\,ON>B[Y0VD^?+W&I.!^+S/X3178H""CP< ]
MQ\$%69A'D2(@Y.O@L&RA9]Z+&7OL]L12V)(*L5/T<P2A&UT&0NA-_P=^=G/5
M"7OH@N3^(/NB&L+'PPWZF*7S]5F*:6PJC#I1?PQ] YODF>2TUWV7NLD"A80O
MM;N+S2\;*)P.E.=D1DVNJ/)N>@X3.\3=0%3!OSH*_)(/J!V"!T_OASO\J>R=
M:O<RIZF*X)!GLJEOIMV408HD%L :@,*-;E8Z^\L^,3&^LA7H \#!KW;T1"UN
MTX&]96AGLL%@,N0!L$8^>UX_ R5?>KDR9!EZ")M:](I;1^2-:8E.X?,SQJRX
M7[T9@L&6O;?==)?9QO@&Z95_&4^@QHGU/&6^3@9:^%B03?I\,&\0Q%?ZB&[4
M)_>6F:JIDO/U9.O5'1#")U@=S:[ EU2&GU5;.,_;8B5%*GSV WKG5;"TFTF&
M.R=]D<4"%[:LPVX8C7JEY$\?8SLX&0*OZKA.*ZUC9[);@-R2B5A_A*I:684I
M3;/;;THG*>0CQW251VGV[!:I$CN13\<,"=RV.[8W5KJ\FC[[]4*K/NGI$Q.I
MF6I>OU(?!.+YOLF32B_A3A+#^[H!67.XGIO%L8_-$)ER-U^ *'E,;5;"-VZ4
M?2[O"\+<'*(5-9"]-9M*;H+!WKAXC&:$5G7:[BZ,M3'31PJ[YTV[S0D/CZB3
M5J68T=JMLIU/Q&?C&69[+2C'!  (6(TSU-X*.P>+:<#%712B;7Z^\;S[%*<0
M?4A/1"E^@X4W%EY6).^47_3>_N>9GXQ-1063(CQ\>,/F.Q6"H=/5-)L86=O/
M!P"VLS%CKGM=Z[V[./VMB[) _2S=/1+*8@0!/AJRPL&X]#F_GF>ME$CJ9$?=
M@<0<D)L$*UM@;<I\IE'OS.<!4&.@1I3J9&?G!%>PSX:>C&S34NI_\AM3$SL;
MEO7 JIGS3)!]A%/O[G_</  T$P\8!-Z_Y.FVNRX*C'R6,:GGZ7'748%\K,W>
M\ A@O*UR2O5VU/.;$Z=TQ@?@?& 00LH9TG+9;B;]^)DBOCA(LP'J1>S,5DGP
MY9RPQ[-(;E9,ML1@)PZ\Y^%0. _7M[>PT53<4$'3Z5S4)5W/8>+;NSIG!WV]
MP3<!SV(7&]BJ]SIB8;W"_<(Y>1@7G)DQ)?>>G6CY]C[D.Y[H($/]2LFLZCHU
MSH(A\-F>0-QW&IV78  ;"6*^GS2AK;B_8KJ.'P>[W%)5WNT,7+KU'>%76^Y=
M(G^\.HR<^XGZ('/$L@4PW280X(R)%X(TI7T@-.QPC!PE^K(MFCPBU7COP'VE
MY4/<(U?UAQTV_82EY^" BB;@>JFG^I7U]W7BJ.',E?2M_R.ATM] Z_\$J/3_
M6OF#8$I-7?D1*XWY-S\ )GX_,_A#QL3"WZQ$N7_]_ ?T_M\$_$]_$??![MHY
M9QY?_7@&-A=D]N$MA_;KS<Y2;YIP2*5V9@M%K: '[YBO1$Y&#G=7]%!9^?#5
MFF%:EC).K<_5E;;* %(#(RRL#X PG>:"_O!W*S[TH*MPH;CU* $H.3$@='"4
MABJHY,INS7OG]:N;PQR'<H<Z@3AXYQN+J% 2HL6>#3^T.H K\;+ T6':99E/
M"=#$M$$Y/8F[26_\?HO&M-9=XY2J*Z%[6>CH9_AA4?V8V]/'5S_9( L),#*W
MFN99FWP.O*G,Y+U[TC)ZT]A(F5AR@A$[;%>5A".&]-<8B^)B:38'QE9F:H4)
MYA6OQGBK1K$=;*;C5Y67'X2P)<ZB?DT&7QI![W'!.M]&JOHO'<#$I= EF1%*
M#0*/4#2ALWSIMS%TW:]KF]))3]8:Y=]ZKY(!VF0)^M+X4^G ! JKB3+=;*@\
M4C\C8T8"J/_";N4X: 51%Y5"+=5_B'<[ONYSFJ4Z9P 0O :F"6GQ3;#9*JCK
M!R!G!F7]QP5]?Z;\1\1_?Q/\_=?%?__4: 8(O0(E L&5=I=I?4W^$ND%W5AE
M2/E"OWX<\N"IJ0.^/W71>!HNH&CIP99TI,I']&.-IKHC?&,  5 ">Z>SX>@I
M=FJD B/*<N*_2\:][H#AY7L\&7+LY&V@"DL8*%5=PWQ>81UT<:K1JKA^,M#8
M; 5K0@O@$BG>JB) B,YDGX*XD<>Y%"VIBO?V$!V!6^"(2VF,OC_7:0Z^6PL=
MI(W[$]>E-#9,G35E3YF?M);I%>B+/0"XPPMG5_U6I4>X@Y4K/94H=6Z6X4PV
M<\O]3HY=5CI=+[=;T+>E3?V$2B:[R*SG[<V;!(F=C0AX#!=5#$QB-[D6(3 O
MDGX^A,32JY.?+V*[2SW=5U^9X<O57V+0)/.PH*#%I+,)"=U,'\.-E,";#;5C
MP$=XT0$QJ6/YD/J)2U;H>@&,]F7#99C>DUPY;<>^RJJ]M5&]E.'QWFA8PY F
MR3]1)3H_ +H%/&9'W6N78,H\(5G["2D]JXZ"@;-(D>?]I-DXFNM]!H5Y0%T!
M#67SHL5MWN4-*(2-X\E:?:RTI9BYT)9X&<17U0_X#%M0.4L]>A#1</'Z(SDI
M(JKIQ[N7B.*HGH3V3]' 1#/<!B\(RK $.(NR3Q7IB&CBLHS1Q,$<OM1%BZKT
M^;/U@SREB[(0Y_'\52S?KQXTIG%!L@"7I"S\M?I)UVV.S!F?WLF*0TY@4WOH
M7&WKFR_A<XO]"7UH--:394TS<'_TP8HYRF/^G,;W<;.LB:,[VAUKV)/KX23[
ME9SE2:R>!RD@PT^G&L2VA^<T3IEU>?Z%##/!3H5]2N5)!T^2S9Q.5BTR50$N
M!F^]'\GI,,0)3KYG#K%^V[]_W!GFH:D?O3WJM$"HPTFPJ^/A'"6CS[$Q:=X4
M;E.1JQV]G1.#'^^L'G 7X"AAO@/2\%11J#9<-%F&&=>UJB^2D\<7;Q*3;OCY
ML71=R2M'+Y-4S/CX,S)& </=<02YS'IKXWL_4:0!<J@C.2H/WQZX'I LJ;G9
M7HK&G_ ^R6TTO X61A,FH3;4^@B_;,0U@(%?*Y8IG.0GJ;(4AWUC;85F1'6(
MF :X-#H*]V"N*IC-9#?6-3<UA+*"U8<)NS%@^@SXO,\B<;U&_!$,T#IO3&L;
MPE&;@NP\O/ /GP]DU/XZ&;T#M6R->3\!Y$A&8[=R8;@VA&]6DL$\"QI?ZN6K
MHVO07NNG4!2O>XAS:ZYX-O\@<2-OP<:W6Z 4]4Q[(Y+'2_,=^<5E]20P^FI8
M33*8[WL4[SZ/LM>FQ , BN>\4/GBUS'M/=OZT4$XYQUIX4IZ'=B!IJ$-[4!@
MYI*=P@5?(%YJ6Z'/*1(>P.OZD\!.4!=6:P#&WR4Z&GXF)[81\5VNX>,%Y^4"
M6W^&&Y)$K/(Q*FP$5+;#<,I620\EPE,:1%]A&>AWJ4>,9%0$KE/X[&4A[Y0Y
M\=7/BH24-*(SZ7',ZZ@7%V?'7&KA<'GQFZEA@-DJZ4)6&<SPH!Q:W9N(N$4Y
M"#&S;0#YM2Q"F&?LDBQ& S%1OE>$@VLRNG8S[EZ_>6<GLJYHGHEG_"/ 5<Q.
MUTKB+AFEZ%MC#RF*C6]><P]DE'J"ZA.<MN\ZS"C.;CGOXN8"S">.WS6GIW!$
MR[Y#42[:N;@Q*FF :E:G6GP*<CD537:8C@(XNU,_.ZN0N5DR$^BP;$H?#.F]
MDS-3_&J.+AK =-R)'*C+Y@OFGX,V9<FES:HU-Q.5. %W04-L6I3!5\I82)G7
MO2;U1Q6?"Z:<08LK0-SVJ_V9S??H+ID$[J-"(^+5KV-P=M95H5\PF.+ CLEX
MV%NTTY>1F>OBQ4B\/<;TZ=+3^:DSBOL'9_,<QLM<@J)HZEQJOE2II6E5X9Q)
M1-#F^BS9%D:,')MEX?EU<!P)KAS"=8"X)Q-JP[GDTSG;$]'EO.KXQ87Z6=83
M(BQ_BL!A]6/),&K=^&7X,/VM)M0)&C_T#9^616%.O<C%-\ EI@)@V=%S\)P?
MPWRX:CZG26#HP ]_2$^@ZR7IHJX'7&J$55],WLO#B17LS9><Q#7TQB=0)(_[
M=2ASV$^ RR"]D%!)>M>,_UMPWN.L9_PT-/-EL49FY)4B3%P-B!2LFMSESF.D
MS.9!/'.LRI3.#R5FBU/8V(A'4\ELI.=#B$,+K\,T,C&.48>"X\D;*Z!7=''*
M"H>IF&.FU*W*SP*SE-+5C]M&/A62_T)=M<4&VA&6\^9]3%RPL7R'AMV)1C+B
M5>&3A;738.?+&*TZ6P.LW*/%BF=&,$*_S3=U9D&_HR]"U>< -K=\MHK6$._9
M7&%6U!Z]E :N=W@#^/QD;ASP;9,, N;PEV=VA6K(!_'1=%2_8D6-50^>G_7:
MSUB&?N83.2PI7N*SK&PMSM$"'H1S*8S(&XW2KE<3%OV>M,/ME6O$R./+U?\7
M\FPZ.*W%P)-"(@X.(?.Y<KVZ:_&QL[G;!FV2OA5F(NTDH0[Q_DR T&VK"[L(
M='.R1LUQ*A7=>0" 3YD:Y&S0$S7F=?B-OK(FP9S?&1?QQWB4BUR%SOCCV%7
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ML:$B4]++6VVD$%J$P;X[YJ^&/YK!=TPYAB^L"9K?RK'2?J#7U-:RH,#%(;%
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M#K_L]NNXL5ME=MU: KWN=$P^^-PF;C"^U<),8'(2+XQ3ZHAWC,#;IR0D[@&
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MJVPMWF=?!;]9*3_H+NL<TF6;ATVE6=</>;'._EFG T"!AWG* S5MHK'R8L(
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M+G%P^&@=]=6I$O-4'87?+?(SY.M]$R5BDBA/$X428D$1)-A+F?1Y&A,K$1N
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M=-33#D)3=<+!X#19PQ,/6A\V.AB^&7/+;I[>7]2]ZX7 R$<BCM2[%7&($B^
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M/,X"0:@?&CG9/6W,S<.N88(&YQ702!6/0&,UT^H^0OO5UA%-(^OE((:,Q<Z
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MF;+>/52.SH,.B[K=.I[UEN*M_"**AV:"\O/37XMLO1:K#_DZ8VI<2;U(LC2
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MIY]:B'LU255:?;-B^8-XGY?EST+FA5 SVX4O$A1*)&&8J$DDXFH2F:9> FE
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ME$?_) 7.\^4?MC1Y7OR3QA[+?W_ZXH&)6-O$:.\%*463N*-<!%&:!&F,H)I
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MV:[2JFZ0J8GCE^Q!77(K/ZO?ECJV4_WM_39OJ*<\:3_U.&0(4XADBB!A6,*
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M$@S#E"0("DJ%^H<7)QS;18#;@[#Y:J8)"-^"!62+UDYF!G2%F?J,2^_(HJ3
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M61*\ @UA#NLG6'#BMO!K3WO35G<];_A!"5>#6UX\;XSZ:['1AZ7KO*,4Q6&
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MC?J\%T**< &QC?JVLR'#79P1!$K-8(D)+#B4SHPUJNE3X\1S8@IWG7([21>
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MXSY'S :5/LR?S"6?]3?SVXUFPO[MVY:MM^];A70)4YU;D7E92@PPA-CF+$A
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MWC%5&HI6&N18I3(3&2T("2L5>;E1IZ]@U!*1ETM9AU6&[ $\@X)CS2&0B@N
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MEC=8%[N-/Q/IN($'H-KZY(WU\V^)99WDX&IR\+7MT>;ZRMV[Y-B]O1I:U%S
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M%M 6I1DQ<BA)GN62EIX;_1=:FAK9GQ;-7JI* J^Q-WFV217^J9J7@';=Q8\
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MG *:*@$RSE69,9*6&OMP=6]K4Z/AO;%);6W2FNL;5=B'L!M91L-M8!Z\"-D
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MPAX2-9)J1B3.*48<$&XS2QG'@* L!85*<9YS(112$0*HIC;0-&8E;W[_]O[
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M,KB9*4)3L^ 40)D5)\!4%8 )RD ):2%20<T\$M]X>!/'TJEQWG#%03M.WWQ
M$^DM"3Z4&;_O7^4@9JQNCW'P$K=+ACYLB63M:Q^PQ 7=X5 E<H.!&Z"5NM&G
ML^I&G<&Q2<+Z/XJMK32SFC%&=98C,Q3Q$@(L" :DT P@21A"))59ZI4P$&C'
MU(8<\]44GEND@1W@N'DZ/*Q#;ZO6&FJ?SFJHW549JJ(J^-5QYRZQGE12\Q'+
M:-R(9=S=V$!;QMVGO0VPDQW<&Q\7+/\JE)*;#\:]0QUN0^6?];NUDO/MC&,N
ME4@Y$!G137"5%CG@")M?2\1SYJ6D=+7%J9%>:W!B7X%DK7ZL%C_L-$I4UB::
MB6L5G@.1=^/ J'@.S';'4%IK@>E!\Y.UMPJ.KRR.*C[K!DYL0=HKK8XM4NL&
MPAGA6L<;;SR>KFFN.8>5GVU SFZ];@H==D^LB]Q6RU:@4'D&,,L%X,SN=U*$
M85E@B?U*X_H:,#5J^B:^*[FKRVPU<K9/C0\)L]0T7R<_JC-;NXUGN*OQJBK6
MZLE7WIWE>?X]0!>,=B1^UP8\MN9;O/<.5'58[5%Y%1HY[(&Y)XK#G*&[&O$Z
MQ^J>$%T\:?=]SNT3M$YRD T6FA6T))DD"*2E+ $FTJQ2<TP!(T7),HY*)6CH
MU.Q%6U-CON.91#?]T88%AL_$7D+L/P>[ ;A19U_=/,3W?9C=-.FZ@,9@TZV7
M[;W:1.N"XWU3K$NW1#NQV7Q9+>;BYZPP4RA8T@+P@J4 RQ(#"BD$>8EDBC@K
M4B9N/')IFIH:;9S;/+_]C*/%-?B0(@"M5SAEV"2UF<D?S7\'F<I<AV?H'?^V
MN=?>LG_AML.>^\L[@N/]=D^[2EO@DNA$$R=/THQAKA40 ADB89D"I$!F*B+-
M;[-4*D,M/D3BW/+4>*5C>')9R^5_U5HNWN&"CKWA1C^#8#PP&]U_?O?Q@KK_
M #D,W@C%#CET;'WL*$0_4,X$)GH^8(PCOZ_*9CF;IW_6'^8;P19V8WU6Y$(A
ME6G .9( <V*U:@@$DA&NL* $I5[5DR+8-#7&VQMI]YZL .F0YX+G>VF(,\*;
ML9_D>>%19]5^56>(KW5ZV(OR*YXDGK=KPJ>*O4#>=L+8_^C0TBW'RF0?EQ_-
MDG=I7JU*(4QE!<II"B3'%&"!+/]2#,Q*E8N2,T(PGBW5HQU"W'BWMSVGKYK6
M7W6WU>$^[HYQOH5#^G!UX\G;L1JK5$AM7_*FM?1OR7R9N& 74"'$ 9/(I4'Z
M6ARY)HB#\Z?%0%QNND$(MN8KL_+4)$UU!C QDS.,A+);6#G(I&0T5UF9Y<I;
MT;5^]M1F6O5ZLC[>"]!B;0!S(X% & ;^Y&L$[OL1"%,\/?8UOG1I\_SQ-4B/
M'3LK)OKBDH#2/._5#[5858H7']1>/0%I25"6(?-%9AS@M$CML10#T@SO)<%9
M"IG3MWFYB:E]HK]8B@-5Y>ZD8W!B+?8H0W(>SOXO-PY( W_ +S&YOFGC"HY'
M296;01JI HH_6'YE2GIQZ*TJ<O[.\8J ]%I^5+.C_\K@.K9/JV6EY%GK=G[>
M;3=F&67KG,TD3#,MD0(B4V;M@@@'U.Z$%V5&"2PY@I3Z);_V->?SUHZ3]/JN
MHUE\UP@/)ZN#Q>%ZQ+VPN\UJ8D$Y,$LV&'ZK,6S5@SNV1JUD>Q61V*5L+S<X
M=BW;JZZ?*69[_9XP5GE8L^5&FSG*_5)^4^L?<UL[PVZY5&4T;.[,9KNNAIW-
M@VEA<_Y/C9YLKB'G*F, 2RH S@0#' L"2$FQQ*G^O^U]6Y/;.);F^_P*O&QL
M542BAQ>0!.9A(FR7W>M8EYUKNV:VMQ\4N-J<5E(YHN1RSJ]?@!==4A(%4 "3
M&[$1,]7I3)(XYP/YX>#@7&BNG.(C?0HW-YMM)RDX$'5DI5^ODVC':2\U->']
MVV-FQ9D 0\#GE3"]"C@IP8: ]CDA!QGCY4L<=]5:CKO$'99S60BB.,J%U-OJ
M2-,\-:VV-;=K8Y-(3M,X<8RXF%3ZN2T!@6K:=CB<])P\JHOT<I6/K[]D=BO0
M;%^=P$O4+-^:%RV(;#U[LRV,?%V#EPX&##\Y(0LEVPLQUC=3;SXITVU^;Q'(
M^LMJ*19*4"2+G,(D3Q%$*A,01VD$29RB5*DB*:1R]<Q<&FR.?IFZ:1M74^=B
M+@.8VKI=?. 4W.G2 M2(V;!S+R@PDOITN5Q#P[/#Y>)P$[M;KJE]ZFRY>L<X
MDO@L?\AJJZFG;S199#3B>2H@HS*#B*C,'%E)R*($T4(EC&2Q&S4\'V)^A-!+
MZ,8%)]#9,< M< 3^[GO1@C33O*2WUR_\9)!)O^M+*C[_FB]>-[82*=OL=_!M
M%[62:R.BJQLD]3NR6=!4X5SEI@-0H==\DL:01A3#&&'!$%(B8TXU*ZQ&G=ON
M]JOIH ZTE?6XJD#9">E:"],&;3LN\(YA\#-KMCEP0MZ!7F30R=P43!L&=41!
M3 >0/%?$M!EYXI*8#F"<UL1TN3E 1]S/^OGKT@1C-Y>]^I.N1=.G]]UJK62Y
M,17:%S*C.2(9@Q1G$40LP9 4DL HRX20)"H4R=PLD)MEFI_)TO98+=L>JZ+M
ML?K8]5BMNU/2]4ZSKF\N-;K=@:KMFJWV^@7JC&LUW79,.>D4!F91F_ZX>Y7:
MLV_PJIV[KN/Y@6(3=<EUP7BZ1KE64LVG5ZX+B$[M<IT>/"*HL?=,K267Y0_C
MG#*:KU=/=-ETN$[UCI'S)(6$9]JX3&0.<1(KF'))XDS*)%=6V?,V@\W-IMSY
MH_?R=F71&HF?3$>,YFC-(;#O&M[#I.D;Q<!\> 5 Z\P/*^0<@B,](CA1F.2K
MAQ9(L7V.X!WXL]Q\UZO\JI+@R93*U*O(YKL$C.HG<*E7?ZF7%F$ZHOVR6C=_
MJDR!VB4P[?QH4R29/W'3O.3/[R7_KK>P:VU_@.6J^B;7OQIK GQK_(7ZA[IW
M%VJ[@B^W3;";WND*>3#%]:]Z$+H!W^D/+864%1!R6>JGFDI1^A&KI3 Y+ >"
MZ-G07[,1G'5N^+]X"O^TG.G!0-!KSY@N)-12FZ/@4-M[1A=L.M\3<E\9#46Q
M++"(8(8I@8@4>BVA&8&81"G% E&"G,*TK@\YMW7DL'#=8R=]XWR7O>B-Z>Y<
MQ^D:\G8&N%\\ Z\HSSKH'C?0#5ITSAXFW^6>K@T[==4G2QC.%'^RO7.D@Z+[
MS#ZIMW1=Z96IUH9T8T7_5BZWVH)^_=2&MKY9TKIN7I4%51&5-#%%7")CWA(%
M*8]3F,1$YHQA+F/A0DXC9)@S6_5*F%ULNX.] YTB=X ]@2Z(NU'&> A[D^#K
MGZOVE^!WN?F^$MV7Z1AH.F9"+9T.8:<IM)OA)6;(W>DP'F._;H81<DSK6!@/
MU(DKX89'C2YRL'J07_3^IVDI^\&\%J8Q4QO=G5#.TU@AF*4H@@@3!AE"!>1,
M%;1(4IPQYD*O@Z/-C4A;8<%.6M"+.S+N?AAJ.^+S!F!@BKL!NS%U#ZYCXKON
MP<"(4]<]N*[\F;H'%C>-#&ZC]?=WR]6?'[7\^D=34*$V/@IM,791[?IGOBE_
M-(%U^P; NV -E.6*L,:D2SE$7&\U&8\%E)G>B0J9IE@Z=8B\5:"YT=*7[>/C
MLIDWN@1B)ZXQ)JI5!8V.H.R5;#98JE<3T)V>_^(87G?KK-K1VY1S%9@!C2K
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MBP6.-#41GD%&]*8:F4QBED@$>1KQG*M4"6EE!_L19VYDUFL##M31UL"A0N!
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M=XET<>1/;W_R[R;DSA2C79",J,B4RLH0+2!*!(&$)@+*2.81QPPC;+5-NC3
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M@^<YZ8U\RCC"^W=9?ON^D>*5I@?Z3;9VDNF+O=SJW[9$^VF[J3?Z@];\J_?
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M1H1*M8D8Y<;[*K2=R+B *A&"2HF+Q.X :<S@<R/;KG":ZL2^TZ]^(SA@O>2
M=Z*[1N$YS,@P X?&.3 I&[&;0NW'->I,,<P6ZIWPX,TUJ$<$]KECYCGDST&
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M1YJ4: :5?<X8PQ=?^O0/9T83QC_^]9_ZW^C_F%X$__I/_Q=02P,$%     @
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M>K#W!X'*02SM(*3PBM@]_S@E1_8"UGG]Z]<X.Z\9DU=[TDY+*6E/LK@$BK-
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ME-$-?7IC%UEZ+)8VH$4BCN1HR3.@741,DKCC/&-MPMH/T].-%=30TS]>$!W
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M=J6^LTH$I4R!8(, J0LSJ(Q-I4T^SF,4'3VSX<[GWLIE*<(8!C(&6S.(+?A
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M+1.]3U8(W:;<8= .I7XG5QV#SB9*[ &<Z\:<QTX9.I]B(6EYYA2H*,E\MMH
M=]PJ\M:,MVTLSR=)ZB5',P;\!E%3KUUS[_.W/%MSA9\^+:XV;FU^[YB>N%U^
M[" =;WO3/U _V^8;;PBKUP,B:L/ZZ\OE:DX.RDVCDD\NB%2W4]EZ)T4F $-P
M4&1F5GK4(;:)F.U(X-'CQVX%3[I[6S:?O3*EF0G92)<A&D]GKV0.(20)@7ON
M<Q!*VS;+K)^C:NPBFN%Q\V!JV% Z&?&17"Y6DW>+>;J,J[>+JXA#7N<W#3*>
M5?)TRTI'][EA=8@QR8E;QU16,:J=+#7ZP!T\T3]M8^DI"L;%SW"ZG0\HZ#Z
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MO)3(7F@9(B6RA^JZF"[]&&<W>^LW$GB?X_S3;/H_.4WH<J?#:S38',G@$*C
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M<^:B)%/J1+FNG_J&J\#:P;.5ACH W78L@(0@@ZV#"G-M;TC6DWB0 Q:=-<;
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MD%M/]9@P+;-&@[76A83%LJ2;.=3YW2I+R9Q4[,1P6]/5J>U]( IV!=G^*ND
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M[N!JZ@!ZU^&HB1.>18T!I!:RENYP0%$8.(G:!V6-9VTCF>.Z*\/K=CZ H#L
MR,9I2\\(Z#]S[8W,Z=6WO,!/^<]E+I<7OTU+GM UC-(7#29*3_>PHV<X% N6
M),"2T\[*-G,ICJ%Z7.>H.1!/IM!>TY'/I)BN_^C]_.*BS!?_P$5JDSU[YD.M
MTVB[\CA*/LTDE"+6@3P$9% E)0B!##?NE4&CE;2QS3*(D^;3[JK@S94*)HYI
ML^YR"JQ&2PLSX#TGPZ0$'Z+V*%6;[HQ'B#FG#-D^B'GJ33Y4#QT\SS=FA:&+
MV89 /I.NZTF#]8"N!$";),ILG3!M6LOZL-^.5N53YMH^<CT8#U_S8CI/'U:X
M6 V*BNNW_N=UD^Z[]5<F6F'PM3X_6E6797,+CB72:^!!>L5$-FUJE9^C:ERC
MJQ5ZCI9_3S=,%"HGJSB$M [+RMJ6N][';8HCEJRW;294['7#- LR-+MA]I'K
MD3?,+[,TBEW]X!UO8E0_]976%O5.W(UC3HL2E"F9K*%<>TL=O5N%UYF7.B1T
M7!;>^*KOK#R-_%-EC+/D.%>3L3@#3DH-R3+M4L'H99O9#C]F>=H^^#JB/&T?
MK77P8C[#ST_??\?_/5^\OL#E<IWKY,I[$:("6S=?*!D$N(P!M,3L54!I'NPG
M:A[5WR;R;,K8]L+)[L']HY36-QYO&?L#OUP7YBCI+(; (3)/9@@J!4$;4T=X
M2FM+\3FVN23W)+3;C,%Q@-D=F$=K;_3"N,O5_-?9_\Z1_IV/.7Z>S2_FG^HT
MQU69+ZZ3N5%+\K6YAQA=;8'1D2SE*,$11SY&;Q)_T6K<^6O=8NIX7<];"GYL
M)/W___7VP\=??JX#01=3LK\7W^F7Z3)>+Y=23$5C,P=Z!^I,*4%.=QW\+H7B
M-F)D4F^G-Q\'T0L?ZC9Y-"Q^AA3WV-#Y^-NK/WY^NZ%_/>;U>G%4L#8Q4P((
M6S<=6NL 8PX@%<G'D*4ATG;Z\G'0//F)<4,:)X/+,"+NVY2ZS<YJHQV/&:&$
M.@ZXQG)\R1E8<3&3E(KV;;+>@U7J]%#ZV\B8/TQ-'4#OJ+R]E=;$6@QOLT^@
M2(;@"OGM+D;FZG@HF5O-)VE<B#%N1=!>&!JR$&,?A78 WF=XO-IGEFLK8[ (
M(1BR-<EX !^S!1.$%I$XE8W&>[U$6;<&W3 @'%0Q?0/MSNZ2>]/[92Q2%\U!
M(R/G7*1 'HXD7SW+)')@QJDV2^CWI[5;<[$Y&(=07M_PK$O)<HY2)Y' QEH;
M:D.=(E/7Z&@9!2\1V>U6TE-!<=<M<<UF H\)NWV5T@'$?IVE7)[FZ)>_XL5E
MFLX^W>2?&8]&&5% %N] \9( N54@O78R*)ZX:;-B9E]*QYT4W!R&3177!3 ?
MG*U'>"K.F5@739#$:BNP!._)];,>I<[985)M?.==J!MWIO ) #BP@@8;\7JZ
M2I4WEZN:X+YC8K2I57GZ.ZVK57;D<)1Z%6YC3CI'T Q#7?NK(0A'+Z]@6DF)
M2N2V1= GJ5=YSLR]HY;-]+#WN<9>Z6JI,;-EQ(O_RKB8&"ZBJ>>NF,BJW6MJ
MAZ."J$*4@EDAQ<GK!G8E_IPJ7/9!Y#[N3 L]=_#&[\?R'W3)?/Q'OOB6?Y_/
M5I^7$Y]\P, #^%2S ;%8^E6DMT::H+5/S,LV YR.H[N/XN7> 'V4=L\.R_6T
M?OS'?*(]DAG/.<2Z]58)@EOP)D/FW#"1A*%#VP&$-^3V45+=&W(/T>5Y I80
MF"=.L>"*EB"MU:"DE?3&, U612V""8B-)D8?2/"XX:BN0;NW/L\2MF_FEXN)
M1<>+K.M\DTZ@M/% +B[]*DL?F$ZH&DT:/8S><8-7/8-V;VV.73#T-(N5J[B5
MHB 67Q7Z\BVKEJL2N0,;5)V+:"U@#=$4YD54WJ:"VR/?'J\J.HZ.<8-9[0%Y
M:E7U?9/61(:HTR(R6H@RU%96K^L<X52+DCT=,)>\/_D[OVMVJ=GNK"YNQGVU
MTVM@];?Y[-/'O/CR<PXKXND/7-2=!M_R$3'4EW[D(.'2O>@>*#):O_78Q&^>
M52JIT$/(?9V 6+=)K->',,=\\#$WRL8]3L^Q5U+]J;_.Z&==UGT6UY5]0@GB
M$33=H62?UL$U*M1EXL9PGP6+OLVH@D>(&3<6.0 &MF^98P7>P3-VGX5U TT*
M*JA<!SBN=Z$(R\'+$ !C0$\>>HFQ3;C[(2WC(^8H]3X+E[UEW1U:[E2K"QT4
MB\I +"CHK689R/-EH#ERP;A/F;49F/@413TA9W]-/PN< \4^MB?WBC/V>C[[
MELD%H)/T(<^F\\4?\U5>_GQ)YT:X39>"5$YJZWC-=Q=0OA!/@==6!:D5C_13
MV(XM:+M]L">D'*K:>6,YCXX=)O1S/-GK6;2>&2.3A,QK[Z?6 M![ ]R$E(+)
MT3Y8C/T$=G;[X+C)J ;8:2#GT;'#_^TIIM*:*77=1Z>*$B0L<.0=TH&(%D(T
M]-*70L)S0A:_Z\6SVQ?'30BUN'D:2'IL^+RF[TU7KSXM<JYRNAZ=+;6)7F:0
MWM!KKI#727@%BG!!JVCKRN6=L/+HCQ\WZ3(\,(Z787>V[_N<\I>O5257D\:N
M1@\X&4P@RT[P4'.86H'WHLY'E"E'A\GH-IU?+]/6TTLUM"=UM"ZZ1]?F &KG
ME8@I0E2,@6*% 4HOZ=F5=/Z<4]ZU*=C=A;J>[.CC$;$7X Y03_>0>SN[7A,A
M8PA61$W/<RUS%NNV<<,AAIRY,HPSV:;*9D<">P;>(<C8"WJ'J:E[]'W\QWS#
MEL[*VMJ:CIA#'7OFP5DR/U*T+-$3HDBV(Z#OAL">'M:3H^\P-76 OIJ$6FV2
M4!_IOUD_$)XKEK)4()Q 4 FK6Z+((B'[UKL8T>8VS:F/4=.3<WB\P7:TO#O$
MS/7ILB&*E!6PDNOZ*_*/?$TE8?&V&/0DIS;IDL?I&?<U/%[/+P#G *%W )T[
M09'*R/6=*:*1)6G@J2Y.XY;\:1\]1!N4UK$8J=K4B#Q*3E_ .43/\Z&%/G;L
M:==PK(F8;1T4H:VH*VKH;4=.]A_]ODH\H-5^NY7]C,/> T*EF93'1DXML/EM
MCK,W&*<7T]7W#0LVZZBEJ/WTI8 *A/L@Z3J6/+BH<RHB[ :4QW_^N#;+T+@8
M0(8]++E=/\'2!"R11^ 9R3F4=5UCEHDHC[X4M.0$[)2?;[#Z^$1Q[,-MV,,E
MV8/Z-ZCE@4N3%3E],I /J(RL_6 >M%'1N(#&J9VFG9SCCN.]5/;$CN-]Y#?V
MDMM[VWFQ9)WJ)"EZN^H6.0([!DV(1^WIRJ*;W>WDU)[KCN.]%/?DCN-]I'BP
M^LD""?/!MQQ+ES2KNU>SK>]?M!H"77,@BN$8-0K!=O(RSG7+\<$ .%B*HP+@
M^O7[#UQ,ZY/W'E=YD_[PL7 9H42Z %65""K+(,FH-'*94VH3QM^F9-SNK*$C
M6T?)N8/0Q%WZ-Q:S=;:N%"%)6%^K>PS2B6$)Z))+J'7QSK59/O60EG&#$L?I
M]AF@'"#H#J#R(<=+^NI;NJ9F=5;JF^D,9W$Z^U19^C OBYL_J>.U_OKP#_Q:
M_^3Z"0T1Z2#)6M]1"^WKMGFI(FB=O+5!!QO;1->/(KL? !Z"F>TU0"=38 =H
M?9-)-WCQYG*6EK^4DF-M,MIB2?*2N9,%T#)ZU6M9$Q(M=+R5RM'[(G.;%;@[
M$#=ND&U@Y VMC [P]1,N\QWJ-<_2ISH#@ Q+>AH$>0BZ;O'(W.C"G4V-ABK?
MIV/<$-S J#E"Q!T Y*KJ\3IZ>&4_E&*,<Q*TH+_0%<K ^Q#!>*VLM4GZ!X'Z
M@3(^#V@9MR5]:"O\2%EWAY;-X<'(A%;!@TF&@TK&0S"$^"@B#]I%XV6;W/)C
MU(QK"AVKX6<!<X"X.X#,^_QM?O&-S+?[S&QN2Q$M(C<&2D"Z>(-DX&J!#G?1
M,EZ$R:)-Y^^S9/4$HD.T/F^E@K$SAJ]FLTN\^'5&/RXO5^_P>[V8[U3/1I.=
M9UE#0DF/K\5,UC\=.Z&#B8K)XG%[4>$3.>;G/S3NA(JAWJ7!1=HQ/#;'* 2'
M1@0.Y W6.&MT!':ZDE4HTA*'C/OM%./> !GS(1I>I3MBY0#YCHV6^\?HAJNM
MBN7,8\B:)TAB79=*3[<7@0%7Z*1T!DF0.R%FI\_UB9I#E#MO*NF>L7-;;^P*
M%QFM@V)3KC7-'IQTQ)'32L8HT-CM5JO]L3-RD?>8V#E,TEUCI\YKO,X)<H:F
M#F.0)=&3SE(!Y[4!(TEPP4=6W/$WSYT/CA.5&14_!TJ[9P35,74;EEA!Q24/
M$(,,H$I(@#9H8$%X;A*W9/H?#:#;[XU32#4F?@Z4]=CPN1L ?3W_\G4^NY[_
M$HI62@@!V>@Z;B,J0)1UT5%P1A4;8MJM]/+)3^P$$C<T2)IX3L.(L4LP7!\:
M$;U':R'X7"TR+2!D%."B]:H(4_!!9&\/.(SN)PVDP!<Q<8 TNT3%K:ENO,O*
MN]HL8Q&4<;59CR1%8N,N<BF"W&VRQ//?Z0T;ARCR170<)M4N 7)KCQLF$SUY
M#K2IUI3RBGPYGZ!&'M"7[)3<;:3Q\]\9T>4Y'4 .DVH'H?_[K^UO-RO)6, 0
M"R.<!U]M,4DOKM66#";)"G.Z%'V*;NG?]MJ [GNW28:4>G?@N;:[US5 J[KT
ME2SP6-7T*4^D*:HNY 1C8P+%=2+GGUOPA3%F9/7KVA3([$YC3^,?#H3$LS ;
M3#_=(>\-QKH;[W*VFI043 PF@T2D]]D3(+PN'G).RG.&&D^"LUN*>AKKT )5
M!\J^B]+V+4[R-2-*6Q.+S(")S +E-0./.D(=3>8E6L7S*69=WQ#4TPB')A@Z
M2/(=7$/O%O-(Z%Z^(:%M=8E/=.".CD AKU2$.JP@D*E9QZ*67!(6ST.C-HEG
MB.JICW(8( VE@1[ =!427;XM:T$MEY<XB^1B+%>U\]![SWP&RX4%Y<CL=-DC
M),V"BD%8*=K4O#]#5$_M-P.!:2 -= "F^^*Y<S)J/F7Y>7YQQ_A[6SZLYO'O
M[Q;3F#\NII\^D1L;F1>Z& O",5MKJ(G=$BUDE#X8Q[/#-H [DO">JE%;/)5M
M-7D6P/VXP+K<_&?\OIR$+!0R5!"8)"<<DP<T(0'74@G.&&?Z%"LF7B"SIU*T
M4X'R4"V=!03I]Y8Y7M;>DSM\\HE IWGP%I@D::JH#83($$3.SF=+?]4X$AR?
M(+FG7-^IH#F$]L:.[>_%Y4^72Q+M<KD^C&3YFFP9@\#)-%;%*7 J,Y*M2IGK
M;"3;7L&Y2\7!'B3T%,L]#G,G5$7/]^+5+Y>DP/=5C7S",#EE'!G+0=1"'1_)
M6#;DT"=I=;",)[^=6FI\#VZ3N%NPEYT#"-NJYSQPM[9X^40*'XO.'HH@\T(I
M\OB]"@043=8'4]Y&UZ8M;F<2=\/=&6<9AE)/9P\L?GV-%Q=D+LR6&*NZZ'?6
M7)'S]>$SR7Z2;<#,8H"2E2(CMS:5%I1D3#A5>+1)V$-*05_^\FZ0.HL40WO)
MCPVK#WAQZZ7G+]/++W54PF^X7+W/7^>+54[UW[CF[SH[IQ73:+( 9R5=TTY)
M<-5&Y<H%;H3,:<=59@=]?C> G47^X40ZZ.#1O,?DW=,2O-)*VKHD*=0)9,J!
M3X[,3[(ZI:/CHAIM87B*HMW@=599B4&$/_95M8F&OYDOZ,;]FM/6-;R<"!.*
MRZ(.1#.YGH@$J$6&K)@S.BG/=BP]?>E+NR'D+%(-PTNV@[N&KLV;S,EV$HXQ
M%#HE U8%#<I[ 5XK!!-"B<%Q6TR;55;/$+4;GLXJ2S"4"CI 4Z7YUG78,)/3
MG36XZUH!/BG19.1&@S2J=L7G $YG6V,H06OKLDOM:A1WH7 WG)U=X']PY713
M#/0L9^L7?%FSPCGQ28P<69T!ZA0GIR,Z#Z'4C35:>)D]"5&T6U2].YV[0?#L
M OR-%-7![??K+%W&G&X9?'"?__+7USQ;DD-2!&I6# 1)=[L2.8$3J<X<H1L^
M<E92HR5^.Y.X&_C.(M+?5CT=X*Z*AWBY/WWF:G+Q3_/%8OZ/.IL&O]*?K+Y/
MBD+$+ M(6^?11&/ .6*0;GE.;G((TK9Y>?>A<K?*V[,*\3=34@< O%O)5S=P
MK+=FU%S9-<,3B;$DZW1MMB#)649WNN,<;/8NE)!L4>TK*A\E;3>HG554?UAU
M=("O^T+Z"9?3Y0>B!=/;V=V6+C[A)@D7G83(E025K*WK>0R(;*SG=*LKWF9J
M]:X4[H:VLPCX-U5.!Z![[,)^/?_R9;K:U+W?"3 'DS7WBD'&NE^@B+I?P$4H
M'&7 ',E]:I.\W(/(W:!W%JF UBKJ 'T_;SY[-9[[JI#Y;XOY<CE)=+5+SS4P
MB9E<(:L Z\3+H+-GRKF$:;L(:*@[[@F2=D/6664!AA%_%SBZ*YP_9_AE3O[.
M_^3T\W09:[AGDT9[-4L/"N?_R*M)BB9%Q5P=84<NN# 9O),2A#1,J(19A>V1
MCRU>U+T)WPV39Y%W&$.5@R'W__WW!PH@:?Q]_4?K/ZG_U?M<_N_Z]S_?_WKO
MY]>,R_]\_Y+_+<Z_7/WX:W.V,D@\O<;%XCLY3E>1R_E=?_YJ>6->X?1B>9^K
MY?3+UXL7<^X'?NG?;SG;YGGSP0<X:\-E_FN59RFG_^?X^Z/BZV*^O%SD5X'@
MAW$UB5*D++FKRZ^PID 38 D%#%.A%)&9PW9ME@_I&?:6O!H2H'7@@94 Q"BQ
M6./AZ,EPU9$X)=^\;OL\P<VW)F;\_O8C,?#\7;:_P+M[6:^67+/:::8]Y,+K
M=EAE(6!$2 QY5N02^4:M?@]I&1\Q1ZGW6;CL+>ONT/('?KG>C9'JZ!I)K[+2
M,9)77"?;U4+RG+ED7N5B=)N=(4]1U!-R]M?TL\ Y4.QC5_.\XO_VU';JM-Y.
MK38#C)2W7 L;(,;U%,9"1TR2\NGGY5",EQ%WJS7<]8L]8>50Y<Y;2WIT^.RX
MVYQ[H44V'J*JJS10<G Q:""OA!OG2O!^M^ZBL]@@WP \#>0\.G8X8\_QY*X7
MHG.NDBL9I%:I-J,80$?/O%#2>A8S,WR[>_*IFV>G#_8T5F68BV=X.7=G]=R&
M08RF0\!M@6")%T7, )I<Z$2PS%"69+!5#//P$74GNHJ&MI8/DWIWX+D[K"I;
M@SS6#J2:PJRK-@(F#KQDSZ4ME<\3H&?/06$G3R'OI>Z=!X7M(?ON,/1(S'0B
MC"E9>@?1<Y(2%QF<51E06*F\K/O%3N&S/T):3Y=2"U0=JXW]X>6OX#7+G^H(
MQ6&RQ'="M:\O%U6R$^>RITO:@;8N$!/9@/.%0TQ9FY!+X*J-2_\(,3T92L.
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M KJ&>NK@31X@PL:C]T9(#BD1VXIE!C[Z!,)%QQ@/C*MM9/XKM]:/ W5B!/2
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MC35YI"ZZ0]/=901:E2B)A5@XB45S 3Z[# PSMQX-B:A-1. IBL9]8H_5]+/
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M,G1O8W)E9&ET+FAT;5!+ 0(4 Q0    ( !V"J59:2VY_I0@  (LR   2
M          "  =$-  !E>#,Q,3$P<7$Q,C R,RYH=&U02P$"% ,4    "  =
M@JE6[D#5EI0(  !/,@  $@              @ &F%@  97@S,3(Q,'%Q,3(P
M,C,N:'1M4$L! A0#%     @ '8*I5IF$CW_T!0  Y34  !$
M ( !:A\  &5X,S(Q,'%Q,3(P,C,N:'1M4$L! A0#%     @ '8*I5IJAW6>Q
MK@( T;\9 !$              ( !C24  &AA;&\M,C R,S S,S$N:'1M4$L!
M A0#%     @ '8*I5G(X' = $P  P]@  !$              ( !;=0" &AA
M;&\M,C R,S S,S$N>'-D4$L! A0#%     @ '8*I5E;?V/IR(P  7&L! !4
M             ( !W.<" &AA;&\M,C R,S S,S%?8V%L+GAM;%!+ 0(4 Q0
M   ( !V"J5:P[?]NAF8  *65!  5              "  8$+ P!H86QO+3(P
M,C,P,S,Q7V1E9BYX;6Q02P$"% ,4    "  =@JE60XQ3O/0@  #@/0  %
M            @ $Z<@, :&%L;RTR,#(S,#,S,5]G,2YJ<&=02P$"% ,4
M"  =@JE6H8J4$3U8 0 )N0$ %               @ %@DP, :&%L;RTR,#(S
M,#,S,5]G,BYJ<&=02P$"% ,4    "  =@JE6?SO >F95 0 5R0$ %
M        @ '/ZP0 :&%L;RTR,#(S,#,S,5]G,RYJ<&=02P$"% ,4    "  =
M@JE68R<VT2GY  #&<@H %0              @ %G008 :&%L;RTR,#(S,#,S
M,5]L86(N>&UL4$L! A0#%     @ '8*I5I-M6(OYG0  >2L' !4
M     ( !PSH' &AA;&\M,C R,S S,S%?<')E+GAM;%!+!08     #0 - %L#
(  #OV <    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
